{
  "FullStudiesResponse":{
    "APIVrs":"1.01.02",
    "DataVrs":"2021:03:02 22:19:02.771",
    "Expression":"ALL",
    "NStudiesAvail":369328,
    "NStudiesFound":103,
    "MinRank":1,
    "MaxRank":100,
    "NStudiesReturned":100,
    "FullStudies":[
      {
        "Rank":1,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780763",
              "OrgStudyIdInfo":{
                "OrgStudyId":"NU391"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"S64737",
                    "SecondaryIdType":"Other Identifier",
                    "SecondaryIdDomain":"Ethische Commissie Onderzoek UZ/KU Leuven"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Danone Research",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"Effect of 4-week Oral Administration of a Fermented Dairy Product Containing Lactobacillus Rhamnosus CNCM I-3690, on Subjective State Anxiety Levels in Healthy Women Undergoing Academic Stress.",
              "OfficialTitle":"Effect of 4-week Oral Administration of a Fermented Dairy Product Containing Lactobacillus Rhamnosus CNCM I-3690, on Subjective State Anxiety Levels in Healthy Women Undergoing Academic Stress. A Proof-of-efficacy, Randomized, Controlled, Double-blind, Monocentric, Parallel Arms Design Study.",
              "Acronym":"Tara"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 4, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"July 31, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"July 31, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Danone Research",
                "LeadSponsorClass":"INDUSTRY"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of this study is to assess the effect of Lactobacillus rhamnosus CNCM I-3690 consumption on subjective anxiety levels in healthy subjects undergoing academic stress."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Anxious Healthy Subjects"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "anxiety, academic stress, healthy women, fermented diary product, randomized controlled trial"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"A proof-of-efficacy, randomized, controlled, double-blind, monocentric, parallel arms design",
                "DesignPrimaryPurpose":"Supportive Care",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignMaskingDescription":"The study Test and Control products have been developed in order to guarantee the blinding, they will be similar by their taste, texture, color, packaging, nutritional content and flavor.\n\nThe blinding of study products will be performed by assigning a study product number corresponding to the randomization list. Then blinded study product packages will then be carried to the investigational site for assignment to the subject.\n\nProduct allocation will be performed by randomized method (IWRS validated system) as a Randomized Controlled Trial. The participants are thus assigned to intervention groups randomly.",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"168",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Arm 1, Test: Fermented milk product containing probiotics L. rhamnosus CNCM I-3690",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Milk product fermented by lactic bacteria or not fermented"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Arm 2, Control: Milk-based non-fermented dairy product",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Milk product fermented by lactic bacteria or not fermented"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Milk product fermented by lactic bacteria or not fermented",
                    "InterventionDescription":"2 bottles of 100g consumed daily during 28 days",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Arm 1, Test: Fermented milk product containing probiotics L. rhamnosus CNCM I-3690",
                        "Arm 2, Control: Milk-based non-fermented dairy product"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Comparison between groups of the State-Trait Anxiety Inventory (STAI)-state questionnaire score during 4 weeks of investigational product consumption.",
                    "PrimaryOutcomeTimeFrame":"At Baseline and after stress challenge (4 weeks after baseline)."
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Comparison between groups of cortisol level in saliva, Perceived Stress Scale (PSS) questionnaire score and Heart Rate Variability (HRV) during 4 weeks of investigational product consumption.",
                    "SecondaryOutcomeTimeFrame":"At Baseline and after stress challenge (4 weeks from baseline)."
                  },{
                    "SecondaryOutcomeMeasure":"Comparison between groups of sleep efficiency, total sleep time, and deep sleep (Non-REM 3 sleep cycle) duration, during 4 weeks of investigational product consumption.",
                    "SecondaryOutcomeTimeFrame":"At Baseline and at stress challenge (4 weeks from baseline)."
                  },{
                    "SecondaryOutcomeMeasure":"Comparison between groups of Bond-Lader visual analogue scale (VAS) score during 4 weeks of investigational product consumption.",
                    "SecondaryOutcomeTimeFrame":"At Baseline and at stress challenge (4 weeks from baseline)."
                  },{
                    "SecondaryOutcomeMeasure":"Comparison between groups of cortisol levels in saliva after 4 weeks of investigational product consumption.",
                    "SecondaryOutcomeTimeFrame":"Time course of cortisol secretion on the day of the stress challenge (5 timepoints)."
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nSI01: Free-living Participant who fully understands and agree to the objectives of the study, who gave signed and dated informed consent\nSI02: Women of 20 to 30 years of age inclusive\nSI03: Participants who are healthy as determined by medical evaluation including medical and surgical history and full physical examination.\nSI04: Body mass index (BMI) within the range 18 and 30 kg/m2 (bounds included).\nSI05: Woman participants.\nSI06: Student defending a bachelor's or master's thesis in front of a jury\nSI07: Subject who regularly consumes dairy fermented products containing live bacteria and willing to consume 2 units of investigational product per day during the study.\nSI08: Subject willing to strictly follow instructions on diet, medication and substance use for the entire duration of the study.\n\nExclusion Criteria:\n\nSE01: subject with chronic gastrointestinal disorders or symptoms, with celiac disease, diagnosed type 1 or type 2 diabetes mellitus, with psychiatric disease including but not limited to depression and general anxiety disorder\nSE03: subject with food allergy, history of atopic conditions (eczema, allergic asthma, allergic rhino conjunctivitis) requiring active treatment, with first degree relatives with coeliac disease, inflammatory bowel disease (IBD) or type 1 diabetes, with known or suspected lactose intolerance\nSE4: Subject with eating disorders, chronic or iatrogenic immunodeficiency (e.g. Chemotherapy, HIV), presenting a severe evolutive or chronic pathology (e.g. cancer, tuberculosis, Crohn's disease, cirrhosis, multiple sclerosis)\nSE5: Subject with cardiac, respiratory (including asthma) or renal insufficiency, cardiomyopathy, valvulopathy and medical history of rheumatic fever and/or with a positive test for COVID-19 infection or presenting any symptoms of COVID infection in the past 2 weeks\nSE6: Subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (antibiotics, intestinal or respiratory antiseptics, anti-rheumatics, and steroids prescribed in chronic inflammatory diseases, antiphlogistic, anti-inflammatory and PPIs)\nSE7: Subject who has planned to participate in another investigational study OR subject involved in any other clinical study within the preceding month\nSE8: Subjects planning to significantly change their diet during the period of the study or who have changed his/her dietary habits within the 4 weeks preceding the study (e.g. start of a diet high in fibres)\nSE9: Pregnant woman or woman planning to become pregnant during the study; breast-feeding woman.",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"Female",
              "GenderBased":"Yes",
              "GenderDescription":"This study is reproducing a previous study with interesting results seen in women participants.",
              "MinimumAge":"20 Years",
              "MaximumAge":"30 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Silvia MIRET-CATALAN",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+33 (0)6 15 37 21 02",
                    "CentralContactEMail":"silvia.miret-catalan@danone.com"
                  },{
                    "CentralContactName":"Jennifer LOURENCO",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+33 (0)6 29 22 03 68",
                    "CentralContactEMail":"Jennifer.lourenco@danone.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Rim HASSOUNA, PhD",
                    "OverallOfficialAffiliation":"DANONE RESEARCH, PALAISEAU, FRANCE",
                    "OverallOfficialRole":"Study Chair"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"UZ/KU Leuven",
                    "LocationCity":"Leuven",
                    "LocationZip":"3000",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Karlien Geboers",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+32 16 34 52 82",
                          "LocationContactEMail":"karlien.geboers@uzleuven.be"
                        },{
                          "LocationContactName":"Tim Vanuytsel, MD Prof.",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001008",
                    "ConditionMeshTerm":"Anxiety Disorders"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M2905",
                    "ConditionBrowseLeafName":"Anxiety Disorders",
                    "ConditionBrowseLeafAsFound":"Anxiety",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"T355",
                    "InterventionBrowseLeafName":"Acidophilus",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Ot",
                    "InterventionBrowseBranchName":"Other Dietary Supplements"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":2,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780750",
              "OrgStudyIdInfo":{
                "OrgStudyId":"head and neck cancers"
              },
              "Organization":{
                "OrgFullName":"Assiut University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Concurent Chemoradiotherapy in Head and Neck Cancers",
              "OfficialTitle":"Phase III Study Comparing Concurrent Chemoradiotherapy With Weekly Docitaxel Plus Cisplatin Versus the Standard Concurrent Radiotherapy With Cisplatin in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 1, 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"September 1, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 15, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"doaa abd elaleem alsayed mohamed",
                "ResponsiblePartyInvestigatorTitle":"principle investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Assiut University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Assiut University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\\m2) for locally advanced HNSCC",
              "DetailedDescription":"Head and neck cancer is the eighth most common cancer in the United States . For locally advanced HNSCC, concurrent chemoradiotherapy (chemo-RT) is the standard treatment established with multiple randomized trials . The survival benefit of chemo-RT in locally advanced HNSCC has been confirmed by meta-analyses, which revealed a 19% reduction in mortality and an absolute survival benefit of 8% at 5years when chemotherapy was administered concurrently with radiation Despite incremental improvements in local regional control and survival in HNSCC patients treated with chemo-RT, a substantial fraction of patients suffer persistent or recurrent diseases. Combining novel agents with radiation therapy therefore remains of great interest to further improving the treatment outcomes of HNSCC .\n\nCisplatin is the most commonly used chemotherapeutic agent given concurrently with radiation. However, introduction of additional effective radiosensitizing agents is urgently needed. A significant percentage of patients appropriate for definitive concurrent chemo-RT are not candidates for cisplatin based treatment.\n\nFurthermore, recent data have emerged that cisplatin might not be the most optimal cytotoxic radiosensitizing agent when addition of novel targeted agents to concurrent chemo-RT is evaluated.\n\nRadiation Therapy Oncology Group (RTOG) 0234 is a phase II randomized clinical trial evaluating postoperative radiation plus concurrent docetaxel and cetuximab versus postoperative radiation plus cisplatin and cetuximab for high-risk HNSCC after surgery. The results showed an impressive improvement in overall survival and disease-free survival of the docetaxel arm compared to the cisplatin arm (79% versus 69% and 66% versus 57% respectively . These results are pointing to the possibility that a non-cisplatin based regimen chemo-RT should be explored for further development of novel targeted agents and led to a recently opened phase III randomized RTOG trial, RTOG 1216, which compares postoperative radiation with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high-risk HNSCC patients . docetaxel appears to have active antitumor activity in advanced SCCHN . In preclinical studies, docetaxel leads to tumor cell reoxygenation and mitotic arrest with potent radiosensitization."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Squamous Cell Carcinoma of Head and Neck"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 3"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Factorial Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"60",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Docetaxel"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Arm B (standard regimen):concurrent chemoradiotherapy with cisplatin (100mg\\m2 every 3 weeks)",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Docetaxel"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Docetaxel",
                    "InterventionDescription":"Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks",
                        "Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "taxoter"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"locoregional recurrence free survival in months",
                    "PrimaryOutcomeDescription":"comparison of the locoregional recurence free survival in both arms",
                    "PrimaryOutcomeTimeFrame":"1 years"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"overall survival",
                    "SecondaryOutcomeDescription":"overall survival in months in both arms",
                    "SecondaryOutcomeTimeFrame":"5 years"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\npathologically confirmed squmous cell carcinoma performance status 0-1 adequte renal and hepatic function\n\nExclusion Criteria:\n\npoor performance status\n\nimpaired renal or hepatic function\n\n=Squamous cell carcinoma of salivary gland,parotid and paranasal carcinomas were --0excluded from the study\n\npatients with â‰¥ grade 2 pre-existing peripheral neuropathy, history of allergic reactions to the chemotherapeutic agents, and uncontrolled intercurrent diseases as well as HIV positive patients.",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"70 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"doaa abdelaleem alsayed, MASTER",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"01142753583",
                    "CentralContactEMail":"dodoalemo@yahoo.com"
                  },{
                    "CentralContactName":"amal rayan ibrahim, Master",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"01022454482"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"doAA ABDELALEEM, Master",
                    "OverallOfficialAffiliation":"Assiut University",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "SeeAlsoLinkList":{
                "SeeAlsoLink":[
                  {
                    "SeeAlsoLinkLabel":"Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.",
                    "SeeAlsoLinkURL":"https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.3322/caac.21153"
                  },{
                    "SeeAlsoLinkLabel":"Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharyngeal carcinoma. J Clin Oncol. 2004; 22:69-76.",
                    "SeeAlsoLinkURL":"https://www.researchgate.net/profile/Etienne_Bardet/publication/8975191_Final_Results_of_the_94-01_French_Head_and_Neck_Oncology_and_Radiotherapy_Group_Randomized_Trial_Comparing_Radiotherapy_Alone_With_Concomitant_Radiochemotherapy_in_Advanced-Stage_Oropharynx_Carcinoma/links/568cf18c08aeb488ea31c87c.pdf"
                  },{
                    "SeeAlsoLinkLabel":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced larynx cancer. N Engl J Med. 2003; 349:2091-2098.",
                    "SeeAlsoLinkURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3577950/"
                  },{
                    "SeeAlsoLinkLabel":"Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. Lancet. 2000; 355:949-955.",
                    "SeeAlsoLinkURL":"https://www.sciencedirect.com/science/article/pii/S0140673600900114"
                  },{
                    "SeeAlsoLinkLabel":"Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92:4-14.",
                    "SeeAlsoLinkURL":"https://www.sciencedirect.com/science/article/pii/S0167814009001881?casa_token=egrt4XMYwcEAAAAA:afO0ENCle2OMP81FOq42fUT9LhyBZL2NVvTf8DY3munppWHoZJyLLr2Ts1gfuTTGIxW5I4tAxQTo"
                  },{
                    "SeeAlsoLinkLabel":"Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234). Int J Rad Onc. 2009;75(3):S14-15.",
                    "SeeAlsoLinkURL":"https://www.redjournal.org/article/S0360-3016(09)01099-2/abstract"
                  },{
                    "SeeAlsoLinkLabel":"RTOG 1216",
                    "SeeAlsoLinkURL":"https://onlinelibrary.wiley.com/doi/abs/10.1002/hed.25359"
                  },{
                    "SeeAlsoLinkLabel":"Role of taxoids in head and neck cancer. Oncologist 2000;5:199-208",
                    "SeeAlsoLinkURL":"https://www.sciencedirect.com/science/article/pii/S0923753419453088"
                  },{
                    "SeeAlsoLinkLabel":"Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999;10:119-22",
                    "SeeAlsoLinkURL":"https://www.sciencedirect.com/science/article/pii/S0923753419570508"
                  },{
                    "SeeAlsoLinkLabel":"Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003;25:152-67",
                    "SeeAlsoLinkURL":"https://onlinelibrary.wiley.com/doi/abs/10.1002/hed.10232"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000002277",
                    "ConditionMeshTerm":"Carcinoma"
                  },{
                    "ConditionMeshId":"D000002294",
                    "ConditionMeshTerm":"Carcinoma, Squamous Cell"
                  },{
                    "ConditionMeshId":"D000077195",
                    "ConditionMeshTerm":"Squamous Cell Carcinoma of Head and Neck"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000009375",
                    "ConditionAncestorTerm":"Neoplasms, Glandular and Epithelial"
                  },{
                    "ConditionAncestorId":"D000009370",
                    "ConditionAncestorTerm":"Neoplasms by Histologic Type"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  },{
                    "ConditionAncestorId":"D000018307",
                    "ConditionAncestorTerm":"Neoplasms, Squamous Cell"
                  },{
                    "ConditionAncestorId":"D000006258",
                    "ConditionAncestorTerm":"Head and Neck Neoplasms"
                  },{
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M4116",
                    "ConditionBrowseLeafName":"Carcinoma",
                    "ConditionBrowseLeafAsFound":"Carcinoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4132",
                    "ConditionBrowseLeafName":"Carcinoma, Squamous Cell",
                    "ConditionBrowseLeafAsFound":"Squamous Cell Carcinoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M1689",
                    "ConditionBrowseLeafName":"Squamous Cell Carcinoma of Head and Neck",
                    "ConditionBrowseLeafAsFound":"Squamous Cell Carcinoma of Head and Neck",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M7931",
                    "ConditionBrowseLeafName":"Head and Neck Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10903",
                    "ConditionBrowseLeafName":"Neoplasms, Glandular and Epithelial",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10898",
                    "ConditionBrowseLeafName":"Neoplasms by Histologic Type",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19035",
                    "ConditionBrowseLeafName":"Neoplasms, Squamous Cell",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000077143",
                    "InterventionMeshTerm":"Docetaxel"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000000970",
                    "InterventionAncestorTerm":"Antineoplastic Agents"
                  },{
                    "InterventionAncestorId":"D000050257",
                    "InterventionAncestorTerm":"Tubulin Modulators"
                  },{
                    "InterventionAncestorId":"D000050256",
                    "InterventionAncestorTerm":"Antimitotic Agents"
                  },{
                    "InterventionAncestorId":"D000050258",
                    "InterventionAncestorTerm":"Mitosis Modulators"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M1668",
                    "InterventionBrowseLeafName":"Docetaxel",
                    "InterventionBrowseLeafAsFound":"Evaluation",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M4765",
                    "InterventionBrowseLeafName":"Cisplatin",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M24784",
                    "InterventionBrowseLeafName":"Tubulin Modulators",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M24783",
                    "InterventionBrowseLeafName":"Antimitotic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"ANeo",
                    "InterventionBrowseBranchName":"Antineoplastic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":3,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780737",
              "OrgStudyIdInfo":{
                "OrgStudyId":"RAC 164/2017/ O/Oss"
              },
              "Organization":{
                "OrgFullName":"Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis",
              "OfficialTitle":"Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 2000",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 2019",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"July 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"January 8, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Carlo Ingaldi, MD",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"To evaluate two competitive strategies in patients undergoing resection of Small-intestine Neuroendocrine neoplasms (Si-NEN): Prophylactic Cholecystectomy (PC) versus On-demand delayed cholecystectomy",
              "DetailedDescription":"This is a retrospective study based on 230 Si-NENs candidates to the primary tumor resection. Patients were divided into two arms: PC and OC. Propensity score matching was performed, reporting the d value. The primary outcome was the re-hospitalization rate for any cause. The secondary endpoints were the re-hospitalization rate for biliary stone disease (BSD), the mean number of re-hospitalization (any cause and BSD), the complication rate (all and severe), and the total costs. A P-value < 0.05 was considered significant, and NNT< 10 was considered clinically relevant."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Neuroendocrine Tumors",
                  "Surgery",
                  "Gut Tumor"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"Yes",
              "TargetDuration":"5 Years",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Other"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"230",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Prophylactic cholecystectomy",
                    "ArmGroupDescription":"Patient who undergo resection of primary ileal neuroendocrine tumor and contemporarly cholecystectomy",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Cholecystectomy"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"On-demand cholecystectomy",
                    "ArmGroupDescription":"Patient resected for primary ileal neuroendocrine tumor, treated with cholecystectomy in a different operation and only if needed, for the development of biliary stone disease",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Cholecystectomy"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"Cholecystectomy",
                    "InterventionDescription":"Laparoscopic or laparotomic cholecystectomy",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "On-demand cholecystectomy",
                        "Prophylactic cholecystectomy"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"re-hospitalization rate for any cause",
                    "PrimaryOutcomeDescription":"the re-hospitalization rate for any cause after primary tumor surgery",
                    "PrimaryOutcomeTimeFrame":"through study completion, an average of 7 years"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"re-hospitalization rate for biliary stone disease",
                    "SecondaryOutcomeDescription":"the re-hospitalization rate for biliary stone disease after primary tumor surgery",
                    "SecondaryOutcomeTimeFrame":"through study completion, an average of 7 years"
                  },{
                    "SecondaryOutcomeMeasure":"mean number of re-hospitalization any cause",
                    "SecondaryOutcomeDescription":"the mean number of re-hospitalization for any cause after primary tumor surgery",
                    "SecondaryOutcomeTimeFrame":"through study completion, an average of 7 years"
                  },{
                    "SecondaryOutcomeMeasure":"mean number of re-hospitalization biliary stone disease",
                    "SecondaryOutcomeDescription":"the mean number of re-hospitalization for biliary stone disease after primary tumor surgery",
                    "SecondaryOutcomeTimeFrame":"through study completion, an average of 7 years"
                  },{
                    "SecondaryOutcomeMeasure":"total costs",
                    "SecondaryOutcomeDescription":"total costs for primary tumor surgery plus any re-hospitalization",
                    "SecondaryOutcomeTimeFrame":"through study completion, an average of 7 years"
                  },{
                    "SecondaryOutcomeMeasure":"COmplication rate",
                    "SecondaryOutcomeDescription":"COmplication rate after primary tumor resection",
                    "SecondaryOutcomeTimeFrame":"through study completion, an average of 7 years"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\npatients with a diagnosis of Si-NEN;\nresection of the primary tumor with or without concomitant cholecystectomy;\nabsence of a history of a biliary stone disease or cholecystectomy before Si-NEN diagnosis\n\nExclusion Criteria:\n\n- presence of a history of a biliary stone disease or cholecystectomy before Si-NEN diagnosis",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"For each patient sex, age, comorbidity, presence of symptoms, type of surgery (emergency or elective), ENETS TNM stage, WHO 2019 grading of the primary tumor, type of resection (R0/1 vs. R2), administration of SSA therapy, duration of follow-up, were collected",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Carlo Ingaldi, MD",
                    "OverallOfficialAffiliation":"Azienda Ospedaliero Universitaria, Ospedale S.Orsola Malpighi",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol",
                  "Clinical Study Report (CSR)"
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000009369",
                    "ConditionMeshTerm":"Neoplasms"
                  },{
                    "ConditionMeshId":"D000018358",
                    "ConditionMeshTerm":"Neuroendocrine Tumors"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000017599",
                    "ConditionAncestorTerm":"Neuroectodermal Tumors"
                  },{
                    "ConditionAncestorId":"D000009373",
                    "ConditionAncestorTerm":"Neoplasms, Germ Cell and Embryonal"
                  },{
                    "ConditionAncestorId":"D000009370",
                    "ConditionAncestorTerm":"Neoplasms by Histologic Type"
                  },{
                    "ConditionAncestorId":"D000009380",
                    "ConditionAncestorTerm":"Neoplasms, Nerve Tissue"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M19079",
                    "ConditionBrowseLeafName":"Neuroendocrine Tumors",
                    "ConditionBrowseLeafAsFound":"Neuroendocrine Tumors",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5839",
                    "ConditionBrowseLeafName":"Digestive System Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7469",
                    "ConditionBrowseLeafName":"Gastrointestinal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M18428",
                    "ConditionBrowseLeafName":"Neuroectodermal Tumors",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M18971",
                    "ConditionBrowseLeafName":"Neuroectodermal Tumors, Primitive",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10901",
                    "ConditionBrowseLeafName":"Neoplasms, Germ Cell and Embryonal",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10898",
                    "ConditionBrowseLeafName":"Neoplasms by Histologic Type",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10908",
                    "ConditionBrowseLeafName":"Neoplasms, Nerve Tissue",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T4091",
                    "ConditionBrowseLeafName":"Neuroendocrine Tumor",
                    "ConditionBrowseLeafAsFound":"Neuroendocrine Tumors",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"T4092",
                    "ConditionBrowseLeafName":"Neuroepithelioma",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":4,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780724",
              "OrgStudyIdInfo":{
                "OrgStudyId":"smartwatch21"
              },
              "Organization":{
                "OrgFullName":"Czech Technical University in Prague",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Evaluation of SpO2 Measurement Using a Smartwatch",
              "OfficialTitle":"Evaluation of SpO2 Measurement Using a Smartwatch",
              "Acronym":"ESMUS"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Active, not recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 15, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"March 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Czech Technical University in Prague",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The aim of the study is to compare the measurement of peripheral blood oxygen saturation using a smartwatch with a medical-grade pulse oximeter.",
              "DetailedDescription":"Recently, wearables, like smartwatches, have been gaining new possibilities in monitoring biological signals and they are used for home monitoring of health conditions. The newest models of smartwatches even measure peripheral blood oxygen saturation (SpO2). The study aims to compare the measurement of peripheral blood oxygen saturation using the latest smartwatch with a medical-grade pulse oximeter under the condition of normobaric hypoxia. Healthy participants will breathe oxygen-reduced mixtures (the hypoxic gas mixture of 12% O2 and 88% N2 and the hypercapnic and hypoxic gas mixture of 12% O2, 5% CO2, and 83% N2), which will temporarily reduce their blood oxygen saturation. SpO2 measurements will be taken by hand from the watch and the pulse oximeter simultaneously. The agreement of the measurements of both devices will be evaluated."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Hypoxia",
                  "Hypercapnia"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "SpO2",
                  "pulse oximetry",
                  "smartwatch"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Crossover Assignment",
                "DesignInterventionModelDescription":"All participants go through all study arms, in random order. Two measuring devices are active simultaneously during measurement on each participant and their functioning is compared.",
                "DesignPrimaryPurpose":"Other",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"24",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Hypoxic",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Participants inhale ambient air, the hypoxic gas mixture, and ambient air.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Hypoxic gas mixture",
                        "Other: SpO2 measurement"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Hypercapnic",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Participants inhale ambient air, the hypercapnic and hypoxic gas mixture, and the ambient air.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Hypercapnic and hypoxic gas mixture",
                        "Other: SpO2 measurement"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Hypoxic gas mixture",
                    "InterventionDescription":"Gas mixture of 12% O2 and 88% N2 for five minutes.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Hypoxic"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"Hypercapnic and hypoxic gas mixture",
                    "InterventionDescription":"Gas mixture of 12% O2, 5% CO2, and 88% N2 for five minutes.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Hypercapnic"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"SpO2 measurement",
                    "InterventionDescription":"Two SpO2 measuring devices are active simultaneously during measurement.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Hypercapnic",
                        "Hypoxic"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Similarity of SpO2 readings",
                    "PrimaryOutcomeDescription":"The agreement of SpO2 measurements of both monitoring devices will be evaluated.",
                    "PrimaryOutcomeTimeFrame":"2 hours"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nhealthy volunteers from the Czech Technical University\n\nExclusion Criteria:\n\npregnancy\nsevere cardiovascular conditions\nsevere asthma or other severe respiratory conditions\ninjury to the upper limbs or hands that could affect the peripheral perfusion\ndiabetes\nhypotension or hypertension",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"30 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Veronika Rafl Huttova",
                    "OverallOfficialAffiliation":"Czech Technical University in Prague",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Faculty of Biomedical Engineering, Czech Technical University in Prague",
                    "LocationCity":"Kladno",
                    "LocationZip":"27201",
                    "LocationCountry":"Czechia"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"28802098",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Rafl J, Kulhanek F, Kudrna P, Ort V, Roubik K. Response time of indirectly accessed gas exchange depends on measurement method. Biomed Tech (Berl). 2018 Nov 27;63(6):647-655. doi: 10.1515/bmt-2017-0070."
                  },{
                    "ReferencePMID":"32633688",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Lauterbach CJ, Romano PA, Greisler LA, Brindle RA, Ford KR, Kuennen MR. Accuracy and Reliability of Commercial Wrist-Worn Pulse Oximeter During Normobaric Hypoxia Exposure Under Resting Conditions. Res Q Exerc Sport. 2020 Jul 7:1-10. doi: 10.1080/02701367.2020.1759768. [Epub ahead of print]"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000000860",
                    "ConditionMeshTerm":"Hypoxia"
                  },{
                    "ConditionMeshId":"D000006935",
                    "ConditionMeshTerm":"Hypercapnia"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000012818",
                    "ConditionAncestorTerm":"Signs and Symptoms, Respiratory"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M2766",
                    "ConditionBrowseLeafName":"Hypoxia",
                    "ConditionBrowseLeafAsFound":"Hypoxia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8569",
                    "ConditionBrowseLeafName":"Hypercapnia",
                    "ConditionBrowseLeafAsFound":"Hypercapnia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M14206",
                    "ConditionBrowseLeafName":"Signs and Symptoms, Respiratory",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"C000041364",
                    "InterventionMeshTerm":"Nitrox"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000011837",
                    "InterventionAncestorTerm":"Radiation-Protective Agents"
                  },{
                    "InterventionAncestorId":"D000020011",
                    "InterventionAncestorTerm":"Protective Agents"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M32190",
                    "InterventionBrowseLeafName":"Nitrox",
                    "InterventionBrowseLeafAsFound":"Trousers",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M20453",
                    "InterventionBrowseLeafName":"Protective Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M13267",
                    "InterventionBrowseLeafName":"Radiation-Protective Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":5,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780711",
              "OrgStudyIdInfo":{
                "OrgStudyId":"AIBU-FTR-EY-01"
              },
              "Organization":{
                "OrgFullName":"Abant Izzet Baysal University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Prevalance of Temporomandibular Joint Disease",
              "OfficialTitle":"Prevalance of Temporomandibular Joint Disease in Medical School Students"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 20, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"May 20, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 1, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 21, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Abant Izzet Baysal University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Temporomandibular joint (TMJ) disorders are common problems in the society and involve the masticator muscles, jaw joint and related structures. Since TMJ disorders affect functions such as eating and speaking, they can cause important problems in the daily life of the patient. Therefore, its diagnosis and treatment are of great importance. In the treatment of these patients, methods such as analgesic and anti-inflammatory drugs, splint, exercise, physical therapy modalities can be applied.",
              "DetailedDescription":"Although the prevalence of TMJ disease detected in the community is between 40-60%, the rate of symptoms or clinical findings was reported to be 87% in a study including 1040 people. Incomplete clarification of the etiology and pathogenesis, the lack of standard diagnostic and treatment approaches cause patients to learn to live with this problem, and severe pain and limitation of movement cause a decrease in quality of life and loss of workforce. Specific pathologies such as systemic inflammatory diseases, tumor, fracture, developmental anomaly cause temporomandibular joint diseases. It also causes a wider group of non-specific TMB originating from the musculoskeletal system.When the literature was reviewed, no publications on the frequency of TMJ joint disease were found in medical faculty students."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Temporomandibular Joint Disorders"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Temporomandibular Joint Disorders"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Other"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"500",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Diagnostic Group",
                    "ArmGroupDescription":"Demographic data, symptoms for TMJ of the students will be recorded. Physical examination will be included range of motion of temporomandibular joint, right and left TMJ lateral range of motion, whether there is a gradual opening, during deflection and deviation during the opening and subluxation for palpation and measurements. Opening and closing clicks, crepitation and popping will be recorded during palpation. Deep palpation of the skin, masseter and temporal muscles will be determined, posture analysis will be recorded and dental interventions, missing teeth, orthodontic treatments and bruxism histories will be taken. An appropriate diagnosis will be determined for students who are found to have pathology as a result of all these examinations and information about this diagnosis will be provided."
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Mouth opening",
                    "PrimaryOutcomeDescription":"The patient opens her mouth to the maximum, the lower border of the anterior upper teeth and the distance to the upper border of the lower teeth are measured.",
                    "PrimaryOutcomeTimeFrame":"Baseline"
                  },{
                    "PrimaryOutcomeMeasure":"Tenderness in the masseter and temporal muscles on deep palpation",
                    "PrimaryOutcomeDescription":"Tenderness in the masseter and temporal muscles on deep palpation",
                    "PrimaryOutcomeTimeFrame":"Baseline"
                  },{
                    "PrimaryOutcomeMeasure":"Click in the temporomandibular joint",
                    "PrimaryOutcomeDescription":"The patient's temporomandibular joint is palpated, and it is checked whether there is click or popping when opening or closing the mouth.",
                    "PrimaryOutcomeTimeFrame":"Baseline"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nBeing a medical student\nBeing between the ages of 18-35\n\nExclusion Criteria:\n\nStudents who do not want to participate in the study",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"35 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              },
              "StudyPopulation":"We planned to include 500 volunteer students between the ages of 18-35, studying at Bolu Abant Izzet Baysal University Faculty of Medicine, with or without TMJ symptoms and agreeing to participate in the study.",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Elif YakÅŸi, md",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+905069078505",
                    "CentralContactEMail":"elifyaksi@hotmail.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Elif YakÅŸi, MD",
                    "OverallOfficialAffiliation":"Abant Ä°zzet Baysal University Medical Faculty",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Elif YakÅŸi",
                    "LocationCity":"Bolu",
                    "LocationZip":"14030",
                    "LocationCountry":"Turkey"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000007592",
                    "ConditionMeshTerm":"Joint Diseases"
                  },{
                    "ConditionMeshId":"D000013705",
                    "ConditionMeshTerm":"Temporomandibular Joint Disorders"
                  },{
                    "ConditionMeshId":"D000013706",
                    "ConditionMeshTerm":"Temporomandibular Joint Dysfunction Syndrome"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000009140",
                    "ConditionAncestorTerm":"Musculoskeletal Diseases"
                  },{
                    "ConditionAncestorId":"D000017271",
                    "ConditionAncestorTerm":"Craniomandibular Disorders"
                  },{
                    "ConditionAncestorId":"D000008336",
                    "ConditionAncestorTerm":"Mandibular Diseases"
                  },{
                    "ConditionAncestorId":"D000007571",
                    "ConditionAncestorTerm":"Jaw Diseases"
                  },{
                    "ConditionAncestorId":"D000009135",
                    "ConditionAncestorTerm":"Muscular Diseases"
                  },{
                    "ConditionAncestorId":"D000009057",
                    "ConditionAncestorTerm":"Stomatognathic Diseases"
                  },{
                    "ConditionAncestorId":"D000009209",
                    "ConditionAncestorTerm":"Myofascial Pain Syndromes"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M9204",
                    "ConditionBrowseLeafName":"Joint Diseases",
                    "ConditionBrowseLeafAsFound":"Joint Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M15060",
                    "ConditionBrowseLeafName":"Temporomandibular Joint Disorders",
                    "ConditionBrowseLeafAsFound":"Temporomandibular Joint Disorders",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M15061",
                    "ConditionBrowseLeafName":"Temporomandibular Joint Dysfunction Syndrome",
                    "ConditionBrowseLeafAsFound":"Temporomandibular Joint Disorders",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M14938",
                    "ConditionBrowseLeafName":"Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10680",
                    "ConditionBrowseLeafName":"Musculoskeletal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M18149",
                    "ConditionBrowseLeafName":"Craniomandibular Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9910",
                    "ConditionBrowseLeafName":"Mandibular Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9184",
                    "ConditionBrowseLeafName":"Jaw Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10675",
                    "ConditionBrowseLeafName":"Muscular Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10600",
                    "ConditionBrowseLeafName":"Stomatognathic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10744",
                    "ConditionBrowseLeafName":"Myofascial Pain Syndromes",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7069",
                    "ConditionBrowseLeafName":"Fibromyalgia",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M11649",
                    "ConditionBrowseLeafName":"Pain",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC05",
                    "ConditionBrowseBranchName":"Muscle, Bone, and Cartilage Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC07",
                    "ConditionBrowseBranchName":"Mouth and Tooth Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":6,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780698",
              "OrgStudyIdInfo":{
                "OrgStudyId":"27042"
              },
              "Organization":{
                "OrgFullName":"Temple University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"DCI COVID-19 Surveillance Project",
              "OfficialTitle":"DCI COVID-19 Surveillance Project"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"October 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 12, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Temple University",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Dialysis Clinic, Inc.",
                    "CollaboratorClass":"INDUSTRY"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a prospective longitudinal census study conducted at a single center (DCI Inc., Henry Avenue, Philadelphia). The purpose of this study is to gain information about COVID-19 infection and antibody response in an in-center dialysis population. The investigators hypothesize that screening and surveillance for COVID-19 positive test (viral infection) and antibodies response to infection (potential immunity) in a dialysis center population within a high-prevalence region can provide foundational information to guide approaches toward prevention of COVID-19 related illness in a susceptible population. Participants will be given a questionnaire initially and monthly over the study period to find out whether they have had COVID-19 infection, hospitalization, or symptoms. A nasopharyngeal swab test for COVID-19 infection and a blood sample for COVID-19 antibody will be collected monthly for the study period."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Screening",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"160",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Study Cohort",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Diagnostic Test: SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Diagnostic Test",
                    "InterventionName":"SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection",
                    "InterventionDescription":"COVID-19 infection and antibody testing",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Study Cohort"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Beckman Coulter Access SARS-CoV-2 IgG Antibody Test",
                        "Mount Sinai COVID-19 ELISA IgG Antibody Test"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Incidence of COVID-19 infection in the cohort",
                    "PrimaryOutcomeTimeFrame":"monthly through study completion (average of 6 months)"
                  },{
                    "PrimaryOutcomeMeasure":"Link the presence of COVID-19 infection to COVID-19 antibody formation (seroconversion) from quantitative and qualitative testing",
                    "PrimaryOutcomeTimeFrame":"monthly through study completion (average of 6 months)"
                  },{
                    "PrimaryOutcomeMeasure":"Incidence of COVID-19 reinfection",
                    "PrimaryOutcomeTimeFrame":"monthly through study completion (average of 6 months)"
                  },{
                    "PrimaryOutcomeMeasure":"Presence of antibodies in cases of reinfection",
                    "PrimaryOutcomeTimeFrame":"monthly through study completion (average of 6 months)"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPatients who receive in-center chronic dialysis (>3 months) at DCI Henry Avenue\nPatients who are able to consent for study\n\nExclusion Criteria:\n\nPatients receiving transient hemodialysis at DCI or receiving hemodialysis for Acute Renal Failure\nPatients who are unable to consent\nPatients who are receiving other forms of dialysis therapy (e.g. home hemodialysis, peritoneal dialysis)\nPatients whose life expectancy is <12 months\nPatients who are planning to leave the dialysis center within 12 months",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"90 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Sally B Quinn, RN, MSN",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"215-707-7576",
                    "CentralContactEMail":"Sally.Quinn@tuhs.temple.edu"
                  },{
                    "CentralContactName":"Jean Lee, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"215-707-0744",
                    "CentralContactEMail":"jean.lee@tuhs.temple.edu"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Crystal A Gadegbeku, MD",
                    "OverallOfficialAffiliation":"Temple University",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Dialysis Clinic, Inc.",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Philadelphia",
                    "LocationState":"Pennsylvania",
                    "LocationZip":"19129",
                    "LocationCountry":"United States"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000000906",
                    "InterventionMeshTerm":"Antibodies"
                  },{
                    "InterventionMeshId":"D000007136",
                    "InterventionMeshTerm":"Immunoglobulins"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000007155",
                    "InterventionAncestorTerm":"Immunologic Factors"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2806",
                    "InterventionBrowseLeafName":"Antibodies",
                    "InterventionBrowseLeafAsFound":"Sessions",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M8767",
                    "InterventionBrowseLeafName":"Immunoglobulins",
                    "InterventionBrowseLeafAsFound":"Sessions",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M17700",
                    "InterventionBrowseLeafName":"Immunoglobulins, Intravenous",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8784",
                    "InterventionBrowseLeafName":"Immunologic Factors",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":7,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780685",
              "OrgStudyIdInfo":{
                "OrgStudyId":"STEM-107-COVID-19"
              },
              "Organization":{
                "OrgFullName":"Stemedica Cell Technologies, Inc.",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19",
              "OfficialTitle":"A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Moderate to Severe ARDS Due to COVID-19"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 20, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 31, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 31, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Stemedica Cell Technologies, Inc.",
                "LeadSponsorClass":"INDUSTRY"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"bioRASI, LLC",
                    "CollaboratorClass":"INDUSTRY"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"Yes",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in Patients with moderate to severe lung injury due to COVID-19 or other potential viral and bacterial pathogens.",
              "DetailedDescription":"This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in Patients with moderate to severe lung injury due to COVID-19 or other potential viral and bacterial pathogens. The study will enroll up to 40 Patients into two cohorts, randomized 1:1 to receive active study drug plus standard treatment or placebo (LRS) plus standard treatment. On the treatment (Day 0) Cohort 1 will receive a single IV dose of hMSCs Cohort 2 will receive Lactated Ringer's Solution. A second dose of MSCs or LRS will be given to Cohort 1 or Cohort 2, respectively on Day 3 after the first dose. Patients who discontinue the study before Month 1 for reasons other than adverse events will be replaced."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignMaskingDescription":"This is double-blind study",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"40",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"hMSCs",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"hMSCs will be given via IV administration.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: hMSC"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Lactated Ringer's Solution",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Lactated Ringer's Solution will be given via IV administration.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: hMSC"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Biological",
                    "InterventionName":"hMSC",
                    "InterventionDescription":"IV administration",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Lactated Ringer's Solution",
                        "hMSCs"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "allogeneic mesenchymal bone marrow cells"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Survival",
                    "PrimaryOutcomeDescription":"Number of patients alive at day 14 post treatment",
                    "PrimaryOutcomeTimeFrame":"14 days post treatment"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Number of patients with treatment-related adverse events as assessed by CTCAE v4.0",
                    "SecondaryOutcomeDescription":"Frequency of adverse events in patients treated with hMSCs and Lactate Ringer's solutions will be compared.",
                    "SecondaryOutcomeTimeFrame":"9 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nLaboratory-confirmed diagnosis of COVID-19 <= 14 days prior to randomization\n\nThe presence of moderate to severe Acute Respiratory Distress Syndrome (ARDS) as defined by the Berlin Definition:\n\nBilateral chest radiograph infiltrates.\nPaO2:FiO2 ratio of less than 200.\nAbsence of other clinical conditions that could present in a similar manner (non-infectious pneumonitis, cardiogenic pulmonary edema)\nAbsence of moribund state that would indicate imminent demise and poor chance of survival.\n\nExclusion Criteria:\n\nFemales of childbearing potential who are pregnant or unwilling to undergo pregnancy testing; females with a positive pregnancy test on screening day will be excluded.\nBreastfeeding mothers\nPatients on ECMO\nReceiving concurrent treatment with an investigational agent in a clinical trial.\nException: Use of COVID-19 convalescent plasma is permitted.\nMore than 72hrs on mechanical ventilation before randomization\nReceiving concurrent investigational vaccine",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Lev Verkh, PhD/MS",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"8586580910",
                    "CentralContactEMail":"lverkh@stemedica.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Lev Verkh, PhD/MS",
                    "OverallOfficialAffiliation":"Stemedica Cell Technologies, Inc.",
                    "OverallOfficialRole":"Study Director"
                  },{
                    "OverallOfficialName":"Santosh Kesari, MD",
                    "OverallOfficialAffiliation":"Providence Saint John's Health Center - Saint John's Cancer",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Providence Saint John's Health Center - Saint John's Cancer Institute",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Santa Monica",
                    "LocationState":"California",
                    "LocationZip":"90404",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Ashley Archer",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"310-582-7460",
                          "LocationContactEMail":"ArcherA@jwci.org"
                        },{
                          "LocationContactName":"Santosh Kesari, MD",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"PRX Research, Dallas Regional Medical Center",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"Mesquite",
                    "LocationState":"Texas",
                    "LocationZip":"75149",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Adeel Shibli, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"972-777-4428",
                          "LocationContactEMail":"admin@prxresearch.com"
                        },{
                          "LocationContactName":"Adeel Shibli, MD",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M20444",
                    "InterventionBrowseLeafName":"Pharmaceutical Solutions",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"PhSol",
                    "InterventionBrowseBranchName":"Pharmaceutical Solutions"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":8,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780672",
              "OrgStudyIdInfo":{
                "OrgStudyId":"MNCV-III/2-2020"
              },
              "Organization":{
                "OrgFullName":"Pharma VAM",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Clinical Study in the Treatment of Patients With COVID-19",
              "OfficialTitle":"Clinical Study to Analyze the Safety and Efficacy of MolixanÂ® as Part of Standard Therapy in the Treatment of Patients With the Severe Course of New Coronavirus Infection (COVID-19)"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 5, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 19, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"October 19, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 25, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Pharma VAM",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Multicenter, prospective, double-blind, placebo-controlled, randomized, parallel-group phase III study.\n\nThe study is designed for 2 treatment groups:\n\nGroup 1 of the investigational drug - Patients receive standard therapy and the investigational drug.\nGroup 2 of comparison - Patients receive standard therapy and placebo.",
              "DetailedDescription":"Patients with the severe course of COVID-19 infection confirmed by PCR laboratory test will be involved in the study on a voluntary basis.\n\nIn accordance with regulatory enactments, these patients receive specialized medical care in specialized medical institutions, where the conduct of the study is planned.\n\nThe study is planned as a double-blind, which will be achieved by using Molixan and placebo (0.9% NaCl solution) in the same packaging with the same labeling, indistinguishable in color and smell.\n\nPatients will be randomized in an unpredictable manner using the IWRS system.\n\nIt is planned to divide patients into 2 parallel groups:\n\nGroup 1. Standard therapy + Molixan;\nGroup 2. Standard therapy + placebo. The regimen (1 or 2) assigned to each study subject will not be known to either the Investigator or the patient."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "COVID-19"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "COVID-19",
                  "METABOLIC DRUG",
                  "Severe course of COVID-19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 3"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Triple",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"330",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Molixan",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"30 mg/ml solution for intravenous and intramuscular injection. Pharmacotherapeutic group: Metabolic agent. ATC code: V03AX - other medicinal products",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Molixan"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Sol. of NaCl (Sodium chloride) - 0.9% Pharmacotherapeutic group: Regulators of water-electrolytic balance and acid-base balance.\n\nATC: B05CB01 Sodium chloride",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Molixan",
                    "InterventionDescription":"The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: MolixanÂ® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Molixan"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Inosine glycyl-cysteinyl-glutamate disodium"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Placebo"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Sodium chloride"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"WHO Ordinal Scale for Clinical Improvement",
                    "PrimaryOutcomeDescription":"The median time to reach the clinical improvement on the WHO Ordinal Scale for Clinical Improvement (follow-up period 28 days after initiation of treatment) using hazard ratio estimates.",
                    "PrimaryOutcomeTimeFrame":"28 days"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Mortality",
                    "SecondaryOutcomeDescription":"All-cause mortality (follow-up period of 28 days after the start of treatment)",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Duration of hospitalization",
                    "SecondaryOutcomeDescription":"Duration of hospitalization from the start of therapy, days (observation period of 28 days after the start of treatment)",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Mechanical ventilation",
                    "SecondaryOutcomeDescription":"The need for mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation or high-flow oxygen delivery by nasal cannula (observation period of 28 days after the start of treatment).",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Time to cancellation of oxygen support",
                    "SecondaryOutcomeDescription":"Time to cancellation of oxygen support, if available, days (observation period of 28 days after the start of treatment)",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Invasive mechanical ventilation",
                    "SecondaryOutcomeDescription":"The need for invasive mechanical ventilation of the lungs (observation period of 28 days after the start of treatment)",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Stay in the intensive care unit",
                    "SecondaryOutcomeDescription":"The need to stay in the intensive care unit (observation period of 28 days after the start of treatment).",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"The transition of the disease to an extremely severe course",
                    "SecondaryOutcomeDescription":"The frequency of the transition of the disease to an extremely severe course (observation period of 28 days after the start of treatment).",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Fever",
                    "SecondaryOutcomeDescription":"Duration of fever (â‰¥38Ð¾C), days (observation period of 28 days after the start of treatment)",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"The dynamics of the National Early Warning Score (NEWS)",
                    "SecondaryOutcomeDescription":"The dynamics of the National Early Warning Score (NEWS) decrease in comparison with the baseline value (observation period of 10 days).\n\nNEWS uses six physiological measurements: respiratory rate; oxygen saturation; temperature; systolic blood pressure; heart rate and level of consciousness. Each scores 0-3 and individual scores are added together for an overall score. An additional one points are added if the patient is receiving oxygen therapy.\n\nHigher scores mean a worse outcome.",
                    "SecondaryOutcomeTimeFrame":"10 days"
                  },{
                    "SecondaryOutcomeMeasure":"The dynamics of changes in the level of C-reactive protein",
                    "SecondaryOutcomeDescription":"The dynamics of changes in the level of C-reactive protein compared with the baseline value (observation period of 10 days).",
                    "SecondaryOutcomeTimeFrame":"10 days"
                  },{
                    "SecondaryOutcomeMeasure":"The dynamics of residual symptoms",
                    "SecondaryOutcomeDescription":"The dynamics of residual symptoms compared to baseline values (observation period of 10 days).",
                    "SecondaryOutcomeTimeFrame":"10 days"
                  },{
                    "SecondaryOutcomeMeasure":"The dynamics of residual symptoms",
                    "SecondaryOutcomeDescription":"The dynamics of residual symptoms on the 28th day after the start of treatment.",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"The dynamics of blood biochemical parameters",
                    "SecondaryOutcomeDescription":"The dynamics of blood biochemical parameters in comparison with the initial value (observation period of 10 days) Any clinically significant deviations from laboratory parameters detected at visits after the first dosing of the drugs.\n\nBiochemical blood assay: urea, creatinine, glucose, alanine aminotransferase, aspartate aminotransferase, bilirubin, albumin, lactate, lactate dehydrogenase, troponin, ferritin.\n\nLocal laboratories of research centers will be used for laboratory tests and assessments.\n\nAfter collecting and verification 100% values of laboratory parameters according to the Protocol from all local laboratories, the units of measurement will be unified before Statistical process control by valid formulas for transitions.",
                    "SecondaryOutcomeTimeFrame":"10 days"
                  },{
                    "SecondaryOutcomeMeasure":"The dynamics of CT signs",
                    "SecondaryOutcomeDescription":"The dynamics of CT signs on the 14th day after the start of therapy compared with the baseline value.\n\nIn the conclusion CT study, a probabilistic assessment of the relationship of the detected changes with COVID 19 according to international recommendations and the approximate volume of lung damage according to the \"empirical\" scale of assessment shall be given.\n\nThe scale is based on a visual assessment of the approximate volume of compacted lung tissue in both lungs: 1. Absence of characteristic manifestations (CT-0) 2. Minimum volume/site < 25% of lung volume (CT-1) 3. Average volume/site 25 - 50% of lung volume (CT-2) 4. Significant volume/site 50 - 75% of lung volume (CT-3) 5. Critical volume/site > 75% of lung volume (CT-4).",
                    "SecondaryOutcomeTimeFrame":"14 days"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nHospitalized male and female patients aged 18 to 75 and weighing no more than 120 kg inclusively with a diagnosis of the severe course of COVID-19 confirmed by the result of a laboratory study for the presence of SARS-CoV-2 RNA using nucleic acid amplification methods (to be performed on Screening, or results with sampling 72 hours prior to Screening may be accepted);\nChanges in the lungs on CT (X-ray) typical for viral damage (the damage size is significant or subtotal; CT 3-4);\n\nOne or more criteria for a severe course:\n\nRR > 30/min\nSpO2 â‰¤ 93%\nPaO2 /FiO2 â‰¤ 300 mm Hg\nDecreased consciousness, agitation\nUnstable hemodynamics (systolic blood pressure less than 90 mm Hg or diastolic blood pressure less than 60 mm Hg, urine output less than 20 ml/hour)\nArterial blood lactate > 2 mmol/l\nqSOFA > 2 points\nSigned informed consent of the patient to participate in the study*;\n\nThe patient's ability to adequately cooperate (the ability to understand the information provided about the clinical study, the willingness to comply with the requirements of the study protocol)*;\n\n*In case of impossibility of the criteria No. 4 and 5 fulfilling the decision on including the patient shall be taken by a medical council. After the normalization of the status the patient shall compulsorily be proposed to acquaint themselves with the Patient Information Leaflet and take a decision on further participation in the study (Informed Consent Form signing) or withdrawal.\n\nFor women with preserved reproductive function - a negative pregnancy test and consent to use adequate methods of contraception from the moment of inclusion in the study until the end of the study;\nFor men - consent to use adequate methods of contraception from the moment of inclusion in the study to the end of the study.\n\nNon-inclusion criteria:\n\nPatients cannot be included in the study if at least one of the following criteria is met:\n\nAssociated with the underlying disease:\n\nMild, moderate and extremely severe COVID-19 disease upon admission to the hospital;\nA condition requiring invasive oxygen support;\n\nFailure to meet the criteria for inclusion and severity of the condition in terms of the main parameters;\n\nRelated to the investigational drug, prior and concomitant therapy:\n\nHypersensitivity or individual intolerance to the components of the investigational drug according to the history;\n\nTaking any antiviral or immunomodulatory drugs after the manifestation of COVID-19 (except for those planned for appointment as part of the study);\n\nAssociated with concomitant pathology:\n\nAccording to the history and physical examination:\n\nA history of active tuberculosis;\nImpossibility of intravenous administration of the drug;\n\nSevere, decompensated or unstable somatic diseases according to the history and outpatient card/medical history:\n\nChild-Pugh class B and C cirrhosis;\nMyocardial infarction, CVA/TIA, PE less than 3 months before the start of the study, large aortic aneurysm (more than 6 cm);\nType 1 diabetes mellitus. Diseases of the thyroid gland with decompensation.\nThe presence of signs of severe damage to the central nervous system (history of severe TBI, meningitis, consequences of CVA, encephalopathy of various origin, epilepsy, etc.);\nCurrent severe blood disorders or history of such diseases (i.e. baseline anemia Hb<80, myeloid leukemia, myelodysplastic syndrome, etc.);\nNo less than 3 months after the surgery for coronary artery bypass grafting/stenting before inclusion in the study;\nMalignant neoplasm of any localization at present or within 5 years prior to inclusion in the study, with the exception of completely healed carcinoma in situ;\n\nAny other comorbidities or conditions that, in the opinion of the investigator, make it difficult to interpret the results of treatment or may limit the patient's participation in the study;\n\nAccording to laboratory tests at screening:\n\nA positive result for HIV, syphilis, hepatitis B and C at screening;\n\nAssociated with the patient compliance in the study:\n\nA history of alcohol abuse, drug dependence or drug addiction;\nPatients who, in the opinion of the investigator, are obviously or likely to be unable to understand and evaluate the information on this study as part of the informed consent signing process, in particular regarding the expected risks and possible discomfort;\nPatient's inability or unwillingness to follow the rules for conducting and participating in the clinical study;\nSevere visual and/or hearing impairments, severe speech impairments and/or other abnormalities that may prevent the patient from adequately cooperating during the study;\n\nA history of mental illness;\n\nOther:\n\nPregnancy;\nBreast-feeding;\nParticipation in other clinical studies within 3 months prior to enrollment in this study.\n\nExclusion Criteria:\n\nErroneous inclusion (violation of inclusion/non-inclusion criteria).\nIndividual intolerance to the investigational drug.\nRefusal of the patient to continue participating in the study/withdrawal of informed consent by the patient.\nTermination of the study.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"75 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Mark Borisovich Balazovskij",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+7 (812) 714-10-10",
                    "CentralContactEMail":"vam@glutoxim.ru"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Viktor Borisovich Filimonov",
                    "OverallOfficialAffiliation":"Federal State Budgetary Educational Institution of Higher Education",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"All of the individual participant data collected during the trial, after deidentification",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol",
                  "Statistical Analysis Plan (SAP)",
                  "Informed Consent Form (ICF)",
                  "Clinical Study Report (CSR)",
                  "Analytic Code"
                ]
              },
              "IPDSharingTimeFrame":"Immediately following publication. No end date",
              "IPDSharingAccessCriteria":"Anyone who wishes to access the data."
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19074",
                    "ConditionBrowseLeafName":"Coronavirus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M24032",
                    "ConditionBrowseLeafName":"Severe Acute Respiratory Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T5186",
                    "ConditionBrowseLeafName":"Severe Acute Respiratory Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M20444",
                    "InterventionBrowseLeafName":"Pharmaceutical Solutions",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T5",
                    "InterventionBrowseLeafName":"Glutamic Acid",
                    "InterventionBrowseLeafAsFound":"Open reduction",
                    "InterventionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"PhSol",
                    "InterventionBrowseBranchName":"Pharmaceutical Solutions"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"AA",
                    "InterventionBrowseBranchName":"Amino Acids"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":9,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780659",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2021-000175-37"
              },
              "Organization":{
                "OrgFullName":"Karolinska University Hospital",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)",
              "OfficialTitle":"Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study",
              "Acronym":"COVAXID"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 23, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 31, 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 31, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 19, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Soo Aleman",
                "ResponsiblePartyInvestigatorTitle":"MD, PhD",
                "ResponsiblePartyInvestigatorAffiliation":"Karolinska Institutet"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Karolinska University Hospital",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Karolinska Institutet",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The study is designed as an open, non-randomized, phase IV cohort study in which the mRNA vaccine Comirnaty will be given in two doses. Analyses will be performed on blood and saliva, investigating humoral and cellular vaccine responses. Occurence of local or systemic reactogenicity will be evaluated, as well as adverse events. The study will include persons with primary or secondary immunosuppressive disorders, as well as immunocompetent persons, with the aim of investigating if the immune responses after given Comirnaty mRNA vaccine against COVID-19.",
              "DetailedDescription":"In this study with 450 patients with primary or secondary immunosuppressive disorders (patients with primary immunodeficiency, HIV infected patients, patients with allogenic stem cell transplantation/CAR T cell treated, solid organ transplanted, and patients with chronic lymphatic leukemia) from Karolinska University Hospital, and healthy controls of 90 individuals for comparison, we will investigate the safety and the immune responses after mRNA vaccination with Comirnaty after two doses, under 6 months of time for each participant. The study is In collaboration with research groups at Karolinska Institutet and SciLifeLab, with planned in-depth detailed analyses of antibody responses as well as cellular responses. The study has obtained permission from Swedish Medical Agency and Swedish Ethical Review Authority."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 4"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Prevention",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"540",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Vaccination with Comirnaty according to standard of care treatment",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"All study participants will receive Comirnaty according to current approval.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: Comirnaty (COVID-19, mRNA vaccine)"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Biological",
                    "InterventionName":"Comirnaty (COVID-19, mRNA vaccine)",
                    "InterventionDescription":"Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Vaccination with Comirnaty according to standard of care treatment"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "tozinameran",
                        "Pfizer mRNA vaccine"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Assessment of seroconversion, defined as development of immunoglobulin G (IgG) antibodies against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) after vaccination of 2 doses in seronegative individuals.",
                    "PrimaryOutcomeDescription":"Proportion (95% confidence interval, CI) seroconverting to positive response to SARS-CoV-2 IgG serology test after two doses of vaccine, measured 2 weeks after second dose of vaccine.",
                    "PrimaryOutcomeTimeFrame":"2 weeks after second dose of vaccine."
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Assessment of any Adverse Events (AE) of the given vaccine [Safety and tolerability].",
                    "SecondaryOutcomeDescription":"Proportion (95% CI) of study objects experiencing AE including reactogenicity, Serious Adverse Events (SAE), and Suspected Unexpected Serious Adverse Reaction (SUSAR).",
                    "SecondaryOutcomeTimeFrame":"Duration of 0-14 days after each given vaccine dose."
                  },{
                    "SecondaryOutcomeMeasure":"Frequency of SARS-CoV-2 infection documented by positive polymerase chain reaction (PCR) test.",
                    "SecondaryOutcomeDescription":"Proportion (95% CI) of study objects with SARS-CoV-2 infection.",
                    "SecondaryOutcomeTimeFrame":"Day 0 - 6 months."
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of humoral and cellular immune responses in blood and saliva.",
                    "SecondaryOutcomeDescription":"Description of humoral and cellular immune responses in blood and saliva at baseline, and at time points day 0 (first vaccine dose), day 10 after first dose, day 21 (second vaccine dose), and 2 weeks, 3 months and 6 months after the second vaccine dose.",
                    "SecondaryOutcomeTimeFrame":"Day 0- 6 months."
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of escape mutations of sequencing SARS-CoV-2 at breakthrough infection.",
                    "SecondaryOutcomeDescription":"Genomic sequencing of SARS-CoV-2 at breakthrough infection.",
                    "SecondaryOutcomeTimeFrame":"Day 0-6 months."
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of graft versus host disease in allogenic stem cell transplanted persons after given vaccine.",
                    "SecondaryOutcomeDescription":"Number of occurrence or worsening of graft versus host disease in allogenic stem cell transplanted persons after given vaccine will be described.",
                    "SecondaryOutcomeTimeFrame":"Day 0-6 months."
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of biopsy verified rejection in solid organ transplanted persons after given vaccine.",
                    "SecondaryOutcomeDescription":"Number of occurrence of biopsy verified rejection in solid organ transplanted persons after given vaccine.",
                    "SecondaryOutcomeTimeFrame":"Day 0-6 months."
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of viremia, defined as HIV ribonucleic acid (RNA) > 50 copies/milliliter after vaccination in HIV infected persons.",
                    "SecondaryOutcomeDescription":"Number of HIV infected persons with HIV ribonucleic acid (RNA) > 50 copies/milliliter after vaccination.",
                    "SecondaryOutcomeTimeFrame":"Day 0-6 months."
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of HIV deoxyribonucleic acid (DNA) levels after given vaccine in HIV infected persons.",
                    "SecondaryOutcomeDescription":"HIV DNA levels at baseline, and 3 and 6 months after second dose of vaccine.",
                    "SecondaryOutcomeTimeFrame":"Day 0-6 months."
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of oral and gut microbiota in immunosuppressed and controls, in relation to immune response to vaccination.",
                    "SecondaryOutcomeDescription":"Description of oral and fecal microbiota at baseline and association to immune responses.",
                    "SecondaryOutcomeTimeFrame":"Day 0-6 months."
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\n1. Individuals â‰¥18 years old\n\n2a. In the opinion of the investigator, individuals with immunosuppressive disease who meet one of the following criteria:\n\nPrimary immunodeficiency\nHuman immunodeficiency virus (HIV)-infection\nAllogeneic stem cell transplantation / Chimeric antigen receptor (CAR T cell) therapy\nSolid organ transplant\nChronic lymphatic leukemia\n\nor\n\n2b. In the opinion of the investigator, individuals without immunosuppressive disease or treatment without significant co-morbidity\n\n3. Provision of signed informed consent to participate in the study\n\nExclusion Criteria:\n\nPrevious or ongoing Coronavirus Disease-19 (COVID-19).\nCoagulation disorders, other conditions associated with prolonged bleeding time or anticoagulant treatments, which according to the investigator contraindicate intramuscular injection. Conditions which can be corrected with measures such as platelet concentrate treatments, coagulation factors or other measures for people responsible for anticoagulants are not exclusion criteria.\nPlanned to receive another vaccine within 14 days before the first dose of the study vaccine, or during the period from the first dose of the study vaccine up to 14 days after the second dose of the study vaccine, and vaccination with another vaccine which in the investigator's opinion cannot be planned outside these time periods\nPregnancy or breast feeding.\nHypersensitivity to the active substance or to any of the excipients contained in the vaccine\nIndividuals who cannot understand the informed consent.\nIndividuals who for other reasons are considered by investigators as not suitable for inclusion",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Soo Aleman, MD, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+46 72 595 7225",
                    "CentralContactEMail":"soo.aleman@sll.se"
                  },{
                    "CentralContactName":"Lena Dillner, MD, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+46 70 085 6871",
                    "CentralContactEMail":"lena.dillner@sll.se"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Soo Aleman, MD, PhD",
                    "OverallOfficialAffiliation":"Karolinska University Hospital, ME Infectious Diseases",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Karolinska University Hospital",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Stockholm",
                    "LocationState":"Huddinge",
                    "LocationZip":"14186",
                    "LocationCountry":"Sweden",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Soo Aleman, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+ 46 8 58 58 0000",
                          "LocationContactEMail":"soo.aleman@sll.se"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result. Will share research results and data through national COVID-19 data portal, operated by SciLifeLab Data Centre, Sweden.",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol",
                  "Statistical Analysis Plan (SAP)",
                  "Clinical Study Report (CSR)"
                ]
              },
              "IPDSharingTimeFrame":"Within one year after study end.",
              "IPDSharingAccessCriteria":"Published in EudraCT and national COVID-19 data portal (SciLifeLab Data Centre)",
              "IPDSharingURL":"https://eudract.ema.europa.eu/index.html"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8782",
                    "ConditionBrowseLeafName":"Immunologic Deficiency Syndromes",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC20",
                    "ConditionBrowseBranchName":"Immune System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000014612",
                    "InterventionMeshTerm":"Vaccines"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000007155",
                    "InterventionAncestorTerm":"Immunologic Factors"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M15943",
                    "InterventionBrowseLeafName":"Vaccines",
                    "InterventionBrowseLeafAsFound":"Active",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M8784",
                    "InterventionBrowseLeafName":"Immunologic Factors",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":10,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780646",
              "OrgStudyIdInfo":{
                "OrgStudyId":"Stadtnatur"
              },
              "Organization":{
                "OrgFullName":"Charite University, Berlin, Germany",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Effects of Urban Nature on Stress and Quality of Life",
              "OfficialTitle":"Effects of Urban Nature on Stress and Quality of Life of Subjects With Elevated Stress Levels - a Three-armed Randomized Controlled Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 15, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 15, 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 15, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 22, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Andreas Michalsen",
                "ResponsiblePartyInvestigatorTitle":"Prof. Dr.",
                "ResponsiblePartyInvestigatorAffiliation":"Charite University, Berlin, Germany"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Charite University, Berlin, Germany",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The aim of this study is to investigate the effects of regular nature therapy in urban nature with guidance of a licensed nature therapist on stress, quality of life and physical symptoms of subjects with elevated stress levels."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Stress, Psychological"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Nature therapy",
                  "Stress"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"93",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Nature therapy in urban nature",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Subjects receive a 90-minute nature therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Nature therapy in urban nature"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"City Walk",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Subjects receive a 90-minute city walk through urban sourroundings once per week for 8 weeks with a city guide, who talks about city architecture and gives information about the history of the surroundings.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: City Walk"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Waiting List",
                    "ArmGroupType":"No Intervention",
                    "ArmGroupDescription":"Subjects don't receive any therapy."
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"Nature therapy in urban nature",
                    "InterventionDescription":"Nature therapy means visits in nature, actively perceiving the flora and fauna",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Nature therapy in urban nature"
                      ]
                    }
                  },{
                    "InterventionType":"Behavioral",
                    "InterventionName":"City Walk",
                    "InterventionDescription":"City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "City Walk"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Stress questionnaire (Cohen Perceived Stress Scale, CPSS)",
                    "PrimaryOutcomeDescription":"Change from Baseline in the CPSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress.",
                    "PrimaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Zerssen symptom list (B-LR and B-LR')",
                    "SecondaryOutcomeDescription":"Assessing full scale, range 20-80, higher score meaning a better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"International Physical Activity Questionnaire (IPAQ)",
                    "SecondaryOutcomeDescription":"MET minutes represent the amount of energy expended carrying out physical activity. To get a continuous variable score from the IPAQ (MET minutes a week) we will consider walking to be 3.3 METS, moderate physical activity to be 4 METS and vigorous physical activity to be 8 METS; higher score meaning better outcome; range 0 to around 3000 MET minutes a week",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Maslach Burnout Inventory (MBI)",
                    "SecondaryOutcomeDescription":"Assessing full scale, range 0-96, higher score meaning a better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Mindfulness (Freiburger Fragebogen zur Achtsamkeit, FFA)",
                    "SecondaryOutcomeDescription":"Assessing full scale, range 0-56, higher score meaning a better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Multidimensional Assessment of Interoceptive Awareness (MAIA)",
                    "SecondaryOutcomeDescription":"Assessing full scale, range 0-160, higher score meaning a better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Perceived Benefits of Nature Questionnaire (PBNQ)",
                    "SecondaryOutcomeDescription":"mean score of the 11 items, range 1-7, lower score meaning a better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Insomnia Severity Index (ISI)",
                    "SecondaryOutcomeDescription":"Assessing full scale, range from 0-28, lower score meaning a better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Flourishing Scale (FS)",
                    "SecondaryOutcomeDescription":"Assessing full scale, range 8-56, higher score meaning a better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Depression-Fear-Stress-Scale (DASS)",
                    "SecondaryOutcomeDescription":"Assessing three subscales on depression, stress and fear; each ranging from 0-21, lower score meaning a better outcome betrÃ¤gt 10, fÃ¼r Angst ist ein CutOff von 6, fÃ¼r Stress ein Wert von 10 sinnvoll",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Awe and Gratitude (GrAw-7)",
                    "SecondaryOutcomeDescription":"Assessing 7 items, referring them to a 100% scale (transferred scale score) - Assessing full score, the scores can be referred to a 100% level (transformed scale score), higher score meaning better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Inner Correspondence and feelings of Peaceful Relief (ICPH)",
                    "SecondaryOutcomeDescription":"Assessing full score, the scores can be referred to a 100% level (transformed scale score), which reflects the degree of inner congruence, higher score meaning better outcome",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Sociodemographic Measurements",
                    "SecondaryOutcomeDescription":"Age, gender, marital status, number of people in household, education level, employment status, job, personal net income, household income",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Behavioural questions: doctor visits and health",
                    "SecondaryOutcomeDescription":"amount of doctor visits, amount of sick leave days in the last 2 months",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Expectation questions",
                    "SecondaryOutcomeDescription":"for intervention 1 and 2 on a 6-point likert scale from 1 (very strong) to 6 (nothing at all)",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Behavioural questions: cigarette consumption",
                    "SecondaryOutcomeDescription":"Number of cigarettes on average per day in the last month",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Behavioural questions: alcohol consumption",
                    "SecondaryOutcomeDescription":"Number of alcoholic beverages on average per week in the last month",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Behavioural questions: time in nature",
                    "SecondaryOutcomeDescription":"amount of hours spent in nature per week in the last month",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Behavioural questions: nature as priority",
                    "SecondaryOutcomeDescription":"if spending time in nature is seen as a priority on a 6-point likert scale 1 (very strong) to 6 (nothing at all)",
                    "SecondaryOutcomeTimeFrame":"Date of Inclusion (Baseline), after 8 weeks and after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Heart Rate (HR)",
                    "SecondaryOutcomeDescription":"24h measuring by smartwatch",
                    "SecondaryOutcomeTimeFrame":"Date of inclusion (baseline), after 8 weeks, after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Heart Rate Variability (HRV)",
                    "SecondaryOutcomeDescription":"24h measuring by smartwatch",
                    "SecondaryOutcomeTimeFrame":"Date of inclusion (baseline), after 8 weeks, after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Interbeat Interval (IBI)",
                    "SecondaryOutcomeDescription":"24h measuring by smartwatch",
                    "SecondaryOutcomeTimeFrame":"Date of inclusion (baseline), after 8 weeks, after 16 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of steps",
                    "SecondaryOutcomeDescription":"24h measuring by smartwatch",
                    "SecondaryOutcomeTimeFrame":"Date of inclusion (baseline), after 8 weeks, after 16 weeks"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Qualitative interviews in focus groups interviews",
                    "OtherOutcomeDescription":"Qualitative assessment will be carried out in 45-minute focus group interviews in 20 (randomized selected) patients participating in the study. The interviews will be recorded, transcribed and analyzed with qualitative content analysis.",
                    "OtherOutcomeTimeFrame":"16 weeks after inclusion"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nstress with at least 4 of 10 points on the Numeric Analogue Scale (NAS) at least 1 month\nat least 3 of the following 8 stress-associated symptoms: sleep disturbances, inappetence or increased appetite, shoulder neck tension/back pain, tension headache, concentration disturbances, exhaustion, nervousness/irritability, stress-associated digestive complaints.\n\nExclusion Criteria:\n\nserious acute or chronic diseases\npregnancy or lactation\nknown serious mental illness\nimmobility or restriction for gymnastics exercises due to orthopaedic, neurological or other medical cause\nparticipation in another study",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"70 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Miriam RÃ¶sner",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"00493080505682",
                    "CentralContactEMail":"m.roesner@immanuel.de"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Andreas Michalsen, Prof. Dr.",
                    "OverallOfficialAffiliation":"CharitÃ© Hochschulambulanz fÃ¼r Naturheilkunde am Immanuel Krankenhaus",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000013315",
                    "ConditionMeshTerm":"Stress, Psychological"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000001526",
                    "ConditionAncestorTerm":"Behavioral Symptoms"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M14688",
                    "ConditionBrowseLeafName":"Stress, Psychological",
                    "ConditionBrowseLeafAsFound":"Stress, Psychological",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3399",
                    "ConditionBrowseLeafName":"Behavioral Symptoms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T6034",
                    "ConditionBrowseLeafName":"Quality of Life",
                    "ConditionBrowseLeafAsFound":"Quality of Life",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":11,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780633",
              "OrgStudyIdInfo":{
                "OrgStudyId":"Approval No: 2017-3/20"
              },
              "Organization":{
                "OrgFullName":"Ataturk University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"PRECEDE-PROCEED Model-based Program on Genital Hygiene Behaviors",
              "OfficialTitle":"The Effects of a PRECEDE-PROCEED Model-based Program on Genital Hygiene Behaviors: A Randomized Controlled Trial"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"June 15, 2017",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"September 30, 2017",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"October 15, 2017",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 21, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Manolya Parlas",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Ataturk University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Ataturk University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The study was conducted to investigate the effect of a training program based on the PRECEDE-PROCEED Model on improving genital hygiene behaviors.It was carried out using experimental research design with pre-test and post-test, randomized and a control group. The study was conducted at Erzurum Saltuklu Family Health Center between June 2017 and January 2018. Of the women with genital infections, 120 women were included in the study, of which 60 were in the experimental group and 60 were in the control group. The data were collected by \"Personal Information Form,\" \"Genital Hygiene Knowledge, Attitude and Beliefs, Questionnaire\" and \"Genital Hygiene Behavior Inventory\". In study, genital hygiene training intervention prepared according to the Precede-Proceed model was applied to the women in the experimental group. The women in the experimental group were measured at three different times: pre-test before training, post-test through training completition, and follow-up test after 4 weeks. The women in the control group did not receive any training intervention, the pre-test at the first encounter in the family health center and the post-test 5 weeks later."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Genital Infection Female"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Genital hygiene behavior",
                  "Women's health",
                  "Precede-Proceed model",
                  "Health education",
                  "Nursing"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Supportive Care",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"120",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Precede-Proceed based Training Program",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"The experimental group is the group in which five training sessions interventions are applied.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Precede-Proceed based Training Program on Genital Hygiene Behaviors"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Control group",
                    "ArmGroupType":"No Intervention",
                    "ArmGroupDescription":"The control group is the group in which have no educational intervention."
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"Precede-Proceed based Training Program on Genital Hygiene Behaviors",
                    "InterventionDescription":"A Training Program for Genital Hygiene Behaviors prepared in line with the Precede-Proceed model was presented to the women in the experimental group. The trainings started one week after the pre-test data were collected and were conducted in a total of 5 sessions, each lasting an average of 40 minutes, once a week. At the end of the five-week training, a post-test was applied. In order to determine the behavior changes of the women in the experimental group, a follow-up test was applied 4 weeks after the training ended. At the end of the training, women were given a training booklet prepared by the researcher.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Precede-Proceed based Training Program"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"H1 hypothesis: PRECEDE-PROCEED training-based program affects on improving genital hygiene behavior.",
                    "PrimaryOutcomeDescription":"Linear regression analysis was performed to determine the factors that are independently effective in determining the Genital Hygiene Behavior Inventory (GHBI) score differences between the pre-test and post-test measurements of the women in the experimental group.",
                    "PrimaryOutcomeTimeFrame":"5 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nBetween the ages of 18-49,\nmarried,\nAt least primary school graduate,\nNo mental and communication problems,\nNo chronic disease,\nNon-pregnant.\n\nExclusion Criteria:\n\nWomen who have entered menopause,\nWomen who had received any training on genital hygiene before",
              "HealthyVolunteers":"No",
              "Gender":"Female",
              "GenderBased":"Yes",
              "GenderDescription":"This study was conducted women who diagnosed with genital infections.",
              "MinimumAge":"18 Years",
              "MaximumAge":"49 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Manolya Parlas",
                    "LocationCity":"Izmir",
                    "LocationState":"None Selected",
                    "LocationZip":"35210",
                    "LocationCountry":"Turkey"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":12,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780620",
              "OrgStudyIdInfo":{
                "OrgStudyId":"098-2020"
              },
              "Organization":{
                "OrgFullName":"Centre for Addiction and Mental Health",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Pilot Trial of a Group Intervention to Decrease Parent-Adolescent Conflict",
              "OfficialTitle":"Addressing Parent-Adolescent Relationship Issues in the Treatment of Adolescent Depression: A Pilot Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"March 2023",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 2023",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Madison Aitken",
                "ResponsiblePartyInvestigatorTitle":"Clinician Investigator at Cundill Centre for Child and Youth Depression; Psychologist in the Child, Youth and Emerging Adult Program",
                "ResponsiblePartyInvestigatorAffiliation":"Centre for Addiction and Mental Health"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Centre for Addiction and Mental Health",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This pilot randomized control trial investigates whether a psychosocial intervention targeting parent-adolescent conflict is feasible and acceptable, in preparation for a future trial that will test whether the intervention can improve treatment outcomes for youth diagnosed with depression.",
              "DetailedDescription":"Parent involvement in psychosocial interventions for youth diagnosed with internalizing disorders has been cited as a contributor to better outcomes for these youth, and parent components have been included in several evidence-based interventions for adolescent mental health problems. Additionally, youth experiencing mood and behaviour changes that come about as a result of a depressive episode can lead to frustrated/overprotective reactions from parents, which can contribute to worse outcomes for these adolescents. Interventions focused on addressing parent-adolescent conflict and reducing negative interactions can potentially support recovery from depression and reduce episode relapse. However, there is very little research on including parent components in psychosocial interventions specifically aimed at youth depression. This randomized control trial aims to fill this gap by randomizing parents of youth receiving treatment for depression into either 1) an 8-week virtual or in-person group parent intervention, or 2) usual care.\n\nParticipants will be parents or caregivers (for simplicity, the term \"parent\" is used to refer to parents or caregivers) of adolescents aged 13-18 with depression who are part of the care pathway for youth depression at a mental health research hospital in Toronto, Canada. Their adolescents will also participate in the study in order to provide multi-informant data; however, should adolescents decline to participate in the study, their parent will still be able to take part.\n\nParents and adolescents will complete a combination of questionnaire, interview, and observationally coded measures at pre- and posttreatment, along with questionnaire measures at mid-treatment and 3 months follow-up."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Depression"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "youth depression",
                  "adolescent depression",
                  "psychosocial intervention",
                  "parent-adolescent conflict"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Supportive Care",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignMaskingDescription":"Research personnel involved in data collection will be blind to participants' treatment condition (single blind). In addition, coders for the interaction task and speech sample will be blind to treatment condition (intervention versus control) and measurement time point (baseline vs. posttreatment).",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"60",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Parent Intervention Group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"The parent intervention group will undergo 8 weekly, manualized group sessions, with between 6 and 10 parent participants. Sessions are structured and follow an agenda including check-in and review of home practice, discussion of a skill or strategy, and review and assignment of home practice. Group sessions are held weekly for 1.5 hours and include both didactic, discussion, and practice elements, as well as assigned home practice.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Parent Intervention Group"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Usual Care Group",
                    "ArmGroupType":"No Intervention",
                    "ArmGroupDescription":"Parents in the usual care condition will be involved in their adolescent's care as is standard in our clinical program. With adolescent consent, parents are invited to participate in a single, 2-hour orientation session for parents/caregivers that provides information about depression, as well as the role of sleep, diet, and exercise in improving mood. Based on adolescent preference, parents can also attend regular psychiatric appointments with their adolescent, in which they will receive further information about depression and may receive and provide information about their adolescent's depression symptoms and response to psychosocial and pharmacological interventions. This control condition will allow us to determine whether the parent intervention is more effective than a relevant clinical alternative."
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Parent Intervention Group",
                    "InterventionDescription":"Parents will be involved in 8 weekly sessions.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Parent Intervention Group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Feasibility Outcomes",
                    "PrimaryOutcomeDescription":"Feasibility defined as:\n\nParticipant recruitment rates, retention in the study, and completion of measures across time points\nParent satisfaction with the intervention\nParent attendance at the group and dropout from the group\nClinician fidelity to the intervention",
                    "PrimaryOutcomeTimeFrame":"2 years (study duration)"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Parent Expressed Emotion",
                    "SecondaryOutcomeDescription":"Parent report on the Family Questionnaire; Adolescent report on the Level of Expressed Emotion questionnaire; Observational coding of parent Five Minute Speech Sample",
                    "SecondaryOutcomeTimeFrame":"Pre-, mid- (4 weeks), and post-treatment (8 weeks), and at 3-month follow-up"
                  },{
                    "SecondaryOutcomeMeasure":"Parent Affective Responding",
                    "SecondaryOutcomeDescription":"Parent and adolescent report on the Coping with Children's Negative Emotions Scale and the Responding to Adolescents' Happy Affect Scale",
                    "SecondaryOutcomeTimeFrame":"Pre-, mid- (4 weeks), and post-treatment (8 weeks), and at 3-month follow-up"
                  },{
                    "SecondaryOutcomeMeasure":"Parent-Adolescent Conflict",
                    "SecondaryOutcomeDescription":"Parent and adolescent report on the Issues Checklist",
                    "SecondaryOutcomeTimeFrame":"Pre-, mid- (4 weeks), and post-treatment (8 weeks), and at 3-month follow-up"
                  },{
                    "SecondaryOutcomeMeasure":"Parent-Adolescent Interaction",
                    "SecondaryOutcomeDescription":"Observational coding of parent-adolescent discussion of a topic of conflict (drawn from the Issues Checklist), coded using the System for Coding Interactions in Family Functioning",
                    "SecondaryOutcomeTimeFrame":"Pre- & post-treatment (8 weeks)"
                  },{
                    "SecondaryOutcomeMeasure":"Adolescent depression",
                    "SecondaryOutcomeDescription":"Adolescent self-report on the Mood and Feelings Questionnaire",
                    "SecondaryOutcomeTimeFrame":"Pre-, mid- (4 weeks), and post-treatment (8 weeks), and at 3-month follow-up"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nparent/caregiver of an adolescent aged 13-18 years\nadolescent is part of care pathway for depression at the time of the referral to the parent group\nadolescent has a primary diagnosis of a depressive disorder (Major Depressive Disorder and/or Persistent Depressive Disorder) according to their clinician, and a self-reported score of 23 or higher on the Mood and Feelings Questionnaire\nparent or youth endorse problematic levels of conflict in their relationship, having either: a) a total score of 9 or greater on the adolescent version, or a total score of 11 or greater on the parent version, of the 20-item Conflict Behavior Questionnaire; or b) a rating of 2 or higher on item 2 or 3 (Item 2 \"getting along with your mother/mother figure;\" item 3 \"getting along with your father/father figure\") of the youth-report version of the Columbia Impairment Scale\nboth parent and adolescent speak, read, and write English at a Grade 6 level or above\n\nExclusion Criteria:\n\nthe adolescent's primary diagnosis is not depression, based on information in their health record\nthe adolescent has been diagnosed with bipolar disorder (I or II), schizophrenia, moderate-severe eating disorder, moderate-severe substance use disorder, or an intellectual disability (as the clinical and family needs of these adolescents are not likely to be sufficiently addressed by a general group for parents of adolescents with depression), or requires immediate hospitalization for suicide risk\nthe parent/caregiver does not consent to participate\n(specific only to the virtual format of the study) the parent is not comfortable communicating via email or using WebEx for virtual appointments (as the use of WebEx and email is required for study visits and for participation in the parent intervention)",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"13 Years",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Madison Aitken, Ph.D.",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"416-535-8501",
                    "CentralContactPhoneExt":"34091",
                    "CentralContactEMail":"madison.aitken@camh.ca"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Madison Aitken, Ph.D.",
                    "OverallOfficialAffiliation":"Centre for Addiction and Mental Health",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Centre for Addiction and Mental Health",
                    "LocationCity":"Toronto",
                    "LocationState":"Ontario",
                    "LocationZip":"M6J 1H4",
                    "LocationCountry":"Canada",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Madison Aitken, Ph.D.",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"416-535-8501",
                          "LocationContactPhoneExt":"34091",
                          "LocationContactEMail":"madison.aitken@camh.ca"
                        },{
                          "LocationContactName":"Yola El Dahr, M.Sc.",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"yola.eldahr@camh.ca"
                        },{
                          "LocationContactName":"Madison Aitken, Ph.D.",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No",
              "IPDSharingDescription":"Sharing IPD has not currently been approved by our Research Ethics Board and would also require a data sharing agreement."
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003863",
                    "ConditionMeshTerm":"Depression"
                  },{
                    "ConditionMeshId":"D000003866",
                    "ConditionMeshTerm":"Depressive Disorder"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000001526",
                    "ConditionAncestorTerm":"Behavioral Symptoms"
                  },{
                    "ConditionAncestorId":"D000019964",
                    "ConditionAncestorTerm":"Mood Disorders"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5641",
                    "ConditionBrowseLeafName":"Depression",
                    "ConditionBrowseLeafAsFound":"Depression",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5644",
                    "ConditionBrowseLeafName":"Depressive Disorder",
                    "ConditionBrowseLeafAsFound":"Depression",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3399",
                    "ConditionBrowseLeafName":"Behavioral Symptoms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20419",
                    "ConditionBrowseLeafName":"Mood Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":13,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780607",
              "OrgStudyIdInfo":{
                "OrgStudyId":"MARS"
              },
              "Organization":{
                "OrgFullName":"Beijing Anzhen Hospital",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Outcomes of Mitral Valve Surgery in Patients Affected by Rheumatic Heart Disease",
              "OfficialTitle":"Multicenter Results of Mitral Valve Surgery in Patients With Rheumatic Heart Disease"
            },
            "StatusModule":{
              "StatusVerifiedDate":"January 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 1, 2011",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"January 1, 2024",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"April 1, 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Xu Meng",
                "ResponsiblePartyInvestigatorTitle":"NO.9 department of Cardiac surgery center",
                "ResponsiblePartyInvestigatorAffiliation":"Beijing Anzhen Hospital"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Beijing Anzhen Hospital",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"Yes"
            },
            "DescriptionModule":{
              "BriefSummary":"rheumatic heart disease remains the majority valvular disease in low and middle income countries, which mostly affected mitral valve, surgical treatment is the most effective strategy to improve the outcomes of middle or late-stage RHD patient, however, whether mitral valve repair surgery is superior to replacement or other evolving interventional device remains controversial, this study aims to investigate the results of repair surgery compared with replacement or other treatment strategy from international multicenters."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Outcomes of Mitral Valve Surgery in Patients Affected by Rheumatic Heart Disease"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "rheumtic heart disease",
                  "mitral valve surgery"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"Yes",
              "TargetDuration":"10 Years",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"4000",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Device",
                    "InterventionName":"mitral valve repair",
                    "InterventionDescription":"different repair techniques to construct rheumatic mitral valve lesion"
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"all-cause mortality",
                    "PrimaryOutcomeDescription":"death from any cause",
                    "PrimaryOutcomeTimeFrame":"2011-2024"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\n1ã€rheumatic heart disease 2ã€mitral valve disease 3ã€combined with other heart valve disease(aortic valve, tricuspid valve, pulmonary valve) 4ã€patients underwent initial mitral valve surgery or intervention\n\nExclusion Criteria:\n\n1ã€congenital heart disease degenerative heart valve disease 2ã€isolated aortic valve or tricuspid valve, pulmonary valve disease( doesn't affect mitral valve ) 3ã€patients received more than 1 time mitral valve operation",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"patients with rheumatic heart disease\nmitral valve disease\npatients underwent initial mitral valve surgery or intervention",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"xu meng, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactEMail":"mengxu191116@163.com"
                  },{
                    "CentralContactName":"jintao fu, MD, postdoctor",
                    "CentralContactRole":"Contact",
                    "CentralContactEMail":"doctorfu0709@126.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"xu meng, MD",
                    "OverallOfficialAffiliation":"Beijing Anzhen Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Beijing Anzhen Hospital",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Beijing",
                    "LocationState":"Beijing",
                    "LocationZip":"100086",
                    "LocationCountry":"China",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"xu meng, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"mengxu191116@163.com"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000012214",
                    "ConditionMeshTerm":"Rheumatic Heart Disease"
                  },{
                    "ConditionMeshId":"D000012216",
                    "ConditionMeshTerm":"Rheumatic Diseases"
                  },{
                    "ConditionMeshId":"D000006331",
                    "ConditionMeshTerm":"Heart Diseases"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  },{
                    "ConditionAncestorId":"D000009140",
                    "ConditionAncestorTerm":"Musculoskeletal Diseases"
                  },{
                    "ConditionAncestorId":"D000003240",
                    "ConditionAncestorTerm":"Connective Tissue Diseases"
                  },{
                    "ConditionAncestorId":"D000012213",
                    "ConditionAncestorTerm":"Rheumatic Fever"
                  },{
                    "ConditionAncestorId":"D000013290",
                    "ConditionAncestorTerm":"Streptococcal Infections"
                  },{
                    "ConditionAncestorId":"D000016908",
                    "ConditionAncestorTerm":"Gram-Positive Bacterial Infections"
                  },{
                    "ConditionAncestorId":"D000001424",
                    "ConditionAncestorTerm":"Bacterial Infections"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M13626",
                    "ConditionBrowseLeafName":"Rheumatic Heart Disease",
                    "ConditionBrowseLeafAsFound":"Rheumatic Heart Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13628",
                    "ConditionBrowseLeafName":"Rheumatic Diseases",
                    "ConditionBrowseLeafAsFound":"Rheumatic",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8002",
                    "ConditionBrowseLeafName":"Heart Diseases",
                    "ConditionBrowseLeafAsFound":"Heart Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4906",
                    "ConditionBrowseLeafName":"Collagen Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10680",
                    "ConditionBrowseLeafName":"Musculoskeletal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5047",
                    "ConditionBrowseLeafName":"Connective Tissue Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7047",
                    "ConditionBrowseLeafName":"Fever",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13625",
                    "ConditionBrowseLeafName":"Rheumatic Fever",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14663",
                    "ConditionBrowseLeafName":"Streptococcal Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3303",
                    "ConditionBrowseLeafName":"Bacterial Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M17835",
                    "ConditionBrowseLeafName":"Gram-Positive Bacterial Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T4999",
                    "ConditionBrowseLeafName":"Rheumatic Fever",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T163",
                    "ConditionBrowseLeafName":"Acute Articular Rheumatism",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC05",
                    "ConditionBrowseBranchName":"Muscle, Bone, and Cartilage Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC17",
                    "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":14,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780594",
              "OrgStudyIdInfo":{
                "OrgStudyId":"COVID19 surgical impact"
              },
              "Organization":{
                "OrgFullName":"Hospital Universitari de Bellvitge",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University Hospital",
              "OfficialTitle":"Impact of the SARS-CoV-2 (COVID-19) Pandemic on the Morbidity and Mortality of Patients Undergoing Surgery at Bellvitge University Hospital"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 13, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"May 15, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 9, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Marta Caballero Milan",
                "ResponsiblePartyInvestigatorTitle":"Medical Staff in Anaesthesiology and Reanimation",
                "ResponsiblePartyInvestigatorAffiliation":"Hospital Universitari de Bellvitge"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Hospital Universitari de Bellvitge",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"COVID-19 has been a challenge for hospitals; there was an obvious need to reconvert many spaces in specific areas to attend this pathology, without forgetting the attention to other pathologies and surgery. The objective of the investigators is to evaluate the impact of this pandemic in the patients who underwent surgery in Bellvitge University Hospital, analyzing 2 periods of time: the months before the COVID-19 peak and the COVID-19 peak months.",
              "DetailedDescription":"A total of 2.530 procedures have been evaluated in this retrospective observational study. Two groups have been generated (pre-pandemic period and pandemic period), classified into scheduled and emergency surgery. The investigators determined age, type of surgery and specialty, hospital stay, destination at discharge including mortality and severity according to Diagnostic Related to Group (DRG) scale. The investigators have also determined the number of confirmed COVID-19 infections in patients who underwent surgery during these 2 periods and evaluated if the infection was due to a nosocomial infection (confirmation of the COVID-19 during the hospitalization period). Comparisons were made between subgroups: scheduled surgery performed during the 2 periods and emergency surgery performed during the 2 periods."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19",
                  "Surgery--Complications",
                  "Nosocomial Infection"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "COVID19",
                  "Hospital stay",
                  "mortality",
                  "surgery complications",
                  "scheduled surgery",
                  "emergency surgery"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Crossover"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Retrospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"2530",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Pre-pandemic COVID-19 group (PreCOVID)",
                    "ArmGroupDescription":"All patients who underwent surgery from 13th January until 29th February 2020, which are considered free of COVID-19 patients, therefore pre-pandemic period.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: The study evaluates all surgical patients operated, both elective scheduled and emergent cases"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Pandemic COVID-19 group (COVID)",
                    "ArmGroupDescription":"All patients who underwent surgery from 11th March 2020 until 15th May 2020, which were done during the first wave of the pandemic crisis.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: The study evaluates all surgical patients operated, both elective scheduled and emergent cases"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"The study evaluates all surgical patients operated, both elective scheduled and emergent cases",
                    "InterventionDescription":"Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Pandemic COVID-19 group (COVID)",
                        "Pre-pandemic COVID-19 group (PreCOVID)"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Register the post-surgical complications",
                    "PrimaryOutcomeDescription":"Register and Compare the Rate of Surgical Reintervention between both periods.",
                    "PrimaryOutcomeTimeFrame":"PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020."
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Register the rate of surgical reintervention",
                    "SecondaryOutcomeDescription":"Register and compare the Rate of reintervention between both periods.",
                    "SecondaryOutcomeTimeFrame":"PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020."
                  },{
                    "SecondaryOutcomeMeasure":"Register the ICU admission",
                    "SecondaryOutcomeDescription":"register and compare the ICU admission between both periods.",
                    "SecondaryOutcomeTimeFrame":"PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020."
                  },{
                    "SecondaryOutcomeMeasure":"Register the Hospital stay",
                    "SecondaryOutcomeDescription":"register and compare the ICU admission between both periods.",
                    "SecondaryOutcomeTimeFrame":"PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020."
                  },{
                    "SecondaryOutcomeMeasure":"Register the Mortality",
                    "SecondaryOutcomeDescription":"register and compare the Mortality between both periods.",
                    "SecondaryOutcomeTimeFrame":"PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020."
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAll surgical patients operated, both elective scheduled and emergent cases\n\nExclusion Criteria:\n\nMinor-intermediate surgery that involves discharge from the hospital on the same day of the surgery from the Pre-pandemic period.\nProcedures related to medical treatment or complications of COVID-19 patients, such as chest tubes, extracorporeal oxygenation or tracheostomy.\nThose scheduled elective surgery patients in the Covid period that resulted RT-PCR positive, surgery was posponed, were not considered eligible for the analysis.",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"The requirement to include patients was that they required surgery, either urgent or scheduled, during the periods described (PreCOVID and COVID). As there is no paediatric service in the hospital, the minimum age of the sample is 18 years old but there is no maximum age for inclusion.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Maria Jose MJ Colomina, PhD",
                    "OverallOfficialAffiliation":"Head of the Department",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Marta Caballero",
                    "LocationCity":"Hospitalet de Llobregat",
                    "LocationState":"Barcelona",
                    "LocationZip":"08907",
                    "LocationCountry":"Spain"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DocumentSection":{
            "LargeDocumentModule":{
              "LargeDocList":{
                "LargeDoc":[
                  {
                    "LargeDocTypeAbbrev":"Prot_SAP",
                    "LargeDocHasProtocol":"Yes",
                    "LargeDocHasSAP":"Yes",
                    "LargeDocHasICF":"No",
                    "LargeDocLabel":"Study Protocol and Statistical Analysis Plan",
                    "LargeDocDate":"May 27, 2020",
                    "LargeDocUploadDate":"02/03/2021 12:32",
                    "LargeDocFilename":"Prot_SAP_000.pdf"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003428",
                    "ConditionMeshTerm":"Cross Infection"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000007239",
                    "ConditionAncestorTerm":"Infection"
                  },{
                    "ConditionAncestorId":"D000007049",
                    "ConditionAncestorTerm":"Iatrogenic Disease"
                  },{
                    "ConditionAncestorId":"D000020969",
                    "ConditionAncestorTerm":"Disease Attributes"
                  },{
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5225",
                    "ConditionBrowseLeafName":"Cross Infection",
                    "ConditionBrowseLeafAsFound":"Nosocomial Infection",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6379",
                    "ConditionBrowseLeafName":"Emergencies",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8682",
                    "ConditionBrowseLeafName":"Iatrogenic Disease",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21284",
                    "ConditionBrowseLeafName":"Disease Attributes",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T4202",
                    "ConditionBrowseLeafName":"Oculocerebral Syndrome With Hypopigmentation",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":15,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780581",
              "OrgStudyIdInfo":{
                "OrgStudyId":"MP3-pulses-COVID-19"
              },
              "Organization":{
                "OrgFullName":"FundaciÃ³n Instituto de Estudios de Ciencias de la Salud de Castilla y LeÃ³n",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients",
              "OfficialTitle":"MP3-pulses-COVID-19. Methylprednisolone Pulses Versus Dexamethasone According RECOVERY Protocol in Patients With Pneumonia Due to SARS-COV-2 Coronavirus Infection"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 1, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 1, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 31, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 15, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"FundaciÃ³n Instituto de Estudios de Ciencias de la Salud de Castilla y LeÃ³n",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Instituto de InvestigaciÃ³n BiomÃ©dica de Salamanca",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Treatment with glucocorticoids in COVID patients. Low-intervention, phase IV, open-label, randomised, low-intervention clinical trial comparing 2 active treatments.",
              "DetailedDescription":"The use of high-dose bolus glucocorticoids in the treatment of patients with COVID-19 infection will increase the anti-inflammatory effect without increasing side effects. This will allow a better patient outcome, reducing the number of deaths and the need for intubation or admission to the Intensive Care Unit."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Corona Virus Infection"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 4"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"Open-label, randomised clinical trial comparing 2 active treatments.",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"290",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"RECOVERY",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"intermediate-dose dexamethasone (6mg/24h - 10 days)",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Dexamethasone"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"BOLUS",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"high-dose methylprednisolone bolus (250mg/4h - 3 days)",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Methylprednisolone"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Dexamethasone",
                    "InterventionDescription":"6 mg/24h - 10 days",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "RECOVERY"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Recovery"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Methylprednisolone",
                    "InterventionDescription":"250 mg/ 24h - 3 days",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "BOLUS"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Bolus"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Mortality rate in COVID-19 patients after high-dose methylprednisolone bolus administration versus mortality rate intermediate-dose dexamethasone pattern (RECOVERY trial)",
                    "PrimaryOutcomeDescription":"Mortality rate (percentage)",
                    "PrimaryOutcomeTimeFrame":"28 days"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Admission in Intensive Unit Care (ICU)",
                    "SecondaryOutcomeDescription":"Incidence of ICU admission",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Evaluation of respiratory support requirements",
                    "SecondaryOutcomeDescription":"Proportion of patients (number of cases with respiratory support requirement / total number of patients) with non-invasive mechanical ventilation and/or high-flow oxygen requirements.\nProportion of patients (number of cases with respiratory support requirement / total number of patients) with invasive mechanical ventilation or intubation requirements.",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Days in hospital",
                    "SecondaryOutcomeDescription":"Number of days in hospital from the star of the treatment until discharge",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Evaluation of presence of adverse events related with use of high dose of glucocorticoids.",
                    "SecondaryOutcomeDescription":"Presence or absence of adverse effects (infections, hyperglycaemia, psychotic states or other adverse effects).\nIncidence of infections, hyperglycaemia, psychotic states or other adverse effects, if applicable",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Evaluation of other immunosuppressors requirements.",
                    "SecondaryOutcomeDescription":"Occurrence of use of other immunosuppressors (active substance, dose, duration, if applicable)",
                    "SecondaryOutcomeTimeFrame":"28 days"
                  },{
                    "SecondaryOutcomeMeasure":"Status according to the World Health Organization (WHO) 10-category scale.",
                    "SecondaryOutcomeDescription":"Clinical evaluation of patient status according to the WHO 10-category scale.",
                    "SecondaryOutcomeTimeFrame":"3 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nOver 18 years of age\nInpatient\nDiagnosis of SARS-CoV-2 infection confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or antigen\nThey present evidence in computerized axial tomography (CT) of pulmonary involvement attributed to the infection by COVID. Patients in whom CT scans are not performed must have suspected pulmonary involvement by clinical examination with simple compatible or suggestive radiology.\nRequires supplementary oxygen due to basal saturation â‰¤ 93% (with ambient O2, 21%)\n\nExclusion Criteria:\n\nThe patient's situation is so serious that the doctor in charge thinks he could die within 24 hours.\n\nAt the time of randomisation, patients require one of the following 4 ventilatory supports:\n\nhigh-flow oxygen devices.\nnon-invasive mechanical ventilation.\ninvasive mechanical ventilation.\nExtracorporeal membrane oxygenation (ECMO).\nThe patient is or has been treated in the 2 weeks prior to randomisation with glucocorticoids or inflammation modifying drugs, both conventional (thiopurines, cyclophosphamide, cyclosporine, tacrolimus), leflunomide, methotrexate, mycophenolate mofetil/mycophenolic acid, sulfasalazine, hydroxychloroquine or chloroquine) as synthetics or biologics directed against therapeutic targets (abatacept, belimumab, CD-20, IL1, IL6, Il12. 23, IL-23, Il.17, TNF, integrin Î±4Î²7 or Janus kinase inhibitors JAK). Patients who are only on maintenance treatment with doses of steroids less than or equal to 7.5 mg of prednisone or equivalent per day will not be excluded.\nThe patient is pregnant or breastfeeding.\nThe patient has a chronic renal disease is stage 4 or 5 (CCr <30 ml/min).\nModerate to severe dementia at the investigator's discretion.\nHypersensitivity to any of the active ingredients or to any of the excipients included in its formulation.\nUntreated systemic infections not caused by COVID-19.\nActive stomach or duodenal ulcer.\nRecent vaccination with live vaccines.\nOther infection or disease that explains the lung disorder.\nInability of the patient to understand the study or to sign the informed consent unless consent is delegated to a legal representative.\nActive participation in another clinical study in the last 15 days.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Luis Corral Gudino",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"983 420400",
                    "CentralContactEMail":"lcorral@saludcastillayleon.es"
                  },{
                    "CentralContactName":"Esperanza LÃ³pez Franco",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"923 291100",
                    "CentralContactEMail":"esperanza.lopez@scren.es"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Luis Corral Gudino",
                    "OverallOfficialAffiliation":"Investigator",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Complejo Asistencial Universitario de Burgos",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"Burgos",
                    "LocationZip":"09006",
                    "LocationCountry":"Spain",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"MarÃ­a LÃ³pez Veloso",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"mlopezvel@saludcastillayleon.es"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Complejo Asistencial Universitario de LeÃ³n",
                    "LocationStatus":"Active, not recruiting",
                    "LocationCity":"LeÃ³n",
                    "LocationZip":"24071",
                    "LocationCountry":"Spain"
                  },{
                    "LocationFacility":"Complejo Asistencial Universitario de Salamanca",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Salamanca",
                    "LocationZip":"37007",
                    "LocationCountry":"Spain",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"JosÃ© Ignacio MartÃ­n GonzÃ¡lez",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"jmartingo@saludcastillayleon.es"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Hospital ClÃ­nico Universitario de Valladolid",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"Valladolid",
                    "LocationZip":"47003",
                    "LocationCountry":"Spain",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"IvÃ¡n CusÃ¡covich Torres",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"icusacovich@saludcastillayleon.es"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Hospital Universitario RÃ­o Hortega",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Valladolid",
                    "LocationZip":"47012",
                    "LocationCountry":"Spain",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Luis Corral Gudino",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"lcorral@saludcastillayleon.es"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000007239",
                    "ConditionMeshTerm":"Infection"
                  },{
                    "ConditionMeshId":"D000018352",
                    "ConditionMeshTerm":"Coronavirus Infections"
                  },{
                    "ConditionMeshId":"D000045169",
                    "ConditionMeshTerm":"Severe Acute Respiratory Syndrome"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000003333",
                    "ConditionAncestorTerm":"Coronaviridae Infections"
                  },{
                    "ConditionAncestorId":"D000030341",
                    "ConditionAncestorTerm":"Nidovirales Infections"
                  },{
                    "ConditionAncestorId":"D000012327",
                    "ConditionAncestorTerm":"RNA Virus Infections"
                  },{
                    "ConditionAncestorId":"D000014777",
                    "ConditionAncestorTerm":"Virus Diseases"
                  },{
                    "ConditionAncestorId":"D000012141",
                    "ConditionAncestorTerm":"Respiratory Tract Infections"
                  },{
                    "ConditionAncestorId":"D000012140",
                    "ConditionAncestorTerm":"Respiratory Tract Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafAsFound":"Infection",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M19074",
                    "ConditionBrowseLeafName":"Coronavirus Infections",
                    "ConditionBrowseLeafAsFound":"Corona Virus Infection",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M24032",
                    "ConditionBrowseLeafName":"Severe Acute Respiratory Syndrome",
                    "ConditionBrowseLeafAsFound":"Corona Virus Infection",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M12487",
                    "ConditionBrowseLeafName":"Pneumonia",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16105",
                    "ConditionBrowseLeafName":"Virus Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14938",
                    "ConditionBrowseLeafName":"Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5138",
                    "ConditionBrowseLeafName":"Coronaviridae Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M22269",
                    "ConditionBrowseLeafName":"Nidovirales Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13732",
                    "ConditionBrowseLeafName":"RNA Virus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13561",
                    "ConditionBrowseLeafName":"Respiratory Tract Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13560",
                    "ConditionBrowseLeafName":"Respiratory Tract Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T5186",
                    "ConditionBrowseLeafName":"Severe Acute Respiratory Syndrome",
                    "ConditionBrowseLeafAsFound":"Corona Virus Infection",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000003907",
                    "InterventionMeshTerm":"Dexamethasone"
                  },{
                    "InterventionMeshId":"D000008775",
                    "InterventionMeshTerm":"Methylprednisolone"
                  },{
                    "InterventionMeshId":"D000077555",
                    "InterventionMeshTerm":"Methylprednisolone Acetate"
                  },{
                    "InterventionMeshId":"D000008776",
                    "InterventionMeshTerm":"Methylprednisolone Hemisuccinate"
                  },{
                    "InterventionMeshId":"D000011239",
                    "InterventionMeshTerm":"Prednisolone"
                  },{
                    "InterventionMeshId":"C000009935",
                    "InterventionMeshTerm":"Prednisolone acetate"
                  },{
                    "InterventionMeshId":"C000021322",
                    "InterventionMeshTerm":"Prednisolone hemisuccinate"
                  },{
                    "InterventionMeshId":"C000009022",
                    "InterventionMeshTerm":"Prednisolone phosphate"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000000893",
                    "InterventionAncestorTerm":"Anti-Inflammatory Agents"
                  },{
                    "InterventionAncestorId":"D000000932",
                    "InterventionAncestorTerm":"Antiemetics"
                  },{
                    "InterventionAncestorId":"D000001337",
                    "InterventionAncestorTerm":"Autonomic Agents"
                  },{
                    "InterventionAncestorId":"D000018373",
                    "InterventionAncestorTerm":"Peripheral Nervous System Agents"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  },{
                    "InterventionAncestorId":"D000005765",
                    "InterventionAncestorTerm":"Gastrointestinal Agents"
                  },{
                    "InterventionAncestorId":"D000005938",
                    "InterventionAncestorTerm":"Glucocorticoids"
                  },{
                    "InterventionAncestorId":"D000006728",
                    "InterventionAncestorTerm":"Hormones"
                  },{
                    "InterventionAncestorId":"D000006730",
                    "InterventionAncestorTerm":"Hormones, Hormone Substitutes, and Hormone Antagonists"
                  },{
                    "InterventionAncestorId":"D000018931",
                    "InterventionAncestorTerm":"Antineoplastic Agents, Hormonal"
                  },{
                    "InterventionAncestorId":"D000000970",
                    "InterventionAncestorTerm":"Antineoplastic Agents"
                  },{
                    "InterventionAncestorId":"D000018696",
                    "InterventionAncestorTerm":"Neuroprotective Agents"
                  },{
                    "InterventionAncestorId":"D000020011",
                    "InterventionAncestorTerm":"Protective Agents"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M5685",
                    "InterventionBrowseLeafName":"Dexamethasone",
                    "InterventionBrowseLeafAsFound":"Period",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M10332",
                    "InterventionBrowseLeafName":"Methylprednisolone",
                    "InterventionBrowseLeafAsFound":"Position",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M1833",
                    "InterventionBrowseLeafName":"Methylprednisolone Acetate",
                    "InterventionBrowseLeafAsFound":"Position",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M10333",
                    "InterventionBrowseLeafName":"Methylprednisolone Hemisuccinate",
                    "InterventionBrowseLeafAsFound":"Position",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M12703",
                    "InterventionBrowseLeafName":"Prednisolone",
                    "InterventionBrowseLeafAsFound":"Position",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M237203",
                    "InterventionBrowseLeafName":"Prednisolone acetate",
                    "InterventionBrowseLeafAsFound":"Position",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M218859",
                    "InterventionBrowseLeafName":"Prednisolone hemisuccinate",
                    "InterventionBrowseLeafAsFound":"Position",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M243004",
                    "InterventionBrowseLeafName":"Prednisolone phosphate",
                    "InterventionBrowseLeafAsFound":"Position",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M243574",
                    "InterventionBrowseLeafName":"Dexamethasone acetate",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M7630",
                    "InterventionBrowseLeafName":"Glucocorticoids",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2798",
                    "InterventionBrowseLeafName":"Anti-Inflammatory Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2832",
                    "InterventionBrowseLeafName":"Antiemetics",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M7464",
                    "InterventionBrowseLeafName":"Gastrointestinal Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8372",
                    "InterventionBrowseLeafName":"Hormones",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8371",
                    "InterventionBrowseLeafName":"Hormone Antagonists",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19550",
                    "InterventionBrowseLeafName":"Antineoplastic Agents, Hormonal",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19357",
                    "InterventionBrowseLeafName":"Neuroprotective Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M20453",
                    "InterventionBrowseLeafName":"Protective Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Infl",
                    "InterventionBrowseBranchName":"Anti-Inflammatory Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"ANeo",
                    "InterventionBrowseBranchName":"Antineoplastic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"AnEm",
                    "InterventionBrowseBranchName":"Antiemetics"
                  },{
                    "InterventionBrowseBranchAbbrev":"Gast",
                    "InterventionBrowseBranchName":"Gastrointestinal Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"NeuroAg",
                    "InterventionBrowseBranchName":"Neuroprotective Agents"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":16,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780568",
              "OrgStudyIdInfo":{
                "OrgStudyId":"OSU-20298"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"NCI-2021-01360",
                    "SecondaryIdType":"Registry Identifier",
                    "SecondaryIdDomain":"CTRP (Clinical Trial Reporting Program)"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Ohio State University Comprehensive Cancer Center",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer",
              "OfficialTitle":"A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 31, 2023",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 31, 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Regan Memmott",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Ohio State University Comprehensive Cancer Center"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Ohio State University Comprehensive Cancer Center",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"Yes",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",
              "DetailedDescription":"PRIMARY OBJECTIVE:\n\nI. Assess the safety and tolerability of osimertinib (AZD9291) in combination with tegavivint (BC2059) in patients with metastatic EGFR-mutant non-small lung cancer (NSCLC) and determine the recommended phase 2 dose (RP2D).\n\nSECONDARY OBJECTIVES:\n\nI. Determine the objective response rate (ORR) in patients with metastatic EGFR-mutant NSCLC treated with the combination of AZD9291 and BC2059.\n\nII. Determine the progression free survival (PFS) in patients with metastatic EGFR-mutant NSCLC treated with the combination of AZD9291 and BC2059.\n\nIII. Determine the duration of response (DOR) in patients with metastatic EGFR-mutant NSCLC treated with the combination of AZD9291 and BC2059.\n\nIV. Determine the overall survival (OS) in patients with metastatic EGFR-mutant NSCLC treated with the combination of AZD9291 and BC2059.\n\nCORRELATIVE/EXPLORATORY OBJECTIVES:\n\nI. Evaluate biomarkers of EGFR, Notch3, and beta-catenin pathway activity in tumor biopsies and blood samples.\n\nII. Assess the pharmacokinetics (PK) of AZD9291 and BC2059 in patients with metastatic EGFR-mutant NSCLC.\n\nIII. Assess circulating tumor deoxyribonucleic acid (DNA) (ctDNA) at baseline, following 2 and 4 weeks of treatment to evaluate for clearance, and at time of progression to assess for changes in EGFR mutation status.\n\nIV. Measure response using computed tomography (CT) tumor volumetry and dynamic positron emission tomography (PET)/CT.\n\nV. Identify a gene signature that may be predictive of treatment response or resistance using ribonucleic acid (RNA) sequencing of tumor tissue.\n\nOUTLINE:\n\nPatients receive osimertinib orally (PO) once daily (QD) on days 1-28 and tegavivint intravenously (IV) on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive osimertinib PO QD on days 1-28. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed up for 30 days and then for 4 years."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Metastatic Lung Non-Small Cell Carcinoma",
                  "Stage IV Lung Cancer AJCC v8",
                  "Stage IVA Lung Cancer AJCC v8",
                  "Stage IVB Lung Cancer AJCC v8"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 1"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"18",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Treatment (osimertinib, tegavivint)",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Patients receive osimertinib PO QD on days 1-28 and tegavivint IV on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive osimertinib PO QD on days 1-28. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Osimertinib",
                        "Drug: Tegavivint"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Osimertinib",
                    "InterventionDescription":"Given PO",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Treatment (osimertinib, tegavivint)"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "AZD-9291",
                        "AZD9291",
                        "Mereletinib",
                        "Tagrisso"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Tegavivint",
                    "InterventionDescription":"Given IV",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Treatment (osimertinib, tegavivint)"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "BC 2059",
                        "BC-2059",
                        "BC2059",
                        "Tegatrabetan"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Maximum tolerated dose",
                    "PrimaryOutcomeTimeFrame":"Up to 28 days"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Overall response rate (ORR)",
                    "SecondaryOutcomeDescription":"Defined as patients with complete or partial response using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. will be calculated as the proportion of patients who achieve a response to therapy divided by the total number of evaluable patients. An evaluable patient is defined as an eligible patient who has received at least one dose of therapy. All evaluable patients will be included in calculating the ORR for the study along with corresponding 95% binomial confidence intervals (CIs) (assuming that the number of patients who respond is binomially distributed).",
                    "SecondaryOutcomeTimeFrame":"Up to 4 years"
                  },{
                    "SecondaryOutcomeMeasure":"Progression free survival",
                    "SecondaryOutcomeDescription":"Survival will initially be modeled using Kaplan-Meier methods, resulting in median survival times with 95% CI, assuming sufficient events have occurred.",
                    "SecondaryOutcomeTimeFrame":"From initiation of therapy to disease progression or death, assessed up to 4 years"
                  },{
                    "SecondaryOutcomeMeasure":"Duration of response",
                    "SecondaryOutcomeTimeFrame":"From objective response to disease progression or death, assessed up to 4 years"
                  },{
                    "SecondaryOutcomeMeasure":"Overall survival",
                    "SecondaryOutcomeDescription":"Survival will initially be modeled using Kaplan-Meier methods, resulting in median survival times with 95% CI, assuming sufficient events have occurred.",
                    "SecondaryOutcomeTimeFrame":"From start of treatment until death of any cause, assessed up to 4 years"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Tegavivint (BC2059) pharmacokinetics (PK)",
                    "OtherOutcomeDescription":"Assessed by BC2059 drug levels following combination therapy with BC2059 and AZD9291 in patients with metastatic EGFR activating mutation positive non-small cell lung cancer (NSCLC).",
                    "OtherOutcomeTimeFrame":"Pre-dose on day 1 of cycles 1, 8, and 15 and day 22 of cycle 1, 96 hours after treatment on days 5 and 19 of cycle 1 and, 4 hours after treatment on day 15 cycle 1"
                  },{
                    "OtherOutcomeMeasure":"Osimertinib (AZD9291) PK",
                    "OtherOutcomeDescription":"Assessed by AZD9291 drug levels following combination therapy with BC2059 and AZD9291 in patients with metastatic EGFR activating mutation positive NSCLC.",
                    "OtherOutcomeTimeFrame":"Pre-dose on day 1 of cycles 1, 8, and 15 and day 22 of cycle 1 and 30 minutes, 1.5 hours, and 4 hours on day 15 cycle 1"
                  },{
                    "OtherOutcomeMeasure":"Î’-catenin pathway activity",
                    "OtherOutcomeDescription":"Will be evaluated by measuring serum levels of the secreted transcriptional targets, PAI1 and MMP7 pre- and post-treatment. EGFR and Notch3/B-catenin expression, cellular localization, and pathway activity will also be assessed in voluntary serial tumor biopsies using immunohistochemical analysis.",
                    "OtherOutcomeTimeFrame":"Up to 4 years"
                  },{
                    "OtherOutcomeMeasure":"Circulating tumor deoxyribonucleic acid (ctDNA)",
                    "OtherOutcomeDescription":"Will be assessed pre- and posttreatment to evaluate for clearance, as well as at time of progression to assess for changes in EGFR mutation status.",
                    "OtherOutcomeTimeFrame":"Up to 4 years"
                  },{
                    "OtherOutcomeMeasure":"Fludeoxyglucose F 18 (18F-FDG) positron emission tomography (PET) imaging",
                    "OtherOutcomeDescription":"Assessed by static (standardized uptake value [SUV]max, average SUV, tumor-to-background ratio, metabolic tumor volume, total lesion glycolysis) and dynamic (net influx rate constant and glucose metabolic rate at 30 and 60 minutes) parameters will be assessed in patients with metastatic EGFR activating mutation positive NSCLC. 18F-FDG-PET parameters will also be summarized at baseline and after treatment using mean +/- SEM, range, and median. The changes in the FDG-PET/computed tomography parameter measurements from baseline to after treatment will be compared between responders and non-responders using two sample t-test or Wilcoxon test, whichever is appropriate. Logistics regression model might also be used to identify potential predictive and prognostic biomarkers beyond any genomic alteration with response to study drugs.",
                    "OtherOutcomeTimeFrame":"Baseline to 4 years"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAge >= 18 years. Children are excluded from this study because neither dosing nor safety data are currently available for AZD9291 or BC2059 in patients < 18 years of age\nPathology-confirmed metastatic NSCLC\nA common activating mutation must be present in the EGFR gene, i.e., exon 19 deletion or L858R. The presence of uncommon EGFR mutations, e.g., G719X, S768I, or L861Q are also permitted if they co-occur with a common activating mutation. Mutation status must be determined using a tumor biopsy by local Clinical Laboratory Improvement Act (CLIA)-certified assessment. Mutations identified by blood-based testing can be provided, but must be verified by tumor biopsy\nThe presence of a concurrent T790M mutation, while uncommon in patients who are naÃ¯ve to treatment with EGFR TKIs, is also permitted\nMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria\nEastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\nThe patient must be able to swallow pills\nLife expectancy > 3 months\nLeukocytes >= 3,000/mcL\nAbsolute neutrophil count >= 1,500/mcL\nPlatelets >= 100,000/mcL\nHemoglobin >= 90 g/L\nTotal bilirubin =< 1.5 x institutional upper limit normal (ULN) and up to 3 mg/dL for patients with Gilbert's\nAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase ALT (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN and =< 5 x institutional ULN for patients with liver metastases\nCreatinine within 1.5 x ULN OR glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2 (measured or calculated by Cockcroft and Gault equation) -confirmation of creatinine clearance is only required for patients with creatinine levels above institutional upper limit of normal\nIf evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy if indicated\nIf history of hepatitis C virus (HCV) infection, it must be treated and have an undetectable viral load\nPatients with treated brain metastases are asymptomatic and not requiring ongoing treatment\nPatients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS)-specific treatment is not required and is unlikely to be required during the first cycle of therapy. Clinical stability on a stable dose of decadron is permitted\nPatients with a prior or concurrent malignancy whose natural history or treatment will not interfere with the safety or efficacy assessment of the investigational drugs are eligible for this trial\nPatients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better\nAbility to understand and sign a written informed consent document\n\nExclusion Criteria:\n\nPrior treatment with an EGFR TKI in any setting\nPatients who have not recovered from adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia\nPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease\nPatients who are receiving any other investigational agent or immunotherapy within five half-lives of the compound or 3 months, whichever is greater\nPatients with an uncontrolled intercurrent illness\nPatients with psychiatric illness/social situations that would limit compliance with study requirements\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition as BC2059 or AZD9291. Patients with hypersensitivity to any of the inactive excipients should also be excluded\nCurrently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (wash-out periods vary. All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4\nPregnant women are excluded from this study because BC2059 has the potential for teratogenic or abortifacient effects. There is also an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with AZD9291 or BC2059. Breastfeeding patients will be excluded\nPatients with a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last 6 months)\n\nAny of the following cardiac criteria:\n\nMean resting corrected QT interval (corrected QT [QTc] using Fredericia's formula [QTcF]) > 470 msec. RR is the time from the interval of 1 QRS complex to the next measured in seconds and is commonly calculated as (60/HR)\nAny clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)\nAny factors that increase the risk of QTc prolongation or risk of arrhythmic events such as decompensated heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives, or any concomitant medication known to prolong the QT interval\nLeft ventricular ejection fraction (LVEF) < lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)\nPatients with active malignancies other than NSCLC or patients with prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers, ductal carcinoma in-situ (DCIS), or indolent cancer currently on observation (i.e. chronic lymphocytic leukemia [CLL] or low-risk prostate cancer)\nAny evidence of severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection with human immunodeficiency virus (HIV). Screening for chronic conditions is not required\nPatients who are at risk for impaired absorption of oral medication including, but not limited to, refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9291\nJudgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, or requirements\nInvolvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site)",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Regan M Memmott",
                    "OverallOfficialAffiliation":"Ohio State University Comprehensive Cancer Center",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Ohio State University Comprehensive Cancer Center",
                    "LocationCity":"Columbus",
                    "LocationState":"Ohio",
                    "LocationZip":"43210",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Regan M. Memmott",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"614-366-1618",
                          "LocationContactEMail":"regan.memmott@osumc.edu"
                        },{
                          "LocationContactName":"Regan M. Memmott",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000008175",
                    "ConditionMeshTerm":"Lung Neoplasms"
                  },{
                    "ConditionMeshId":"D000002289",
                    "ConditionMeshTerm":"Carcinoma, Non-Small-Cell Lung"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000012142",
                    "ConditionAncestorTerm":"Respiratory Tract Neoplasms"
                  },{
                    "ConditionAncestorId":"D000013899",
                    "ConditionAncestorTerm":"Thoracic Neoplasms"
                  },{
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  },{
                    "ConditionAncestorId":"D000008171",
                    "ConditionAncestorTerm":"Lung Diseases"
                  },{
                    "ConditionAncestorId":"D000012140",
                    "ConditionAncestorTerm":"Respiratory Tract Diseases"
                  },{
                    "ConditionAncestorId":"D000002283",
                    "ConditionAncestorTerm":"Carcinoma, Bronchogenic"
                  },{
                    "ConditionAncestorId":"D000001984",
                    "ConditionAncestorTerm":"Bronchial Neoplasms"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M4116",
                    "ConditionBrowseLeafName":"Carcinoma",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9755",
                    "ConditionBrowseLeafName":"Lung Neoplasms",
                    "ConditionBrowseLeafAsFound":"Lung Cancer",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4128",
                    "ConditionBrowseLeafName":"Carcinoma, Non-Small-Cell Lung",
                    "ConditionBrowseLeafAsFound":"Lung Non-Small Cell Carcinoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13562",
                    "ConditionBrowseLeafName":"Respiratory Tract Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M15241",
                    "ConditionBrowseLeafName":"Thoracic Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9751",
                    "ConditionBrowseLeafName":"Lung Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13560",
                    "ConditionBrowseLeafName":"Respiratory Tract Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4122",
                    "ConditionBrowseLeafName":"Carcinoma, Bronchogenic",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3842",
                    "ConditionBrowseLeafName":"Bronchial Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"C000603933",
                    "InterventionMeshTerm":"Osimertinib"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000000970",
                    "InterventionAncestorTerm":"Antineoplastic Agents"
                  },{
                    "InterventionAncestorId":"D000047428",
                    "InterventionAncestorTerm":"Protein Kinase Inhibitors"
                  },{
                    "InterventionAncestorId":"D000004791",
                    "InterventionAncestorTerm":"Enzyme Inhibitors"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M246927",
                    "InterventionBrowseLeafName":"Osimertinib",
                    "InterventionBrowseLeafAsFound":"Contiguous",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M24407",
                    "InterventionBrowseLeafName":"Protein Kinase Inhibitors",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"ANeo",
                    "InterventionBrowseBranchName":"Antineoplastic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":17,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780555",
              "OrgStudyIdInfo":{
                "OrgStudyId":"AIBU-FTR-EY-02"
              },
              "Organization":{
                "OrgFullName":"Abant Izzet Baysal University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Evaluation of Musculoskeletal System Symptoms and Biochemical Parameters in COVID-19",
              "OfficialTitle":"Evaluation of Pain Symptoms Correlation With Biochemical and Radiological Findings in COVID-19"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"May 1, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 1, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 21, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Abant Izzet Baysal University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The neutrophil-lymphocyte ratio (NLR) used to demonstrate inflammatory status in recent years can be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count at routine blood tests.",
              "DetailedDescription":"Dysregulation in immune responses has been reported in association with hyperinflammation in COVID-19 patients, NLR has been linked to the severity of the patient's clinical status, and an increase in NLR is reported to be an independent risk factor for in-hospital mortality. Pain is a frequently seen symptom at the onset of viral infections and throughout the course of the disease. Although the pain mechanisms triggered by viral pathogens are not yet entirely understood, pain is thought to arise as a result of direct activation of nociceptor neurons by pathogens and their interaction with molecular ligands. Toll-like receptor 7 (TLR7), a pathogen recognition receptor that plays an important role in immune responses to viruses by binding to viral RNA, is known to be involved in pain development in different RNA virus infections. Park et al. showed that extracellular micro RNAs activate nociceptive neurons via the TLR7 pathway. Although these mechanisms have been demonstrated for different viral infections, the viral pathogenesis leading to pain in COVID-19 is still unclear. The purpose of this study was to investigate the prevalence of headache and muscular pain in patients diagnosed with COVID-19 and to determine the relationship between these symptoms and inflammatory parameters."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "pain"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "BioSpec":{
                "BioSpecRetention":"Samples Without DNA",
                "BioSpecDescription":"Peripheral venous blood specimens will be collected using standard surgical procedures during presentation and were investigated in the Abant Ä°zzet Baysal University Medical Faculty central laboratory. Complete blood count parameters (hemoglobin, leukocytes, erythrocytes, platelets, and leukocyte subtypes) will be analyzed using a Syxmex XN-1000 (Kobe, Japan) automatic analyzer. D-dimer and fibrinogen parameters will be measured on a Sysmex CS-2500 (Kobe, Japan) device, and biochemical parameters (CRP, ferritin, procalcitonin, LDH, troponin) on an automatic biochemical analyzer (Abbott Architect C8000, USA). In addition, the NLR will be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count."
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"150",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Neutrophil-lymphocyte ratio (NLR)",
                    "PrimaryOutcomeDescription":"It can be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count at routine blood tests",
                    "PrimaryOutcomeTimeFrame":"Baseline"
                  },{
                    "PrimaryOutcomeMeasure":"D-dimer",
                    "PrimaryOutcomeDescription":"Peripheral venous blood specimens were collected using standard surgical procedures",
                    "PrimaryOutcomeTimeFrame":"Baseline"
                  },{
                    "PrimaryOutcomeMeasure":"Fibrinogen",
                    "PrimaryOutcomeDescription":"Peripheral venous blood specimens were collected using standard surgical procedures",
                    "PrimaryOutcomeTimeFrame":"Baseline"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAged 18-70\nDiagnosed with COVID-19\n\nExclusion Criteria:\n\nPatients with suspected SARS-CoV-2 infection, with two negative RT-PCR tests, hospitalized in the intensive care unit during inclusion in the study\nMusculoskeletal pains in the previous three months, with diseases capable of causing myalgia prior to diagnosis (such as fibromyalgia and inflammatory muscle disease)\nCognitive disorders capable of preventing history-taking and physical examination such as mental disability and dementia,\nprevious history of headache (migraine, tension type headache)",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"70 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Patients aged 18-65 and diagnosed with COVID-19 will be included in the study.",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Elif YakÅŸi, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+905069078505",
                    "CentralContactEMail":"elifyaksi@hotmail.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Nalan DoÄŸan, MD",
                    "OverallOfficialAffiliation":"Beykoz State Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Dursun KarakaÅŸ, MD",
                    "OverallOfficialAffiliation":"Sancaktepe Åžehit Ä°lhan Varank Research Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Osman YakÅŸi, MD",
                    "OverallOfficialAffiliation":"Abant Ä°zzet Baysal University Medical Faculty",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M11649",
                    "ConditionBrowseLeafName":"Pain",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":18,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780542",
              "OrgStudyIdInfo":{
                "OrgStudyId":"EP20142"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"R01MH120648-01A1",
                    "SecondaryIdType":"U.S. NIH Grant/Contract",
                    "SecondaryIdLink":"https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MH120648-01A1&Fy=all"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Instituto Nacional de PsiquiatrÃ­a Dr. RamÃ³n de la Fuente",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Internet-delivered Cognitive Behavioral Treatment of Depression and Anxiety in Latin American College Students",
              "OfficialTitle":"Computerized Detection and Internet-based Treatment of Common Mental Disorders Among College Students in Two Latin American LMICs"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"May 2025",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 2025",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Corina Benjet",
                "ResponsiblePartyInvestigatorTitle":"Researcher in Medical Sciences",
                "ResponsiblePartyInvestigatorAffiliation":"Instituto Nacional de PsiquiatrÃ­a Dr. RamÃ³n de la Fuente"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Instituto Nacional de PsiquiatrÃ­a Dr. RamÃ³n de la Fuente",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"National Institute of Mental Health (NIMH)",
                    "CollaboratorClass":"NIH"
                  },{
                    "CollaboratorName":"Harvard Medical School",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"We aim to evaluate short term and longer term treatment effects of internet-delivered cognitive behavioral therapy compared to treatment as usual for college students with anxiety and/or depression in low-middle income countries of Latin America.",
              "DetailedDescription":"This study is designed to detect, engage, and experimentally evaluate the effects of internet-based cognitive behavior therapy (e-CBT) to treat college students in two Latin American low-middle income countries (LMICs; Colombia and Mexico) with major depressive disorder and/or generalized anxiety disorder, with or without other comorbid common mental disorders (CMDs). Detection and engagement will be based on inexpensive internet-based recruitment and administration of self-report surveys. The intervention will be based on inexpensive e-CBT to address the low resources in LMICs. The study builds on prior research by collaborators in the WHO World Mental Health (WMH) survey consortium and WMH International College Study (WMH-ICS) initiative documenting high prevalence, impairment, and unmet need for treatment of CMDs among college students around the world and significant effects of e-CBT in treating these disorders in high income countries.\n\nFirst, we will carry out a pragmatic clinical trial with students seeking treatment for CMDs at student clinics in universities in Colombia and Mexico. Students on waitlists for student clinic services will be offered a possibility of receiving guided or self-guided e-CBT immediately while staying on the list. 33% of the students with CMD who express interest will be randomized to guided e-CBT, another 33% to self-guided e-CBT, and the remaining 33% to treatment as usual (TAU), where the latter is defined as remaining on the waiting list. Short-term aggregate intervention effects will be assessed 90 days after randomization and longer-term effects 12 months after randomization. We will then use ensemble machine learning methods to predict heterogeneity of treatment effects of e-CBT versus TAU and develop a precision treatment rule (PTR) to predict which students will respond best to which intervention. We will then implement a SMART design in which we randomize 50% of a second cohort of students from the same sample frame (i.e., students seeking treatment for CMDs at student clinics in the participating universities) to the treatment arm predicted to be optimal by the PTR and the other 50% to randomization across arms.\n\nAdditionally, we will use outreach to recruit students into the trial who might not otherwise seek treatment from student clinics. Two procedures will be used here. In the first, we will recruit from annual WMH-ICS internet-based mental health needs assessment surveys we will carry out with a probability sample of students to estimate unmet need for treatment and barriers to treatment. Students who respond to these surveys and meet inclusion criteria and are not in treatment will be randomized to guided e-CBT, self-guided e-CBT, and treatment as usual in student clinics to determine if access to guided and self-guided e-CBT reduces the unmet need for treatment among students with CMDs who fail to seek treatment at student health clinics. The second will expand recruitment by sending emails to random subsamples of students notifying them of the availability of our internet-based interventions and inviting them to participate in a trial. Students that contact us in response to this announcement will then be recruited and randomized into the same three arms as among students that participated in our annual WMH-ICS survey."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Major Depressive Disorder",
                  "Generalized Anxiety Disorder"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "iCBT",
                  "Latin America",
                  "College Students",
                  "Depression",
                  "Anxiety"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)",
                  "DesignMaskingDescription":"Participant recruiters will be blinded to the participant's intended treatment arm."
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"1500",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Clinician-Guided iCBT",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Both help-seeking students recruited from university clinics and non-help-seeking students recruited from needs assessment survey and outreach will receive internet delivered cognitive behavioral therapy guided by clinicians",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Yo Puedo Sentirme Bien- Clinician-Guided version"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Treatment as usual",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Help-seeking students recruited from university clinics will remain on waitlist until they receive treatment as usual. Non-help-seeking students recruited from needs assessment survey and outreach will be referred to university health clinic.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Treatment as usual"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Self-guided iCBT",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Help-seeking students recruited from university clinics will receive self-guided internet delivered cognitive behavioral therapy while on waitlist. Non-help seeking students recruited from needs assessment survey and outreach will receive the self-guided version of internet delivered cognitive behavioral therapy.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Yo Puedo Sentirme Bien- Self-Guided version"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"Yo Puedo Sentirme Bien- Clinician-Guided version",
                    "InterventionDescription":"Internet delivered Cognitive Behavioral Therapy- Guided version",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Clinician-Guided iCBT"
                      ]
                    }
                  },{
                    "InterventionType":"Behavioral",
                    "InterventionName":"Yo Puedo Sentirme Bien- Self-Guided version",
                    "InterventionDescription":"Internet delivered Cognitive Behavioral Therapy- Self-Guided version",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Self-guided iCBT"
                      ]
                    }
                  },{
                    "InterventionType":"Behavioral",
                    "InterventionName":"Treatment as usual",
                    "InterventionDescription":"Waitlist until appointment and then treatment as usually provided by student clinic",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Treatment as usual"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Patient Health Questionnaire-9 (PHQ-9)",
                    "PrimaryOutcomeDescription":"Self-report measure of depressive symptoms in the prior 2 weeks",
                    "PrimaryOutcomeTimeFrame":"90 days"
                  },{
                    "PrimaryOutcomeMeasure":"Generalized Anxiety Disorder-7 (GAD-7)",
                    "PrimaryOutcomeDescription":"Self-report measure of anxiety symptoms in the prior 2 weeks",
                    "PrimaryOutcomeTimeFrame":"90 days"
                  },{
                    "PrimaryOutcomeMeasure":"Patient Health Questionnaire-9 (PHQ-9)",
                    "PrimaryOutcomeDescription":"Self-report measure of depressive symptoms in the prior 2 weeks",
                    "PrimaryOutcomeTimeFrame":"12 months"
                  },{
                    "PrimaryOutcomeMeasure":"Generalized Anxiety Disorder-7 (GAD-7)",
                    "PrimaryOutcomeDescription":"Self-report measure of anxiety symptoms in the prior 2 weeks",
                    "PrimaryOutcomeTimeFrame":"12 months"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Sheehan Disability Scale (SDS)",
                    "SecondaryOutcomeDescription":"Self-report measure of impairment due to mental health in four life areas in the prior 2 weeks",
                    "SecondaryOutcomeTimeFrame":"90 days"
                  },{
                    "SecondaryOutcomeMeasure":"Sheehan Disability Scale (SDS)",
                    "SecondaryOutcomeDescription":"Self-report measure of impairment due to mental health in four life areas in the prior 2 weeks",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAt least 18 years of age, screens positive for major depressive disorder and/or generalized anxiety disorder, student enrolled in one of the participating universities\n\nExclusion Criteria:\n\nScreens positive for bipolar disorder, screens positive for psychosis, active suicidality",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Corina Benjet, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+525541605332",
                    "CentralContactEMail":"cbenjet@gmail.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Corina Benjet, PhD",
                    "OverallOfficialAffiliation":"Instituto Nacional de PsiquiatrÃ­a",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"First, we will document and make available all imputations, weights, and constructed variables used in our analyses. Second, we will host a project webinars to present an overview of the data and answer questions. The webinars will be widely advertised in list serves, including any such sites recommended by NIMH, as well as to NIH training programs. An English version of the webinars will be hosted by the US collaborators. A Spanish version will be hosted by the Mexican collaborators. Third, we will set up and man a project Q&A web site in which public users can ask questions and get answers about issues involved in working with the data. Again, the site will be both in English and Spanish. Fourth, we will gather up written versions of all questions asked by public users along with our written response (including any documentation or computer files sent along with these answers) and post these on the website in both English and Spanish as reference documents for future public users.",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol",
                  "Clinical Study Report (CSR)"
                ]
              },
              "IPDSharingTimeFrame":"Data will become available in Year 5, once trials are concluded",
              "IPDSharingAccessCriteria":"By written request"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000004194",
                    "ConditionMeshTerm":"Disease"
                  },{
                    "ConditionMeshId":"D000001008",
                    "ConditionMeshTerm":"Anxiety Disorders"
                  },{
                    "ConditionMeshId":"D000003866",
                    "ConditionMeshTerm":"Depressive Disorder"
                  },{
                    "ConditionMeshId":"D000003865",
                    "ConditionMeshTerm":"Depressive Disorder, Major"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  },{
                    "ConditionAncestorId":"D000019964",
                    "ConditionAncestorTerm":"Mood Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M2905",
                    "ConditionBrowseLeafName":"Anxiety Disorders",
                    "ConditionBrowseLeafAsFound":"Anxiety Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5641",
                    "ConditionBrowseLeafName":"Depression",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5644",
                    "ConditionBrowseLeafName":"Depressive Disorder",
                    "ConditionBrowseLeafAsFound":"Depressive Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5643",
                    "ConditionBrowseLeafName":"Depressive Disorder, Major",
                    "ConditionBrowseLeafAsFound":"Major Depressive Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20419",
                    "ConditionBrowseLeafName":"Mood Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":19,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780529",
              "OrgStudyIdInfo":{
                "OrgStudyId":"ICT-GC"
              },
              "Organization":{
                "OrgFullName":"Innovative Cellular Therapeutics Co., Ltd.",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"CART Therapy in Digestive System Tumors",
              "OfficialTitle":"Chimeric Antigen Receptor T Cells (CART) Therapy in GUCY2C Positive Digestive System Tumors"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 2026",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Innovative Cellular Therapeutics Co., Ltd.",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Anhui Provincial Cancer Hospital",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric junction.\n\nIct-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.",
              "DetailedDescription":"The primary objective of phase 1 is to evaluate the safety of CART regimens. The primary objective of phase 2 is to evaluate the efficacy of CART, as measured by objective response rate in subjects with colorectal cancer. Secondary objectives will include assessing the safety and tolerability of CART and additional efficacy endpoints."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Malignant Neoplasms of Digestive Organs"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"20",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Patients with late malignant digestive tract tumor",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: gucy2c cart cells"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Biological",
                    "InterventionName":"gucy2c cart cells",
                    "InterventionDescription":"Patients with advanced malignant gastrointestinal tumors were injected with CART cells",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Patients with late malignant digestive tract tumor"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 24 months ]",
                    "PrimaryOutcomeDescription":"The investigator is responsible for ensuring that all adverse events observed by the investigator or reported by the subject during the 3-month period from enrollment (i.e. initiation of leukocyte separation) to 3 months after targeted car-t infusion are monitored and reported. After three months, researchers will be required to monitor and report targeted adverse events, including neurological, blood, infection, autoimmune diseases, and secondary malignant tumors, for 24 months or until disease progression, whichever occurs first.",
                    "PrimaryOutcomeTimeFrame":"24 months"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"The event of cytokine release syndrome was reported using the grading scale in the protocol.",
                    "SecondaryOutcomeDescription":"We will summarize the classification of cytokine release syndrome (CRS) according to the severity and system organ classification.",
                    "SecondaryOutcomeTimeFrame":"24 months"
                  },{
                    "SecondaryOutcomeMeasure":"Efficacy will be assessed according to RECIST1.1 or EORTC or PERCIST criteria",
                    "SecondaryOutcomeDescription":"Remission will be evaluated by the central investigator at the time indicated in the evaluation plan. The disease was evaluated according to the response evaluation criteria in solid tumors RECIST version 1.1 or EORTC or percist. Flow cytometry, molecular or cytogenetic studies used in the trial will be used to assist, but will not be used alone to determine remission.",
                    "SecondaryOutcomeTimeFrame":"24 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAged between 18 and 70;\nPositive expression of immunohistochemical (IHC) assay targets in a laboratory approved by the partner;\nPathology confirmed digestive tract tumor;\nPatients who have failed or relapsed after at least the first and second line standard treatment, and patients who are intolerant to or voluntarily give up the standardized treatment;\nAt least one extracranial measurable lesion according to RECIST1.1 or EORTC or PERCIST;\nExpected survival â‰¥90 days;\n\nThe main organs are functioning normally, i.e. they meet the following criteria:\n\nECOG physical condition score is 0~1 or KPS score is >70;\nserum test criteria were as follows: HBâ‰¥90g/L (no blood transfusion within 14 days), ANCâ‰¥ 1.5 x 10^9/L, PLTâ‰¥80 x 10^9/L, Alb â‰¥ 2.8g/dL, serum lipase and amylase < 1.5Ã—ULN (upper limit of normal value).\nBiochemical examination shall meet the following standards: TBILâ‰¤ 1.5x ULN (upper limit of normal value); ALT and ASTâ‰¤ 2.5x ULN; ALT and ASTâ‰¤5xULN in case of liver metastasis; Serum Crâ‰¤1xULN, endogenous creatinine clearance rate >50 ml/min (Cockcroft-Gault formula);\ncardiac ejection fraction >55%;\nNo hemorrhagic disease or coagulation disorder;\nNo allergy to the developer;\nWomen of childbearing age must undergo a pregnancy test (serum or urine) within 7 days prior to enrollment, with negative results, and be willing to use an appropriate method of contraception during and 8 weeks after the last dose of CART (women who have undergone sterilization or have been postmenopausal for at least 2 years may be considered sterile);\nThe subjects voluntarily joined the study, signed the informed consent form, had good compliance and cooperated with the follow-up.\n\nExclusion Criteria:\n\nT cell transduction efficiency <5% or T cell amplification < 2 times after culture;\nParticipated in other drug clinical trials within 4 weeks before the start of the study;\nPatients with hypertension and unable to obtain good control by single antihypertensive drugs (systolic blood pressure > 140 mmHg, diastolic blood pressure b> 90 mmHg, the specific conditions shall be evaluated by the researchers) have myocardial ischemia or infarction of grade I or above, arrhythmia of grade I or above (including QT interval â‰¥ 440ms) or cardiac insufficiency;\nA wound or fracture in the chest or other area that has not healed for a long time;\nHas a history of substance abuse and is unable to quit or has a history of mental disorders;\nPatients with past or present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-related pneumonia, severe pulmonary function impairment, etc.;\nFungus, bacteria, virus or other infection that cannot be controlled or requires antibiotic treatment. The presence of a simple urinary tract infection and uncomplicated bacterial pharyngitis is permitted after consultation with a medical supervisor;\nFor subjects who have used chemotherapy before, according to NCI-CTCAE 4.0, there is grade â‰¥2 hematological toxicity or grade â‰¥3 non-hematological toxicity at the time of enrollment;\nA known history of HIV, or a positive nucleic acid test for hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive);\nThe presence of any indwered catheter or drainage tube (e.g., bile drainage tube or pleural/peritoneal/pericardial catheter). The use of specialized central venous catheters was permitted (the influence of fistula, percutaneous nephrostomy, and indwsed Foley catheters in colorectal cancer patients was considered by the investigators);\nBrain metastases; A history or medical condition of CNS, such as seizure disorder, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS;\nmetastases to brain;\nSignificant immunodeficiency;\nThe major therapeutic drugs in this study (including fludalabine, cyclophosphamide, sodium meth, and tozumab and anti-infective drugs used to prevent and treat CRS) have a history of severe hypersensitivity reaction;\nHistory of deep vein thrombosis or pulmonary embolism 6 months before enrollment;\nA history of an autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) that has resulted in injury to the terminal organs or that requires systemic immunosuppressive/disease-modulating drugs in the past 2 years;\nAny disease that may interfere with the evaluation of the safety or efficacy of the study treatment.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"70 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Yifu He",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"18611718093",
                    "CentralContactEMail":"liudaiyan@sidansai.com"
                  },{
                    "CentralContactName":"Daiyan Liu",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"18611718093",
                    "CentralContactEMail":"liudaiyan@sidansai.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Yifu he",
                    "OverallOfficialAffiliation":"Anhui Provincial Cancer Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Anhui provincial cancer hospital",
                    "LocationCity":"Hefei",
                    "LocationState":"Anhui",
                    "LocationCountry":"China"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000009369",
                    "ConditionMeshTerm":"Neoplasms"
                  },{
                    "ConditionMeshId":"D000004067",
                    "ConditionMeshTerm":"Digestive System Neoplasms"
                  },{
                    "ConditionMeshId":"D000005770",
                    "ConditionMeshTerm":"Gastrointestinal Neoplasms"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  },{
                    "ConditionAncestorId":"D000005767",
                    "ConditionAncestorTerm":"Gastrointestinal Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5839",
                    "ConditionBrowseLeafName":"Digestive System Neoplasms",
                    "ConditionBrowseLeafAsFound":"Digestive System Tumors",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M7469",
                    "ConditionBrowseLeafName":"Gastrointestinal Neoplasms",
                    "ConditionBrowseLeafAsFound":"Digestive System Tumors",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":20,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780516",
              "OrgStudyIdInfo":{
                "OrgStudyId":"P20-439"
              },
              "Organization":{
                "OrgFullName":"AbbVie",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care",
              "OfficialTitle":"Prospective Non-Interventional Study to Investigate the Durable Effectiveness of Risankizumab Using Digital and Remote Evaluation Tools in Moderate to Severe Psoriasis Patients - prIMMa Study",
              "Acronym":"prIMMa"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 14, 2024",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"August 14, 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"AbbVie",
                "LeadSponsorClass":"INDUSTRY"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Psoriasis is a chronic inflammatory skin condition that is characterized by symptoms such as pain, itching and discomfort. This can have severe impact on the quality of life including depression, embarrassment, and social isolation. The objective of this study is to evaluate how effective risankizumab is in changing the disease symptoms in adult participants with moderate to severe psoriasis.\n\nRisankizumab is an approved drug being developed for the treatment of psoriasis. Adult participants who are prescribed risankizumab treatment according to the local label will be enrolled in this study. Approximately 125 adult participants with moderate to severe psoriasis will be enrolled at multiple sites across Israel.\n\nParticipants who are prescribed to receive subcutaneous risankizumab injection by their physician according to local label will be enrolled and will be followed for approximately 2 years.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects, patient charts, questionnaires, and remote monitoring device (patch sensor)."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Psoriasis"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Psoriasis",
                  "Risankizumab",
                  "Skyrizi",
                  "prIMMa"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"125",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Participants Treated With Risankizumab",
                    "ArmGroupDescription":"Participants will receive risankizumab (Skyrizi) as prescribed by the physician according to the local label."
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) 0 or 1",
                    "PrimaryOutcomeDescription":"DLQI is a patient-administered, ten-question, quality of life questionnaire that covers six domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment.",
                    "PrimaryOutcomeTimeFrame":"Week 52"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) 0 or 1",
                    "SecondaryOutcomeDescription":"DLQI is a patient-administered, ten-question, quality of life questionnaire that covers six domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 104 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Change From Baseline in Average Nightly Nocturnal Scratch Activity",
                    "SecondaryOutcomeDescription":"Average nightly nocturnal scratch activity (number of scratch events, total scratch time, and scratch intensity) will be measured by a digital monitoring device.",
                    "SecondaryOutcomeTimeFrame":"Baseline (Week 0) to Week 52"
                  },{
                    "SecondaryOutcomeMeasure":"Percentage of Participants With Physician Assessment Static Psoriasis Global Assessment (sPGA) 0 or 1",
                    "SecondaryOutcomeDescription":"Disease duration and disease severity will be assessed by sPGA.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 104 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Change From Baseline in Average Pruritus Numeric Rating Scale (PNRS)",
                    "SecondaryOutcomeDescription":"PNRS is a patient reported score that assesses itch severity on a scale of 0 to 10, with 0 being \"no itch\" and 10 being \"worst imaginable itch\".",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 4 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Change From Baseline in Medical Outcome Study Sleep Scale (MOS-SS)",
                    "SecondaryOutcomeDescription":"Medical Outcomes Study Sleep Scale (MOS-Sleep) includes 12 items assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache over the past 4 weeks.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 4 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Change From Baseline in Psoriasis Symptoms Scale (PSS)",
                    "SecondaryOutcomeDescription":"PSS is a 4-item scale designed to measure patient-reported psoriasis symptoms. The PSS consists of four items assessing severity of pain, itching, redness, and burning during the past 24 h. A 5-point severity scale was used as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 104 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Change From Baseline in Dermatology Life Quality Index (DLQI)",
                    "SecondaryOutcomeDescription":"DLQI is a patient-administered, ten-question, quality of life questionnaire that covers six domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 104 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Change From Baseline in Work Productivity and Activity Impairment (WPAI)",
                    "SecondaryOutcomeDescription":"WPAI measures the effect of general health and symptom severity on work productivity and regular activities during the past 7 days.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 104 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Percentage of Participants With Change From Baseline DLQI > Minimal Clinically Important Difference (MCID)",
                    "SecondaryOutcomeDescription":"DLQI is a patient-administered, ten-question, quality of life questionnaire that covers six domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. The MCID is defined as an improvement of >= 5 points in DLQI.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 104 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Percentage of Participants With Durability of Response Among sPGA Responders ar Week 24",
                    "SecondaryOutcomeDescription":"Durability of response is measured by the maintenance of the sPGA 0/1 at weeks 52 and 104.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 104 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of Participants With Adverse Events (AEs)",
                    "SecondaryOutcomeDescription":"An adverse event (AE) is defined as any untoward medical occurrence in a patient which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 104 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nClinical diagnosis of moderate to severe psoriasis.\nPrescribed risankizumab as the standard treatment for psoriasis, according to the local label. The decision to prescribe risankizumab will be made solely by the physician, based on his clinical judgment, and is done prior to any decision to approach the participant to participate in this study.\nWilling to be involved in the study, to sign an informed consent form and complete study questionnaires.\nParticipants participating in digital component: Pruritus Numeric Rating Scale (PNRS) score >=4 at baseline.\n\nExclusion Criteria:\n\nParticipants participating in a concurrent clinical interventional study or within 30 days.\nParticipants treated with risankizumab prior to baseline visit.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Adult participants with moderate to severe psoriasis who are prescribed risankizumab according to local label prior to enrolling in this study.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"ABBVIE CALL CENTER",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"844-663-3742",
                    "CentralContactEMail":"abbvieclinicaltrials@abbvie.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"AbbVie Inc.",
                    "OverallOfficialAffiliation":"AbbVie",
                    "OverallOfficialRole":"Study Director"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "SeeAlsoLinkList":{
                "SeeAlsoLink":[
                  {
                    "SeeAlsoLinkLabel":"Related Info",
                    "SeeAlsoLinkURL":"https://www.rxabbvie.com/"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000011565",
                    "ConditionMeshTerm":"Psoriasis"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000017444",
                    "ConditionAncestorTerm":"Skin Diseases, Papulosquamous"
                  },{
                    "ConditionAncestorId":"D000012871",
                    "ConditionAncestorTerm":"Skin Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M13005",
                    "ConditionBrowseLeafName":"Psoriasis",
                    "ConditionBrowseLeafAsFound":"Psoriasis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M14257",
                    "ConditionBrowseLeafName":"Skin Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M18296",
                    "ConditionBrowseLeafName":"Skin Diseases, Papulosquamous",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC17",
                    "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":21,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780503",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2020-GOKAE-0011"
              },
              "Organization":{
                "OrgFullName":"Izmir Katip Celebi University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"The Value of Rapid Shallow Breathing Indeks in Predicting Non-invasive Mechanical",
              "OfficialTitle":"The Rapid Shallow Breathing Index as an Early Predictor for Intubation and Mortality in Patients Undergoing Non-invasive Mechanical Ventilation in Acute Respiratory Failure",
              "Acronym":"RSBI"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 9, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"January 9, 2021",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"January 9, 2021",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Adnan YamanoÄŸlu",
                "ResponsiblePartyInvestigatorTitle":"Emergency Medicine Specialist",
                "ResponsiblePartyInvestigatorAffiliation":"Izmir Katip Celebi University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Izmir Katip Celebi University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"There are some criteria such as the most frequently used parameters to predict the failure of non-invasive mechanical ventilation, the APACHE 2 score, the presence of pneumonia and ARDS in the etiology, and no improvement in one hour of treatment. However, APECHE 2 score, which is the broadest of these criteria and includes others, is a complex scoring in which a large number of parameters are evaluated together, dependent on laboratory results and still leaves the final decision to the physician with a complete evaluation. In addition, the APACHE 2 score is a more commonly used method for intensive care patients rather than emergency patients who need a quick decision. Therefore, there is a need for a fast and practical method that can predict NIMV failure and determine early intubation decision in the management of patients admitted to the emergency department with acute dyspnea. Rapid Shallow Breathing Index (RSBI) is a parameter calculated by dividing the respiratory rate by the tidal volume and is used to predict whether patients who are intubated in intensive care unit can be extubated successfully.\n\nThe aim of this study is to evaluate the success of RSBI in predicting intubation and mortality in patients presented to the emergency department with acute respiratory failure and had NIMV indication.",
              "DetailedDescription":"Respiratory failure is a challenging health problem that constitutes a significant part of emergency room visits (1). Acute respiratory failure treatment is a complex process in which pharmacological and non-pharmacological methods are used in combination. Non-invasive Mechanical Ventilation (NIMV) and Invasive Mechanical Ventilation (IMV) are life-saving methods commonly used in the emergency department in severe respiratory failure (2). In patients with severe dyspnea, NIMV improves alveolar gas exchange, with very successful results in selected patients (3). However, while NIMV cannot be used in patients who are unconscious, unable to protect the airway, have upper gastrointestinal bleeding and facial trauma and cannot adapt to non-invasive mechanical ventilation, these patients have IMV indication. Both methods are quite successful when used in selected cases. Therefore, patient selection is very important for NIMV and IMV (4). It is known that endotracheal intubation increases the risk of developing complications such as ventilator-associated pneumonia and sepsis. Therefore, unnecessary endotracheal intubation and invasive mechanical ventilation therapy are expected to increase mortality (5). On the other hand, delayed intubation decision is known to be an independent risk factor for increased mortality when NIMV fails (6) (7) (8). A method that predicts NIMV failure and enables effective mortality estimation may be useful in facilitating patient selection and providing appropriate treatment to patients. There are some criteria predicting that NIMV will fail in patients with severe respiratory distress and may be guiding for early intubation. The most commonly used of these are high APACHE 2 score, ARDS or pneumonia as the etiology of respiratory distress, advanced age, and no clinical improvement after 1 hour of treatment (9). However, APECHE 2 score, which is the broadest of these criteria and includes others, is a complex scoring in which a large number of parameters are evaluated together, dependent on laboratory results and still leaves the final decision to the physician with a complete evaluation. In addition, the APACHE 2 score is a more commonly used method for intensive care patients rather than emergency patients who need a quick decision. Therefore, there is a need for a fast and practical method that can predict NIMV failure and determine early intubation decision in the management of patients admitted to the emergency department with acute dyspnea. Rapid Shallow Breathing Index (RSBI) is a parameter calculated by dividing the respiratory rate by the tidal volume and is used to predict whether patients who are intubated in intensive care unit can be extubated successfully (10). In a study by Berg et al. (11) evaluating the endotracheal intubation and mortality rates of patients who underwent NIMV, it was found that the RSBI value above 105 obtained with a single measurement was significant in predicting NIV failure. Although this result is significant, it is not sufficient to make an early intubation decision. Considering that serial measurements are found to be more meaningful than a single measurement while predicting weaning success (12), serial measurements can provide more successful results in predicting intubation and mortality of patients receiving NIMV. Although the RSBI value obtained immediately after the initiation of NIMV is high, it is possible for the patient to be relieved after the patient has been treated with NIMV for a while and thus, the RSBI value may also decrease. For this reason, after these patients have been treated for a while, obtaining RSBI value once again and looking at the patient's response to treatment may provide more meaningful results.\n\nThe aim of this study is to evaluate the success of RSBI in predicting intubation and mortality in patients presented to the emergency department with acute respiratory failure and had NIMV indication."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Acute Respiratory Failure"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"267",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Intubation Group/ Non-Intubation Group",
                    "ArmGroupDescription":"Intubation group: Patients who failed noninvasive mechanical ventilation and who underwent endotracheal intubation Non-Intubation Group: Patients whose noninvasive mechanical ventilation is successful and endotracheal intubation is not applied",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Diagnostic Test: Rapid Shallow Breathing Index"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Dying patients / Surviving patients",
                    "ArmGroupDescription":"Dying patients :Patients with in-hospital mortality presenting with acute respiratory failure Surviving patients: Patients presenting and surviving due to acute respiratory failure",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Diagnostic Test: Rapid Shallow Breathing Index"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Diagnostic Test",
                    "InterventionName":"Rapid Shallow Breathing Index",
                    "InterventionDescription":"The RSBI is defined as the ratio of respiratory frequency to tidal volume.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Dying patients / Surviving patients",
                        "Intubation Group/ Non-Intubation Group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Rapid Shallow Breathing Index (RSBI)",
                    "PrimaryOutcomeDescription":"The RSBI is the ratio of respiratory frequency to tidal volume (f/VT). RSBI values measured at admission and 30 minutes are the primary outcome measures of the study.",
                    "PrimaryOutcomeTimeFrame":"0-30 minute."
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Mean arterial pressure",
                    "SecondaryOutcomeDescription":"It is obtained by summing twice the diastolic pressure with the systolic pressure and dividing the obtained value by 3.",
                    "SecondaryOutcomeTimeFrame":"0-30 minute"
                  },{
                    "SecondaryOutcomeMeasure":"Respiratory rate",
                    "SecondaryOutcomeDescription":"It refers to the patient's respiratory rate in 1 minute.",
                    "SecondaryOutcomeTimeFrame":"0-30 minute"
                  },{
                    "SecondaryOutcomeMeasure":"Heart rate",
                    "SecondaryOutcomeDescription":"It refers to the patient's Heart rate in 1 minute.",
                    "SecondaryOutcomeTimeFrame":"0-30 minute"
                  },{
                    "SecondaryOutcomeMeasure":"Oxygen saturation",
                    "SecondaryOutcomeDescription":"Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the blood.",
                    "SecondaryOutcomeTimeFrame":"0-30 minute"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nThis study included patients 18 years of age and older with acute respiratory failure of any etiology and in need of NIVM. NIMV Initiation Criteria;\nPresentation of acute respiratory acidosis (pH â©½7.35)\nTachypnea (respiratory rate >20-24 breaths/minute) despite the standart medical teraphy\nArterial oxygen tension/inspiratory oxygen fraction ratio (PaO2/FIO2) â©½200\n\nExclusion Criteria:\n\nPregnancy, trauma, NIMV intolerance and IMV initiation criteria;\nCardiac or respiratory arrest\nUnstable cardiac arrhythmias\nHemodynamic instability\nSevere encephalopathy (GCS <10)\nSevere upper gastrointestinal bleeding\nFacial trauma\nUpper airway obstruction\nInability to protect the airway",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"The study population consisted of only patients (patients admitted to the emergency department with acute respiratory failure)",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Fatih Topal, MD",
                    "OverallOfficialAffiliation":"Izmir Katip Celebi University",
                    "OverallOfficialRole":"Study Chair"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"IKCU, Ataturk Training and Research Hospital, Department of Emergency Medicine",
                    "LocationCity":"Ä°zmir",
                    "LocationZip":"35360",
                    "LocationCountry":"Turkey"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"8686717",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Chatila W, Jacob B, Guaglionone D, Manthous CA. The unassisted respiratory rate-tidal volume ratio accurately predicts weaning outcome. Am J Med. 1996 Jul;101(1):61-7."
                  },{
                    "ReferencePMID":"32329452",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Shrestha AP, Shrestha R, Shrestha SK, Pradhan A. Prevalence of Dyspnea among Patients Attending the Emergency Department of a Tertiary Care Hospital: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2019 Sep-Oct;57(219):302-306."
                  },{
                    "ReferencePMID":"32232782",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Huang CC, Muo CH, Wu TF, Chi TY, Shen TC, Hsia TC, Shih CM. The application of non-invasive and invasive mechanical ventilation in the first episode of acute respiratory failure. Intern Emerg Med. 2021 Jan;16(1):83-91. doi: 10.1007/s11739-020-02315-1. Epub 2020 Mar 30."
                  },{
                    "ReferencePMID":"25143721",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Mas A, Masip J. Noninvasive ventilation in acute respiratory failure. Int J Chron Obstruct Pulmon Dis. 2014 Aug 11;9:837-52. doi: 10.2147/COPD.S42664. eCollection 2014. Review."
                  },{
                    "ReferenceType":"result",
                    "ReferenceCitation":"Hayzy RC, McSpasson JI. Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2020."
                  },{
                    "ReferencePMID":"11066187",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Girou E, Schortgen F, Delclaux C, Brun-Buisson C, Blot F, Lefort Y, Lemaire F, Brochard L. Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients. JAMA. 2000 Nov 8;284(18):2361-7."
                  },{
                    "ReferencePMID":"15190137",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, ApezteguÃ­a C, GonzÃ¡lez M, Epstein SK, Hill NS, Nava S, Soares MA, D'Empaire G, AlÃ­a I, Anzueto A. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med. 2004 Jun 10;350(24):2452-60."
                  },{
                    "ReferencePMID":"28860265",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, Navalesi P Members Of The Steering Committee, Antonelli M, Brozek J, Conti G, Ferrer M, Guntupalli K, Jaber S, Keenan S, Mancebo J, Mehta S, Raoof S Members Of The Task Force. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017 Aug 31;50(2). pii: 1602426. doi: 10.1183/13993003.02426-2016. Print 2017 Aug. Review."
                  },{
                    "ReferencePMID":"26464393",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Demoule A, Chevret S, Carlucci A, Kouatchet A, Jaber S, Meziani F, Schmidt M, Schnell D, Clergue C, Aboab J, Rabbat A, Eon B, GuÃ©rin C, Georges H, Zuber B, Dellamonica J, Das V, Cousson J, Perez D, Brochard L, Azoulay E; oVNI Study Group; REVA Network (Research Network in Mechanical Ventilation). Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries. Intensive Care Med. 2016 Jan;42(1):82-92. doi: 10.1007/s00134-015-4087-4. Epub 2015 Oct 13."
                  },{
                    "ReferencePMID":"11810114",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M, Pelaia P, Principi T, Gregoretti C, Beltrame F, Pennisi MA, Arcangeli A, Proietti R, Passariello M, Meduri GU. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. Intensive Care Med. 2001 Nov;27(11):1718-28. Epub 2001 Oct 16."
                  },{
                    "ReferencePMID":"27512505",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Karthika M, Al Enezi FA, Pillai LV, Arabi YM. Rapid shallow breathing index. Ann Thorac Med. 2016 Jul-Sep;11(3):167-76. doi: 10.4103/1817-1737.176876. Review."
                  },{
                    "ReferencePMID":"22417884",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Berg KM, Lang GR, Salciccioli JD, Bak E, Cocchi MN, Gautam S, Donnino MW. The rapid shallow breathing index as a predictor of failure of noninvasive ventilation for patients with acute respiratory failure. Respir Care. 2012 Oct;57(10):1548-54. Epub 2012 Mar 12."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No",
              "IPDSharingDescription":"We have a plan to make individual participant data (IPD) available to other researchers."
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000012131",
                    "ConditionMeshTerm":"Respiratory Insufficiency"
                  },{
                    "ConditionMeshId":"D000012128",
                    "ConditionMeshTerm":"Respiratory Distress Syndrome, Adult"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000012120",
                    "ConditionAncestorTerm":"Respiration Disorders"
                  },{
                    "ConditionAncestorId":"D000012140",
                    "ConditionAncestorTerm":"Respiratory Tract Diseases"
                  },{
                    "ConditionAncestorId":"D000008171",
                    "ConditionAncestorTerm":"Lung Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M13551",
                    "ConditionBrowseLeafName":"Respiratory Insufficiency",
                    "ConditionBrowseLeafAsFound":"Respiratory Failure",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M25724",
                    "ConditionBrowseLeafName":"Respiratory Aspiration",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13102",
                    "ConditionBrowseLeafName":"Pulmonary Valve Insufficiency",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13548",
                    "ConditionBrowseLeafName":"Respiratory Distress Syndrome, Adult",
                    "ConditionBrowseLeafAsFound":"Acute Respiratory Failure",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13547",
                    "ConditionBrowseLeafName":"Respiratory Distress Syndrome, Newborn",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14938",
                    "ConditionBrowseLeafName":"Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M26731",
                    "ConditionBrowseLeafName":"Acute Lung Injury",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13540",
                    "ConditionBrowseLeafName":"Respiration Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13560",
                    "ConditionBrowseLeafName":"Respiratory Tract Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9751",
                    "ConditionBrowseLeafName":"Lung Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T4927",
                    "ConditionBrowseLeafName":"Respiratory Distress Syndrome, Infant",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T192",
                    "ConditionBrowseLeafName":"Acute Respiratory Distress Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC16",
                    "ConditionBrowseBranchName":"Diseases and Abnormalities at or Before Birth"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":22,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780490",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2018/374"
              },
              "Organization":{
                "OrgFullName":"Istanbul University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Comparison of Liberal and Restrictive Fluid Management on the Endothelial Glycocalyx in Radical Cystectomy",
              "OfficialTitle":"Comparison of the Effects of Perioperative Liberal and Restrictive Fluid Management on the Endothelial Glycocalyx Layer in Radical Cystectomy and Urinary Diversion"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2018",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"March 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"April 1, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 6, 2020",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Meltem Savran Karadeniz",
                "ResponsiblePartyInvestigatorTitle":"Associate Professor",
                "ResponsiblePartyInvestigatorAffiliation":"Istanbul University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Istanbul University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The aim of this study is to compare the effect of the liberal and restrictive fluid treatments which are routinely performed in major urological surgeries in the perioperative period on ANP release and the endothelial glycocalyx layer.\n\nIn the study, the investigators aimed to compare changes in the glycocalyx structure by measuring the blood levels of ANP and heparan sulfate, hyaluronan and syndecan 1, which form the glycocalyx structure on the patients who received the liberal and restrictive fluid treatments during major urological surgeries.",
              "DetailedDescription":"There is no strong evidence about the optimal fluid resuscitation for the patients undergoing major surgeries. Avoiding excess fluid resuscitation in the perioperative period is essential for reducing postoperative complications, morbidity and long-term mortality. In the perioperative period, ANP is released with increased wall stress in the cardiac atrium due to excess fluid loading. With the release of ANP, damage occurs in the glycocalyx layer, which is the structure primarily responsible for the permeability in the vascular endothelium.\n\nThus, the amount of ANP released from atrium and heparan sulfate, syndecan 1, hyaluronan in the glycocalyx layer structure increases in the blood.\n\nThe aim of this study is to compare changes in the glycocalyx structure by measuring the blood levels of ANP and heparan sulfate, hyaluronan and syndecan 1, which form the glycocalyx structure on the patients who received the liberal and restrictive fluid treatments during major urological surgeries. The blood samples will be taken at the beginning and at the end of the surgery.\n\nThe primary outcome of this study is the increase in ANP levels and heparan sulfate , hyaluronic acid, syndecan 1 levels which are the glycocalyx damage products in blood.\n\nSecondary outcomes are intraoperative advanced hemodynamic cardiac measurement values, the amount of blood and blood products replaced to patients, duration of intensive care stay, duration of hospital stay, cardiac and respiratory complications, gastrointestinal complications, urinary complications, surgical complications such as anastomotic leaks, wound infection and fistula."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Fluid Retention Tissue"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "peroperative fluid management",
                  "restrictive fluid therapy",
                  "endothelial glycocalyx",
                  "Liberal fluid therapy"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Triple",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"37",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"liberal fluid therapy",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine (No medication from the epidural catheter will be administered during surgery).\n\nStandard anesthesia induction will be applied (fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ), and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.\n\nFluid resuscitation will be started with 10 ml / kg / hr Ringer's lactate solution.\n\nIn patients with MAP <65 mmHg, 250 ml of Ringer's lactate solution will be given as a bolus.\n\nIf the hypotension persists, the bolus 250 ml Ringer's lactate solution will be repeated up to 10 times.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: liberal fluid management"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"restrictive fluid therapy",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine ( No medication from the epidural catheter will be administered during surgery. ) Standard anesthesia induction will be applied ( fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ) and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.\n\nFluid resuscitation will be started with 2 ml / kg / hr Ringer's lactate solution and norepinephrine infusion at a dose of 2 mcg / kg / hr.\n\nIn patients with MAP<65 mmHg, norepinephrine dose will be increased up to 8 mcg / kg / hr.\n\nIf the hypotension persists although the norepinephrine dose is 8 mcg / kg / hr, 250 ml bolus Ringer's lactate solution will be given.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: restrictive fluid management"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"liberal fluid management",
                    "InterventionDescription":"10 ml/ kg/ hr Ringer's lactate solution",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "liberal fluid therapy"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"restrictive fluid management",
                    "InterventionDescription":"2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "restrictive fluid therapy"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Atrial Natriuretic Peptide (ANP)( pg/mL)",
                    "PrimaryOutcomeDescription":"Blood ANP concentration will be determined using an enzyme-linked immunosorbent assay kit",
                    "PrimaryOutcomeTimeFrame":"The blood sample will be taken at beginning and end of the surgery"
                  },{
                    "PrimaryOutcomeMeasure":"Heparan sulfate (ng/L)",
                    "PrimaryOutcomeDescription":"Blood Heparan sulfate concentration will determine using an enzyme-linked immunosorbent assay kit",
                    "PrimaryOutcomeTimeFrame":"The blood sample will be taken at beginning and end of the surgery"
                  },{
                    "PrimaryOutcomeMeasure":"Syndecan 1 (pg/mL)",
                    "PrimaryOutcomeDescription":"Blood Syndecan 1 concentration will be determined using an enzyme-linked immunosorbent",
                    "PrimaryOutcomeTimeFrame":"The blood sample will be taken at beginning and end of the surgery"
                  },{
                    "PrimaryOutcomeMeasure":"Hyaluronan (ng/L)",
                    "PrimaryOutcomeDescription":"Blood Hyaluronan concentration will be determined using an enzyme-linked immunosorbent",
                    "PrimaryOutcomeTimeFrame":"The blood sample will be taken at beginning and end of the surgery"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Amount of blood transfusion (unit)",
                    "SecondaryOutcomeDescription":"Including red cell, fresh frozen plasma",
                    "SecondaryOutcomeTimeFrame":"From the beginning surgery to day 2 postoperatively"
                  },{
                    "SecondaryOutcomeMeasure":"Total intensive care unit (ICU) stay (Hour, day)",
                    "SecondaryOutcomeDescription":"Including initial ICU admission and readmission times",
                    "SecondaryOutcomeTimeFrame":"30 days postoperative"
                  },{
                    "SecondaryOutcomeMeasure":"Hospital stay (Hour, day)",
                    "SecondaryOutcomeDescription":"From the beginning of surgery until actual hospital discharge",
                    "SecondaryOutcomeTimeFrame":"90 days postoperative"
                  },{
                    "SecondaryOutcomeMeasure":"Gastrointestinal complications",
                    "SecondaryOutcomeDescription":"Ileus, constipation, gastrointestinal bleeding, gastric ulcer, anastomotic intestinal leakage",
                    "SecondaryOutcomeTimeFrame":"30 days postoperative"
                  },{
                    "SecondaryOutcomeMeasure":"Infectious complications",
                    "SecondaryOutcomeDescription":"Urinary tract infection, pyelonephritis, urosepsis, pneumonia, wound infection",
                    "SecondaryOutcomeTimeFrame":"30 days postoperative"
                  },{
                    "SecondaryOutcomeMeasure":"Surgical site complications",
                    "SecondaryOutcomeDescription":"Wound dehiscence, evisceration",
                    "SecondaryOutcomeTimeFrame":"30 days postoperative"
                  },{
                    "SecondaryOutcomeMeasure":"Genitourinary complications",
                    "SecondaryOutcomeDescription":"Acute kidney injury, urethral anastamosis leak",
                    "SecondaryOutcomeTimeFrame":"30 days postoperative"
                  },{
                    "SecondaryOutcomeMeasure":"Cardiac complications",
                    "SecondaryOutcomeDescription":"Acute myocardial infarction, congestive heart failure, arrhythmia",
                    "SecondaryOutcomeTimeFrame":"30 days postoperative"
                  },{
                    "SecondaryOutcomeMeasure":"Thromboembolic complications",
                    "SecondaryOutcomeDescription":"pulmonary embolism",
                    "SecondaryOutcomeTimeFrame":"30 days postoperative"
                  },{
                    "SecondaryOutcomeMeasure":"Stroke Volume Variation (SVV)(%)",
                    "SecondaryOutcomeDescription":"SVV will be measured with Flo-Trac system (Edward Life Sciences). Normal range is about %10-15",
                    "SecondaryOutcomeTimeFrame":"From onset of the surgery up to end of the surgery, every 30 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Cardiac Index(CI )(l min-1 m-2),",
                    "SecondaryOutcomeDescription":"CI will be measured with Flo-Trac system (Edward Life Sciences). Normal value is 2,6-4,2 l min-1 m-2",
                    "SecondaryOutcomeTimeFrame":"From onset of the surgery up to end of the surgery, every 30 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Systemic Vascular Resistance Index (SVRI )(dyn*s.cm-5 )",
                    "SecondaryOutcomeDescription":"SVRI will be measured with Flo-Trac system (Edward Life Sciences). Normal value is about 900-1300 dyn*s.cm-5",
                    "SecondaryOutcomeTimeFrame":"From onset of the surgery up to end of the surgery, every 30 minutes"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nASA (The American Society of Anesthesiologists) status I-II-III patients\nCases undergoing major urological surgery\nCases for invasive artery monitoring and central venous catheterization\nPatients receiving general anesthesia\nVolunteering to participate in the study\n\nExclusion Criteria:\n\nCoagulopathy\nPatients with severe heart, kidney and liver dysfunction (EF <35% and / or GFR <30, Cre:> 2.5 and / or impaired liver function tests)",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Burcu Kulaksiz Mammadov, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+905447361952",
                    "CentralContactEMail":"burcukulaksiz@istanbul.edu.tr"
                  },{
                    "CentralContactName":"Meltem Savran Karadeniz, Assoc. Prof",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+902124142153",
                    "CentralContactEMail":"mskaradeniz@gmail.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Meltem Savran KARADENÄ°Z",
                    "OverallOfficialAffiliation":"Istanbul University",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Istanbul University",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Istanbul",
                    "LocationZip":"34093",
                    "LocationCountry":"Turkey",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Burcu Kulaksiz Mammadov, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+905447361952",
                          "LocationContactEMail":"burcukulaksiz@istanbul.edu.tr"
                        },{
                          "LocationContactName":"Meltem Savran Karadeniz, Assoc. Prof",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+902124142153",
                          "LocationContactEMail":"mskaradeniz@gmail.com"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "ReferencesModule":{
              "SeeAlsoLinkList":{
                "SeeAlsoLink":[
                  {
                    "SeeAlsoLinkLabel":"Restrictive deferred hydration combined with preemptive norepinephrine infusion during radical cystectomy reduces postoperative complications and hospitalization time: a randomized clinical trial.",
                    "SeeAlsoLinkURL":"https://www.ncbi.nlm.nih.gov/pubmed/23887199"
                  },{
                    "SeeAlsoLinkLabel":"Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx.",
                    "SeeAlsoLinkURL":"https://www.ncbi.nlm.nih.gov/pubmed/25497357"
                  },{
                    "SeeAlsoLinkLabel":"Revised Starling equation and the glycocalyx model of transvascular ï¬‚uid exchange: an improved paradigm for prescribing intravenous ï¬‚uid therapy",
                    "SeeAlsoLinkURL":"https://www.ncbi.nlm.nih.gov/pubmed/22290457"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2688",
                    "InterventionBrowseLeafName":"Anesthetics",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M11158",
                    "InterventionBrowseLeafName":"Norepinephrine",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M9597",
                    "InterventionBrowseLeafName":"Lidocaine",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M1673",
                    "InterventionBrowseLeafName":"Sevoflurane",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M16890",
                    "InterventionBrowseLeafName":"Propofol",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M10428",
                    "InterventionBrowseLeafName":"Midazolam",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M20444",
                    "InterventionBrowseLeafName":"Pharmaceutical Solutions",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M7001",
                    "InterventionBrowseLeafName":"Fentanyl",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M1666",
                    "InterventionBrowseLeafName":"Rocuronium",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"CNSDep",
                    "InterventionBrowseBranchName":"Central Nervous System Depressants"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"VaCoAg",
                    "InterventionBrowseBranchName":"Vasoconstrictor Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"AnArAg",
                    "InterventionBrowseBranchName":"Anti-Arrhythmia Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"ChanBlk",
                    "InterventionBrowseBranchName":"Channel Blockers"
                  },{
                    "InterventionBrowseBranchAbbrev":"PlAggInh",
                    "InterventionBrowseBranchName":"Platelet Aggregation Inhibitors"
                  },{
                    "InterventionBrowseBranchAbbrev":"AdjAn",
                    "InterventionBrowseBranchName":"Adjuvants, Anesthesia"
                  },{
                    "InterventionBrowseBranchAbbrev":"PsychDr",
                    "InterventionBrowseBranchName":"Psychotropic Drugs"
                  },{
                    "InterventionBrowseBranchAbbrev":"PhSol",
                    "InterventionBrowseBranchName":"Pharmaceutical Solutions"
                  },{
                    "InterventionBrowseBranchAbbrev":"Analg",
                    "InterventionBrowseBranchName":"Analgesics"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":23,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780477",
              "OrgStudyIdInfo":{
                "OrgStudyId":"STUDY00000563"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"R01CA245063",
                    "SecondaryIdType":"U.S. NIH Grant/Contract",
                    "SecondaryIdLink":"https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01CA245063&Fy=all"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Emory University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer",
              "OfficialTitle":"Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"February 2026",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"February 2026",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 2, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Terry Hartman",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Emory University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Emory University",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"National Cancer Institute (NCI)",
                    "CollaboratorClass":"NIH"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The study will target a population at high risk for colorectal cancer, overweight and obese participants with a history of a colon polyp in the past 3 years to test whether a high-legume, high-fiber diet will simultaneously increase weight loss and suppress intestinal biomarkers of cancer risk compared to a control diet (healthy American). In addition, it will explore potential mechanisms through which the high-legume intervention diet facilitates weight loss and intestinal health.",
              "DetailedDescription":"The goal of the research is to conduct a clinical trial featuring study-provided pre-portioned entrÃ©es (2 entrÃ©es per day months 1-3, 1 entrÃ©e per day months 4-6) and strategic nutritional instruction to guide participants to integrate legumes into a healthy high-fiber diet pattern. The research will target a population at high risk for colorectal cancer, overweight and obese participants with a history of a colon polyp in the past 3 years, to test whether a high-legume, high-fiber diet will simultaneously increase weight loss and suppress intestinal biomarkers of cancer risk compared to a control diet (healthy American). In addition, it will explore potential mechanisms through which the high-legume intervention diet facilitates weight loss and intestinal health."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Colon Cancer",
                  "Obesity"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Fiber-rich Foods",
                  "Legumes",
                  "Weight loss",
                  "Intestinal health",
                  "Cancer prevention"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Prevention",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"70",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"High Fiber Diet (HFD)",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"High Fiber Diet (HFD) will add approximately 25-30 grams of dietary fiber/d from legume dishes.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Experimental: High Fiber Diet (HFD)"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Healthy American Diet",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Healthy American Diet pre-portioned meal replacement entrÃ©es with legumes replaced by lean chicken/meat.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Healthy American Diet"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Experimental: High Fiber Diet (HFD)",
                    "InterventionDescription":"Experimental: High Fiber Diet (HFD) pre-portioned entrÃ©es for two meals/d in mos. 1-3, and one meal/d in mos. 4-6. Participants continue on their respective diets in mos. 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250g of legumes per day (~1 Â½ cups cooked) in months 1-3 provided in two pre-portioned single serving entrÃ©es (i.e. ~125g each). A study nutritionist will provide in-person and written guidance for including sides that are nutritionally balanced with energy intake to lose 1-2 lbs. /wk.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "High Fiber Diet (HFD)"
                      ]
                    }
                  },{
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Healthy American Diet",
                    "InterventionDescription":"Healthy American Diet pre-portioned meal replacement entrÃ©es with legumes replaced by lean chicken/meat. A study nutritionist will provide in-person and written guidance for including sides that are nutritionally balanced with energy intake to lose 1-2 lbs. /wk.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Healthy American Diet"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Body weight measured in pounds",
                    "PrimaryOutcomeDescription":"Participants will have their body weight measured in light clothing without shoes on a regularly calibrated digital scale",
                    "PrimaryOutcomeTimeFrame":"6 months"
                  },{
                    "PrimaryOutcomeMeasure":"Ki-67+ level",
                    "PrimaryOutcomeDescription":"Colonic mucosal proliferative marker Ki-67+ will be measured",
                    "PrimaryOutcomeTimeFrame":"6 months"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Body weight measured in pounds",
                    "SecondaryOutcomeDescription":"Participants will have their body weight measured in light clothing without shoes on a regularly calibrated digital scale",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  },{
                    "SecondaryOutcomeMeasure":"Ki-67+ level",
                    "SecondaryOutcomeDescription":"Colonic mucosal proliferative marker Ki-67+ will be measured",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  },{
                    "SecondaryOutcomeMeasure":"Gut transit time",
                    "SecondaryOutcomeDescription":"Gut transit time will be assessed using an indigestible single-use SmartPill capsule, a receiver, and display software.",
                    "SecondaryOutcomeTimeFrame":"6 months"
                  },{
                    "SecondaryOutcomeMeasure":"Fasting plasma insulin level",
                    "SecondaryOutcomeDescription":"Biomarker of insulin resistance - fasting plasma insulin - will be measured by blood test",
                    "SecondaryOutcomeTimeFrame":"6 months"
                  },{
                    "SecondaryOutcomeMeasure":"Fasting plasma insulin level",
                    "SecondaryOutcomeDescription":"Biomarker of insulin resistance - fasting plasma insulin - will be measured by blood test",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  },{
                    "SecondaryOutcomeMeasure":"Fasting plasma glucose level",
                    "SecondaryOutcomeDescription":"Biomarker of insulin resistance - fasting plasma glucose - will be measured by blood test",
                    "SecondaryOutcomeTimeFrame":"6 months"
                  },{
                    "SecondaryOutcomeMeasure":"Fasting plasma glucose level",
                    "SecondaryOutcomeDescription":"Biomarker of insulin resistance - fasting plasma glucose - will be measured by blood test",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  },{
                    "SecondaryOutcomeMeasure":"Serum C-reactive protein",
                    "SecondaryOutcomeDescription":"Systemic inflammation indicator - serum C-reactive protein - will be measured by blood test",
                    "SecondaryOutcomeTimeFrame":"6 months"
                  },{
                    "SecondaryOutcomeMeasure":"Serum C-reactive protein",
                    "SecondaryOutcomeDescription":"Systemic inflammation indicator - serum C-reactive protein - will be measured by blood test",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  },{
                    "SecondaryOutcomeMeasure":"CD3+ intraepithelial lymphocytes count",
                    "SecondaryOutcomeDescription":"Colonic mucosal inflammatory biomarker - CD3+ intraepithelial lymphocytes - will be measured",
                    "SecondaryOutcomeTimeFrame":"6 months"
                  },{
                    "SecondaryOutcomeMeasure":"CD3+ intraepithelial lymphocytes count",
                    "SecondaryOutcomeDescription":"Colonic mucosal inflammatory biomarker - CD3+ intraepithelial lymphocytes - will be measured",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  },{
                    "SecondaryOutcomeMeasure":"CD68+ lamina propia macrophages count",
                    "SecondaryOutcomeDescription":"Colonic mucosal inflammatory biomarker - CD68+ lamina propia macrophages - will be measured",
                    "SecondaryOutcomeTimeFrame":"6 months"
                  },{
                    "SecondaryOutcomeMeasure":"CD68+ lamina propia macrophages count",
                    "SecondaryOutcomeDescription":"Colonic mucosal inflammatory biomarker - CD68+ lamina propia macrophages - will be measured",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nfree-living adults 40-75 yrs. old\nBMI 25-40 kg/m2\ncolonoscopy within 3 years that found â‰¥1 adenoma >0.5 cm\nEnglish speaking,\nambulatory, able to pick up food, participate in clinical exams and laboratory tests - able to provide informed consent\n\nExclusion Criteria:\n\nserious medical condition (e.g., cancer, heart disease, kidney disease, diabetes,)\nhistory of CRC, bowel resection, polyposis syndrome, or inflammatory bowel disease\nsmoked regularly in the past year\ndietary restrictions substantially limiting compliance (e.g., must be willing to be randomized to either diet)\nplanning on substantially changing usual exercise behavior in the next 6 mos\nregular use of medication that may alter inflammation markers, insulin, glucose, or gut function (e.g., non-steroidal anti-inflammatory drugs, antibiotics, insulin, steroids)\npregnant women, breast feeding women, or women planning pregnancy within the year of active study participation",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"40 Years",
              "MaximumAge":"75 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Terry Hartman, PhD, MPH, RD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"404-727-8713",
                    "CentralContactEMail":"tjhartm@emory.edu"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Terry Hartman, PhD, MPH, RD",
                    "OverallOfficialAffiliation":"Emory University",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Rollins School of Public Health, Emory University",
                    "LocationCity":"Atlanta",
                    "LocationState":"Georgia",
                    "LocationZip":"30322",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Terry Hartman, PHD, MPH",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"404-727-8713",
                          "LocationContactEMail":"terryl.johnson.hartman@emory.edu"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"Limited de-identified participant phenotypic data will be shared but limited to health/biomedical purposes including age, obesity status, presence of colon polyps and history of diabetes. The data will be coded. Only the coded data set and not the master list will be shared.",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol"
                ]
              },
              "IPDSharingTimeFrame":"Beginning 9 months and ending 36 months following article publication",
              "IPDSharingAccessCriteria":"Proposals should be directed to tjhartm@emory.edu. To gain access requestors will need to sign a data access agreement.\n\nTo meet NIH data sharing requirements selected data will be deposited in appropriate research data repositories (e.g., NIH Common Fund Metabolomics Workbench). For genomic data, all data generated by this project will be made publicly available through adequate public genomic data warehouses as appropriate to the data type (NCBI Short Read Archives, Gene expression omnibus, etc.). Sequence data will be screened for the presence of sequences from human and these will be removed from public submissions unless directed otherwise by the NIH. Our algorithms will be made available through publications and as standalone programs when this is feasible. All new genomic and microbiome datasets will be deposited in public databases."
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003110",
                    "ConditionMeshTerm":"Colonic Neoplasms"
                  },{
                    "ConditionMeshId":"D000009765",
                    "ConditionMeshTerm":"Obesity"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000044343",
                    "ConditionAncestorTerm":"Overnutrition"
                  },{
                    "ConditionAncestorId":"D000009748",
                    "ConditionAncestorTerm":"Nutrition Disorders"
                  },{
                    "ConditionAncestorId":"D000050177",
                    "ConditionAncestorTerm":"Overweight"
                  },{
                    "ConditionAncestorId":"D000001835",
                    "ConditionAncestorTerm":"Body Weight"
                  },{
                    "ConditionAncestorId":"D000015179",
                    "ConditionAncestorTerm":"Colorectal Neoplasms"
                  },{
                    "ConditionAncestorId":"D000007414",
                    "ConditionAncestorTerm":"Intestinal Neoplasms"
                  },{
                    "ConditionAncestorId":"D000005770",
                    "ConditionAncestorTerm":"Gastrointestinal Neoplasms"
                  },{
                    "ConditionAncestorId":"D000004067",
                    "ConditionAncestorTerm":"Digestive System Neoplasms"
                  },{
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  },{
                    "ConditionAncestorId":"D000005767",
                    "ConditionAncestorTerm":"Gastrointestinal Diseases"
                  },{
                    "ConditionAncestorId":"D000003108",
                    "ConditionAncestorTerm":"Colonic Diseases"
                  },{
                    "ConditionAncestorId":"D000007410",
                    "ConditionAncestorTerm":"Intestinal Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M11284",
                    "ConditionBrowseLeafName":"Obesity",
                    "ConditionBrowseLeafAsFound":"Obesity",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3696",
                    "ConditionBrowseLeafName":"Body Weight",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16685",
                    "ConditionBrowseLeafName":"Weight Loss",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4921",
                    "ConditionBrowseLeafName":"Colonic Neoplasms",
                    "ConditionBrowseLeafAsFound":"Colon Cancer",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M23894",
                    "ConditionBrowseLeafName":"Overnutrition",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M11267",
                    "ConditionBrowseLeafName":"Nutrition Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M24773",
                    "ConditionBrowseLeafName":"Overweight",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16473",
                    "ConditionBrowseLeafName":"Colorectal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9031",
                    "ConditionBrowseLeafName":"Intestinal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5839",
                    "ConditionBrowseLeafName":"Digestive System Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7469",
                    "ConditionBrowseLeafName":"Gastrointestinal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4919",
                    "ConditionBrowseLeafName":"Colonic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9027",
                    "ConditionBrowseLeafName":"Intestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC18",
                    "ConditionBrowseBranchName":"Nutritional and Metabolic Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"T120",
                    "InterventionBrowseLeafName":"Cola",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"HB",
                    "InterventionBrowseBranchName":"Herbal and Botanical"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":24,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780464",
              "OrgStudyIdInfo":{
                "OrgStudyId":"EORTC-1976-STBSG"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"2021-000125-27",
                    "SecondaryIdType":"EudraCT Number"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"European Organisation for Research and Treatment of Cancer - EORTC",
                "OrgClass":"NETWORK"
              },
              "BriefTitle":"A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma",
              "OfficialTitle":"a 3 Arm Randomized Study on Health-related Quality of Life of Elderly Patients With Advanced Soft Tissue Sarcoma Undergoing Doxorubicin Alone Three Weekly or Doxorubicin Weekly or Cyclophosphamide Plus Prednisolone Treatment",
              "Acronym":"Tolerance"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"September 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 1, 2025",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 1, 2027",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 2, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"European Organisation for Research and Treatment of Cancer - EORTC",
                "LeadSponsorClass":"NETWORK"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a multi-centre, open label, randomized phase 3 selection study (1:2:2 randomization).\n\nAfter confirmation of the eligibility criteria, 185 patients will be randomized 1:2:2 to either the control arm (doxorubicin 60-75 mg/mÂ² IV every 3 weeks) or experimental arm 1 (doxorubicin 12 mg/m2 IV every week) or experimental arm 2 (cyclophosphamide 100 mg orally BD plus prednisolone 10-20 mg orally on day 1 to day 7 of each 14 day cycle).\n\nHRQoL assessment will be performed every 3 weeks during the first 12 weeks and every 12 weeks thereafter until month 12 after start of treatment.\n\nDisease evaluation will be performed every 12 weeks until progression. The primary endpoint of the study is difference among the study arms in physical and role functioning at 12 weeks."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Advanced Soft-tissue Sarcoma"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Quality of Life",
                  "Elderly"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 3"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"185",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Standard doxorubicin",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Doxorubicin"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Metronomic doxorubicin",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Doxorubicin"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Metronomic oral cyclophosphamide + prednisolone",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Cyclophosphamide Oral Product",
                        "Drug: Prednisolone"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Doxorubicin",
                    "InterventionDescription":"60 to 75 mg/mÂ² intravenous, every 3 weeks for max 6 cycles until PD",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Standard doxorubicin"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Adriamycin;"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Doxorubicin",
                    "InterventionDescription":"12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Metronomic doxorubicin"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Adriamycin;"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Cyclophosphamide Oral Product",
                    "InterventionDescription":"100 mg BD on day 1 to day 7 of each 14 day cycle until PD",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Metronomic oral cyclophosphamide + prednisolone"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Prednisolone",
                    "InterventionDescription":"10-20 mg on day 1 to day 7 of each 14 day cycle until PD",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Metronomic oral cyclophosphamide + prednisolone"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Health-related Quality of Life",
                    "PrimaryOutcomeDescription":"Difference in physical and role functioning at 12 weeks",
                    "PrimaryOutcomeTimeFrame":"4 years after first patient in"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Tumour response",
                    "SecondaryOutcomeDescription":"tumor response according to RECIST criteria (version 1.1)",
                    "SecondaryOutcomeTimeFrame":"5.5 years after first patient in"
                  },{
                    "SecondaryOutcomeMeasure":"Progression-free-survival",
                    "SecondaryOutcomeDescription":"Progression-free-survival from the date of randomization to the date of first progression or death, whatever comes first",
                    "SecondaryOutcomeTimeFrame":"5.5 years after first patient in"
                  },{
                    "SecondaryOutcomeMeasure":"Overall survival",
                    "SecondaryOutcomeDescription":"Overall survival from the date of randomization to the date of death, whatever the cause",
                    "SecondaryOutcomeTimeFrame":"5.5 years after first patient in"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nHistologically proven advanced unresectable or metastatic soft tissue sarcoma\nRepresentative formalin fixed, paraffin embedded tumor blocks or a minimum of 10 unstained tissue slides, either from the primary tumor or a metastatic lesion, must be available for histological central review. Histological central review is not required before treatment start but it is mandatory to send at least 10 unstained tumor slides (blocks optional) at time of study entry. Local histopathological diagnosis will be accepted for entry into this trial.\nAge â‰¥ 65 years of age (patients between 65 and 69 years old are eligible if G8 score â‰¤ 14; patients â‰¥ 70 years old are eligible independent of G8 score)\nWHO performance status 0 - 2\nLife expectancy based on other significant morbidity of â‰¥ 6 months\nPresence of measurable disease (according to RECIST 1.1), as confirmed by imaging within the 28 days prior to randomization. CT with IV contrast is the preferred imaging modality. In case of any contra-indications (medical or regulatory), it is allowed to perform a non-contrast CT + MRI.\nProgressive disease at entry based on RECIST 1.1\nPatients amenable to receive doxorubicin according to investigator's assessment\nAdequate haematological and organ function assessed prior to randomization:\n\nHaematological function:\n\nhaemoglobin â‰¥ 9.0 g/dL or 5.6 mmol/L\nabsolute neutrophil count (ANC) â‰¥ 1.5 x 109/L\nplatelet count â‰¥ 100 x 109/L\nCoagulation: partial thromboplastin time (PTT) â‰¤ 1.0 times upper limit of normal (1.0 x ULN) of institutional limits and prothrombin time (PT) â‰¤ 1.0 x ULN of institutional limits\nRenal function: estimated glomerular filtration rate (eGFR) > 50 ml/min/m2 (calculated by the MDRD formula in appendix E); no proteinuria â‰¥ grade 2 (CTCAE version 5.0);\nHepatic function: bilirubin â‰¤ 1.0 x ULN of institutional limits, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) â‰¤1.5 x ULN.\n\nIf isolated elevated bilirubin <2 x ULN and Gilberts syndrome suspected, suggest repeating bloods after food. If bilirubin improves to meet the criteria above this is acceptable. More severe persistent hepatic impairment of whatever cause would exclude the patient from treatment till resolved.\n\nCardiac function: clinically normal function based on the institutional lower limit of normal for left ventricular ejection fraction (LVEF) as assessed either by multi-gated acquisition scan (MUGA) or cardiac ultrasound and 12 lead electrocardiogram (ECG) without clinically relevant abnormalities. Measurement should include investigator assessment of a potential participant's risk for heart failure with a validated clinical classification system, i.e. the New York Heart Association Functional Classification. Only patients with NYHA class 1 and 2 according to appendix D are eligible.\nCompletion of EORTC QLQ-C30 and EORTC QLQ-ELD14 at baseline.\nAssessment of G8 geriatric screening tool\nAssessment of Katz Index of Independence in Activities of Daily Living (ADL)\nFor men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:\nWith female partners of childbearing potential, men must remain abstinent or use a condom during the treatment period and for a period of 6 months after the last dose of doxorubicin-based chemotherapy and for a period of 12 months after the last dose of cyclophosphamide-based chemotherapy. Men must refrain from donating sperm during this same period. Contraception should be considered for the female partners of childbearing potential as well.\nWith pregnant female partners, men must remain abstinent or use a condom during the treatment period and for a period of 6 months after the last dose of doxorubicin-based chemotherapy and for a period of 12 months after the last dose of cyclophosphamide-based chemotherapy to avoid exposing the embryo.\nBefore patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations including commitment to completing questionnaires during the course of the study.\n\nExclusion Criteria:\n\nSymptomatic or known brain metastasis\nAny prior treatment with anthracyclines\nAny prior systemic treatment for metastatic STS\nInability to swallow and/ or retain oral tablets\nRare hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption\nHypersensitivity to doxorubicin, cyclophosphamide, prednisolone or to any of their metabolites or to any of their excipients\nUncontrolled severe illness, including but not limited to:\nCongestive heart failure\nAngina pectoris\nAcute inflammatory heart disease\nMyocardial infarction within 1 year before randomization\nArterial hypertension defined as blood pressure â‰¥ 150/100 mm Hg despite optimal medical therapy\nUncontrolled cardiac arrhythmia\nIncreased haemorragic tendency\nUncontrolled diabetes\nBone marrow aplasia\nPsychosis\nActive or uncontrolled infections among which those requiring systemic antibiotics or antimicrobial therapy.\nInflammation of the urinary bladder (interstitial cystitis) and/or obstructions of the urine flow.\nVaccination with live vaccines within 30 days prior to study entry\nPatients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial.\nKnown contraindication to imaging tracer or contrast medium and contraindication to MRI\nAny psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and its active requirements (including completion of questionnaires) and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"EORTC HQ",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+32 2 774 1611",
                    "CentralContactEMail":"eortc@eortc.org"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Winette van der Graaf",
                    "OverallOfficialAffiliation":"Nationaal Kanker Instituut, Amsterdam, NL",
                    "OverallOfficialRole":"Study Chair"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000012509",
                    "ConditionMeshTerm":"Sarcoma"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000018204",
                    "ConditionAncestorTerm":"Neoplasms, Connective and Soft Tissue"
                  },{
                    "ConditionAncestorId":"D000009370",
                    "ConditionAncestorTerm":"Neoplasms by Histologic Type"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M13910",
                    "ConditionBrowseLeafName":"Sarcoma",
                    "ConditionBrowseLeafAsFound":"Soft Tissue Sarcoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M18933",
                    "ConditionBrowseLeafName":"Neoplasms, Connective and Soft Tissue",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10898",
                    "ConditionBrowseLeafName":"Neoplasms by Histologic Type",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T6034",
                    "ConditionBrowseLeafName":"Quality of Life",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T5284",
                    "ConditionBrowseLeafName":"Soft Tissue Sarcoma",
                    "ConditionBrowseLeafAsFound":"Soft Tissue Sarcoma",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000011239",
                    "InterventionMeshTerm":"Prednisolone"
                  },{
                    "InterventionMeshId":"D000003520",
                    "InterventionMeshTerm":"Cyclophosphamide"
                  },{
                    "InterventionMeshId":"D000004317",
                    "InterventionMeshTerm":"Doxorubicin"
                  },{
                    "InterventionMeshId":"C000506643",
                    "InterventionMeshTerm":"Liposomal doxorubicin"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000007166",
                    "InterventionAncestorTerm":"Immunosuppressive Agents"
                  },{
                    "InterventionAncestorId":"D000007155",
                    "InterventionAncestorTerm":"Immunologic Factors"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  },{
                    "InterventionAncestorId":"D000018501",
                    "InterventionAncestorTerm":"Antirheumatic Agents"
                  },{
                    "InterventionAncestorId":"D000018906",
                    "InterventionAncestorTerm":"Antineoplastic Agents, Alkylating"
                  },{
                    "InterventionAncestorId":"D000000477",
                    "InterventionAncestorTerm":"Alkylating Agents"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  },{
                    "InterventionAncestorId":"D000000970",
                    "InterventionAncestorTerm":"Antineoplastic Agents"
                  },{
                    "InterventionAncestorId":"D000019653",
                    "InterventionAncestorTerm":"Myeloablative Agonists"
                  },{
                    "InterventionAncestorId":"D000000903",
                    "InterventionAncestorTerm":"Antibiotics, Antineoplastic"
                  },{
                    "InterventionAncestorId":"D000059005",
                    "InterventionAncestorTerm":"Topoisomerase II Inhibitors"
                  },{
                    "InterventionAncestorId":"D000059003",
                    "InterventionAncestorTerm":"Topoisomerase Inhibitors"
                  },{
                    "InterventionAncestorId":"D000004791",
                    "InterventionAncestorTerm":"Enzyme Inhibitors"
                  },{
                    "InterventionAncestorId":"D000000893",
                    "InterventionAncestorTerm":"Anti-Inflammatory Agents"
                  },{
                    "InterventionAncestorId":"D000005938",
                    "InterventionAncestorTerm":"Glucocorticoids"
                  },{
                    "InterventionAncestorId":"D000006728",
                    "InterventionAncestorTerm":"Hormones"
                  },{
                    "InterventionAncestorId":"D000006730",
                    "InterventionAncestorTerm":"Hormones, Hormone Substitutes, and Hormone Antagonists"
                  },{
                    "InterventionAncestorId":"D000018931",
                    "InterventionAncestorTerm":"Antineoplastic Agents, Hormonal"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M10332",
                    "InterventionBrowseLeafName":"Methylprednisolone",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M1833",
                    "InterventionBrowseLeafName":"Methylprednisolone Acetate",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M10333",
                    "InterventionBrowseLeafName":"Methylprednisolone Hemisuccinate",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M12703",
                    "InterventionBrowseLeafName":"Prednisolone",
                    "InterventionBrowseLeafAsFound":"Docetaxel",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M237203",
                    "InterventionBrowseLeafName":"Prednisolone acetate",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M218859",
                    "InterventionBrowseLeafName":"Prednisolone hemisuccinate",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M243004",
                    "InterventionBrowseLeafName":"Prednisolone phosphate",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M5310",
                    "InterventionBrowseLeafName":"Cyclophosphamide",
                    "InterventionBrowseLeafAsFound":"Procedure",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M6075",
                    "InterventionBrowseLeafName":"Doxorubicin",
                    "InterventionBrowseLeafAsFound":"Chemotherapy",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M235025",
                    "InterventionBrowseLeafName":"Liposomal doxorubicin",
                    "InterventionBrowseLeafAsFound":"Chemotherapy",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M8795",
                    "InterventionBrowseLeafName":"Immunosuppressive Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8784",
                    "InterventionBrowseLeafName":"Immunologic Factors",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19188",
                    "InterventionBrowseLeafName":"Antirheumatic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2401",
                    "InterventionBrowseLeafName":"Alkylating Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2803",
                    "InterventionBrowseLeafName":"Anti-Bacterial Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2805",
                    "InterventionBrowseLeafName":"Antibiotics, Antitubercular",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2798",
                    "InterventionBrowseLeafName":"Anti-Inflammatory Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M7630",
                    "InterventionBrowseLeafName":"Glucocorticoids",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8372",
                    "InterventionBrowseLeafName":"Hormones",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8371",
                    "InterventionBrowseLeafName":"Hormone Antagonists",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19550",
                    "InterventionBrowseLeafName":"Antineoplastic Agents, Hormonal",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Infl",
                    "InterventionBrowseBranchName":"Anti-Inflammatory Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"AnEm",
                    "InterventionBrowseBranchName":"Antiemetics"
                  },{
                    "InterventionBrowseBranchAbbrev":"NeuroAg",
                    "InterventionBrowseBranchName":"Neuroprotective Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"Gast",
                    "InterventionBrowseBranchName":"Gastrointestinal Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"ANeo",
                    "InterventionBrowseBranchName":"Antineoplastic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"ARhu",
                    "InterventionBrowseBranchName":"Antirheumatic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"Infe",
                    "InterventionBrowseBranchName":"Anti-Infective Agents"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":25,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780451",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2018/31/N/NZ7/02962"
              },
              "Organization":{
                "OrgFullName":"Gdansk University of Physical Education and Sport",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Omega-3 Supplementation Combined With Endurance Training Improve Running Economy in Recreational Runners.",
              "OfficialTitle":"12 Weeks of Omega-3 Supplementation Combined With Endurance Training Improve Running Economy in Recreational Runners. The Potential Role of the Myokines-NO Pathway."
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"September 16, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 20, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 2, 2021",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"March 2, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Gdansk University of Physical Education and Sport",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Medical University of Gdansk",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"University of Southampton",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Recreational male runners participated in 12 weeks training and omega-3 supplementation programme. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.",
              "DetailedDescription":"40 healthy, recreational male runners participated in 12 weeks training and supplementation programme. The training protocol was built based on undulatory load manipulation 3:1, which was suggested to be effective to prevent overtraining and stress due to oscillations between volume/intensity. Throughout the study all participants took 4 identical-looking capsules per day (2 in the morning and 2 in the evening) containing either omega-3 fatty acids or medium chain triglycerides as placebo in total amount of 4g of fat per day. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed. Additionally, blood was collected to determine the concentrations of selected proteins (including eNOS, irisin, adiponectin) that may be associated with potential changes in participants' oxygen uptake during the treadmill test."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Effect of Omega-3 Supplementation on Exercise Performance and Muscle Tissue Functions"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "omega-3",
                  "supplementation",
                  "endurance training",
                  "running"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 3"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Basic Science",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Investigator"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"40",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Omega",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Omega-3 supplementation in recreational runners"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Omega-3 supplementation in recreational runners"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Omega-3 supplementation in recreational runners",
                    "InterventionDescription":"Male recreational runners participated in 12 weeks of endurance training combined with omega-3 fatty acids supplementation. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Omega",
                        "Placebo"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"changes in oxygen consumption during running test",
                    "PrimaryOutcomeTimeFrame":"between 10 and 25 minutes of the running test"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nnon smoking\nno chronic diseases\nno supplements and medicines\npersonal best in 10km run between 35 and 59 min at the turn of 2016 and 2020 y\n\nExclusion Criteria:\n\n-",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"Male",
              "MinimumAge":"29 Years",
              "MaximumAge":"42 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Gdansk University of Physical Education and Sport",
                    "LocationCity":"GdaÅ„sk",
                    "LocationZip":"80-336",
                    "LocationCountry":"Poland"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"T415",
                    "InterventionBrowseLeafName":"Omega 3 Fatty Acid",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Ot",
                    "InterventionBrowseBranchName":"Other Dietary Supplements"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":26,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780438",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2662"
              },
              "Organization":{
                "OrgFullName":"G.Gennimatas General Hospital",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.",
              "OfficialTitle":"Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation."
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"September 1, 2023",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 1, 2023",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 2, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Ioannis Anagnostopoulos",
                "ResponsiblePartyInvestigatorTitle":"MD",
                "ResponsiblePartyInvestigatorAffiliation":"G.Gennimatas General Hospital"
              },
              "LeadSponsor":{
                "LeadSponsorName":"G.Gennimatas General Hospital",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"2nd Department of Cardiology, \"Attikon\" University Hospital, National and Kapodistrian University of Athens",
                    "CollaboratorClass":"UNKNOWN"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Transcatheter left atrial antral ablation, aiming at complete electrical isolation of the pulmonary veins (PVI), has become mainstay in atrial fibrillation (AF) treatment. This approach has been proved superior to medical rhytmh control strategy in maintaining sinus rhythm. Moreover PVI has been associated with significant survival benefit in patients with heart failure and reduced left ventricular ejection fraction. Nevertheless, despite progress in the field of catheter ablation, recurrence rates remain high.\n\nInhibitors of type 2 sodium- glucose co-transporter (SGLT2i) is a relatively recent addition to the array of anti-diabetic agents, becoming part of everyday clinical practice. However, although SGLT2i were first used solely as antidiabetics because of their glycosuric effect, further research demonstrated that these drugs may independently reduce cardiovascular events, especially in patients with heart failure, a benefit that was consistent among diabetic and non-diabetic patients. Moreover, pleiotropic effects have been observed, including a reno-protective action.\n\nThese findings suggest that SGLT2i mechanisms of action extend beyond the obvious increase in urinary sodium and glucose excretion. Various studies propose that these drugs promote favourable metabolic changes in myocardial energetics, while they also inhibit inflamation and sympathetic activation, resulting in restriction of induced fibrosis and structural remodeling, which are key elements in atrial fibrillation generation and maintenance.\n\nThese findings suggest that the use of SGLT2i could offer antiarrhythmic benefit by reducing and/or reversing structural and electrical remodeling, leading to the assumption that use of theese drugs could reduce recurrences after transcatheter AF ablation."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Atrial Fibrillation Recurrent",
                  "Pulmonary Venous Isolation",
                  "Catheter Ablation",
                  "Sodium-glucose Co-transporter 2 Inhibitors"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "dapagliflozin",
                  "Sodium-glucose co-transporter 2 inhibitors",
                  "Atrial Fibrillation",
                  "recurrence",
                  "catheter ablation",
                  "SGLT2 inhibitors"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Early Phase 1"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Prevention",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"350",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Dapagliflozin",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Patients who will be randomized to receive dapagliflozin following catheter ablation.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Dapagliflozin"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Patients who will be randomized to receive placebo following catheter ablation.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Dapagliflozin",
                    "InterventionDescription":"Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Dapagliflozin"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"Patients rendomized in this arm will receive placebo.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Placebo"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Comparison of survival free of AF/ atrial tachycardia (AT) recurrence between the two study arms.",
                    "PrimaryOutcomeDescription":"AF/AT are defined as any episodes of AF or atrial flutter or other re-entrant atrial tachycardia recorded either on surface ECG or on Holter monitoring and lasting for at least 30 s. All episodes will be reviewed by two independent electrophysiologists, who will be blinded as to patient identity and randomization.The first 3 months after the ablation procedure will be regarded as a blanking period.",
                    "PrimaryOutcomeTimeFrame":"18 months from the PVI procedure"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Incidence (cases per 100 patient-years) of hypoglycemia in both arms",
                    "OtherOutcomeDescription":"Any episode of hypoglycemia defined as serum glucose 60< mg/dl associated with symptoms of hypoglycemia.",
                    "OtherOutcomeTimeFrame":"18 months from the PVI procedure"
                  },{
                    "OtherOutcomeMeasure":"Incidence (cases per 100 patient-years)of diabetic ketoacidosis",
                    "OtherOutcomeDescription":"Any episode of metabolic acidosis (pH<7.3) with decreased serum bicarbonate (<18mEq/ml) and increased anion gap (>10) and increased serum glucose (>250mg/dl) and positive urine dipstick test for ketones.",
                    "OtherOutcomeTimeFrame":"18 months from the PVI procedure"
                  },{
                    "OtherOutcomeMeasure":"Incidence (cases per 100 patient-years)of lower urinary tract infections",
                    "OtherOutcomeTimeFrame":"18 months from the PVI procedure"
                  },{
                    "OtherOutcomeMeasure":"Comparison of all cause mortality between the two groups",
                    "OtherOutcomeTimeFrame":"18 months from the PVI procedure"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAge>18 years Atrial Fibrillation (paroxysmal or sustained); Written informed consent; Glomerular Filtration Rate (GFR) >45 ml/min/1.73m2 (Cockroft-Gault equation) Guideline Class I or equivalent indication for treatment with a SGLT2 inhibitor\n\nExclusion Criteria:\n\nHypertrophic cardiomyopathy (Left ventricular wall thickness â‰¥15mm, not explained by abnormal pressure/volume conditions); Severe mitral valve stenosis (as defined in European Guidelines); Active malignancy; Participation in other intervention studies; Pregnancy or willing of pregnancy during the follow up period\n\n*Eligible patients randomized in the active comparator arm will be also included in a prospective observational registry study regarding the role of SGLT2 inhibitors in post-ablation AF recurrence.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"100 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Spyridon Deftereos, Prof.",
                    "CentralContactRole":"Contact",
                    "CentralContactEMail":"spdeftereos@gmail.com"
                  },{
                    "CentralContactName":"Georgios Giannopoulos, Prof.",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+302107768132",
                    "CentralContactEMail":"spdeftereos@gmail.comgeorgios.giannopolous@yale.edu"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Spyridon Deftereos, MD",
                    "OverallOfficialAffiliation":"2nd Department of Cardiology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Cardiology Department, Athens General Hospital \"G. Gennimatas\", Athens, Greece",
                    "LocationCity":"Athens",
                    "LocationZip":"11527",
                    "LocationCountry":"Greece",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Ioannis Anagnostopoulos, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+302107768132",
                          "LocationContactEMail":"iannis.anagnostopoulos@gmail.com"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"2nd Department of Cardiology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece.",
                    "LocationCity":"Athens",
                    "LocationZip":"12462",
                    "LocationCountry":"Greece",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Dimitrios Vrachatis, MD,PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"dvrachatis@gmail.com"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"9725923",
                    "ReferenceType":"result",
                    "ReferenceCitation":"HaÃ¯ssaguerre M, JaÃ¯s P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le MÃ©tayer P, ClÃ©menty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66."
                  },{
                    "ReferencePMID":"31431051",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circ Arrhythm Electrophysiol. 2019 Sep;12(9):e007414. doi: 10.1161/CIRCEP.119.007414. Epub 2019 Aug 21."
                  },{
                    "ReferencePMID":"30874766",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693."
                  },{
                    "ReferencePMID":"23537812",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, Sullivan T, Roberts-Thomson KC, Sanders P. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013 Mar 18;2(2):e004549. doi: 10.1161/JAHA.112.004549. Review."
                  },{
                    "ReferencePMID":"26378978",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17."
                  },{
                    "ReferencePMID":"30415602",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10."
                  },{
                    "ReferencePMID":"28605608",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12."
                  },{
                    "ReferencePMID":"31535829",
                    "ReferenceType":"result",
                    "ReferenceCitation":"McMurray JJV, Solomon SD, Inzucchi SE, KÃ¸ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, BÄ›lohlÃ¡vek J, BÃ¶hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, DukÃ¡t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, SjÃ¶strand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19."
                  },{
                    "ReferencePMID":"32865377",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, BÃ¶hm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28."
                  },{
                    "ReferencePMID":"32877652",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30."
                  },{
                    "ReferencePMID":"32970396",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Heerspink HJL, StefÃ¡nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, SjÃ¶strÃ¶m CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24."
                  },{
                    "ReferencePMID":"32613148",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. doi: 10.1016/j.jacbts.2020.02.004. eCollection 2020 Jun. Review."
                  },{
                    "ReferencePMID":"30132036",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 Oct;61(10):2108-2117. doi: 10.1007/s00125-018-4670-7. Epub 2018 Aug 22. Review."
                  },{
                    "ReferencePMID":"29311992",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, Nikolaou PE, Maratou E, Lambadiari V, Ikonomidis I, Kostomitsopoulos N, Brizzi MF, Dimitriadis G, Iliodromitis EK. Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects. Front Physiol. 2017 Dec 19;8:1077. doi: 10.3389/fphys.2017.01077. eCollection 2017."
                  },{
                    "ReferencePMID":"30093883",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Wan N, Rahman A, Hitomi H, Nishiyama A. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. Front Endocrinol (Lausanne). 2018 Jul 26;9:421. doi: 10.3389/fendo.2018.00421. eCollection 2018."
                  },{
                    "ReferencePMID":"31970162",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Maejima Y. SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function. Front Cardiovasc Med. 2020 Jan 8;6:186. doi: 10.3389/fcvm.2019.00186. eCollection 2019. Review."
                  },{
                    "ReferencePMID":"32847602",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020 Aug 26;19(1):130. doi: 10.1186/s12933-020-01105-5. Review."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001281",
                    "ConditionMeshTerm":"Atrial Fibrillation"
                  },{
                    "ConditionMeshId":"D000012008",
                    "ConditionMeshTerm":"Recurrence"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000001145",
                    "ConditionAncestorTerm":"Arrhythmias, Cardiac"
                  },{
                    "ConditionAncestorId":"D000006331",
                    "ConditionAncestorTerm":"Heart Diseases"
                  },{
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  },{
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  },{
                    "ConditionAncestorId":"D000020969",
                    "ConditionAncestorTerm":"Disease Attributes"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3167",
                    "ConditionBrowseLeafName":"Atrial Fibrillation",
                    "ConditionBrowseLeafAsFound":"Atrial Fibrillation",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13433",
                    "ConditionBrowseLeafName":"Recurrence",
                    "ConditionBrowseLeafAsFound":"Recurrence",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3034",
                    "ConditionBrowseLeafName":"Arrhythmias, Cardiac",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8002",
                    "ConditionBrowseLeafName":"Heart Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21284",
                    "ConditionBrowseLeafName":"Disease Attributes",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"C000529054",
                    "InterventionMeshTerm":"2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000077203",
                    "InterventionAncestorTerm":"Sodium-Glucose Transporter 2 Inhibitors"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  },{
                    "InterventionAncestorId":"D000007004",
                    "InterventionAncestorTerm":"Hypoglycemic Agents"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M1691",
                    "InterventionBrowseLeafName":"Sodium-Glucose Transporter 2 Inhibitors",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M266366",
                    "InterventionBrowseLeafName":"2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol",
                    "InterventionBrowseLeafAsFound":"/week",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M8637",
                    "InterventionBrowseLeafName":"Hypoglycemic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Hypo",
                    "InterventionBrowseBranchName":"Hypoglycemic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":27,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780425",
              "OrgStudyIdInfo":{
                "OrgStudyId":"KBTH-IRB 100017512020"
              },
              "Organization":{
                "OrgFullName":"Korle-Bu Teaching Hospital, Accra, Ghana",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Structured Diabetes Self-Management Education and Care Outcomes in Adults liVIng With Type 2 Diabetes in Accra, Ghana",
              "OfficialTitle":"A Randomised Parallel-group Multi-centre Study to Evaluate the Effect of Structured Diabetes Self-management Education Versus Standard of Care on Glycaemic Control , Self-efficacy and Quality of Life in Adults in Two Low Resource Settings in Accra Subsequent to COVID-19",
              "Acronym":"SMS COVID"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Active, not recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 26, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"February 2, 2021",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"May 22, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Korle-Bu Teaching Hospital, Accra, Ghana",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"University of Leicester",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"Utrecht University",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"We aim to study the effect of a structured diabetes education program (DESMOND) on diabetes outcomes in a ghanaian population over 3 months",
              "DetailedDescription":"Protocol summary Background: Health systems in low-income countries are overburdened. Corona virus disease-19 (COVID-19) is a pandemic caused by a novel corona virus, Severe acute respiratory syndrome-corona virus 2 (SARS-CoV2) while diabetes is a long-standing global epidemic. COVID-19 further stresses the already overburdened health systems and Public Health measures to contain COVID-19 have severely disrupted health service delivery, particularly routine care. Delivery of diabetes specific education has traditionally been tied to routine visits and delivered in-person. COVID-19 will likely continue to influence service delivery beyond the pandemic, thus alternative ways of delivering diabetes specific education is needed.\n\nDiabetes self-management education is vital to providing diabetes care. It equips patients with critical knowledge and skills for self-care. Recent edicts to stay home in relation to COVID-19 have further heightened the importance of self-care. Appropriate self-management behaviours are associated with lower levels of diabetes related distress, better quality of life and diabetes outcomes overall. Maintaining tight glycaemic control, early in diabetes is associated with fewer microvascular complications and vice versa. Complications of diabetes are prevalent in low resource settings in Africa; partly because of inadequate knowledge on self-care. Diabetes self-management education which is structured and tailor-made for low resource settings may modify self-care behaviors and result in improved self-care, glycaemic control and quality of life.\n\nAim:\n\nTo compare structured diabetes self-management education with standard of care among adults living with type 2 diabetes\n\nMethods:\n\nA prospective parallel-group randomised controlled trial with three months follow-up will be conducted in KBTH Polyclinic/Family Medicine Centre and Weija Gbawe Municipal Hospital, two primary care facilities in Accra. Participants will be individually randomised to standard of care or 6 hours of structured diabetes self-management education (DSME) delivered in person on one day . Each arm will have hundred participants. The standard of care arm will receive unstructured DSME as per existing protocols at each study site. The study population will be adults living with diabetes. The primary outcome, mean glycated haemoglobin (HbA1c ) will be measured at three months.\n\nExpected outcomes:\n\nIt is expected that there will be no difference in change in mean glycaemic control, self-efficacy or quality of life at three months between the two arms."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Diabetes Mellitus, Type 2"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "structured diabetes self-management education",
                  "DESMOND",
                  "SSA"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Supportive Care",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignMaskingDescription":"Persons delivering the intervention are not involved in patient care",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Care Provider"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"206",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"DESMOND",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"receive usual care plus a structured diabetes self-management education program delivered once over 6hours",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: DESMOND"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"USUAL CARE",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Receive usual care as per standard treatment guidelines of ghana unstructured education during clinic visits for routine care",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: usual care"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"DESMOND",
                    "InterventionDescription":"as previously described",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "DESMOND"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"usual care",
                    "InterventionDescription":"usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "USUAL CARE"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"1. Change in mean HbA1c (glycaemic control) at three months",
                    "PrimaryOutcomeDescription":"change in glycaemic control",
                    "PrimaryOutcomeTimeFrame":"3 months"
                  },{
                    "PrimaryOutcomeMeasure":"2. Change in mean SDSCA (summary of diabetes self-care activities) score (self-efficacy) at three months",
                    "PrimaryOutcomeDescription":"change in self-efficacy",
                    "PrimaryOutcomeTimeFrame":"3 months"
                  },{
                    "PrimaryOutcomeMeasure":"3. Change in mean WHOQoL BREF score at three months",
                    "PrimaryOutcomeDescription":"change in quality of life",
                    "PrimaryOutcomeTimeFrame":"3 months"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"1. Change in mean FPG at three months",
                    "SecondaryOutcomeDescription":"change in fasting plasma glucose",
                    "SecondaryOutcomeTimeFrame":"3 months"
                  },{
                    "SecondaryOutcomeMeasure":"1. Change in mean FbG at three months",
                    "SecondaryOutcomeDescription":"change in fasting blood glucose",
                    "SecondaryOutcomeTimeFrame":"3 months"
                  },{
                    "SecondaryOutcomeMeasure":"1. Change in mean BP at three months",
                    "SecondaryOutcomeDescription":"change in blood pressure",
                    "SecondaryOutcomeTimeFrame":"3 months"
                  },{
                    "SecondaryOutcomeMeasure":"1. Change in WC at three months",
                    "SecondaryOutcomeDescription":"change in waist circumference",
                    "SecondaryOutcomeTimeFrame":"3 months"
                  },{
                    "SecondaryOutcomeMeasure":"1. Change in NC at three months",
                    "SecondaryOutcomeDescription":"change in neck circumference",
                    "SecondaryOutcomeTimeFrame":"3 months"
                  },{
                    "SecondaryOutcomeMeasure":"1. Change in BW at three months",
                    "SecondaryOutcomeDescription":"change in BODY WEIGHT",
                    "SecondaryOutcomeTimeFrame":"3 months"
                  },{
                    "SecondaryOutcomeMeasure":"Change in PAID-5 scores",
                    "SecondaryOutcomeDescription":"Change in diabetes related distress at three months",
                    "SecondaryOutcomeTimeFrame":"3 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\n- Inclusion criteria\n\nSelf-identified as Ghanaian\nAbility to speak either English and or Twi\nbe aged > 18 years\nbe receiving treatment at the study site as an out-patient\nbe willing to accept the 6-hour DSME intervention\nbe physically able to participate\nbe primarily responsible for their own care\nbe ambulant at time of recruitment\nbe able to participate in activities in a group setting\nhave permanent residence in Greater Accra\n\nExclusion Criteria:\n\nknown to have cognitive defects\nknown to have type I diabetes\nknown to be pregnant at the time of recruitment or planning to become pregnant during the study or have given birth less than three months prior to recruitment\nknown to have sickle cell disease\nParticipating in another intervention study at time of recruitment\nknown to have chronic medical complications of diabetes (cardiac, renal, neuropathy, hepatic) or systemic illness at the time of recruitment\nrecruitment of a member of the patients household for this study",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Roberta Lamptey, FWACP; MSc",
                    "OverallOfficialAffiliation":"Korle Bu Teaching Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Korle Bu Teaching Hospital",
                    "LocationCity":"Accra",
                    "LocationCountry":"Ghana"
                  },{
                    "LocationFacility":"Weija Gbawe Municipal Hospital",
                    "LocationCity":"Accra",
                    "LocationCountry":"Ghana"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003920",
                    "ConditionMeshTerm":"Diabetes Mellitus"
                  },{
                    "ConditionMeshId":"D000003924",
                    "ConditionMeshTerm":"Diabetes Mellitus, Type 2"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000044882",
                    "ConditionAncestorTerm":"Glucose Metabolism Disorders"
                  },{
                    "ConditionAncestorId":"D000008659",
                    "ConditionAncestorTerm":"Metabolic Diseases"
                  },{
                    "ConditionAncestorId":"D000004700",
                    "ConditionAncestorTerm":"Endocrine System Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5698",
                    "ConditionBrowseLeafName":"Diabetes Mellitus",
                    "ConditionBrowseLeafAsFound":"Diabetes",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5702",
                    "ConditionBrowseLeafName":"Diabetes Mellitus, Type 2",
                    "ConditionBrowseLeafAsFound":"Diabetes Mellitus, Type 2",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M10222",
                    "ConditionBrowseLeafName":"Metabolic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M23990",
                    "ConditionBrowseLeafName":"Glucose Metabolism Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6445",
                    "ConditionBrowseLeafName":"Endocrine System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T6034",
                    "ConditionBrowseLeafName":"Quality of Life",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC18",
                    "ConditionBrowseBranchName":"Nutritional and Metabolic Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC19",
                    "ConditionBrowseBranchName":"Gland and Hormone Related Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":28,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780412",
              "OrgStudyIdInfo":{
                "OrgStudyId":"Misoprostol"
              },
              "Organization":{
                "OrgFullName":"Ain Shams University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section",
              "OfficialTitle":"Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Active, not recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"September 1, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"March 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 24, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Samar Ali",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Ain Shams University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Ain Shams University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Neonatal respiratory morbidities represent a common group of post natal complications including respiratory distress syndrome, transient tachypnea of newborn, and persistent pulmonary hypertension of newborn.\n\nIt is thought that preoperative vaginal misoprostol administration may decrease the incidence of neonatal respiratory morbidity especially transient tachypnea of newborn. And therefore, it may decrease the incidence of admission to neonatal intensive care units for respiratory causes."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Transient Tachypnea of the Newborn",
                  "Neonatal Respiratory Distress"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 3"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Prevention",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"210",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Misoprostol Group",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Misoprostol"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo Group",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Misoprostol",
                    "InterventionDescription":"Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Misoprostol Group"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "prostaglandin E1"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"Vaginal placebo pills given 90-120 minutes before an elective caesarian section.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Placebo Group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"incidence of neonatal respiratory morbidity (NRM)",
                    "PrimaryOutcomeDescription":"The incidence of neonatal respiratory morbidity, especially transient tachypnea of newborn, in early term neonates born to elective caesarian section.",
                    "PrimaryOutcomeTimeFrame":"up to 24 hours after birth"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Neonatal intensive care unit (NICU) admission",
                    "SecondaryOutcomeDescription":"The incidence of the need for neonatal intensive care unit admission during the first ten days after delivery in early term neonates born to elective caesarian section.",
                    "SecondaryOutcomeTimeFrame":"up to 24 hours after birth"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAge: 18 years or more.\nEarly term singleton pregnancy.\nElective caesarian section at (37 - 38+6) weeks of gestation.\nAny indication for lower uterine segment caesarian section other than labor (as malpresentations, severe preeclampsia, placenta previa with no previous bleeding attacks, Diabetes Mellitus, macrosomic fetus, non reassuring cardiotocogram (CTG), and fetal growth restriction).\nInformed written consent signed by the participating pregnant woman.\n\nExclusion Criteria:\n\nWomen having any contraindication to Prostaglandin E1 as hypersensitivity, respiratory disease (especially bronchial asthma), or glaucoma.\nAny mental problems that block understanding of the nature and all the possible consequences of the procedure and the study.\nPregnancies of known fetal diseases or chromosomal abnormalities.\nNon-singleton pregnancies.\nEmergency caesarian section as in ruptured membrane and women in labor pain.",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"Female",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Samar A. Kandeel",
                    "OverallOfficialAffiliation":"Ain Shams University - Faculty of Medicine",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Ain Shams University - Faculty of Medicine",
                    "LocationCity":"Cairo",
                    "LocationCountry":"Egypt"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000059246",
                    "ConditionMeshTerm":"Tachypnea"
                  },{
                    "ConditionMeshId":"D000012127",
                    "ConditionMeshTerm":"Respiratory Distress Syndrome, Newborn"
                  },{
                    "ConditionMeshId":"D000059245",
                    "ConditionMeshTerm":"Transient Tachypnea of the Newborn"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000012120",
                    "ConditionAncestorTerm":"Respiration Disorders"
                  },{
                    "ConditionAncestorId":"D000012140",
                    "ConditionAncestorTerm":"Respiratory Tract Diseases"
                  },{
                    "ConditionAncestorId":"D000012818",
                    "ConditionAncestorTerm":"Signs and Symptoms, Respiratory"
                  },{
                    "ConditionAncestorId":"D000008171",
                    "ConditionAncestorTerm":"Lung Diseases"
                  },{
                    "ConditionAncestorId":"D000007235",
                    "ConditionAncestorTerm":"Infant, Premature, Diseases"
                  },{
                    "ConditionAncestorId":"D000007232",
                    "ConditionAncestorTerm":"Infant, Newborn, Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M27998",
                    "ConditionBrowseLeafName":"Tachypnea",
                    "ConditionBrowseLeafAsFound":"Tachypnea",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13547",
                    "ConditionBrowseLeafName":"Respiratory Distress Syndrome, Newborn",
                    "ConditionBrowseLeafAsFound":"Neonatal Respiratory Distress",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M27997",
                    "ConditionBrowseLeafName":"Transient Tachypnea of the Newborn",
                    "ConditionBrowseLeafAsFound":"Transient Tachypnea of the Newborn",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13548",
                    "ConditionBrowseLeafName":"Respiratory Distress Syndrome, Adult",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14938",
                    "ConditionBrowseLeafName":"Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13540",
                    "ConditionBrowseLeafName":"Respiration Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13560",
                    "ConditionBrowseLeafName":"Respiratory Tract Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14206",
                    "ConditionBrowseLeafName":"Signs and Symptoms, Respiratory",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9751",
                    "ConditionBrowseLeafName":"Lung Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M24456",
                    "ConditionBrowseLeafName":"Premature Birth",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8862",
                    "ConditionBrowseLeafName":"Infant, Premature, Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8859",
                    "ConditionBrowseLeafName":"Infant, Newborn, Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T4927",
                    "ConditionBrowseLeafName":"Respiratory Distress Syndrome, Infant",
                    "ConditionBrowseLeafAsFound":"Neonatal Respiratory Distress",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"T192",
                    "ConditionBrowseLeafName":"Acute Respiratory Distress Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC16",
                    "ConditionBrowseBranchName":"Diseases and Abnormalities at or Before Birth"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXS",
                    "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000000527",
                    "InterventionMeshTerm":"Alprostadil"
                  },{
                    "InterventionMeshId":"D000016595",
                    "InterventionMeshTerm":"Misoprostol"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000000020",
                    "InterventionAncestorTerm":"Abortifacient Agents, Nonsteroidal"
                  },{
                    "InterventionAncestorId":"D000000019",
                    "InterventionAncestorTerm":"Abortifacient Agents"
                  },{
                    "InterventionAncestorId":"D000012102",
                    "InterventionAncestorTerm":"Reproductive Control Agents"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  },{
                    "InterventionAncestorId":"D000000897",
                    "InterventionAncestorTerm":"Anti-Ulcer Agents"
                  },{
                    "InterventionAncestorId":"D000005765",
                    "InterventionAncestorTerm":"Gastrointestinal Agents"
                  },{
                    "InterventionAncestorId":"D000010120",
                    "InterventionAncestorTerm":"Oxytocics"
                  },{
                    "InterventionAncestorId":"D000010975",
                    "InterventionAncestorTerm":"Platelet Aggregation Inhibitors"
                  },{
                    "InterventionAncestorId":"D000014665",
                    "InterventionAncestorTerm":"Vasodilator Agents"
                  },{
                    "InterventionAncestorId":"D000064804",
                    "InterventionAncestorTerm":"Urological Agents"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2449",
                    "InterventionBrowseLeafName":"Alprostadil",
                    "InterventionBrowseLeafAsFound":"Matrix-M",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M17562",
                    "InterventionBrowseLeafName":"Misoprostol",
                    "InterventionBrowseLeafAsFound":"Part of",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M2769",
                    "InterventionBrowseLeafName":"Antacids",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2800",
                    "InterventionBrowseLeafName":"Anti-Ulcer Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M7464",
                    "InterventionBrowseLeafName":"Gastrointestinal Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M12448",
                    "InterventionBrowseLeafName":"Platelet Aggregation Inhibitors",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M15995",
                    "InterventionBrowseLeafName":"Vasodilator Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"VaDiAg",
                    "InterventionBrowseBranchName":"Vasodilator Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"PlAggInh",
                    "InterventionBrowseBranchName":"Platelet Aggregation Inhibitors"
                  },{
                    "InterventionBrowseBranchAbbrev":"Urol",
                    "InterventionBrowseBranchName":"Urological Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"Gast",
                    "InterventionBrowseBranchName":"Gastrointestinal Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"Repr",
                    "InterventionBrowseBranchName":"Reproductive Control Agents"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":29,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780399",
              "OrgStudyIdInfo":{
                "OrgStudyId":"P2020-03-BDY-12-V02"
              },
              "Organization":{
                "OrgFullName":"Dongzhimen Hospital, Beijing",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease",
              "OfficialTitle":"Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease:a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clicnial Trial"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"March 1, 2024",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 30, 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Jinzhou Tian",
                "ResponsiblePartyInvestigatorTitle":"Vice president",
                "ResponsiblePartyInvestigatorAffiliation":"Dongzhimen Hospital, Beijing"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Dongzhimen Hospital, Beijing",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"As a traditional Chinese medicine compound, Yangxue Qingnao Pills is proven to have beneficial effects on learning and memory ability in animal models of Alzheimer's disease(AD). The purpose of the study is to evaluate the efficacy and safety of Yangxue Qingnao Pills on patients with mild to moderate AD. This phase II randomized, double-blind, parallel controlled trial include a 2 weeks run-in period, and a 48 weeks double-blind treatment period of after randomization. Participants will be randomly allocated to Yangxue Qingnao pills high dose group (7.5 g per time,2 times per day) ; and Yangxue Qingnao pills low dose group (5 g per time,2 times per day), or placebo group. The outcome measures include general cognitive function, ability of daily living, and behavioural and psychological symptoms in AD patients.",
              "DetailedDescription":"Yangxue Qingnao pills is a traditional Chinese herbal medicine, which is composed of Angelicae Sinensis Radix , Chuanxiong Rhizoma , Paeoniae Radix Alba, Rehmannia glutinosa, Uncaria macrophylla Wall, Caulis spatholobi, Spica Prunellae, Catsia tora Linn , Mater Margarita, Corydalis ambigua and Asarum sieboldii. The function of Yangxue Qingnao pills is nourishing blood and calming liver, promoting blood circulation and dredging collaterals in Chinese traditional medicine theory. This study is a 48-weeks, multicenter, randomized, double-blind, parallel controlled phase II trial being carried out in China. The study population includes mild to moderate Alzheimer's disease (planned a total of 216) aged 65-85 in both gender. Participants will be randomly allocated to Yangxue Qingnao pills high dose group (7.5 g per time,2 times per day) ; and Yangxue Qingnao pills low dose group (5 g per time,2 times per day), or placebo group for a 48-weeks double-blind treatment period. The primary outcome measure is change from baseline in the Alzheimer's Disease Assessment Scale- Cognition Subscale (ADAS-cog) and the clinical dementia rating scale. The secondary outcomes are changes from baseline in the Mini-Mental State Examination(MMSE), Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL/24) and Neuropsychiatric Inventory. Besides, the blood biomarkers including AÎ²42, AÎ²40, T-tau, P-tau181, NfL, TOM1, IL-1R1,IL-1b, IL-6, IL-8, TNF-a, FB, FH, sCR1, MCP-1, eotaxin-1, Ach, ChEI and the hippocampal volume on MRI. Safety is being assessed by observing side effects and adverse reaction during the entire treatment period. Statistical analysis will be conducted according to per-protocol population and intend-to-treat population and the safety will be analyzed in safety set."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Alzheimer Disease",
                  "Yangxue Qingnao Pills",
                  "Randomized"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"216",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Yangxue Qingnao pills high dose group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Yangxue Qingnao pills 7.5 g per time,2 times per day.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Yangxue Qingnao pills"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Yangxue Qingnao pills lower dose group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Yangxue Qingnao pills 5 g per time,2 times per day, and placebo identified to Yangxue Qingnao pills 2.5 g per time, 2 times per day.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Yangxue Qingnao pills"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo group",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Placebo identified to Yangxue Qingnao pills 7.5 g per time,2 times per day",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Yangxue Qingnao pills",
                    "InterventionDescription":"72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Yangxue Qingnao pills high dose group"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Yangxue Qingnao pills",
                    "InterventionDescription":"72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Yangxue Qingnao pills lower dose group"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Placebo group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Alzheimer's Disease Assessment Scale- Cognition Subscale (ADAS-cog)",
                    "PrimaryOutcomeDescription":"The Alzheimer's Disease Assessment Scale-Cognitive Subscale test is one of the most frequently used tests to measure cognition in research studies and clinical trials for new drugs and other interventions.The ADAS-Cog consists of 11 parts and takes approximately 30 minutes to administer.The test administrator adds up points for the errors in each task of the ADAS-Cog for a total score ranging from 0 to 70. The greater the dysfunction, the greater the score. A score of 70 represents the most severe impairment and 0 represents the least impairment.",
                    "PrimaryOutcomeTimeFrame":"Change from baseline ADAS-cog score at Week 48"
                  },{
                    "PrimaryOutcomeMeasure":"Clinical dementia rating scale-sum box(CDR-SB)",
                    "PrimaryOutcomeDescription":"The Clinical Dementia Rating Scale (CDR) is a global assessment instrument that yields global and Sum of Boxes (CDR-SB) scores, with the global score regularly used in clinical and research settings to stage dementia severity. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. Higher score means severe global cognition impairment.",
                    "PrimaryOutcomeTimeFrame":"Change from baseline CDR-SB score at Week 48"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Mini-Mental State Examination(MMSE)",
                    "SecondaryOutcomeDescription":"TThe Mini-Mental Status Examination offers a quick and simple way to quantify cognitive function and screen for cognitive loss. It tests the individual's orientation, attention, calculation, recall, language and motor skills. It takes ~ 5-10 minutes to administer The range for the total MMSE score is 0 to 30, higher score means better cognition.",
                    "SecondaryOutcomeTimeFrame":"Change from baseline MMSE score at Week 48"
                  },{
                    "SecondaryOutcomeMeasure":"Neuropsychiatric Inventory(NPI)",
                    "SecondaryOutcomeDescription":"The NPI is a semistructured clinician interview of caretakers in which the severity and frequency of disturbance in 12 symptom domains is rated",
                    "SecondaryOutcomeTimeFrame":"Change from baseline NPI score at Week 48"
                  },{
                    "SecondaryOutcomeMeasure":"Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL/23)",
                    "SecondaryOutcomeDescription":"The Alzheimer's Disease Cooperative Study (ADCS) tested 23-item version (ADCS-ADL/23) includes more complex ADL for the assessment of mild to moderate AD, such as reading books or magazines, pastime activities, or household chores. Ratings take about 20 minutes and are based on information obtained from the patient and caregiver. The scores range from 0 to 78, higher scores indicating less functional impairment.",
                    "SecondaryOutcomeTimeFrame":"Change from baseline ADCS-ADL/23 score at Week 48"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Blood biomarkers including AÎ²42, AÎ²40, T-tau, P-tau181, NfL, TOM1, IL-1R1,IL-1b, IL-6, IL-8, TNF-a, FB, FH, sCR1, MCP-1, eotaxin-1, Ach, ChEI",
                    "OtherOutcomeTimeFrame":"Change from baseline of AÎ²42, AÎ²40, T-tau, P-tau181, NfL, TOM1, IL-1R1,IL-1b, IL-6, IL-8, TNF-a, FB, FH, sCR1, MCP-1, eotaxin-1, Ach, ChEI at Week 48"
                  },{
                    "OtherOutcomeMeasure":"Hippocampus volume with MRI",
                    "OtherOutcomeTimeFrame":"Change of hippocampus volume with MRI after 48 weeks'treatment from baseline"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPatients, Chinese speaking, in both gender are eligible to be included in the study only if they meet all of the following criteria:\n\nMeets NIA/AA core clinical criteria for probable AD;\nThe body weight is between 45-90kg;\nAged â‰¥ 65 and â‰¤ 85 years old;\nMild to moderate stage of AD, defined as( MMSE score of 15 through 26) at baseline;\nHas had an MRI scan performed at baseline that has confirmed with a diagnosis of AD, Medial temporal atrophy scale (MTA) is used for routine assessment of the medial temporal lobe, and the MTA score need â‰¥1.5 (adjusted by age: 65-74 years â‰¥ 1.5 points, 75-84 years old â‰¥ 2.0 points);\nHas a PIB-PET scan or CSF result consistent with the presence of amyloid pathology at screening;\nAnd the patients must have adequate vision and hearing to participate in study assessments; has normal swallowing function, and can complete the medication;\nHave a stable caregiver;\nCan read simple articles and write simple sentences;\nInformed consent, signed informed consent by legal guardian.\n\nExclusion Criteria:\n\nPatients who confirmed with any of the following excluding criteria conditions were not enrolled for the study:\n\nEarly-onset Alzheimer disease (oneset at <65 years of age) and moderate to severe AD dementia (MMSE 14-0);\nEvidence of other reasons caused cognitive impairment, like vascular dementia, frontotemporal dementia, Parkinson's disease dementia, Lewy body dementia, Huntington's disease, subdural hematoma, communicating hydrocephalus, brain tumor, thyroid disease, vitamin deficiency Or other diseases that may cause cognitive impairment, or serious brain infections (including neurosyphilis, meningitis or encephalitis), etc.;\nThere are unstable mental disorders, including major depression (HAMDâ‰¥17), severe anxiety disorder (HAMAâ‰¥12 points), bipolar disorder, schizophrenia, etc.;\nHistory of drug or alcohol abuse in the past 5 years;\nOther uncontrolled chronic illnesses, such as severe arrhythmia (ventricular rate <60 beats/min or >100 beats/min, or patients with myocardial infarction within 3 months before participating in the trial, or severe heart failure (NY classification III and IV), or severe abnormal blood pressure, systolic blood pressure â‰¤90mmHg or â‰¥180mmHg;\nSevere liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase was more than 1.5 times the upper limit of normal, or serum creatinine was more than the upper limit of normal);\nA history of taking cholinesterase inhibitors, memantine, or proprietary Chinese medicines with clear nootropic effects within the past 1 month;\nHas received medications that affect the central nervous system (CNS), except treatments for AD for less than 4 weeks; that is, doses of chronic medications that affect the CNS should be stable for at least 4 weeks;\nOne of the following manifestations on cranial MRI:> 4 cerebral microhemorrhages, evidence of a prior macrohemorrhage, > 3 lacunar infarcts over 10 mm each, any cortical infarct over 10 mm, or any other clinically significant finding (e.g., any lesion that may account for their cognitive impairment, including but not limited to brain tumor, severe white matter disease with a rating of 3 on the Fazekas scale for WM lesions ,arteriovenous malformation, cavernous hemangioma, or any infarct in a strategic subcortical location);\nHistory of hypersensitivity to the treatment drugs;\nParticipate in other clinical study within the last 30 days;\nHas metal (ferromagnetic) implants, or a cardiac pacemaker and other conditions that could not undergo MRI scan;\nor other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"65 Years",
              "MaximumAge":"85 Years",
              "StdAgeList":{
                "StdAge":[
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Jinzhou Tian, MD.PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+861084013380",
                    "CentralContactEMail":"jztian@hotmail.com"
                  },{
                    "CentralContactName":"Jing Shi, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"86-10-84011920",
                    "CentralContactEMail":"shijing87@hotmail.com"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000000544",
                    "ConditionMeshTerm":"Alzheimer Disease"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000003704",
                    "ConditionAncestorTerm":"Dementia"
                  },{
                    "ConditionAncestorId":"D000001927",
                    "ConditionAncestorTerm":"Brain Diseases"
                  },{
                    "ConditionAncestorId":"D000002493",
                    "ConditionAncestorTerm":"Central Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000024801",
                    "ConditionAncestorTerm":"Tauopathies"
                  },{
                    "ConditionAncestorId":"D000019636",
                    "ConditionAncestorTerm":"Neurodegenerative Diseases"
                  },{
                    "ConditionAncestorId":"D000019965",
                    "ConditionAncestorTerm":"Neurocognitive Disorders"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M2466",
                    "ConditionBrowseLeafName":"Alzheimer Disease",
                    "ConditionBrowseLeafAsFound":"Alzheimer's Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5487",
                    "ConditionBrowseLeafName":"Dementia",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3786",
                    "ConditionBrowseLeafName":"Brain Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4325",
                    "ConditionBrowseLeafName":"Central Nervous System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21586",
                    "ConditionBrowseLeafName":"Tauopathies",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20142",
                    "ConditionBrowseLeafName":"Neurodegenerative Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20420",
                    "ConditionBrowseLeafName":"Neurocognitive Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T2192",
                    "ConditionBrowseLeafName":"Familial Alzheimer Disease",
                    "ConditionBrowseLeafAsFound":"Alzheimer's Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":30,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780386",
              "OrgStudyIdInfo":{
                "OrgStudyId":"NVP-1805_BE"
              },
              "Organization":{
                "OrgFullName":"Navipharm Corporation",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"Compare the Pharmacokinetics of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2",
              "OfficialTitle":"A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Male Volunteers",
              "Acronym":"NVP-1805"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"August 29, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"November 2, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"February 16, 2021",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Navipharm Corporation",
                "LeadSponsorClass":"INDUSTRY"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of this study is to compare the pharmacokinetics of NVP-1805 and coadministration of NVP-1805-R1 with NVP-1805-R2.",
              "DetailedDescription":"pharmacokinetics and safety of NVP-1805 compared to coadministration of NVP-1805-R1 with NVP-1805-R2"
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Healthy"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 1"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Crossover Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"58",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"NVP-1805",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"NVP-1805",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: NVP-1805"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"NVP-1805-R1 and NVP-1805-R2",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"coadministration of NVP-1805-R1 and NVP-1805-R2",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: NVP-1805-R1and NVP-1805-R2"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"NVP-1805",
                    "InterventionDescription":"orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "NVP-1805"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"NVP-1805-R1and NVP-1805-R2",
                    "InterventionDescription":"orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "NVP-1805-R1 and NVP-1805-R2"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Pharmacokinetics of plasma: AUClast",
                    "PrimaryOutcomeTimeFrame":"0hours - 72hours"
                  },{
                    "PrimaryOutcomeMeasure":"Pharmacokinetics of plasma: Cmax",
                    "PrimaryOutcomeTimeFrame":"0hours - 72hours"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nHealthy adult subjects who signed informed consent\nBMI of >18.0 kg/ãŽ¡ and <30.0 kg/ãŽ¡ subject, weight more than 50kg(45 kg or more for woman)\n\nExclusion Criteria:\n\nSubjects participated in another clinical trial within 6 months prior to administration of the study drug\nInadequate subject for the clinical trial by the investigator's decision\nSubjects participated in another clinical trial within 6 months prior to administration of the study drug",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"19 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Jaewoo Kim, M.D.",
                    "OverallOfficialAffiliation":"H Plus Yangji Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"H Plus Yangji Hospital",
                    "LocationCity":"Seoul",
                    "LocationState":"Nambusunhwan-ro",
                    "LocationZip":"08779",
                    "LocationCountry":"Korea, Republic of"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            }
          }
        }
      },{
        "Rank":31,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780373",
              "OrgStudyIdInfo":{
                "OrgStudyId":"prot. N. 71726"
              },
              "Organization":{
                "OrgFullName":"University of L'Aquila",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Prognostic Score in Covid-19",
              "OfficialTitle":"Identification of a Clinical Score to Support the Clinician in Phase 2 of Covid-19"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 27, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 30, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"May 15, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"January 22, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Clara Balsano",
                "ResponsiblePartyInvestigatorTitle":"Full Professor",
                "ResponsiblePartyInvestigatorAffiliation":"University of L'Aquila"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of L'Aquila",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The aim of the study is to define the clinical and biochemical parameters that characterize COVID-19 patients with a negative prognostic evolution. Our clinical score will be capable to recognize patient with favorable prognosis or patient with poor prognosis by statistical data analysis."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19 Prognostic Parameters"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"200",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Development cohort",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: data collection"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Validation cohort",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: data collection"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"data collection",
                    "InterventionDescription":"clinical data collection",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Development cohort",
                        "Validation cohort"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Data collection of clinical and demographical parameters of patients affected by COVID-19",
                    "PrimaryOutcomeDescription":"Data about sex, age, symptom start date, vital parameters, comorbidity, symptoms, hematochemicals blood tests, therapy, oxygen support, radiology, condition evaluation will be manual collected.",
                    "PrimaryOutcomeTimeFrame":"2 months"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Application of statistical analysis on data of patients affected by COVID-19",
                    "SecondaryOutcomeDescription":"The collected data will be analyzed through descriptive statistics analysis, ROC curves, regression analysis, and Machine Learning techniques to predict the prognosis of patients affected by COVID-19.",
                    "SecondaryOutcomeTimeFrame":"2 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\npatients over 18 and symptomatic and positive for COVID-19 by polymerase chain reaction assay for rhino-pharingeal swab\n\nExclusion Criteria:\n\nUnder 18",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Italian Caucasian Patients â‰¥ 18 years old SARS-CoV-2 infection confirmed by PCR",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"University of L'Aquila",
                    "LocationCity":"L'Aquila",
                    "LocationZip":"67100",
                    "LocationCountry":"Italy"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            }
          }
        }
      },{
        "Rank":32,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780360",
              "OrgStudyIdInfo":{
                "OrgStudyId":"567"
              },
              "Organization":{
                "OrgFullName":"Cairo University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Cyanoacrylate Tissue Adhesives Versus Polyproplene Suture at the Palatal Donor Site of Sub Epithelial Connective Tissue Graft",
              "OfficialTitle":"Evaluation of Post Operative Pain, Early Wound Healing, and the Time of Application of Cyanoacrylates Tissue Adhesives Versus Polypropylene Sutures at the Palatal Donor Area of Subepithelial Connective Tissue Grafts (CTG) A Randomized Clinical Trial: Comparative Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 1, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 1, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 1, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"November 17, 2019",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Mohamed Saeed Mohamed Ibrahuim Abdullah",
                "ResponsiblePartyInvestigatorTitle":"Researcher",
                "ResponsiblePartyInvestigatorAffiliation":"Cairo University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Cairo University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Subepithelial connective tissue grafts (CTG) are considered the gold standard procedure with proven clinical success when it comes to gingival augmentation aims to to improve periodontal health, which can enhance the long-term prognosis of teeth by obtaining soft tissue coverage of exposed root surfaces and/or augmentation the dimensions of gingival tissue. The procedure require harvesting tissue from a the palate, which increases the complexity of the procedure and patient discomfort. Complications after harvesting a graft would be pain, inflammation, bleeding, flap necrosis and infection in the donor site."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "The Effect of Local Aplication of Cayanoacrylate Tissue Adhesives on Improving the Healing"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Supportive Care",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"20",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Cayanoacrylate tissue adhesives",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"thin layers of high viscosity blend of n-butyl and 2-octyl cayanoacrylate tissue adhesive will be applied and rinsed with saline at least three times with interval of at least 30 seconds",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Cayanoacrylate tissue adhesives"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Silk suture material",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"interrupted knots",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Silk suture"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"Cayanoacrylate tissue adhesives",
                    "InterventionDescription":"Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Cayanoacrylate tissue adhesives"
                      ]
                    }
                  },{
                    "InterventionType":"Procedure",
                    "InterventionName":"Silk suture",
                    "InterventionDescription":"Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Silk suture material"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Early Wound Healing",
                    "PrimaryOutcomeDescription":"Measured By Modified Early Wound Healing Index",
                    "PrimaryOutcomeTimeFrame":"1 week"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPatients with mucogingival defects scheduled for sub epithelial connective tissue graft\nAge at least 18 years.\nNot having any systemic disease that could compromise wound healing\nNo periodontal surgery on the experimental sites.\nNo smoking,\nNo pregnancy or lactation\n\nExclusion Criteria:\n\nPatients with coagulation disorders\npatients on corticosteroids, with uncontrolled diabetes, or with any systemic disease that precluded periodontal surgery\npatients with a history of contact dermatitis to formaldehyde\nLoss of maxillary premolars and molars\nMedications or antibiotics used in the previous 6 months\nPregnancy or lactation\nSmoking",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"50 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Mohamed S Mohamed Ibrahium Abdullah, Invistegator",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"01283626196",
                    "CentralContactPhoneExt":"02",
                    "CentralContactEMail":"dr.mohamed15.ms@gmail.com"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Faculty of Dentistry, Cairo Universty",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Cairo",
                    "LocationZip":"0000",
                    "LocationCountry":"Egypt",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Hassan Ahmed, Adminstrator",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"23634965",
                          "LocationContactPhoneExt":"02",
                          "LocationContactEMail":"hassan.ahmed@dentistry.cu.edu.eg"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M11652",
                    "ConditionBrowseLeafName":"Pain, Postoperative",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16268",
                    "ConditionBrowseLeafName":"Wounds and Injuries",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M11649",
                    "ConditionBrowseLeafName":"Pain",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC26",
                    "ConditionBrowseBranchName":"Wounds and Injuries"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":33,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780347",
              "OrgStudyIdInfo":{
                "OrgStudyId":"YBCSG-21-03"
              },
              "Organization":{
                "OrgFullName":"Fudan University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer",
              "OfficialTitle":"A Phase II, Single-center, Randomized Study of Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"December 15, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 30, 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"February 25, 2023",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Jian Zhang,MD",
                "ResponsiblePartyInvestigatorTitle":"Chief physician",
                "ResponsiblePartyInvestigatorAffiliation":"Fudan University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Fudan University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer",
              "DetailedDescription":"A Phase II, single-center, randomized study of albumin-bound paclitaxel combination with capecitabine versus capecitabine monotherapy in paclitaxel/docetaxel-resistant advanced breast cancer."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Breast Cancer"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Breast cancer",
                  "Albumin-bound paclitaxel",
                  "paclitaxel/docetaxel-resistant"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"92",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Albumin-bound paclitaxel plus capecitabine",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Albumin-bound paclitaxel combined with capecitabine",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Albumin-bound paclitaxel plus capecitabine"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Capecitabine",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Capecitabine",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: capecitabine"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Albumin-bound paclitaxel plus capecitabine",
                    "InterventionDescription":"Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3wï¼› capecitabine 1000 mg/m2, POï¼Œbid, D1-14,q3w.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Albumin-bound paclitaxel plus capecitabine"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"capecitabine",
                    "InterventionDescription":"capecitabine: capecitabine 1000 mg/m2, POï¼Œbid, D1-14,q3w.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Capecitabine"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"PFS",
                    "PrimaryOutcomeDescription":"Progression Free Survival",
                    "PrimaryOutcomeTimeFrame":"approximately 6 weeks"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"ORR",
                    "SecondaryOutcomeDescription":"Objective Response Rate",
                    "SecondaryOutcomeTimeFrame":"approximately 6 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"OS",
                    "SecondaryOutcomeDescription":"Overall Survival",
                    "SecondaryOutcomeTimeFrame":"Up to approximately 30 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nFemales with age between 18 and 70 years old\nHistological proven unresectable recurrent or advanced breast cancer\nNegative for human epithelial receptor-2 (HER2) by immunohistochemistry. A negative Her2 gene amplification should be verified by FISH test for those patients with Her2 (2+). For those with Her2 (1+), FISH test might be considered by the investigator.\nPatients who developed disease progression within 12 months of previous paclitaxel-containing chemotherapy regimens.\nAt least one measurable disease according to the response evaluation criteria in solid tumor (RECIST 1.1)\nPerformance status no more than 1\nAll patients enrolled are required to have adequate hematologic, hepatic, and renal function\nLife expectancy longer than 12 weeks\nNo serious medical history of heart, lung, liver and kidney\nBe able to understand the study procedures and sign informed consent.\nPatients with good compliance.\n\nExclusion Criteria:\n\nPregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days before the first day of drug dosing, or, if positive, a pregnancy should be ruled out by ultrasound)\nWomen of child-bearing potential, unwilling to use adequate contraceptive protection during the process of the study\nTreatment with radiotherapy at the axial skeleton within 4 weeks before the first treatment or has not recovered from all toxicities of previous radiotherapy\nTreatment with an investigational product within 4 weeks before the first treatment\nPatients with symptomatic central nervous system metastases are not permitted, except for those with stable and asymptomatic brain metastases who have completed cranial irradiation, and have at least one measurable lesion outside the brain. Radiotherapy should be completed within 4 weeks prior to the registration\nOther active malignancies (including other hematologic malignancies) or other malignancies within the last 5 years, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.\nPatients having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions\nUncontrolled serious infection",
              "HealthyVolunteers":"No",
              "Gender":"Female",
              "MinimumAge":"18 Years",
              "MaximumAge":"70 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Fudan University Shanghai Cancer center",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Shanghai",
                    "LocationZip":"200032",
                    "LocationCountry":"China",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Jian Zhang, MD,PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+8618121299359",
                          "LocationContactEMail":"syner2000@163.com"
                        },{
                          "LocationContactName":"Yiqun Du, MD,PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+8618121299359",
                          "LocationContactEMail":"dyqlh2010@163.com"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001943",
                    "ConditionMeshTerm":"Breast Neoplasms"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  },{
                    "ConditionAncestorId":"D000001941",
                    "ConditionAncestorTerm":"Breast Diseases"
                  },{
                    "ConditionAncestorId":"D000012871",
                    "ConditionAncestorTerm":"Skin Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3802",
                    "ConditionBrowseLeafName":"Breast Neoplasms",
                    "ConditionBrowseLeafAsFound":"Breast Cancer",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3800",
                    "ConditionBrowseLeafName":"Breast Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14257",
                    "ConditionBrowseLeafName":"Skin Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC17",
                    "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000017239",
                    "InterventionMeshTerm":"Paclitaxel"
                  },{
                    "InterventionMeshId":"D000069287",
                    "InterventionMeshTerm":"Capecitabine"
                  },{
                    "InterventionMeshId":"D000068196",
                    "InterventionMeshTerm":"Albumin-Bound Paclitaxel"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000000972",
                    "InterventionAncestorTerm":"Antineoplastic Agents, Phytogenic"
                  },{
                    "InterventionAncestorId":"D000000970",
                    "InterventionAncestorTerm":"Antineoplastic Agents"
                  },{
                    "InterventionAncestorId":"D000050257",
                    "InterventionAncestorTerm":"Tubulin Modulators"
                  },{
                    "InterventionAncestorId":"D000050256",
                    "InterventionAncestorTerm":"Antimitotic Agents"
                  },{
                    "InterventionAncestorId":"D000050258",
                    "InterventionAncestorTerm":"Mitosis Modulators"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  },{
                    "InterventionAncestorId":"D000000964",
                    "InterventionAncestorTerm":"Antimetabolites, Antineoplastic"
                  },{
                    "InterventionAncestorId":"D000000963",
                    "InterventionAncestorTerm":"Antimetabolites"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M1668",
                    "InterventionBrowseLeafName":"Docetaxel",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M18120",
                    "InterventionBrowseLeafName":"Paclitaxel",
                    "InterventionBrowseLeafAsFound":"Spontaneous",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M377",
                    "InterventionBrowseLeafName":"Capecitabine",
                    "InterventionBrowseLeafAsFound":"Lung",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M231",
                    "InterventionBrowseLeafName":"Albumin-Bound Paclitaxel",
                    "InterventionBrowseLeafAsFound":"Spontaneous",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M24784",
                    "InterventionBrowseLeafName":"Tubulin Modulators",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M24783",
                    "InterventionBrowseLeafName":"Antimitotic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2862",
                    "InterventionBrowseLeafName":"Antimetabolites",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"ANeo",
                    "InterventionBrowseBranchName":"Antineoplastic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":34,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780334",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2021_0063"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"2021-A00387-34",
                    "SecondaryIdType":"Other Identifier",
                    "SecondaryIdDomain":"ID-RCB number, ANSM"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"University Hospital, Lille",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept",
              "OfficialTitle":"Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept",
              "Acronym":"COR-DIAL-S"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"April 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 2, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University Hospital, Lille",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The main objective of this CorDial-S proof-of-concept study is to evaluate the ability to detect COVID-19 infection in nasopharyngeal swabs with CorDial-S and compare it to the PCR technique currently in use. Saliva analysis will be the subject of secondary analysis.\n\nThe CorDial-S medical device could allow the specimens to be analyzed using a small portable device and the results to be returned in minutes to the medical team and the patient, and communicated in real time with a telemedicine and remote monitoring system to the health authorities to allow the necessary protective, containment and therapeutic management measures to be put in place if necessary.\n\nThe benefits would be\n\ngreater sensitivity\na great speed because 8tests could be performed at the same time with a result in a few minutes\na very high specificity at least equivalent to PCR.\n\nThis new diagnostic strategy could become extremely valuable in the fight against COVID-19, especially in the case of very long-term persistence and incomplete vaccination of the French and foreign population."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "SARS-CoV Infection",
                  "Covid19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Control"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "BioSpec":{
                "BioSpecRetention":"None Retained",
                "BioSpecDescription":"nasopharyngeal swab and saliva"
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"200",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Positive diagnosis of SARS-CoV-2",
                    "ArmGroupDescription":"100 patients with a positive diagnosis of SARS-CoV-2",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Diagnostic Test: COVID-19 RT-PCR",
                        "Diagnostic Test: Biosensor"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Negative diagnosis of SARS-CoV-2",
                    "ArmGroupDescription":"100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Diagnostic Test: COVID-19 RT-PCR",
                        "Diagnostic Test: Biosensor"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Diagnostic Test",
                    "InterventionName":"COVID-19 RT-PCR",
                    "InterventionDescription":"Nasopharyngeal swabs for COVID-19 RT-PCR",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Negative diagnosis of SARS-CoV-2",
                        "Positive diagnosis of SARS-CoV-2"
                      ]
                    }
                  },{
                    "InterventionType":"Diagnostic Test",
                    "InterventionName":"Biosensor",
                    "InterventionDescription":"Portable and Connected Biosensor viral",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Negative diagnosis of SARS-CoV-2",
                        "Positive diagnosis of SARS-CoV-2"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Sensitivity and specificity of CorDial-S based on the first nasopharyngeal swab taken on patient admission, compared to the final positive or negative diagnosis of COVID-19 by the medical team",
                    "PrimaryOutcomeTimeFrame":"at patient admission (Baseline)"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and CorDial-S based on nasopharyngeal swabs taken at patient admission.",
                    "SecondaryOutcomeTimeFrame":"at patient admission (Baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Sensitivity and specificity of CorDial-S based on the first saliva sample taken at patient admission compared to the final positive or negative diagnosis of COVID-19 by the medical team.",
                    "SecondaryOutcomeTimeFrame":"at patient admission (Baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and CorDial-S based on saliva samples taken at patient admission.",
                    "SecondaryOutcomeTimeFrame":"at patient admission (Baseline)"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nMale or female or child without age limit\nAdmitted to a Reference Health Establishment (RHS) in an emergency unit, hospitalization or intensive care unit for suspicion of SARS-CoV-2 infection regardless of clinical presentation and degree of severity.\nPatient to be diagnosed by PCR test on nasopharyngeal swab.\nSocial insured\n\nExclusion Criteria:\n\nRefusal of the person to participate (collection of information, second use of his sample, collection of saliva by spitting)\nPregnant and breastfeeding women\nProtected Majors",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"patients admitted to a Reference Health Establishment for suspicion of SARS-CoV-2",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Enagnon Kazali ALIDJINOU, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"0320445962",
                    "CentralContactPhoneExt":"+33",
                    "CentralContactEMail":"EnagnonKazali.ALIDJINOU@CHRU-LILLE.FR"
                  },{
                    "CentralContactName":"David Devos, MD,PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactEMail":"david.devos@chru-lille.fr"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Enagnon Kazali ALIDJINOU, MD",
                    "OverallOfficialAffiliation":"University Hospital, Lille",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000018352",
                    "ConditionMeshTerm":"Coronavirus Infections"
                  },{
                    "ConditionMeshId":"D000045169",
                    "ConditionMeshTerm":"Severe Acute Respiratory Syndrome"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000003333",
                    "ConditionAncestorTerm":"Coronaviridae Infections"
                  },{
                    "ConditionAncestorId":"D000030341",
                    "ConditionAncestorTerm":"Nidovirales Infections"
                  },{
                    "ConditionAncestorId":"D000012327",
                    "ConditionAncestorTerm":"RNA Virus Infections"
                  },{
                    "ConditionAncestorId":"D000014777",
                    "ConditionAncestorTerm":"Virus Diseases"
                  },{
                    "ConditionAncestorId":"D000012141",
                    "ConditionAncestorTerm":"Respiratory Tract Infections"
                  },{
                    "ConditionAncestorId":"D000012140",
                    "ConditionAncestorTerm":"Respiratory Tract Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19074",
                    "ConditionBrowseLeafName":"Coronavirus Infections",
                    "ConditionBrowseLeafAsFound":"SARS-CoV Infection",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M24032",
                    "ConditionBrowseLeafName":"Severe Acute Respiratory Syndrome",
                    "ConditionBrowseLeafAsFound":"SARS-CoV Infection",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14938",
                    "ConditionBrowseLeafName":"Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5138",
                    "ConditionBrowseLeafName":"Coronaviridae Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M22269",
                    "ConditionBrowseLeafName":"Nidovirales Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16105",
                    "ConditionBrowseLeafName":"Virus Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13732",
                    "ConditionBrowseLeafName":"RNA Virus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13561",
                    "ConditionBrowseLeafName":"Respiratory Tract Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13560",
                    "ConditionBrowseLeafName":"Respiratory Tract Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T5186",
                    "ConditionBrowseLeafName":"Severe Acute Respiratory Syndrome",
                    "ConditionBrowseLeafAsFound":"SARS-CoV Infection",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":35,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780321",
              "OrgStudyIdInfo":{
                "OrgStudyId":"JS016-002-Ib/II"
              },
              "Organization":{
                "OrgFullName":"Shanghai Junshi Bioscience Co., Ltd.",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects",
              "OfficialTitle":"A Randomized, Double-blind, Placebo-controlled, Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetic Profiles and Immunogenicity of JS016 in Participants With Mild and Moderate COVID-19 or of SARS-CoV-2 Asymptomatic Infection"
            },
            "StatusModule":{
              "StatusVerifiedDate":"September 2020",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"October 30, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"March 31, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 30, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"September 23, 2020",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Shanghai Junshi Bioscience Co., Ltd.",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"JS016-002-Ib/II is a randomized, double-blinded, placebo-controlled study, to investigate the safety, PK profiles, preliminary efficacy and immunogenicity of intravenous Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody (JS016) in participants with mild and moderate COVID-19 or of SARS-CoV-2 Asymptomatic Infection.\n\nThree doses of JS016 are to be investigated, including 25mg/kg, 50mg/kg and 100mg/kg, given as single dose of intravenous infusion. In total, 90 participants will be enrolled with 30 participants each for 25, 50 and 100mg/kg dose cohort at a ratio of 2:1 to receive investigational product or placebo treatment, respectively.",
              "DetailedDescription":"\"Each participant will receive JS016 or matched placebo intravenous infusion on D1 (randomizing day). Non-pharmaceutical supportive background therapy (e.g. oxygen inhalation) for COVID-19 is allowed per clinical needs.\n\nInvestigators will be kept blinded to review the preliminary efficacy and safety data on a regular basis. Meanwhile, a study evaluation team (SET) composed of medical monitors, safety assessors and statisticians will be set up to review the study status, safety and preliminary efficacy of the participants at the pre-specified time points or as necessary."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "COVID-19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 1",
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Sequential Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"90",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Anti-SARS-CoV-2 Monoclonal Antibody dose 1/2/3",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"use Anti-SARS-CoV-2 Monoclonal Antibody,dose 1/2/3 to treat COVID-19",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"use placebo to treat COVID-19",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Biological",
                    "InterventionName":"Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)",
                    "InterventionDescription":"use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Anti-SARS-CoV-2 Monoclonal Antibody dose 1/2/3"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"30 patients receipt placebo intravenous infusion on day 1",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Placebo"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Efficacy Measurs(Time to negative conversion in viral nucleic acid test(by RT-PCR) for diagnostic samples)",
                    "PrimaryOutcomeDescription":"Time to negative conversion in viral nucleic acid test (by RT-PCR) for diagnostic samples, negative conversion is defined as two consecutive negative nucleic acid test for diagnostic samples after randomization",
                    "PrimaryOutcomeTimeFrame":"0-85days"
                  },{
                    "PrimaryOutcomeMeasure":"Safety Measurements : 90 of participants with treatment-related adverse events as assessed byCTCAE v5.0",
                    "PrimaryOutcomeDescription":"Any adverse event, serious adverse events (SAEs) occurring during the clinical study, including clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, myocardial enzymogram, etc.) and abnormality of 12-lead ECGs will be observed for all the participants",
                    "PrimaryOutcomeTimeFrame":"0-85days"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"PK Measures:AUC0-tau",
                    "SecondaryOutcomeDescription":"Area under the plasma drug concentration-time curve from time 0 to one dosing interval (AUC0-tau)",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  },{
                    "SecondaryOutcomeMeasure":"PK Measuresï¼šCmax",
                    "SecondaryOutcomeDescription":"Maximum plasma drug concentration after administration (Cmax)",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  },{
                    "SecondaryOutcomeMeasure":"PK Measuresï¼šTmax",
                    "SecondaryOutcomeDescription":"Time to the maximum plasma drug concentrations after administration (Tmax)",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  },{
                    "SecondaryOutcomeMeasure":"PK Measuresï¼št1/2",
                    "SecondaryOutcomeDescription":"Terminal half life (t1/2)",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  },{
                    "SecondaryOutcomeMeasure":"PK Measuresï¼šCL",
                    "SecondaryOutcomeDescription":"Total clearance (CL)",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  },{
                    "SecondaryOutcomeMeasure":"PK Measuresï¼šVd",
                    "SecondaryOutcomeDescription":"Apparent volume of distribution (Vd)",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  },{
                    "SecondaryOutcomeMeasure":"Proportions of participants with negative conversion in viral nucleic acid test",
                    "SecondaryOutcomeDescription":"Proportions of participants with negative conversion in viral nucleic acid test 7 days and 14 days after administration (performed on each day of the first week after dosing, every other day of the 2nd week, once a week from the 3rd week)",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  },{
                    "SecondaryOutcomeMeasure":"Viral load change from baseline",
                    "SecondaryOutcomeDescription":"Viral load change from baseline (performed on each day of the first week after dosing, every other day of the 2nd week, once a week from the 3rd week)",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  },{
                    "SecondaryOutcomeMeasure":"Pulmonary CTï¼ˆobserve by imaging reports to degree of pulmonary inflammation, degree of vitreous fibrosis)",
                    "SecondaryOutcomeDescription":"Pulmonary CT changes during the study period",
                    "SecondaryOutcomeTimeFrame":"Day 0 to Day 85"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAge of 18-65 years (inclusive) ,women or man\nSARS-CoV-2 detected in the diagnostic specimen (nasopharyngeal swab)\nHigh homology of viral gene sequencing with the known SARS-CoV-2.\"\nMild/moderateillness COVID-19 or SARS-CoV-2 asymptomatic infection\nWithin 7 days from the onset time of symptoms to randomization or within 5 days from the first time of SARS-CoV-2 positive test to randomization with required viral load\nNo plan of pregnancy and being willing to use effective contraceptive measures\nSigned the informed consent form, sufficiently understanding of the content\n\nExclusion Criteria:\n\npositive IgM/IgG against SARS-CoV-2 prior to randomization.\nSevereor critical illness\nUncontrolled hypertension, cardiovascular/cerebrovascular diseases,lung diseases\nType 1 diabetes, or newly diagnosed or poorly controlled type 2 diabetes\nLiver and kidney dysfunction, immune or inflammatory diseases, infections, surgery, tumors, and other major diseases\nHistory of SARS-CoV-2 vaccination or participation in clinical trial with neutralizing antibody against SARS-CoV-2.\nUse of therapeutic biologics within 3 months prior to screening, or within the elimination period (5 half-lives) of such drugs as the day of dosing\nHas participated in any other interventional clinical study involving anstudy drug within 3 months prior to screening, or within the elimination period (5 half-lives) of the study drug as the day of dosing\nPlatelets and hemoglobin test results during screening period are abnormal and have clinical significanc.\nAnaphylaxis, urine drug screening, alcohol dependence, lactation during pregnancy, blood loss, and others",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"jingjing sheng",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"17317890616",
                    "CentralContactEMail":"jingjing_sheng@junshipharma.com"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Beijing Ditan Hospital affiliated to Capital Medical University",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"Beijing",
                    "LocationZip":"100010",
                    "LocationCountry":"China",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Fujie Zhang, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"010-84322581",
                          "LocationContactEMail":"treatment@chinaaids.cn"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Huashan Hospital affiliated to Fudan University",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Shanghai",
                    "LocationCountry":"China",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Wenhong Zhang, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"021-52889305",
                          "LocationContactEMail":"yurancao@126.com"
                        },{
                          "LocationContactName":"Jing zhang, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000058345",
                    "ConditionMeshTerm":"Asymptomatic Infections"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000058070",
                    "ConditionAncestorTerm":"Asymptomatic Diseases"
                  },{
                    "ConditionAncestorId":"D000020969",
                    "ConditionAncestorTerm":"Disease Attributes"
                  },{
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M27627",
                    "ConditionBrowseLeafName":"Asymptomatic Infections",
                    "ConditionBrowseLeafAsFound":"Asymptomatic Infections",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M27555",
                    "ConditionBrowseLeafName":"Asymptomatic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21284",
                    "ConditionBrowseLeafName":"Disease Attributes",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000000906",
                    "InterventionMeshTerm":"Antibodies"
                  },{
                    "InterventionMeshId":"D000000911",
                    "InterventionMeshTerm":"Antibodies, Monoclonal"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000007155",
                    "InterventionAncestorTerm":"Immunologic Factors"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2806",
                    "InterventionBrowseLeafName":"Antibodies",
                    "InterventionBrowseLeafAsFound":"Sessions",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M8767",
                    "InterventionBrowseLeafName":"Immunoglobulins",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2811",
                    "InterventionBrowseLeafName":"Antibodies, Monoclonal",
                    "InterventionBrowseLeafAsFound":"Administration",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M8784",
                    "InterventionBrowseLeafName":"Immunologic Factors",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":36,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780308",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2014/18/05"
              },
              "Organization":{
                "OrgFullName":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital",
                "OrgClass":"OTHER_GOV"
              },
              "BriefTitle":"Pediatric Type III Supracondylar Humeral Fracture",
              "OfficialTitle":"How Many K Wires do we Need in the Surgical Treatment of Pediatric Type III Supracondylar Humeral Fracture?",
              "Acronym":"Fracture"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 1, 2010",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 31, 2013",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"February 20, 2015",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 7, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Alkan Bayrak",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital",
                "LeadSponsorClass":"OTHER_GOV"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of this study was to compare pin configuration effects on early secondary displacement in the surgical treatment of pediatric supracondylar humeral fractures (SCHF).",
              "DetailedDescription":"The study consisted of 100 (68M, 32F) children who underwent surgery between 2010 and 2013 for Gartland Type 3 (SCHF). The patients divided into five groups according to the top in configurations (crossed 1 lateral 1 medial, crossed 2 lateral 1 medial, crossed 1 lateral 2 medial, 2 lateral divergent, and 3 lateral divergent). The average age at the time of injury was 7.34 (between 2 and 14 years). Bauman angle (BA), Humerocapital angle (HCA), Anterior humeral line (AHL), flexion range, extension range, and Carrying angle (CA) were compared at preoperative, postoperative 1st-day, postoperative last control, and non-operated side. The mean follow-up time 24,96Â±11,06 with a range of 12-54 months."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Supracondylar Humerus Fracture",
                  "Pediatric Fractures"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "pediatric",
                  "supracondylar humeral fracture",
                  "k wires",
                  "closed reduction",
                  "pin configuration"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"Yes",
              "TargetDuration":"12 Months",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Control"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Other"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"100",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"1 medial 1 lateral K-wire",
                    "ArmGroupDescription":"Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 1 lateral K-wire",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"1 medial 2 lateral K-wire",
                    "ArmGroupDescription":"Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 2 lateral K-wire",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"2 medial 1 lateral K-wire",
                    "ArmGroupDescription":"Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 medial 1 lateral K-wire",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"2 lateral K-wire",
                    "ArmGroupDescription":"Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 lateral K-wire",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"3 lateral K-wire",
                    "ArmGroupDescription":"Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 3 lateral K-wire",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires",
                    "InterventionDescription":"The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "1 medial 1 lateral K-wire",
                        "1 medial 2 lateral K-wire",
                        "2 lateral K-wire",
                        "2 medial 1 lateral K-wire",
                        "3 lateral K-wire"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Baumann Angle",
                    "PrimaryOutcomeDescription":"This angle is formed by the humeral axis and a straight line through the epiphyseal plate of the capitellum. Preoperative and postoperative angle differences are measured in anteroposterior and lateral X rays. These differences are measured for reduction quality and these parameters shows the success of the surgery.",
                    "PrimaryOutcomeTimeFrame":"postoperative 1. day, 1. month and 12. month"
                  },{
                    "PrimaryOutcomeMeasure":"Anterior Humeral Line",
                    "PrimaryOutcomeDescription":"A line drawn down the anterior surface of the humerus should intersect the middle third of the capitellum. Preoperative and postoperative angle differences are measured in anteroposterior and lateral X rays. These differences are measured for reduction quality and these parameters shows the success of the surgery.",
                    "PrimaryOutcomeTimeFrame":"postoperative 1. day, 1. month and 12. month"
                  },{
                    "PrimaryOutcomeMeasure":"Humero-Capital Angle",
                    "PrimaryOutcomeDescription":"On lateral X-ray angle between capitellum and humeral shaft. Preoperative and postoperative angle differences are measured in anteroposterior and lateral X rays. These differences are measured for reduction quality and these parameters shows the success of the surgery.",
                    "PrimaryOutcomeTimeFrame":"postoperative 1. day, 1. month and 12. month"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria\n\nPediatric Gartland Type 3 supracondylar humeral fracture\nPatients operated between 2010-2013\nPatients under 16 years old\n\nExclusion Criteria:\n\nPathological fractures\nConservative treated supracondylar fractures\nLess than the 1-year follow-up\nPatients with incomplete postoperative follow-up\nPatients older than 16 years\nPediatric Gartland Type 1 and 2 supracondylar humeral fracture",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MaximumAge":"16 Years",
              "StdAgeList":{
                "StdAge":[
                  "Child"
                ]
              },
              "StudyPopulation":"Patients under 16 years.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DocumentSection":{
            "LargeDocumentModule":{
              "LargeDocList":{
                "LargeDoc":[
                  {
                    "LargeDocTypeAbbrev":"Prot_SAP",
                    "LargeDocHasProtocol":"Yes",
                    "LargeDocHasSAP":"Yes",
                    "LargeDocHasICF":"No",
                    "LargeDocLabel":"Study Protocol and Statistical Analysis Plan",
                    "LargeDocDate":"December 29, 2014",
                    "LargeDocUploadDate":"02/28/2021 11:27",
                    "LargeDocFilename":"Prot_SAP_000.pdf"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000050723",
                    "ConditionMeshTerm":"Fractures, Bone"
                  },{
                    "ConditionMeshId":"D000006810",
                    "ConditionMeshTerm":"Humeral Fractures"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000014947",
                    "ConditionAncestorTerm":"Wounds and Injuries"
                  },{
                    "ConditionAncestorId":"D000001134",
                    "ConditionAncestorTerm":"Arm Injuries"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M24957",
                    "ConditionBrowseLeafName":"Fractures, Bone",
                    "ConditionBrowseLeafAsFound":"Fracture",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8452",
                    "ConditionBrowseLeafName":"Humeral Fractures",
                    "ConditionBrowseLeafAsFound":"Humeral Fractures",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M16268",
                    "ConditionBrowseLeafName":"Wounds and Injuries",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3025",
                    "ConditionBrowseLeafName":"Arm Injuries",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC26",
                    "ConditionBrowseBranchName":"Wounds and Injuries"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2688",
                    "InterventionBrowseLeafName":"Anesthetics",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"CNSDep",
                    "InterventionBrowseBranchName":"Central Nervous System Depressants"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":37,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780295",
              "OrgStudyIdInfo":{
                "OrgStudyId":"CTH C010"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"DRKS00022277",
                    "SecondaryIdType":"Registry Identifier",
                    "SecondaryIdDomain":"DRKS (Deutsches Register klinischer Studien, engl.: German Clinical Studies Register)"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Johannes Gutenberg University Mainz",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"COvid-19 REgistry on THROMBOSIS Complications",
              "OfficialTitle":"COvid-19 REgistry on THROMBOSIS Complications Associated With Hospitalization: the CORE-THROMBOSIS",
              "Acronym":"CORE-THROMB"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 15, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 9, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor-Investigator",
                "ResponsiblePartyInvestigatorFullName":"Prof. Stavros Konstantinides, MD",
                "ResponsiblePartyInvestigatorTitle":"Prof Stavros Konstantinides, MD, Medical Director of the \"Center for Thrombosis and Hemostasis\" (CTH) at the University Medical Center Mainaz",
                "ResponsiblePartyInvestigatorAffiliation":"Johannes Gutenberg University Mainz"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Prof. Stavros Konstantinides, MD",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"University of Zurich",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This online-based, observational retrospective registry aims to (i) study the rate of cardiovascular events, encompassing venous thromboembolic and arterial events, in consecutive hospitalized patients with coronavirus (Covid19), (ii) investigate the prevalent use of thromboprophylaxis, (iii) describe the use of imaging tests for the detection of cardiovascular events in patients with Covid19. This will also facilitate and constitute the basis for the conduction of interventional thromboprophylaxis studies in patients with Covid19."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Covid19",
                  "thromboembolism",
                  "thromboprophylaxis",
                  "pulmonary embolism",
                  "anticoagulation"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Retrospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"5000",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Fatal or non-fatal venous thromboembolism (VTE)",
                    "PrimaryOutcomeTimeFrame":"during index hospitalization for Covid19"
                  },{
                    "PrimaryOutcomeMeasure":"Fatal or non-fatal cardiovascular events, encompassing stroke and myocardial infarction",
                    "PrimaryOutcomeTimeFrame":"during index hospitalization for Covid19"
                  },{
                    "PrimaryOutcomeMeasure":"All-cause death",
                    "PrimaryOutcomeTimeFrame":"during index hospitalization for Covid19"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Prevalence of cardiovascular risk factors",
                    "SecondaryOutcomeTimeFrame":"at baseline/enrollment"
                  },{
                    "SecondaryOutcomeMeasure":"Length of hospitalization",
                    "SecondaryOutcomeTimeFrame":"first index hospitalization for Covid19"
                  },{
                    "SecondaryOutcomeMeasure":"Prevalent use of in-hospital thromboprophylaxis",
                    "SecondaryOutcomeTimeFrame":"during index hospitalization for Covid19"
                  },{
                    "SecondaryOutcomeMeasure":"In-hospital course of D-dimer (Î¼g/mL)",
                    "SecondaryOutcomeTimeFrame":"during index hospitalization for Covid19"
                  },{
                    "SecondaryOutcomeMeasure":"In-hospital course of Troponin (ng/ml)",
                    "SecondaryOutcomeTimeFrame":"during index hospitalization for Covid19"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nHospitalized patients aged â‰¥ 18 years with a positive test for severe acute respiratory syndrome corona virus 2 (SARS-CoV2)\n\nExclusion Criteria:\n\nNone",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Given the observational nature of this registry, no exclusion criteria will be applied.",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Stavros Konstantinides, MD, Prof",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+49 6131 17-8382",
                    "CentralContactEMail":"Stavros.Konstantinides@unimedizin-mainz.de"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Stavros Konstantinides, MD, Prof",
                    "OverallOfficialAffiliation":"University Medical Center Mainz, Johannes Gutenberg University Mainz",
                    "OverallOfficialRole":"Study Chair"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Unicamp (Universidade Estadual de Campinas; University of Campinas)",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Campinas",
                    "LocationZip":"13083-970",
                    "LocationCountry":"Brazil",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Joyce M. Annichino Bizzacchi, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"joyce@unicamp.br"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Hospital SÃ­rio-LibanÃªs",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"SÃ£o Paulo",
                    "LocationZip":"01308-050",
                    "LocationCountry":"Brazil",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Carolina Kassab Wroclawski, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"carolinakassab@hotmail.com"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Hospital de Campanha Anhembi",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"SÃ£o Paulo",
                    "LocationZip":"02012-021",
                    "LocationCountry":"Brazil",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Tassiana S. Pitta Diaz, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"tassiana.pitta@iabas.org.br"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Amager and Hvidovre Hospital",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Hvidovre",
                    "LocationZip":"2650",
                    "LocationCountry":"Denmark",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Klaus Nielsen Jeschke, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"talpadanica@gmail.com"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"DRK Kliniken Berlin KÃ¶penick",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Berlin KÃ¶penick",
                    "LocationZip":"12559",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Christian Opitz, MD, Prof",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"c.opitz@drk-kliniken-berlin.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"DRK Kliniken Berlin Westend",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Berlin Westend",
                    "LocationZip":"14050",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Christian Opitz, MD, Prof",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"c.opitz@drk-kliniken-berlin.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"UniversitÃ¤tsklinikum Koeln",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Cologne",
                    "LocationZip":"50937",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Stephan Rosenkranz, MD, Prof",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"stephan.rosenkranz@uk-koeln.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Augusta-Krankenhaus Duesseldorf",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Duesseldorf",
                    "LocationZip":"40472",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Anamaria Wolf-Puetz, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"anamaria.wolf-puetz@vkkd-kliniken.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"UniversitÃ¤ts-Herzzentrum Freiburg",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Freiburg",
                    "LocationZip":"79106",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Daniel Duerschmied, MD, Prof",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"daniel.duerschmied@universitaets-herzzentrum.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"UniversitÃ¤tsklinikum des Saarlandes und Medizinische FakultÃ¤t der UniversitÃ¤t des Saarlandes",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Homburg",
                    "LocationZip":"66421",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Heinrike Wilkens, MD, Prof",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"anamaria.wolf-puetz@vkkd-kliniken.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"UniversitÃ¤tsmedizin Mainz",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Mainz",
                    "LocationZip":"55131",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Stavros Konstantinides, MD, Prof",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"stavros.konstantinides@unimedizin-mainz.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Krankenhaus Neuwittelsbach",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Munich",
                    "LocationZip":"80639",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Hanno Leuchte, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"dr.leuchte@krankenhaus-neuwittelsbach.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Paracelsus Medizinische PrivatuniversitÃ¤t am Klinikum Nuernberg",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Nuremberg",
                    "LocationZip":"90419",
                    "LocationCountry":"Germany",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Joachim Ficker, MD, Prof",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"Joachim.Ficker@klinikum-nuernberg.de"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Mater Misericordiae University Hospital",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Dublin",
                    "LocationCountry":"Ireland",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Barry Kevane, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"barrykevane@mater.ie"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"University of Bologna",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Bologna",
                    "LocationZip":"40126",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Stefano Nava, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"stefano.nava@unibo.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Azienda Socio Sanitaria Territoriale (ASST) Lariana",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Como",
                    "LocationZip":"22100",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Claudio Sorino, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"claudio.sorino@hsacomo.org"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Ospedale Sacra Famiglia Fatebenefratelli",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Erba",
                    "LocationZip":"22036",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Davide Agnelli, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"davideagnelli@interfree.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Presidio Ospedaliero Santa Croce di Fano",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Fano",
                    "LocationZip":"61032",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Luciano Mucci, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"luciano.mucci@ospedalimarchenord.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"IRCCS Ospedale Policlinico San Martino",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Genova",
                    "LocationZip":"16132",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Giorgio Ghigliotti, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"gghiglio@unige.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Ospedale Civile di Guastalla - Azienda UnitÃ  Sanitaria Locale (AUSL) Reggio Emilia",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Guastalla",
                    "LocationZip":"42016",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Elisabetta Teopompi, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"Elisabetta.Teopompi@ausl.re.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Azienda Ospedaliera di Padova",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"Padova",
                    "LocationZip":"35128",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Giampiero Avruscio, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"giampiero.avruscio@aopd.veneto.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Ospedale Maggiore di Parma - Azienda Ospedaliero Universitaria di Parma",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Parma",
                    "LocationZip":"43126",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Pietro Rossetti, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"prossetti@ao.pr.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Ospedale Maggiore di Parma - Azienda Ospedaliero Universitaria di Parma",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"Parma",
                    "LocationZip":"43126",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Alessandro Vignali, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"avignali@ao.pr.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Fondazione IRCCS Policlinico San Matteo",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Pavia",
                    "LocationZip":"27100",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Alessandro Pecci, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"alessandro.pecci@unipv.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Ospedale Civile di Castel San Giovanni - Azienda UnitÃ  Sanitaria Locale (AUSL) di Piacenza",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Piacenza",
                    "LocationZip":"29015",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Daniela Aschieri, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"daschieri@ausl.pc.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Santa Maria Nuova Hospital - Azienda UnitÃ  Sanitaria Locale (AUSL) IRCCS di Reggio Emilia",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Reggio Emilia",
                    "LocationZip":"42123",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Matteo Iotti, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"iotti.matteo@ausl.re.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"IRCCS Humanitas Clinical and Research Hospital",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Rozzano",
                    "LocationZip":"20089",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Corrado Lodigiani, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"corrado.lodigiani@humanitas.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"UniversitÃ  degli studi dell' Insubria (University of Insubria)",
                    "LocationStatus":"Not yet recruiting",
                    "LocationCity":"Varese",
                    "LocationZip":"21100",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Francesco Dentali, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"Francesco.Dentali@asst-settelaghi.it"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Instituto Nacional de Cardiologia Ignacio Chavez (National Institute of Cardiology Igancio Chavez)",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Mexico City",
                    "LocationZip":"14080",
                    "LocationCountry":"Mexico",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Flavio A. Grimaldo Gomez, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"dr.grimaldo@yahoo.com"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Hospital QuirÃ³nsalud",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"MÃ¡laga",
                    "LocationZip":"29004",
                    "LocationCountry":"Spain",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Alejandro Rodriguez Morata, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"alejandro.rmorata@quironsalud.es"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Erdem Medical Center",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Istanbul",
                    "LocationZip":"34768",
                    "LocationCountry":"Turkey",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"SavaÅŸ Ã–zsu, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"savasozsu@gmail.com"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000013927",
                    "ConditionMeshTerm":"Thrombosis"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000016769",
                    "ConditionAncestorTerm":"Embolism and Thrombosis"
                  },{
                    "ConditionAncestorId":"D000014652",
                    "ConditionAncestorTerm":"Vascular Diseases"
                  },{
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M15269",
                    "ConditionBrowseLeafName":"Thrombosis",
                    "ConditionBrowseLeafAsFound":"Thrombosis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M15265",
                    "ConditionBrowseLeafName":"Thromboembolism",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13092",
                    "ConditionBrowseLeafName":"Pulmonary Embolism",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6367",
                    "ConditionBrowseLeafName":"Embolism",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M17711",
                    "ConditionBrowseLeafName":"Embolism and Thrombosis",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M15983",
                    "ConditionBrowseLeafName":"Vascular Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":38,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780282",
              "OrgStudyIdInfo":{
                "OrgStudyId":"1614823"
              },
              "Organization":{
                "OrgFullName":"BahÃ§eÅŸehir University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Effects of Scapular Stabilization Exercises on Water Polo Players",
              "OfficialTitle":"Effect of Scapular Stabilization Exercises on Proprioception, Muscle Strength, Disability and Throwing Performance in Water Polo Players"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 28, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"May 1, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 1, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Ceren Ã‡etin",
                "ResponsiblePartyInvestigatorTitle":"Physcial Therapist",
                "ResponsiblePartyInvestigatorAffiliation":"BahÃ§eÅŸehir University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"BahÃ§eÅŸehir University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"36 water polo players will be included in this study. It will be divided into 2 groups as the scapular stabilization exercise group and the control group. Scapular stabilization exercise group;\n\n1) Squat with a towel slide on the wall 2) Wall push-ups with one leg extension 3) Cross squat 4) Elastic band pull while one leg squats 5) Double leg squat exercises will be given. These exercises will be 8 weeks and 3 days a week. The measurements of the exercises will be taken before the first session and at the end of the last session of the 8th week. Without giving exercise to the control group, only measurements will be taken in the 1st and 8th weeks. The study will take place in Burhan Felek Swimming Pool. Measurement evaluation tests;\n\nArm, Shoulder and Hand Problems Questionnaire (DASH): It is a questionnaire used to determine the levels of upper extremity functionality.\nProprioception measurement: Digital goniometer device, which includes the use of constant gravity as a reference point to evaluate joint mobility, will be considered as active and passive repetitive positioning.\nMeasurement of muscle strength: The measurement will be made using a hand-held manual dynamometer J-TEC for isometric muscle strength evaluation.\nSitting medicine ball throwing (OSTA): The distance the participant throws the ball while in the long sitting position will be measured in \"meters\".\n\nStatistical analysis to be used in the research will be done with SPSS 20.0 package program (SPSS inc, Chicago, USA).",
              "DetailedDescription":"Water polo is a high-intensity team sport that originated in England in the 1860's as a sort of water rugby. The national team of water polo, which is one of the oldest team sports included in the Olympic programme, was formed in our country in 1934. Water polo is a sports branch in which basic and auxiliary biomotor skills are used high level in accordance with its technical and tactical features. Water polo players; are performing actions which consist of a combination of movements such as rising, diving, blocking, sprinting, controlling the ball, agility and shooting. The most important action among major movements that determines the result of the match is the skill of shooting. Water polo training, swimming, scissors, shooting and passing. After all of these, the players continue the technical-tactical team training in the water for the matches.\n\nThe essential physical suitability parameters of water polo players during performance are muscle endurance, flexibility,joint stabilization, muscular strength, muscle-strength balance and skills specific to water polo. It has been suggested that, in the case of weakness in these basic parameters, a risk factor for pain and injury may occur. The mostly injured parts of water polop players are; shoulder, hand, head, elbow and groin respectirely. It was reported that 13% of 260 water polo players were injured in London Summer Olympic Games(2012). Water polo players have their injuries mostly in the shoulder area and the reason is; the shoulder area carries 70% of the whole body weight while the legs carry 30%. Considering this ratio, it is seen that the risk of injury is inevitable. Among teh risk factors for shoulder injuries there take place insufficient shoulder stabilizaiton, hypermobility, repetitive throwing, rapid rotational movements for grasping and defensive movements.\n\nIn determining the rate and strength of shooting, shoulder joint stabilization is important. To optimize the function of the shoulder, scapula supports optimal muscle activation, increases the muscle strength and transfers the muscle strength and energy through the kinetic chain during shoulder movements, the dynamic movement of the scapula increases the stability of the glenohumeral joint. Scapular stabilization exercises are neuromuscular control exercises which support the posterior curvature and external rotation of the scapula and aims to develop the stabilization of the scapula and the shoulder and improve the motor control usually including visual, verbal and kinesthetic feedback. Studies done in the literature have shown that scapular stabilization exercises reduce the pain and disability in shoulder problems and increase the strength of the muscle in shoulder area.\n\nProprioception is an important part of shoulder stability and neuromuscular control. Disruption of the proprioceptive system leads to malfunctions in muscular activity and badly affected joint stabilization. The joint, whose stabilization and protective muscular activity is impaired, becomes vulnerable to external traumas. Deficiencies in the proprioceptive sense have been associated with a decrease in sporting performance. Also, repetitive throwing activities increase the risk of injury in the shoulder complex by causing a short-term weakening in shoulder muscle strength and proprioceptive functions. It has been claimed that greater sensory acvity contributes to the motor control of the joint through improved proprioception."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Sport Injury"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "exercise",
                  "muscle strength",
                  "physical performance",
                  "proprioception",
                  "sports injury"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Non-Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"It will be divided into 2 groups as scapular stabilization exercise group and control group.",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"36",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Scapular Stabilization Group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"In the study, Adalar Water Sports Club (AWSK) takes places with its A team players; 18 players aged from 16-25 as the scapular stabilization group. The players in the scapular stabilization group will be applied scapular stabilization exercises for 8 weeks, 3 days a week in company with a physiotherapist. As stabilization exercises for the players; 1)Squatting while sliding a towel on the wall, 2)Wall push-ups with one leg extension, 3)Cross squat, 4)Pulling elastic band while squatting on one leg, 5)Double-leg squatting",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Scapular Stabilization Group"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Control group",
                    "ArmGroupType":"No Intervention"
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Scapular Stabilization Group",
                    "InterventionDescription":"Participants will apply the 5 exercises given.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Scapular Stabilization Group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH)",
                    "PrimaryOutcomeDescription":"In the first part of the questionnaire, there are 20 questions on physical competence and in the following, of the questionnaire there are 10 questions on pain and a total of 30 questions evaluating the functional and environmental limitation as a outcome of it. In the second part of the questionnaire, there is a module consists of 4 questions for athletes-musicians who want high performance. There are 5 answer options in each item. The scores resulting from the answers given for all items of the questionnaire will be summed up and calculated. When the score gets higheri the degree of disability also gets higher.",
                    "PrimaryOutcomeTimeFrame":"Change between baseline and 8 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Proprioception Measurement",
                    "PrimaryOutcomeDescription":"Digital goniometer device, which includes the use of constant gravity as a reference point to evaluate joint mobility, will be considered as active and passive repetitive positioning. researcher will initially bring the extremity to the target angle and wait there for a minimum of ten seconds for the patient to recall this position. Then the extremity will be placed in the starting position. The patient will be asked to actively bring his extremity back to the target angle or passively bring it to the previously determined angle. The deviation from the target angle (angular error) will be recorded.",
                    "PrimaryOutcomeTimeFrame":"Change between baseline and 8 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Muscle Strength Measurement",
                    "PrimaryOutcomeDescription":"The measurement will be made using a hand-held manual dynamometer J-TEC for isometric muscle strength evaluation. Measurement will be applied to shoulder area flexion-extension, abduction-adduction, internal rotation-external rotation muscle groups",
                    "PrimaryOutcomeTimeFrame":"Change between baseline and 8 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Throwing medicine ball in sitting position",
                    "PrimaryOutcomeDescription":"The distance the participant throws the ball while in the long sitting position will be measured in 'meters'.",
                    "PrimaryOutcomeTimeFrame":"Change between baseline and 8 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nBeing a players of Adalar Water Sports Club\nBeing in the age rande of 16-25\nAgreeing to participate in the research voluntarily\n\nExclusion Criteria:\n\nNot being a player of Adalar Water Sports Club\nHaving a history of fracture in the shoulder area\nHaving received physiotherapy in the shoulder elbow and wrist 6 months ago",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"Male",
              "GenderBased":"Yes",
              "GenderDescription":"Male A team players will be taken",
              "MinimumAge":"16 Years",
              "MaximumAge":"25 Years",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Ceren Ã‡ETÄ°N, PT",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+905369450382",
                    "CentralContactEMail":"cetceren95@gmail.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Leyla ATAÅž BALCI, Assist Prof",
                    "OverallOfficialAffiliation":"BahÃ§eÅŸehir University",
                    "OverallOfficialRole":"Study Director"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Burhan Felek Swimming Club",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Ä°stanbul",
                    "LocationState":"ÃœskÃ¼dar",
                    "LocationZip":"34668",
                    "LocationCountry":"Turkey",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Levent SAÄžLAM, Trainer",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+905072746936",
                          "LocationContactEMail":"info@assk.org.tr"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001265",
                    "ConditionMeshTerm":"Athletic Injuries"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000014947",
                    "ConditionAncestorTerm":"Wounds and Injuries"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3151",
                    "ConditionBrowseLeafName":"Athletic Injuries",
                    "ConditionBrowseLeafAsFound":"Sport Injury",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M16268",
                    "ConditionBrowseLeafName":"Wounds and Injuries",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC26",
                    "ConditionBrowseBranchName":"Wounds and Injuries"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":39,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780269",
              "OrgStudyIdInfo":{
                "OrgStudyId":"[2020]31201"
              },
              "Organization":{
                "OrgFullName":"Guangzhou Women and Children's Medical Center",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Foley Catheter Versus PGE2 for Labor Induction at Term: a Pilot Study",
              "OfficialTitle":"Foley Catheter Versus Prostaglandin E2 Vaginal Suppository for Labor Induction at Term: a Pilot Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"October 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 2023",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2023",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 22, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Zehong Zhou",
                "ResponsiblePartyInvestigatorTitle":"Principle investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Guangzhou Women and Children's Medical Center"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Guangzhou Women and Children's Medical Center",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Induction of labor is one of the most common interventions in obstetrics. In the past decade, the rates of labor induction at term have doubled from approximately 9% to 23% in the United States and from 10% to 20.4% in China. The majority of women undergoing labor induction requires cervical ripening for the unfavorable cervixes. As globally, it is still required to explore an optimal induction method. Foley catheter was among the oldest mechanical approaches, while prostaglandin E2 vaginal suppository (PGE2) one of the most popular pharmacological agents for cervical ripening. There were studies reporting similar cesarean section rates between these two methods. However, there are no randomized control trials (RCTs) with adequate power to compare their frequencies of severe perinatal complications. The investigators aim to compare the effectiveness and safety of Foley catheter versus PGE2 for induction of labor among term pregnant women with an unfavourable cervix.",
              "DetailedDescription":"The investigators propose a single center, open-label, randomized controlled clinical trial (1:1 treatment ratio) in Guangzhou Women and Children's Medical Center. Women with a term pregnancy, an indication for induction of labor, and a live singleton fetus at cephalic presentation, intact membranes, an unfavorable cervix, no prior cesarean section or contraindication to vaginal delivery, are eligible to participate. After informed consent, they will be randomized to undergo induction of labor by Foley catheter or PGE2.\n\nOur primary outcomes will be (I) a composite of severe perinatal complications and (II) vaginal delivery. Before the formal recruitment of this RCT, a pilot study with a sample size of 200 pregnant women will be performed."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Labor Induction",
                  "Induced Delivery"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Labor induction",
                  "Term delivery with an unfavorable cervix",
                  "Foley catheter",
                  "Prostaglandin E2"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 4"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"200",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Induction of labor with Foley catheter",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"A Foley catheter will be introduced transcervically in women allocated in this group.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: Induction of labor with Foley catheter"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Induction of labor with PGE2",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"PGE2 (1mg) will be inserted into the posterior vaginal fornix.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Induction of labor with PGE2"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Device",
                    "InterventionName":"Induction of labor with Foley catheter",
                    "InterventionDescription":"A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Induction of labor with Foley catheter"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Foley Catheter"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Induction of labor with PGE2",
                    "InterventionDescription":"PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Induction of labor with PGE2"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Dinoprostone suppositories"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Number of cases with perinatal complications",
                    "PrimaryOutcomeDescription":"This primary outcome will be a composite of cases with severe perinatal complications and consists of one or more of the following: need for respiratory support within hours after birth, Apgar score < 7 at 1 minutes, Apgar score <7 at 5 minutes, umbilical cord arterial potential of hydrogen (pH ) < 7.10, birth trauma (including bone fracture, neurologic injury, or retinal hemorrhage), hypoxic-ischemic encephalopathy or need for therapeutic hypothermia, seizure, pneumonia, meconium aspiration syndrome, neonatal meningitis, neonatal sepsis, infant respiratory distress syndrome, pneumothorax or pneumomediastinum, apnoea, necrotising enterocolitis, clinical diagnosis of asphyxia, intraventricular haemorrhage, perinatal death (fetal or neonatal death occurring during childbirth, or up to 7 completed days after birth) or admission to the neonatal intensive care unit (NICU) for >48 hours. Each component of this outcome is described from outcome 3 to outcome 21.",
                    "PrimaryOutcomeTimeFrame":"Up to 3 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Percentage of vaginal delivery",
                    "PrimaryOutcomeDescription":"The co-primary outcome is vaginal delivery.",
                    "PrimaryOutcomeTimeFrame":"Up to 1 week"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Number of neonates need for respiratory support",
                    "SecondaryOutcomeDescription":"Respiratory support within hours after birth",
                    "SecondaryOutcomeTimeFrame":"Up to 1 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with Apgar score < 7 at 1 minutes",
                    "SecondaryOutcomeDescription":"Apgar scores of less than 7 at 1 min",
                    "SecondaryOutcomeTimeFrame":"On the day of delivery"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with Apgar score < 7 at 5 minutes",
                    "SecondaryOutcomeDescription":"Apgar scores of less than 7 at 5 min",
                    "SecondaryOutcomeTimeFrame":"On the day of delivery"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with umbilical cord arterial pH < 7.10",
                    "SecondaryOutcomeDescription":"An assay of arterial cord blood pH of less than 7.10",
                    "SecondaryOutcomeTimeFrame":"On the day of delivery"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with birth trauma",
                    "SecondaryOutcomeDescription":"Birth trama including bone fracture, neurologic injury, or retinal hemorrhage",
                    "SecondaryOutcomeTimeFrame":"Up to 1 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with hypoxic-ischemic encephalopathy or need for therapeutic hypothermia",
                    "SecondaryOutcomeDescription":"Neonates diagnosed with hypoxic-ischemic encephalopathy or require therapeutic hypothermia",
                    "SecondaryOutcomeTimeFrame":"Up to 1 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with pneumonia",
                    "SecondaryOutcomeDescription":"Pneumonia revealed by physical examination, blood test and image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with seizure",
                    "SecondaryOutcomeDescription":"Clinical signs of seizure",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with meconium aspiration syndrome",
                    "SecondaryOutcomeDescription":"Diagnosed according to clinical symptoms, blood test and image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with neonatal meningitis",
                    "SecondaryOutcomeDescription":"Diagnosed by blood and cerebrospinal fluid test and image",
                    "SecondaryOutcomeTimeFrame":"Up to 4 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with neonatal sepsis",
                    "SecondaryOutcomeDescription":"Diagnosed by clinical symptoms, blood test and bacterial culture",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with infant respiratory distress syndrome",
                    "SecondaryOutcomeDescription":"Diagnosed by blood test and image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with infant pneumothorax or pneumomediastinum",
                    "SecondaryOutcomeDescription":"Diagnosed by thorax image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with apnoea",
                    "SecondaryOutcomeDescription":"Clinical diagnosis of apnoea",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with necrotising enterocolitis",
                    "SecondaryOutcomeDescription":"Diagnosed by clinical symptoms, stool examination and image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with clinical diagnosis of asphyxia",
                    "SecondaryOutcomeDescription":"Clinical diagnosis of neonatal asphyxia",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of perinatal deaths",
                    "SecondaryOutcomeDescription":"Fetal or neonatal death occurring during childbirth",
                    "SecondaryOutcomeTimeFrame":"up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with intraventricular hemorrhage",
                    "SecondaryOutcomeDescription":"Intraventricular haemorrhage diagnosed by clinical symptoms and image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates admission to the NICU for >48 hours",
                    "SecondaryOutcomeDescription":"Length of admission to the NICU for less than 48 hours",
                    "SecondaryOutcomeTimeFrame":"up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of cases with maternal secondary outcomes",
                    "SecondaryOutcomeDescription":"This secondary outcome will be a composite of maternal complications and consists of one or more of the following: cardio-respiratory arrest, damage to internal organs (bowel, bladder or ureters), postpartum hemorrhage (estimated blood loss >500 milliliter (mL) in the 24 hours after delivery), hysterectomy for any complications resulting from birth, intensive care admission, uterine rupture: separation of the uterine wall, maternal infection, pulmonary embolism, stroke, maternal satisfaction, maternal death. Each component of this outcome is described from outcome 23 to outcome 33.",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of mothers with cardio-respiratory arrest",
                    "SecondaryOutcomeDescription":"Clinical diagnosis of cardio-respiratory arrest",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of mothers with damage to internal organs",
                    "SecondaryOutcomeDescription":"Damage to internal organs, including bowel, bladder or ureters",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of mothers with postpartum hemorrhage",
                    "SecondaryOutcomeDescription":"Postpartum hemorrhage is defined as estimated blood loss >500 mL in the 24 hours after delivery",
                    "SecondaryOutcomeTimeFrame":"Up to 1 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of mothers have hysterectomy",
                    "SecondaryOutcomeDescription":"Hysterectomy for any complications resulting from birth",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of mothers have intensive care admission",
                    "SecondaryOutcomeDescription":"Admission of puerpera to ICU",
                    "SecondaryOutcomeTimeFrame":"Up to 3 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of mothers have uterine rupture",
                    "SecondaryOutcomeDescription":"Uterine rupture refers to separation of the uterine wall",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of maternal infection",
                    "SecondaryOutcomeDescription":"Maternal infection diagnosed by clinical symptoms, blood test, bacterial culture.",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of mothers have pulmonary embolism",
                    "SecondaryOutcomeDescription":"Diagnosed by clinical symptoms, blood test and image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of mothers have stroke",
                    "SecondaryOutcomeDescription":"Diagnosed by clinical signs, blood test and cerebral image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Scores of maternal satisfaction with the intervention of labor induction",
                    "SecondaryOutcomeDescription":"Maternal satisfaction will be evaluated by a questionaire consisted of 11 questions scored on a 5-point Likert scale.",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of maternal death",
                    "SecondaryOutcomeDescription":"Maternal death due to delivery",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with hyperbilirubinemia",
                    "SecondaryOutcomeDescription":"Hyperbilirubinemia requiring photo-therapy or exchange transfusion",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with hypoglycemia",
                    "SecondaryOutcomeDescription":"Hypoglycemia requiring intravenous therapy",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Length of neonatal admission (days)",
                    "SecondaryOutcomeDescription":"Length of admission of neonate",
                    "SecondaryOutcomeTimeFrame":"Up to 3 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates with cephalohematoma",
                    "SecondaryOutcomeDescription":"Diagnosed by physical examination and image",
                    "SecondaryOutcomeTimeFrame":"Up to 2 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates have shoulder dystocia",
                    "SecondaryOutcomeDescription":"Diagnosed by physical examination and image",
                    "SecondaryOutcomeTimeFrame":"Up to 1 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of neonates have admission to the NICU < 48 hours",
                    "SecondaryOutcomeDescription":"Admission of neonates to NICU for less than 48 hours",
                    "SecondaryOutcomeTimeFrame":"Up to 1 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of cases with indication of caesarean section",
                    "SecondaryOutcomeDescription":"Indication of caesarean section including failure to progress at first stage, failure to progress at second stage, failed instrumental delivery, suspected fetal distress, suspected fetal distress and failure to progress at first stage, suspected fetal distress and failure to progress at second stage, and maternal complications or other",
                    "SecondaryOutcomeTimeFrame":"Up to 1 week"
                  },{
                    "SecondaryOutcomeMeasure":"Number of cases with indication of instrumental delivery",
                    "SecondaryOutcomeDescription":"Indication of instrumental delivery including failure to progress at second stage, suspected fetal distress, suspected fetal distress and failure to progress at second stage, and maternal complications or other",
                    "SecondaryOutcomeTimeFrame":"Up to 1 week"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Number of cases with suspected intrapartum infection",
                    "OtherOutcomeDescription":"Temperature â‰¥ 38Â°C during labor and/or use of broad-spectrum antibiotics due to suspected infection",
                    "OtherOutcomeTimeFrame":"Up to 1 week"
                  },{
                    "OtherOutcomeMeasure":"Number of cases with uterine hyperstimulation",
                    "OtherOutcomeDescription":"Single contractions lasting 2 minutes or more, or five or more contractions in a 10 minutes period more than one induction agent required",
                    "OtherOutcomeTimeFrame":"Up to 1 week"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nWomen scheduled for induction of labor.\nWomen aged â‰¥ 18 years old\nâ‰¥ 37 weeks of gestation\nLive singleton pregnancy in cephalic presentation\nIntact membranes\nCervical Bishop score < 6\nInformed consent.\n\nExclusion Criteria:\n\nContraindications for vaginal delivery.\nPrior cesarean section\nKnown hypersensitivity for Foley catheter or PGE2\nNon-reassuring fetal status\nLethal fetal congenital anomaly",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"Female",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Zehong Zhou, MD.",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+8613318890706",
                    "CentralContactEMail":"rainbow_0706@163.com"
                  },{
                    "CentralContactName":"Jinying Yang, MD.",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+8613560092369",
                    "CentralContactEMail":"yangjinying1981@126.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"JinYing Yang, MD.",
                    "OverallOfficialAffiliation":"Guangzhou Women and Children's Medical Center",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Guangzhou Women and Children's Medical Center",
                    "LocationCity":"Guangzhou",
                    "LocationState":"Guangdong",
                    "LocationZip":"510623",
                    "LocationCountry":"China",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Zehong Zhou, MD.",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+8613318890706",
                          "LocationContactEMail":"rainbow_0706@163.com"
                        },{
                          "LocationContactName":"Jinying Yang, MD.",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+8613560092369",
                          "LocationContactEMail":"yangjinying1981@126.com"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"22145497",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews TJ, Osterman MJ. Births: final data for 2008. Natl Vital Stat Rep. 2010 Dec 8;59(1):1, 3-71."
                  },{
                    "ReferencePMID":"30089070",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Grobman WA, Rice MM, Reddy UM, Tita ATN, Silver RM, Mallett G, Hill K, Thom EA, El-Sayed YY, Perez-Delboy A, Rouse DJ, Saade GR, Boggess KA, Chauhan SP, Iams JD, Chien EK, Casey BM, Gibbs RS, Srinivas SK, Swamy GK, Simhan HN, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med. 2018 Aug 9;379(6):513-523. doi: 10.1056/NEJMoa1800566."
                  },{
                    "ReferencePMID":"22030144",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Jozwiak M, Oude Rengerink K, Benthem M, van Beek E, Dijksterhuis MG, de Graaf IM, van Huizen ME, Oudijk MA, Papatsonis DN, Perquin DA, Porath M, van der Post JA, Rijnders RJ, Scheepers HC, Spaanderman ME, van Pampus MG, de Leeuw JW, Mol BW, Bloemenkamp KW; PROBAAT Study Group. Foley catheter versus vaginal prostaglandin E2 gel for induction of labour at term (PROBAAT trial): an open-label, randomised controlled trial. Lancet. 2011 Dec 17;378(9809):2095-103. doi: 10.1016/S0140-6736(11)61484-0. Epub 2011 Oct 24."
                  },{
                    "ReferencePMID":"30790569",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Saad AF, Villarreal J, Eid J, Spencer N, Ellis V, Hankins GD, Saade GR. A randomized controlled trial of Dilapan-S vs Foley balloon for preinduction cervical ripening (DILAFOL trial). Am J Obstet Gynecol. 2019 Mar;220(3):275.e1-275.e9. doi: 10.1016/j.ajog.2019.01.008. Epub 2019 Feb 18."
                  },{
                    "ReferencePMID":"29981523",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Dos Santos F, Drymiotou S, Antequera Martin A, Mol BW, Gale C, Devane D, Van't Hooft J, Johnson MJ, Hogg M, Thangaratinam S. Development of a core outcome set for trials on induction of labour: an international multistakeholder Delphi study. BJOG. 2018 Dec;125(13):1673-1680. doi: 10.1111/1471-0528.15397. Epub 2018 Sep 10."
                  },{
                    "ReferencePMID":"26850983",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Ten Eikelder ML, Oude Rengerink K, Jozwiak M, de Leeuw JW, de Graaf IM, van Pampus MG, Holswilder M, Oudijk MA, van Baaren GJ, Pernet PJ, Bax C, van Unnik GA, Martens G, Porath M, van Vliet H, Rijnders RJ, Feitsma AH, Roumen FJ, van Loon AJ, Versendaal H, Weinans MJ, Woiski M, van Beek E, Hermsen B, Mol BW, Bloemenkamp KW. Induction of labour at term with oral misoprostol versus a Foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trial. Lancet. 2016 Apr 16;387(10028):1619-28. doi: 10.1016/S0140-6736(16)00084-2. Epub 2016 Feb 3."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000015232",
                    "InterventionMeshTerm":"Dinoprostone"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000010120",
                    "InterventionAncestorTerm":"Oxytocics"
                  },{
                    "InterventionAncestorId":"D000012102",
                    "InterventionAncestorTerm":"Reproductive Control Agents"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M16519",
                    "InterventionBrowseLeafName":"Dinoprostone",
                    "InterventionBrowseLeafAsFound":"Subarachnoid",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M20444",
                    "InterventionBrowseLeafName":"Pharmaceutical Solutions",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Repr",
                    "InterventionBrowseBranchName":"Reproductive Control Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"PhSol",
                    "InterventionBrowseBranchName":"Pharmaceutical Solutions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":40,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780256",
              "OrgStudyIdInfo":{
                "OrgStudyId":"CORE 3"
              },
              "Organization":{
                "OrgFullName":"Arcispedale Santa Maria Nuova-IRCCS",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Endoscopic Resection of Gastrointestinal Neoplasms",
              "OfficialTitle":"Retrospective Study of Efficacy and Safety of the Endoscopic Removal of Cancerous and Precancerous Lesions of the Upper and Lower Digestive Tract"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 2014",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Paolo Cecinato",
                "ResponsiblePartyInvestigatorTitle":"MD",
                "ResponsiblePartyInvestigatorAffiliation":"Arcispedale Santa Maria Nuova-IRCCS"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Arcispedale Santa Maria Nuova-IRCCS",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the eophagus, stomach, duodenum, colon and rectum."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Endoscopic Eucosal Resection",
                  "Endoscopic Submucosal Dissection",
                  "Gastric Neoplasm",
                  "Colonic Neoplasms",
                  "Esophageal Neoplasms",
                  "Duodenal Neoplasms"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "EMR",
                  "ESD",
                  "EFTR"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Retrospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"2000",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"Endoscopic resection",
                    "InterventionDescription":"The endoscopic resection is the procedure that allows to remove cancerous or precancerous conritions of digestive tract. Endoscopic resection can be preformed by several techniques:\n\nEndoscopic mucosal resection (EMR): it allows to remove mucosal lesions\nEndoscopic submucosal dissection: it allows to remove mucosal lesions that involved submucosal layer and large lesions\nFull-thickness resection: it allows to remove infiltrating lesions by the resection of a little piece of the entire gastrointestinal wall"
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"en bloc resection rate",
                    "PrimaryOutcomeDescription":"the en bloc resection is the ability to remove the neoplasia in a single piece",
                    "PrimaryOutcomeTimeFrame":"one month"
                  },{
                    "PrimaryOutcomeMeasure":"complete resection rate",
                    "PrimaryOutcomeDescription":"the complete resection is the ability to remove the neoplasia with clear margins (R0)",
                    "PrimaryOutcomeTimeFrame":"one month"
                  },{
                    "PrimaryOutcomeMeasure":"recurrence rate",
                    "PrimaryOutcomeDescription":"recurrence is the recurrence of the neoplasm at the resection site during follow-up",
                    "PrimaryOutcomeTimeFrame":"one year"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"adverse events rate",
                    "SecondaryOutcomeDescription":"complication rate, early or late, related to the procedure used for endoscopic resection",
                    "SecondaryOutcomeTimeFrame":"one month"
                  },{
                    "SecondaryOutcomeMeasure":"costs",
                    "SecondaryOutcomeDescription":"evaluation of the costs incurred to perform the endoscopic resection",
                    "SecondaryOutcomeTimeFrame":"one month"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\n18 years or older\nall patients who have undergone endoscopic resection of an upper or lower digestive tract tumor\n\nExclusion Criteria:\n\nage under 18\ninability to provide informed consent",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"100 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Patients> 18 years of age who have undergone endoscopic resection of cancerous or pre-cancerous lesions of the digestive tract will be included in the study",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Paolo Cecinato, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+393476117414",
                    "CentralContactEMail":"paolo.cecinato@ausl.re.it"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"IRCCS-AUSL Reggio Emilia",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Reggio Emilia",
                    "LocationState":"RE",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Matteo Lucarini, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"matteo.lucarini@ausl.re.it"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000009369",
                    "ConditionMeshTerm":"Neoplasms"
                  },{
                    "ConditionMeshId":"D000004938",
                    "ConditionMeshTerm":"Esophageal Neoplasms"
                  },{
                    "ConditionMeshId":"D000003110",
                    "ConditionMeshTerm":"Colonic Neoplasms"
                  },{
                    "ConditionMeshId":"D000013274",
                    "ConditionMeshTerm":"Stomach Neoplasms"
                  },{
                    "ConditionMeshId":"D000004379",
                    "ConditionMeshTerm":"Duodenal Neoplasms"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000005770",
                    "ConditionAncestorTerm":"Gastrointestinal Neoplasms"
                  },{
                    "ConditionAncestorId":"D000004067",
                    "ConditionAncestorTerm":"Digestive System Neoplasms"
                  },{
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  },{
                    "ConditionAncestorId":"D000006258",
                    "ConditionAncestorTerm":"Head and Neck Neoplasms"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  },{
                    "ConditionAncestorId":"D000004935",
                    "ConditionAncestorTerm":"Esophageal Diseases"
                  },{
                    "ConditionAncestorId":"D000005767",
                    "ConditionAncestorTerm":"Gastrointestinal Diseases"
                  },{
                    "ConditionAncestorId":"D000015179",
                    "ConditionAncestorTerm":"Colorectal Neoplasms"
                  },{
                    "ConditionAncestorId":"D000007414",
                    "ConditionAncestorTerm":"Intestinal Neoplasms"
                  },{
                    "ConditionAncestorId":"D000003108",
                    "ConditionAncestorTerm":"Colonic Diseases"
                  },{
                    "ConditionAncestorId":"D000007410",
                    "ConditionAncestorTerm":"Intestinal Diseases"
                  },{
                    "ConditionAncestorId":"D000013272",
                    "ConditionAncestorTerm":"Stomach Diseases"
                  },{
                    "ConditionAncestorId":"D000004378",
                    "ConditionAncestorTerm":"Duodenal Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5839",
                    "ConditionBrowseLeafName":"Digestive System Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7469",
                    "ConditionBrowseLeafName":"Gastrointestinal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4921",
                    "ConditionBrowseLeafName":"Colonic Neoplasms",
                    "ConditionBrowseLeafAsFound":"Colonic Neoplasms",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M6671",
                    "ConditionBrowseLeafName":"Esophageal Neoplasms",
                    "ConditionBrowseLeafAsFound":"Esophageal Neoplasms",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M14647",
                    "ConditionBrowseLeafName":"Stomach Neoplasms",
                    "ConditionBrowseLeafAsFound":"Gastric Neoplasm",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M6136",
                    "ConditionBrowseLeafName":"Duodenal Neoplasms",
                    "ConditionBrowseLeafAsFound":"Duodenal Neoplasms",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M7931",
                    "ConditionBrowseLeafName":"Head and Neck Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6668",
                    "ConditionBrowseLeafName":"Esophageal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16473",
                    "ConditionBrowseLeafName":"Colorectal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9031",
                    "ConditionBrowseLeafName":"Intestinal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4919",
                    "ConditionBrowseLeafName":"Colonic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9027",
                    "ConditionBrowseLeafName":"Intestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14645",
                    "ConditionBrowseLeafName":"Stomach Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6135",
                    "ConditionBrowseLeafName":"Duodenal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T2141",
                    "ConditionBrowseLeafName":"Esophageal Cancer",
                    "ConditionBrowseLeafAsFound":"Esophageal Neoplasms",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"T5486",
                    "ConditionBrowseLeafName":"Stomach Cancer",
                    "ConditionBrowseLeafAsFound":"Gastric Neoplasm",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":41,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780243",
              "OrgStudyIdInfo":{
                "OrgStudyId":"abe16muluneh"
              },
              "Organization":{
                "OrgFullName":"Hawassa University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Expanded Program for Immunization, a Missed Opportunity for Postpartum Family Planning Utilization",
              "OfficialTitle":"Enhancing Postpartum Family Planning Utilization Through Integration With Expanded Program for Immunization in Sidama, South Ethiopia: A Quasi Experimental Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Active, not recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 1, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 30, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 17, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"January 30, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Abebaw Abeje Muluneh",
                "ResponsiblePartyInvestigatorTitle":"Mr.",
                "ResponsiblePartyInvestigatorAffiliation":"Hawassa University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Hawassa University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This study is aimed to enhance postpartum family planning by integrating family planning information with infant immunization services, which is the most widely utilized health services globally.",
              "DetailedDescription":"In this study, a before-and-after type of quasi-experimental study will be conducted in purposely selected health centers Sidama region, Ethiopia. base line assessment of postpartum contraceptive utilization rate will be done which will be followed by an intervention. The intervention consists of screening, counseling for family planning and referring mothers coming for infant immunization services to family planning units. All mothers coming for infant immunization service will be screened for and counseled for family planning and those who will be voluntary to take any method will be referred to family planning unit. All mothers who will not be voluntary will be re-counseled by the next visit.\n\nFinally, the effect of this intervention on postpartum contraceptive utilization rate will be reassessed. The expected outcome will be to see an improved contraceptive uptake during the first year after delivery."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Contraceptive Usage"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Non-Randomized",
                "DesignInterventionModel":"Sequential Assignment",
                "DesignPrimaryPurpose":"Prevention",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"1474",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Pre-intervention group",
                    "ArmGroupType":"No Intervention",
                    "ArmGroupDescription":"Pre-intervention group: women participated during the base line assessment will be labeled as Pre-intervention group"
                  },{
                    "ArmGroupLabel":"postintervention group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Postintervention group: women participated after the intervention was initiated will be labeled as postintervention group.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: counseling"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"counseling",
                    "InterventionDescription":"Mothers presented to infant immunization units are going to be counseled for family planning services and if decide to take any method, they will be linked to family planning services",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "postintervention group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"After the initiation of the intervention, improved Contraceptive prevalence rate will be expected as an outcome",
                    "PrimaryOutcomeDescription":"After counseling of the postpartum mothers for family planning, their informed decision making capacity to use contraceptives will be increased.",
                    "PrimaryOutcomeTimeFrame":"the outcome is measured two months after the initiation of the intervention"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nall women visiting health facilities for infant immunization for at least two times will be included.\n\nExclusion Criteria:\n\nWomen who are in difficulty of communicating during the study period will be excluded.",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"Female",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Abebaw Muluneh",
                    "OverallOfficialAffiliation":"Hawassa University",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Sidama regional health bureau",
                    "LocationCity":"Hawassa",
                    "LocationState":"Sidama",
                    "LocationCountry":"Ethiopia"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M15943",
                    "InterventionBrowseLeafName":"Vaccines",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":42,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780230",
              "OrgStudyIdInfo":{
                "OrgStudyId":"CRESC201906"
              },
              "Organization":{
                "OrgFullName":"The Hong Kong Polytechnic University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Non-invasive Brain Stimulation to Enhance Treatment of Dysarthria Post-stroke",
              "OfficialTitle":"Modulation of Primary Motor Cortex to Enhance Treatment of Dysarthria Post-stroke"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"December 21, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"November 2023",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"November 2023",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 19, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Dr Min Wong",
                "ResponsiblePartyInvestigatorTitle":"Assistant Professor",
                "ResponsiblePartyInvestigatorAffiliation":"The Hong Kong Polytechnic University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"The Hong Kong Polytechnic University",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"The University of Hong Kong",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"Tuen Mun Hospital",
                    "CollaboratorClass":"OTHER_GOV"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The proposed study aims to determine if transcranial direct current stimulation can enhance the effect of speech therapy in post-stroke patients with dysarthria.",
              "DetailedDescription":"A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups. All the participants will receive individualized speech therapy based on the results of their speech assessment.\n\nFor the real tDCS group, an anodal high-definition tDCS of 2 milliamperes (mA) lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy. For the sham tDCS group, stimulation given during speech therapy will only last for 30 seconds in order to cause a similar sensation on the scalp as the real stimulation group. There will be a total of 10 daily sessions during a 2-week period."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Dysarthria",
                  "Stroke"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"60",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"real tDCS",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: tDCS active"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"sham tDCS",
                    "ArmGroupType":"Sham Comparator",
                    "ArmGroupDescription":"A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: tDCS sham"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Device",
                    "InterventionName":"tDCS active",
                    "InterventionDescription":"An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "real tDCS"
                      ]
                    }
                  },{
                    "InterventionType":"Device",
                    "InterventionName":"tDCS sham",
                    "InterventionDescription":"An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "sham tDCS"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Perceptual speech assessments",
                    "PrimaryOutcomeDescription":"All participants will be required to produce a sustained vowel /a/, repeat some syllables (i.e., /pa/, /ta/, /ka/ and /pataka/), read a standard Chinese paragraph and have a 1-2 mins conversation with the researcher.",
                    "PrimaryOutcomeTimeFrame":"Change Before and After tDCS Stimulation at immediately post-treatment, 1-month and 3-month post treatment"
                  },{
                    "PrimaryOutcomeMeasure":"Communication effectiveness measures",
                    "PrimaryOutcomeDescription":"The Modified Communication Effectiveness Index (CETI-M) is a 10-item patient-reported measure of change in functional communication ability.",
                    "PrimaryOutcomeTimeFrame":"Change Before and After tDCS Stimulation at immediately post-treatment, 1-month and 3-month post treatment"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Kinematic Measurements",
                    "SecondaryOutcomeDescription":"The lip and tongue function during speech production will be traced real time and objectively using the 3D-Electromagnetic Articulography (EMA, AG501-system).",
                    "SecondaryOutcomeTimeFrame":"Change Before and After tDCS Stimulation at immediately post-treatment, 1-month and 3-month post treatment"
                  },{
                    "SecondaryOutcomeMeasure":"Acoustic measurements",
                    "SecondaryOutcomeDescription":"Acoustic measurements will be obtained from both sustained vowel phonation and connected speech.",
                    "SecondaryOutcomeTimeFrame":"Change Before and After tDCS Stimulation at immediately post-treatment, 1-month and 3-month post treatment"
                  },{
                    "SecondaryOutcomeMeasure":"Quality of Life measurement",
                    "SecondaryOutcomeDescription":"The Chinese version of The Quality of Life of the Dysarthric Speaker (QOL-DyS) questionnaire will be used to assess participants' subjective speech related quality of life.",
                    "SecondaryOutcomeTimeFrame":"Change Before and After tDCS Stimulation at immediately post-treatment, 1-month and 3-month post treatment"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nCantonese-speaking adults who had their first stroke and have suffered dysarthria post-stroke.\nBoth acute and chronic stroke participants will be recruited.\n\nExclusion Criteria:\n\nIndividuals with a personal or family history of epilepsy or seizures;\nIndividuals with a history of another neurological condition (which is not a result from the initial stroke);\nIndividuals with a history of speech disorders, voice disorders, oro-maxillo-facial surgery involving the tongue and/or lip, severe cognitive impairment, severe aphasia;\nIn an unstable or serious medical condition;\nHave a cardiac implant metallic foreign body implant and/or any medications that lower neural thresholds (e.g. antidepressants, neuroleptic agents, etc.).",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"75 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Min Ney Wong, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"(852) 2766 7268",
                    "CentralContactEMail":"min.wong@polyu.edu.hk"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Min Ney Wong, PhD",
                    "OverallOfficialAffiliation":"The Hong Kong Polytechnic University",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"The Hong Kong Polytechnic University",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Hong Kong",
                    "LocationCountry":"Hong Kong",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Min Ney Wong",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"(852) 2766 7268",
                          "LocationContactEMail":"min.wong@polyu.edu.hk"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000020521",
                    "ConditionMeshTerm":"Stroke"
                  },{
                    "ConditionMeshId":"D000004401",
                    "ConditionMeshTerm":"Dysarthria"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000002561",
                    "ConditionAncestorTerm":"Cerebrovascular Disorders"
                  },{
                    "ConditionAncestorId":"D000001927",
                    "ConditionAncestorTerm":"Brain Diseases"
                  },{
                    "ConditionAncestorId":"D000002493",
                    "ConditionAncestorTerm":"Central Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000014652",
                    "ConditionAncestorTerm":"Vascular Diseases"
                  },{
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  },{
                    "ConditionAncestorId":"D000001184",
                    "ConditionAncestorTerm":"Articulation Disorders"
                  },{
                    "ConditionAncestorId":"D000013064",
                    "ConditionAncestorTerm":"Speech Disorders"
                  },{
                    "ConditionAncestorId":"D000007806",
                    "ConditionAncestorTerm":"Language Disorders"
                  },{
                    "ConditionAncestorId":"D000003147",
                    "ConditionAncestorTerm":"Communication Disorders"
                  },{
                    "ConditionAncestorId":"D000019954",
                    "ConditionAncestorTerm":"Neurobehavioral Manifestations"
                  },{
                    "ConditionAncestorId":"D000009461",
                    "ConditionAncestorTerm":"Neurologic Manifestations"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M20890",
                    "ConditionBrowseLeafName":"Stroke",
                    "ConditionBrowseLeafAsFound":"Stroke",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M6158",
                    "ConditionBrowseLeafName":"Dysarthria",
                    "ConditionBrowseLeafAsFound":"Dysarthria",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4393",
                    "ConditionBrowseLeafName":"Cerebrovascular Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3786",
                    "ConditionBrowseLeafName":"Brain Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4325",
                    "ConditionBrowseLeafName":"Central Nervous System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M15983",
                    "ConditionBrowseLeafName":"Vascular Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3073",
                    "ConditionBrowseLeafName":"Articulation Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14447",
                    "ConditionBrowseLeafName":"Speech Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9406",
                    "ConditionBrowseLeafName":"Language Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4957",
                    "ConditionBrowseLeafName":"Communication Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20410",
                    "ConditionBrowseLeafName":"Neurobehavioral Manifestations",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10987",
                    "ConditionBrowseLeafName":"Neurologic Manifestations",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":43,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780217",
              "OrgStudyIdInfo":{
                "OrgStudyId":"MVR-T3011-003"
              },
              "Organization":{
                "OrgFullName":"ImmVira Pharma Co. Ltd",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"A Clinical Study of T3011 When Administered Via Intravenous Infustion in Patients With Advanced or Metastatic Solid Tumors",
              "OfficialTitle":"A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Via Intravenous Infusion as a Single Agent and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 2023",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"October 2023",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 6, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"ImmVira Pharma Co. Ltd",
                "LeadSponsorClass":"INDUSTRY"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"Yes",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a Phase 1/2a open-label study of T3011 when administered via IV as a single agent and in combination with pembrolizumab, to evaluate safety, tolerability, preliminary clinical activity in patients with advanced or metastatic solid tumors in dose escalation portion (Phase 1 Part A and Part B) or patients with NSCLC, solid tumors with metastasis in liver and/or lung in dose expansion portion (Phase 2a), who have relapsed, or are refractory to or are not considered medically suitable to receive standard of care (SOC) treatment.",
              "DetailedDescription":"This is a Phase 1/2a open-label study of T3011 as a single agent and in combination with pembrolizumab. The Phase 1 portion of the study will be conducted in 2 parts: Part A dose escalation of single agent T3011 and Part B dose escalation of T3011 in combination with pembrolizumab. The Phase 2a portion will evaluate T3011 in combination with pembrolizumab. The objectives of the Phase 1 are to evaluate the safety and tolerability of escalating doses of T3011 alone and in combination with pembrolizumab, and to determine the dose(s) of T3011 to be further examined. During Phase 2a, the safety and tolerability of T3011 in combination with pembrolizumab at the dose selected in Phase 1 Part B will be evaluated. The safety, pharmacokinetic (PK) and viral shedding, immunogenicity, and clinical activity of T3011 will be evaluated. Pharmacodynamic markers related to T3011 exposure will be characterized.\n\nThis study will enroll patients with pathologically confirmed locally recurrent or metastatic solid tumors (Phase 1 Part A and Part B) or patients with histologically and cytologically confirmed NSCLC that is recurrent or metastatic or histologically or cytologically diagnosed advanced solid tumors with metastasis in liver and/or lung (Phase 2a), who have relapsed, or are refractory to or are not considered medically suitable to receive standard of care (SOC) treatment. These patients represent a population with a high unmet need. Patients will be informed of available treatment options and, in consultation with the study Investigator, will decide whether or not to participate in the T3011 study."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Head and Neck Cancer",
                  "Soft Tissue Tumor and/or Sarcoma",
                  "Neoplasm of Skin",
                  "Neoplasm Metastasis",
                  "Melanoma",
                  "Nsclc",
                  "Metastasis in Lung",
                  "Metastasis in Liver",
                  "Solid Tumor"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 1",
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Non-Randomized",
                "DesignInterventionModel":"Sequential Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"78",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Single Agent T3011 Dose Escalation",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: T3011"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"T3011 Dose Escalation in Combination with Pembrolizumab",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Combination Product: T3011+Pembrolizumab"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Dose expansion of T3011 in Combination with Pembrolizumab with recommended dose",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Combination Product: T3011+Pembrolizumab"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Biological",
                    "InterventionName":"T3011",
                    "InterventionDescription":"T3011 will be administered in a 10 mL solution as an IV infusion over 15 minutes (Â± 5 minutes).",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Single Agent T3011 Dose Escalation"
                      ]
                    }
                  },{
                    "InterventionType":"Combination Product",
                    "InterventionName":"T3011+Pembrolizumab",
                    "InterventionDescription":"T3011 will be administered in a 10 mL solution as an IV infusion over 15 minutes (Â± 5 minutes), followed by administration of pembrolizumab as an IV infusion at least 30 minutes after the completion of T3011 dosing.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Dose expansion of T3011 in Combination with Pembrolizumab with recommended dose",
                        "T3011 Dose Escalation in Combination with Pembrolizumab"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Safety and tolerability of escalating doses of single agent IV T3011 (Part A) and and of IV T3011 in combination with pembrolizumab (Part B).",
                    "PrimaryOutcomeDescription":"Number of participants in both dose escalating arms (Single agent IV T3011 and combination) with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.",
                    "PrimaryOutcomeTimeFrame":"From first dose of single agent IV T3011 and IV T3011 in combination with pembrolizumab (D1 of Cycle1, each cycle consists 21 days) untill at 30 (Â± 5) days after the last dose of study treatment (up to 2 years)"
                  },{
                    "PrimaryOutcomeMeasure":"The maximum tolerated dose (MTD) and/or the recommended dose (RD) of single agent IV T3011 (Part A) .",
                    "PrimaryOutcomeDescription":"Identification of MTD and/or RD in Part A study.",
                    "PrimaryOutcomeTimeFrame":"From the first dose of single agent IV T3011 untill the end of dose escalation in Part A study, up to 24 months"
                  },{
                    "PrimaryOutcomeMeasure":"The MTD and/or the recommended phase 2 dose (RP2D) of IV T3011 in combination with pembrolizumab (Part B).",
                    "PrimaryOutcomeDescription":"Identification of the MTD and/or RP2D of IV T3011 in combination with Pembrolizumab (Part B) .",
                    "PrimaryOutcomeTimeFrame":"From the first dose of IV T3011 in combination with Pembrolizumab untill the end of dose escalation in Part B study, up to 24months."
                  },{
                    "PrimaryOutcomeMeasure":"Safety and tolerability of the RP2D of IV T3011 in combination with pembrolizumab selected from Phase 1 Part B in disease specific cohorts.",
                    "PrimaryOutcomeDescription":"Number of participants in dose expansion arm (Phase 2a) with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.",
                    "PrimaryOutcomeTimeFrame":"From first dose in phase 2a (D1 of Cycle1,each cycle consists 21 days) untill at 30 (Â± 5) days after the last dose of study treatment (up to 2 years)"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Quantitative viral DNA level of T3011 in urine and saliva.",
                    "SecondaryOutcomeDescription":"To evaluate viral shedding in participants dosed with single agent IV T3011 and IV T3011 in combination with Pembrolizumab.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "SecondaryOutcomeMeasure":"Quantitative measurements of blood viral DNA level, serum IL-12 and anti-PD-1 antibody concentrationIL-12 and anti-PD-1 antibody concentration.",
                    "SecondaryOutcomeDescription":"To evaluate the pharmacokinetic (PK) of single agent IV T3011 and of IV T3011 in combination with pembrolizumab.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "SecondaryOutcomeMeasure":"Presence of anti-herpes simplex virus type 1 (HSV-1) immunoglobulin G (IgG) and anti-PD-1 idiotypic antibody.",
                    "SecondaryOutcomeDescription":"To evaluate the immunogenicity of single agent IV T3011 and of IV T3011 in combination with pembrolizumab.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "SecondaryOutcomeMeasure":"Overall response rate (ORR)",
                    "SecondaryOutcomeDescription":"ORR is defined as the proportion of participants who have a partial response (PR) or complete response (CR) to intervention, based on investigator assessments per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and iRECIST, to evaluate the preliminary clinical activity of single agent IV T3011 (Part A) and of IV T3011 in combination with pembrolizumab (Part B) and of treatment in Phase 2a.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "SecondaryOutcomeMeasure":"Disease control rate (DCR)",
                    "SecondaryOutcomeDescription":"DCR is defined as the percentage of participants who have achieved CR, PR, or stable disease (SD) based on investigator assessments per RECIST 1.1 and iRECIST, to evaluate the preliminary clinical activity of single agent IV T3011 (Part A) and of IV T3011 in combination with pembrolizumab (Part B) and of treatment in Phase 2a.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "SecondaryOutcomeMeasure":"Duration of response (DOR)",
                    "SecondaryOutcomeDescription":"DOR is defined as the time from the first met CR or PR until disease progression or death due to any cause, whichever occurs first, to evaluate the preliminary clinical activity of single agent IV T3011 (Part A) and of IV T3011 in combination with pembrolizumab (Part B) and of treatment in Phase 2a.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "SecondaryOutcomeMeasure":"Durable response (DR)",
                    "SecondaryOutcomeDescription":"DR is defined as objective response (CR or PR) according to RECIST 1.1, to evaluate the preliminary clinical activity of single agent IV T3011 (Part A) and of IV T3011 in combination with pembrolizumab (Part B) and of treatment in Phase 2a.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "SecondaryOutcomeMeasure":"Progression-free survival (PFS)",
                    "SecondaryOutcomeDescription":"PFS is defined as the time from enrollment to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first per RECIST 1.1 and iRECIST, to evaluate the preliminary clinical activity of single agent IV T3011 (Part A) and of IV T3011 in combination with pembrolizumab (Part B) and of treatment in Phase 2a.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "SecondaryOutcomeMeasure":"Overall survival (OS)",
                    "SecondaryOutcomeDescription":"OS is defined as the time from enrollment to death from any cause, to evaluate the preliminary clinical activity of single agent IV T3011 (Part A) and of IV T3011 in combination with pembrolizumab (Part B) and of treatment in Phase 2a.",
                    "SecondaryOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Expression level of IL-12/anti-PD-1 antibody.",
                    "OtherOutcomeDescription":"Assess expression the potential predictive biomarker post-dosing.",
                    "OtherOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "OtherOutcomeMeasure":"Assessment of tumor genomics.",
                    "OtherOutcomeDescription":"Sequencing analysis of biopsied samples",
                    "OtherOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "OtherOutcomeMeasure":"Tumor environment reponse to treatment.",
                    "OtherOutcomeDescription":"IF analysis of biopsied samples",
                    "OtherOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  },{
                    "OtherOutcomeMeasure":"Assessment of systemic immune response",
                    "OtherOutcomeDescription":"Assess the lymphocyte profiling and level of blood cytokine",
                    "OtherOutcomeTimeFrame":"From the first dose untill the EOT in each portion of study (up to 2 years)."
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nParticipants with one of the following cancers:\n\nPathologically confirmed, locally recurrent or metastatic solid tumors (Phase 1 Part A and B)\nHistologically or cytologically confirmed NSCLC that is recurrent or metastatic (Phase 2a)\nHistologically or cytologically diagnosed advanced solid tumors with metastasis in liver and/or lung (Phase 2a).\nDisease progression after SOC therapy or in the opinion of the Investigator unlikely to benefit from SOC therapy.\nAge 18 years or older.\nMeasurable disease per RECIST version 1.1.\nEastern Cooperative Oncology Group (ECOG) performance status 0 - 1.\nLife expectancy > 12 weeks.\nAdequate bone marrow function defined by absolute neutrophil count (ANC) of â‰¥ 1.5 Ã— 10^9/L, platelet count of â‰¥ 100 Ã— 10^9/L, and hemoglobin of â‰¥ 8.5 g/dL.\nAdequate hepatic function defined as aspartate aminotransferase (AST)/alanine aminotransferase (ALT) â‰¤ 3 Ã— upper limit of normal (ULN) and total bilirubin â‰¤ 1.5 Ã— ULN (except patients with Gilbert's Syndrome, who can have total bilirubin < 3.0 mg/dL).\nAdequate renal function defined as creatinine clearance > 50 mL/min as determined by the Cockcroft-Gault equation.\nFemale participants must be surgically sterile (or have a monogamous partner who is surgically sterile), or be at least 2 years postmenopausal, or commit to using 2 acceptable forms of birth control for the duration of the study and for 6 months following the last dose of study treatment. Male participants must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study and for 6 months following the last dose of study treatment.\nWomen of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening within 14 days of dosing with T3011 and a negative urine pregnancy test pre-dose on C1D1.\nLast dose of previous anticancer therapy â‰¥ 21 days; radiotherapy > 21 days (except prior focal palliative radiotherapy must have been completed at least 1 week prior to the first dose of study treatment); major surgery > 21 days; or last dose of therapy with tyrosine kinase inhibitors within 5 times the half-life of the inhibitor prior to first dose of study treatment. Last dose of checkpoint inhibitor â‰¥ 14 days, as long as treatment related toxicities resolve to â‰¤ Grade 1.\nResolution of all prior anticancer therapy toxicities (except for alopecia) to â‰¤ Grade 1. Note: patients previously treated with immunotherapy may enroll if on adequate replacement therapy. Patients with toxicities attributed to systemic prior anticancer therapy, which are not expected to resolve and result in long lasting sequelae are permitted to enroll.\nWillingness to provide pre- and post-treatment fresh tumor biopsy specimens. Participant may be eligible to participate without providing fresh tumor biopsy specimens, following discussion with and approval from the Medical Monitor.\nCapable of understanding and complying with protocol requirements.\nSigned and dated institutional review board/independent ethics committee (IRB/IEC) approved informed consent form (ICF) before any protocol-directed screening procedures are performed.\n\nExclusion Criteria:\n\nPrior treatment with another OV or cellular therapy.\nPrevious unacceptable intolerance to anti-PD-1 monoclonal antibody.\nRequires continued concurrent systemic therapy with any drug active against HSV. Topical use of drugs against HSV are allowed.\nLive vaccines within 4 weeks of initiation of study treatment.\nPrimary or acquired immunodeficient states.\nPregnant or lactating.\nSplenectomy, previous allogenic tissue/solid organ transplant.\n\nActive hepatitis B virus, hepatitis C virus, or a positive serological test at Screening.\n\nPatients who test positive for anti-HCV Ab but negative for HCV ribonucleic acid (RNA) are considered eligible to participate in the study.\nPatients who are HBsAg+ and/or HBcAb+ and have a DNA load < 2000 IU/mL (104 copies/mL) are considered eligible to participate in the study.\nActive autoimmune disease or other medical conditions requiring chronic systemic steroid (> 10 mg/day prednisone or equivalent) or immunosuppressive therapy within 6 months prior to first administration of study treatment (unless agreed otherwise between the Medical Monitor and the Investigator on a case-by-case basis). Non-systemic corticosteroids (eg, topical, inhaled) are allowed.\nPatients with untreated and/or symptomatic metastatic central nervous system (CNS) disease. However, patients with brain/CNS metastases who have undergone surgery or radiotherapy, whose disease is stable and who have been on a stable dose of corticosteroids (â‰¤ 10 mg prednisone or equivalent) for at least 4 weeks prior to the first administration of study treatment will be eligible.\nHistory of seizure disorders within 6 months of Screening.\nActive oral or skin herpes lesion at Screening.\nCongestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias.\nHistory of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or their excipients.\nKnown or suspected active infection with SARS-CoV-2 virus.\nOther systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and/or interpretation of the current study.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000009369",
                    "ConditionMeshTerm":"Neoplasms"
                  },{
                    "ConditionMeshId":"D000009362",
                    "ConditionMeshTerm":"Neoplasm Metastasis"
                  },{
                    "ConditionMeshId":"D000016609",
                    "ConditionMeshTerm":"Neoplasms, Second Primary"
                  },{
                    "ConditionMeshId":"D000012983",
                    "ConditionMeshTerm":"Soft Tissue Neoplasms"
                  },{
                    "ConditionMeshId":"D000012878",
                    "ConditionMeshTerm":"Skin Neoplasms"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000009385",
                    "ConditionAncestorTerm":"Neoplastic Processes"
                  },{
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  },{
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  },{
                    "ConditionAncestorId":"D000012871",
                    "ConditionAncestorTerm":"Skin Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M13910",
                    "ConditionBrowseLeafName":"Sarcoma",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10890",
                    "ConditionBrowseLeafName":"Neoplasm Metastasis",
                    "ConditionBrowseLeafAsFound":"Metastases",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M14368",
                    "ConditionBrowseLeafName":"Soft Tissue Neoplasms",
                    "ConditionBrowseLeafAsFound":"Soft Tissue Tumors",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M14264",
                    "ConditionBrowseLeafName":"Skin Neoplasms",
                    "ConditionBrowseLeafAsFound":"Neoplasm of Skin",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M10111",
                    "ConditionBrowseLeafName":"Melanoma",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7931",
                    "ConditionBrowseLeafName":"Head and Neck Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M17572",
                    "ConditionBrowseLeafName":"Neoplasms, Second Primary",
                    "ConditionBrowseLeafAsFound":"Metastases",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M10913",
                    "ConditionBrowseLeafName":"Neoplastic Processes",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14257",
                    "ConditionBrowseLeafName":"Skin Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T5284",
                    "ConditionBrowseLeafName":"Soft Tissue Sarcoma",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC17",
                    "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"C000582435",
                    "InterventionMeshTerm":"Pembrolizumab"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000074322",
                    "InterventionAncestorTerm":"Antineoplastic Agents, Immunological"
                  },{
                    "InterventionAncestorId":"D000000970",
                    "InterventionAncestorTerm":"Antineoplastic Agents"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M262566",
                    "InterventionBrowseLeafName":"Pembrolizumab",
                    "InterventionBrowseLeafAsFound":"Follow-",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M20444",
                    "InterventionBrowseLeafName":"Pharmaceutical Solutions",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M1346",
                    "InterventionBrowseLeafName":"Antineoplastic Agents, Immunological",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"ANeo",
                    "InterventionBrowseBranchName":"Antineoplastic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"PhSol",
                    "InterventionBrowseBranchName":"Pharmaceutical Solutions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":44,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780204",
              "OrgStudyIdInfo":{
                "OrgStudyId":"AMC 2020-1615"
              },
              "Organization":{
                "OrgFullName":"Asan Medical Center",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels",
              "OfficialTitle":"A Multicenter, Open-label, Randomized Controlled Trial for the Effectiveness of Antiviral TreAtment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels (ATTACH)",
              "Acronym":"ATTACH"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"August 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 2025",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2025",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Young-Suk Lim",
                "ResponsiblePartyInvestigatorTitle":"PhD",
                "ResponsiblePartyInvestigatorAffiliation":"Asan Medical Center"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Asan Medical Center",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"National Evidence-Based Healthcare Collaborating Agency",
                    "CollaboratorClass":"OTHER_GOV"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Multicenter, Open-label, Randomized Controlled Trial Male and female adults with liver cirrhosis due to chronic hepatitis B virus infection who have low-level viremia and are beyond treatment indications by current guidelines.\n\nTo assess the efficacy of Tenofovir Alafenamide (TAF) in reducing liver-related events (hepatocellular carcinoma, liver-related events and death, decompensated liver cirrhosis) in cirrhotic chronic hepatitis B patients with low-level viremia beyond treatment indications by current guidelines, compared with best supportive care",
              "DetailedDescription":"This clinical trial is a multicenter, open label, randomized controlled study in cirrhotic chronic hepatitis B patients with low-level viremia beyond treatment indications by current guidelines.\n\nApproximately 400 subjects meeting eligibility criteria will be enrolled and randomized (1:1) to Treatment Arm (A) or Observational Arm (B), as below:\n\nTreatment Arm (A): 200 subjects, TAF 25mg once daily with food for 3 years\nObservational Arm (B): 200 subjects, best supportive care for 3 years This study was designed to randomly assign treatment groups to subjects in order to prevent biases that may be intervened, and to increase comparability between the groups. Since HBeAg status could affect the clinical outcome in the eligible subjects, randomization will be stratified by HBeAg status (positive or negative) at screening at a 1:1 ratio by using centralized stratified block randomization.\n\nBoth groups (i.e. Treatment Arm and Observational Arm) are scheduled to be followed up to 3 years. When subjects in the Observational Arm group meets the treatment indications by current guidelines (HBV DNA â‰¥2,000 IU/mL or progressed to decompensated cirrhosis with detectable HBV DNA level), antiviral treatment will be initiated.\n\nThe primary endpoint will be analyzed with Kaplan-Meier methods and compared by the log-rank test between the two groups. Between-group comparisons of continuous or categorical baseline characteristics will be conducted using Student's t-test, Chi-square test or Fisher's exact test, as appropriate."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Hepatitis B, Chronic"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 4"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"400",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Antiviral Treatment",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Tenofovir Alafenamide 25mg once daily , Oral",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Treatment"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Observation",
                    "ArmGroupType":"Other",
                    "ArmGroupDescription":"Best supportive care",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Observation of Hepatitis B"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Treatment",
                    "InterventionDescription":"Tenofovir Alafenamide 25 mg oral once daily",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Antiviral Treatment"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Tenofovir alafenamide"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Observation of Hepatitis B",
                    "InterventionDescription":"Best Supportive care",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Observation"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"cumulative incidence rate of composite clinical events",
                    "PrimaryOutcomeDescription":"hepatocellular carcinoma, death, liver transplantation, decompensated liver cirrhosis defined as Child-Pugh score â‰¥8, liver cirrhosis-related complications,liver-related unexpected hospital admission",
                    "PrimaryOutcomeTimeFrame":"From randomization the composite clinical events will be collected every 6weeks , assessed up to 36months"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Cumulative incidence",
                    "SecondaryOutcomeDescription":"death, hepatocellular carcinoma , Liver transplantation, decompensated liver cirrhosis",
                    "SecondaryOutcomeTimeFrame":"From randomization the composite clinical events will be collected every 1year , assessed up to 3years"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nWilling and able to provide written informed consent prior to study entry\nAge â‰¥40 years and â‰¤80 years at the time of screening\nChronic hepatitis B infection defined as HBsAg (+) or HBV DNA (+) for at least 6 months prior to the Screening visit, or medical records indication a chronic hepatitis B virus infection by meeting all of the following criteria at the time of screening. (1) HBsAg (+), (2) HBV DNA (+), and (3) HBcAb IgM (-)\nEither HBeAg (+) or HBeAg (-)\nSerum HBV DNA levels â‰¥20 IU/mL and <2,000 IU/mL at the time of screening\n\nEvidence of liver cirrhosis defined as meeting any of the following criteria:\n\nRadiological evidence of liver cirrhosis by ultrasound, CT, or MRI\nPlatelet count <150,000 /mm3\nPresence of esophageal or gastric varices by endoscopy in 2 years before the timing of screening\nClinically significant portal hypertension\nFibroscan â‰¥12.0 kPa (if the test was done in 6 months before the time of screening)\nEstimated creatinine clearance â‰¥30 ml/min (by calculation of creatinine clearance or using the CKD-EPI equation)\nAbility to comply with all study requirements\n\nExclusion Criteria:\n\nConfirmed known co-infection with HCV, HIV, or HDV\nCurrent alcohol (60g/day) or substance abuse judged by the investigator that will potentially interfere with subject compliance\nAny history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy, variceal hemorrhage, or Child-Pugh score of â‰¥8, with the exception of Gilbert syndrome) in 1 year before the time of screening\nCurrently on or have received therapy with Interferon or immunosuppressant (including systemic chemotherapy) within 12 months prior to the screening\nRequirement for chronic use of systemic immunosuppressant including, but not limited to, corticosteroid (prednisone equivalent of >40 mg/day for >2 weeks), azathioprine, or monoclonal antibodies\nReceived solid organ or bone marrow transplant\nHistory of severe, life-threatening or other significant sensitivity to any excipients of the study drugs\nAny other clinical conditions (cardiovascular, respiratory, neurologic, or renal conditions) or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.\nCurrently on or have received antiviral treatment for â‰¥ 2 weeks within 6 months prior to the screening\nHistory or current evidence of hepatocellular carcinoma (HCC), or high Î±-fetoprotein (AFP) > 20 ng/mL. But, the patients with AFP > 20 ng/mL can be enrolled if AFP shows decreasing trend and there is no evidence of HCC by dynamic CT or MRI)\nMalignancy other than hepatocellular carcinoma within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (within 2 years prior to screening with confirmation of no evidence of disease). Subjects under evaluation for possible malignancy are not eligible.\nConcurrent enrollment in another clinical study for other type of antiviral treatment for CHB or immune modulatory drug within 3 months prior to randomization, participation to an observational (non-interventional) clinical studies or interventional studies not using anti-HBV or immune modulatory drugs, or during the follow-up period of an interventional study are not exclusion criteria.\nPregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"40 Years",
              "MaximumAge":"80 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Young-Suk Lim, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"82-2-3010-3190",
                    "CentralContactEMail":"limys@amc.seoul.kr"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Young-Suk Lim, PhD",
                    "OverallOfficialAffiliation":"Asan Medical Center",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000006506",
                    "ConditionMeshTerm":"Hepatitis A"
                  },{
                    "ConditionMeshId":"D000006509",
                    "ConditionMeshTerm":"Hepatitis B"
                  },{
                    "ConditionMeshId":"D000019694",
                    "ConditionMeshTerm":"Hepatitis B, Chronic"
                  },{
                    "ConditionMeshId":"D000006505",
                    "ConditionMeshTerm":"Hepatitis"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000008107",
                    "ConditionAncestorTerm":"Liver Diseases"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  },{
                    "ConditionAncestorId":"D000006525",
                    "ConditionAncestorTerm":"Hepatitis, Viral, Human"
                  },{
                    "ConditionAncestorId":"D000014777",
                    "ConditionAncestorTerm":"Virus Diseases"
                  },{
                    "ConditionAncestorId":"D000004769",
                    "ConditionAncestorTerm":"Enterovirus Infections"
                  },{
                    "ConditionAncestorId":"D000010850",
                    "ConditionAncestorTerm":"Picornaviridae Infections"
                  },{
                    "ConditionAncestorId":"D000012327",
                    "ConditionAncestorTerm":"RNA Virus Infections"
                  },{
                    "ConditionAncestorId":"D000018347",
                    "ConditionAncestorTerm":"Hepadnaviridae Infections"
                  },{
                    "ConditionAncestorId":"D000004266",
                    "ConditionAncestorTerm":"DNA Virus Infections"
                  },{
                    "ConditionAncestorId":"D000006521",
                    "ConditionAncestorTerm":"Hepatitis, Chronic"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8175",
                    "ConditionBrowseLeafName":"Hepatitis A",
                    "ConditionBrowseLeafAsFound":"Hepatitis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8178",
                    "ConditionBrowseLeafName":"Hepatitis B",
                    "ConditionBrowseLeafAsFound":"Hepatitis B",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M20193",
                    "ConditionBrowseLeafName":"Hepatitis B, Chronic",
                    "ConditionBrowseLeafAsFound":"Hepatitis B, Chronic",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8174",
                    "ConditionBrowseLeafName":"Hepatitis",
                    "ConditionBrowseLeafAsFound":"Hepatitis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M16105",
                    "ConditionBrowseLeafName":"Virus Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9690",
                    "ConditionBrowseLeafName":"Liver Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8193",
                    "ConditionBrowseLeafName":"Hepatitis, Viral, Human",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6513",
                    "ConditionBrowseLeafName":"Enterovirus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M12328",
                    "ConditionBrowseLeafName":"Picornaviridae Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13732",
                    "ConditionBrowseLeafName":"RNA Virus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19071",
                    "ConditionBrowseLeafName":"Hepadnaviridae Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6025",
                    "ConditionBrowseLeafName":"DNA Virus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8190",
                    "ConditionBrowseLeafName":"Hepatitis, Chronic",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T2787",
                    "ConditionBrowseLeafName":"Herpes Simiae (B Virus)",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000068698",
                    "InterventionMeshTerm":"Tenofovir"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000000998",
                    "InterventionAncestorTerm":"Antiviral Agents"
                  },{
                    "InterventionAncestorId":"D000000890",
                    "InterventionAncestorTerm":"Anti-Infective Agents"
                  },{
                    "InterventionAncestorId":"D000018894",
                    "InterventionAncestorTerm":"Reverse Transcriptase Inhibitors"
                  },{
                    "InterventionAncestorId":"D000019384",
                    "InterventionAncestorTerm":"Nucleic Acid Synthesis Inhibitors"
                  },{
                    "InterventionAncestorId":"D000004791",
                    "InterventionAncestorTerm":"Enzyme Inhibitors"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  },{
                    "InterventionAncestorId":"D000044966",
                    "InterventionAncestorTerm":"Anti-Retroviral Agents"
                  },{
                    "InterventionAncestorId":"D000019380",
                    "InterventionAncestorTerm":"Anti-HIV Agents"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M296",
                    "InterventionBrowseLeafName":"Tenofovir",
                    "InterventionBrowseLeafAsFound":"Screening",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M2895",
                    "InterventionBrowseLeafName":"Antiviral Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2795",
                    "InterventionBrowseLeafName":"Anti-Infective Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19519",
                    "InterventionBrowseLeafName":"Reverse Transcriptase Inhibitors",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M24015",
                    "InterventionBrowseLeafName":"Anti-Retroviral Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19934",
                    "InterventionBrowseLeafName":"Anti-HIV Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Infe",
                    "InterventionBrowseBranchName":"Anti-Infective Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":45,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780191",
              "OrgStudyIdInfo":{
                "OrgStudyId":"C16-124"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"2017-A02060-53",
                    "SecondaryIdType":"Registry Identifier",
                    "SecondaryIdDomain":"ID RCB"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",
                "OrgClass":"OTHER_GOV"
              },
              "BriefTitle":"Investigation of Treatment Using the MyoRegulatorâ„¢ Device in Patients With Spasticity in the Lower Limb Due to Stroke",
              "OfficialTitle":"Investigation of Treatment Using the MyoRegulatorâ„¢ Device in Patients With Spasticity in the Lower Limb Due to Stroke",
              "Acronym":"SPAST"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"July 19, 2018",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"January 19, 2021",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"January 19, 2021",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"July 13, 2018",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",
                "LeadSponsorClass":"OTHER_GOV"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"PathMaker Neurosystems Inc.",
                    "CollaboratorClass":"INDUSTRY"
                  },{
                    "CollaboratorName":"MedPass International",
                    "CollaboratorClass":"INDUSTRY"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a single center, randomized, double-blind (patient and evaluator), sham-controlled study. The main objectives of this study are to evaluate the performance and safety of the MyoRegulatorÂ® device in active versus sham treated stroke patients with lower-limb spasticity after 5 consecutive days of treatment.",
              "DetailedDescription":"Spasticity prevalence after stroke is highly variable, ranging from 17% to 43% three months post-stroke. In the lower limbs, adduction and extension of the knee with equinovarus foot is the most observed pattern. Spasticity can lead to pain, ankylosis, and tendon retraction which may limit the potential success of rehabilitation. Spasticity can also affect quality-of-life and can be highly detrimental to daily activities such as walking.\n\nAn initial clinical trial of safety and feasibility suggested that five sessions of treatment with the MyoRegulatorÂ® device temporarily reduces spasticity and overall stiffness of the affected extremity with optimal reductions in spasticity occurring 2-3 weeks post stimulation intervention.\n\nMyoRegulatorÂ® is a non-invasive neuromodulation device using multi-site direct current stimulation for the treatment of spasticity. The main objectives of this study are to evaluate the performance and safety of the MyoRegulatorÂ® device in active versus sham treated patients during and after 5 consecutive days of treatment sessions. Patients can take part in an optional 3-month follow-up.\n\nThe primary performance endpoint is defined as the reduction in ankle joint spasticity. The study will be considered to have a successful outcome if the actively treated subjects demonstrate a statistically greater reduction in spasticity, as measured by the Tardieu Scale, as compared to the sham treated subjects two weeks after five treatment sessions.\n\nThe primary safety endpoint is defined as the incidence of device-related serious adverse events. The safety of the device will be demonstrated if there are no incidents of serious adverse events caused or contributed to by the device treatment that are clinically unacceptable in light of the treatment benefits."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Muscle Spasticity",
                  "Stroke"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "stroke rehabilitation",
                  "spasticity",
                  "neuromodulation",
                  "trans-spinal direct current stimulation"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Investigator"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"44",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Active MyoRegulatorÂ® treatment",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Five consecutive days of 20 minutes active stimulation with MyoRegulatorÂ® device",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: MyoRegulatorÂ®"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Sham MyoRegulatorÂ® treatment",
                    "ArmGroupType":"Sham Comparator",
                    "ArmGroupDescription":"Five consecutive days of 20 minutes sham stimulation with MyoRegulatorÂ® device",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: MyoRegulatorÂ®"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Device",
                    "InterventionName":"MyoRegulatorÂ®",
                    "InterventionDescription":"Trans-spinal DC stimulation paired with peripheral DC stimulation",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Active MyoRegulatorÂ® treatment",
                        "Sham MyoRegulatorÂ® treatment"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Change in spasticity from baseline to 2 weeks post-treatment",
                    "PrimaryOutcomeDescription":"Change in spasticity as measured by the Modified Tardieu Scale (MTS) two weeks after 5 treatments as compared to baseline.",
                    "PrimaryOutcomeTimeFrame":"Two weeks after last treatment session"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Change in gait parameters from baseline to 3 months post-treatment",
                    "SecondaryOutcomeDescription":"Change in walking up to 3 months after 5 treatments as compared to baseline as measured using a gait analysis system",
                    "SecondaryOutcomeTimeFrame":"Up to 3 months after last treatment session"
                  },{
                    "SecondaryOutcomeMeasure":"Change in walking performance from baseline to 3 months post-treatment",
                    "SecondaryOutcomeDescription":"Change in walking performance up to 3 months after 5 treatments as compared to baseline as measured using the 10-meter walk test",
                    "SecondaryOutcomeTimeFrame":"Up to 3 months after last treatment session"
                  },{
                    "SecondaryOutcomeMeasure":"Change in functional performance from baseline to 3 months post-treatment",
                    "SecondaryOutcomeDescription":"Change in functional performance up to 3 months after 5 treatments as compared to baseline as measured using the Fugl Meyer assessment",
                    "SecondaryOutcomeTimeFrame":"Up to 3 months after last treatment session"
                  },{
                    "SecondaryOutcomeMeasure":"Change in muscle reaction from baseline to 3 months post-treatment",
                    "SecondaryOutcomeDescription":"Change in muscle reaction up to 3 months after 5 treatments as compared to baseline as measured using the H-reflex",
                    "SecondaryOutcomeTimeFrame":"Up to 3 months after last treatment session"
                  },{
                    "SecondaryOutcomeMeasure":"Change in subject's self-assessment of their spasticity from baseline to 3 months post-treatment",
                    "SecondaryOutcomeDescription":"Change in subject's self-assessment of their spasticity up to 3 months after 5 treatments as compared to baseline as measured using an 11-point Numerical Rating Scale",
                    "SecondaryOutcomeTimeFrame":"Up to 3 months after last treatment session"
                  },{
                    "SecondaryOutcomeMeasure":"Change in subject's quality of life from baseline to 3 months post-treatment",
                    "SecondaryOutcomeDescription":"Change in subject's self-assessment of quality of life up to 3 months after 5 treatments as compared to baseline as measured using the SF-36 scale",
                    "SecondaryOutcomeTimeFrame":"Up to 3 months after last treatment session"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nStroke, with cortical and/or subcortical lesions, of at least 6-months duration at study inclusion\nSpasticity in the lower extremity plantarflexors (gastrocnemius, soleus muscles) due to stroke with a baseline score of 1-4 as assessed by the Tardieu scale\nMinimum 1-month duration of spasticity as confirmed by medical history\nModified Rankin score < 4\nCognitive functions sufficient to understand the experiments and follow instructions and ability to provide informed consent in accordance with ICH and GCP\nAffiliated with the French social security scheme, universal medical coverages (CMU), or an equivalent scheme.\n\nExclusion Criteria:\n\nEnrollment in another biomedical research study at the time of the MyoRegulator study.\nFixed contractures or profound muscle atrophy in the spastic limb\nOngoing use of digitalis, morphine, intrathecal pump\nPlantar orthosis or history of orthopedic surgery that can interfere with gait analysis\nBotulinum toxin treatment within 12 weeks of study enrollment\nPrior phenol or alcohol injections within 6 months of study enrollment\nChange in the antispastic treatment (baclofen, clonidine, benzodiazepine, dantrolene, gabapentine, tizanidin) in the 2 months prior to visit 1.\nAllergy to latex\n\nPresence of potential tsDCS risk factors:\n\nDamaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, cancerous lesions, etc.)\nLack of sensory perception at the stimulation sites\nPresence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker, epidural stimulation electrodes, etc.), an intravascular clip or any other electrically sensitive support system\nMetal in or on the body in the direct path of the stimulation current (jewelry must be removed during stimulation)\nPast history of seizures or unexplained spells of loss of consciousness during the previous 36 months\nPrior trans-spinal direct current stimulation for any reason or prior trans-cranial direct current stimulation in the past 12 months\nAny medical condition that would prevent the subject from being able to participate in the clinical outcome measures\nPregnancy in women (as determined by a urine pregnancy test in pre-menopausal women), or lactating women or women planning pregnancy during the course of the study\nPatient under guardianship or curatorship, or under judicial supervision",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"85 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Jean-Christophe Corvol, MD, PhD",
                    "OverallOfficialAffiliation":"Institut du Cerveau et de la Moelle Ã©piniÃ¨re",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Centre d'investigation clinique, Institut du Cerveau et de la Moelle",
                    "LocationCity":"Paris",
                    "LocationZip":"75013",
                    "LocationCountry":"France"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"32232101",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Paget-Blanc A, Chang JL, Saul M, Lin R, Ahmed Z, Volpe BT. Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation. Bioelectron Med. 2019 Jul 23;5:11. doi: 10.1186/s42234-019-0028-9. eCollection 2019."
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000009128",
                    "ConditionMeshTerm":"Muscle Spasticity"
                  },{
                    "ConditionMeshId":"D000020521",
                    "ConditionMeshTerm":"Stroke"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000002561",
                    "ConditionAncestorTerm":"Cerebrovascular Disorders"
                  },{
                    "ConditionAncestorId":"D000001927",
                    "ConditionAncestorTerm":"Brain Diseases"
                  },{
                    "ConditionAncestorId":"D000002493",
                    "ConditionAncestorTerm":"Central Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000014652",
                    "ConditionAncestorTerm":"Vascular Diseases"
                  },{
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  },{
                    "ConditionAncestorId":"D000009135",
                    "ConditionAncestorTerm":"Muscular Diseases"
                  },{
                    "ConditionAncestorId":"D000009140",
                    "ConditionAncestorTerm":"Musculoskeletal Diseases"
                  },{
                    "ConditionAncestorId":"D000009122",
                    "ConditionAncestorTerm":"Muscle Hypertonia"
                  },{
                    "ConditionAncestorId":"D000020879",
                    "ConditionAncestorTerm":"Neuromuscular Manifestations"
                  },{
                    "ConditionAncestorId":"D000009461",
                    "ConditionAncestorTerm":"Neurologic Manifestations"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M20890",
                    "ConditionBrowseLeafName":"Stroke",
                    "ConditionBrowseLeafAsFound":"Stroke",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M10668",
                    "ConditionBrowseLeafName":"Muscle Spasticity",
                    "ConditionBrowseLeafAsFound":"Spasticity",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4393",
                    "ConditionBrowseLeafName":"Cerebrovascular Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3786",
                    "ConditionBrowseLeafName":"Brain Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4325",
                    "ConditionBrowseLeafName":"Central Nervous System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M15983",
                    "ConditionBrowseLeafName":"Vascular Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10675",
                    "ConditionBrowseLeafName":"Muscular Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10680",
                    "ConditionBrowseLeafName":"Musculoskeletal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10662",
                    "ConditionBrowseLeafName":"Muscle Hypertonia",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21203",
                    "ConditionBrowseLeafName":"Neuromuscular Manifestations",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10987",
                    "ConditionBrowseLeafName":"Neurologic Manifestations",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC05",
                    "ConditionBrowseBranchName":"Muscle, Bone, and Cartilage Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":46,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780178",
              "OrgStudyIdInfo":{
                "OrgStudyId":"10320"
              },
              "Organization":{
                "OrgFullName":"Indiana University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults With Alzheimer's Disease and Related Dementias",
              "OfficialTitle":"Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults With Alzheimer's Disease and Related Dementias (TACTICs): A Pilot Randomized Controlled Trial (RRF)",
              "Acronym":"(TACTICs)"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 25, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Nicole R. Fowler, PhD",
                "ResponsiblePartyInvestigatorTitle":"Associate Professor of Medicine",
                "ResponsiblePartyInvestigatorAffiliation":"Indiana University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Indiana University",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Cleveland State University",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of the study is to test if Acceptance and Commitment Therapy (ACT), a behavioral intervention designed to increase psychological flexibility in the face of challenges, reduces anxiety associated psychological distress in dementia caregivers compared to the control group who will receive self-help and educational materials. This version of ACT is delivered over the phone in six primary sessions and one booster session."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Anxiety",
                  "Caregiver Burden"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Dementia",
                  "Alzheimer's disease",
                  "Caregiving",
                  "Caregiver",
                  "Anxiety",
                  "Telehealth"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"Participants will be randomly assigned to receive either the TACTICs telephone therapy or the minimally enhanced usual care packet of information.",
                "DesignPrimaryPurpose":"Supportive Care",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignMaskingDescription":"Outcome assessors are blinded to participant group assignment.",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"60",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"TACTICs",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Our ACT intervention will include 6 weekly 1-hour telephone sessions and 1 booster session offered 1 month after session 6 designed to increase psychological flexibility through practice of one or more of the six skills in each session. Although these are ideally spaced 1 week apart, participants will have up to 12 weeks to complete the 6 sessions. Each session will include guided mindfulness practice that encourages non-judgmental awareness of the present moment to increase psychological flexibility; brief (10-minute) study-provided audio recordings will enable participants to practice mindfulness at home. Caregivers will also identify deeply-held values to serve as a guide when choosing how to spend limited time or energy and will set values-based action goals each week. A booster session will be provided one month after session 6 to reinforce skills learned.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Minimally Enhanced Usual Care",
                    "ArmGroupType":"No Intervention",
                    "ArmGroupDescription":"All caregivers randomized to the mEUC group will receive a mailed packet containing 1) a letter from the Co-PIs thanking them for participating, 2) printed selections from of the NIH Alzheimer's caregiving website (https://www.nia.nih.gov/health/alzheimers/caregiving), and 3) a listing of Alzheimer's Association sponsored support groups closest to the caregiver's home address. Caregivers will also receive a brief phone call from the research coordinator to verify receipt of the packet. Since this is a usual care group with a minimally-enhanced component, it will be up to the mEUC participants to decide whether or not to engage with these intervention materials."
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias",
                    "InterventionDescription":"A telephone-based acceptance and commitment therapy for caregivers",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "TACTICs"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "TACTICs"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Generalized Anxiety Disorder Scale (GAD-7)",
                    "PrimaryOutcomeDescription":"The Generalized Anxiety Disorder Scale (GAD-7) contains 7 items with total scores ranging from 0 to 21. Scores of 5, 10, and 15 are cut-offs for mild, moderate, and severe anxiety, respectively. An add-on item assessing the patient's global impression of symptom-related impairment helps researchers understand the extent to which anxiety interferes in daily life. The GAD-7 has factorial validity for the diagnosis of general anxiety disorder and is sensitive to change.",
                    "PrimaryOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Patient Health Questionnaire-8",
                    "OtherOutcomeDescription":"8-item Patient Health Questionnaire-8 assesses depressive symptoms. With total scores ranging from 0 to 24, scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively. The PHQ-8 has factorial validity for the diagnosis of major depressive disorder.",
                    "OtherOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  },{
                    "OtherOutcomeMeasure":"Zarit Burden Interview",
                    "OtherOutcomeDescription":"The Zarit Burden Interview is a two-factor, 22-item scale that measures personal strain and role strain in caregiving by summing responses to a total score (0-20 little or no burden; 21-40 mild to moderate burden; 41-60 moderate to severe burden; and 61-88 severe burden). The ZBI measures change over time resulting from the progression of the patient's symptoms or from interventions aimed at reducing burden.",
                    "OtherOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  },{
                    "OtherOutcomeMeasure":"Experience of Suffering Scale",
                    "OtherOutcomeDescription":"The Experience of Suffering Scale contains 33 items across 3 subscales: physical (9 items), psychological (15 items), and existential (9 items) suffering. Total scores for each subscale are calculated with higher scores indicating more suffering within each domain.",
                    "OtherOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  },{
                    "OtherOutcomeMeasure":"Mutidimensional Psychological Flexibility Inventory",
                    "OtherOutcomeDescription":"The 24-item Mutidimensional Psychological Flexibility Inventory - Short form measures psychological flexibility and inflexibility. Respondents rate how true each statement is for them on a 6-point Likert-type scale anchored from 1=never true to 6=always true. Higher scores indicate higher levels of the dimension being assessed (i.e., psychological flexibility, psychological inflexibility).",
                    "OtherOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  },{
                    "OtherOutcomeMeasure":"Satisfaction with Life Scale",
                    "OtherOutcomeDescription":"The 5-item Satisfaction with Life Scale measures wellbeing. On a 7-point scale, participants indicate how much they agree or disagree with each of the 5 items to assess cognitive judgments of life satisfaction.",
                    "OtherOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  },{
                    "OtherOutcomeMeasure":"Quality of Life in Alzheimer's Disease",
                    "OtherOutcomeDescription":"Quality of Life in Alzheimer's Disease measures caregiver reported measure about the patient's quality of life and will provide preliminary data on the potential impact of the intervention on the person with ADRD for whom enrolled caregiver is caring for.",
                    "OtherOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  },{
                    "OtherOutcomeMeasure":"Intervention Acceptability",
                    "OtherOutcomeDescription":"Intervention acceptability is measured at T2 using an investigator-created 5-item measure of quantitative and qualitative satisfaction items.",
                    "OtherOutcomeTimeFrame":"Post-intervention (7-9 weeks post-baseline)"
                  },{
                    "OtherOutcomeMeasure":"Health Care and Resource Utilization",
                    "OtherOutcomeDescription":"Health care and resource utilization will be measured using an investigator-created 8-item measure. Items will assess caregiver-reported health and mental care utilization (e.g., emergency department [ED], inpatient, outpatient) and services accessed or used to support their caregiving (e.g., support groups, respite care, in-home aid).",
                    "OtherOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  },{
                    "OtherOutcomeMeasure":"Inventory of Complicated Grief",
                    "OtherOutcomeDescription":"The 19-item Inventory of Complicated Grief measures post death grief and bereavement in participants who have lost their loved one with dementia during the study. Each item is rated on a 5-point Likert scale with responses ranging from \"never\" to \"always\".",
                    "OtherOutcomeTimeFrame":"Baseline, post-intervention (7-9 weeks post-baseline), 3-month, 6-month"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nListed in ADRD patient's chart as primary caregiver or self-identifies as ADRD patient's primary caregiver\nIntends to continue caregiving for â‰¥12 months\nClinically-significant anxiety (score â‰¥10 on GAD-7)\n21 years or older\nAble to communicate in English\nAble to provide informed consent\n\nExclusion Criteria:\n\nCaregiver is a non-family member\nCare recipient is in an assisted living or nursing home (at baseline)\nHas ADRD or other serious mental illness diagnosis such as schizophrenia as determined by ICD-10 code or self-report\nCaregiver is enrolled in an existing ADRD collaborative program at Eskenazi Health, IU Health or the VA.\nCaregiver is enrolled in another IU study that is testing a ADRD caregiver intervention",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"21 Years",
              "MaximumAge":"95 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Eleanor Batista-Malat, BA",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"317-274-9172",
                    "CentralContactEMail":"evbatist@regenstrief.org"
                  },{
                    "CentralContactName":"Anna Williams, BS",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"317-274-9503",
                    "CentralContactEMail":"anpwilli@regenstrief.org"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Nicole R Fowler, PhD",
                    "OverallOfficialAffiliation":"Indiana University",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"In future manuscripts, the authors will list contact information and state that the IPD is available upon request"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000000544",
                    "ConditionMeshTerm":"Alzheimer Disease"
                  },{
                    "ConditionMeshId":"D000003704",
                    "ConditionMeshTerm":"Dementia"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000001927",
                    "ConditionAncestorTerm":"Brain Diseases"
                  },{
                    "ConditionAncestorId":"D000002493",
                    "ConditionAncestorTerm":"Central Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000024801",
                    "ConditionAncestorTerm":"Tauopathies"
                  },{
                    "ConditionAncestorId":"D000019636",
                    "ConditionAncestorTerm":"Neurodegenerative Diseases"
                  },{
                    "ConditionAncestorId":"D000019965",
                    "ConditionAncestorTerm":"Neurocognitive Disorders"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M2905",
                    "ConditionBrowseLeafName":"Anxiety Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M2466",
                    "ConditionBrowseLeafName":"Alzheimer Disease",
                    "ConditionBrowseLeafAsFound":"Alzheimer's Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5487",
                    "ConditionBrowseLeafName":"Dementia",
                    "ConditionBrowseLeafAsFound":"Dementia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3786",
                    "ConditionBrowseLeafName":"Brain Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4325",
                    "ConditionBrowseLeafName":"Central Nervous System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21586",
                    "ConditionBrowseLeafName":"Tauopathies",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20142",
                    "ConditionBrowseLeafName":"Neurodegenerative Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20420",
                    "ConditionBrowseLeafName":"Neurocognitive Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T2192",
                    "ConditionBrowseLeafName":"Familial Alzheimer Disease",
                    "ConditionBrowseLeafAsFound":"Alzheimer's Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":47,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780165",
              "OrgStudyIdInfo":{
                "OrgStudyId":"LTPIVBDX19"
              },
              "Organization":{
                "OrgFullName":"Laboratoires Thea",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"Efficacy and Tolerability of Blephademodex Wipes",
              "OfficialTitle":"Prospective, Open Label, Multicenter Trial to Investigate the Efficacy and Tolerability of Blephademodex Wipes in Patients With Demodex Blepharitis"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"September 11, 2019",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"March 13, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"May 14, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"September 23, 2020",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Laboratoires Thea",
                "LeadSponsorClass":"INDUSTRY"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Primary Objective\n\n- To evaluate efficacy of Blephademodex eyelid hygiene wipe treatment with a subsequent maintenance period with Blephaclean lid cleansing wipes in Demodex blepharitis, as assessed by the change in ocular symptoms by a Global Discomfort Scale (GDS).\n\nSecondary Objectives\n\nTo evaluate the efficacy of Blephademodex eyelid hygiene wipe treatment in Demodex blepharitis as assessed by the change alone and in combination with a subsequent maintenance period of treatment with Blephaclean eyelid cleansing wipes ocular symptoms by: adapted TOSS; SANDE; specific blepharitis symptoms; Demodex count; ocular surface redness (Efron scale); lid margin redness/swelling (Efron / custom scale); Dandruff coverage at bases of eyelashes; ocular surface staining (Oxford scale; corneal only)\nTo evaluate subject and physician satisfaction with Blephademodex eyelid hygiene wipes\nTo evaluate ease of use for Blephademodex eyelid hygiene wipes\nAdverse events are documented and analyzed."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Demodex Blepharitis"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"50",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Single-arm",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: Blephademodex"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Device",
                    "InterventionName":"Blephademodex",
                    "InterventionDescription":"During the first 28 days of the trial, subjects will use one BlephademodexÂ® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes. At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Single-arm"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Blephaclean"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Global Discomfort Score",
                    "PrimaryOutcomeDescription":"Change from Baseline at Day 28 The Global (overall) discomfort score (GDS) consists of a single question, which can be answered by the subject by choosing a value between 0 (no discomfort) and 10 (worst discomfort): Thinking about today, how would you rate the discomfort of your eyes?",
                    "PrimaryOutcomeTimeFrame":"Day 28"
                  },{
                    "PrimaryOutcomeMeasure":"Global Discomfort Score",
                    "PrimaryOutcomeDescription":"Change from D28 at Day 56",
                    "PrimaryOutcomeTimeFrame":"Day 56"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Specific Blepharitis symptoms",
                    "SecondaryOutcomeDescription":"Symptoms will be rated by the patient on the day of visit using 10-grade scales (0 = none to 10 = severe) for each of the following items Severity of any eyelid itching today / Severity of lid redness today / Severity of eyelid swelling today / How severe was the eyelid crusting this morning when you woke up? / How severe is missing lashes today?",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"adapted Total Ocular Symptom Score (TOSS)",
                    "SecondaryOutcomeDescription":"8-item questionnaire with an overall score ranging from 0 (\"none of the time\") to 4 (\"all of the time\"). It contains of a single question concerning the frequency with which 8 different symptoms (itchy eyelids, eyelid redness, red eyes generally, swollen (puffy) eyes, tearing (eyes watering), crusting around the lashes, burning or stinging sensations and noticed eyelash loss) were experienced in the course of a week.",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Symptom Assessment in Dry Eye (SANDE)",
                    "SecondaryOutcomeDescription":"Comprised of two questions: 1) How often do your eyes feel dry and/or irritated? And 2) How severe you feel your symptoms of dryness and/or irritation are? This questionnaire uses a 100 mm horizontal line as visual analogue scale (VAS) for each question to assess ocular discomfort and/or dryness experienced by the patients. In the SANDE questionnaire, frequency of symptoms ranges from \"rarely\" to \"all of the time\" and the severity of symptoms ranges from \"very mild\" to \"very severe\".",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Demodex count",
                    "SecondaryOutcomeDescription":"Sideways 'pull' on 10 eyelashes - upper or lower lashes Extent (mites present? yes or no) and Severity/Intensity (1=1 tail; 2=2 tails; 3 =2+tails)",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Ocular surface redness",
                    "SecondaryOutcomeDescription":"Efron scale",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Lid margin redness/swelling",
                    "SecondaryOutcomeDescription":"Efron/custom scale",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Cylindrical dandruff",
                    "SecondaryOutcomeDescription":"Lash line coverage (%) and severity (mild/moderate/severe)",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Ocular surface staining",
                    "SecondaryOutcomeDescription":"Oxford scale; corneal only",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Physician's impression and patient impression",
                    "SecondaryOutcomeDescription":"Answer the item 'the treatment has been sufficiently effective' on a 4-point scale (strongly disagree, disagree, agree, strongly agree)",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Tolerability of the wipes",
                    "SecondaryOutcomeDescription":"Tolerability assessment by the physician and patient (0 = intolerable; 1 = somewhat tolerable; 2 = tolerable; 3 = fully tolerable)",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Visual acuity",
                    "SecondaryOutcomeDescription":"Snellen eye chart",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of ease of use",
                    "SecondaryOutcomeDescription":"as experienced by the subjects, rated on a five-point scale of \"Very Difficult\" to \"Very Easy\".",
                    "SecondaryOutcomeTimeFrame":"Day 56"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPatient > 18 years old, all genders\nAble to read, to write and to fully understand German language\nGood general health as determined by the investigator by medical history and physical appearance\nProvision of written informed consent prior to inclusion\nModerate to Severe Blepharitis - grade â‰¥ 2 (Efron Scale)\nGlobal discomfort score (GDS) â‰¥ 4\nProof of demodex infestation by at least ONE of the following:Demodex visible after lash manipulation;Cylindrical dandruff along the lash line; Lid margin itching; Madarosis\n\nExclusion Criteria:\n\nHistory of ocular trauma, ocular infection or intra-ocular inflammation within the 3 months before screening visit\nHistory of ocular refractive surgery and any other ocular surgeries within 3 months before screening visit\nHistory of ocular allergy or ocular herpes within the 3 months before screening visit\nHistory of inflammatory corneal ulcer within the 6 months before screening visit\nSjogren syndrome or any other rheumatologic disease related dry eye\nConcurrent treatment with other eye drops (anti-infectives, steroids, prostaglandins (but artificial tears are ok).\nSpecific Exclusion Criteria for Women:Patient who verbally confirms pregnancy or lactation; Childbearing potential woman who is not using a reliable method of contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch or condom) and is not surgically sterilised",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Consultation office",
                    "LocationCity":"Heidelberg",
                    "LocationZip":"69121",
                    "LocationCountry":"Germany"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001762",
                    "ConditionMeshTerm":"Blepharitis"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000005141",
                    "ConditionAncestorTerm":"Eyelid Diseases"
                  },{
                    "ConditionAncestorId":"D000005128",
                    "ConditionAncestorTerm":"Eye Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3625",
                    "ConditionBrowseLeafName":"Blepharitis",
                    "ConditionBrowseLeafAsFound":"Blepharitis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M6867",
                    "ConditionBrowseLeafName":"Eyelid Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6854",
                    "ConditionBrowseLeafName":"Eye Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC11",
                    "ConditionBrowseBranchName":"Eye Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":48,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780152",
              "OrgStudyIdInfo":{
                "OrgStudyId":"54/20"
              },
              "Organization":{
                "OrgFullName":"El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic",
              "OfficialTitle":"Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"September 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 2, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"DANIEL SAN JUAN ORTA",
                "ResponsiblePartyInvestigatorTitle":"Master in Clinical Research",
                "ResponsiblePartyInvestigatorAffiliation":"El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez"
              },
              "LeadSponsor":{
                "LeadSponsorName":"El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico",
                    "CollaboratorClass":"OTHER_GOV"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of this study is to assess safety and efficacy of nodal transcranial direct current stimulation in pediatric and teenager population with major depressive disorder in the COVID-19 pandemic.",
              "DetailedDescription":"After being widely informed about the study and potential risks, all the patients giving voluntary informed consent will be randomized in a 1:1 ratio to a tDCS group (a-tDCS+ standard treatment) or control group (placebo-simulations a-tDCS+ standard treatment)."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Major Depressive Disorder"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "TDCS",
                  "Pediatrics",
                  "COVID-19",
                  "Adolescents"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2",
                  "Phase 3"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"A multicentric, randomized, clinical trial, phase 2/3 of superiority, with two parallel arms, comparative, controlled with placebo, in which changes in a major depressive disorder scale will be assessed (change in CDI score measured at week 10 compared with initial score) comparing with basal score and between the two groups (>40% measured at 2 weeks, 1,2, 3 months of treatment).",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignMaskingDescription":"In addition some of the personnel (evaluators, data analyst, result analyst) will be blinded in order to increase the internal validity of our study. A blind person is considered by the person that apply the intervention.",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"172",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"tDCS arm",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 mintutes and 2 mA) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: Transcranial Direct Current Stimulation",
                        "Drug: Fluoxetine Tablets"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Control arm",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Participant receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: Pacebo-simulation of transcranial direct current stimulation",
                        "Drug: Fluoxetine Tablets"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Device",
                    "InterventionName":"Transcranial Direct Current Stimulation",
                    "InterventionDescription":"Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 mintutes and 2 mA). Anodal stimulation will be applied on F3 according to the intenational 10/20 system, and the cathode will be applied on the contra lateral position (F4).",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "tDCS arm"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "TDCS",
                        "Anodal electric transcranial direct current stimulation"
                      ]
                    }
                  },{
                    "InterventionType":"Device",
                    "InterventionName":"Pacebo-simulation of transcranial direct current stimulation",
                    "InterventionDescription":"Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Control arm"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Fluoxetine Tablets",
                    "InterventionDescription":"Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Control arm",
                        "tDCS arm"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Antidepressants"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Change of Children Depression Inventory score from the begining to the end of the study",
                    "PrimaryOutcomeDescription":"It is one of the most widely used self-applied scales to assess depressive symptoms in children and teenagers. The scale consists of 27 items, each item with 3 response options, where 0= absence of symptoms, 1= moderate symptoms, and 2= severe symptoms. The total score ranges from 0-54. The scale manual contains the psychometric properties reported by the author. It is recommended for use in children from 7-17 years old. a SCORE OF 20 was established as a cut-off point for indicating depression problems",
                    "PrimaryOutcomeTimeFrame":"At the beginning of the study and at the end of weeks 2, 4, 8, and 12"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Change of Columbia-Suicide Severity Rating Scale score from the begining to the end of the study",
                    "SecondaryOutcomeDescription":"The C-SSRS is a semi-structured interview which collects the onset, severity and frequency of behavior and thoughts related to suicide during the assessement period. Therefore, 4 constructs are measured.",
                    "SecondaryOutcomeTimeFrame":"At the beginning of the study and at the end of weeks 2, 4, 8, and 12"
                  },{
                    "SecondaryOutcomeMeasure":"Change of Young Mania Rating Scale score from the begining to the end of the study",
                    "SecondaryOutcomeDescription":"It is an instrument for quantifying mania symptoms that consist of 11 items, each one with 5 response options, which reflect higher score if great intensity. It is applied by the clinician and is based on the subjective report of the patient during 48 hrs prior to the evaluation, as well as on the observation of the patient's behavior during the interview. The patient selects the intensity level of the symptom for each item with an option from 0 to 4.\n\nThe total range of the scale from 0-60 points where higher scores indicate a greater degree of manic characteristics; the minimum score to define new-onset mania or hypomania is 8 points at the end of the weeks 2, 4, 8 and 12 to assess mania or hypomania during the clinical trial.",
                    "SecondaryOutcomeTimeFrame":"At the beginning of the study and at the end of weeks 2, 4, 8, and 12"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nMajor Depressive Disorder (MDD) diagnosed through the clinical interview based on the Affective Disorders and Schizophrenia Agenda for schoolchildren-current version and for life K- SADS-PL for its acronym in English, with a single or recurrent episode lasting â‰¥4 weeks.\nThe current depressive episode must have a duration of less than 5 years and be at least greater than 2 months in which the patient meets the operational definition of MDD from the DSM-V.\nCID scale with values equal to 17 or higher in the clinical evaluation.\nNo use of another medication during the intervention days.\nThey should not be taking antidepressants at the beginning of the study (last 4 weeks) or it must have passed the adequate time of \"washing\"/ clearance of antidepressant drugs established as 5 or more biological half-lifes or 5 days before the randomization.\nTo be able and willing to give their informed consent, both, the parent or tutor and the participant who is between the ages of 14-17 years. In the age group of 10-13 years the assent of the patient and the consent of the parent or tutor.\nUse of benzodiazepines (eg lorazepam) equivalent to 20 mg of diazepam and which remains stable during the study.\nPatients with an unchanged drug treatment for MDD in the last 4 weeks and who agree to switch the fluoxetine at the time of randomization, meeting the previously described antidepressant criteria.\n\nExclusion Criteria:\n\nPrevious skull surgery.\nRecent skull injury (6 months).\nUse of central nervous system stimulants.\nRespiratory System infections.\nDoes NOT sign or is unable to sign informed consent or legal tutors/parents do not consent.\nClinical condition or anomaly, which in the researcher's opinion, compromises patientÂ´s safety or data quality.\nUncontrolled co-existent medical condition, progressive cerebral disorder, severe systemic diseases, symptomatic disease, cardiac disease, skin chronic diseases or damaged scalp which could interfere with tDCS stimulation.\nAny skull metal implant (excluding dental filling or titanium plates) or medical devices (cardiac pacemaker, deep cerebral stimulator, drug infusion pump, cochlear implant, vagus nerve stimulator).\nDirect researcher relatives or personnel directly involved in the study.\nAcute suicide risk measured thourgh the Montgomery Asberg depression rating scale (MADRS) >4 points or positivity of the 4th or 5th item of The Columbia Suicide Severity Rating Scale (C-SSRS).\nDepression resistant to treatment with >4 well indicated drugs during the current episode.\nBipolar disorder history or current mania symptoms.\nTreatment with electroshock therapy concomitantly and during the last 12 months.\nOther relevant psychiatric disorders according to the DSM 5 (except generalized anxiety disorder, specific phobia or separation anxiety disorder).\nPrevious treatment with tDCS for a different disease to the major depressive disorder.\nIntellectual development disorder previously documented or clinical evaluation fulfilling the CIE-F79 criteria.\nDue to the fact that treatment with tDCS has counter-indications, will be excluded: those with history of non provoked seizures, convulsive disorders, history of febrile seizure, family history of epilepsy or brain tumor, pregnancy.\nCounter-indication or history of adverse reactions from mild to severe to fluoxetine.\n\nElimination criteria:\n\nPatients that do not complete the neuropsychological assessment tests.\nInterruption of the intervention of less than 50% of what was scheduled.\nOnset of active suicidal ideation.\nActive psychosis.\nStart of emerging mania treatment.\nPregnancy.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"10 Years",
              "MaximumAge":"17 Years",
              "StdAgeList":{
                "StdAge":[
                  "Child"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Daniel San Juan, M.D.",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"(55)56063822",
                    "CentralContactPhoneExt":"2527",
                    "CentralContactEMail":"pegaso31@yahoo.com"
                  },{
                    "CentralContactName":"Angel R Chow, M.D",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"(55)56063822",
                    "CentralContactPhoneExt":"1033",
                    "CentralContactEMail":"aaruizchow@gmail.com"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Instituto Nacional de NeurologÃ­a y NeurocirugÃ­a",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Mexico City",
                    "LocationState":"Ciudad De MÃ©xico",
                    "LocationZip":"14269",
                    "LocationCountry":"Mexico",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Daniel San-Juan, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"525556063822",
                          "LocationContactPhoneExt":"2527",
                          "LocationContactEMail":"pegaso31@yahoo.com"
                        },{
                          "LocationContactName":"Angel R. Chow, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"525556063822",
                          "LocationContactPhoneExt":"1033",
                          "LocationContactEMail":"aaruizchow@gmail.com"
                        },{
                          "LocationContactName":"Daniel San-Juan, MD",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferenceType":"background",
                    "ReferenceCitation":"(Editors) Medina Mora, M.E. & Sarti Gutierrez, E.J. & Real Quintanar, T. (2015) 'La depresiÃ³n y otros trastornos psiquiÃ¡tricos. Documento de postura.', ColecciÃ³n, p. 410. Available at: nfo@cempro.org.mx (reproducci? prohibida) (Accessed: 11 May 2020)."
                  },{
                    "ReferencePMID":"29803629",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacol Ther. 2018 Oct;190:148-158. doi: 10.1016/j.pharmthera.2018.05.010. Epub 2018 May 25. Review."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Acosta-HernÃ¡ndez, M. E. et al. (2011) 'DepresiÃ³n en la infancia y adolescencia: Enfermedad de nuestro tiempo', Archivos de Neurociencias, 16(1), pp. 20-25."
                  },{
                    "ReferencePMID":"27158026",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Al-HalabÃ­ S, SÃ¡iz PA, BurÃ³n P, Garrido M, Benabarre A, JimÃ©nez E, Cervilla J, Navarrete MI, DÃ­az-Mesa EM, GarcÃ­a-Ãlvarez L, MuÃ±iz J, Posner K, Oquendo MA, GarcÃ­a-Portilla MP, Bobes J. Validation of a Spanish version of the Columbia-Suicide Severity Rating Scale (C-SSRS). Rev Psiquiatr Salud Ment. 2016 Jul-Sep;9(3):134-42. doi: 10.1016/j.rpsm.2016.02.002. Epub 2016 May 2. English, Spanish."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Alon, G., Syron, S. C. and Smith, G. V. (1998) 'Is Transcranial Electrical Stimulation (TCES) a Safe Intervention for Children with Cerebral Palsy?', Neurorehabilitation and Neural Repair, 12(2), pp. 65-71. doi: 10.1177/154596839801200204"
                  },{
                    "ReferencePMID":"31005790",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Alonzo A, Fong J, Ball N, Martin D, Chand N, Loo C. Pilot trial of home-administered transcranial direct current stimulation for the treatment of depression. J Affect Disord. 2019 Jun 1;252:475-483. doi: 10.1016/j.jad.2019.04.041. Epub 2019 Apr 10."
                  },{
                    "ReferencePMID":"16037080",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Ardolino G, Bossi B, Barbieri S, Priori A. Non-synaptic mechanisms underlie the after-effects of cathodal transcutaneous direct current stimulation of the human brain. J Physiol. 2005 Oct 15;568(Pt 2):653-63. Epub 2005 Jul 21."
                  },{
                    "ReferencePMID":"26879095",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Bandeira ID, GuimarÃ£es RS, Jagersbacher JG, Barretto TL, de Jesus-Silva JR, Santos SN, Argollo N, Lucena R. Transcranial Direct Current Stimulation in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD): A Pilot Study. J Child Neurol. 2016 Jun;31(7):918-24. doi: 10.1177/0883073816630083. Epub 2016 Feb 15."
                  },{
                    "ReferencePMID":"23339180",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Batsikadze G, Moliadze V, Paulus W, Kuo MF, Nitsche MA. Partially non-linear stimulation intensity-dependent effects of direct current stimulation on motor cortex excitability in humans. J Physiol. 2013 Apr 1;591(7):1987-2000. doi: 10.1113/jphysiol.2012.249730. Epub 2013 Jan 21."
                  },{
                    "ReferencePMID":"30470559",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Belleau EL, Treadway MT, Pizzagalli DA. The Impact of Stress and Major Depressive Disorder on Hippocampal and Medial Prefrontal Cortex Morphology. Biol Psychiatry. 2019 Mar 15;85(6):443-453. doi: 10.1016/j.biopsych.2018.09.031. Epub 2018 Oct 10. Review."
                  },{
                    "ReferencePMID":"30949092",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Bernaras E, Jaureguizar J, Garaigordobil M. Child and Adolescent Depression: A Review of Theories, Evaluation Instruments, Prevention Programs, and Treatments. Front Psychol. 2019 Mar 20;10:543. doi: 10.3389/fpsyg.2019.00543. eCollection 2019. Review."
                  },{
                    "ReferencePMID":"31358456",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Bikson M, Esmaeilpour Z, Adair D, Kronberg G, Tyler WJ, Antal A, Datta A, Sabel BA, Nitsche MA, Loo C, Edwards D, Ekhtiari H, Knotkova H, Woods AJ, Hampstead BM, Badran BW, Peterchev AV. Transcranial electrical stimulation nomenclature. Brain Stimul. 2019 Nov - Dec;12(6):1349-1366. doi: 10.1016/j.brs.2019.07.010. Epub 2019 Jul 17. Review."
                  },{
                    "ReferencePMID":"8936909",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, Perel J, Nelson B. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. 1996 Nov;35(11):1427-39. Review."
                  },{
                    "ReferencePMID":"19640209",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Bobo WV, Shelton RC. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother. 2009 Sep;10(13):2145-59. doi: 10.1517/14656560903130609. Review."
                  },{
                    "ReferencePMID":"21511342",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Bora E, Fornito A, Pantelis C, YÃ¼cel M. Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord. 2012 Apr;138(1-2):9-18. doi: 10.1016/j.jad.2011.03.049. Epub 2011 Apr 20."
                  },{
                    "ReferencePMID":"21910935",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Bora E, Harrison BJ, Davey CG, YÃ¼cel M, Pantelis C. Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder. Psychol Med. 2012 Apr;42(4):671-81. doi: 10.1017/S0033291711001668. Epub 2011 Sep 13. Review."
                  },{
                    "ReferencePMID":"22037126",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Brunoni AR, Nitsche MA, Bolognini N, Bikson M, Wagner T, Merabet L, Edwards DJ, Valero-Cabre A, Rotenberg A, Pascual-Leone A, Ferrucci R, Priori A, Boggio PS, Fregni F. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul. 2012 Jul;5(3):175-195. doi: 10.1016/j.brs.2011.03.002. Epub 2011 Apr 1. Review."
                  },{
                    "ReferencePMID":"23615118",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Brunoni AR, Kemp AH, Shiozawa P, Cordeiro Q, Valiengo LC, Goulart AC, Coprerski B, Lotufo PA, Brunoni D, Perez AB, Fregni F, BenseÃ±or IM. Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system. Eur Neuropsychopharmacol. 2013 Nov;23(11):1530-40. doi: 10.1016/j.euroneuro.2013.03.009. Epub 2013 Apr 21."
                  },{
                    "ReferencePMID":"22626867",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Brunoni AR, Vanderhasselt MA, Boggio PS, Fregni F, Dantas EM, Mill JG, Lotufo PA, BenseÃ±or IM. Polarity- and valence-dependent effects of prefrontal transcranial direct current stimulation on heart rate variability and salivary cortisol. Psychoneuroendocrinology. 2013 Jan;38(1):58-66. doi: 10.1016/j.psyneuen.2012.04.020. Epub 2012 May 22."
                  },{
                    "ReferencePMID":"23389323",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Brunoni AR, Valiengo L, Baccaro A, ZanÃ£o TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA, BenseÃ±or IM, Fregni F. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry. 2013 Apr;70(4):383-91. doi: 10.1001/2013.jamapsychiatry.32."
                  },{
                    "ReferencePMID":"27056623",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D, Haffen E, Alonzo A, Loo CK. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016 Jun;208(6):522-31. doi: 10.1192/bjp.bp.115.164715. Epub 2016 Apr 7. Review."
                  },{
                    "ReferencePMID":"28657871",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP, Nogueira BS, Aparicio LVM, Razza LB, Chamorro R, Tort LC, Fraguas R, Lotufo PA, Gattaz WF, Fregni F, BenseÃ±or IM; ELECT-TDCS Investigators. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med. 2017 Jun 29;376(26):2523-2533. doi: 10.1056/NEJMoa1612999."
                  },{
                    "ReferencePMID":"12057034",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol. 2002 Mar;5(1):73-103. doi: 10.1017/S1461145702002791."
                  },{
                    "ReferencePMID":"7796248",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Canals J, Marti-Henneberg C, FernÃ¡ndez-Ballart J, DomÃ¨nech E. A longitudinal study of depression in an urban Spanish pubertal population. Eur Child Adolesc Psychiatry. 1995 Apr;4(2):102-11."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"CDC COVID-19 Response Team (2020) 'Morbidity and mortality weekly report (mmwr) - Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020', Morbidity and Mortality Weekly Report, 69, pp. 2-6. Available at: https://www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"CDI. Inventario de DepresiÃ³n Infantil (no date). Available at: http://web.teaediciones.com/CDI--INVENTARIO-DE-DEPRESION-INFANTIL.aspx (Accessed: 13 September 2020)."
                  },{
                    "ReferencePMID":"17217921",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Chen CH, Ridler K, Suckling J, Williams S, Fu CH, Merlo-Pich E, Bullmore E. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. 2007 Sep 1;62(5):407-14. Epub 2007 Jan 9."
                  },{
                    "ReferencePMID":"24890068",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014 Jun;13(2):153-60. doi: 10.1002/wps.20128."
                  },{
                    "ReferencePMID":"29576498",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Chhatbar PY, Kautz SA, Takacs I, Rowland NC, Revuelta GJ, George MS, Bikson M, Feng W. Evidence of transcranial direct current stimulation-generated electric fields at subthalamic level in human brain in vivo. Brain Stimul. 2018 Jul - Aug;11(4):727-733. doi: 10.1016/j.brs.2018.03.006. Epub 2018 Mar 13."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"CofrÃ©, F. et al. (2017) 'GuÃ­a ClÃ­nica', Rev Chil Obstet Ginecol, 82(2), pp. 83-123. Available at: http://www.revistasochog.cl/files/pdf/GC_010.pdf (Accessed: 24 April 2020)."
                  },{
                    "ReferencePMID":"25604912",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Collange Grecco LA, de Almeida Carvalho Duarte N, MendonÃ§a ME, Galli M, Fregni F, Oliveira CS. Effects of anodal transcranial direct current stimulation combined with virtual reality for improving gait in children with spastic diparetic cerebral palsy: a pilot, randomized, controlled, double-blind, clinical trial. Clin Rehabil. 2015 Dec;29(12):1212-23. doi: 10.1177/0269215514566997. Epub 2015 Jan 20."
                  },{
                    "ReferencePMID":"28509901",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Corfield EC, Yang Y, Martin NG, Nyholt DR. A continuum of genetic liability for minor and major depression. Transl Psychiatry. 2017 May 16;7(5):e1131. doi: 10.1038/tp.2017.99."
                  },{
                    "ReferencePMID":"26267861",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Cosmo C, Baptista AF, de AraÃºjo AN, do RosÃ¡rio RS, Miranda JG, Montoya P, de Sena EP. A Randomized, Double-Blind, Sham-Controlled Trial of Transcranial Direct Current Stimulation in Attention-Deficit/Hyperactivity Disorder. PLoS One. 2015 Aug 12;10(8):e0135371. doi: 10.1371/journal.pone.0135371. eCollection 2015."
                  },{
                    "ReferencePMID":"26590479",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Costanzo F, Menghini D, Casula L, Amendola A, Mazzone L, Valeri G, Vicari S. Transcranial Direct Current Stimulation Treatment in an Adolescent with Autism and Drug-Resistant Catatonia. Brain Stimul. 2015 Nov-Dec;8(6):1233-5. doi: 10.1016/j.brs.2015.08.009. Epub 2015 Aug 24."
                  },{
                    "ReferencePMID":"26890096",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Costanzo F, Varuzza C, Rossi S, Sdoia S, Varvara P, Oliveri M, Giacomo K, Vicari S, Menghini D. Evidence for reading improvement following tDCS treatment in children and adolescents with Dyslexia. Restor Neurol Neurosci. 2016;34(2):215-26. doi: 10.3233/RNN-150561."
                  },{
                    "ReferencePMID":"26848997",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Costanzo F, Varuzza C, Rossi S, Sdoia S, Varvara P, Oliveri M, Koch G, Vicari S, Menghini D. Reading changes in children and adolescents with dyslexia after transcranial direct current stimulation. Neuroreport. 2016 Mar 23;27(5):295-300. doi: 10.1097/WNR.0000000000000536."
                  },{
                    "ReferencePMID":"12912767",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry. 2003 Aug;60(8):837-44."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO (2017)."
                  },{
                    "ReferencePMID":"25451389",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Dichter GS, Gibbs D, Smoski MJ. A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. J Affect Disord. 2015 Feb 1;172:8-17. doi: 10.1016/j.jad.2014.09.028. Epub 2014 Sep 26. Review."
                  },{
                    "ReferencePMID":"22532165",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Ditye T, Jacobson L, Walsh V, Lavidor M. Modulating behavioral inhibition by tDCS combined with cognitive training. Exp Brain Res. 2012 Jun;219(3):363-8. doi: 10.1007/s00221-012-3098-4. Epub 2012 Apr 25."
                  },{
                    "ReferencePMID":"26937618",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016 Mar;22(3):238-49. doi: 10.1038/nm.4050."
                  },{
                    "ReferencePMID":"30946828",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019 Apr 3;102(1):75-90. doi: 10.1016/j.neuron.2019.03.013. Review."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"East, M. and Surveillance, G. (2020) 'Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts', (March), pp. 17-20. Available at: https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts (Accessed: 3 April 2020)."
                  },{
                    "ReferencePMID":"31872943",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Esmaeilpour Z, Shereen AD, Ghobadi-Azbari P, Datta A, Woods AJ, Ironside M, O'Shea J, Kirk U, Bikson M, Ekhtiari H. Methodology for tDCS integration with fMRI. Hum Brain Mapp. 2020 May;41(7):1950-1967. doi: 10.1002/hbm.24908. Epub 2019 Dec 24. Review."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"'ESTADÃSTICAS A PROPÃ“SITO DEL DÃA MUNDIAL PARA LA PREVENCIÃ“N DEL SUICIDIO (10 DE SEPTIEMBRE)' DATOS NACIONALES (no date). Available at: http://www.who.int/mediacentre/news/releases/2004/pr61/es/, (Accessed: 20 June 2020)."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fang, Y. (2019) Depressive Disorders: Mechanisms, Measurement and Management, Depressive Disorders: Mechanisms, Measurement and Management. doi: 10.1007/978-981-32-9271-0."
                  },{
                    "ReferencePMID":"23123281",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Faria P, Fregni F, SebastiÃ£o F, Dias AI, Leal A. Feasibility of focal transcranial DC polarization with simultaneous EEG recording: preliminary assessment in healthy subjects and human epilepsy. Epilepsy Behav. 2012 Nov;25(3):417-25. doi: 10.1016/j.yebeh.2012.06.027. Epub 2012 Nov 1."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"FDA greenlights Neuroelectrics to help patients with Major Depression at home amidst Covid-19 restrictions - Neuroelectrics Blog - Latest news about EEG & Brain Stimulation (no date). Available at:https://www.neuroelectrics.com/blog/2020/05/15/fda-greenlights-neuroelectrics-to-treat-patients-with-major-depression-at-home/ (Accessed: 8 July 2020)."
                  },{
                    "ReferencePMID":"15999258",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fregni F, Boggio PS, Nitsche M, Bermpohl F, Antal A, Feredoes E, Marcolin MA, Rigonatti SP, Silva MT, Paulus W, Pascual-Leone A. Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory. Exp Brain Res. 2005 Sep;166(1):23-30. Epub 2005 Jul 6."
                  },{
                    "ReferencePMID":"16148743",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fregni F, Boggio PS, Mansur CG, Wagner T, Ferreira MJ, Lima MC, Rigonatti SP, Marcolin MA, Freedman SD, Nitsche MA, Pascual-Leone A. Transcranial direct current stimulation of the unaffected hemisphere in stroke patients. Neuroreport. 2005 Sep 28;16(14):1551-5."
                  },{
                    "ReferencePMID":"16817194",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fregni F, Boggio PS, Santos MC, Lima M, Vieira AL, Rigonatti SP, Silva MT, Barbosa ER, Nitsche MA, Pascual-Leone A. Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease. Mov Disord. 2006 Oct;21(10):1693-702."
                  },{
                    "ReferencePMID":"16542193",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A. Treatment of major depression with transcranial direct current stimulation. Bipolar Disord. 2006 Apr;8(2):203-4."
                  },{
                    "ReferencePMID":"32710772",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fregni F, El-Hagrassy MM, Pacheco-Barrios K, Carvalho S, Leite J, Simis M, Brunelin J, Nakamura-Palacios EM, Marangolo P, Venkatasubramanian G, San-Juan D, Caumo W, Bikson M, Brunoni AR; Neuromodulation Center Working Group. Evidence-based guidelines and secondary meta-analysis for the use of transcranial direct current stimulation (tDCS) in neurological and psychiatric disorders. Int J Neuropsychopharmacol. 2020 Jul 26. pii: pyaa051. doi: 10.1093/ijnp/pyaa051. [Epub ahead of print]"
                  },{
                    "ReferencePMID":"20434997",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fritsch B, Reis J, Martinowich K, Schambra HM, Ji Y, Cohen LG, Lu B. Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuron. 2010 Apr 29;66(2):198-204. doi: 10.1016/j.neuron.2010.03.035."
                  },{
                    "ReferencePMID":"22659303",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fu CH, Steiner H, Costafreda SG. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis. 2013 Apr;52:75-83. doi: 10.1016/j.nbd.2012.05.008. Epub 2012 Jun 1."
                  },{
                    "ReferencePMID":"24223470",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Gallegos J, Langley A, Villegas D. Anxiety, Depression, and Coping Skills Among Mexican School Children: A Comparison of Students With and Without Learning Disabilities. Learn Disabil Q. 2012 Feb 1;35(1). doi: 10.1177/0731948711428772."
                  },{
                    "ReferencePMID":"31165566",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Golberstein E, Gonzales G, Meara E. How do economic downturns affect the mental health of children? Evidence from the National Health Interview Survey. Health Econ. 2019 Aug;28(8):955-970. doi: 10.1002/hec.3885. Epub 2019 Jun 4."
                  },{
                    "ReferencePMID":"32286618",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Golberstein E, Wen H, Miller BF. Coronavirus Disease 2019 (COVID-19) and Mental Health for Children and Adolescents. JAMA Pediatr. 2020 Sep 1;174(9):819-820. doi: 10.1001/jamapediatrics.2020.1456."
                  },{
                    "ReferencePMID":"32123347",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. Epub 2020 Mar 2."
                  },{
                    "ReferencePMID":"32109013",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28."
                  },{
                    "ReferencePMID":"21145043",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Hamani C, Mayberg H, Stone S, Laxton A, Haber S, Lozano AM. The subcallosal cingulate gyrus in the context of major depression. Biol Psychiatry. 2011 Feb 15;69(4):301-8. doi: 10.1016/j.biopsych.2010.09.034. Epub 2010 Dec 8. Review."
                  },{
                    "ReferencePMID":"28229395",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Hameed MQ, Dhamne SC, Gersner R, Kaye HL, Oberman LM, Pascual-Leone A, Rotenberg A. Transcranial Magnetic and Direct Current Stimulation in Children. Curr Neurol Neurosci Rep. 2017 Feb;17(2):11. doi: 10.1007/s11910-017-0719-0. Review."
                  },{
                    "ReferencePMID":"20975857",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry. 2010 Oct;9(3):155-61."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Hedden, S. L. et al. (no date) Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health. Available at: http://www.samhsa.gov/data/ (Accessed: 26 April 2020)."
                  },{
                    "ReferencePMID":"11457424",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Herwig U, Padberg F, Unger J, Spitzer M, SchÃ¶nfeldt-Lecuona C. Transcranial magnetic stimulation in therapy studies: examination of the reliability of \"standard\" coil positioning by neuronavigation. Biol Psychiatry. 2001 Jul 1;50(1):58-61."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Hidalgo Vicario, M. H. and RodrÃ­guez HernÃ¡ndez, P. R. (2013) DSM-5. manual diagnÃ³stico y estadÃ­stico de los trastornos mentales. Ãºltimas novedades, Pediatria Integral."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Horvath, J. C., Najib, U. and Press, D. (2014) 'Transcranial magnetic stimulation (TMS) clinical applications: Therapeutics', Neuromethods. Humana Press Inc., 89, pp. 235-257. doi: 10.1007/978-1-4939-0879-0_12."
                  },{
                    "ReferencePMID":"28169833",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Huang Y, Liu AA, Lafon B, Friedman D, Dayan M, Wang X, Bikson M, Doyle WK, Devinsky O, Parra LC. Measurements and models of electric fields in the in vivo human brain during transcranial electric stimulation. Elife. 2017 Feb 7;6. pii: e18834. doi: 10.7554/eLife.18834. Erratum in: Elife. 2018 Feb 15;7:."
                  },{
                    "ReferencePMID":"30297323",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Huang Y, Parra LC. Can transcranial electric stimulation with multiple electrodes reach deep targets? Brain Stimul. 2019 Jan - Feb;12(1):30-40. doi: 10.1016/j.brs.2018.09.010. Epub 2018 Sep 26. Review."
                  },{
                    "ReferencePMID":"16270180",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Ilyukhina VA, Kozhushko NY, Matveev YK, Ponomareva EA, Chernysheva EM, Shaptilei MA. Transcranial micropolarization in the combined therapy of speech and general psychomotor retardation in children of late preschool age. Neurosci Behav Physiol. 2005 Nov;35(9):969-76."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"INEGI COMUNICADO DE PRENSA NUM. 455/19 10 DE SEPTIEMBRE DE 2019 PÃGINA 1/9 - Buscar con Google (no date). Available at: https://www.google.com/search?sxsrf=ALeKk01JBW760RYZRSJRSP54SHpa-UGe8Q%3A1592707941359&ei=ZcvuXp63FdiFtQbCzo_oAg&q=INEGI+COMUNICADO+DE+PRENSA+NUM.+455%2F19+10+DE+SEPTIEMBRE+DE+2019+PÃGINA+1%2F9&oq=INEGI+COMUNICADO+DE+PRENSA+NUM.+455%2F19+10+DE+SEPTIEMBRE+DE+2019+PÃGINA+1%2F9&gs_lcp=CgZwc3ktYWIQAzIECAAQRzIECAAQRzIECAAQRzIECAAQRzIECAAQRzIECAAQRzIECAAQRzIECAAQR1AAWABgnBhoAHABeACAAQCIAQCSAQCYAQCqAQdnd3Mtd2l6&sclient=psy-ab&ved=0ahUKEwje_cy485HqAhXYQs0KHULnAy0Q4dUDCAw&uact=5 (Accessed: 20 June 2020)."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Marcela CÃ¡rdenas Miriam Feria Lino Palacios Francisco de la PeÃ±a GUÃAS, E. et al. (2010) CLÃNICAS PARA LA ATENCIÃ“N DE TRASTORNOS MENTALES GuÃ­a clÃ­nica para los trastornos de ansiedad en niÃ±os y adolescentes, Instituto Nacional de PsiquiatrÃ­a RamÃ³n de la Fuente MuÃ±iz. Available at: https://s3.amazonaws.com/academia.edu.documents/40579737/trastornos_de_ansiedad.pdf?AWSAc cessKeyId=AKIAIWOWYYGZ2Y53UL3A&Expires=1524569155&Signature=VyM4VFWuFjyCkOY4Ml 7rnE2WN10%3D&response-content-disposition=inline%3B filename%3DTrastornos_de_ansiedad. (Accessed: 14 April 2020)."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Rey, Joseph M; Bella-Awusah, Tolulope T; Liu, J. (2017) 'DepresiÃ³n E.1 Manual de Salud Mental Infantil y Adolescente de la IACAPAP de la Sociedad AsiÃ¡tica de PsiquiatrÃ­a Infantil y Adolescente y Profesionales Afines Conflictos de interÃ©s: No se declaran', pp. 1-41."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Tamayo, J. M. et al. (2011) DefiniciÃ³n e impacto de las depresiones resistentes/refractarias al tratamiento, ActualizaciÃ³n por temas Salud Mental."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Tochoy, P. P. and Chaskel, R. (no date) 'DepresiÃ³n en niÃ±os y adolescentes', pp. 30-38."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Ulloa-Flores, R. E. and De La PeÃ±a-Olvera, F. (2011) Tratamiento multimodal de niÃ±os y adolescentes con depresiÃ³n, ArtÃ­culo original Salud Mental."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"World Health Organization (2020a) Situation Report-75 HIGHLIGHTS. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200404-sitrep-75-covid- 19.pdf?sfvrsn=99251b2b_2 (Accessed: 4 April 2020)."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"World Health Organization (2020b) WHO Director-General ' s remarks at the media briefing on 2019-nCoV on 11 February. Available at: https://www.who.int/dg/speeches/detail/who-director-general- s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed: 2 April 2020)."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"World Health Organization, W. (2020a) Situation Report-83 HIGHLIGHTS. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200412-sitrep-83-covid- 19.pdf?sfvrsn=697ce98d_4 (Accessed: 12 April 2020)."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"World Health Organization, W. (2020b) WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020, WHO Director General's speeches. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media- briefing-on-covid-19---3-march-2020 (Accessed: 2 April 2020)."
                  },{
                    "ReferencePMID":"31683491",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Jiang N, Wei J, Li G, Wei B, Zhu FF, Hu Y. Effect of dry-electrode-based transcranial direct current stimulation on chronic low back pain and low back muscle activities: A double-blind sham-controlled study. Restor Neurol Neurosci. 2020;38(1):41-54. doi: 10.3233/RNN-190922."
                  },{
                    "ReferencePMID":"32570296",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Kontoangelos K, Economou M, Papageorgiou C. Mental Health Effects of COVID-19 Pandemia: A Review of Clinical and Psychological Traits. Psychiatry Investig. 2020 Jun;17(6):491-505. doi: 10.30773/pi.2020.0161. Epub 2020 Jun 15."
                  },{
                    "ReferencePMID":"17591596",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Kuo MF, Paulus W, Nitsche MA. Boosting focally-induced brain plasticity by dopamine. Cereb Cortex. 2008 Mar;18(3):648-51. Epub 2007 Jun 24."
                  },{
                    "ReferencePMID":"22189047",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. 2012 Mar 17;379(9820):1045-55. doi: 10.1016/S0140-6736(11)60602-8. Epub 2011 Dec 19. Review."
                  },{
                    "ReferencePMID":"27866120",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29. Review."
                  },{
                    "ReferencePMID":"9827321",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev. 1998 Nov;18(7):765-94. Review."
                  },{
                    "ReferencePMID":"12244081",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Liebetanz D, Nitsche MA, Tergau F, Paulus W. Pharmacological approach to the mechanisms of transcranial DC-stimulation-induced after-effects of human motor cortex excitability. Brain. 2002 Oct;125(Pt 10):2238-47."
                  },{
                    "ReferencePMID":"19403329",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Liebetanz D, Koch R, Mayenfels S, KÃ¶nig F, Paulus W, Nitsche MA. Safety limits of cathodal transcranial direct current stimulation in rats. Clin Neurophysiol. 2009 Jun;120(6):1161-7. doi: 10.1016/j.clinph.2009.01.022. Epub 2009 Apr 28."
                  },{
                    "ReferencePMID":"19671217",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Loo CK, Sachdev P, Martin D, Pigot M, Alonzo A, Malhi GS, Lagopoulos J, Mitchell P. A double-blind, sham-controlled trial of transcranial direct current stimulation for the treatment of depression. Int J Neuropsychopharmacol. 2010 Feb;13(1):61-9. doi: 10.1017/S1461145709990411. Epub 2009 Aug 12."
                  },{
                    "ReferencePMID":"22215866",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry. 2012 Jan;200(1):52-9. doi: 10.1192/bjp.bp.111.097634."
                  },{
                    "ReferencePMID":"29111077",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM, McClintock SM, Mohan A, Lisanby SH; International Consortium of Research in tDCS (ICRT). International randomized-controlled trial of transcranial Direct Current Stimulation in depression. Brain Stimul. 2018 Jan - Feb;11(1):125-133. doi: 10.1016/j.brs.2017.10.011. Epub 2017 Oct 27."
                  },{
                    "ReferencePMID":"19332318",
                    "ReferenceType":"result",
                    "ReferenceCitation":"LÃ¶scher W, Cole AJ, McLean MJ. Commentary: physical approaches for the treatment of epilepsy: electrical and magnetic stimulation and cooling. Neurotherapeutics. 2009 Apr;6(2):258-62. doi: 10.1016/j.nurt.2009.01.014. Review."
                  },{
                    "ReferencePMID":"31575486",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Maceira-Elvira P, Popa T, Schmid AC, Hummel FC. Feasibility of home-based, self-applied transcranial direct current stimulation to enhance motor learning in middle-aged and older adults. Brain Stimul. 2020 Jan - Feb;13(1):247-249. doi: 10.1016/j.brs.2019.08.014. Epub 2019 Sep 24."
                  },{
                    "ReferencePMID":"30396512",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Malhi GS, Mann JJ. Depression. Lancet. 2018 Nov 24;392(10161):2299-2312. doi: 10.1016/S0140-6736(18)31948-2. Epub 2018 Nov 2. Review."
                  },{
                    "ReferencePMID":"22032743",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Mattai A, Miller R, Weisinger B, Greenstein D, Bakalar J, Tossell J, David C, Wassermann EM, Rapoport J, Gogtay N. Tolerability of transcranial direct current stimulation in childhood-onset schizophrenia. Brain Stimul. 2011 Oct;4(4):275-80. doi: 10.1016/j.brs.2011.01.001. Epub 2011 Feb 1."
                  },{
                    "ReferencePMID":"11063978",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000 Oct 15;48(8):830-43."
                  },{
                    "ReferencePMID":"15987799",
                    "ReferenceType":"result",
                    "ReferenceCitation":"McCaig CD, Rajnicek AM, Song B, Zhao M. Controlling cell behavior electrically: current views and future potential. Physiol Rev. 2005 Jul;85(3):943-78. Review."
                  },{
                    "ReferencePMID":"29066167",
                    "ReferenceType":"result",
                    "ReferenceCitation":"McLaren ME, Nissim NR, Woods AJ. The effects of medication use in transcranial direct current stimulation: A brief review. Brain Stimul. 2018 Jan - Feb;11(1):52-58. doi: 10.1016/j.brs.2017.10.006. Epub 2017 Oct 12. Review."
                  },{
                    "ReferencePMID":"19853048",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Merzagora AC, Foffani G, Panyavin I, Mordillo-Mateos L, Aguilar J, Onaral B, Oliviero A. Prefrontal hemodynamic changes produced by anodal direct current stimulation. Neuroimage. 2010 Feb 1;49(3):2304-10. doi: 10.1016/j.neuroimage.2009.10.044. Epub 2009 Oct 21."
                  },{
                    "ReferencePMID":"26321911",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Munz MT, Prehn-Kristensen A, Thielking F, MÃ¶lle M, GÃ¶der R, Baving L. Slow oscillating transcranial direct current stimulation during non-rapid eye movement sleep improves behavioral inhibition in attention-deficit/hyperactivity disorder. Front Cell Neurosci. 2015 Aug 11;9:307. doi: 10.3389/fncel.2015.00307. eCollection 2015."
                  },{
                    "ReferencePMID":"9164317",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997 May 17;349(9063):1436-42."
                  },{
                    "ReferencePMID":"23273725",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Musazzi L, Treccani G, Mallei A, Popoli M. The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol Psychiatry. 2013 Jun 15;73(12):1180-8. doi: 10.1016/j.biopsych.2012.11.009. Epub 2012 Dec 28. Review."
                  },{
                    "ReferencePMID":"25309825",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Ngernyam N, Jensen MP, Auvichayapat N, Punjaruk W, Auvichayapat P. Transcranial Direct Current Stimulation in Neuropathic Pain. J Pain Relief. 2013 Apr 21;Suppl 3. pii: 001."
                  },{
                    "ReferencePMID":"14677403",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nitsche MA, Liebetanz D, Antal A, Lang N, Tergau F, Paulus W. Modulation of cortical excitability by weak direct current stimulation--technical, safety and functional aspects. Suppl Clin Neurophysiol. 2003;56:255-76. Review."
                  },{
                    "ReferencePMID":"12949224",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nitsche MA, Fricke K, Henschke U, Schlitterlau A, Liebetanz D, Lang N, Henning S, Tergau F, Paulus W. Pharmacological modulation of cortical excitability shifts induced by transcranial direct current stimulation in humans. J Physiol. 2003 Nov 15;553(Pt 1):293-301. Epub 2003 Aug 29."
                  },{
                    "ReferencePMID":"15147306",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nitsche MA, Liebetanz D, Schlitterlau A, Henschke U, Fricke K, Frommann K, Lang N, Henning S, Paulus W, Tergau F. GABAergic modulation of DC stimulation-induced motor cortex excitability shifts in humans. Eur J Neurosci. 2004 May;19(10):2720-6."
                  },{
                    "ReferencePMID":"15351385",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nitsche MA, Niehaus L, Hoffmann KT, Hengst S, Liebetanz D, Paulus W, Meyer BU. MRI study of human brain exposed to weak direct current stimulation of the frontal cortex. Clin Neurophysiol. 2004 Oct;115(10):2419-23."
                  },{
                    "ReferencePMID":"16002441",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nitsche MA, Seeber A, Frommann K, Klein CC, Rochford C, Nitsche MS, Fricke K, Liebetanz D, Lang N, Antal A, Paulus W, Tergau F. Modulating parameters of excitability during and after transcranial direct current stimulation of the human motor cortex. J Physiol. 2005 Oct 1;568(Pt 1):291-303. Epub 2005 Jul 7."
                  },{
                    "ReferencePMID":"20633386",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, Paulus W, Hummel F, Boggio PS, Fregni F, Pascual-Leone A. Transcranial direct current stimulation: State of the art 2008. Brain Stimul. 2008 Jul;1(3):206-23. doi: 10.1016/j.brs.2008.06.004. Epub 2008 Jul 1. Review."
                  },{
                    "ReferencePMID":"10990547",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3:633-9."
                  },{
                    "ReferencePMID":"11723286",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nitsche MA, Paulus W. Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. Neurology. 2001 Nov 27;57(10):1899-901."
                  },{
                    "ReferencePMID":"27535462",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Opitz A, Falchier A, Yan CG, Yeagle EM, Linn GS, Megevand P, Thielscher A, Deborah A R, Milham MP, Mehta AD, Schroeder CE. Spatiotemporal structure of intracranial electric fields induced by transcranial electric stimulation in humans and nonhuman primates. Sci Rep. 2016 Aug 18;6:31236. doi: 10.1038/srep31236."
                  },{
                    "ReferencePMID":"32559282",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Otto WR, Geoghegan S, Posch LC, Bell LM, Coffin SE, Sammons JS, Harris RM, Odom John AR, Luan X, Gerber JS. The Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Healthcare Network in the United States. J Pediatric Infect Dis Soc. 2020 Nov 10;9(5):523-529. doi: 10.1093/jpids/piaa074."
                  },{
                    "ReferencePMID":"27173384",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Palm U, Segmiller FM, Epple AN, Freisleder FJ, Koutsouleris N, Schulte-KÃ¶rne G, Padberg F. Transcranial direct current stimulation in children and adolescents: a comprehensive review. J Neural Transm (Vienna). 2016 Oct;123(10):1219-34. doi: 10.1007/s00702-016-1572-z. Epub 2016 May 12. Review."
                  },{
                    "ReferencePMID":"28870754",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Paniccia M, Paniccia D, Thomas S, Taha T, Reed N. Clinical and non-clinical depression and anxiety in young people: A scoping review on heart rate variability. Auton Neurosci. 2017 Dec;208:1-14. doi: 10.1016/j.autneu.2017.08.008. Epub 2017 Aug 26. Review."
                  },{
                    "ReferencePMID":"25522391",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Pelletier SJ, Cicchetti F. Cellular and molecular mechanisms of action of transcranial direct current stimulation: evidence from in vitro and in vivo models. Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu047. doi: 10.1093/ijnp/pyu047. Review."
                  },{
                    "ReferencePMID":"22193671",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704."
                  },{
                    "ReferencePMID":"25153776",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Prehn-Kristensen A, Munz M, GÃ¶der R, Wilhelm I, Korr K, Vahl W, Wiesner CD, Baving L. Transcranial oscillatory direct current stimulation during sleep improves declarative memory consolidation in children with attention-deficit/hyperactivity disorder to a level comparable to healthy controls. Brain Stimul. 2014 Nov-Dec;7(6):793-9. doi: 10.1016/j.brs.2014.07.036. Epub 2014 Jul 23."
                  },{
                    "ReferencePMID":"9694210",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Priori A, Berardelli A, Rona S, Accornero N, Manfredi M. Polarization of the human motor cortex through the scalp. Neuroreport. 1998 Jul 13;9(10):2257-60."
                  },{
                    "ReferencePMID":"22341482",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Rafful C, Medina-Mora ME, Borges G, Benjet C, Orozco R. Depression, gender, and the treatment gap in Mexico. J Affect Disord. 2012 Apr;138(1-2):165-9. doi: 10.1016/j.jad.2011.12.040. Epub 2012 Feb 14."
                  },{
                    "ReferencePMID":"21068312",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Reato D, Rahman A, Bikson M, Parra LC. Low-intensity electrical stimulation affects network dynamics by modulating population rate and spike timing. J Neurosci. 2010 Nov 10;30(45):15067-79. doi: 10.1523/JNEUROSCI.2059-10.2010."
                  },{
                    "ReferencePMID":"16794566",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF; ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006 Sep;31(9):1841-53. Epub 2006 Jun 21. Review."
                  },{
                    "ReferencePMID":"21890211",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Sacher J, Neumann J, FÃ¼nfstÃ¼ck T, Soliman A, Villringer A, Schroeter ML. Mapping the depressed brain: a meta-analysis of structural and functional alterations in major depressive disorder. J Affect Disord. 2012 Oct;140(2):142-8. doi: 10.1016/j.jad.2011.08.001. Epub 2011 Sep 3."
                  },{
                    "ReferencePMID":"31988433",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Salloum NC, Fava M, Ball S, Papakostas GI. Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review. Mol Psychiatry. 2020 Sep;25(9):1967-1974. doi: 10.1038/s41380-020-0646-3. Epub 2020 Jan 27. Review."
                  },{
                    "ReferencePMID":"23920122",
                    "ReferenceType":"result",
                    "ReferenceCitation":"SÃ¤mann PG, HÃ¶hn D, Chechko N, Kloiber S, Lucae S, Ising M, Holsboer F, Czisch M. Prediction of antidepressant treatment response from gray matter volume across diagnostic categories. Eur Neuropsychopharmacol. 2013 Nov;23(11):1503-15. doi: 10.1016/j.euroneuro.2013.07.004. Epub 2013 Aug 3."
                  },{
                    "ReferencePMID":"21167786",
                    "ReferenceType":"result",
                    "ReferenceCitation":"San-Juan D, CalcÃ¡neo Jde D, GonzÃ¡lez-AragÃ³n MF, BermÃºdez Maldonado L, AvellÃ¡n AM, Argumosa EV, Fregni F. Transcranial direct current stimulation in adolescent and adult Rasmussen's encephalitis. Epilepsy Behav. 2011 Jan;20(1):126-31. doi: 10.1016/j.yebeh.2010.10.031. Epub 2010 Dec 17."
                  },{
                    "ReferencePMID":"23851401",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Schestatsky P, Morales-Quezada L, Fregni F. Simultaneous EEG monitoring during transcranial direct current stimulation. J Vis Exp. 2013 Jun 17;(76). doi: 10.3791/50426."
                  },{
                    "ReferencePMID":"21631313",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Schneider HD, Hopp JP. The use of the Bilingual Aphasia Test for assessment and transcranial direct current stimulation to modulate language acquisition in minimally verbal children with autism. Clin Linguist Phon. 2011 Jun;25(6-7):640-54. doi: 10.3109/02699206.2011.570852. Epub 2011 Jun 1."
                  },{
                    "ReferencePMID":"24486425",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Segrave RA, Arnold S, Hoy K, Fitzgerald PB. Concurrent cognitive control training augments the antidepressant efficacy of tDCS: a pilot study. Brain Stimul. 2014 Mar-Apr;7(2):325-31. doi: 10.1016/j.brs.2013.12.008. Epub 2013 Dec 19."
                  },{
                    "ReferencePMID":"32221973",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Sorbello M, El-Boghdadly K, Di Giacinto I, Cataldo R, Esposito C, Falcetta S, Merli G, Cortese G, Corso RM, Bressan F, Pintaudi S, Greif R, Donati A, Petrini F; SocietÃ  Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva (SIAARTI) Airway Research Group, and The European Airway Management Society. The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice. Anaesthesia. 2020 Jun;75(6):724-732. doi: 10.1111/anae.15049. Epub 2020 Mar 30."
                  },{
                    "ReferencePMID":"29213226",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Thair H, Holloway AL, Newport R, Smith AD. Transcranial Direct Current Stimulation (tDCS): A Beginner's Guide for Design and Implementation. Front Neurosci. 2017 Nov 22;11:641. doi: 10.3389/fnins.2017.00641. eCollection 2017."
                  },{
                    "ReferencePMID":"32240634",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, CucunubÃ¡ Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-677. doi: 10.1016/S1473-3099(20)30243-7. Epub 2020 Mar 30. Erratum in: Lancet Infect Dis. 2020 Apr 15;:. Lancet Infect Dis. 2020 May 4;:."
                  },{
                    "ReferencePMID":"23893039",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Villamar MF, Volz MS, Bikson M, Datta A, Dasilva AF, Fregni F. Technique and considerations in the use of 4x1 ring high-definition transcranial direct current stimulation (HD-tDCS). J Vis Exp. 2013 Jul 14;(77):e50309. doi: 10.3791/50309."
                  },{
                    "ReferencePMID":"29396478",
                    "ReferenceType":"result",
                    "ReferenceCitation":"VÃ¶rÃ¶slakos M, Takeuchi Y, Brinyiczki K, Zombori T, Oliva A, FernÃ¡ndez-Ruiz A, KozÃ¡k G, Kincses ZT, IvÃ¡nyi B, BuzsÃ¡ki G, BerÃ©nyi A. Direct effects of transcranial electric stimulation on brain circuits in rats and humans. Nat Commun. 2018 Feb 2;9(1):483. doi: 10.1038/s41467-018-02928-3."
                  },{
                    "ReferencePMID":"31986257",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 29;:."
                  },{
                    "ReferencePMID":"32329784",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Xie X, Xue Q, Zhou Y, Zhu K, Liu Q, Zhang J, Song R. Mental Health Status Among Children in Home Confinement During the Coronavirus Disease 2019 Outbreak in Hubei Province, China. JAMA Pediatr. 2020 Sep 1;174(9):898-900. doi: 10.1001/jamapediatrics.2020.1619."
                  },{
                    "ReferencePMID":"31413023",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Yan T, Goldman RD. Time-to-effect of fluoxetine in children with depression. Can Fam Physician. 2019 Aug;65(8):549-551."
                  },{
                    "ReferencePMID":"32226295",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020 Mar 15;16(10):1753-1766. doi: 10.7150/ijbs.45134. eCollection 2020. Review."
                  },{
                    "ReferencePMID":"28330592",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Yip AG, George MS, Tendler A, Roth Y, Zangen A, Carpenter LL. 61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial. Brain Stimul. 2017 Jul - Aug;10(4):847-849. doi: 10.1016/j.brs.2017.02.013. Epub 2017 Mar 10."
                  },{
                    "ReferencePMID":"32091533",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648."
                  },{
                    "ReferencePMID":"32289678",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Zewdie E, Ciechanski P, Kuo HC, Giuffre A, Kahl C, King R, Cole L, Godfrey H, Seeger T, Swansburg R, Damji O, Rajapakse T, Hodge J, Nelson S, Selby B, Gan L, Jadavji Z, Larson JR, MacMaster F, Yang JF, Barlow K, Gorassini M, Brunton K, Kirton A. Safety and tolerability of transcranial magnetic and direct current stimulation in children: Prospective single center evidence from 3.5 million stimulations. Brain Stimul. 2020 May - Jun;13(3):565-575. doi: 10.1016/j.brs.2019.12.025. Epub 2019 Dec 30."
                  },{
                    "ReferencePMID":"32363492",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Zhou SJ, Zhang LG, Wang LL, Guo ZC, Wang JQ, Chen JC, Liu M, Chen X, Chen JX. Prevalence and socio-demographic correlates of psychological health problems in Chinese adolescents during the outbreak of COVID-19. Eur Child Adolesc Psychiatry. 2020 Jun;29(6):749-758. doi: 10.1007/s00787-020-01541-4. Epub 2020 May 3."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No",
              "IPDSharingDescription":"Personal data information will remain with strictly confidential character in the research center. However, personal data will be examined by all individuals related to the research project and/or those selected for its analysis, including representatives of Mexican health authorities and other regulatory agencies with inspection purposes.\n\nIf the data obtained through this study is published, the report will be written in a way no person could identify their personal data or identity, unless such information is officially required by any mexican or foreign authority."
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003866",
                    "ConditionMeshTerm":"Depressive Disorder"
                  },{
                    "ConditionMeshId":"D000003863",
                    "ConditionMeshTerm":"Depression"
                  },{
                    "ConditionMeshId":"D000003865",
                    "ConditionMeshTerm":"Depressive Disorder, Major"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000019964",
                    "ConditionAncestorTerm":"Mood Disorders"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  },{
                    "ConditionAncestorId":"D000001526",
                    "ConditionAncestorTerm":"Behavioral Symptoms"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5641",
                    "ConditionBrowseLeafName":"Depression",
                    "ConditionBrowseLeafAsFound":"Depressive Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5644",
                    "ConditionBrowseLeafName":"Depressive Disorder",
                    "ConditionBrowseLeafAsFound":"Depressive Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5643",
                    "ConditionBrowseLeafName":"Depressive Disorder, Major",
                    "ConditionBrowseLeafAsFound":"Major Depressive Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M20419",
                    "ConditionBrowseLeafName":"Mood Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3399",
                    "ConditionBrowseLeafName":"Behavioral Symptoms",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000005473",
                    "InterventionMeshTerm":"Fluoxetine"
                  },{
                    "InterventionMeshId":"D000000928",
                    "InterventionMeshTerm":"Antidepressive Agents"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000017367",
                    "InterventionAncestorTerm":"Serotonin Uptake Inhibitors"
                  },{
                    "InterventionAncestorId":"D000014179",
                    "InterventionAncestorTerm":"Neurotransmitter Uptake Inhibitors"
                  },{
                    "InterventionAncestorId":"D000049990",
                    "InterventionAncestorTerm":"Membrane Transport Modulators"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  },{
                    "InterventionAncestorId":"D000018377",
                    "InterventionAncestorTerm":"Neurotransmitter Agents"
                  },{
                    "InterventionAncestorId":"D000018490",
                    "InterventionAncestorTerm":"Serotonin Agents"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  },{
                    "InterventionAncestorId":"D000018687",
                    "InterventionAncestorTerm":"Antidepressive Agents, Second-Generation"
                  },{
                    "InterventionAncestorId":"D000011619",
                    "InterventionAncestorTerm":"Psychotropic Drugs"
                  },{
                    "InterventionAncestorId":"D000065690",
                    "InterventionAncestorTerm":"Cytochrome P-450 CYP2D6 Inhibitors"
                  },{
                    "InterventionAncestorId":"D000065607",
                    "InterventionAncestorTerm":"Cytochrome P-450 Enzyme Inhibitors"
                  },{
                    "InterventionAncestorId":"D000004791",
                    "InterventionAncestorTerm":"Enzyme Inhibitors"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M7184",
                    "InterventionBrowseLeafName":"Fluoxetine",
                    "InterventionBrowseLeafAsFound":"Treatment arm",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M2828",
                    "InterventionBrowseLeafName":"Antidepressive Agents",
                    "InterventionBrowseLeafAsFound":"In vitro",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M14095",
                    "InterventionBrowseLeafName":"Serotonin",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M18232",
                    "InterventionBrowseLeafName":"Serotonin Uptake Inhibitors",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19088",
                    "InterventionBrowseLeafName":"Neurotransmitter Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M13057",
                    "InterventionBrowseLeafName":"Psychotropic Drugs",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M29124",
                    "InterventionBrowseLeafName":"Cytochrome P-450 Enzyme Inhibitors",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"PsychDr",
                    "InterventionBrowseBranchName":"Psychotropic Drugs"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":49,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780139",
              "OrgStudyIdInfo":{
                "OrgStudyId":"FMASU R 25/2020/2021"
              },
              "Organization":{
                "OrgFullName":"Ain Shams University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Ultrasonographic Evaluation of Internal Jugular Vein Cross Sectional Area for Prediction of Post Spinal Hypotension",
              "OfficialTitle":"Ultrasonographic Evaluation of Internal Jugular Vein Cross Sectional Area for Prediction of Post Spinal Hypotension in Patients Undergoing Orthopedic Surgeries"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"May 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"May 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Walid Nofal",
                "ResponsiblePartyInvestigatorTitle":"Assisstant professor",
                "ResponsiblePartyInvestigatorAffiliation":"Ain Shams University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Ain Shams University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The aim of this study is to evaluate the efficacy of internal jugular cross sectional area for predicting the occurrence of PSAH.",
              "DetailedDescription":"The aim of this study is to evaluate the efficacy of internal jugular cross sectional area for predicting the occurrence of PSAH. Spinal anaesthesia is frequently used in daily clinical practice. Postspinal anaesthesia hypotension (PSAH) is a common side effect with an incidence of 15.3 to 33% that may result in organ hypoperfusion and ischaemic events. Patients' susceptibility to intraoperative hypotension can be influenced by the sensory block level, age, preoperative volume status , physical status, pre-operative medications and fasting.\n\nPSAH due to spinal blockade is principally a consequence of diminished systemic vascular resistance after blockade of preganglionic sympathetic fibres. Many attempts have been tried to prevent PSAH, such as intravenous volume preload or prophylactic vasopressors. However, fluid infusion has been proved to lower the incidence of PSAH and significantly decrease vasopressor requirements. At the same time, empirical volume loading carries the potential of volume overload, particularly in patients with cardiac disease. Consequently, the search for predictors of PSAH is becoming mandatory to avoid blind volume loading and reserve it only for patients who are expected to develop PSAH. .\n\n."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Post-spinal Anesthesia Hypotension"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "internal jugular vein",
                  "ultrasound",
                  "spinal anesthesia",
                  "Hypotension"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Ecologic or Community"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"62",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Diagnostic Test",
                    "InterventionName":"Ultrasonographic Evaluation of Internal Jugular Vein Cross Sectional Area",
                    "InterventionDescription":"Measuring the internal jugular vein cross section area and relate this to the incidence of hypotension after spinal anesthesia."
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Predictive value of internal jugular vein (IJV) cross sectional area.",
                    "PrimaryOutcomeDescription":"The primary outcome is to evaluate the predictive value of internal jugular diameter cross sectional area for detecting PSAH",
                    "PrimaryOutcomeTimeFrame":"30 minutes"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\npatients more than 40 years of age with American Society of Anesthesiologists' (ASA) physical status 1 or 2 who will be scheduled for elective surgery under spinal anaesthesia in the supine position.\n\nExclusion Criteria:\n\nBMI more than 35 kg m2 , taking angiotensin converting enzyme inhibitors, pregnant women, emergency cases, absolute or relative contraindications to spinal anaesthesia, Also, patients with a baseline arterial systolic blood pressure less than 90 mmHg or mean arterial blood pressure (MBP) less than 70 mmHg will be excluded",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"40 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"patients more than 40 years of age with American Society of Anesthesiologists' (ASA) physical status 1 or 2 who will be scheduled for elective orthopedic surgery under spinal anaesthesia in the supine position",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"WALID Nofal, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"01097121743",
                    "CentralContactEMail":"w201077@yahoo.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Sanaa Farag Mahmoud, MD",
                    "OverallOfficialAffiliation":"Anesthesiology Department, Faculty of Medicine, Ain Shams University",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Eman Sabek, MD",
                    "OverallOfficialAffiliation":"Radiology department, National Centre of Radiation Research and Technology, Atomic Energy Authority",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"WALID Nofal, MD",
                    "OverallOfficialAffiliation":"Anesthesiology department, Faculty of Medicine, Ain Shams Unive",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000007022",
                    "ConditionMeshTerm":"Hypotension"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000014652",
                    "ConditionAncestorTerm":"Vascular Diseases"
                  },{
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8655",
                    "ConditionBrowseLeafName":"Hypotension",
                    "ConditionBrowseLeafAsFound":"Hypotension",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M15983",
                    "ConditionBrowseLeafName":"Vascular Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T4202",
                    "ConditionBrowseLeafName":"Oculocerebral Syndrome With Hypopigmentation",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2688",
                    "InterventionBrowseLeafName":"Anesthetics",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"CNSDep",
                    "InterventionBrowseBranchName":"Central Nervous System Depressants"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":50,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780126",
              "OrgStudyIdInfo":{
                "OrgStudyId":"21/090-E_COVID"
              },
              "Organization":{
                "OrgFullName":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Sarco-COVID Study: Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19",
              "OfficialTitle":"Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19",
              "Acronym":"SARCO-COVID"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 26, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 30, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"May 31, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 19, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Yale Tung Chen",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The COVID-19 pandemic is having a devastating global impact, and older adults who experience it are at higher risk of death from the disease. However, survivors of the disease have a greater risk of suffering from pathologies such as sarcopenia, which is more frequent in younger adults and with greater severity of the disease.\n\nSarcopenia is present in 5-13% of people between 60 and 70 years old and in 11-50% of the population over 80 years of age. The diagnosis of sarcopenia has advanced in recent years by establishing homogeneous criteria in different consensuses that necessarily combine two elements: generalized loss of strength accompanied by loss of skeletal muscle mass. Today there are three consensuses for the diagnosis of sarcopenia: the international (IWGS), the European (EWGSOP), and the most recent from a US cohort (FNIH). In all of them, the measurement of skeletal muscle mass constitutes one of the two diagnostic criteria.\n\nThe main methods to measure this muscle loss that are established are imaging techniques (computerized tomography (CT), magnetic resonance imaging (MRI), dual-energy X-ray absorptiometry (DEXA) and ultrasound.\n\nThe most common ultrasound measurements used for this purpose are the muscle thickness (cm) at the point of the ultrasound path of maximum muscle thickness, the cross-sectional area (area calculated by the basic software at the point of maximum muscle thickness), and the pennation angle (angle formed between deep muscle fascia and muscle fibers). The first two measurements can be made on several long muscles, while the pennation angle is usually made primarily on the medial gastrocnemius (internal twin) muscle. They are easy to obtain, bloodless, and reproducible measurements.\n\nResearch efforts at this point in the pandemic should focus on the longer-term consequences of the disease, sequelae such as sarcopenia in patients who have suffered from COVID-19. At the same time, clinicians must become increasingly aware of the condition and its measurement integrated into clinical practice. The knowledge provided by studies such as the one presented will allow the development of specific interventions.\n\nThe risk of sarcopenia should be considered when carrying out a risk / benefit assessment of the established treatment (for example, dexamethasone), and considering a multidisciplinary treatment that includes dietary inputs.",
              "DetailedDescription":"Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included. The prevalence of sarcopenia in hospitalized patients is 15-20%. Assuming an alpha risk of 0.05 and a beta risk of 0.2 in a unilateral contrast, 64 subjects are required to detect a difference equal to or greater than 20% loss of muscle mass. A loss to follow-up rate of 0% has been estimated."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Sarcopenia",
                  "Covid19"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "sarcopenia",
                  "covid19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"Yes",
              "TargetDuration":"1 Month",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Ecologic or Community"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"64",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"COVID-19 pneumonia patients",
                    "ArmGroupDescription":"Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Sarcopenia diagnosis"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Sarcopenia diagnosis",
                    "InterventionDescription":"History, physical, laboratory and ultrasound parameters to diagnose sarcopenia",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "COVID-19 pneumonia patients"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Loss of muscle mass",
                    "PrimaryOutcomeDescription":"Quantify the loss of muscle mass in hospitalized patients in areas of Internal Medicine with a diagnosis of COVID-19",
                    "PrimaryOutcomeTimeFrame":"1 month"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Prevalence of sarcopenia",
                    "SecondaryOutcomeDescription":"Analyze the clinical characteristics and the prevalence of sarcopenia in the patients included in the study.",
                    "SecondaryOutcomeTimeFrame":"1 month"
                  },{
                    "SecondaryOutcomeMeasure":"Normal values of muscle ultrasound thickness",
                    "SecondaryOutcomeDescription":"Analyze the thickness of the rectus femoris, vastus medialis, vastus lateralis, medial gastrocnemius in all patients.",
                    "SecondaryOutcomeTimeFrame":"1 month"
                  },{
                    "SecondaryOutcomeMeasure":"C reactive protein (CRP) correlated to the presence of sarcopenia",
                    "SecondaryOutcomeDescription":"Analyze the correlation between CRP and the presence of sarcopenia",
                    "SecondaryOutcomeTimeFrame":"1 month"
                  },{
                    "SecondaryOutcomeMeasure":"Therapy with corticosteroids impact on muscle thickness",
                    "SecondaryOutcomeDescription":"Determine the correlation between muscle thickness and the corticotherapy received (dexamethasone, methylprednisolone, prednisone)",
                    "SecondaryOutcomeTimeFrame":"1 month"
                  },{
                    "SecondaryOutcomeMeasure":"Normal values of medial gastrocnemius pennation angle in all patients",
                    "SecondaryOutcomeDescription":"Measure medial gastrocnemius pennation angle in all patients",
                    "SecondaryOutcomeTimeFrame":"1 month"
                  },{
                    "SecondaryOutcomeMeasure":"Ferritin correlated to the presence of sarcopenia",
                    "SecondaryOutcomeDescription":"Analyze the correlation between Ferritin and the presence of sarcopenia",
                    "SecondaryOutcomeTimeFrame":"1 month"
                  },{
                    "SecondaryOutcomeMeasure":"Fibrinogen correlated to the presence of sarcopenia",
                    "SecondaryOutcomeDescription":"Analyze the correlation between Fibrinogen and the presence of sarcopenia",
                    "SecondaryOutcomeTimeFrame":"1 month"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nOver 18 years old, men or women.\nMain diagnosis is pneumonia due to COVID-19\nSubjects who, after having received information about the design, the purposes of the project, the possible risks that may arise from it and who at any time may deny their collaboration, verbally grant their consent to participate in the study.\n\nExclusion Criteria:\n\nRefusal of the patient to participate in the study.\nPresent a malignant neoplasm in active phase except spino- or basal cell Ca in local stage\nClinical situation of agony.\nAmputation of limb (s).",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included.",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Yale Tung Chen, MD PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"0034676030131",
                    "CentralContactEMail":"yale.tung@salud.madrid.org"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Yale Tung Chen, MD PhD",
                    "OverallOfficialAffiliation":"Hospital Universitario Puerta de Hierro",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Hospital de Emergencias Isabel Zendal",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Madrid",
                    "LocationZip":"28046",
                    "LocationCountry":"Spain",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Yale Tung Chen, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"2816807",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19-21, 1988. Am J Clin Nutr. 1989 Nov;50(5 Suppl):1121-235."
                  },{
                    "ReferencePMID":"21475695",
                    "ReferenceType":"result",
                    "ReferenceCitation":"von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):129-133. Epub 2010 Dec 17."
                  },{
                    "ReferencePMID":"20392703",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, TopinkovÃ¡ E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13."
                  },{
                    "ReferencePMID":"21527165",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011 May;12(4):249-56. doi: 10.1016/j.jamda.2011.01.003. Epub 2011 Mar 4."
                  },{
                    "ReferencePMID":"24737557",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58. doi: 10.1093/gerona/glu010."
                  },{
                    "ReferencePMID":"28703496",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nijholt W, Scafoglieri A, Jager-Wittenaar H, Hobbelen JSM, van der Schans CP. The reliability and validity of ultrasound to quantify muscles in older adults: a systematic review. J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):702-712. doi: 10.1002/jcsm.12210. Epub 2017 Jul 12. Review."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DocumentSection":{
            "LargeDocumentModule":{
              "LargeDocList":{
                "LargeDoc":[
                  {
                    "LargeDocTypeAbbrev":"Prot_SAP_ICF",
                    "LargeDocHasProtocol":"Yes",
                    "LargeDocHasSAP":"Yes",
                    "LargeDocHasICF":"Yes",
                    "LargeDocLabel":"Study Protocol, Statistical Analysis Plan, and Informed Consent Form",
                    "LargeDocDate":"February 16, 2021",
                    "LargeDocUploadDate":"03/02/2021 04:08",
                    "LargeDocFilename":"Prot_SAP_ICF_000.pdf"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000055948",
                    "ConditionMeshTerm":"Sarcopenia"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000009133",
                    "ConditionAncestorTerm":"Muscular Atrophy"
                  },{
                    "ConditionAncestorId":"D000020879",
                    "ConditionAncestorTerm":"Neuromuscular Manifestations"
                  },{
                    "ConditionAncestorId":"D000009461",
                    "ConditionAncestorTerm":"Neurologic Manifestations"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000001284",
                    "ConditionAncestorTerm":"Atrophy"
                  },{
                    "ConditionAncestorId":"D000020763",
                    "ConditionAncestorTerm":"Pathological Conditions, Anatomical"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M26983",
                    "ConditionBrowseLeafName":"Sarcopenia",
                    "ConditionBrowseLeafAsFound":"Sarcopenia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3170",
                    "ConditionBrowseLeafName":"Atrophy",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10673",
                    "ConditionBrowseLeafName":"Muscular Atrophy",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21203",
                    "ConditionBrowseLeafName":"Neuromuscular Manifestations",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10987",
                    "ConditionBrowseLeafName":"Neurologic Manifestations",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21103",
                    "ConditionBrowseLeafName":"Pathological Conditions, Anatomical",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":51,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780113",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2020-A03283-36"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"CHES NÂ°20/01",
                    "SecondaryIdType":"Other Identifier",
                    "SecondaryIdDomain":"CH Eure-Seine"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Centre Hospitalier Eure-Seine",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Evolution of Perceived Stress in General Practice Residents During COVID-19 Sanitary Crisis",
              "OfficialTitle":"Evaluation of Evolution of Perceived Stress in General Practice Residents of Rouen and Caen During COVID-19 Sanitary Crisis"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 25, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"October 25, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"October 25, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Centre Hospitalier Eure-Seine",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Over the last several years, distress among healthcare professionnals is well described, and general practice residents are also affected. Because of COVID-19 sanitary crisis, stress factors are increased, and that may cause anxiety, exhaustion, psychic distress, depression, addictions, or post traumatic stress.",
              "DetailedDescription":"This prospective non-interventional study aims to evaluate via two questionnaires the evolution of perceived stress in general practice residents of two centres in France, Rouen and Caen. The two questionnaires contain the Perceived Stress Scale, as well as items regarding socio-demographic data and stress factors. The first questionnaire is to be distributed during the epidemic COVID-19 wave and the second questionnaire at the end of the epidemic COVID-19 wave."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Stress"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"285",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Evolution of perceived stress during the epidemic wave of COVID19 vs. at the end of the epidemic wave of COVID19",
                    "PrimaryOutcomeDescription":"The perceived stress will be evaluated using the Perceived Stress Scale",
                    "PrimaryOutcomeTimeFrame":"maximum 6 months, according to the evolution of the epidemic"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Description of general characteristics of residents and their feelings and experiences with the sanitary crisis",
                    "SecondaryOutcomeDescription":"This include socio-demographic characteristics, work-related information and potential stress factors",
                    "SecondaryOutcomeTimeFrame":"maximum 6 months, according to the evolution of the epidemic"
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of residents' profile stress according to their socio-demographic and working characteristics",
                    "SecondaryOutcomeDescription":"Identification of stress factors among residents",
                    "SecondaryOutcomeTimeFrame":"maximum 6 months, according to the evolution of the epidemic"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nBeing a general practice resident in Rouen or Caen\nParticipant informed and non-objection of him/her\n\nExclusion Criteria:\n\nBeing on maternity leave or not working during the period concerned with the questionnaires",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Participants being general practice residents in Caen or Rouen",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Sorina Mihailescu, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+33232338833",
                    "CentralContactEMail":"sorina-dana.mihailescu@ch-eureseine.fr"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"SÃ©golÃ¨ne Guillemette, MD",
                    "OverallOfficialAffiliation":"General Practice Physician",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"CH Eure-Seine",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Ã‰vreux",
                    "LocationZip":"27015",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Sorina Mihailescu, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+33232338833",
                          "LocationContactEMail":"sorina-dana.mihailescu@ch-eureseine.fr"
                        },{
                          "LocationContactName":"SÃ©golÃ¨ne Guillemette, MD",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            }
          }
        }
      },{
        "Rank":52,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780100",
              "OrgStudyIdInfo":{
                "OrgStudyId":"N202005040"
              },
              "Organization":{
                "OrgFullName":"Taipei Medical University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Distinguishing Acetabulum Cup Retroversion From Anteversion on Anteroposterior Radiographs After Total Hip Arthroplasty",
              "OfficialTitle":"Distinguishing Acetabulum Cup Retroversion From Anteversion on Anteroposterior Radiographs After Total Hip Arthroplasty"
            },
            "StatusModule":{
              "StatusVerifiedDate":"July 2020",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"May 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"May 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 22, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Taipei Medical University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"In this study, investigators will demonstrate and prove a ellipse method (Liaw's version) for measurement and detection of acetabulum cup retroversion.",
              "DetailedDescription":"Total hip arthroplasty (THA) is considered to be the best and most reliable treatment of end-stage hip disorders with satisfactory long-term clinical outcomes. However,the incidence of postoperative dislocation ranges from 0.3% to 3% in primary THA. The most important risk factor is malpositioning of implant components. Generally, excessive anteversion and retroversion increase risk of anterior and posterior hip dislocation respectively. Several radiological methods have been proposed to measure anteversion of the acetabular cup on plain radiographs, but most of these methods cannot accurately distinguish cup retroversion from anteversion. In this study, investigators will demonstrate and prove a ellipse method (Liaw's version) for measurement and detection of acetabulum cup retroversion."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Orthopedics"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Only"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Retrospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"20",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"A computerized ellipse method (Liaw's version) for measurement and detection of acetabulum cup retroversion.",
                    "PrimaryOutcomeDescription":"Total hip arthroplasty (THA) is considered to be the best and most reliable treatment of end-stage hip disorders with satisfactory long-term clinical outcomes. However,the incidence of postoperative dislocation ranges from 0.3% to 3% in primary THA. The most important risk factor is malpositioning of implant components. Generally, excessive anteversion and retroversion increase risk of anterior and posterior hip dislocation respectively. Several radiological methods have been proposed to measure anteversion of the acetabular cup on plain radiographs, but most of these methods cannot accurately distinguish cup retroversion from anteversion. In this article, we will demonstrate and prove a computerized ellipse method (Liaw's version) for measurement and detection of acetabulum cup retroversion.",
                    "PrimaryOutcomeTimeFrame":"10 days"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPatients undergone total hip arthroplasty\nPatients undergone total hip arthroplasty with more than two postoperative anteroposterior radiographs of pelvis\nPatients undergone total hip arthroplasty with postoperative pelvic CT\n\nExclusion Criteria:\n\nPatients with congenital pelvis abnormality or pelvic fracture history\nPatients with postoperative periprosthetic fracture(s)\nPatients with postoperative infection or implants loosening\nPatients undergone total hip arthroplasty without more than two postoperative anteroposterior radiographs of pelvis\nPatients undergone total hip arthroplasty without postoperative pelvic CT",
              "Gender":"All",
              "MinimumAge":"30 Years",
              "MaximumAge":"90 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Patients from Shuang Ho Hospital",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Chen-Kun Liaw",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+886963969162",
                    "CentralContactEMail":"chenkunliaw@tmu.edu.tw"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Chen-Kun Liaw",
                    "OverallOfficialAffiliation":"Taipei Medical University",
                    "OverallOfficialRole":"Study Chair"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            }
          }
        }
      },{
        "Rank":53,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780087",
              "OrgStudyIdInfo":{
                "OrgStudyId":"170066"
              },
              "Organization":{
                "OrgFullName":"Ostfold University College",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Pregnant Women Doing Resistance Exercise Training",
              "OfficialTitle":"Experiences by Pregnant Power Athletes, and Health Related Outcomes in Mother and Infants, After Resistance Exercise Training During Pregnancy",
              "Acronym":"PREG_RET"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"November 1, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 31, 2023",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 31, 2023",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"October 10, 2020",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Therese Fostervold Mathisen",
                "ResponsiblePartyInvestigatorTitle":"Associate Professor",
                "ResponsiblePartyInvestigatorAffiliation":"Ostfold University College"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Ostfold University College",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Despite the increase in numbers of women who engage in heavy, free-weight resistance exercise training (e.g. powerlifting, weightlifting, cross fit), the knowledge on how such exercise may affect fertility, pregnancy and birth outcomes is poor. Based on observational and associational studies of pregnant women in labour, recommendations are not to lift more than 11 kg in external load after mid-term, or to lift more than a total of 100 kg during a day. Ignoring such recommendations is associated to increased risk of miscarriage and preeclampsia, and of low birthweight and premature birth, respectively. As such, fit women who continue to exercise during pregnancy, are met with scepticism and warnings, resulting in shame and insecurity. Such attitudes may also result in physical inactivity during pregnancy, being on the contrary of what is recommended for a healthy pregnancy and delivery. Elite athletes may additionally be deprived from an early return to sport if not being able to keep exercise intensity close to pre-pregnancy period. With poor knowledge on how fit, strong women respond to high external loads during pregnancy exercise, recommendations are to follow the general guidelines.\n\nThe aim of this observational study, is to explore how regular resistance exercise training may affect fertility, and how high external loads in resistance exercise training during pregnancy in resistance trained women affect; a)their pregnancy and birth outcome, and b)health of the women and their children up to 12 months post-delivery.",
              "DetailedDescription":"Pregnant women who are experienced in heavy, free-weight resistance exercise training, and who choose to continue their exercise regimes during pregnancy, are recruited in social media to regularly respond to an online questionnaire on personal health, foetus development, and the newborn child health.\n\nA reference group of pregnant women being regularly physical active (still not lifting free weights of high loads) are concurrently recruited.\n\nAll will respond to questionnaire at mid-term, and week 23, 30 and 40 of pregnancy. During maternity leave the women will be asked to respond to questionnaires at 1 month, 3 months, 6 months and 12 months post-delivery."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Pregnancy Related"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Pregnancy",
                  "Powerlifting",
                  "Weightlifting",
                  "Female athlete",
                  "Fertility",
                  "Delivery",
                  "Maternity leave",
                  "Resistance exercise training"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Control"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"20",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Weight lifting women",
                    "ArmGroupDescription":"Experienced resistance exercise trained and pregnant women"
                  },{
                    "ArmGroupLabel":"Reference women",
                    "ArmGroupDescription":"Physically active pregnant women (not experienced with free weight lifting)"
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Delivery week",
                    "PrimaryOutcomeDescription":"The selfreported pregnancy week for delivery",
                    "PrimaryOutcomeTimeFrame":"At delivery time"
                  },{
                    "PrimaryOutcomeMeasure":"Delivery method",
                    "PrimaryOutcomeDescription":"Participants report the method for delivery, choosing from natural delivery, delivery with assistance (e.g. birth forceps, vacuum delivery), caesarean section.",
                    "PrimaryOutcomeTimeFrame":"At delivery time"
                  },{
                    "PrimaryOutcomeMeasure":"Pregnancy complications at week 23",
                    "PrimaryOutcomeDescription":"Number of participants who report any complications during pregnancy, choosing from a list of alternatives (yes/no) (preeclampsia, nausea, fatigue, low back pain, pelvic pain, constipation, mood swings, birth anxiety, gestational depression, anemia, hypertension, pregnancy diabetes, foetus growth retardation)",
                    "PrimaryOutcomeTimeFrame":"During pregnancy up to week 23"
                  },{
                    "PrimaryOutcomeMeasure":"Pregnancy complications at week 30",
                    "PrimaryOutcomeDescription":"Number of participants who report any complications during pregnancy, choosing from a list of alternatives (yes/no) (preeclampsia, nausea, fatigue, low back pain, pelvic pain, constipation, mood swings, birth anxiety, gestational depression, anemia, hypertension, pregnancy diabetes, foetus growth retardation)",
                    "PrimaryOutcomeTimeFrame":"Pregnancy week 23 to 30"
                  },{
                    "PrimaryOutcomeMeasure":"Pregnancy complications at week 40",
                    "PrimaryOutcomeDescription":"Number of participants who report any complications during pregnancy, choosing from a list of alternatives (yes/no) (preeclampsia, nausea, fatigue, low back pain, pelvic pain, constipation, mood swings, birth anxiety, gestational depression, anemia, hypertension, pregnancy diabetes, foetus growth retardation)",
                    "PrimaryOutcomeTimeFrame":"Pregnancy week 30 to 40"
                  },{
                    "PrimaryOutcomeMeasure":"Childs weight at birth",
                    "PrimaryOutcomeDescription":"The weight of the child",
                    "PrimaryOutcomeTimeFrame":"At delivery time"
                  },{
                    "PrimaryOutcomeMeasure":"Childs length at birth",
                    "PrimaryOutcomeDescription":"The length of the child",
                    "PrimaryOutcomeTimeFrame":"At delivery time"
                  },{
                    "PrimaryOutcomeMeasure":"Apgar score 5 minutes",
                    "PrimaryOutcomeDescription":"The Apgar score 5 minutes post-delivery. This test checks a baby's heart rate, muscle tone, and other signs to see if extra medical care or emergency care is needed. The test is usually given twice: once at 1 minute after birth, and again at 5 minutes after birth. Scores below 4 indicates need for lifesaving measures, and higher scores indicates better health.",
                    "PrimaryOutcomeTimeFrame":"At delivery time (5 minutes post-delivery)"
                  },{
                    "PrimaryOutcomeMeasure":"Miscarriage",
                    "PrimaryOutcomeDescription":"Number of miscarriages",
                    "PrimaryOutcomeTimeFrame":"Previous and up to October 2023"
                  },{
                    "PrimaryOutcomeMeasure":"Urinary incontinence before pregnancy",
                    "PrimaryOutcomeDescription":"Number of participants reporting any challenges with urinary incontinence, and if it occurs; if it is only during increased abdominal pressure (coughing, laughing), or heavy lifting (choosing from a list of \"always\", only during increased abdominal pressure, only during lifting of heavy load)",
                    "PrimaryOutcomeTimeFrame":"Any experience before pregnancy"
                  },{
                    "PrimaryOutcomeMeasure":"Urinary incontinence during pregnancy",
                    "PrimaryOutcomeDescription":"Number of participants reporting any urinary incontinence, and if it occurs; if it is only during increased abdominal pressure (coughing, laughing), or heavy lifting (choosing from a list of \"always\", only during increased abdominal pressure, only during lifting of heavy load)",
                    "PrimaryOutcomeTimeFrame":"At pregnancy week 23, 30 and 40"
                  },{
                    "PrimaryOutcomeMeasure":"Urinary incontinence after delivery",
                    "PrimaryOutcomeDescription":"Number of participants reporting any urinary incontinence, and if it occurs; if it is only during increased abdominal pressure (coughing, laughing), or heavy lifting (choosing from a list of \"always\", only during increased abdominal pressure, only during lifting of heavy load)",
                    "PrimaryOutcomeTimeFrame":"Post-delivery: 1 month-, 3months-, 6 months- and 12 months"
                  },{
                    "PrimaryOutcomeMeasure":"Anal insufficiency before pregnancy",
                    "PrimaryOutcomeDescription":"Number of participants reporting any challenges with fecal incontinence",
                    "PrimaryOutcomeTimeFrame":"Any experience before pregnancy"
                  },{
                    "PrimaryOutcomeMeasure":"Anal insufficiency during pregnancy",
                    "PrimaryOutcomeDescription":"Number of participants reporting any challenges with fecal incontinence",
                    "PrimaryOutcomeTimeFrame":"At pregnancy week 23, 30 and 40"
                  },{
                    "PrimaryOutcomeMeasure":"Anal insufficiency after delivery",
                    "PrimaryOutcomeDescription":"Number of participants reporting any fecal incontinence and if it has worsened after giving birth",
                    "PrimaryOutcomeTimeFrame":"Post-delivery: 1 month-, 3months-, 6 months- and 12 months"
                  },{
                    "PrimaryOutcomeMeasure":"Injuries during pregnancy up to week 23",
                    "PrimaryOutcomeDescription":"Number of participants reporting on any exercise related injuries occuring during pregnancy, choosing from a list of anatomical locations",
                    "PrimaryOutcomeTimeFrame":"During pregnancy up to week 23"
                  },{
                    "PrimaryOutcomeMeasure":"Injuries during pregnancy, up to week 30",
                    "PrimaryOutcomeDescription":"Number of participants reporting on any exercise related injuries occuring during pregnancy, choosing from a list of anatomical locations",
                    "PrimaryOutcomeTimeFrame":"Pregnancy week 23 to 30"
                  },{
                    "PrimaryOutcomeMeasure":"Injuries during pregnancy, up to week 40",
                    "PrimaryOutcomeDescription":"Number of participants reporting on any exercise related injuries occuring during pregnancy, choosing from a list of anatomical locations (yes/no)",
                    "PrimaryOutcomeTimeFrame":"Pregnancy week 30 to 40"
                  },{
                    "PrimaryOutcomeMeasure":"Analgesic during delivery",
                    "PrimaryOutcomeDescription":"Number of participants reporting use of analgesic during delivery, and what type of analgesic (e.g. nitrous oxide, epidural)",
                    "PrimaryOutcomeTimeFrame":"At delivery time"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Body weight at week 23",
                    "SecondaryOutcomeDescription":"Participants report on body weight changes during pregnancy",
                    "SecondaryOutcomeTimeFrame":"Pregnancy week 23"
                  },{
                    "SecondaryOutcomeMeasure":"Body weight at week 30",
                    "SecondaryOutcomeDescription":"Participants report on body weight changes during pregnancy",
                    "SecondaryOutcomeTimeFrame":"Pregnancy week 30"
                  },{
                    "SecondaryOutcomeMeasure":"Body weight at week 40",
                    "SecondaryOutcomeDescription":"Participants report on body weight changes during pregnancy",
                    "SecondaryOutcomeTimeFrame":"Pregnancy week 40"
                  },{
                    "SecondaryOutcomeMeasure":"Body weight post-delivery, 1month",
                    "SecondaryOutcomeDescription":"Participants report on body weight changes after pregnancy",
                    "SecondaryOutcomeTimeFrame":"Postpartum, 1 month after delivery"
                  },{
                    "SecondaryOutcomeMeasure":"Body weight post-delivery, 3 months",
                    "SecondaryOutcomeDescription":"Participants report on body weight changes after pregnancy",
                    "SecondaryOutcomeTimeFrame":"Postpartum, 3 months after delivery"
                  },{
                    "SecondaryOutcomeMeasure":"Body weight post-delivery, 6 months",
                    "SecondaryOutcomeDescription":"Participants report on body weight changes after pregnancy",
                    "SecondaryOutcomeTimeFrame":"Postpartum, 6 months after delivery"
                  },{
                    "SecondaryOutcomeMeasure":"Body weight post-delivery, 12 months",
                    "SecondaryOutcomeDescription":"Participants report on body weight changes after pregnancy",
                    "SecondaryOutcomeTimeFrame":"Postpartum, 12 months after delivery"
                  },{
                    "SecondaryOutcomeMeasure":"Changes in external loads used in exercise training",
                    "SecondaryOutcomeDescription":"Participants report on changes in external loads used in exercise during pregnancy (% of normal loading used pre-pregnancy)",
                    "SecondaryOutcomeTimeFrame":"During pregnancy"
                  },{
                    "SecondaryOutcomeMeasure":"Changes in external loads used in exercise training, up to week 23",
                    "SecondaryOutcomeDescription":"Participants report on changes in external loads used in exercise during pregnancy (% of normal loading used pre-pregnancy)",
                    "SecondaryOutcomeTimeFrame":"During pregnancy, week 23"
                  },{
                    "SecondaryOutcomeMeasure":"Changes in external loads used in exercise training",
                    "SecondaryOutcomeDescription":"Participants report on changes in external loads used in exercise after pregnancy (% of normal loading used pre-pregnancy)",
                    "SecondaryOutcomeTimeFrame":"Post-delivery: 1 month-, 3months-, 6 months- and 12 months"
                  },{
                    "SecondaryOutcomeMeasure":"Changes in exercise volume during pregnancy, up to week 23",
                    "SecondaryOutcomeDescription":"Participants report on changes in exercise volume (number of sessions per week) during pregnancy",
                    "SecondaryOutcomeTimeFrame":"During pregnancy, week 23"
                  },{
                    "SecondaryOutcomeMeasure":"Changes in exercise volume during pregnancy, up to week 30",
                    "SecondaryOutcomeDescription":"Participants report on changes in exercise volume (number of sessions per week) during pregnancy",
                    "SecondaryOutcomeTimeFrame":"During pregnancy, week 30"
                  },{
                    "SecondaryOutcomeMeasure":"Changes in exercise volume during pregnancy, up to week 40",
                    "SecondaryOutcomeDescription":"Participants report on changes in exercise volume (number of sessions per week) during pregnancy",
                    "SecondaryOutcomeTimeFrame":"During pregnancy, week 40"
                  },{
                    "SecondaryOutcomeMeasure":"Changes in exercise volume after pregnancy",
                    "SecondaryOutcomeDescription":"Participants report on changes in exercise volume (number of sessions per week) after pregnancy",
                    "SecondaryOutcomeTimeFrame":"Post-delivery: 1 month-, 3months-, 6 months- and 12 months"
                  },{
                    "SecondaryOutcomeMeasure":"Injuries from exercise during maternity leave",
                    "SecondaryOutcomeDescription":"Reporting on any exercise related injuries occuring during maternity leave (up to 12 months post-delivery), choosing from a list of anatomical locations",
                    "SecondaryOutcomeTimeFrame":"Post-delivery: 1 month-, 3months-, 6 months- and 12 months"
                  },{
                    "SecondaryOutcomeMeasure":"Fertility",
                    "SecondaryOutcomeDescription":"Reports on any fertility problems or use of fertility techniques in order to become pregnant",
                    "SecondaryOutcomeTimeFrame":"Before pregnancy"
                  },{
                    "SecondaryOutcomeMeasure":"Bloodpressure",
                    "SecondaryOutcomeDescription":"Bloodpressure measures, and numbers above/below clinical cut offs (having hypo-or hypertension)",
                    "SecondaryOutcomeTimeFrame":"At pregnancy week 23, 30 and 40, and at 1 month-, 3months-, 6 months- and 12 months postdelivery,"
                  },{
                    "SecondaryOutcomeMeasure":"Symphysis-fundus measure",
                    "SecondaryOutcomeDescription":"symphysis fundus measure during pregnancy; as a measure for growth of the fetus, evaluated according to national/international standards",
                    "SecondaryOutcomeTimeFrame":"At pregnancy week 23, 30 and 40"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Use of supplements",
                    "OtherOutcomeDescription":"Number of participants reporting use of dietary supplements, and what kind of supplements",
                    "OtherOutcomeTimeFrame":"At pregnancy week 23, 30 and 40, and at 1 month-, 3months-, 6 months- and 12 months postdelivery,"
                  },{
                    "OtherOutcomeMeasure":"Use of caffein (coffee, energydrinks, sodawater)",
                    "OtherOutcomeDescription":"Number of participants reporting use of caffein, and in what doses per day",
                    "OtherOutcomeTimeFrame":"At pregnancy week 23, 30 and 40, and at 1 month-, 3months-, 6 months- and 12 months postdelivery,"
                  },{
                    "OtherOutcomeMeasure":"Intake of alcohol",
                    "OtherOutcomeDescription":"Number of participants reporting intake of alcohol, and how regularly (choosing between no, daily, weekly, monthly)",
                    "OtherOutcomeTimeFrame":"At pregnancy week 23, 30 and 40, and at 1 month-, 3months-, 6 months- and 12 months postdelivery,"
                  },{
                    "OtherOutcomeMeasure":"Use of tobacco/cigarettes or snus",
                    "OtherOutcomeDescription":"Number of participants reporting any use",
                    "OtherOutcomeTimeFrame":"At pregnancy week 23, 30 and 40, and at 1 month-, 3months-, 6 months- and 12 months postdelivery,"
                  },{
                    "OtherOutcomeMeasure":"Use of any prescribed drugs",
                    "OtherOutcomeDescription":"Number of participants reporting any use, and what type of drug",
                    "OtherOutcomeTimeFrame":"At pregnancy week 23, 30 and 40, and at 1 month-, 3months-, 6 months- and 12 months postdelivery,"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nBeing pregnant\nGroup of interest: Being experienced with heavy, free-weight resistance exercise training, and aiming to continue exercise at comparable level during pregnancy\nReference group: being regularly physical active before pregnancy (i.e. at least 2 work- outs per week), but not experienced in heavy, free-weight resistance exercise training\n\nExclusion Criteria:\n\nAny known metabolic condition or contraindication on doing physical activity during pregnancy (i.e. miscarriages, bleedings).",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"Female",
              "GenderBased":"Yes",
              "GenderDescription":"Based on sex, as this study evaluates the effects from resistance exercise training on pregnancy outcomes",
              "MinimumAge":"18 Years",
              "MaximumAge":"45 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              },
              "StudyPopulation":"Women included in \"group of interest\" are pregnant women who are experienced in heavy, free-weigth resistance exercise training (i.e. powerlifter, weightlifter, cross fit) who aim to continue exercise training during pregnancy.\n\nReference group are pregnant women with no experience in heavy, free-weight resistance exercise, but who are regurlarly physically active in any sport activity (at least 2 times per week), and who aim to continue to exercise during pregnancy.",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Therese F Mathisen, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+4795752818",
                    "CentralContactEMail":"therese.f.mathisen@hiof.no"
                  },{
                    "CentralContactName":"Jorunn Sundgot-Borgen, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+4792241745",
                    "CentralContactEMail":"jorunn.sundgot-borgen@nih.no"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Therese F Mathisen, PhD",
                    "OverallOfficialAffiliation":"Ã˜stfold University College",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Therese Fostervold Mathisen",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Fredrikstad",
                    "LocationZip":"1671",
                    "LocationCountry":"Norway",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Therese F Mathisen, PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"95752818",
                          "LocationContactPhoneExt":"+47",
                          "LocationContactEMail":"theresfm@hiof.no"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No",
              "IPDSharingDescription":"Data are kept within the research group"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            }
          }
        }
      },{
        "Rank":54,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780074",
              "OrgStudyIdInfo":{
                "OrgStudyId":"TISHCON/CoQ10-01"
              },
              "Organization":{
                "OrgFullName":"Nutrition Institute, Slovenia",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Comparative Single-dose Bioavailability Study of Different CoQ10 Formulations",
              "OfficialTitle":"Comparative Single-dose Bioavailability Study of Different CoQ10 Formulations in Healthy Adults"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 28, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"May 20, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 31, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 23, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Igor Pravst",
                "ResponsiblePartyInvestigatorTitle":"Prof. Dr. Igor Pravst",
                "ResponsiblePartyInvestigatorAffiliation":"Nutrition Institute, Slovenia"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Nutrition Institute, Slovenia",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Vizera d.o.o.",
                    "CollaboratorClass":"INDUSTRY"
                  },{
                    "CollaboratorName":"ADM, Ambulanta druÅ¾inske medicine, Ljubljana, Slovenia",
                    "CollaboratorClass":"UNKNOWN"
                  },{
                    "CollaboratorName":"Adrialab d.o.o., Ljubljana, Slovenia",
                    "CollaboratorClass":"UNKNOWN"
                  },{
                    "CollaboratorName":"Tishcon Corp., USA",
                    "CollaboratorClass":"UNKNOWN"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The single-center, randomized, open-label, five-period crossover single-dose bioavailability study with five CoQ10 formulations",
              "DetailedDescription":"The single-center, randomized, open-label, five-period crossover bioavailability study will include 30 subjects who will test five CoQ10 formulations. Study will be conducted with single dose CoQ10 to assess bioavailability."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Bioavailability of Coenzyme Q10"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "coenzyme q10",
                  "single dose bioavailability"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Crossover Assignment",
                "DesignInterventionModelDescription":"Five-period crossover bioavailability study will include 30 subjects who will test five CoQ10 formulations. Subjects will test 5 formulations of single dose CoQ10 with 2 week wash-out. to assess bioavailability.",
                "DesignPrimaryPurpose":"Other",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"30",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Standard product (SP)",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"USP CoQ10 powder 100mg, hard capsules (100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10)",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Single dose intervention with Standard product (SP)"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Investigational product 1 (IP1)",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"CoQ10 100 mg in soybean oil, softgels (100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Single dose intervention with Investigational product (IP1)"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Investigational product 2 (IP2)",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Q-Gel 100 mg hydrosoluble/bioenhanced CoQ10, softgels (100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Single dose intervention with Investigational product (IP2)"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Investigational product 3 (IP3)",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Qunol Mega Ubiquinol 100 mg, softgels (100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Single dose intervention with Investigational product (IP3)"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Investigational product 4 (IP4)",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"HydroQsorb Coenzyme Q10 100 mg, hard capsules (100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Single dose intervention with Investigational product (IP4)"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Single dose intervention with Standard product (SP)",
                    "InterventionDescription":"2 capsules - 200 mg total CoQ10",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Standard product (SP)"
                      ]
                    }
                  },{
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Single dose intervention with Investigational product (IP1)",
                    "InterventionDescription":"2 softgels - 200 mg total CoQ10",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Investigational product 1 (IP1)"
                      ]
                    }
                  },{
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Single dose intervention with Investigational product (IP2)",
                    "InterventionDescription":"2 softgels - 200 mg total CoQ10",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Investigational product 2 (IP2)"
                      ]
                    }
                  },{
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Single dose intervention with Investigational product (IP3)",
                    "InterventionDescription":"2 softgels - 200 mg total CoQ10",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Investigational product 3 (IP3)"
                      ]
                    }
                  },{
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Single dose intervention with Investigational product (IP4)",
                    "InterventionDescription":"2 capsules - 200 mg total CoQ10",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Investigational product 4 (IP4)"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Relative single dose bioavailability (AUC48) of IP (in comparison to SP)",
                    "PrimaryOutcomeDescription":"Relative bioavailability between the investigational products and the standard product (IP1 vs. SP, IP2 vs. SP, IP3 vs. SP, and IP4 vs. SP) expressed as ratio of baseline corrected AUC0-72h, i.e. area under the plasma concentration curve from the administration time to the last observation point (72h) of CoQ10 plasma concentrations above the baseline value.",
                    "PrimaryOutcomeTimeFrame":"72 hours"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Relative single dose bioavailability (AUCinf) of IP (in comparison to SP)",
                    "SecondaryOutcomeDescription":"Relative bioavailability between the investigational products and the standard product (IP1 vs. SP, IP2 vs. SP, IP3 vs. SP, and IP4 vs. SP) expressed as ratio of baseline corrected AUCinf, i.e. extrapolated area under the CoQ10 plasma concentration curve above the baseline CoQ10 concentration.",
                    "SecondaryOutcomeTimeFrame":"72 hours"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Relative single dose bioavailability (AUC48) among all the investigational products",
                    "OtherOutcomeDescription":"Relative bioavailability among all the investigational products (IP1 vs. IP2, IP1 vs. IP3, IP1 vs. IP4, IP2 vs. IP3, IP2 vs. IP4, and IP3 vs. IP4) expressed as ratio of baseline corrected AUC0-72h, i.e. area under the plasma concentration curve from the administration time to the last observation point (72h) of CoQ10 plasma concentrations above the baseline value.",
                    "OtherOutcomeTimeFrame":"72 hours"
                  },{
                    "OtherOutcomeMeasure":"Relative single dose bioavailability (AUCinf) among all investigational products",
                    "OtherOutcomeDescription":"Relative bioavailability among all investigational products (IP1 vs. IP2, IP1 vs. IP3, IP1 vs. IP4, IP2 vs. IP3, IP2 vs. IP4, and IP3 vs. IP4) expressed as ratio of baseline corrected AUCinf, i.e. extrapolated area under the CoQ10 plasma concentration curve above the baseline CoQ10 concentration.",
                    "OtherOutcomeTimeFrame":"72 hours"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nSubject Informed consent form (ICF) is singed\nAged between 18 and 65 years at the time of the signature of ICF\nA body mass index between 18.5-29.9 kg/m2\nTotal blood cholesterol range 3,11 - 6,50 mmol/L (not treated with medications)\nHealthy, meaning absence of any prescribed medication for a month prior to the inclusion to the study and during the study\nWilling to avoid a consumption of any food supplements except vitamin D and calcium at least 2 weeks before and during the study\nConsumption of dairy and cereal products (standardised breakfast will include low lactose dairy and bread)\nWilling to follow all study procedures, including attending all site visits (including sessions during which a venous line will be inserted for blood sampling)\n\nExclusion criteria:\n\nIntake of any prescribed medication within 2 weeks of the beginning of the study\nIntake of any food supplements within 2 weeks of the beginning of the study, except vitamin D and calcium\nPregnancy or planned pregnancy\nBreast-feeding mother\nHypotension\nAny clinically significant history of serious digestive tract, liver, kidney, cardiovascular or haematological disease, diabetes\nGastrointestinal disorders or other serious acute or chronic diseases\nKnown lactose/gluten intolerances/ food allergies (limitation for standardisation of meals)\nInadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal\nKnown drug and/or alcohol abuse\nUsing any form of nicotine or tobacco\nMental incapacity that precludes adequate understanding or cooperation\nParticipation in another investigational study or blood donation within 3 months prior to or during this study",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Igor Pravst, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+386 590 68871",
                    "CentralContactEMail":"igor.pravst@nutris.org"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Igor Pravst",
                    "OverallOfficialAffiliation":"Nutrition Institute, Ljubljana",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Tina Modrej Zadnikar",
                    "OverallOfficialAffiliation":"ADM, Ambulanta druÅ¾inske medicine, Ljubljana, Slovenia",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"ADM, ambulanta druÅ¾inske medicine, Ljubljana, Slovenia",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Ljubljana",
                    "LocationZip":"1000",
                    "LocationCountry":"Slovenia",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Tina Modrej Zadnikar",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+386 1 422 29 15",
                          "LocationContactEMail":"info@adm.si"
                        },{
                          "LocationContactName":"Tina Modrej Zadnikar",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M15784",
                    "InterventionBrowseLeafName":"Ubiquinone",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M268804",
                    "InterventionBrowseLeafName":"Coenzyme Q10",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T294",
                    "InterventionBrowseLeafName":"Soy Bean",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T383",
                    "InterventionBrowseLeafName":"Coenzyme Q10",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Micro",
                    "InterventionBrowseBranchName":"Micronutrients"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"HB",
                    "InterventionBrowseBranchName":"Herbal and Botanical"
                  },{
                    "InterventionBrowseBranchAbbrev":"Ot",
                    "InterventionBrowseBranchName":"Other Dietary Supplements"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":55,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780061",
              "OrgStudyIdInfo":{
                "OrgStudyId":"20210072-01H"
              },
              "Organization":{
                "OrgFullName":"The Canadian College of Naturopathic Medicine",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Dietary Supplements for COVID-19",
              "OfficialTitle":"Dietary Supplements to Reduce Symptom Severity and Duration in People With SARS-CoV-2: A Randomized, Double Blind, Placebo Controlled Clinical Trial"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"October 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"The Canadian College of Naturopathic Medicine",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Ottawa Hospital Research Institute",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a double blind, placebo controlled, phase III randomized controlled trial evaluating the effects of the dietary supplements vitamin C, vitamin D, vitamin K, and zinc versus placebo on the overall health, symptom severity, and symptom duration of outpatients diagnosed with SARS-CoV-2.",
              "DetailedDescription":"This study proposed is a double-blind, placebo-controlled, phase III randomized controlled trial powered to detect meaningful differences in the overall health and symptom severity of people with COVID-19 between the treatment and control arms. Eligible participants will be randomly assigned, using a web randomization system, in a ratio of 1:1 to one of the following groups: (1) nutrient therapy with vitamin D, vitamin C, vitamin K2, and zinc or (2) placebo. Total trial duration will be 12 weeks. Nutrients or placebo will be given for a period of 21 days following enrolment and randomization. Total trial duration will be 12 weeks. Adverse events will be collected during the treatment phase plus one additional week (maximum 4 weeks).\n\nWith respect to the primary outcome of participant-reported overall health, power calculations were conducted based on between-group differences at a single time point (21 days) and Cohen's guideline for a small effect size of 0.3. A sample size of 176 (88 per arm) provides 80% power to detect a difference at an Î± of 0.05. To account for an approximate 10-15% lost to follow-up we will enrol 200 participants (100 per arm)."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Natural Health Products",
                  "NHP",
                  "Dietary Supplements",
                  "Vitamin C",
                  "Vitamin D",
                  "Vitamin K",
                  "Zinc",
                  "COVID-19",
                  "SARS-CoV-2"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 3"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"200",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Treatment",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Specific Product: Vitamin D3 50,000 IU\n\nFormulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period\n\nSpecific Product: Vitamin K2/D\n\nFormulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3).\n\nDose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day.\n\nSpecific Product: Vitamin C/Zinc\n\nFormulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Vitamin D3 50,000 IU",
                        "Dietary Supplement: Vitamin C/Zinc",
                        "Dietary Supplement: Vitamin K2/D"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Control",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Specific Product: Vitamin D3 50,000 IU\n\nPlacebo Equivalent: microcrystalline cellulose capsule, 350 mg\n\nSpecific Product: Vitamin K2/D\n\nPlacebo Equivalent: Medium chain triglyceride oil\n\nSpecific Product: Vitamin C/Zinc\n\nPlacebo Equivalent: microcrystalline cellulose capsule, 350 mg",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Microcrystalline Cellulose Capsule",
                        "Other: Medium Chain Triglyceride Oil"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Vitamin D3 50,000 IU",
                    "InterventionDescription":"This is a loading dose of Vitamin D. Vitamin D (cholecalciferol [vitamin D3]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Treatment"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Cholecalciferol"
                      ]
                    }
                  },{
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Vitamin C/Zinc",
                    "InterventionDescription":"This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Treatment"
                      ]
                    }
                  },{
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Vitamin K2/D",
                    "InterventionDescription":"This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 [vitamin K2]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Treatment"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"Microcrystalline Cellulose Capsule",
                    "InterventionDescription":"Placebo equivalent of Vitamin C/Zinc and Vitamin D3.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Control"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"Medium Chain Triglyceride Oil",
                    "InterventionDescription":"Placebo equivalent of Vitamin K2/D",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Control"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Participant-reported overall health",
                    "PrimaryOutcomeDescription":"Difference in overall health measured using the EuroQol Visual Assessment Scale (EQ-VAS)",
                    "PrimaryOutcomeTimeFrame":"During the intervention period (Daily for 21 days)"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Effect of COVID-19 on the health status of participants",
                    "SecondaryOutcomeDescription":"Measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire",
                    "SecondaryOutcomeTimeFrame":"Baseline plus weeks 1, 2, 3, 4, 8, and 12"
                  },{
                    "SecondaryOutcomeMeasure":"Symptom Severity of common COVID-19 symptoms",
                    "SecondaryOutcomeDescription":"Measured using an internally-developed questionnaire. Includes fever, cough, shortness of breath, fatigue, headache, myalgia/arthralgia, nausea, vomiting, diarrhea, congestion, loss of taste, and loss of smell.",
                    "SecondaryOutcomeTimeFrame":"During the intervention period (Daily for 21 days)"
                  },{
                    "SecondaryOutcomeMeasure":"Total symptom duration",
                    "SecondaryOutcomeDescription":"Measured as the time to a complete reduction of symptoms with no relapses (i.e., a 0 in all categories on the symptom questionnaire).",
                    "SecondaryOutcomeTimeFrame":"During the intervention period (21 days)"
                  },{
                    "SecondaryOutcomeMeasure":"Incidence of delayed return to usual health",
                    "SecondaryOutcomeDescription":"Measured by the number of people experiencing \"ongoing symptomatic COVID-19\" (symptoms persisting between 4 and 12 weeks) and the number of people experiencing \"post-COVID-19 syndrome\" (symptoms persisting longer than 12 weeks)",
                    "SecondaryOutcomeTimeFrame":"12 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Frequency of Hospitalizations",
                    "SecondaryOutcomeDescription":"Includes ER visits, acute care admissions, and ICU admissions",
                    "SecondaryOutcomeTimeFrame":"12 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Hospital Length of Stay",
                    "SecondaryOutcomeDescription":"Number of days in acute care or ICU",
                    "SecondaryOutcomeTimeFrame":"12 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"All-cause mortality",
                    "SecondaryOutcomeTimeFrame":"12 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAdults (â‰¥18) who test positive for SARS-CoV-2 in an outpatient setting\nAccess to internet\n\nExclusion Criteria:\n\nSymptom onset greater than 4 days prior to enrolment\nSupplementing regularly with >500 mg vitamin C, >1000 units vitamin D, >120 mcg vitamin K (any form), or >15 mg zinc taken daily within the past month\nCurrently taking warfarin or an equivalent vitamin K antagonist anticoagulant\nEnd stage chronic kidney disease\nHistory of calcium oxalate kidney stones\nActive granulomatosis (sarcoidosis, tuberculosis, lymphoma)\nKnown hypercalcemia or hypervitaminosis D\nCurrently taking either of the following antibiotics: cephalexin, tetracyclines\nParticipating in an investigational study or participation in an investigational study within the past 30 days\nAny reason which, under the discretion of the qualified investigator or delegate, would preclude the patient from participating.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Mark Legacy, BSc",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"6137921222",
                    "CentralContactPhoneExt":"1",
                    "CentralContactEMail":"mlegacy@thechi.ca"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Dugald Seely, ND, MSc",
                    "OverallOfficialAffiliation":"Canadian College of Naturopathic Medicine",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Kumanan Wilson, MD, MSc",
                    "OverallOfficialAffiliation":"The Ottawa Hospital Research Institute",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"The Centre for Health Innovation",
                    "LocationCity":"Ottawa",
                    "LocationState":"Ontario",
                    "LocationZip":"K2P0M7",
                    "LocationCountry":"Canada",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Mark Legacy, BSc",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"6137921222",
                          "LocationContactPhoneExt":"1",
                          "LocationContactEMail":"mlegacy@thechi.ca"
                        },{
                          "LocationContactName":"Ellen Conte, ND",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Athanasios Psihogios, ND",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Dean Fergusson, PhD",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Tim Ramsay, PhD",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Salmaan Kanji, BSc, PharmD",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Graydon Simmons, MD",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Mark Legacy, BSc",
                          "LocationContactRole":"Sub-Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000014807",
                    "InterventionMeshTerm":"Vitamin D"
                  },{
                    "InterventionMeshId":"D000002762",
                    "InterventionMeshTerm":"Cholecalciferol"
                  },{
                    "InterventionMeshId":"D000014815",
                    "InterventionMeshTerm":"Vitamins"
                  },{
                    "InterventionMeshId":"D000014812",
                    "InterventionMeshTerm":"Vitamin K"
                  },{
                    "InterventionMeshId":"D000024482",
                    "InterventionMeshTerm":"Vitamin K 2"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000018977",
                    "InterventionAncestorTerm":"Micronutrients"
                  },{
                    "InterventionAncestorId":"D000078622",
                    "InterventionAncestorTerm":"Nutrients"
                  },{
                    "InterventionAncestorId":"D000006133",
                    "InterventionAncestorTerm":"Growth Substances"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  },{
                    "InterventionAncestorId":"D000050071",
                    "InterventionAncestorTerm":"Bone Density Conservation Agents"
                  },{
                    "InterventionAncestorId":"D000077264",
                    "InterventionAncestorTerm":"Calcium-Regulating Hormones and Agents"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  },{
                    "InterventionAncestorId":"D000000933",
                    "InterventionAncestorTerm":"Antifibrinolytic Agents"
                  },{
                    "InterventionAncestorId":"D000050299",
                    "InterventionAncestorTerm":"Fibrin Modulating Agents"
                  },{
                    "InterventionAncestorId":"D000006490",
                    "InterventionAncestorTerm":"Hemostatics"
                  },{
                    "InterventionAncestorId":"D000003029",
                    "InterventionAncestorTerm":"Coagulants"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M16133",
                    "InterventionBrowseLeafName":"Vitamin D",
                    "InterventionBrowseLeafAsFound":"Women",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M4586",
                    "InterventionBrowseLeafName":"Cholecalciferol",
                    "InterventionBrowseLeafAsFound":"Prostate Cancer",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M16141",
                    "InterventionBrowseLeafName":"Vitamins",
                    "InterventionBrowseLeafAsFound":"/kg",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M16138",
                    "InterventionBrowseLeafName":"Vitamin K",
                    "InterventionBrowseLeafAsFound":"Adult acute myeloid leukemia",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M21550",
                    "InterventionBrowseLeafName":"Vitamin K 2",
                    "InterventionBrowseLeafAsFound":"Sildenafil Citrate",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M3963",
                    "InterventionBrowseLeafName":"Calcium",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M3094",
                    "InterventionBrowseLeafName":"Ascorbic Acid",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M215227",
                    "InterventionBrowseLeafName":"Vitamin MK 7",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M3980",
                    "InterventionBrowseLeafName":"Calcium, Dietary",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19593",
                    "InterventionBrowseLeafName":"Micronutrients",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M15468",
                    "InterventionBrowseLeafName":"Trace Elements",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M12315",
                    "InterventionBrowseLeafName":"Vitamin K 1",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M16351",
                    "InterventionBrowseLeafName":"Zinc",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M1986",
                    "InterventionBrowseLeafName":"Nutrients",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8372",
                    "InterventionBrowseLeafName":"Hormones",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2833",
                    "InterventionBrowseLeafName":"Antifibrinolytic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8159",
                    "InterventionBrowseLeafName":"Hemostatics",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M4842",
                    "InterventionBrowseLeafName":"Coagulants",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T479",
                    "InterventionBrowseLeafName":"Vitamin D3",
                    "InterventionBrowseLeafAsFound":"Ablation",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"T442",
                    "InterventionBrowseLeafName":"Cholecalciferol",
                    "InterventionBrowseLeafAsFound":"Prostate Cancer",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"T477",
                    "InterventionBrowseLeafName":"Vitamin C",
                    "InterventionBrowseLeafAsFound":"Profile",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"T481",
                    "InterventionBrowseLeafName":"Vitamin K",
                    "InterventionBrowseLeafAsFound":"Adult acute myeloid leukemia",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"T450",
                    "InterventionBrowseLeafName":"Menaquinone",
                    "InterventionBrowseLeafAsFound":"Sildenafil Citrate",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"T440",
                    "InterventionBrowseLeafName":"Calciferol",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T437",
                    "InterventionBrowseLeafName":"Ascorbic Acid",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T449",
                    "InterventionBrowseLeafName":"Menadione",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T452",
                    "InterventionBrowseLeafName":"Naphthoquinone",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T458",
                    "InterventionBrowseLeafName":"Phylloquinone",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"BDCA",
                    "InterventionBrowseBranchName":"Bone Density Conservation Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"Micro",
                    "InterventionBrowseBranchName":"Micronutrients"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"Coag",
                    "InterventionBrowseBranchName":"Coagulants"
                  },{
                    "InterventionBrowseBranchAbbrev":"Vi",
                    "InterventionBrowseBranchName":"Vitamins"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":56,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780048",
              "OrgStudyIdInfo":{
                "OrgStudyId":"L#12086"
              },
              "Organization":{
                "OrgFullName":"New York Medical College",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Complex Abdominal Wall Reconstruction Using Biologic Mesh",
              "OfficialTitle":"Complex Abdominal Wall Reconstruction Using Biologic Mesh Outcomes Prospective Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"July 7, 2017",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"July 6, 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 6, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"August 13, 2020",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Rifat Latifi",
                "ResponsiblePartyInvestigatorTitle":"Professor, General surgery",
                "ResponsiblePartyInvestigatorAffiliation":"New York Medical College"
              },
              "LeadSponsor":{
                "LeadSponsorName":"New York Medical College",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of this study is to determine how the patient factors, co-morbid conditions, pre-operative workup, anatomy of the defect, reconstruction details, operative techniques, and type of repairs contribute to the final outcome of abdominal wall reconstruction. The outcomes of interest are: in-hospital complications, discharge disposition, hospital and ICU length of stay, long term follow-up (recurrence, reoperation, and explantation rates).",
              "DetailedDescription":"Background:\n\nAbdominal wall defects are commonly seen in trauma and EGS patients. During the last decade numerous advances have been made in the management of patients with abdominal wall defects. These defects are repaired by various surgical techniques including mesh repair (synthetic vs. biologic), primary repair, etc. However, the outcomes of patients after these injuries are highly variable and many of these patients suffer from in-hospital complications, mesh infections requiring explantation, and recurrence. Various factors play a role in the final outcome of the patient. These include factors associated with the initial surgery or disease (trauma or emergency general surgery), patient demographics (age, gender, co-morbidities), preoperative features (hemoglobin and laboratory parameters), technique of repair (onlay, inlay, retro rectus) and the types of mesh used. However, the role of each of these factors in the final outcome of patients remains unclear in the literature.\n\nStudy Design Study Type: Observational Observational Study Model: Cohort Time Perspective: Prospective Enrollment: 250 Number of Groups/Cohorts: 1\n\nRecruitment Procedures:\n\nAttending physicians will discuss possible participation in the study with patients who meet initial screening criteria and have been scheduled for abdominal wall repair/ventral hernia repair. If a patient agrees, they will be approached by our research coordinator to discuss consenting. The research coordinator will introduce herself and her role with Westchester Medical Center, and read the following script. A translator for Spanish speaking patients will be available.\n\nHello, my name is _______________. I am a research coordinator with the Department of Surgery here at Westchester Medical Center. I'm talking to you today because you or your family member are scheduled to have a surgery that involves abdominal wall repair. Dr. Latifi, the Director of the Department of Surgery, is conducting a study looking at outcomes from this surgery. We are interested in how this procedure and personal factors, such as having diabetes, may contribute to how long you stay in the hospital, have a recurrence or develop an infection. Participation in this study does not require anything additional from you. You will receive the same care if you do or do not participate. The only difference is we would maintain your outcome data for analysis purposes. Would you be interested in learning more about the study and discussing study details with me and Dr. Latifi? If so, are you able to meet and when would you like to meet? Or, if you do not know yet, can you provide me with your phone number or the best way to contact you to schedule a follow-up meeting to discuss the study?\n\nResearch Coordinator meets and collects potential participant contact information.\n\nMeeting will be held to describe study in more detail and to consent participant and/or representative. If participant is already in the hospital for the procedure, the meeting will be held as soon as possible.\n\nData management:\n\nThe research involves no more than minimal risk to subjects as it provides no additional treatment for patients who had abdominal wall defects and are undergoing surgery. Data will be obtained on their pre and perioperative details, their interventions, and final outcomes. This study will use a chart review of data from electronic medical records for current patients. Subjects will be recruited, consented, and medical record data will be gathered prospectively.\n\nMedical records containing Protective Health Information such as admission and discharge date will be obtained from the hospital Electronic Medical Record database in the form of a query spreadsheet to determine hospital and ICU length of stay. All data will be de-identified using a unique identifier that is assigned to each record.\n\nData will be queried from the database and kept in a password protected excel spreadsheet. Only the PI and designated research personnel will have the access to the Protective Health Information and data linkage file. The PI designated research team members will have the access to the de-identified data.\n\nData will be stored and secured in a logbook/secured computer with the PI. Hard copies will also be stored in closed envelopes in locked cabinets in PI's office. The data will be kept for a period of seven years and then later will be destroyed. Data will be stored by the Westchester Medical Center (WMC) Lead PI.\n\nAnalytic Plan: Chi-square difference tests will be used to assess significant differences in predictors on categorical outcomes. T-tests will be used to assess mean differences in predictors on continuous outcomes. Univariable and multivariable logistic regression analyses will be conducted for outcomes such as all-cause mortality, pneumonia, sepsis, and multi-organ failure. Univariable and multivariable linear regression will be performed for hospital length of stay."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Hernia"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Hernia repair"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"250",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"In Hospital Complications",
                    "PrimaryOutcomeDescription":"Infection, re-procedures, explantation rates, length of hospital stay and ICU stay.",
                    "PrimaryOutcomeTimeFrame":"3 years"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nâ€¢ All patients aged 18 years and above undergoing Abdominal wall reconstruction with biological mesh.\n\nExclusion Criteria:\n\nâ€¢ Vulnerable patient population (Neonates, Prisoners, Pregnant) will not be included in our study",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"80 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"All patients aged 18 years and above undergoing Abdominal wall reconstruction with biological mesh irrespective of gender, ethnicity, socio-economic status will be included in the study.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Agon Kajmolli, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"9144937936",
                    "CentralContactEMail":"agon.kajmolli@wmchealth.org"
                  },{
                    "CentralContactName":"Matthew McGuirk, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"9144937936",
                    "CentralContactEMail":"Matthew.McGuirk@wmchealth.org"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Rifat Latifi, MD",
                    "OverallOfficialAffiliation":"Chairman Department of Surgery",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Westchester Medical center",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Valhalla",
                    "LocationState":"New York",
                    "LocationZip":"10595",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Agon Kajmolli, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"914-493-7936",
                          "LocationContactEMail":"agon.kajmolli@wmchealth.org"
                        },{
                          "LocationContactName":"Matthew McGuirk, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"9144937936",
                          "LocationContactEMail":"Matthew.McGuirk@wmchealth.org"
                        },{
                          "LocationContactName":"Rifat Latifi, MD",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided",
              "IPDSharingDescription":"no plans"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000006547",
                    "ConditionMeshTerm":"Hernia"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000020763",
                    "ConditionAncestorTerm":"Pathological Conditions, Anatomical"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8208",
                    "ConditionBrowseLeafName":"Hernia",
                    "ConditionBrowseLeafAsFound":"Hernia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M21103",
                    "ConditionBrowseLeafName":"Pathological Conditions, Anatomical",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":57,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780035",
              "OrgStudyIdInfo":{
                "OrgStudyId":"COV/pept-03/20"
              },
              "Organization":{
                "OrgFullName":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"",
                "OrgClass":"OTHER_GOV"
              },
              "BriefTitle":"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19",
              "OfficialTitle":"Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Active, not recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"November 18, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"September 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 25, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"",
                "LeadSponsorClass":"OTHER_GOV"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The objective of the clinical study is to evaluate the tolerability, safety, immunogenicity and prophylactic efficacy of the EpiVacCorona vaccine in volunteers aged 18 and above.\n\nThe study tasks are to:\n\nevaluate the safety of the EpiVacCorona vaccine when administered twice intramuscularly;\nevaluate the tolerability of the EpiVacCorona vaccine when administered twice intramuscularly;\nidentify any adverse events to the administration of the EpiVacCorona vaccine;\ninvestigate the humoral immune response following two doses of the EpiVacCorona vaccine;\ninvestigate the cell-mediated immune response following two doses of the EpiVacCorona vaccine;\nevaluate the prophylactic efficacy of the EpiVacCorona vaccine when administered twice intramuscularly.",
              "DetailedDescription":"The study will screen a maximum of 4,929 volunteers of both sexes aged 18 and above, of which 3,000 volunteers who meet the inclusion criteria and do not have the exclusion criteria will be randomized:\n\n2,250 volunteers who will be vaccinated with the EpiVacCorona vaccine, twice intramuscularly at a dose of 0.5 ml;\n750 volunteers who will be vaccinated with a placebo, twice intramuscularly at a dose of 0.5 ml.\n\nIf volunteers drop out of the study, they will not be replaced. All volunteers will be followed up by an investigator physician for 6 months following the first vaccination in order to identify possible late adverse events. In case the volunteer has any late reactions, he/she will be invited to the clinic to correct his/her condition."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "COVID-19"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "EpiVacCorona vaccine"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 3"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Prevention",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Investigator"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"3000",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Group \"Vaccine\"",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"2,250 volunteers who will be vaccinated with the EpiVacCorona vaccine, twice intramuscularly at a dose of 0.5 ml.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"\"Control Group\"",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"750 volunteers who will be vaccinated with a placebo, twice intramuscularly at a dose of 0.5 ml.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Biological",
                    "InterventionName":"EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)",
                    "InterventionDescription":"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).\n\nThe vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.\n\nThe EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Group \"Vaccine\""
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)",
                    "InterventionDescription":"The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "\"Control Group\""
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"The proportion of vaccinated volunteers with no laboratory confirmed symptoms caused by SARS-CoV-2, within 6 months post vaccination versus a placebo",
                    "PrimaryOutcomeDescription":"The proportion of vaccinated volunteers with no laboratory confirmed symptoms caused by SARS-CoV-2, in combination with one or more of the following symptoms: fever or chills; cough; shortness of breath or labored breathing; fatigue; muscle pain; headache; loss of taste or smell; sore throat; a stuffy nose or runny nose; nausea or vomiting; diarrhea, within 6 months post vaccination versus a placebo",
                    "PrimaryOutcomeTimeFrame":"within 6 months after the first vaccination"
                  },{
                    "PrimaryOutcomeMeasure":"The prophylactic efficacy of the vaccine",
                    "PrimaryOutcomeDescription":"The prophylactic efficacy of the vaccine under study is â‰¥50% compared to a placebo, with the lower limit of the confidence interval of the point estimate for the primary efficacy variable > 30%",
                    "PrimaryOutcomeTimeFrame":"9 months after the first vaccination"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"The proportion of volunteers with increased levels of the immune response in terms of geometric mean titers of specific antibodies",
                    "SecondaryOutcomeDescription":"The proportion of volunteers with increased levels of the immune response in terms of geometric mean titers of specific antibodies in ELISA is more than 4 times greater 21 to 28 days following the second vaccination",
                    "SecondaryOutcomeTimeFrame":"21-28 days after the second vaccination"
                  },{
                    "SecondaryOutcomeMeasure":"The proportion of volunteers with increased levels of the immune response in terms of specific neutralizing antibody titers",
                    "SecondaryOutcomeDescription":"The proportion of volunteers with increased levels of the immune response in terms of specific neutralizing antibody titers in ELISA is more than 4 times greater 21 to 28 days following the second vaccination",
                    "SecondaryOutcomeTimeFrame":"21-28 days after the second vaccination"
                  },{
                    "SecondaryOutcomeMeasure":"The frequency of severe cases of COVID-19 following a single / double vaccination",
                    "SecondaryOutcomeDescription":"The frequency of severe cases of COVID-19 following a single / double vaccination (including hospitalization, transfer to an intensive care unit, death, etc.)",
                    "SecondaryOutcomeTimeFrame":"through the whole study, an average of 9 months"
                  },{
                    "SecondaryOutcomeMeasure":"Duration of disease",
                    "SecondaryOutcomeDescription":"Duration of illness in case of COVID-19 disease",
                    "SecondaryOutcomeTimeFrame":"through the whole study, an average of 9 months"
                  },{
                    "SecondaryOutcomeMeasure":"The incidence of asymptomatic COVID-19 following a single / double vaccination",
                    "SecondaryOutcomeDescription":"The incidence of asymptomatic COVID-19 following a single / double vaccination (to assess the effectiveness of vaccination in preventing SARS-CoV-2 infection)",
                    "SecondaryOutcomeTimeFrame":"through the whole study, an average of 9 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAvailability of a signed and dated informed consent of the volunteer to participate in a clinical trial, prior to any of the study procedures.\nVolunteers (men and women) above the age of 18 years with stable indicators of basic vital functions.\nAbility to attend all scheduled visits and all planned procedures and examinations.\nConsent of volunteers to use effective contraceptive methods throughout the study, including the observation period for possible post-vaccination reactions.\n\nExclusion Criteria:\n\nHistory of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) or another coronavirus infection (HCoV-229E, HCOV-OC43, HCoV-NL63, HCoV-HKU1).\nHistory of exposure to confirmed or suspected cases of SARS-CoV-2 infection within 1 month prior to randomization.\nPositive for IgM or IgG to SARS-CoV-2 as detected during screening.\nPositive PCR test for SARS-CoV-2 as detected during screening.\nClinically and laboratory (according to PCR data) confirmed disease caused by SARS-CoV-2 coronavirus, at the moment or in the past.\nSerious post-vaccination reaction (body temperature above 40 Â°C , hyperemia or edema greater than 8 cm in diameter) or complication (collapse or shock-like state that developed within 48 hours after vaccination; convulsions, with or without of a febrile state) to a previous vaccination in the past.\nAggravated allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, history of serum disease, history of hypersensitivity or allergic reactions to the administration of any vaccines, any known allergic reactions to vaccine components, etc.).\nHypersensitivity to any component of the product, allergy to vaccine components.\nHistory of vaccination with any vaccine within one month prior to randomization.\nPrevious vaccination with rabies vaccines less than 2 months prior to randomization, or planned vaccination with rabies vaccines within 1 month after immunization with the vaccine under study.\nPregnancy or breastfeeding.\nThe military.\nPersons in custody in detention facilities and those serving sentences in correctional facilities.\nChildren under the age of 18.\nHistory of any acute respiratory illness less than 3 months prior to randomization.\nAcute infectious or non-infectious diseases, exacerbation of chronic diseases less than 4 weeks prior to randomization.\nHistory of tuberculosis (pulmonary and extrapulmonary), cancer, autoimmune diseases, skin diseases.\nLong-term use (more than 14 days) of immunosuppressants, systemic glucocorticosteroids or immunomodulatory drugs within 6 months prior to randomization.\nUse of immunoglobulin drugs or blood products within 3 months prior to randomization.\nChronic diseases of the cardiovascular, bronchopulmonary, endocrine systems, gastrointestinal tract, liver, kidneys, blood, disease of the endocrine system in the exacerbation phase or that in the decompensation phase in the past or as detected during laboratory and imaging examination.\nHistory of surgery within 6 months prior to randomization.\nParticipation in other clinical trials less than 3 months prior to randomization.\nPersons with alcohol or drug abuse (medications or narcotics). Use of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to Â½ liter of beer, or 200 ml of wine or 50 ml of alcohol) or history of alcoholism, narcomania or drug (medication) abuse.\nMental illness or neurasthenia.\nPositive test for HIV, viral hepatitis B and C, or syphilis.\nPremenopausal women (last menstrual period â‰¤ 1 year prior to signing the informed consent) who are not surgically sterile and women who have reproductive potential but do not use or plan to use approved birth control products throughout the study nor they agree to a urine pregnancy test while participating in the study.\nSerious concomitant diseases or pathological conditions not listed above, which, according to the investigator's opinion, could complicate the assessment of the study results, including any pathological deviations from the age norms and laboratory norms of blood and urine parameters, clinically significant in the investigator's opinion.\n\nAnd:\n\nThe investigator's decision to exclude the volunteer for the benefit of the volunteer.\nFalse inclusion (violation of inclusion or non-inclusion criteria) or the appearance of non-inclusion criteria during the study.\nThe decision of the investigator or the Sponsor to exclude the volunteer from the study due to a clinically significant deviation from the protocol/violation of the protocol.\nAny undesirable phenomenon requiring the appointment of drugs not authorized by the protocol of this study.\nVolunteer's desire to complete the study early for any reason.\nVolunteer's failure to show up for a scheduled visit without the warning the investigator or loss of communication with the volunteer.\nPositive urine drug test and / or alcohol breath test during the visit.",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Rinat A. Maksyutov, PhD",
                    "OverallOfficialAffiliation":"Federal Budgetary Research Institution - State Research Center of Virology and Biotechnology \"Vector\", Federal Service for Surveillance on Consumer Rights Protection and Human Well-being",
                    "OverallOfficialRole":"Study Director"
                  },{
                    "OverallOfficialName":"Nikita V. Lomakin",
                    "OverallOfficialAffiliation":"Federal State Budgetary Institution - Central Clinical Hospital with Polyclinic, Administrative Office of the President of the Russian Federation",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Vitaly G. Gusarov",
                    "OverallOfficialAffiliation":"Federal State Budgetary Institution - N.I. Pirogov National Medical and Surgical Center, Ministry of Health of the Russian Federation",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Maria A. Chukina",
                    "OverallOfficialAffiliation":"Federal State Budgetary Research Institution - Academician B.V. Petrovsky Russian Research Center for Surgery",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Stanislav A. Terpigorev",
                    "OverallOfficialAffiliation":"State Budgetary Healthcare Institution of the Moscow region - M.F. Vladimirsky Moscow Regional Research Clinical Institute",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Svetlana B. Erofeeva",
                    "OverallOfficialAffiliation":"State Budgetary Healthcare Institution of the Moscow region - Krasnogorsk City Hospital # 1",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Olga A. Rychkova",
                    "OverallOfficialAffiliation":"State Budgetary Educational Institution of Higher Professional Education - Tyumen State Medical University, Ministry of Health of the Russian Federation",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Viktoria Y. Delyan, Associate Professor",
                    "OverallOfficialAffiliation":"State Autonomous Healthcare Institution - Clinical City Hospital # 7 of Kazan",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Vladimir V. Rafalsky",
                    "OverallOfficialAffiliation":"Federal State Autonomous Educational Institution of Higher Education - Immanuel Kant Baltic University (short name: FSAEIHE- I. Kant Baltic Federal University)",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"State Budgetary Healthcare Institution of the Moscow region - Krasnogorsk City Hospital # 1 (short name: SBHI MR KCH # 1)",
                    "LocationCity":"Krasnogorsk",
                    "LocationState":"Moscow Region",
                    "LocationZip":"143408",
                    "LocationCountry":"Russian Federation"
                  },{
                    "LocationFacility":"Federal State Autonomous Educational Institution of Higher Education - Immanuel Kant Baltic University (short name: FSAEIHE- I. Kant Baltic Federal University)",
                    "LocationCity":"Kaliningrad",
                    "LocationZip":"236016",
                    "LocationCountry":"Russian Federation"
                  },{
                    "LocationFacility":"State Autonomous Healthcare Institution - Clinical City Hospital # 7 of Kazan (short name: SAHI CCH # 7)",
                    "LocationCity":"Kazan",
                    "LocationZip":"420103",
                    "LocationCountry":"Russian Federation"
                  },{
                    "LocationFacility":"Federal State Budgetary Institution - N.I. Pirogov National Medical and Surgical Center, Ministry of Health of the Russian Federation (short name: FSBI - N.I. Pirogov NMSC, Ministry of Health of the Russian Federation)",
                    "LocationCity":"Moscow",
                    "LocationZip":"105203",
                    "LocationCountry":"Russian Federation"
                  },{
                    "LocationFacility":"Federal State Budgetary Research Institution - Academician B.V. Petrovsky Russian Research Center for Surgery (short name: FSBRI - Academician B.V. Petrovsky RRCS)",
                    "LocationCity":"Moscow",
                    "LocationZip":"119991",
                    "LocationCountry":"Russian Federation"
                  },{
                    "LocationFacility":"Research Center: Federal State Budgetary Institution - Central Clinical Hospital with Polyclinic, Administrative Office of the President of the Russian Federation (short name: FSBI Central Clinical Hospital with Polyclinic)",
                    "LocationCity":"Moscow",
                    "LocationZip":"121359",
                    "LocationCountry":"Russian Federation"
                  },{
                    "LocationFacility":"State Budgetary Healthcare Institution of the Moscow region - M.F. Vladimirsky Moscow Regional Research Clinical Institute (short name: M.F. Vladimirsky SBHI MRRCI)",
                    "LocationCity":"Moscow",
                    "LocationZip":"129110",
                    "LocationCountry":"Russian Federation"
                  },{
                    "LocationFacility":"State Budgetary Educational Institution of Higher Professional Education - Tyumen State Medical University, Ministry of Health of the Russian Federation (short name: SBEIHPE - Tyumen State Medical University, Ministry of Health of Russian Federation)",
                    "LocationCity":"Tyumen",
                    "LocationZip":"625023",
                    "LocationCountry":"Russian Federation"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M15943",
                    "InterventionBrowseLeafName":"Vaccines",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M20444",
                    "InterventionBrowseLeafName":"Pharmaceutical Solutions",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2458",
                    "InterventionBrowseLeafName":"Aluminum Hydroxide",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"PhSol",
                    "InterventionBrowseBranchName":"Pharmaceutical Solutions"
                  },{
                    "InterventionBrowseBranchAbbrev":"Gast",
                    "InterventionBrowseBranchName":"Gastrointestinal Agents"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":58,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780022",
              "OrgStudyIdInfo":{
                "OrgStudyId":"PFO-Elderly"
              },
              "Organization":{
                "OrgFullName":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Patent Foramen Ovale Closure in Older Patients",
              "OfficialTitle":"Patent Foramen Ovale Closure in Older Patients: A Collaborative Multicenter Retrospective Study",
              "Acronym":"PFO-Elderly"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 1, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 1, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 25, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Josep Rodes-Cabau",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Toronto General Hospital",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"Montreal Heart Institute",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"Ottawa Heart Institute",
                    "CollaboratorClass":"UNKNOWN"
                  },{
                    "CollaboratorName":"St. Boniface Hospital",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"Hospital Clinico de Madrid",
                    "CollaboratorClass":"UNKNOWN"
                  },{
                    "CollaboratorName":"Hospital Clinic of Barcelona",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Describe the baseline and procedural characteristics of older patients undergoing PFO closure due to cryptogenic embolism.\nAssess the long-term follow-up of this cohort, focusing on neurological events and their origin, major cardiac outcomes, as well as survival rates and death origin.\nSeek for predictors of neurological event recurrence after the procedure.",
              "DetailedDescription":"In patients with cryptogenic stroke, up to 4 randomized trials and subsequent meta-analyses have recently shown a significant reduction in recurrent ischemic stroke events following percutaneous closure of patent foramen ovale (PFO) . All randomized trials but one excluded patients older than 60 years, and a mean patient age of about 50 years was reported in the single randomized trial including older patients. Thus, whereas PFO closure has been established as the new gold-standard therapy in young patients with cryptogenic stroke and PFO, there are no definite recommendations on the management of patients older than 60 years. Some studies have shown that older patients with cryptogenic stroke exhibit a much higher prevalence of PFO (compared with patients with stroke of known cause), similar to that in younger populations, but scarce data exist on acute and mid-term clinical outcomes of older patients undergoing PFO closure.\n\nThe investigators have recently reported the results of study comparing the long-term clinical outcomes of patients older (vs. younger) than 60 years in our centre. A total of 475 consecutive patients (90 older than 60 years) were included, and the main results can be summarized as follows: 1) older patients with cryptogenic embolism and PFO exhibited a higher burden of cardiovascular risk factors; 2) PFO closure was safe in older patients, with no differences in periprocedural complications compared with younger patients; 3) at long-term (median of 8 years) follow-up post-PFO closure, the global mortality rate was higher among older patients, but differences were driven by noncardiovascular mortality (mainly cancer), and 4) the rate of recurrent stroke/TIA was low (much lower than that predicted by the RoPE score), but there was a tendency toward a higher incidence of recurrent stroke/TIA among older patients, which appeared to be partially related to cardiovascular risk factor burden (no differences in recurrent ischemic event rate were observed after adjustment for baseline differences in cardiovascular risk factors between groups). The main limitation of this study was the relatively low number of patients older than 60 years, precluding an appropriate evaluation of the factors associated with poorer clinical outcomes in this population. Thus, the investigators are planning to confirm prior findings in a collaborative project including a much larger cohort of patients. Also, the results of this retrospective study would provide the rationale for a CIHR submission on a randomized trial targeting this group of patients."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Patent Foramen Ovale",
                  "Ischemic Stroke",
                  "Older People"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Retrospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"350",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Older patients with cryptogenic embolism and PFO closure",
                    "ArmGroupDescription":"Data (clinical events at last follow-up) on patients older than 60 years who have experienced a previous paradoxical embolism of unknown origin and underwent transcatheter PFO closure will be collected.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Clinical events at last follow-up"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Clinical events at last follow-up",
                    "InterventionDescription":"Clinical events (stroke, transient ischemic attack, peripheral embolism, deep venous thrombosis, atrial fibrillation, myocardial infarction, bleeding episode, death) at last follow-up",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Older patients with cryptogenic embolism and PFO closure"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Rate of stroke",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 1 year"
                  },{
                    "PrimaryOutcomeMeasure":"Rate of transient ischemic attack",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 1 year"
                  },{
                    "PrimaryOutcomeMeasure":"Rate of peripheral embolism",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 1 year"
                  },{
                    "PrimaryOutcomeMeasure":"Rate of deep venous thrombosis",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 1 year"
                  },{
                    "PrimaryOutcomeMeasure":"Rate of atrial fibrillation",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 1 year"
                  },{
                    "PrimaryOutcomeMeasure":"Rate of myocardial infarction",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 1 year"
                  },{
                    "PrimaryOutcomeMeasure":"Rate of bleeding",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 1 year"
                  },{
                    "PrimaryOutcomeMeasure":"Rate of death",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 1 year"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPatients older than 60 years who have experienced a previous paradoxical embolism (stroke, transient ischaemic attack or peripheral embolism) of unknown origin and underwent transcatheter PFO closure.\n\nExclusion Criteria:\n\nPFO closure indication other than paradoxical embolism (example: platypnea orthodeoxia syndrome).\nSurgical PFO closure.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"60 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Patients older than 60 years who have experienced a previous paradoxical embolism of unknown origin and underwent transcatheter PFO closure.",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Josep Rodes-Cabau, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"418-656-8711",
                    "CentralContactEMail":"josep.rodes@criucpq.ulaval.ca"
                  },{
                    "CentralContactName":"Melanie Cote, MSc",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"418-656-8711",
                    "CentralContactPhoneExt":"2646",
                    "CentralContactEMail":"melanie.cote@criucpq.ulaval.ca"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"28902580",
                    "ReferenceType":"background",
                    "ReferenceCitation":"SÃ¸ndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, SjÃ¶strand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L; Gore REDUCE Clinical Study Investigators. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017 Sep 14;377(11):1033-1042. doi: 10.1056/NEJMoa1707404. Erratum in: N Engl J Med. 2020 Mar 5;382(10):978."
                  },{
                    "ReferencePMID":"28902593",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, BÃ©jot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, GuÃ©rin P, Piot C, Rossi R, Dubois-RandÃ© JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G; CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017 Sep 14;377(11):1011-1021. doi: 10.1056/NEJMoa1705915."
                  },{
                    "ReferencePMID":"28902590",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017 Sep 14;377(11):1022-1032. doi: 10.1056/NEJMoa1610057."
                  },{
                    "ReferencePMID":"29544871",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, Lee D, Kwon HS, Yun SC, Sun BJ, Park JH, Lee JH, Jeong HS, Song HJ, Kim J, Park SJ. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol. 2018 May 22;71(20):2335-2342. doi: 10.1016/j.jacc.2018.02.046. Epub 2018 Mar 12."
                  },{
                    "ReferencePMID":"31585849",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Wintzer-Wehekind J, Alperi A, Houde C, CÃ´tÃ© JM, Del Val D, CÃ´tÃ© M, RodÃ©s-Cabau J. Transcatheter closure of patent foramen ovale in patients older than 60 years of age with cryptogenic embolism. Rev Esp Cardiol (Engl Ed). 2020 Mar;73(3):219-224. doi: 10.1016/j.rec.2019.07.003. Epub 2019 Oct 1. English, Spanish."
                  },{
                    "ReferencePMID":"23864310",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, Di Tullio MR, Lutz JS, Elkind MS, Griffith J, Jaigobin C, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Thaler DE. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013 Aug 13;81(7):619-25. doi: 10.1212/WNL.0b013e3182a08d59. Epub 2013 Jul 17."
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000054092",
                    "ConditionMeshTerm":"Foramen Ovale, Patent"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000006344",
                    "ConditionAncestorTerm":"Heart Septal Defects, Atrial"
                  },{
                    "ConditionAncestorId":"D000006343",
                    "ConditionAncestorTerm":"Heart Septal Defects"
                  },{
                    "ConditionAncestorId":"D000006330",
                    "ConditionAncestorTerm":"Heart Defects, Congenital"
                  },{
                    "ConditionAncestorId":"D000018376",
                    "ConditionAncestorTerm":"Cardiovascular Abnormalities"
                  },{
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  },{
                    "ConditionAncestorId":"D000006331",
                    "ConditionAncestorTerm":"Heart Diseases"
                  },{
                    "ConditionAncestorId":"D000000013",
                    "ConditionAncestorTerm":"Congenital Abnormalities"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M20890",
                    "ConditionBrowseLeafName":"Stroke",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M26157",
                    "ConditionBrowseLeafName":"Foramen Ovale, Patent",
                    "ConditionBrowseLeafAsFound":"Patent Foramen Ovale",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M9126",
                    "ConditionBrowseLeafName":"Ischemia",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8014",
                    "ConditionBrowseLeafName":"Heart Septal Defects",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8015",
                    "ConditionBrowseLeafName":"Heart Septal Defects, Atrial",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8001",
                    "ConditionBrowseLeafName":"Heart Defects, Congenital",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M12",
                    "ConditionBrowseLeafName":"Congenital Abnormalities",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19087",
                    "ConditionBrowseLeafName":"Cardiovascular Abnormalities",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8002",
                    "ConditionBrowseLeafName":"Heart Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC16",
                    "ConditionBrowseBranchName":"Diseases and Abnormalities at or Before Birth"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":59,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04780009",
              "OrgStudyIdInfo":{
                "OrgStudyId":"MCC-17-0605-F1V"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"R41CA243600-01",
                    "SecondaryIdType":"U.S. NIH Grant/Contract",
                    "SecondaryIdLink":"https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R41CA243600-01&Fy=all"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"University of Kentucky",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Loupe-Based Intraoperative Fluorescence Imaging",
              "OfficialTitle":"Loupe-Based Intraoperative Fluorescence Imaging for the Guidance of Brain Tumor Surgery"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"November 17, 2017",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"July 31, 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"July 31, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor-Investigator",
                "ResponsiblePartyInvestigatorFullName":"Guoqiang Yu",
                "ResponsiblePartyInvestigatorTitle":"Professor",
                "ResponsiblePartyInvestigatorAffiliation":"University of Kentucky"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Guoqiang Yu",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Bioptics Technology LLC",
                    "CollaboratorClass":"UNKNOWN"
                  },{
                    "CollaboratorName":"National Cancer Institute (NCI)",
                    "CollaboratorClass":"NIH"
                  },{
                    "CollaboratorName":"Kentucky Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR)",
                    "CollaboratorClass":"UNKNOWN"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Consequently, a great deal of effort has been directed at developing techniques and technologies that allow more extensive, safe resections.\n\nThis study will test a loupe-based wearable device in the clinical setting and compare its accuracy with a large operative microscope to identify tumor tissues. Postoperative histopathological analysis on tumor tissues will be used as gold standards for comparison. The outcome from this study will be a low-cost, miniaturized, easy-to-operate, loupe-based fluorescence imaging device for intraoperative guidance of brain tumor resection with the same level of accuracy as the large microscope.",
              "DetailedDescription":"This is a prospective, observational study to compare the measurement accuracies of a wearable loupe-based device and the large microscope against the gold standards of postoperative histopathological analysis on tumor tissues.\n\nAt the induction of anesthesia, patients will receive 5 mg/kg of intravenous sodium 5-aminolevulinic acid (5-ALA) or fluorescein. Surgery will be performed under the guidance of the operative fluorescence microscope (PENTERO with fluorescence kit + YELLOW 560, Carl Zeiss) or (PENTERO 900 + BLUE 400, Carl Zeiss). The operating room light will be dimmed for optimum reproduction of the fluorescent light. Tumor removal will be continued until no fluorescent area is visualized. To evaluate the accuracy of the device in the identification of tumor tissue, six samples will be biopsied from the tumor resection margin for each patient; three in the fluorescent area and three in the non-fluorescent area for the assessment of positive and negative predictive values of the devices, respectively. These biopsied tissues will be taken to the clinical pathology laboratory for the standard histological analysis.\n\nTo compare the accuracy of the two imaging systems in identifying tumor tissues, the tumor resection area will be visually observed by the surgeon and video recorded using the new loupe-based device at two time points (at least): immediately before and immediately after tumor removal. Additional fluorescence images may be taken during surgery as long as the surgical workflow is not impacted. Moreover, the four fresh biopsies (2 in the fluorescent area and 2 in the non-fluorescent area) taken from the tumor margin based on the operative microscope diagnosis will also be examined intraoperatively by the loupe-based device to determine whether they are fluorescent or non-fluorescent.\n\nTo discriminate between clear tumor tissue and the peritumoral areas, the postoperative histological analysis of the biopsied samples taken from the tumor margins will be classified on the basis of the current 2016 WHO classification. The neuropathologist will be blinded to the fluorescence characteristics of the biopsied samples."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Glioblastoma Multiforme",
                  "Anaplastic Astrocytoma"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "fluorescence",
                  "resection",
                  "5-ALA",
                  "fluorescein",
                  "optical"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Only"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "BioSpec":{
                "BioSpecRetention":"Samples With DNA",
                "BioSpecDescription":"Biopsies in and adjacent to the tumor will be collected for histopathology."
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"20",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Positive Predictive Value (PPV)",
                    "PrimaryOutcomeDescription":"The proportion of samples that are histologically confirmed as tumor-positive among all fluorescent samples will be calculated.",
                    "PrimaryOutcomeTimeFrame":"1 day"
                  },{
                    "PrimaryOutcomeMeasure":"Negative Predictive Value (NPV)",
                    "PrimaryOutcomeDescription":"The proportion of samples that are histologically confirmed as tumor-negative among all fluorescent samples will be calculated.",
                    "PrimaryOutcomeTimeFrame":"1 day"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Residual Tumor",
                    "SecondaryOutcomeDescription":"The proportion of positive results among all tumors with residual as well as the proportion of negative results among tumors without residual will be calculated relative to post-operative histopathological analysis.",
                    "SecondaryOutcomeTimeFrame":"1 day"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nadults with brain malignant gliomas undergoing resection\nat least 18 years of age\nable to understand the consent\n\nExclusion Criteria:\n\npregnant women\nunder 18 years of age\npatients undergoing emergency surgery\ninability to give consent due to dysphagia or language barrier",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"90 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Patients undergoing glioblastoma multiforme and anaplastic astrocytoma resection recruited from the University of Kentucky Multidisciplinary Oncology Clinic (UK-MOC).",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Guoqiang Yu, PhD",
                    "OverallOfficialAffiliation":"University of Kentucky",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"University of Kentucky",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Lexington",
                    "LocationState":"Kentucky",
                    "LocationZip":"40536",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Thomas Pittman, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"859-323-8986",
                          "LocationContactEMail":"thomas.pittman@uky.edu"
                        },{
                          "LocationContactName":"Thomas Pittman, MD",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000005909",
                    "ConditionMeshTerm":"Glioblastoma"
                  },{
                    "ConditionMeshId":"D000001254",
                    "ConditionMeshTerm":"Astrocytoma"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000005910",
                    "ConditionAncestorTerm":"Glioma"
                  },{
                    "ConditionAncestorId":"D000018302",
                    "ConditionAncestorTerm":"Neoplasms, Neuroepithelial"
                  },{
                    "ConditionAncestorId":"D000017599",
                    "ConditionAncestorTerm":"Neuroectodermal Tumors"
                  },{
                    "ConditionAncestorId":"D000009373",
                    "ConditionAncestorTerm":"Neoplasms, Germ Cell and Embryonal"
                  },{
                    "ConditionAncestorId":"D000009370",
                    "ConditionAncestorTerm":"Neoplasms by Histologic Type"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  },{
                    "ConditionAncestorId":"D000009375",
                    "ConditionAncestorTerm":"Neoplasms, Glandular and Epithelial"
                  },{
                    "ConditionAncestorId":"D000009380",
                    "ConditionAncestorTerm":"Neoplasms, Nerve Tissue"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M7602",
                    "ConditionBrowseLeafName":"Glioblastoma",
                    "ConditionBrowseLeafAsFound":"Glioblastoma Multiforme",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3142",
                    "ConditionBrowseLeafName":"Astrocytoma",
                    "ConditionBrowseLeafAsFound":"Anaplastic Astrocytoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3791",
                    "ConditionBrowseLeafName":"Brain Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7603",
                    "ConditionBrowseLeafName":"Glioma",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19030",
                    "ConditionBrowseLeafName":"Neoplasms, Neuroepithelial",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M18428",
                    "ConditionBrowseLeafName":"Neuroectodermal Tumors",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M18971",
                    "ConditionBrowseLeafName":"Neuroectodermal Tumors, Primitive",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10901",
                    "ConditionBrowseLeafName":"Neoplasms, Germ Cell and Embryonal",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10898",
                    "ConditionBrowseLeafName":"Neoplasms by Histologic Type",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10903",
                    "ConditionBrowseLeafName":"Neoplasms, Glandular and Epithelial",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10908",
                    "ConditionBrowseLeafName":"Neoplasms, Nerve Tissue",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T2518",
                    "ConditionBrowseLeafName":"Glioblastoma",
                    "ConditionBrowseLeafAsFound":"Glioblastoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"T364",
                    "ConditionBrowseLeafName":"Anaplastic Astrocytoma",
                    "ConditionBrowseLeafAsFound":"Anaplastic Astrocytoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"T2519",
                    "ConditionBrowseLeafName":"Glioma",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T4092",
                    "ConditionBrowseLeafName":"Neuroepithelioma",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2541",
                    "InterventionBrowseLeafName":"Aminolevulinic Acid",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Derm",
                    "InterventionBrowseBranchName":"Dermatologic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":60,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779996",
              "OrgStudyIdInfo":{
                "OrgStudyId":"CCAM 21-01"
              },
              "Organization":{
                "OrgFullName":"Auxilio Mutuo Cancer Center",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment",
              "OfficialTitle":"Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 16, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 31, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"February 28, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 2, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Fernando Cabanillas",
                "ResponsiblePartyInvestigatorTitle":"Fernando Cabanillas, MD",
                "ResponsiblePartyInvestigatorAffiliation":"Auxilio Mutuo Cancer Center"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Auxilio Mutuo Cancer Center",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a Phase II study designed to investigate if the Covid 19 vaccines are capable of eliciting production of antibodies against S protein of Sar-S-Cov-2 virus among patients with medical history of cancer previously treated with monoclonal anti CD-20 antibodies. The antibody production is defined based on the detection of antibodies in the serologic Covid-19 rapid test against S protein or with semiquantitative assay when it becomes available."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19",
                  "Cancer",
                  "HIV Infections"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Control"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Cross-Sectional"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"250",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Diagnostic Test",
                    "InterventionName":"Laboratory Samples",
                    "InterventionDescription":"After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level\nLaboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio ClÃ­nico. Likewise, the Immuno Reference Lab might be used as an alternative.\nSince monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Primary Objective",
                    "PrimaryOutcomeDescription":"To determine if patients with cancer history or HIV positivity previously treated with monoclonal anti CD-20 are able to produce antibodies after Covid-19 vaccination.\n\na. Antibody Production defined as: 1. Positive serologic Covid-19 antibodies rapid test against S protein.",
                    "PrimaryOutcomeTimeFrame":"Two weeks after full dose vaccination."
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Secondary objective 1",
                    "SecondaryOutcomeDescription":"Evaluate the Correlation of immunoglobulin levels and the development of Covid-19 antibodies.",
                    "SecondaryOutcomeTimeFrame":"Two weeks after full dose vaccination."
                  },{
                    "SecondaryOutcomeMeasure":"Secondary objective 2",
                    "SecondaryOutcomeDescription":"Evaluate the correlation of CD4/CD8 counts with the development of Covid-19 antibodies.",
                    "SecondaryOutcomeTimeFrame":"Two weeks after full dose vaccination."
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAll patients either diagnosed with cancer or with HIV positivity or treated with an antineoplastic regimen including anti CD-20 after Covid-19 vaccine will be registered on the study regardless of their type of cancer or type of antineoplastic regimen.\nPatients 21 years or older diagnosed with cancer treated with antineoplastic regimen or anti CD-20, or with HIV infection vaccinated with 2 doses of anti Covid-19 vaccine.\nEligible patients will be registered on study after a Covid -19 vaccine has been scheduled.\nIn order to be screened for Covid 19 antibodies, they must be tested at least two weeks after the second dose of Covid-19 vaccination.\n\nExclusion Criteria:\n\nAnyone who has not been treated with anti-CD20 antibodies or with chemotherapy who doesn't have HIV infection or who has not received chemotherapy for cancer.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"21 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"All patients either diagnosed with cancer or with HIV positivity or treated with an antineoplastic regimen including anti CD-20 after Covid-19 vaccine.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Fernando Cabanillas, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"787-758-2000",
                    "CentralContactPhoneExt":"3503",
                    "CentralContactEMail":"cabanillasmd@gmail.com"
                  },{
                    "CentralContactName":"Carmen Morales",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"787-758-2000",
                    "CentralContactPhoneExt":"3503",
                    "CentralContactEMail":"camorales@auxiliomutuo.com"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Auxilio Mutuo Cancer Center",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"San Juan",
                    "LocationZip":"00918",
                    "LocationCountry":"Puerto Rico",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Fernando Cabanillas, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"787-758-2000",
                          "LocationContactPhoneExt":"3503",
                          "LocationContactEMail":"cabanillasmd@gmail.com"
                        },{
                          "LocationContactName":"Carmen Morales",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"787-758-2000",
                          "LocationContactPhoneExt":"3503",
                          "LocationContactEMail":"camorales@auxiliomutuo.com"
                        },{
                          "LocationContactName":"Fernando Cabanillas, MD",
                          "LocationContactRole":"Principal Investigator"
                        },{
                          "LocationContactName":"Javier Morales, MD",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Josselyn Molina, MD",
                          "LocationContactRole":"Sub-Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"32671831",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020 Nov;202(2):149-161. doi: 10.1111/cei.13495. Epub 2020 Aug 1. Review."
                  },{
                    "ReferencePMID":"32619884",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Houot R, Levy R, Cartron G, Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer. 2020 Sep;136:4-6. doi: 10.1016/j.ejca.2020.06.017. Epub 2020 Jun 25."
                  },{
                    "ReferencePMID":"9704735",
                    "ReferenceType":"background",
                    "ReferenceCitation":"McLaughlin P, Grillo-LÃ³pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33."
                  }
                ]
              },
              "SeeAlsoLinkList":{
                "SeeAlsoLink":[
                  {
                    "SeeAlsoLinkLabel":"OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients.",
                    "SeeAlsoLinkURL":"https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000015658",
                    "ConditionMeshTerm":"HIV Infections"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000016180",
                    "ConditionAncestorTerm":"Lentivirus Infections"
                  },{
                    "ConditionAncestorId":"D000012192",
                    "ConditionAncestorTerm":"Retroviridae Infections"
                  },{
                    "ConditionAncestorId":"D000012327",
                    "ConditionAncestorTerm":"RNA Virus Infections"
                  },{
                    "ConditionAncestorId":"D000014777",
                    "ConditionAncestorTerm":"Virus Diseases"
                  },{
                    "ConditionAncestorId":"D000015229",
                    "ConditionAncestorTerm":"Sexually Transmitted Diseases, Viral"
                  },{
                    "ConditionAncestorId":"D000012749",
                    "ConditionAncestorTerm":"Sexually Transmitted Diseases"
                  },{
                    "ConditionAncestorId":"D000007153",
                    "ConditionAncestorTerm":"Immunologic Deficiency Syndromes"
                  },{
                    "ConditionAncestorId":"D000007154",
                    "ConditionAncestorTerm":"Immune System Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16833",
                    "ConditionBrowseLeafName":"HIV Infections",
                    "ConditionBrowseLeafAsFound":"HIV Infections",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M2103",
                    "ConditionBrowseLeafName":"Acquired Immunodeficiency Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M17223",
                    "ConditionBrowseLeafName":"Lentivirus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13609",
                    "ConditionBrowseLeafName":"Retroviridae Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16105",
                    "ConditionBrowseLeafName":"Virus Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13732",
                    "ConditionBrowseLeafName":"RNA Virus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14141",
                    "ConditionBrowseLeafName":"Sexually Transmitted Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16516",
                    "ConditionBrowseLeafName":"Sexually Transmitted Diseases, Viral",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14938",
                    "ConditionBrowseLeafName":"Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8782",
                    "ConditionBrowseLeafName":"Immunologic Deficiency Syndromes",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8783",
                    "ConditionBrowseLeafName":"Immune System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC20",
                    "ConditionBrowseBranchName":"Immune System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXS",
                    "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2806",
                    "InterventionBrowseLeafName":"Antibodies",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8767",
                    "InterventionBrowseLeafName":"Immunoglobulins",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M15943",
                    "InterventionBrowseLeafName":"Vaccines",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2811",
                    "InterventionBrowseLeafName":"Antibodies, Monoclonal",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M7419",
                    "InterventionBrowseLeafName":"gamma-Globulins",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M17700",
                    "InterventionBrowseLeafName":"Immunoglobulins, Intravenous",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M18774",
                    "InterventionBrowseLeafName":"Rho(D) Immune Globulin",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":61,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779983",
              "OrgStudyIdInfo":{
                "OrgStudyId":"RECHMPL21_0100"
              },
              "Organization":{
                "OrgFullName":"University Hospital, Montpellier",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"IL-6 as a Biomarker for Personalized Treatment of PR",
              "OfficialTitle":"Evaluation of Professional Practices in the Prescription of Biological Treatments for RA Taking Into Account IL6 as a Biomarker",
              "Acronym":"REMISIX"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 18, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"July 30, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"August 1, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University Hospital, Montpellier",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Several studies have shown the relevance of the IL6 level before treatment or after 6 months, as a predictive biomarker for the persistence of remission. The IL6 assay is now routinely available using the instruments available at the Montpellier University Hospital and with reagents provided by the ROCHE Laboratory. Moreover medical practices should incorporate this parameter. However, relevant threshold shlould be defined before being able to integrate biomarkers such as IL6 for monitoring bDMARDs in an algorithm.\n\nThe medical staff of Clinical Immunology Unit has decided to include the dosage of IL-6 during a routine biological assessment during patient visit to follow the new EULAR recommendations . This measument will be perfom in addition to the CRP and biochemical parameters on subjects with active RA or in remission upon the introduction of biological treatments or JAKi or during remission after at least 6 months of treatment. From March to July 2021, 200 patients will beenrolled and will benefit of this assessement. The investigators will retrospectively define clinical correlations with serum IL6 levels in order to define a threshold. In the second stage, a decisional algorithm based on the results of this project will be create. This will allow an improvement of the medical practices thanks to the integrationof of serum IL6 dosage as a standard during patients visits. The IL-6 assay will be performed on the e801 module of the Cobas lines (Roche Diagnostics) currently in place in the Biochemistry and Hormonology laboratory. The ElecsysÂ® IL-6 - Roche Diagnostics test, high sensitivity, is an electrochemiluminescence immunoassay."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Rheumatoid Arthritis"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "IL-6",
                  "Biomarker"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"200",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"serum IL6 levels.",
                    "PrimaryOutcomeDescription":"serum IL6 levels. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.",
                    "PrimaryOutcomeTimeFrame":"1 day"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"The clinical correlations das 28 with the serum IL6 level",
                    "SecondaryOutcomeDescription":"The clinical correlations das 28 with the serum IL6 level",
                    "SecondaryOutcomeTimeFrame":"1 day"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion criteria:\n\n18 to 65 years old\n\npatients with rheumatoid arthritis according to 2010 ACR/EULAR criteria who have one of the following conditions:\n\nSubjects with active RA (DAS28> 3.6) who have failed methotrexate treatement and with a standard medical care for which an indication for biotherapy is retained or\nSubjects with remission of RA (DAS28<2.6) for which a biotherapy delay (anti-TNF or anti-IL6R or JAKi) is proposed.\n\nExclusion criteria:\n\n- Age under 18 years old",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Subjects with active RA (DAS28> 3.6) who have failed methotrexate treatement and with a standard medical care for which an indication for biotherapy is retained.\n\nSubjects with remission of RA (DAS28<2.6) for which a biotherapy delay (anti-TNF or anti-IL6R or JAKi) is proposed.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Rosanna Ferreira, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"467 337902",
                    "CentralContactPhoneExt":"33",
                    "CentralContactEMail":"r-ferreira@chu-montpellier.fr"
                  },{
                    "CentralContactName":"Christian Jorgensen, PU PH",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"0467337231",
                    "CentralContactPhoneExt":"33",
                    "CentralContactEMail":"christian.jorgensen@inserm.fr"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Christian Jorgensen, PU PH",
                    "OverallOfficialAffiliation":"University Hospitals of Montpellier",
                    "OverallOfficialRole":"Study Director"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"UH Montpellier",
                    "LocationCity":"Montpellier",
                    "LocationZip":"34295",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Christian Jorgensen, PU PH",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"046733723",
                          "LocationContactPhoneExt":"33",
                          "LocationContactEMail":"christian.jorgensen@inserm.fr"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided",
              "IPDSharingDescription":"NC"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001168",
                    "ConditionMeshTerm":"Arthritis"
                  },{
                    "ConditionMeshId":"D000001172",
                    "ConditionMeshTerm":"Arthritis, Rheumatoid"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000007592",
                    "ConditionAncestorTerm":"Joint Diseases"
                  },{
                    "ConditionAncestorId":"D000009140",
                    "ConditionAncestorTerm":"Musculoskeletal Diseases"
                  },{
                    "ConditionAncestorId":"D000012216",
                    "ConditionAncestorTerm":"Rheumatic Diseases"
                  },{
                    "ConditionAncestorId":"D000003240",
                    "ConditionAncestorTerm":"Connective Tissue Diseases"
                  },{
                    "ConditionAncestorId":"D000001327",
                    "ConditionAncestorTerm":"Autoimmune Diseases"
                  },{
                    "ConditionAncestorId":"D000007154",
                    "ConditionAncestorTerm":"Immune System Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3057",
                    "ConditionBrowseLeafName":"Arthritis",
                    "ConditionBrowseLeafAsFound":"Arthritis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3061",
                    "ConditionBrowseLeafName":"Arthritis, Rheumatoid",
                    "ConditionBrowseLeafAsFound":"Rheumatoid Arthritis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M9204",
                    "ConditionBrowseLeafName":"Joint Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10680",
                    "ConditionBrowseLeafName":"Musculoskeletal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13628",
                    "ConditionBrowseLeafName":"Rheumatic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4906",
                    "ConditionBrowseLeafName":"Collagen Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5047",
                    "ConditionBrowseLeafName":"Connective Tissue Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3210",
                    "ConditionBrowseLeafName":"Autoimmune Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8783",
                    "ConditionBrowseLeafName":"Immune System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC05",
                    "ConditionBrowseBranchName":"Muscle, Bone, and Cartilage Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC17",
                    "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC20",
                    "ConditionBrowseBranchName":"Immune System Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":62,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779970",
              "OrgStudyIdInfo":{
                "OrgStudyId":"1.0"
              },
              "Organization":{
                "OrgFullName":"University Hospital, Antwerp",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"COIN-B: Controlled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Infections",
              "OfficialTitle":"Controlled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Patients - a Cost-benefit Analysis and Assessment of the Role of Ethnicity",
              "Acronym":"COIN-B"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"July 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"July 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University Hospital, Antwerp",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Universiteit Antwerpen",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"In this study we will prospectively stop NA in both Caucasian and non-Caucasian patients matched for gender and age, to validate the observed host and viral parameters for future roll-out of this treatment strategy.",
              "DetailedDescription":"An estimated 290 million people worldwide are chronically infected with the Hepatitis B Virus (HBV). One fourth of untreated patients develop progressive liver damage and are at risk of liver-related death, which can be prevented by treatment with Nucleos(t)ide Analogues (NA). These drugs efficiently suppress viral replication, but seroclearance of the virus, defined as loss of Hepatitis B surface Antigen (HBsAg), is predicted to require an average of 36 to 52 years (2, 3). Cessation of NA after long-term viral suppression in patients without HBV seroclearance might reduce costs and may even increase the chance of subsequent HBsAg loss. We have recently shown in a retrospective multicentric international study, that Caucasian ethnicity and off-treatment viral control are associated with HBsAg loss after NA cessation. In this study we will prospectively stop NA in both Caucasian and non-Caucasian patients matched for gender and age, to validate the observed host and viral parameters for future roll-out of this treatment strategy."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Chronic Hepatitis b"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Chronic Hepatitis B"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Non-Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"90",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Caucasian patients",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Cessation of treatment",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Cessation of ongoing treatment"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"non-Caucasian patients",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Cessation of treatment",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Cessation of ongoing treatment"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Cessation of ongoing treatment",
                    "InterventionDescription":"Cessation of ongoing treatment",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Caucasian patients",
                        "non-Caucasian patients"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"sustained viral control at week 72 after cessation",
                    "PrimaryOutcomeDescription":"sustained viral control at week 72 after cessation",
                    "PrimaryOutcomeTimeFrame":"72 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nChronic hepatitis B: HBsAg+ or HBV DNA+ >6 months\nUnder continuous NA treatment (Lamivudin, Adefovir, Tenofovir or Entecavir)\n>18 years old\nHBeAg negative at start of treatment\nHBV DNA undetectable >36 months or <100 IU/mL >48 months\n\nExclusion Criteria:\n\nFibrosis >F2 at pre-treatment start biopsy and/or fibrosis >F2 at any Fibroscan/ShearWave (unless they agree for a new biopsy)\nCoÃ¯nfection: Hepatitis C, hepatitis delta, HIV\nChronic immune suppressive medication\nEver HCC\nEver participated in HBV siRNA therapeutic trials\nParticipation in other HBV therapeutic intervention studies <6 months before inclusion",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Thomas Vanwolleghem, MD PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+32 3 281 38 53",
                    "CentralContactEMail":"thomas.vanwolleghem@uza.be"
                  },{
                    "CentralContactName":"Arno Furquim d'Almeida, PharmD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+32 3 265 26 89",
                    "CentralContactEMail":"arno.furquimdalmeida@uantwerpen.be"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Thomas Vanwolleghem, MD PhD",
                    "OverallOfficialAffiliation":"University Hospital, Antwerp",
                    "OverallOfficialRole":"Study Chair"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"ASZ Aalst",
                    "LocationCity":"Aalst",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Isabelle Colle, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"ZNA Stuivenberg",
                    "LocationCity":"Antwerp",
                    "LocationZip":"2060",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Stefan Bourgeois, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Antwerp University Hospital",
                    "LocationCity":"Antwerp",
                    "LocationZip":"2650",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Thomas Vanwolleghem, MD PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+32 3 281 38 53",
                          "LocationContactEMail":"thomas.vanwolleghem@uza.be"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"GZA Antwerp",
                    "LocationCity":"Antwerp",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Dirk Sprengers, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"AZ Sint-Jan Brugge",
                    "LocationCity":"Brugge",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Hans Orlent, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CHU Brugmann",
                    "LocationCity":"Brussels",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Baro Deressa, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CHU Saint-Pierre",
                    "LocationCity":"Brussels",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Thomas SerstÃ©, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"ULB Erasme Hospital",
                    "LocationCity":"Brussels",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Christophe MorÃ©no, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"UZ Brussels",
                    "LocationCity":"Brussels",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Hendrik Reynaert, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CHU Charleroi",
                    "LocationCity":"Charleroi",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Sergio Negrin-Dastis, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"ZOL Genk",
                    "LocationCity":"Genk",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Geert Robaeys, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"AZ Maria Middelares Gent",
                    "LocationCity":"Gent",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Christophe Vansteenkiste, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"AZ Virga Jesse Hasselt",
                    "LocationCity":"Hasselt",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Filip Janssens, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Groupe Jolimont",
                    "LocationCity":"La LouviÃ¨re",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Jean Henrion, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CHU Sart-Tilmann",
                    "LocationCity":"LiÃ¨ge",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Jean Delwaide, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"AZ Damiaan",
                    "LocationCity":"Ostend",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Mike Cool, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"AZ Nikolaas",
                    "LocationCity":"Sint-Niklaas",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Wim Verlinden, MD PhD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"AZ Turnhout",
                    "LocationCity":"Turnhout",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Guy Van Roey, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"Upon publication of the findings",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol",
                  "Statistical Analysis Plan (SAP)",
                  "Informed Consent Form (ICF)",
                  "Clinical Study Report (CSR)",
                  "Analytic Code"
                ]
              },
              "IPDSharingTimeFrame":"Upon publication of the findings",
              "IPDSharingAccessCriteria":"Through request to the study chair, prof. dr. Thomas Vanwolleghem"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000006506",
                    "ConditionMeshTerm":"Hepatitis A"
                  },{
                    "ConditionMeshId":"D000006509",
                    "ConditionMeshTerm":"Hepatitis B"
                  },{
                    "ConditionMeshId":"D000019694",
                    "ConditionMeshTerm":"Hepatitis B, Chronic"
                  },{
                    "ConditionMeshId":"D000006505",
                    "ConditionMeshTerm":"Hepatitis"
                  },{
                    "ConditionMeshId":"D000006521",
                    "ConditionMeshTerm":"Hepatitis, Chronic"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000008107",
                    "ConditionAncestorTerm":"Liver Diseases"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  },{
                    "ConditionAncestorId":"D000006525",
                    "ConditionAncestorTerm":"Hepatitis, Viral, Human"
                  },{
                    "ConditionAncestorId":"D000014777",
                    "ConditionAncestorTerm":"Virus Diseases"
                  },{
                    "ConditionAncestorId":"D000004769",
                    "ConditionAncestorTerm":"Enterovirus Infections"
                  },{
                    "ConditionAncestorId":"D000010850",
                    "ConditionAncestorTerm":"Picornaviridae Infections"
                  },{
                    "ConditionAncestorId":"D000012327",
                    "ConditionAncestorTerm":"RNA Virus Infections"
                  },{
                    "ConditionAncestorId":"D000018347",
                    "ConditionAncestorTerm":"Hepadnaviridae Infections"
                  },{
                    "ConditionAncestorId":"D000004266",
                    "ConditionAncestorTerm":"DNA Virus Infections"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8175",
                    "ConditionBrowseLeafName":"Hepatitis A",
                    "ConditionBrowseLeafAsFound":"Hepatitis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8178",
                    "ConditionBrowseLeafName":"Hepatitis B",
                    "ConditionBrowseLeafAsFound":"Hepatitis B",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M20193",
                    "ConditionBrowseLeafName":"Hepatitis B, Chronic",
                    "ConditionBrowseLeafAsFound":"Chronic Hepatitis B",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8174",
                    "ConditionBrowseLeafName":"Hepatitis",
                    "ConditionBrowseLeafAsFound":"Hepatitis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8190",
                    "ConditionBrowseLeafName":"Hepatitis, Chronic",
                    "ConditionBrowseLeafAsFound":"Chronic Hepatitis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9690",
                    "ConditionBrowseLeafName":"Liver Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8193",
                    "ConditionBrowseLeafName":"Hepatitis, Viral, Human",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16105",
                    "ConditionBrowseLeafName":"Virus Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6513",
                    "ConditionBrowseLeafName":"Enterovirus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M12328",
                    "ConditionBrowseLeafName":"Picornaviridae Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13732",
                    "ConditionBrowseLeafName":"RNA Virus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19071",
                    "ConditionBrowseLeafName":"Hepadnaviridae Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6025",
                    "ConditionBrowseLeafName":"DNA Virus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":63,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779957",
              "OrgStudyIdInfo":{
                "OrgStudyId":"RC31/19/0511"
              },
              "Organization":{
                "OrgFullName":"University Hospital, Toulouse",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy",
              "OfficialTitle":"Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy ; a Pilot Phase II Study.",
              "Acronym":"RAIPONS"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 2024",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"April 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University Hospital, Toulouse",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Graft nephrectomy is associated with massive allo-sensitization following this event. The occurrence of anti-HLA antibodies is a major barrier to perform a second kidney transplantation. Investigators propose here to evaluate in a phase II pilot study, the safety of the use of a single dose of Tocilizumab immediately before or after graft nephrectomy. The primary endpoint evaluated here is the occurrence of serious infectious complications following graft nephrectomy, with a treatment by Tocilizumab. Secondary endpoints evaluated here are - to evaluate all complications after graft nephrectomy, - and the Tocilizumab effectiveness to reduce anti-HLA antibodies at one year post nephrectomy.",
              "DetailedDescription":"Background: graft nephrectomy is associated with massive allo-sensitization following this event The occurrence of anti-HLA antibodies is a major barrier to perform a second kidney transplantation. Moreover, a systemic inflammatory response syndrome can occur which could lead to serious patient's complications, in case of early graft thrombosis. To date, no treatment or strategy is available to reduce these risks, after graft nephrectomy. IL-6 is a key cytokine in inflammation, but also in the development of T and B cells activation. This treatment previously demonstrated a major role in the occurrence of allo-antibodies. Tocilizumab is a monoclonal antibody blocking IL6 receptor, previously used with success in kidney transplantation to reduce anti-HLA antibodies mediated rejection.\n\nObjectives: Investigators hypothetize that Tocilizumab is usefull to prevent allo-sensitization post graft nephrectomy. They propose here to evaluate in a phase II pilot study, the safety of the use of a single dose of Tocilizumab immediately before or after graft nephrectomy."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Kidney Transplantation",
                  "Graft Failure"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Kidney transplantation",
                  "allosensitization",
                  "graft nephrectomy",
                  "Donor-Specific Antibodies"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"18",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Tocilizumab",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Evaluation of the use of Tocilizumab after allograft nephrectomy.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Tocilizumab"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Tocilizumab",
                    "InterventionDescription":"Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Tocilizumab"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"serious infectious complication",
                    "PrimaryOutcomeDescription":"serious infectious complication rate at 1 year post graft nephrectomy",
                    "PrimaryOutcomeTimeFrame":"1 year post graft nephrectomy"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Complications after treatment",
                    "SecondaryOutcomeDescription":"Safety excluding serious infectious complications one year after nephrectomy, used by:\n\nThe occurrence of post-nephrectomy complications\nThe occurrence of death\nThe occurrence of hospitalizations\nThe occurrence of surgical complications\nThe occurrence of infectious complications (mild and moderate)",
                    "SecondaryOutcomeTimeFrame":"1 year post graft nephrectomy"
                  },{
                    "SecondaryOutcomeMeasure":"The effectiveness of the treatment",
                    "SecondaryOutcomeDescription":"-The effectiveness of the treatmentassessed by the rate of immunization after a post nephrectomy",
                    "SecondaryOutcomeTimeFrame":"1 year post graft nephrectomy"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAdult recipients,\naffiliated to the social security\nrequiring a graft nephrectomy, with a project to retransplantation\n\nExclusion Criteria:\n\ncombined transplantations, PRA >20%.\nPatient under protective measures,\nRituximab used for immunosuppression induction\nPrevious transplants not removed,\nActive infectious complications at graft nephrectomy, need for immunosuppressive treatments after graft nephrectomy,\nParticipation to another interventional studies using Rituximab, polyclonal antibodies, Eucizumab, or Tocilizumab.\nadults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision,\npregnancy or breastfeeding.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Arnaud DEL BELLO, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"0561323923",
                    "CentralContactEMail":"delbello.a@chu-toulouse.fr"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Arnaud DEL BELLO, MD",
                    "OverallOfficialAffiliation":"University Hospital, Toulouse",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2806",
                    "InterventionBrowseLeafName":"Antibodies",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8767",
                    "InterventionBrowseLeafName":"Immunoglobulins",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":64,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779944",
              "OrgStudyIdInfo":{
                "OrgStudyId":"AssiutU1235"
              },
              "Organization":{
                "OrgFullName":"Assiut University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Impact of SARS-CoV-2 Pandemic on Psychological State of Health Care Workers",
              "OfficialTitle":"Impact of SARS-CoV-2 Pandemic on Psychological State of Health Care Workers"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 7, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"July 30, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"August 15, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 27, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Heba A Yassa",
                "ResponsiblePartyInvestigatorTitle":"Professor of Forensic Medicine and Clinical Toxicology",
                "ResponsiblePartyInvestigatorAffiliation":"Assiut University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Assiut University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"In COVID-19 pandemic, many health-care workers (HCWs) have worked in high-pressure environments. They have been exposed to and faced moral dilemmas in addition to infection exposure risk are increasing the risk of mental health disorders.",
              "DetailedDescription":"Throughout the SARS-CoV-2 pandemic, many HCWs have worked in high-pressure environments. Moreover, they may have been exposed to trauma and/or faced moral dilemmas relating to challenges in the delivery of high-quality care, possibly due to a lack of experience or equipment, or as a result of low staffing levels. These unfavorable circumstances and exposure risk to infection are likely to increase the risk of mental health disorders such as post-traumatic stress disorder (PTSD) or depression, other anxiety disorders, substance misuse and suicide In the present study, This study aimed to assess the psychological state of HCWs who were facing challenges of SARS-CoV-2pandemic comparing them to non medical staff group based on use of the Hamilton Anxiety and Depression Rating Scale."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "SARS-CoV-2"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "SARS-CoV-2",
                  "Anxiety",
                  "Depression"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"300",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"other",
                    "InterventionDescription":"questionnaire",
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "questionnaire"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Questionnaire to assess the psychological impacts of SARS-CoV-2 on health care workers",
                    "PrimaryOutcomeDescription":"Impact of SARS-CoV-2 on the Psychology of health care workers",
                    "PrimaryOutcomeTimeFrame":"4 month"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAll health workers team\n\nExclusion Criteria:\n\nno exclusion criteria",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"25 Years",
              "MaximumAge":"70 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"All that work in the hospitals either doctors, nurses, dentist, pharmacysit",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Aliae Mohamed Hussein",
                    "OverallOfficialAffiliation":"Assiut university- professor",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Noha Abo Elfetoh",
                    "OverallOfficialAffiliation":"Assiut university- professor",
                    "OverallOfficialRole":"Study Chair"
                  },{
                    "OverallOfficialName":"Hoda Makhlouf",
                    "OverallOfficialAffiliation":"Assiut university- professor",
                    "OverallOfficialRole":"Study Chair"
                  },{
                    "OverallOfficialName":"Nahed Makhlouf",
                    "OverallOfficialAffiliation":"Assiut university- professor",
                    "OverallOfficialRole":"Study Chair"
                  },{
                    "OverallOfficialName":"Ahmed AbdelBaqy",
                    "OverallOfficialAffiliation":"Assiut university- Assistant professor",
                    "OverallOfficialRole":"Study Chair"
                  },{
                    "OverallOfficialName":"Heba Yassa",
                    "OverallOfficialAffiliation":"Assiut university- professor",
                    "OverallOfficialRole":"Study Director"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"heba Yassa",
                    "LocationCity":"Assiut",
                    "LocationZip":"71515",
                    "LocationCountry":"Egypt"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"29786495",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Williamson V, Stevelink SAM, Greenberg N. Occupational moral injury and mental health: systematic review and meta-analysis. Br J Psychiatry. 2018 Jun;212(6):339-346. doi: 10.1192/bjp.2018.55."
                  },{
                    "ReferencePMID":"32179701",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020 May 1;368(6490):489-493. doi: 10.1126/science.abb3221. Epub 2020 Mar 16."
                  },{
                    "ReferencePMID":"32217624",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Greenberg N, Docherty M, Gnanapragasam S, Wessely S. Managing mental health challenges faced by healthcare workers during covid-19 pandemic. BMJ. 2020 Mar 26;368:m1211. doi: 10.1136/bmj.m1211."
                  },{
                    "ReferencePMID":"29420257",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Brooks S, AmlÃ´t R, Rubin GJ, Greenberg N. Psychological resilience and post-traumatic growth in disaster-exposed organisations: overview of the literature. BMJ Mil Health. 2020 Feb;166(1):52-56. doi: 10.1136/jramc-2017-000876. Epub 2018 Feb 2. Review."
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M2905",
                    "ConditionBrowseLeafName":"Anxiety Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5641",
                    "ConditionBrowseLeafName":"Depression",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5644",
                    "ConditionBrowseLeafName":"Depressive Disorder",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":65,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779931",
              "OrgStudyIdInfo":{
                "OrgStudyId":"18-0973"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"K76AG059934",
                    "SecondaryIdType":"U.S. NIH Grant/Contract",
                    "SecondaryIdLink":"https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=K76AG059934&Fy=all"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"University of Colorado, Denver",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Social Convoy Palliative Care (Convoy-Pal) Mobile Health for Older Adults",
              "OfficialTitle":"The Usability and Feasibility of Social Convoy Palliative Care (Convoy-Pal) Mobile Health for Older Adults",
              "Acronym":"ConvoyPal"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"February 28, 2023",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"February 28, 2023",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of Colorado, Denver",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"National Institute on Aging (NIA)",
                    "CollaboratorClass":"NIH"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The aim of this study is to test the feasibility and usability of the Convoy-Pal mobile intervention among older adults. We will conduct a pilot waitlist control RCT with 40 patients and their convoys randomized to one of two arms: Convoy-Pal intervention or waitlist control. Feasibility will be assessed by recruitment, attrition, and data collection on measures of quality of life and social support. Usability will be captured by self-report usability scales and actual back end utilization data."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Chronic Conditions, Multiple"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Health Services Research",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"40",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Convoy-Pal Intervention",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Intervention participants will be sent Convoy-Pal equipment and materials. The equipment can simply be removed from the box, plugged in, and turned on to start. Research staff will provide technical support as needed during the trial. Convoy-Pal is 12-week intervention that uses the Routinify platform to deliver self-management tools and palliative care resources in the participants' home. The platform includes a tablet, charging stand, and smart watch, with additional options for mobile phone access and a website portal.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Convoy-Pal"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Waitlist Control",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Participants will complete baseline assessments and will be recontacted at 11 weeks to complete follow up assessments at week 12. Participants will receive a $25 gift card for each assessment ($50 total). If they would like to try the intervention at that time, we will send them Convoy-Pal equipment and materials. They will then have 12 weeks to use the tool.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Convoy-Pal"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"Convoy-Pal",
                    "InterventionDescription":"12 week mobile self-management intervention with palliative care resources.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Convoy-Pal Intervention",
                        "Waitlist Control"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"User Mobile Application Rating Scale",
                    "PrimaryOutcomeDescription":"Usability; 20 items; Range 0-25, Higher score indicates better usability",
                    "PrimaryOutcomeTimeFrame":"12 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nâ‰¥65 years of age\nself-report diagnosis of heart failure (HF)\nhave multiple chronic conditions (MCC) based on the Disease Burden/Morbidity Assessment by Self-Report (Individuals will be eligible if they self-report the number of diagnosis > 2 and a disease burden score >2 indicating the presence of at least two chronic conditions that limit activities of daily of living)\ncommunity dwelling in the United States\nEnglish speaking\n\nExclusion Criteria:\n\nSelf-reported diagnosis of Alzheimer's disease or dementia\nSelf-reported diagnosis of a severe mental health problem (e.g. schizophrenia, bipolar affective disorder or other psychotic illness)\nParticipation in community-based palliative care in the last 12 months",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Jennifer Portz, PhD, MSW",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"(303) 724-4438",
                    "CentralContactEMail":"Jennifer.portz@cuanschutz.edu"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Jennifer B Portz, PhD, MSW",
                    "OverallOfficialAffiliation":"University of Colorado Denver | Anschutz",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000071069",
                    "ConditionMeshTerm":"Multiple Chronic Conditions"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000002908",
                    "ConditionAncestorTerm":"Chronic Disease"
                  },{
                    "ConditionAncestorId":"D000020969",
                    "ConditionAncestorTerm":"Disease Attributes"
                  },{
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M692",
                    "ConditionBrowseLeafName":"Multiple Chronic Conditions",
                    "ConditionBrowseLeafAsFound":"Chronic Conditions, Multiple",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4730",
                    "ConditionBrowseLeafName":"Chronic Disease",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21284",
                    "ConditionBrowseLeafName":"Disease Attributes",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":66,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779918",
              "OrgStudyIdInfo":{
                "OrgStudyId":"TB.2020.01.01"
              },
              "Organization":{
                "OrgFullName":"Tela Bio Inc",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"Study Evaluating the Clinical Outcomes of Ventral Hernias Treated Robotically With OviTexÂ® Reinforced Tissue Matrix",
              "OfficialTitle":"A Prospective Study Evaluating the Clinical Outcomes of Ventral Hernias Treated Robotically With OviTexÂ® Reinforced Tissue Matrix",
              "Acronym":"BRAVO II"
            },
            "StatusModule":{
              "StatusVerifiedDate":"January 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"June 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Tela Bio Inc",
                "LeadSponsorClass":"INDUSTRY"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Emergent Clinical Consulting",
                    "CollaboratorClass":"UNKNOWN"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"Yes",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This study is designed to evaluate the post-operative complications and re-herniations following the use of OviTex in subjects with ventral hernias. Up to 100 subjects will participate in the study from up to 3 investigator sites.",
              "DetailedDescription":"This study is intended to evaluate the post-operative complications and re-herniations following the use of OviTex in ventral hernias being treated robotically. It is a single-arm study and all subjects will receive OviTex."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Hernia, Ventral"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "use of mesh",
                  "robotic hernia repair"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"100",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"OviTex Reinforced Tissue Matrix",
                    "ArmGroupType":"Other",
                    "ArmGroupDescription":"This is a single-arm study. All study subjects will receive OviTex.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: OviTex Reinforced Tissue Matrix"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Device",
                    "InterventionName":"OviTex Reinforced Tissue Matrix",
                    "InterventionDescription":"All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "OviTex Reinforced Tissue Matrix"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Early surgical site occurrences or wound related events",
                    "PrimaryOutcomeDescription":"Incidence of early peri- and post-operative surgical site occurrences or wound related events noted at the hernia repair site",
                    "PrimaryOutcomeTimeFrame":"occurring within the first 3 months of the ventral hernia repair"
                  },{
                    "PrimaryOutcomeMeasure":"Early post-operative complications",
                    "PrimaryOutcomeDescription":"Incidence of other early post-operative complications",
                    "PrimaryOutcomeTimeFrame":"occurring within the first three months of the ventral hernia repair."
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Late surgical site occurrences or wound related events",
                    "SecondaryOutcomeDescription":"Incidence of late post-operative surgical site occurrences or wound related events noted at the hernia repair site",
                    "SecondaryOutcomeTimeFrame":"occurring > 3 months after index surgery"
                  },{
                    "SecondaryOutcomeMeasure":"Late post-operative complications",
                    "SecondaryOutcomeDescription":"Incidence of other late post-operative complications",
                    "SecondaryOutcomeTimeFrame":"occurring > 3 months after index surgery."
                  },{
                    "SecondaryOutcomeMeasure":"Patient Reported Outcomes",
                    "SecondaryOutcomeDescription":"Patient Reported Outcomes (QoL and pain assessments)",
                    "SecondaryOutcomeTimeFrame":"Assessed at day 30, day 90, 12 months, and 24 months post-op"
                  },{
                    "SecondaryOutcomeMeasure":"Hernia Recurrence",
                    "SecondaryOutcomeDescription":"True hernia recurrence at the site of surgery",
                    "SecondaryOutcomeTimeFrame":"at post-operative day 90 and months 12 and 24"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nSubject suffers from a ventral or incisional hernia that requires surgical repair with the use of an implant to reinforce or replace weakened or missing tissue.\nThe patient is scheduled for a robotic approach.\nThe size of the implant needed for repair is expected to be less than 25 x 40 cm for OviTex Core and 1S and 12 x 18 cm for OviTex LPR.\nSubject meets CDC/SSI Wound Classification Class I (Clean), Class II (Clean-Contaminated) or Class III (Contaminated) criteria.\nSubject has VHWG score of Grade 1, 2 or 3.\nSubject is willing and able to sign an informed consent for the study and has signed the IRB approved Informed Consent form for this study.\nSubject is able to complete Quality of Life (QoL) and pain questionnaires.\nSubject is at least 22 years old, (or considered an adult per state law).\nSubject is able to participate fully in, and for the full duration of, the study.\n\nExclusion Criteria:\n\nSubject has a BMI of > 40\nSubject meets CDC/SSI Wound Classification Class IV (Dirty-Infected) criteria\nSubject has VHWG score of Grade 4.\nSubject is female and is pregnant.\nSubject has a life expectancy of < 2 years making it unlikely that the subject will successfully achieve two-year follow-up.\nSubject has recent history of drug or alcohol abuse (in last 3 years).\nSubject has an allergy to ovine-derived products.\nSubject has participated in another clinical trial within the past 30 days or is currently involved in another clinical trial.",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"22 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Emily Gentile",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"610-454-7200",
                    "CentralContactEMail":"emily@emergentclinical.com"
                  },{
                    "CentralContactName":"Neal Overbeck",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"484-320-2930",
                    "CentralContactPhoneExt":"2958",
                    "CentralContactEMail":"noverbeck@telabio.com"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Investigative Site",
                    "LocationCity":"Overland Park",
                    "LocationState":"Kansas",
                    "LocationZip":"66213",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Emily Gentile",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"emily@emergentclinical.com"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000006547",
                    "ConditionMeshTerm":"Hernia"
                  },{
                    "ConditionMeshId":"D000006555",
                    "ConditionMeshTerm":"Hernia, Ventral"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000020763",
                    "ConditionAncestorTerm":"Pathological Conditions, Anatomical"
                  },{
                    "ConditionAncestorId":"D000046449",
                    "ConditionAncestorTerm":"Hernia, Abdominal"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8208",
                    "ConditionBrowseLeafName":"Hernia",
                    "ConditionBrowseLeafAsFound":"Hernia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8216",
                    "ConditionBrowseLeafName":"Hernia, Ventral",
                    "ConditionBrowseLeafAsFound":"Hernia, Ventral",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M21103",
                    "ConditionBrowseLeafName":"Pathological Conditions, Anatomical",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M24262",
                    "ConditionBrowseLeafName":"Hernia, Abdominal",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":67,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779905",
              "OrgStudyIdInfo":{
                "OrgStudyId":"Soh-Med-21-02-40"
              },
              "Organization":{
                "OrgFullName":"Sohag University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases",
              "OfficialTitle":"Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients",
              "Acronym":"NAFLD"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 28, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"July 30, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"September 15, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Mona Mohammed Abdelrhman",
                "ResponsiblePartyInvestigatorTitle":"Principal investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Sohag University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Sohag University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with metabolic syndrome, obesity, and type II diabetes. NAFLD is considered to be an independent risk factor for cardiovascular disease and there is accumulating evidence to support a causative role in the development of chronic kidney disease (CKD). So, we aim first to assess the prevalence of chronic kidney disease in NAFLD patients, secondly to detect the association between hepatic fibrosis and CKD in NAFLD patients",
              "DetailedDescription":"This study will be conducted on 100 patients 70 patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital, and A control group of 30 healthy volunteers who looks normal on ultrasonography from February 2021 to July 2021.\n\nMethods:\n\nAll included patients will be subjected to:\n\nDetailed history, complete general and systemic examination .\nBMI will be calculated as follow\nAbdominal Ultrasonography.\n\nLaboratory investigations:\n\nFasting and post-prandial blood sugar Serum lipogram. Liver function tests. Serum creatinine, Albumin -creatinine Ratio.\n\nCalculation of estimated Glomerular Filtration Rate eGFR.\nLiver stiffness measurements to detect degree of fibrosis and measurement of the degree of steatosis using (Fibroscan)\n\nEthical considerations:\n\nThe study will be approved by The Ethical committee of Sohag Faculty of Medicine, Sohag University.\n\nThe study protocol will be adherent to practice guidelines of the World Medical Association Code of Ethics (Declaration of Helsinki).\n\nAfter explanation about the nature of the procedures, possible complications, benefits, and steps of the study, All patients will give a written informed consent for participating in the study, performing abdominal ultrasound, taking blood samples, performing fibroscan."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Chronic Kidney Diseases"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "chronic kidney disease, NAFLD, fibrosis"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Control"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Cross-Sectional"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"100",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Non-alcoholic Fatty Liver Diseases",
                    "ArmGroupDescription":"patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Diagnostic Test: urinary albumbin/creatinine ratio"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"control",
                    "ArmGroupDescription":"healthy volunteers who looks normal on ultrasonography",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Diagnostic Test: urinary albumbin/creatinine ratio"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Diagnostic Test",
                    "InterventionName":"urinary albumbin/creatinine ratio",
                    "InterventionDescription":"detection of microalbuminuria in nafld patients",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Non-alcoholic Fatty Liver Diseases",
                        "control"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "estimated glomerular filtration rate"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"prevalence of chronic kidney disease in nafld patient",
                    "PrimaryOutcomeTimeFrame":"February 2021 to July 2021"
                  },{
                    "PrimaryOutcomeMeasure":"correlation of chronic kidney disease and degree of hepatic fibrosis in nafld patient",
                    "PrimaryOutcomeTimeFrame":"February 2021 to July 2021"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\npatients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital\n\nExclusion Criteria:\n\nDiabetic patients.\nHypertensive patients.\nOther causes of chronic liver disease rather than NAFLD.",
              "Gender":"All",
              "MinimumAge":"20 Years",
              "MaximumAge":"80 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"This study will be conducted on 100 patients 70 patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital, and A control group of 30 healthy volunteers who looks normal on ultrasonography from February 2021 to July 2021",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Mona Abdelrahmam, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"01021025895",
                    "CentralContactPhoneExt":"002",
                    "CentralContactEMail":"monamohamed@med.sohag.edu.eg"
                  },{
                    "CentralContactName":"Osama Orabi, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"01010817881",
                    "CentralContactPhoneExt":"002",
                    "CentralContactEMail":"Osamaabbas@med.sohag.edu.eg"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Radwa Farag, MD",
                    "OverallOfficialAffiliation":"Sohag University",
                    "OverallOfficialRole":"Study Chair"
                  },{
                    "OverallOfficialName":"Mohamed Amin, MD",
                    "OverallOfficialAffiliation":"Sohag University",
                    "OverallOfficialRole":"Study Chair"
                  },{
                    "OverallOfficialName":"Shimaa Hemdan, MD",
                    "OverallOfficialAffiliation":"Sohag University",
                    "OverallOfficialRole":"Study Chair"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Mona Mohammed Abdelrahman",
                    "LocationCity":"Sohag",
                    "LocationCountry":"Egypt"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"21623852",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30. Review."
                  },{
                    "ReferencePMID":"22488764",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762."
                  },{
                    "ReferencePMID":"24042449",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90. doi: 10.1038/nrgastro.2013.171. Epub 2013 Sep 17. Review."
                  },{
                    "ReferencePMID":"21965592",
                    "ReferenceType":"background",
                    "ReferenceCitation":"McCullough K, Sharma P, Ali T, Khan I, Smith WC, MacLeod A, Black C. Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant. 2012 May;27(5):1812-21. doi: 10.1093/ndt/gfr547. Epub 2011 Sep 29. Review."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000008107",
                    "ConditionMeshTerm":"Liver Diseases"
                  },{
                    "ConditionMeshId":"D000005234",
                    "ConditionMeshTerm":"Fatty Liver"
                  },{
                    "ConditionMeshId":"D000065626",
                    "ConditionMeshTerm":"Non-alcoholic Fatty Liver Disease"
                  },{
                    "ConditionMeshId":"D000007674",
                    "ConditionMeshTerm":"Kidney Diseases"
                  },{
                    "ConditionMeshId":"D000051436",
                    "ConditionMeshTerm":"Renal Insufficiency, Chronic"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000014570",
                    "ConditionAncestorTerm":"Urologic Diseases"
                  },{
                    "ConditionAncestorId":"D000051437",
                    "ConditionAncestorTerm":"Renal Insufficiency"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M9690",
                    "ConditionBrowseLeafName":"Liver Diseases",
                    "ConditionBrowseLeafAsFound":"Liver Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M6958",
                    "ConditionBrowseLeafName":"Fatty Liver",
                    "ConditionBrowseLeafAsFound":"Fatty Liver",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M29127",
                    "ConditionBrowseLeafName":"Non-alcoholic Fatty Liver Disease",
                    "ConditionBrowseLeafAsFound":"Non-alcoholic Fatty Liver Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M9281",
                    "ConditionBrowseLeafName":"Kidney Diseases",
                    "ConditionBrowseLeafAsFound":"Kidney Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M7068",
                    "ConditionBrowseLeafName":"Fibrosis",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M25304",
                    "ConditionBrowseLeafName":"Renal Insufficiency, Chronic",
                    "ConditionBrowseLeafAsFound":"Chronic Kidney Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M25305",
                    "ConditionBrowseLeafName":"Renal Insufficiency",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M15902",
                    "ConditionBrowseLeafName":"Urologic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T5868",
                    "ConditionBrowseLeafName":"Visceral Steatosis",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXS",
                    "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M9693",
                    "InterventionBrowseLeafName":"Liver Extracts",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Hemat",
                    "InterventionBrowseBranchName":"Hematinics"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":68,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779892",
              "OrgStudyIdInfo":{
                "OrgStudyId":"CMAB008HV-I"
              },
              "Organization":{
                "OrgFullName":"Taizhou Mabtech Pharmaceutical Co.,Ltd",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety",
              "OfficialTitle":"The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety"
            },
            "StatusModule":{
              "StatusVerifiedDate":"January 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 1, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 15, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 15, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Taizhou Mabtech Pharmaceutical Co.,Ltd",
                "LeadSponsorClass":"INDUSTRY"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Rheumatoid Arthritis"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 1"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"Biological: CMAB008 Biological: Remicade",
                "DesignPrimaryPurpose":"Other",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Investigator"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"90",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"CMAB008",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Infliximab"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Remicade",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Infliximab"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Infliximab",
                    "InterventionDescription":"100mg/vial",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "CMAB008",
                        "Remicade"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours After the Single Infusion of CMAB008/Remicade",
                    "PrimaryOutcomeTimeFrame":"up to 1680 hours"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade",
                    "SecondaryOutcomeTimeFrame":"up to 1680 hours"
                  },{
                    "SecondaryOutcomeMeasure":"Time of Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade",
                    "SecondaryOutcomeTimeFrame":"up to 1680 hours"
                  },{
                    "SecondaryOutcomeMeasure":"Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single Infusion of CMAB008/Remicade",
                    "SecondaryOutcomeTimeFrame":"up to 1680 hours"
                  },{
                    "SecondaryOutcomeMeasure":"Total Frequency of AE/SAE Within the Whole Time of the Study",
                    "SecondaryOutcomeTimeFrame":"up to 1680 hours"
                  },{
                    "SecondaryOutcomeMeasure":"Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected",
                    "SecondaryOutcomeTimeFrame":"up to 1680 hours"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nHealthy subject (male) between the ages of 18 and 45 years.\nSubject with a body weight of â‰¥50 kg and â‰¤ 80 kg and a BMI between 19.0~26.0 kg/m2 (both inclusive);\nHealthy as determined by pre-study medical history, physical examination, vital signs and 12-lead electrocardiogram;\n\nExclusion Criteria:\n\nThose who have surgered 4 weeks before signing the informed consent;\nThose with mental, respiratory, cardiovascular, digestive, urinary, reproductive, skeletal and motor, blood, endocrine, nervous and other system diseases, or those with any previous immune diseases;\nThose who have received any drug treatment (including prescription drugs, over-the-counter drugs, biological products, Traditional Chinese medicine, vitamins, dietary supplements, etc.) and health care products within 4 weeks before signing the informed consent;\nThose who accepted biological drugs within 6 months before signing the informed consent, or accepted the TNF monoconal antibody drugs;\nAny one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponema pallidum antibody is positive;\nEither T cell immunospot test (T-SPOT) or antinuclear antibody is positive;\nThose who have infected within 30 days before administration, or serious infection associated with hospitalisation and/or which required inrravenous antibiotics within 3 months before administration.\nVaccinated within 30 months before signing the informed conset, or plan to vaccinate during the trail;\nThose who have used soft drugs within 3 months prior to signing the informed consent or hard drugs within 1 year prior to the trail; those who have positive drug abuse test results;\nThose who drinking too much tea, coffee and/or caffeinated beverages (more than 8 cups, 250ml per cup) every day;\nThose who have a blood donation history of 400 ml within 3 months, or 200 ml within 1 month;\nThose who have a history of drug or food allergy, or are known to be allergic to any component of the test drug or latex, etc.\nThose who are addicted to smoking or smoke more than 10 cigarettes per day on average within 6 months before signing the informed consent;\nAlcoholics or regular drinkers within 3 months before the trail, i.e. those who drink more than 14 units of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits with 40% alcohol), or whose alcohol breath test is positive;\nThose who plan to donate sperm within 6 months after the adminstration of the test drug;",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"Male",
              "MinimumAge":"18 Years",
              "MaximumAge":"45 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Shanghai Xuhui Central Hospital",
                    "LocationCity":"Shanghai",
                    "LocationState":"Shanghai",
                    "LocationZip":"200031",
                    "LocationCountry":"China"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001168",
                    "ConditionMeshTerm":"Arthritis"
                  },{
                    "ConditionMeshId":"D000001172",
                    "ConditionMeshTerm":"Arthritis, Rheumatoid"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000007592",
                    "ConditionAncestorTerm":"Joint Diseases"
                  },{
                    "ConditionAncestorId":"D000009140",
                    "ConditionAncestorTerm":"Musculoskeletal Diseases"
                  },{
                    "ConditionAncestorId":"D000012216",
                    "ConditionAncestorTerm":"Rheumatic Diseases"
                  },{
                    "ConditionAncestorId":"D000003240",
                    "ConditionAncestorTerm":"Connective Tissue Diseases"
                  },{
                    "ConditionAncestorId":"D000001327",
                    "ConditionAncestorTerm":"Autoimmune Diseases"
                  },{
                    "ConditionAncestorId":"D000007154",
                    "ConditionAncestorTerm":"Immune System Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3057",
                    "ConditionBrowseLeafName":"Arthritis",
                    "ConditionBrowseLeafAsFound":"Arthritis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3061",
                    "ConditionBrowseLeafName":"Arthritis, Rheumatoid",
                    "ConditionBrowseLeafAsFound":"Rheumatoid Arthritis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M9204",
                    "ConditionBrowseLeafName":"Joint Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10680",
                    "ConditionBrowseLeafName":"Musculoskeletal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13628",
                    "ConditionBrowseLeafName":"Rheumatic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4906",
                    "ConditionBrowseLeafName":"Collagen Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5047",
                    "ConditionBrowseLeafName":"Connective Tissue Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3210",
                    "ConditionBrowseLeafName":"Autoimmune Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8783",
                    "ConditionBrowseLeafName":"Immune System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC05",
                    "ConditionBrowseBranchName":"Muscle, Bone, and Cartilage Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC17",
                    "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC20",
                    "ConditionBrowseBranchName":"Immune System Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000069285",
                    "InterventionMeshTerm":"Infliximab"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000003879",
                    "InterventionAncestorTerm":"Dermatologic Agents"
                  },{
                    "InterventionAncestorId":"D000005765",
                    "InterventionAncestorTerm":"Gastrointestinal Agents"
                  },{
                    "InterventionAncestorId":"D000018501",
                    "InterventionAncestorTerm":"Antirheumatic Agents"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M375",
                    "InterventionBrowseLeafName":"Infliximab",
                    "InterventionBrowseLeafAsFound":"Inflammation",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M5657",
                    "InterventionBrowseLeafName":"Dermatologic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M7464",
                    "InterventionBrowseLeafName":"Gastrointestinal Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19188",
                    "InterventionBrowseLeafName":"Antirheumatic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"ARhu",
                    "InterventionBrowseBranchName":"Antirheumatic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"Derm",
                    "InterventionBrowseBranchName":"Dermatologic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"Gast",
                    "InterventionBrowseBranchName":"Gastrointestinal Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":69,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779879",
              "OrgStudyIdInfo":{
                "OrgStudyId":"VIR-7831-5006"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"GSK Study 216912",
                    "SecondaryIdType":"Other Identifier",
                    "SecondaryIdDomain":"GlaxoSmithKline"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Vir Biotechnology, Inc.",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19",
              "OfficialTitle":"A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants With Mild to Moderate Coronavirus Disease 2019 (COVID-19)",
              "Acronym":"COMET-PEAK"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 18, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"September 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Vir Biotechnology, Inc.",
                "LeadSponsorClass":"INDUSTRY"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"GlaxoSmithKline",
                    "CollaboratorClass":"INDUSTRY"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"Yes",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Gen1) or VIR-7831 (Gen2) and will be assessed for safety, tolerability, and pharmacokinetics."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "SARS-CoV-2",
                  "coronavirus",
                  "coronavirus disease 2019",
                  "COVID-19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"40",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"VIR-7831 (Gen1)",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: VIR-7831 (Gen1)"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"VIR-7831 (Gen2)",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: VIR-7831 (Gen2)"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Biological",
                    "InterventionName":"VIR-7831 (Gen1)",
                    "InterventionDescription":"VIR-7831 (Gen1) given as IV infusion",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "VIR-7831 (Gen1)"
                      ]
                    }
                  },{
                    "InterventionType":"Biological",
                    "InterventionName":"VIR-7831 (Gen2)",
                    "InterventionDescription":"VIR-7831 (Gen2) given as IV infusion",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "VIR-7831 (Gen2)"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Occurrence of adverse events (AEs)",
                    "PrimaryOutcomeTimeFrame":"Through Day 29"
                  },{
                    "PrimaryOutcomeMeasure":"Occurrence of serious adverse events (SAEs)",
                    "PrimaryOutcomeTimeFrame":"Through Day 29"
                  },{
                    "PrimaryOutcomeMeasure":"Occurrence of adverse events of special interest (AESIs)",
                    "PrimaryOutcomeTimeFrame":"Through Day 29"
                  },{
                    "PrimaryOutcomeMeasure":"Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) readings",
                    "PrimaryOutcomeTimeFrame":"Through Day 29"
                  },{
                    "PrimaryOutcomeMeasure":"Occurrence of disease progression events (not classified as AEs)",
                    "PrimaryOutcomeTimeFrame":"Through Day 29"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Cmax",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Clast",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Tmax",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Tlast",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"AUCD0-28",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"AUCinf",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"AUClast",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"%AUCexp",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"t1/2",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Vz",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Vss",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"CL",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Occurrence of SAEs",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Occurrence of AESIs",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Occurrence of clinically significant abnormalities on 12-lead ECG readings",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Occurrence of disease progression events (not classified as AEs)",
                    "SecondaryOutcomeTimeFrame":"Through 24 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nParticipant must be aged 18 years or older at the time of obtaining informed consent\nParticipants who have a positive SARS-CoV-2 test result â‰¤7 days prior to enrollment and oxygen saturation â‰¥94% on room air and have COVID-19 symptoms and â‰¤7 days from onset of symptoms\n\nExclusion Criteria:\n\nCurrently hospitalized or judged by the investigator as likely to require hospitalization in the next 24 hours\nSymptoms consistent with severe COVID-19\nParticipants who, in the judgement of the investigator are likely to die in the next 7 days.\nSeverely immunocompromised participants",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Study Inquiry",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"415-654-5281",
                    "CentralContactEMail":"clinicaltrials@vir.bio"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Investigative Site",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Anniston",
                    "LocationState":"Alabama",
                    "LocationZip":"36207",
                    "LocationCountry":"United States"
                  },{
                    "LocationFacility":"Investigative Site",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Bakersfield",
                    "LocationState":"California",
                    "LocationZip":"93301",
                    "LocationCountry":"United States"
                  },{
                    "LocationFacility":"Investigative Site",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Fort Pierce",
                    "LocationState":"Florida",
                    "LocationZip":"34982",
                    "LocationCountry":"United States"
                  },{
                    "LocationFacility":"Investigative Site",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Winfield",
                    "LocationState":"Illinois",
                    "LocationZip":"60190",
                    "LocationCountry":"United States"
                  },{
                    "LocationFacility":"Investigative Site",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Rockville",
                    "LocationState":"Maryland",
                    "LocationZip":"20850",
                    "LocationCountry":"United States"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M19074",
                    "ConditionBrowseLeafName":"Coronavirus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":70,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779866",
              "OrgStudyIdInfo":{
                "OrgStudyId":"NCT09384"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"3R01AT009384-04S1",
                    "SecondaryIdType":"U.S. NIH Grant/Contract",
                    "SecondaryIdLink":"https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=3R01AT009384-04S1&Fy=all"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Baylor University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Hypnosis for Sleep Quality in Caregivers of Individuals With Alzheimer's Disease",
              "OfficialTitle":"Feasibility of Self-Administered Hypnosis for Sleep Quality in Caregivers of Individuals With Alzheimer's Disease"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 15, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 31, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"August 31, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 4, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Gary R. Elkins",
                "ResponsiblePartyInvestigatorTitle":"Director of Mind-Body Medicine Research Lab",
                "ResponsiblePartyInvestigatorAffiliation":"Baylor University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Baylor University",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"National Center for Complementary and Integrative Health (NCCIH)",
                    "CollaboratorClass":"NIH"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The long-range goal is to identify an efficacious and practical intervention to improve sleep quality and duration for family caregivers of individuals with Alzheimer's disease and related dementias (ADRD). The main goal of this study is to determine feasibility of a self-administered hypnosis intervention with caregivers of individuals with ADRD by randomizing eligible participants into one of two study arms, self-administered hypnosis (treatment group) or sham white noise hypnosis (control group). The investigators are also examining the feasibility of accrual, outcome measures (diaries, actigraphy) and study design.",
              "DetailedDescription":"Study Objectives\n\nAim 1: Determine the accrual, retention, adherence and feasibility, and randomization to the self-administered hypnosis program among caregivers of individuals with ADRD. Feasibility will be determined by (1) drop-out rate, (2) participants' rating of the program, and (3) participants' rating of treatment satisfaction. Adherence will be determined through at-home practice logs. Essential experience on accrual and retention data as well.\n\nAim 2: Determine feasibility of measures: PSQI, actigraphy recordings, and sleep diaries to assess sleep quality and duration, as well as feasibility of secondary self-report outcome measures of insomnia severity, stress, cognition, and pain among caregivers.\n\nAim 3: Determine perceptions of hypnosis and potential barriers for the caregiver population and feedback.\n\nParticipant Selection and Recruitment Plan\n\nA sample of 20 caregivers, both male and female, of individuals with ADRD, who suffer from poor sleep will be enrolled in the study. A screening checklist will be used for screening participants who are interested.\n\nPotential participants will be identified (1) via advertisements and press releases, (2) via physician referral, and (3) targeted mailings. Participants eligibility will be determined by criteria listed on a screening checklist. We have used these strategies in our prior studies and have demonstrated ability to accrue the required number of participants."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Poor Quality Sleep",
                  "Caregiver Stress",
                  "Alzheimer's Disease (Incl Subtypes)"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"Participants will be randomized and either be assigned to the self-hypnosis group or a self-administered white noise hypnosis group.",
                "DesignPrimaryPurpose":"Supportive Care",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignMaskingDescription":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"20",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Self-Administered Hypnosis",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Self-Administered Hypnosis"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"White Noise Hypnosis Control",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Self-Administered White Noise Hypnosis"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"Self-Administered Hypnosis",
                    "InterventionDescription":"Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Self-Administered Hypnosis"
                      ]
                    }
                  },{
                    "InterventionType":"Behavioral",
                    "InterventionName":"Self-Administered White Noise Hypnosis",
                    "InterventionDescription":"Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "White Noise Hypnosis Control"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Self-Hypnosis Practice Log",
                    "PrimaryOutcomeDescription":"Participants will be instructed in daily practice of hypnosis and asked to keep a daily self-hypnosis practice form during the intervention period.",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Program Rating Scale",
                    "PrimaryOutcomeDescription":"In order to assess participants' perceptions of the value of the hypnosis program they receive, they will be asked \"How do you rate this hypnosis program overall in regard to ease of use?\" and \"How do you rate this hypnosis program overall in regard to improving your sleep?\" Responses will be given on a 10-point scale ranging from 1 (Poor) to 10 (Excellent) at follow-up.",
                    "PrimaryOutcomeTimeFrame":"One week"
                  },{
                    "PrimaryOutcomeMeasure":"Treatment Satisfaction Scale",
                    "PrimaryOutcomeDescription":"Participants will be asked to rate their overall level of satisfaction with the intervention. A 10-point VAS scale anchored with 0 \"Completely Dissatisfied\" to 10 \"Completely Satisfied\" will be given at follow-up.",
                    "PrimaryOutcomeTimeFrame":"One week"
                  },{
                    "PrimaryOutcomeMeasure":"Wrist Actigraphy",
                    "PrimaryOutcomeDescription":"Wrist actigraphy is a widely used and well-validated measure of sleep duration. Participants will be asked to wear an actigraph (Actiwatch Spectrum Pro), resembling a wrist watch, on their non-dominant wrist. A motion detection device located within the actigraph records movement. After data is collected and stored within the actigraph it can be analyzed with the Actiware software program. This program uses a series of logarithms to measure various factors associated with sleep quality, such as total sleep duration, sleep efficiency, sleep onset latency, and the number of times participants woke during the night. For the present study, participants will be asked to wear the actigraph for one week at baseline and for one week at follow-up.",
                    "PrimaryOutcomeTimeFrame":"up to 2 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Pittsburgh Sleep Quality Index",
                    "PrimaryOutcomeDescription":"Participants will be asked to complete the Pittsburgh Sleep Quality Index (PSQI) during screening and at follow-up to measure sleep quality. The PSQI is a 19-item self-report inventory designed to measure sleep quality. The 19 items are grouped into 7 subscales: 1) sleep quality, 2) sleep efficiency, 3) daytime dysfunction, 4) sleep latency, 5) sleep disturbances, 6) sleep duration, and 7) use of sleep medication. These seven subscales are scored on a scale of 0-3 with higher scores indicating greater sleep pathology. Cronbach's alphas for the PSQI range from .70 to .8024.",
                    "PrimaryOutcomeTimeFrame":"up to 2 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Daily Sleep Diaries",
                    "PrimaryOutcomeDescription":"A daily sleep diary where participants record time awake and time to bed will be used. Participants will be asked to complete a daily sleep diary upon awakening each morning for a week at baseline, daily during the intervention weeks, and a week at follow-up.",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Epworth Sleepiness Scale",
                    "PrimaryOutcomeDescription":"Participants will be asked to complete the Epworth Sleepiness Scale (ESS) to assess daytime sleepiness. The ESS is an 8-item self-report measure that asks participants to indicate how likely they are to fall asleep while engaging in eight different everyday activities (e.g., watching television, sitting in traffic). Items are scored on a scale from 0-3 with higher scores indicating a greater probability of falling asleep. Previous research indicates that the ESS has a Cronbach's alpha of .8827.",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Sleep Environment Questionnaire",
                    "PrimaryOutcomeDescription":"Participants will be asked to complete the Sleep Environment Questionnaire during baseline and at follow-up. The Sleep Environment Questionnaire is an 11-item self-report measure that asks about the environment in which a person sleeps. Response options include \"True,\" \"False,\" or \"Not Applicable.\"",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Attitudes Toward Hypnosis Scale",
                    "PrimaryOutcomeDescription":"The 14-item Attitudes Toward Hypnosis Scale will be used to assess attitudes toward hypnosis at baseline and at follow-up. This scale has shown internal consistency in previous studies, Cronbach's alpha = .8128. A total attitude toward hypnosis score will be calculated for each participant by summing scores across the 14 items with higher scores indicating more positive attitudes toward hypnosis.",
                    "PrimaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Insomnia Severity Index",
                    "SecondaryOutcomeDescription":"Participants will be asked to complete the Insomnia Severity Index (ISS) to measure insomnia symptom severity. The ISS consists of seven items that measure the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as the participant's satisfaction with her current sleep pattern, the extent to which lack of sleep interferes with daily functioning, how noticeable this impairment is to other people, and the extent to which the participant is worried or distressed about their lack of sleep. Items are scored on a scale from 0-4 with total score of 15 or higher indicating the presence of clinical insomnia25. Past research indicates that internal reliability estimates for the ISI range from .74 to .7825.",
                    "SecondaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Perceived Stress Scale",
                    "SecondaryOutcomeDescription":"The Perceived Stress Scale (PSS) will be used to measure stress at baseline and follow-up. The PSS includes 14 items that assess levels of perceived stress and to what degree individuals perceive events in their life as stressful during the previous month. Higher scores indicate greater stress. Past research indicates that Cronbach's alpha for the PSS is .8526.",
                    "SecondaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"PROMIS Cognitive Function - Short Form",
                    "SecondaryOutcomeDescription":"Cognition will be assessed using the PROMIS Cognitive Function - Short Form Scale. This scale includes 8 items and measures self-reported cognitive functioning during the past 7 days. Items are scored from a scale of 1 (Very Often) to 5 (Never). Items are summed to create a total score and higher scores indicate better cognitive functioning.",
                    "SecondaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Pain Visual Analog Scale",
                    "SecondaryOutcomeDescription":"Participants will be asked to rate their pain on a 100-mm visual analog scale (VAS) during baseline and follow-up. Participants will be asked to place an \"x\" along the 100-mm line to indicate the severity of their pain over the past week, with the lower end of the scale being anchored by the phrase \"no pain\" and the upper end of the scale being anchored by the phrase \"the most intense pain possible.\"",
                    "SecondaryOutcomeTimeFrame":"Through study completion, an average of 7 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Motivation Scale",
                    "SecondaryOutcomeDescription":"Motivation to use hypnosis is an important factor to be assessed. Motivation to use hypnosis to improve sleep quality will be assessed at baseline using a numerical rating scale that states, \"How motivated are you to use hypnosis to improve sleep?\" This item will be rated on a scale of 1 (Not Motivated at All) to 10 (Very Motivated).",
                    "SecondaryOutcomeTimeFrame":"One week during baseline week"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Post-Participation Interview",
                    "OtherOutcomeDescription":"In order to gather qualitative data to improve future studies, participants will be asked to participate in a post-participation interview. An experienced and trained doctoral student will conduct interviews and create summary statements regarding topics including ease of use of the intervention, barriers of using the audio recordings, finding the time to practice, and improvement of the intervention. Interviews will be recorded and transcripts will be typed out.",
                    "OtherOutcomeTimeFrame":"1 week"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nActive caregiver to an individual with Alzheimer's disease or its related dementias\nSelf-reported sleep duration of 6 or less hours per day/night as indicated on the PSQI\nSigned informed consent\nAccess to a computer or mobile device with reliable Internet connection that will allow for the completion of study visits and study materials online\n\nExclusion Criteria:\n\nUse of any prescription or over-the-counter therapy for sleep\nSevere or unstable medical or psychiatric illness\nCurrent use of hypnosis for any condition\nInability to speak or understand English",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Whitney Williams, M.S.",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"254-296-0824",
                    "CentralContactEMail":"Whitney_Williams@baylor.edu"
                  },{
                    "CentralContactName":"Gary Elkins, Ph.D.",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"254-296-0643",
                    "CentralContactEMail":"Gary_Elkins@baylor.edu"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Baylor University",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Waco",
                    "LocationState":"Texas",
                    "LocationZip":"76798",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Whitney Williams, M.S.",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"254-296-0824",
                          "LocationContactEMail":"whitney_williams@baylor.edu"
                        },{
                          "LocationContactName":"Gary Elkins, Ph.D.",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"254-296-0643",
                          "LocationContactEMail":"gary_elkins@baylor.edu"
                        },{
                          "LocationContactName":"Gary Elkins, Ph.D.",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000000544",
                    "ConditionMeshTerm":"Alzheimer Disease"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000003704",
                    "ConditionAncestorTerm":"Dementia"
                  },{
                    "ConditionAncestorId":"D000001927",
                    "ConditionAncestorTerm":"Brain Diseases"
                  },{
                    "ConditionAncestorId":"D000002493",
                    "ConditionAncestorTerm":"Central Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000024801",
                    "ConditionAncestorTerm":"Tauopathies"
                  },{
                    "ConditionAncestorId":"D000019636",
                    "ConditionAncestorTerm":"Neurodegenerative Diseases"
                  },{
                    "ConditionAncestorId":"D000019965",
                    "ConditionAncestorTerm":"Neurocognitive Disorders"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M2466",
                    "ConditionBrowseLeafName":"Alzheimer Disease",
                    "ConditionBrowseLeafAsFound":"Alzheimer's Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5487",
                    "ConditionBrowseLeafName":"Dementia",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3786",
                    "ConditionBrowseLeafName":"Brain Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4325",
                    "ConditionBrowseLeafName":"Central Nervous System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M21586",
                    "ConditionBrowseLeafName":"Tauopathies",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20142",
                    "ConditionBrowseLeafName":"Neurodegenerative Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20420",
                    "ConditionBrowseLeafName":"Neurocognitive Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T2192",
                    "ConditionBrowseLeafName":"Familial Alzheimer Disease",
                    "ConditionBrowseLeafAsFound":"Alzheimer's Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":71,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779853",
              "OrgStudyIdInfo":{
                "OrgStudyId":"PER00075"
              },
              "Organization":{
                "OrgFullName":"Scientific and practical center of sanitary and epidemiological expertise and monitoring",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Seroprevalence of Pertussis Among Healthy Children and Adolescents in Kazakhstan",
              "OfficialTitle":"Seroprevalence of Pertussis Among Healthy Children and Adolescents in Kazakhstan: A Cross-Sectional Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 25, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"October 17, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"July 5, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"January 25, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Scientific and practical center of sanitary and epidemiological expertise and monitoring",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Seroprevalence of pertussis among older children and adolescents in Kazakhstan: A cross sectional study.\n\nJustification: to describe the distribution of anti-pertussis toxin (PT) antibodies (IgA and IgG) in a population aged 10-18 years old according to sociodemographic characteristics, vaccination history, and risk factors of pertussis infection.",
              "DetailedDescription":"Pertussis due to infection with Bordetella pertussis (B pertussis) is a well-known cause of persistent cough primarily affecting infants and young children. Repeated administration of the vaccine is often needed to reduce the disease burden and control its transmission. At this time, no data are available on the epidemiology of pertussis in adolescents and adults in Kazakhstan.\n\nThe aim of the present study is to estimate the prevalence of pertussis infection in different age groups in Kazakh children and adolescents using the anti-pertussis toxin (PT) antibodies (IgA and IgG) as specific marker of pertussis infection or vaccination. The serosurvey will be conducted in 4 different regions: Aktobe, Karaganda, Taldykorgan, and Shymkent.\n\nParticipants (â‰¥ 10 years & < 19 years) attending the study centers will be asked to participate in the study. The adolescent participants and the parents/guardian(s) of all participants will be informed about the procedures and data handling. Written informed consent from one parent/guardian needs to be obtained by the physician before any blood samples can be taken.\n\nUpon obtaining informed consent for participant parent/guardian, the study coordinator will complete an investigation form (IF) for each participant and collect serum samples. The specimens will be coded by a unique participant number and delivered to the laboratory in charge of the assay. The specimens will be used for serological analyses."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Pertussis"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "pertussis",
                  "seroprevalence",
                  "immunity",
                  "antibodies",
                  "Kazakhstan",
                  "vaccination"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Crossover"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Cross-Sectional"
                  ]
                }
              },
              "BioSpec":{
                "BioSpecRetention":"Samples Without DNA",
                "BioSpecDescription":"This study will be a cross-sectional serosurvey of anti-PT levels in a sample of the population. The study will be conducted in the cities of Aktobe, Karaganda, Taldykorgan, and Shymkent. Enrollment will be done in health centers and pediatric hospitals."
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"520",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM",
                    "ArmGroupDescription":"serum samples will be taken and tested by enzyme-linked immunoassay (ELISA) using the SAVYON SeroPertussisTM kits (Savyon Diagnostics Ltd, Israel).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Diagnostic Test: Blood samples for pertussis antibody testing"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Diagnostic Test",
                    "InterventionName":"Blood samples for pertussis antibody testing",
                    "InterventionDescription":"Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"The anti-PT IgG and Ig A concentrations (in IU/ml) in the population sample.",
                    "PrimaryOutcomeDescription":"To estimate the prevalence of recent infection Bp infection, using increased anti-PT antibody levels as markers of Bp infection in the serology test.",
                    "PrimaryOutcomeTimeFrame":"25.01.2021-17.10.2021"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"The prevalence of recent Bp infection in the test in the selected population sample stratified by demographic and socio-economic criteria, vaccination history, and risk of infection.",
                    "SecondaryOutcomeDescription":"To evaluate the risk factors associated with higher seroprevalence of pertussis.",
                    "SecondaryOutcomeTimeFrame":"25.01.2021-17.10.2021"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"â€¢ Adherence to vaccination status defined as the. number and timeliness of doses received and potential exposure to booster vaccination as well as the concordance with the Kazakh vaccination status.",
                    "OtherOutcomeDescription":"â€¢ To evaluate the compliance with recommended vaccination schedule in study participants",
                    "OtherOutcomeTimeFrame":"25.01.2021-17.10.2021"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\n10-18 years old\n\nInformed consent obtained from parents or guardian(s) and assent from patient.\nEnrollment following a visit at the study center.\nDocumented vaccination history\n\nExclusion Criteria:\n\nInclusion criteria:\n\n10-18 years old\nInformed consent obtained from parents or guardian(s) and assent from patient.\nEnrollment following a visit at the study center.\nDocumented vaccination history\n\nExclusion criteria:\n\nâ‰¤10 years and â‰¥ 19 years\nPertussis immunization during the last 12 months\nNo informed consent obtained from one parent or guardian.\nImmunocompromised patients\nPatients with acute infectious diseases",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"10 Years",
              "MaximumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult"
                ]
              },
              "StudyPopulation":"Participants (â‰¥ 10 years & < 19 years) attending the study centers will be asked to participate in the study. The adolescent participants and the parents/guardian(s) of all participants will be informed about the procedures and data handling. Written informed consent from one parent/guardian needs to be obtained by the physician before any blood samples can be taken.",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Manar SMAGUL, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+77017444681",
                    "CentralContactEMail":"manarka@mail.ru"
                  },{
                    "CentralContactName":"Gauhar NUKENOVA, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+77714007784",
                    "CentralContactEMail":"gnukenova@mail.ru"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Scientific and Practical Center of Sanitary and Epidemiological Expertise and Monitoring",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Almaty",
                    "LocationZip":"050008",
                    "LocationCountry":"Kazakhstan",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Manar SMAGUL, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+77017444681",
                          "LocationContactEMail":"manarka@mail.ru"
                        },{
                          "LocationContactName":"NUKENOVa, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+77714007784",
                          "LocationContactEMail":"gnukenova@mail.ru"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DocumentSection":{
            "LargeDocumentModule":{
              "LargeDocList":{
                "LargeDoc":[
                  {
                    "LargeDocTypeAbbrev":"Prot",
                    "LargeDocHasProtocol":"Yes",
                    "LargeDocHasSAP":"No",
                    "LargeDocHasICF":"No",
                    "LargeDocLabel":"Study Protocol",
                    "LargeDocDate":"October 9, 2020",
                    "LargeDocUploadDate":"02/25/2021 06:14",
                    "LargeDocFilename":"Prot_000.pdf"
                  },{
                    "LargeDocTypeAbbrev":"ICF",
                    "LargeDocHasProtocol":"No",
                    "LargeDocHasSAP":"No",
                    "LargeDocHasICF":"Yes",
                    "LargeDocLabel":"Informed Consent Form",
                    "LargeDocDate":"October 9, 2020",
                    "LargeDocUploadDate":"03/01/2021 05:43",
                    "LargeDocFilename":"ICF_001.pdf"
                  },{
                    "LargeDocTypeAbbrev":"SAP",
                    "LargeDocHasProtocol":"No",
                    "LargeDocHasSAP":"Yes",
                    "LargeDocHasICF":"No",
                    "LargeDocLabel":"Statistical Analysis Plan: Statistical Analysis Plan",
                    "LargeDocDate":"October 9, 2020",
                    "LargeDocUploadDate":"03/01/2021 05:46",
                    "LargeDocFilename":"SAP_002.pdf"
                  },{
                    "LargeDocTypeAbbrev":"SAP",
                    "LargeDocHasProtocol":"No",
                    "LargeDocHasSAP":"Yes",
                    "LargeDocHasICF":"No",
                    "LargeDocLabel":"Statistical Analysis Plan: Survey",
                    "LargeDocDate":"October 9, 2020",
                    "LargeDocUploadDate":"03/01/2021 05:47",
                    "LargeDocFilename":"SAP_003.pdf"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000014917",
                    "ConditionMeshTerm":"Whooping Cough"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000001885",
                    "ConditionAncestorTerm":"Bordetella Infections"
                  },{
                    "ConditionAncestorId":"D000016905",
                    "ConditionAncestorTerm":"Gram-Negative Bacterial Infections"
                  },{
                    "ConditionAncestorId":"D000001424",
                    "ConditionAncestorTerm":"Bacterial Infections"
                  },{
                    "ConditionAncestorId":"D000012141",
                    "ConditionAncestorTerm":"Respiratory Tract Infections"
                  },{
                    "ConditionAncestorId":"D000007239",
                    "ConditionAncestorTerm":"Infection"
                  },{
                    "ConditionAncestorId":"D000012140",
                    "ConditionAncestorTerm":"Respiratory Tract Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M16239",
                    "ConditionBrowseLeafName":"Whooping Cough",
                    "ConditionBrowseLeafAsFound":"Pertussis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5173",
                    "ConditionBrowseLeafName":"Cough",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3745",
                    "ConditionBrowseLeafName":"Bordetella Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3303",
                    "ConditionBrowseLeafName":"Bacterial Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M17832",
                    "ConditionBrowseLeafName":"Gram-Negative Bacterial Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13561",
                    "ConditionBrowseLeafName":"Respiratory Tract Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13560",
                    "ConditionBrowseLeafName":"Respiratory Tract Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T5926",
                    "ConditionBrowseLeafName":"Whooping Cough",
                    "ConditionBrowseLeafAsFound":"Pertussis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"T4202",
                    "ConditionBrowseLeafName":"Oculocerebral Syndrome With Hypopigmentation",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000000906",
                    "InterventionMeshTerm":"Antibodies"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000007155",
                    "InterventionAncestorTerm":"Immunologic Factors"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2806",
                    "InterventionBrowseLeafName":"Antibodies",
                    "InterventionBrowseLeafAsFound":"Sessions",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M8767",
                    "InterventionBrowseLeafName":"Immunoglobulins",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M15943",
                    "InterventionBrowseLeafName":"Vaccines",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8784",
                    "InterventionBrowseLeafName":"Immunologic Factors",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":72,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779840",
              "OrgStudyIdInfo":{
                "OrgStudyId":"WP-2019-06"
              },
              "Organization":{
                "OrgFullName":"Weprom",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Retrospective Study on the Incidence and Management of Anemia in Oncology",
              "OfficialTitle":"Retrospective Study on the Incidence and Management of Anemia in Oncology",
              "Acronym":"RESPIRE"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"May 20, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"January 20, 2021",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"January 20, 2021",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Weprom",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies).\n\nTransfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management.\n\nRecommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Anemia",
                  "Cancer"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Retrospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"349",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"period 2011",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: anemia assessment"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"period 2018",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: anemia assessment"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"anemia assessment",
                    "InterventionDescription":"evaluation of anemia status",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "period 2011",
                        "period 2018"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Incidence of anemia",
                    "PrimaryOutcomeDescription":"number of patient with anemia (<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period",
                    "PrimaryOutcomeTimeFrame":"2 years"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Assessment of transfusion prescriptions",
                    "SecondaryOutcomeDescription":"number of transfusions performed on the number of patients hospitalized over the period",
                    "SecondaryOutcomeTimeFrame":"2 years"
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of erythropoiesis stimulating agents (EPO) prescriptions",
                    "SecondaryOutcomeDescription":"number of prescriptions for erythropoiesis stimulating agents (EPO)",
                    "SecondaryOutcomeTimeFrame":"2 years"
                  },{
                    "SecondaryOutcomeMeasure":"Assessment of iron prescriptions",
                    "SecondaryOutcomeDescription":"number of prescriptions of iron (oral and intravenous)",
                    "SecondaryOutcomeTimeFrame":"2 years"
                  },{
                    "SecondaryOutcomeMeasure":"Time between last transfusion and date of death",
                    "SecondaryOutcomeDescription":"Delay between the date of the last transfusion and the date of patient's death",
                    "SecondaryOutcomeTimeFrame":"2 years"
                  },{
                    "SecondaryOutcomeMeasure":"overall survival",
                    "SecondaryOutcomeDescription":"Delay between the enrollment date and the date of patient's death",
                    "SecondaryOutcomeTimeFrame":"2 years"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAge â‰¥ 18 years old,\nFollow-up for cancer justifying hospitalization,\nPresenting anemia defined by a hemoglobin level <11 g / dL,\nPatient not having objected to the collection of his data after oral and written information.\n\nExclusion Criteria:\n\npatients with a hemoglobin level â‰¥ 11 g / dL,\nadult patients under guardianship, curatorship or deprived of liberty,\npregnancy or breast-feeding in progress at the time of hospitalization.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Adult patients with cancer and justifying continuous hospitalization for more than one night regardless of pattern.\n\nPatient informed and not having expressed opposition to the study.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Katell LE DÃ›, MD",
                    "OverallOfficialAffiliation":"Centre Jean Bernard/Clinique Victor Hugo - LE MANS",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Centre Jean Bernard - Clinique Victor Hugo",
                    "LocationCity":"Le Mans",
                    "LocationZip":"72000",
                    "LocationCountry":"France"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000000740",
                    "ConditionMeshTerm":"Anemia"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000006402",
                    "ConditionAncestorTerm":"Hematologic Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M2651",
                    "ConditionBrowseLeafName":"Anemia",
                    "ConditionBrowseLeafAsFound":"Anemia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8073",
                    "ConditionBrowseLeafName":"Hematologic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC15",
                    "ConditionBrowseBranchName":"Blood and Lymph Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":73,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779827",
              "OrgStudyIdInfo":{
                "OrgStudyId":"827141"
              },
              "Organization":{
                "OrgFullName":"University of Pennsylvania",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks",
              "OfficialTitle":"Improving Health Equity for COVID-19 Vaccination and Related Health Behaviors for At-risk Populations Using Online Social Networks"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 15, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"October 30, 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 30, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 21, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Damon Centola, PhD",
                "ResponsiblePartyInvestigatorTitle":"Professor of Communication, Sociology and Engineering",
                "ResponsiblePartyInvestigatorAffiliation":"University of Pennsylvania"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of Pennsylvania",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"University of California, Davis",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"University of California, San Francisco",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"University of California, Berkeley",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Social technologies for health have already become essential means for providing underserved populations greater social connectedness and increased access to novel health information. However, these technologies have also had negative unintended consequences. The resulting digital divide in social technology takes many forms - from explicit racism that excludes African American and Latinx populations from the resources enjoyed by White and Asian members of online communities, to self-segregation for the purposes of identity preservation and community-building that unintentionally results in limited informational diversity in underserved communities. The result is an often unnoticed, but highly consequential compounding of inequities.\n\nThis research seeks to use an online social network approach to address these challenges, in which the investigators demonstrate how reducing the online levels of network centralization and network homophily among African American community members directly increases their productive engagement with health-promoting information.",
              "DetailedDescription":"To investigate the causal effects of network structure and composition on the acceptance of new or unfamiliar behavior-relevant health information, the investigators propose a randomized controlled experiment that compares several independent populations to identify and address participants' endorsement of biased information, and engagement with novel behavior relevant information (e.g., regarding COVID-19 vaccination). Each population will have its own network structure (i.e., level of centralization) and composition (i.e., level of homophily).\n\nTo run each experimental trial, the investigators will recruit 240 African American participants, aged 18 to 40, collectively to answer behavior-relevant questions over a period of no greater than 8 minutes. Participants can respond asynchronously - i.e., when the participants' time permits. As with previous studies, the technical infrastructure will manage participants' progress through the study to ensure that all participants have the relevant information about each other's responses.\n\nTo ensure causal identification, each network graph will constitute a single observation of how individual decisions change under conditions of interdependent social information. Thus, each trial of 240 people (6 networks x 40 participants per network) produces 6 observations of a community-level social learning process. Power calculations indicate that 8 independent trials are sufficient to produce results of p<0.05 with 85% power, resulting in a desired population of 1920 participants for each health topic (e.g., COVID-19 vaccination is a single \"health topic\"), producing 48 independent observations of collective decision making per health topic.\n\nThe studies will target health topics for which there is substantial racial disparity in outcomes and behavior, such as acceptance of COVID-19 vaccination, and spreading of various categories of COVID-19 misinformation (e.g. beliefs related to assessment of personal risk, effectiveness of protective behaviors, methods of transmission, disease prevention, treatment, origins of the virus) and related health practices (e.g. choice of appropriate contraceptive methods, value of heart disease screenings, etc.)."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Vaccination Refusal",
                  "Covid19",
                  "Contraception Behavior",
                  "Heart Diseases"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Factorial Assignment",
                "DesignPrimaryPurpose":"Basic Science",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"1920",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Egalitarian Networks of Homogeneous Populations",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Online Social Network and Collective Intelligence Intervention"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Egalitarian Networks of Diverse Populations",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Online Social Network and Collective Intelligence Intervention"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Centralized Networks of Homogeneous Populations",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Centralized networks have a small number of influential individuals, called \"hubs,\" with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected \"influencers.\" Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Online Social Network and Collective Intelligence Intervention"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Centralized Networks of Diverse Populations",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Centralized networks have a small number of influential individuals, called \"hubs,\" with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected \"influencers.\" Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Online Social Network and Collective Intelligence Intervention"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Independent Control of Homogeneous Populations",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Independent Control"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Independent Control of Diverse Populations",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Independent Control"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"Online Social Network and Collective Intelligence Intervention",
                    "InterventionDescription":"The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Centralized Networks of Diverse Populations",
                        "Centralized Networks of Homogeneous Populations",
                        "Egalitarian Networks of Diverse Populations",
                        "Egalitarian Networks of Homogeneous Populations"
                      ]
                    }
                  },{
                    "InterventionType":"Behavioral",
                    "InterventionName":"Independent Control",
                    "InterventionDescription":"Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Independent Control of Diverse Populations",
                        "Independent Control of Homogeneous Populations"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"COVID-19 vaccination attitude",
                    "PrimaryOutcomeDescription":"COVID-19 vaccination attitude scale, which is a self-reported scale measuring participants' attitudes toward COVID-19 vaccination. The scale is consisted of 5 questions (e.g., \"How much confidence do you have that the COVID-19 vaccine in the U.S. is safe and effective?\") with responses ranging from 1 (No confidence at all) to 5 (A great deal of confidence); a higher average score means a more positive attitude in favor of COVID-19 vaccination.",
                    "PrimaryOutcomeTimeFrame":"Immediate after intervention"
                  },{
                    "PrimaryOutcomeMeasure":"COVID-19 vaccination intention",
                    "PrimaryOutcomeDescription":"COVID-19 vaccination intention scale, which is a self-reported scale measuring participants' intention toward COVID-19 vaccination. The scale is consisted of 5 questions (e.g., \"Would you get a COVID-19 vaccine when it is available to you?\") with responses ranging from 1 (Definitely Not) to 5 (Definitely); a higher average score means a stronger intention to receive the COVID-19 vaccine.",
                    "PrimaryOutcomeTimeFrame":"Immediate after intervention"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"COVID-19 vaccine belief",
                    "SecondaryOutcomeDescription":"COVID-19 vaccine belief scale, which is a self-reported scale measuring participants' knowledge and belief (including misbelief) about the COVID-19 vaccine safety and effectiveness. The scale is consisted of 12 items (e.g., \"A COVID-19 vaccine will not alter my DNA\") with responses ranging from 1 (completely disagree) to 5 (completely agree); a higher average score means more accurate knowledge and belief towards the COVID-19 vaccine.",
                    "SecondaryOutcomeTimeFrame":"Immediate after intervention"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nSelf-identify as African American\nAged 18 and above\nLiving in the United States\n\nExclusion Criteria:\n\nSelf-identify as not being African American\nAged below 18\nLiving outside of the United States",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Damon Centola",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"215-898-7954",
                    "CentralContactEMail":"dcentola@asc.upenn.edu"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Damon Centola, PhD",
                    "OverallOfficialAffiliation":"University of Pennsylvania",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"32027656",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Guilbeault D, Centola D. Networked collective intelligence improves dissemination of scientific information regarding smoking risks. PLoS One. 2020 Feb 6;15(2):e0227813. doi: 10.1371/journal.pone.0227813. eCollection 2020."
                  },{
                    "ReferencePMID":"30181271",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Guilbeault D, Becker J, Centola D. Social learning and partisan bias in the interpretation of climate trends. Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9714-9719. doi: 10.1073/pnas.1722664115. Epub 2018 Sep 4."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"We will share the data collected from our online experiments. All sets of data are anonymous.",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol",
                  "Statistical Analysis Plan (SAP)",
                  "Analytic Code"
                ]
              },
              "IPDSharingTimeFrame":"Data will be available when the primary intervention paper is published.",
              "IPDSharingAccessCriteria":"Data will be shared as a part of the published paper, in forms of supplementary materials. The public can access the data through the publisher's website."
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000006331",
                    "ConditionMeshTerm":"Heart Diseases"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8002",
                    "ConditionBrowseLeafName":"Heart Diseases",
                    "ConditionBrowseLeafAsFound":"Heart Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M15943",
                    "InterventionBrowseLeafName":"Vaccines",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":74,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779814",
              "OrgStudyIdInfo":{
                "OrgStudyId":"LNE801"
              },
              "Organization":{
                "OrgFullName":"LivaNova",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"A Non-interventional Study Describing the Healthcare Resource Utilisation and Clinical Outcomes Associated With LivaNova Vagus Nerve Stimulation Therapy in the UK.",
              "OfficialTitle":"A Non-interventional Study Describing the Healthcare Resource Utilisation and Clinical Outcomes Associated With LivaNova Vagus Nerve Stimulation Therapy in the UK.",
              "Acronym":"DANTE"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 24, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"LivaNova",
                "LeadSponsorClass":"INDUSTRY"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"OPEN VIE Limited",
                    "CollaboratorClass":"UNKNOWN"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This is a UK, multi-center, non-interventional study based on the use of health service administrative and medical records (paper-based and/or electronic, as applicable) along with the use of prospectively collected subject-reported outcomes on experience with use of VNS therapy using validated and bespoke self-completion questionnaires. Data for hospital resource utilisation will be extracted from the Hospital Episode Statistics (HES) database.",
              "DetailedDescription":"Failure to control seizures in subjects with treatment resistant epilepsy can have a significant burden on the healthcare system. Vagus Nerve Stimulation (VNS) is an adjunctive treatment for patients with drug resistant epilepsy and is reported to reduce the frequency of seizures in adults and children. However, real-world data on healthcare resource utilization by patients with treatment-resistant epilepsy and their clinical outcomes prior to and post VNS device implantation in the UK are limited. The current study aims to describe the resource utilization and clinical outcomes prior to and following the implantation of different VNS devices (DemipulseÂ®/Aspire HCÂ®, Aspire SRÂ® and SenTivaÂ®) in subjects with drug resistant epilepsy"
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Epilepsy"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "VNS",
                  "DRE",
                  "drug resistant epilepsy",
                  "Vagus Nervus Stimulation",
                  "Healthcare Resource Utilization"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Other"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"180",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Cohort 1",
                    "ArmGroupDescription":"DemipulseÂ®/Aspire HCÂ® (30 adult subjects)"
                  },{
                    "ArmGroupLabel":"Cohort 2",
                    "ArmGroupDescription":"DemipulseÂ®/Aspire HCÂ® (30 pediatric subjects)"
                  },{
                    "ArmGroupLabel":"Cohort 3",
                    "ArmGroupDescription":"Aspire SRÂ® (30 adult subjects)"
                  },{
                    "ArmGroupLabel":"Cohort 4",
                    "ArmGroupDescription":"Aspire SRÂ® (30 pediatric subjects)"
                  },{
                    "ArmGroupLabel":"Cohort 5",
                    "ArmGroupDescription":"SenTivaÂ® (30 adult subjects)"
                  },{
                    "ArmGroupLabel":"Cohort 6",
                    "ArmGroupDescription":"SenTivaÂ® (30 pediatric subjects)"
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Change in hospital resource utilization",
                    "PrimaryOutcomeDescription":"To describe the change in hospital resource utilization from the 12-month period pre- to the 18-month period post-implantation of VNS device in subjects with drug resistant epilepsy.",
                    "PrimaryOutcomeTimeFrame":"Change from 12-month pre- implantation of VNS device to 18-month post-implantation of VNS device"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Change in Seizure information using ILAE classification",
                    "SecondaryOutcomeDescription":"Onset and current classification and any prior classification of seizures will be described using ILAE classification",
                    "SecondaryOutcomeTimeFrame":"Change from 12-month pre- implantation of VNS device to 6-month, to 12-month and to 18-month post-implantation of VNS device"
                  },{
                    "SecondaryOutcomeMeasure":"Initial titration period for each VNS device",
                    "SecondaryOutcomeTimeFrame":"18-month period post-implantation of VNS device."
                  },{
                    "SecondaryOutcomeMeasure":"Characteristics and demographics of subjects at the time of implantation of VNS Therapy.",
                    "SecondaryOutcomeTimeFrame":"Implant procedure"
                  },{
                    "SecondaryOutcomeMeasure":"Change of AED treatments",
                    "SecondaryOutcomeDescription":"Assess the change in anti-epileptic drugs including dose change",
                    "SecondaryOutcomeTimeFrame":"Change from 12-month pre- implantation of VNS device to 18-month post-implantation of VNS device"
                  },{
                    "SecondaryOutcomeMeasure":"Change in Seizure severity; using measures such as rescue medication and/or time to recovery.",
                    "SecondaryOutcomeTimeFrame":"Change from 12-month pre- implantation of VNS device to 6-month, to 12-month and to 18-month post-implantation of VNS device"
                  },{
                    "SecondaryOutcomeMeasure":"Change in Seizure frequency (by seizure type*, if available) and any changes in frequency.",
                    "SecondaryOutcomeTimeFrame":"Change from 12-month pre- implantation of VNS device to 6-month, to 12-month and to 18-month post-implantation of VNS device"
                  },{
                    "SecondaryOutcomeMeasure":"Change in frequency of status epilepticus.",
                    "SecondaryOutcomeTimeFrame":"Change from 12-month pre- implantation of VNS device to 6-month, to 12-month and to 18-month post-implantation of VNS device"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nLiving subjects who meet all of the following criteria will be considered for enrolment:\n\nClinical diagnosis of drug resistant epilepsy\nSubjects who have had their first VNS device (DemipulseÂ®/Aspire HCÂ®, Aspire SRÂ® and SenTivaÂ®) implanted at least 18 months prior to their enrolment in the study data (with no change in generator, battery or lead).\nFor SenTivaÂ® and Aspire SRÂ®, AutoStim was first activated within 1 month of implantation.\nFor SenTivaÂ®, scheduled dosing mode was activated within 1 month of implantation.\nSubjects must be able and willing to provide informed consent; subjects aged 7-12 years old and 13-15 years old will be provided with appropriate information and consent forms to explain the study in age appropriate language. These subjects will be asked to provide their assent to take part in the study, with consent provided by their parent/carer. Subjects under 7 years will be included in the study with consent from their parent/carer. For adult subjects (â‰¥16 years) lacking the mental capacity to consent, advice about participation will be sought from an appropriate consultee, according to the Mental Capacity Act 2005.\nAdult and paediatric subjects (aged over 2.5 years at study enrolment) with available medical records for at least 12 months prior to VNS device implantation.\n\nExclusion Criteria:\n\nSubjects whose medical records are not available for review.\nDeceased subjects.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"1 Year",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Male and female adult (aged â‰¥16 years at VNS implantation) and paediatric (aged 1-15 years at VNS implantation) subjects with epilepsy who have had a VNS device DemipulseÂ®/Aspire HCÂ®, Aspire SRÂ® or SenTivaÂ® implanted will be involved in this study.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Jo Hough",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"44 (0) 7714 771 214",
                    "CentralContactEMail":"johough@openvie.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Mike Carter",
                    "OverallOfficialAffiliation":"Bristol Royal Hospital for Children",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000004827",
                    "ConditionMeshTerm":"Epilepsy"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000001927",
                    "ConditionAncestorTerm":"Brain Diseases"
                  },{
                    "ConditionAncestorId":"D000002493",
                    "ConditionAncestorTerm":"Central Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M6566",
                    "ConditionBrowseLeafName":"Epilepsy",
                    "ConditionBrowseLeafAsFound":"Epilepsy",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M369",
                    "ConditionBrowseLeafName":"Drug Resistant Epilepsy",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3786",
                    "ConditionBrowseLeafName":"Brain Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4325",
                    "ConditionBrowseLeafName":"Central Nervous System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":75,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779801",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2004007768"
              },
              "Organization":{
                "OrgFullName":"Drexel University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Attachment-Based Family Therapy for Adolescents With Binge Eating",
              "OfficialTitle":"Attachment-Based Family Therapy for Adolescents With Transdiagnostic Binge Eating",
              "Acronym":"ABFT"
            },
            "StatusModule":{
              "StatusVerifiedDate":"December 2020",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"December 10, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 10, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"April 10, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 25, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Drexel University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of this study is to examine whether Attachment-Based Family Therapy (ABFT), a well-validated treatment for adolescents with depression and suicidality, is feasible and acceptable for adolescents with binge eating and their families.",
              "DetailedDescription":"This study involves a phone screen and baseline assessment to determine eligibility. Participants who are eligible for the study will receive 16 weeks of ABFT treatment. The treatment primarily focuses on improving communication and relationships within the family, and will also address disordered eating behaviors (e.g., binge eating, laxative use, self-induced vomiting). All participants enrolled in the study will receive the same treatment. Participants will also complete research assessments throughout treatment, at the end of treatment, and 3-months after the end of treatment. Research assessments include a battery of questionnaires and interviews."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Bulimia Nervosa",
                  "Binge-Eating Disorder",
                  "Other Specified Feeding or Eating Disorder"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"20",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"ABFT",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Adolescents and one or both parents will complete 16 weeks of Attachment-Based Family Therapy treatment.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Attachment-Based Family Therapy"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"Attachment-Based Family Therapy",
                    "InterventionDescription":"16 weeks of Attachment-Based Family Therapy treatment.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "ABFT"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Five-Minute Speech Sample (FMSS)",
                    "PrimaryOutcomeDescription":"The Five-Minute Speech Sample is a widely-used interview to assess critical comments and emotional overinvolvement in families.",
                    "PrimaryOutcomeTimeFrame":"Change in critical comments and emotional overinvolvement from baseline to treatment completion, at 16 weeks"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Eating Disorder Examination (EDE)",
                    "SecondaryOutcomeDescription":"The Eating Disorder Examination is a widely-used, semi-structured interview for the assessment of eating disorder symptoms.",
                    "SecondaryOutcomeTimeFrame":"Change in frequency of binge-eating and, if applicable, purging from baseline to treatment completion, at 16 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nSpeak, write, and understand English\nAge 12-22 years old\nHave a diagnosis of DSM-5 AN, BN, BED, or OSFED\nMedically stable for outpatient treatment\nMust have a parent, guardian, or primary caregiver who is willing to participate in the study and treatment\n\nExclusion Criteria:\n\nAcute suicide risk\nNo parent or guardian agreement to participate\nAre currently receiving psychological treatment for an eating disorder\nAre currently receiving weight loss treatment\nCo-morbid clinically significant psychological disorder that would require attention beyond the study treatment (e.g., psychotic disorder, substance dependence)\nDiagnosis of intellectual disability",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"12 Years",
              "MaximumAge":"22 Years",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Drexel University",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Philadelphia",
                    "LocationState":"Pennsylvania",
                    "LocationZip":"19104",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Sophie R Abber, B.A.",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"215-553-7110",
                          "LocationContactEMail":"wellteen@drexel.edu"
                        },{
                          "LocationContactName":"Stephanie M Manasse, Ph.D.",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000004194",
                    "ConditionMeshTerm":"Disease"
                  },{
                    "ConditionMeshId":"D000002032",
                    "ConditionMeshTerm":"Bulimia"
                  },{
                    "ConditionMeshId":"D000001068",
                    "ConditionMeshTerm":"Feeding and Eating Disorders"
                  },{
                    "ConditionMeshId":"D000056912",
                    "ConditionMeshTerm":"Binge-Eating Disorder"
                  },{
                    "ConditionMeshId":"D000052018",
                    "ConditionMeshTerm":"Bulimia Nervosa"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  },{
                    "ConditionAncestorId":"D000006963",
                    "ConditionAncestorTerm":"Hyperphagia"
                  },{
                    "ConditionAncestorId":"D000012817",
                    "ConditionAncestorTerm":"Signs and Symptoms, Digestive"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3886",
                    "ConditionBrowseLeafName":"Bulimia",
                    "ConditionBrowseLeafAsFound":"Binge Eating",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M27228",
                    "ConditionBrowseLeafName":"Binge-Eating Disorder",
                    "ConditionBrowseLeafAsFound":"Binge Eating",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M25543",
                    "ConditionBrowseLeafName":"Bulimia Nervosa",
                    "ConditionBrowseLeafAsFound":"Bulimia Nervosa",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M2961",
                    "ConditionBrowseLeafName":"Feeding and Eating Disorders",
                    "ConditionBrowseLeafAsFound":"Eating Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8597",
                    "ConditionBrowseLeafName":"Hyperphagia",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14205",
                    "ConditionBrowseLeafName":"Signs and Symptoms, Digestive",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":76,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779788",
              "OrgStudyIdInfo":{
                "OrgStudyId":"20210218015"
              },
              "Organization":{
                "OrgFullName":"Xuzhou Central Hospital",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma",
              "OfficialTitle":"I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 31, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 30, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Xuzhou Central Hospital",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Malignant biliary obstruction usually arise in patients suffering from primary or metastatic hepatobiliary tumors. Approximately 80% of malignant biliary obstruction patients are not eligible for surgical resection, and as such palliative stent insertion is the only treatment option available for most patients. At present, I-125 seeds loaded stent has been developed to improve the stent patency and patients' survival. Hilar malignant biliary obstruction is an important part of malignant biliary obstruction. Hilar cholangiocarcinoma is the most common disease which causes hilar malignant biliary obstruction. Herein, we assessed the clinical and long-term efficacy of I-125 seeds loaded stent insertion for hilar cholangiocarcinoma patients.",
              "DetailedDescription":"Malignant biliary obstruction usually arise in patients suffering from primary or metastatic hepatobiliary tumors. Approximately 80% of malignant biliary obstruction patients are not eligible for surgical resection, and as such palliative interventions are the only treatment option available for most patients. Of the available palliative treatments, percutaneous or endoscopic stent insertion is the most frequently used to treat malignant biliary obstruction patients.\n\nAlthough stent insertion can achieve the good short-term outcomes for patients with malignant biliary obstruction, stent dysfunction remains a common outcome in these treated patients, limiting the long-term efficacy of this treatment strategy. In order to overcome this shortcoming of the normal stent insertion, many researchers have developed a novel biliary I-125 seeds loaded stent. The I-125 seeds loaded stents not only can effectively relieve the jaundice, but also can provide the brachytherapy to the tumor. Previous meta-analyses also indicated that showed that relative to normal stent insertion, I-125 seeds loaded stent insertion was associated with longer survival and stent patency in inoperable malignant biliary obstruction patients. However, most previous studies included malignant biliary obstruction patients with different cancer types and malignant biliary obstruction sites, and therefore, the risk of bias did exist. Therefore, there is a clear need for a study comparing these two stent types in patients with a single type of cancer.\n\nHilar malignant biliary obstruction is an important part of malignant biliary obstruction. Hilar cholangiocarcinoma is the most common disease which causes hilar malignant biliary obstruction. Herein, we assessed the clinical and long-term efficacy of I-125 seeds loaded stent insertion for hilar cholangiocarcinoma patients."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Hilar Cholangiocarcinoma"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"100",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"I-125 seeds loaded stent group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Patients who receive the I-125 seeds loaded stent insertion",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: I-125 seeds loaded stent"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Normal stent group",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Patients who receive the normal stent insertion",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Device: Normal stent"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Device",
                    "InterventionName":"I-125 seeds loaded stent",
                    "InterventionDescription":"An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "I-125 seeds loaded stent group"
                      ]
                    }
                  },{
                    "InterventionType":"Device",
                    "InterventionName":"Normal stent",
                    "InterventionDescription":"Bare self-expanded metal stent",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Normal stent group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Overall survival",
                    "PrimaryOutcomeDescription":"From the date of randomization until the date of first documented death from any cause.",
                    "PrimaryOutcomeTimeFrame":"From the date of randomization until the date of first documented death from any cause, assessed up to 12 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\n(a) patients with a diagnosed hilar Cholangiocarcinoma , (b) inoperable cases, (c) patients showed evidence of obstructive jaundice and (d) Eastern Cooperative Oncology Group performance status < 4.\n\nExclusion Criteria:\n\n(a) patients who underwent post-operative external radiotherapy, (b) patients in whom prior biliary stent insertion or drainage were performed, and (c) patients suffering from serious dysfunction of the pulmonary, renal, cardiac, or coagulatory systems.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"80 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Yu-Fei Fu, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+8618112000304",
                    "CentralContactEMail":"fuyufei1985@163.com"
                  },{
                    "CentralContactName":"Chi Cao, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+8615829087227",
                    "CentralContactEMail":"xzcaochi@126.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Xian-Chi Li, MD",
                    "OverallOfficialAffiliation":"Xuzhou Central Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Xuzhou Central Hospital",
                    "LocationCity":"Xuzhou",
                    "LocationState":"Jiangsu",
                    "LocationZip":"221009",
                    "LocationCountry":"China"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"32125207",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Chen G, Zhang M, Sheng YG, Yang F, Li ZQ, Liu TG, Fu YF. Stent with radioactive seeds strand insertion for malignant hilar biliary obstruction. Minim Invasive Ther Allied Technol. 2020 Mar 3:1-7. doi: 10.1080/13645706.2020.1735446. [Epub ahead of print]"
                  },{
                    "ReferencePMID":"32769739",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Yang S, Liu Y, Teng F, Wu AL, Lin J, Xian YT, Xu YS. Radioactive Stent Insertion for Inoperable Malignant Common Biliary Obstruction. Surg Laparosc Endosc Percutan Tech. 2020 Aug 5;31(1):61-65. doi: 10.1097/SLE.0000000000000848."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No",
              "IPDSharingDescription":"There is not a plan to make individual participant data available."
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000018281",
                    "ConditionMeshTerm":"Cholangiocarcinoma"
                  },{
                    "ConditionMeshId":"D000018285",
                    "ConditionMeshTerm":"Klatskin Tumor"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000000230",
                    "ConditionAncestorTerm":"Adenocarcinoma"
                  },{
                    "ConditionAncestorId":"D000002277",
                    "ConditionAncestorTerm":"Carcinoma"
                  },{
                    "ConditionAncestorId":"D000009375",
                    "ConditionAncestorTerm":"Neoplasms, Glandular and Epithelial"
                  },{
                    "ConditionAncestorId":"D000009370",
                    "ConditionAncestorTerm":"Neoplasms by Histologic Type"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M19009",
                    "ConditionBrowseLeafName":"Cholangiocarcinoma",
                    "ConditionBrowseLeafAsFound":"Cholangiocarcinoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M19013",
                    "ConditionBrowseLeafName":"Klatskin Tumor",
                    "ConditionBrowseLeafAsFound":"Hilar Cholangiocarcinoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M2166",
                    "ConditionBrowseLeafName":"Adenocarcinoma",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4116",
                    "ConditionBrowseLeafName":"Carcinoma",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10903",
                    "ConditionBrowseLeafName":"Neoplasms, Glandular and Epithelial",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10898",
                    "ConditionBrowseLeafName":"Neoplasms by Histologic Type",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T755",
                    "ConditionBrowseLeafName":"Bile Duct Cancer",
                    "ConditionBrowseLeafAsFound":"Cholangiocarcinoma",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"T3241",
                    "ConditionBrowseLeafName":"Klatskin Tumor",
                    "ConditionBrowseLeafAsFound":"Hilar Cholangiocarcinoma",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":77,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779775",
              "OrgStudyIdInfo":{
                "OrgStudyId":"RISEUP-PPD-DEVOTION- COVID-19"
              },
              "Organization":{
                "OrgFullName":"University of Minho",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Best Practices in Perinatal Mental Health During COVID-19",
              "OfficialTitle":"Best Practices in Perinatal Mental Health During COVID-19 Pandemic: A Collaborative Research Study Between the COST Actions RISEUP-PPD and Devotion"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 15, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 30, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 30, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 10, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Ana Mesquita",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"University of Minho"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of Minho",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Universidad Loyola Andalucia",
                    "CollaboratorClass":"OTHER"
                  },{
                    "CollaboratorName":"Catholic University of Croatia",
                    "CollaboratorClass":"UNKNOWN"
                  },{
                    "CollaboratorName":"University of Coimbra",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The COVID-19 pandemic has caused changes in health care during pregnancy, childbirth and postpartum. Although adverse effects of COVID-19 on perinatal mental health have been documented, changes in the perinatal mental health care provided to women and their families are yet to be established. As a Task Force in Perinatal mental health and COVID-19 pandemic within RISEUP-PPD COST Action, we aim: (i) to identify policies, guidelines and protocols from different European countries concerning the provision of perinatal mental health care in face of COVID-19, and (ii) to select the best practices to alleviate the negative impact of COVID-19 on perinatal mental health. The survey will be conducted among experts in perinatal mental health who are members of the COST Action RISEUP-PPD and COST Action Devotion in 36 European countries. The experts will fill in the online survey designed for this study that includes a series of open-ended questions, checklists, and response ratings on a 7-point scale. The topic areas cover seven domains of interest: 1) mental health policies, guidelines, protocols, and documents; 2) mental health care practices; 3) best practices; 4) barriers; 5) resources; 6) benefits; and 7) short- and long-term expectations. Data analysis will be mainly a qualitative analysis of the experts' professional views and opinions about the policies, guidelines, protocols, and documents regarding perinatal mental health changes in their country. Additionally, a basic quantitative descriptive analysis will be conducted.",
              "DetailedDescription":"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused worldwide pandemic since the breakout from Wuhan, China in December 2019 (Ciotti et al., 2020). It has infected more than 71.5 million people, causing 1.6 million of deaths up to mid of December 2020 (World Health Organization [WHO], 2020a).\n\nPerinatal health care practices have been changed for safety reasons due to the pandemic and are still changing locally according to the epidemiological circumstances. Across Europe antenatal classes have ceased or have been provided online, antenatal regular check-ups are somewhat reduced or offered via telephone, the presence of the supporting person during childbirth is often not allowed in a maternity ward, visits of the father and other family members to the hospital after delivery are reduced or restricted, newborns of infected mothers are sometimes separated, home visits of a midwife after birth and breastfeeding support are also reduced (COST Devotion, 2020, Thapa et al., 2020). Although official and national guidelines for perinatal health in general or infected mothers/newborns may be available (Chen et al., 2020; Queensland Clinical Guidelines, 2020; WHO, 2020c), practices have been changing constantly, some of which may not be evidence-based or are in contradiction with the recommendations. Along with these changes, there are general restrictions, such as distancing from others, restricted socializing, and restricted movement, which may be necessary but can impose substantial psychological distress (Brooks et al., 2020; Saccone et al., 2020; Topalidou, Thomson & Downe, 2020).\n\nThe high impact of COVID-19 on maternal mental health during pregnancy and postpartum has been evident in different countries worldwide (Davenport et al., 2020; Saccone et al., 2020). All these changes due to COVID-19 pandemic and related epidemiological measures were necessary to combat the spread of the virus but lead to an adverse effect on perinatal mental health.\n\nWithin the ongoing COST Action Research Innovation and Sustainable Pan-European Network in Peripartum Depression Disorder - RISEUP-PPD, funded by the European Cooperation in Science and Technology (COST Association), the special Task Force Perinatal mental health and COVID-19 pandemic, in collaboration with the COST Action Perinatal Mental Health and Birth-Related Trauma: Maximising best practice and optimal outcomes - Devotion, has been established with the main aim of investigating the best practices and guidelines to alleviate the negative consequences of COVID-19 on women's mental health (RISEUP-PPD COST Action, 2020). A recent review pointed out emerging issues in the prevention, diagnosis, and treatment of peripartum depression (Fonseca et al., 2020), which are highlighted even more with the ongoing pandemic. The Task Force has already addressed the deleterious impact of COVID-19 on perinatal mental health, the risk factors for mental health vulnerability during the current pandemic and highlighted good psychological practices in perinatal mental health during the COVID-19 pandemic (Motrico et al., 2020). The Task Force pointed out that research on good practices in perinatal mental health in the time of COVID-19 pandemic should (i) capture the wide range of psychological distress presentations, focusing on depression and anxiety, (ii) look into complex roles of physical distancing and social isolation due to epidemiological measures, (iii) take into account the barriers in seeking help augmented by the pandemic that may be overcome by new e-health services, (iv) investigate changes in perinatal healthcare practices and factors that may alleviate them, and finally (v) boost the efforts for further development and validation of specific perinatal mental health assessment tools (Motrico et al., 2020).\n\nHowever, it remains yet to investigate what are the good practices in perinatal mental health and how have those been incorporated in the national policies, guidelines, protocols, and official documents across European countries during the COVID-19 pandemic. This has important clinical implications and can be used to inform policymakers at both the national and the European level - with the ultimate goal of providing the adequate support to women in the peripartum period and promote a pleasant experience for mothers and their families during pregnancy, delivery and the postpartum, in particular challenging situations as it is the case of the present COVID-19 pandemic. The main aim of this study is to identify the best practices to alleviate the negative impact of COVID-19 itself and the related safety measures (in health care facilities) and to promote mental health support during perinatal period. The secondary aim is to identify the themes emerging from the experts' opinions on changes due to COVID-19 pandemic in 1) mental health policies, guidelines, protocols, and documents; 2) mental health care practices; 3) best practices; 4) barriers; 5) resources; 6) benefits; and 7) short- and long-term expectations.\n\nMethods and analysis Study design A cross- sectional study will be conducted in order to identify best practices in perinatal mental health during the COVID-19 pandemic.\n\nParticipants The participants will be experts in perinatal mental health who are the members of the COST Action RISEUP-PPD and the COST Action Devotion. The COST members are applied sciences researchers and clinicians (nurses, midwives, clinical social workers, general practitioners, Obstetrician/Gynaecologist, psychiatrists, clinical psychologist, psychotherapists), added by researchers from other backgrounds such as neuroscience, biology, biomedical engineer, mathematics and statistics, etc.), politicians, decision-makers, peer-support groups, stakeholdersâ€¦. The main aim of the RISEUP-PPD is to gather a multidisciplinary network of researchers to collect and profound the knowledge about prevention, assessment, and treatment in peripartum depression, while Devotion is dedicated to minimising birth trauma and optimising birth experiences. Taken together, both COST Actions include representatives from 35 European COST countries (Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom), Israel as a Cooperating Members, and Brazil, the USA, Canada and Australia as International Partner countries.\n\nAs mainly qualitative data is planned to be collected, no calculation on sample size is necessary.\n\nInstruments Demographic and expertise background questionnaire The Demographic and expertise background questionnaire will comprise questions on the area of specialisation (Nurse, Midwife, Clinical social worker, General practitioner, Obstetrician/Gynaecologist, Psychiatrist, Psychologist, Psychotherapist, Other), academic background and degree, job position in the current institution, years of experience and years working in Perinatal Care and/or Perinatal Mental Health (each with categories: up to 1 year, 2-5 years, 5-10 years, more than 10 years), current employer (tick all that apply: public, private, birth centre, hospital, home birth, primary care service, academic/research, counselling office, non-governmental organization, other), number of patients/clients per year per institution and personally, gender, age and country.\n\nQuestionnaire for experts on perinatal mental health practices during the COVID-19 Pandemic A questionnaire for the consultation of experts was developed by the research group of the Task Force \"Perinatal Mental Health and COVID-19 pandemic\", based on the previous questionnaire for experts on mental health used in Europe (European Commission, 2013). The questionnaire includes a series of open-ended questions, checklists, and response ratings on a 7-point scale (1 = not adequate to 7 = excellent) with specific references to the change of policies, protocols, and practices regarding Perinatal Mental Health during COVID-19 pandemic. The topic areas covered seven domains of interest: 1) mental health policies, guidelines, protocols, and documents; 2) mental health care practices; 3) best practices; 4) barriers; 5) resources; 6) benefits; and 7) short- and long-term expectations.\n\nGuidelines are defined as systematically developed recommendations to assist in practitioner and patient decision making about treatments for clinical conditions. Protocols are a comprehensive set of criteria outlining the management steps for a single clinical condition. Documents are defined as official records that provide information or evidence. Finally, Best Practice is defined as a technique or methodology that through experience and research has proven reliably to lead to the desired result (WHO, 2020).\n\nThe survey was written in English and a pilot study with three experts in perinatal mental health was conducted. Questions for pilot are presented in Table in Appendix 1. Amendments to the questionnaire were made accordingly which included rewording questions to elicit appropriate responses. The questionnaire for key experts can be found in Appendix 2.\n\nProcedure Experts from COST Action RISEUP-PPD and COST Action Devotion will be approached by e-mail invitation to participate in the study. In order to have greater representation, the research group will encourage that, at least, the three experts per country with more expertise received the invitation.\n\nExperts will be asked to complete the questionnaire online (Qualtrics platform). First, they will read an electronic consent form presenting an overview of the study aims, content of the questions asked, potential risks and benefits, and ethical aspects of the study (i.e., voluntary participation, confidentiality and secure storage of the data, and absence of any type of compensation). At the bottom of the form, they will be asked to confirm a eligibility criteria (members of either COST Actions) and to provide their consent to participate in the study. Participants who do not meet the predefined inclusion criteria will be directed to a message thanking them for their interest and informing them of the required eligibility criteria for participation in the study. The questionnaires are estimated to take approximately 15-20 minutes to complete.\n\nData analysis Data analysis will be mainly a qualitative analysis of the experts' views and opinions about the policies, guidelines, protocols, and documents regarding perinatal mental health changes in their country. The analysis will be made across the seven dimensions: 1) mental health policies, guidelines, protocols, and documents; 2) care practices; 3) best practices; 4) barriers; 5) resources; 6) benefits; and 7) short- and long-term expectations. Two authors will develop the coding plan, which will be checked by other authors. Two authors will code all answers to the open-ended questions independently. Inter-rater reliability will be calculated by Cohen's kappa coefficient and all disparities will be discussed to the agreement.\n\nAdditionally, a basic quantitative descriptive analysis will be made to estimate how many experts think that the policies, guidelines, or protocols regarding perinatal mental health have changed since COVID-19 outbreak, including percentages of yes/no answers and central tendency/variance on 7-point scale answers.\n\nThe findings from this study will be disseminated as papers published in peer-reviewed journals, presented at national and international conferences, and most importantly, its results will be used inform policymakers and have an impact on the changes in perinatal mental health care on a national and European level."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Questionnaire on Changes in PMH Care Practices During the COVID-19 Pandemic"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "perinatal mental health policies",
                  "guidelines",
                  "protocols",
                  "perinatal care practices",
                  "best practices during COVID-19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"Yes",
              "TargetDuration":"6 Months",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Other"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Cross-Sectional"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"70",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Changes in perinatal Best practices",
                    "PrimaryOutcomeDescription":"Questionnaire on changes in PMH care practices during the COVID-19 Pandemic",
                    "PrimaryOutcomeTimeFrame":"March 2020- June 2021"
                  },{
                    "PrimaryOutcomeMeasure":"Changes in perinatal mental health protocols",
                    "PrimaryOutcomeDescription":"Questionnaire on changes in PMH care practices during the COVID-19 Pandemic",
                    "PrimaryOutcomeTimeFrame":"March 2020- June 2021"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nexperts working in perinatal care services within the COST actions RISEUP-PPD and Devotion\n\nExclusion Criteria:\n\nCOST members working in perinatal mental health less than 1 year",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Experts in perinatal mental health who are the members of the COST Action RISEUP-PPD and the COST Action Devotion",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Ana Mesquita, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+351253604613",
                    "CentralContactEMail":"ana.mesquita@psi.uminho.pt"
                  },{
                    "CentralContactName":"Ana Rita Carlos",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+351 253604503",
                    "CentralContactEMail":"a.carlos@gap.uminho.pt"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Ana Mesquita, PhD",
                    "OverallOfficialAffiliation":"University of Minho",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Emma Motrico, PhD",
                    "OverallOfficialAffiliation":"University of Loyola",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Sandra NakiÄ‡ RadoÅ¡, PhD",
                    "OverallOfficialAffiliation":"Catholic University of Croatia",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Ana Ganho, PhD",
                    "OverallOfficialAffiliation":"University of Coimbra",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Joan Lalor, PhD",
                    "OverallOfficialAffiliation":"Trinity College of Dublin",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"32112714",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-920. doi: 10.1016/S0140-6736(20)30460-8. Epub 2020 Feb 26. Review."
                  },{
                    "ReferencePMID":"32196655",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Chen D, Yang H, Cao Y, Cheng W, Duan T, Fan C, Fan S, Feng L, Gao Y, He F, He J, Hu Y, Jiang Y, Li Y, Li J, Li X, Li X, Lin K, Liu C, Liu J, Liu X, Pan X, Pang Q, Pu M, Qi H, Shi C, Sun Y, Sun J, Wang X, Wang Y, Wang Z, Wang Z, Wang C, Wu S, Xin H, Yan J, Zhao Y, Zheng J, Zhou Y, Zou L, Zeng Y, Zhang Y, Guan X. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020 May;149(2):130-136. doi: 10.1002/ijgo.13146. Epub 2020 Apr 1. Erratum in: Int J Gynaecol Obstet. 2020 Jul;150(1):136."
                  },{
                    "ReferencePMID":"32645276",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020 Sep;57(6):365-388. doi: 10.1080/10408363.2020.1783198. Epub 2020 Jul 9. Review."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"COST Action \"Devotion\": Perinatal Mental Health and Birth Related Trauma: Maximising Best Practices and Optimal Outcomes. (2020). COVID in different countries - group discussion."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Davenport, M. H., Meyer, S., Meah, V. L., Strynadka, M. C., & Khurana, R. Moms are not OK: COVID-19 and maternal mental health. Frontiers in Global Women's Health. 2020; 1, 1."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"European Commission. (2013). Mental health systems in the European Union member states, status of mental health in populations and benefits to be expected from investments into mental health main report. (July), 1-574."
                  },{
                    "ReferencePMID":"32469800",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Fonseca A, Ganho-Ãvila A, Lambregtse-van den Berg M, Lupattelli A, Rodriguez-MuÃ±oz MF, Ferreira P, RadoÅ¡ SN, Bina R. Emerging issues and questions on peripartum depression prevention, diagnosis and treatment: a consensus report from the cost action riseup-PPD. J Affect Disord. 2020 Sep 1;274:167-173. doi: 10.1016/j.jad.2020.05.112. Epub 2020 May 23. Review."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Motrico, E., Mateus, V., Bina, R., Felice, E., Bramante, A., Kalcev, G., ... & Mesquita, A. Good practices in perinatal mental health during the COVID-19 pandemic: a report from Task-force RISEUP-PPD COVID-19. ClÃ­nica y Salud. 2020; 31(3), 155-160."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Queensland Clinical Guidelines (2020). Perinatal care of suspected or confirmed COVID-19 pregnant women. Guideline No. MN20.63-V2-R25. Queensland Health. Available from: http://www.health.qld.gov.au/qcg"
                  },{
                    "ReferencePMID":"32387321",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Saccone G, Florio A, Aiello F, Venturella R, De Angelis MC, Locci M, Bifulco G, Zullo F, Di Spiezio Sardo A. Psychological impact of coronavirus disease 2019 in pregnant women. Am J Obstet Gynecol. 2020 Aug;223(2):293-295. doi: 10.1016/j.ajog.2020.05.003. Epub 2020 May 7."
                  },{
                    "ReferencePMID":"32374420",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Thapa SB, Mainali A, Schwank SE, Acharya G. Maternal mental health in the time of the COVID-19 pandemic. Acta Obstet Gynecol Scand. 2020 Jul;99(7):817-818. doi: 10.1111/aogs.13894."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Topalidou A, Thomson G, Downe S. COVID-19 and maternal mental health: Are we getting the balance right? medRxiv. 2020; https://doi.org/10.1101/2020.03.30.20047969"
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"World Health Organization [WHO] (2020a). WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/ Accessed 16 December 2020."
                  },{
                    "ReferencePMID":"32729320",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Thomson S, Doan T, Liu D, Schubert KO, Toh J, Boyd MA, Galletly C. Supporting the vulnerable: developing a strategic community mental health response to the COVID-19 pandemic. Australas Psychiatry. 2020 Oct;28(5):492-499. doi: 10.1177/1039856220944701. Epub 2020 Jul 30."
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            }
          }
        }
      },{
        "Rank":78,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779762",
              "OrgStudyIdInfo":{
                "OrgStudyId":"STEDI"
              },
              "Organization":{
                "OrgFullName":"Wolfson Medical Center",
                "OrgClass":"OTHER_GOV"
              },
              "BriefTitle":"Stelara and Diet Trial for Crohn\"s Disease",
              "OfficialTitle":"Stelara and CDED Diet Trial for Crohn\"s Disease"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 2022",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"January 2025",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"January 2026",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 28, 2021",
              "StudyFirstSubmitQCDate":"February 28, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 28, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Wolfson Medical Center",
                "LeadSponsorClass":"OTHER_GOV"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"Sheba Medical Center, Israel",
                    "CollaboratorClass":"UNKNOWN"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Dietary therapy involving the Crohn's disease exclusion diet (CDED) is an evolving strategy to target the microbiome and innate immunity in order to reduce inflammation and promote healing.\n\nThe goal of the current pilot study is to evaluate the added benefit of treatment with Ustekinumab combined with CDED in anti TNF exposed patients compared to treatment with Ustekinumab alone in term of achieving remission.",
              "DetailedDescription":"The induction period is crucial for a patient's response to biologic therapy but also for maintenance of remission, as simple as it sounds, maintenance of remission requires remission. Biological medications using a single monoclonal antibody directed target, seem to be effective only for a segment of the population with Crohn's disease Dietary therapy is highly effective in children and induces remission in approximately 60% of young adults with uncomplicated luminal disease. It was shown to shift the microbiome away from Proteobacteria towards Firmicutes, and to decrease intestinal permeability (i.e improvement in leaky gut).\n\nDietary therapy is widely used in children and both exclusive enteral nutrition (EEN) and the Crohn's disease exclusion diet were highly effective for induction of remission and reduction in inflammation in children in a multinational randomized controlled trial (Levine A, Gastroenterology 2019). Recently a prospective randomized controlled trial in biologic naÃ¯ve adults demonstrated clinical remission in 62% of adults by 6 weeks (Yanai H, UEG Week 2020). A two week course of EEN in adults was effective for improvement of symptoms and reduction in inflammation (Wall CL Inflamm Intest Dis 2018). Xu et al demonstrated clinical remission in 52 and 47% of two adult cohorts (n=104) using EEN for induction of remission (Xu Y, Therap Adv Gastroenterol 2019). Taken together, these studies suggest that dietary therapy could act as a bridge to biologic effect and have a synergistic effect on the disease."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Crohn Disease"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Single",
                  "DesignMaskingDescription":"single blinded",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Investigator"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"40",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Group 1",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Standard induction regimen of Ustekinumab with the Crohn's disease exclusion diet (CDED)",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Crohn's disease exclusion diet (CDED)",
                        "Drug: Ustekinumab Injection [Stelara]"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Group 2",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Standard induction regimen of Ustekinumab as above without diet",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Ustekinumab Injection [Stelara]"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Crohn's disease exclusion diet (CDED)",
                    "InterventionDescription":"Dietary therapy for Crohn's disease",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Group 1"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Ustekinumab Injection [Stelara]",
                    "InterventionDescription":"Drug for Crohn's disease",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Group 1",
                        "Group 2"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"ITT, steroid free remission",
                    "PrimaryOutcomeDescription":"Defined as an improvement in one inflammatory marker (CRP or calprotectin)",
                    "PrimaryOutcomeTimeFrame":"week 12"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Median calprotectin",
                    "SecondaryOutcomeDescription":"Reduction in median calprotectin compared to baseline between groups",
                    "SecondaryOutcomeTimeFrame":"week 12"
                  },{
                    "SecondaryOutcomeMeasure":"Intestinal bowel wall thickness",
                    "SecondaryOutcomeDescription":"Reduction in intestinal bowel wall thickness compared to baseline between groups for patients with increased bowel wall thickness measured on baseline US.",
                    "SecondaryOutcomeTimeFrame":"week 16"
                  },{
                    "SecondaryOutcomeMeasure":"UST trough level",
                    "SecondaryOutcomeDescription":"mean UST trough level between groups.",
                    "SecondaryOutcomeTimeFrame":"week 16"
                  },{
                    "SecondaryOutcomeMeasure":"CDAI between groups",
                    "SecondaryOutcomeDescription":"Median decline in CDAI between groups. Crohn's Disease Activity Index (CDAI) range between 0-800",
                    "SecondaryOutcomeTimeFrame":"week 16"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nInformed consent.\nAge: 18- 65 years (inclusive).\nEstablished diagnosis of CD\nStarting Ustekinumab.\nActive disease defined as a CDAI >220, and have an objective measure of disease activity such as an elevated marker of inflammation (elevated CRP >5mg/L or 0.5 mg/dL or calprotectin >150 mcg/g).\nPatients must have previously received at least one dose of anti TNF at any time in the past.\nStable medication at least 8 weeks.\n\nInclusion criteria comments\n\n1. Patients of any weight will be recruited and randomized to the study regardless of their BMI.\n\nExclusion Criteria:\n\nPregnancy or lactation\nPresence of malignancy\nUse of prednisone >20 mg /day\nOngoing use of concurrent medications with a dose change in the previous 8 weeks with the exception of steroids (Patients receiving prednisone 20 mg or less may be enrolled by must be tapered by week 6).\nTreatment with an anti TNF in the last 4 weeks.\nPatients who will take oral iron oral supplements during the trial (see comment 1 below).\nActive infections, tuberculosis, positive stool test for Clostridium difficile toxin.\nActive perianal fistula (with discharge, or with an abscess during the past 3 months), rectovaginal fistula.\nFever.\nActive extra intestinal disease (arthritis with joint swelling, concurrent liver disease). Patients with skin manifestations and arthralgia may be included.\nSmokers who smoke >5 more cigarettes a day (see comment 2 below).\nRenal failure.\nUncontrolled diabetes that precludes the diet.\nPatients with isolated colonic disease distal to the transverse colon (see comment 3 below).\n\nExclusion criteria comments\n\nPatients taking oral iron supplements may be enrolled if they discontinue the supplements prior to receiving UST, and are NOT ALLOWED to take oral iron supplements during the first 12 weeks of the trial as the diet reduces oral iron exposure to decrease siderophoric pathobionts (patients are allowed to receive intravenous iron or other oral vitamins during the trial).\nPatients who smoke >5 cigarettes per day may be enrolled if they stop smoking from the start of the trial (smoking negates the effect of the diet).\nPatients with isolated colonic disease distal to the transverse colon and no history of ileal disease will be excluded to make sure that IBDU is not recruited.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Michal Yaakov, Ph.D",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"972-35028878",
                    "CentralContactEMail":"michal.yaakov@walla.co.il"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Sheba Medical Center",
                    "LocationCity":"Ramat Gan",
                    "LocationZip":"5262000",
                    "LocationCountry":"Israel",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Uri Kopylev, MD",
                          "LocationContactRole":"Contact"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003424",
                    "ConditionMeshTerm":"Crohn Disease"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000015212",
                    "ConditionAncestorTerm":"Inflammatory Bowel Diseases"
                  },{
                    "ConditionAncestorId":"D000005759",
                    "ConditionAncestorTerm":"Gastroenteritis"
                  },{
                    "ConditionAncestorId":"D000005767",
                    "ConditionAncestorTerm":"Gastrointestinal Diseases"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  },{
                    "ConditionAncestorId":"D000007410",
                    "ConditionAncestorTerm":"Intestinal Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5221",
                    "ConditionBrowseLeafName":"Crohn Disease",
                    "ConditionBrowseLeafAsFound":"Crohn's Disease",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M9027",
                    "ConditionBrowseLeafName":"Intestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16500",
                    "ConditionBrowseLeafName":"Inflammatory Bowel Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7458",
                    "ConditionBrowseLeafName":"Gastroenteritis",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000069549",
                    "InterventionMeshTerm":"Ustekinumab"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000003879",
                    "InterventionAncestorTerm":"Dermatologic Agents"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M460",
                    "InterventionBrowseLeafName":"Ustekinumab",
                    "InterventionBrowseLeafAsFound":"Optional",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M5657",
                    "InterventionBrowseLeafName":"Dermatologic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Derm",
                    "InterventionBrowseBranchName":"Dermatologic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":79,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779749",
              "OrgStudyIdInfo":{
                "OrgStudyId":"PregOutCOV"
              },
              "Organization":{
                "OrgFullName":"Brugmann University Hospital",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Pregnancy Outcomes According to the Gestational Age of Acquiring COVID-19",
              "OfficialTitle":"Pregnancy Outcomes According to the Gestational Age of Acquiring COVID-19 : an International Case-control Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"December 8, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Jani Jacques",
                "ResponsiblePartyInvestigatorTitle":"Head of Gynecology-Obstetrics Department",
                "ResponsiblePartyInvestigatorAffiliation":"Brugmann University Hospital"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Brugmann University Hospital",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"A new coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) appeared in Wuhan, China and it arrived to Europe 2-3 months later. It infected millions of persons and led to the death of thousands until May 2020 where numbers of infections per week decreased significantly. However, starting September, number of infections started to escalate again and continued to rise until now.\n\nHundreds of good quality articles were published during this period to study the relationship and effects of this virus on pregnancy and vice versa, as well as to determine the adverse neonatal and obstetrical outcomes following the infection. In a case-control study using propensity score matching at the level of age, body mass index and comorbidities (diabetes, hypertension, asthma), pregnant women over 20 week's gestation had significantly higher risk for intensive care unit stay, endotracheal intubation, hospitalization for disease related symptoms and need for oxygen therapy. A new systematic review also demonstrated increased risk for ICU admission in pregnant women compared to non-pregnant women and to non-infected pregnant women.\n\nOn the other hand, many researchers have demonstrated that the rates of preterm delivery and cesarean delivery have increased as well, others reported a close relation between SARS-CoV2 infection and preeclampsia or preeclampsia like condition. Enormous effort was done in order to understand adverse outcomes related to this infection, however, most studies included patients in the third or late second trimester. Few studies stratified adverse outcomes of the patients according to the trimester of infection."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Case-Control"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Retrospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"10000",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"COVID positive <20 weeks",
                    "ArmGroupDescription":"Case groups 1 will include pregnant patients infected by SARS-CoV2 before 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Data extraction from medical files"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"COVID positive >20 weeks",
                    "ArmGroupDescription":"Case groups 2 will include pregnant patients infected by SARS-CoV2 after 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Data extraction from medical files"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Control",
                    "ArmGroupDescription":"Patients not infected by SARS-CoV2 during pregnancy during the period starting on February 1st 2020 and ending on November 30th 2020",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Data extraction from medical files"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Data extraction from medical files",
                    "InterventionDescription":"Data extraction from medical files",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "COVID positive <20 weeks",
                        "COVID positive >20 weeks",
                        "Control"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Preterm delivery",
                    "PrimaryOutcomeDescription":"Delivery at a gestational age < 37 weeks",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Preeclampsia",
                    "PrimaryOutcomeDescription":"Preeclampsia is defined as elevated blood pressure (Systolic blood pressure â‰¥140 mmHg or diastolic blood pressure â‰¥90 mmHg on at least 2 occasions at least 4 hours apart after 20 weeks of gestation in a previously normotensive patient) and the new onset of 1 or more of the following:\n\nProteinuria â‰¥0.3 g in a 24-hour urine specimen or protein/creatinine ratio â‰¥0.3 (mg/mg) (30 mg/mmol) in a random urine specimen or dipstick â‰¥2+ if a quantitative measurement is unavailable\nPlatelet count <100,000/microL\nSerum creatinine >1.1 mg/dL (97.2 micromol/L) or doubling of the creatinine concentration in the absence of other renal disease\nLiver transaminases at least twice the upper limit of the normal concentrations for the local laboratory\nPulmonary edema\nNew-onset and persistent headache not accounted for by alternative diagnoses and not responding to usual doses of analgesics\nVisual symptoms (eg, blurred vision, flashing lights or sparks, scotomata)",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Eclampsia",
                    "PrimaryOutcomeDescription":"Eclampsia is defined by the occurrence of a grand mal seizure in a woman with preeclampsia in the absence of other neurologic conditions that could cause seizure.",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Hemolysis Elevated Liver enzymes Low Platelets Syndrome (HELLP)",
                    "PrimaryOutcomeDescription":"HELLP syndrome is considered to be a serious complication or variant of preeclampsia in pregnant women.",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Cesarean delivery (CD)",
                    "PrimaryOutcomeDescription":"Cesarean delivery",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Deep venous thrombosis",
                    "PrimaryOutcomeDescription":"diagnosed by imaging tools such as venous Doppler ultrasound of the lower limbs",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Pulmonary embolism",
                    "PrimaryOutcomeDescription":"diagnosed by imaging tools such as angio-CT scan of the thorax.",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Pregnancy loss at less than 24 weeks' gestation",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Intrauterine Fetal Demise (IUFD)",
                    "PrimaryOutcomeDescription":"Pregnancy loss at 24 weeks or more, or the delivery of a neonate weighing more than 500 g",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Maternal death",
                    "PrimaryOutcomeDescription":"Maternal death",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Low birth weight",
                    "PrimaryOutcomeDescription":"birth weight at less than 2500g",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Neonatal intensive care unit (NICU) admission",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"APGAR score at 5 minutes < 7",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Respiratory distress at birth",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "PrimaryOutcomeMeasure":"Neonatal death",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Delivery < 32 weeks",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Spontaneous delivery < 37 weeks",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Fetal distress",
                    "SecondaryOutcomeDescription":"referred to bradycardia, recurrent late or variable deceleration on antepartum or intrapartum cardiotocogram.",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Unscheduled cesarean delivery",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Postpartum hemorrhage",
                    "SecondaryOutcomeDescription":"defined as the estimated blood loss of > 500 mL",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Intraventricular hemorrhage",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Umbilical cord pH",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Small for gestational age (SGA)",
                    "SecondaryOutcomeDescription":"it refers to an estimated fetal weight of less than the 10th percentile",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  },{
                    "SecondaryOutcomeMeasure":"Large for gestational age (LGA)",
                    "SecondaryOutcomeDescription":"it refers to an estimated fetal weight of more than the 95th percentile",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPregnant women with viable fetus after 10 weeks' gestation and known pregnancy outcome during the period starting on February 1st 2020 and ending on November 30th 2020.\n\nExclusion Criteria:\n\nAll ongoing pregnancies, those with unknown outcomes, those terminated medically or voluntary, as well as patients with spontaneous abortion before the 11th gestational week.",
              "HealthyVolunteers":"No",
              "Gender":"Female",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Study population will include all pregnant women with viable fetus after 10 weeks' gestation and known pregnancy outcome during the period starting on February 1st 2020 and ending on November 30th 2020.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Jacques Jani, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"3224773631",
                    "CentralContactEMail":"JACQUES.JANI@chu-brugmann.be"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Jacques Jani, MD",
                    "OverallOfficialAffiliation":"CHU Brugmann",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"CHU Brugmann",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Brussels",
                    "LocationZip":"1020",
                    "LocationCountry":"Belgium",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Dominique Badr, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"Dominique.BADR@chu-brugmann.be"
                        },{
                          "LocationContactName":"Dominique Badr",
                          "LocationContactRole":"Sub-Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Antoine BÃ©clÃ¨re Hospital",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Clamart",
                    "LocationZip":"92140",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Alexandre Vivanti",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"alexandre.vivanti@aphp.fr"
                        },{
                          "LocationContactName":"Alexandre Vivanti",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"HÃ´pital Louis Mourier",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Colombes",
                    "LocationZip":"92700",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Olivier PICONE",
                          "LocationContactRole":"Contact"
                        },{
                          "LocationContactName":"Olivier PICONE",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Fondazione Policlinico Universitario Agostino Gemelli",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Roma",
                    "LocationZip":"00168",
                    "LocationCountry":"Italy",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Elisa BEVILACQUA",
                          "LocationContactRole":"Contact"
                        },{
                          "LocationContactName":"Elisa BEVILACQUA",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"32730899",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, El Kenz H, Andronikof M, De Bels D, Damoisel C, Preseau T, Vignes D, Cannie MM, Vauloup-Fellous C, Fils JF, Benachi A, Jani JC, Vivanti AJ. Are clinical outcomes worse for pregnant women at â‰¥20 weeks' gestation infected with coronavirus disease 2019? A multicenter case-control study with propensity score matching. Am J Obstet Gynecol. 2020 Nov;223(5):764-768. doi: 10.1016/j.ajog.2020.07.045. Epub 2020 Jul 27."
                  },{
                    "ReferencePMID":"32873575",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, Debenham L, Llavall AC, Dixit A, Zhou D, Balaji R, Lee SI, Qiu X, Yuan M, Coomar D, van Wely M, van Leeuwen E, Kostova E, Kunst H, Khalil A, Tiberi S, Brizuela V, Broutet N, Kara E, Kim CR, Thorson A, Oladapo OT, Mofenson L, Zamora J, Thangaratinam S; for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320. doi: 10.1136/bmj.m3320."
                  },{
                    "ReferencePMID":"32648892",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Khalil A, von Dadelszen P, Draycott T, Ugwumadu A, O'Brien P, Magee L. Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic. JAMA. 2020 Jul 10. doi: 10.1001/jama.2020.12746. [Epub ahead of print]"
                  },{
                    "ReferencePMID":"32633022",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM, Yang YJ, Zhao Z, Baergen RN, DiPace JI, Razavi AS, Skupski DW, Snyder JR, Singh HK, Kalish RB, Oxford CM, Riley LE. Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG. 2020 Nov;127(12):1548-1556. doi: 10.1111/1471-0528.16403. Epub 2020 Aug 13."
                  },{
                    "ReferencePMID":"33083779",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Berghella V, Boelig R, Roman A, Burd J, Anderson K. Decreased incidence of preterm birth during coronavirus disease 2019 pandemic. Am J Obstet Gynecol MFM. 2020 Nov;2(4):100258. doi: 10.1016/j.ajogmf.2020.100258. Epub 2020 Oct 15."
                  },{
                    "ReferencePMID":"32479682",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Mendoza M, Garcia-Ruiz I, Maiz N, Rodo C, Garcia-Manau P, Serrano B, Lopez-Martinez RM, Balcells J, Fernandez-Hidalgo N, Carreras E, Suy A. Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study. BJOG. 2020 Oct;127(11):1374-1380. doi: 10.1111/1471-0528.16339. Epub 2020 Jun 21."
                  },{
                    "ReferencePMID":"33039396",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Cosma S, Carosso AR, Cusato J, Borella F, Carosso M, Bovetti M, Filippini C, D'Avolio A, Ghisetti V, Di Perri G, Benedetto C. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. Am J Obstet Gynecol. 2020 Oct 8. pii: S0002-9378(20)31177-7. doi: 10.1016/j.ajog.2020.10.005. [Epub ahead of print]"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            }
          }
        }
      },{
        "Rank":80,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779736",
              "OrgStudyIdInfo":{
                "OrgStudyId":"8088"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"K23MH124569",
                    "SecondaryIdType":"U.S. NIH Grant/Contract",
                    "SecondaryIdLink":"https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=K23MH124569&Fy=all"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"New York State Psychiatric Institute",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Mitigating Sexual Stigma Within Healthcare Interactions Improve Engagement of MSM in HIV Prevention",
              "OfficialTitle":"Mitigating Sexual Stigma Within Healthcare Interactions to Improve Engagement of MSM in HIV Prevention"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"May 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 2024",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"August 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"January 21, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Bryan Kutner",
                "ResponsiblePartyInvestigatorTitle":"Research Scientist IV",
                "ResponsiblePartyInvestigatorAffiliation":"New York State Psychiatric Institute"
              },
              "LeadSponsor":{
                "LeadSponsorName":"New York State Psychiatric Institute",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"National Institute of Mental Health (NIMH)",
                    "CollaboratorClass":"NIH"
                  },{
                    "CollaboratorName":"Columbia University",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of this study is to explore drivers and mitigators of anal sex stigma in healthcare, and then to develop and pilot an intervention for health workers that mitigates the deterrent effects of stigma on the engagement of gay and bisexual men in HIV-related services.",
              "DetailedDescription":"This 5-year study aims to understand determinants that either perpetuate or mitigate stigma toward anal sex during healthcare encounters, in order to develop and pilot a strategy that responds to these determinants and thereby improves the quality of care and HIV services engagement among men who have sex with men (MSM). The study team will collect data during in-depth interviews with 30 adult MSM as well as 30 adult healthcare workers (HCWs) to identify strategies that could be readily used in health services to reduce stigma. Analysis of this data will then inform consultation with an advisory board of 4 adult MSM and 4 adult HCWs to develop the content of a set of implementation strategies to mitigate stigma and thereby improve health service delivery. Evaluation of a set of implementation strategies will be performed in two high incidence regions in the United States, by pilot testing with 120 adult HCWs who do not specialize in MSM health and who work in clinical sites where MSM are under-engaged in HIV services."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Human Immunodeficiency Virus",
                  "Stigma, Social",
                  "Patient Engagement"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Implementation science",
                  "Health stigma and discrimination framework",
                  "Theoretical domains framework",
                  "Theory and techniques tool",
                  "Anal sex stigma",
                  "Men who have sex with men",
                  "Sexual and gender minority"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Sequential Assignment",
                "DesignPrimaryPurpose":"Health Services Research",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"188",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Stepped Wedge Trial",
                    "ArmGroupType":"Other",
                    "ArmGroupDescription":"The pilot intervention will be evaluated using a stepped wedge design, with participants serving as their own controls within each region and clinical site.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: A set of implementation strategies to reduce sexual stigma"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"A set of implementation strategies to reduce sexual stigma",
                    "InterventionDescription":"The intervention will be finalized based on formative interviews and consultation with an advisory board. It is likely to include an educational mHealth component followed by an in-person workshop for skills development, then supportive coaching components (i.e., coaching calls and an optional email listserve) to encourage and respond to the implementation of recommended practices.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Stepped Wedge Trial"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Acceptability, appropriateness, and feasibility of the mHealth component as assessed by the AFAS",
                    "PrimaryOutcomeDescription":"Quantitative assessment using the 13-item Acceptability, Feasibility, & Appropriateness Scale (AFAS), with three subscales for each construct. Acceptability refers to satisfaction with the implementation strategies. Feasibility refers to compatibility of recommended practices with participants' current practices. Appropriateness refers to perceived fit with participants' work mission and goals. Mean scores for individual items and mean scores for subscales will reflect the response category range from 1 (Not at all) to 5 (Extremely), with higher scores indicating, respectively, greater acceptability, appropriateness and feasibility.",
                    "PrimaryOutcomeTimeFrame":"Post-intervention, 1 week after completion of the mHealth component"
                  },{
                    "PrimaryOutcomeMeasure":"Acceptability, appropriateness, and feasibility of the in-person skills development workshop as assessed by the AFAS",
                    "PrimaryOutcomeDescription":"Quantitative assessment using the 13-item Acceptability, Feasibility, & Appropriateness Scale (AFAS), with three subscales for each construct. Acceptability refers to satisfaction with the implementation strategies. Feasibility refers to compatibility of recommended practices with participants' current practices. Appropriateness refers to perceived fit with participants' work mission and goals. Mean scores for individual items and mean scores for subscales will reflect the response category range from 1 (Not at all) to 5 (Extremely), with higher scores indicating, respectively, greater acceptability, appropriateness and feasibility.",
                    "PrimaryOutcomeTimeFrame":"Post-intervention, 1 week after completion of the in-person workshop"
                  },{
                    "PrimaryOutcomeMeasure":"Acceptability, appropriateness, and feasibility of the coaching calls and optional email listserv as assessed by the AFAS",
                    "PrimaryOutcomeDescription":"Quantitative assessment using the 13-item Acceptability, Feasibility, & Appropriateness Scale (AFAS), with three subscales for each construct. Acceptability refers to satisfaction with the implementation strategies. Feasibility refers to compatibility of recommended practices with participants' current practices. Appropriateness refers to perceived fit with participants' work mission and goals. Mean scores for individual items and mean scores for subscales will reflect the response category range from 1 (Not at all) to 5 (Extremely), with higher scores indicating, respectively, greater acceptability, appropriateness and feasibility.",
                    "PrimaryOutcomeTimeFrame":"Post-intervention, 1 week after completion of coaching calls and optional email listserv"
                  },{
                    "PrimaryOutcomeMeasure":"Reach of the mHealth component as assessed by the RE-AIM Framework",
                    "PrimaryOutcomeDescription":"Quantitative assessment of how many health workers are exposed to implementation strategies and how representative they are of the health worker population within the health delivery setting. This will be calculated as a percentage of health workers reached: (# health workers actually exposed)/(# health workers ideally exposed).",
                    "PrimaryOutcomeTimeFrame":"Post-intervention, 1 week after completion of the mHealth component"
                  },{
                    "PrimaryOutcomeMeasure":"Reach of the in-person skills development workshop as assessed by the RE-AIM Framework",
                    "PrimaryOutcomeDescription":"Quantitative assessment of how many health workers are exposed to implementation strategies and how representative they are of the health worker population within the health delivery setting. This will be calculated as a percentage of health workers reached: (# health workers actually exposed)/(# health workers ideally exposed).",
                    "PrimaryOutcomeTimeFrame":"Post-intervention, 1 week after completion of the in-person workshop"
                  },{
                    "PrimaryOutcomeMeasure":"Reach of the coaching calls and optional email listserv as assessed by the RE-AIM Framework",
                    "PrimaryOutcomeDescription":"Quantitative assessment of how many health workers are exposed to implementation strategies and how representative they are of the health worker population within the health delivery setting. This will be calculated as a percentage of health workers reached: (# health workers actually exposed)/(# health workers ideally exposed).",
                    "PrimaryOutcomeTimeFrame":"Post-intervention, 1 week after completion of coaching calls and optional email listserv"
                  },{
                    "PrimaryOutcomeMeasure":"Acceptability, appropriateness, and feasibility of the set of implementation strategies as assessed by qualitative interviews",
                    "PrimaryOutcomeDescription":"Acceptability, appropriateness, and feasibility will be assessed through in-depth interviews following completion of quantitative assessments, as part of an explanatory sequential mixed-methods design.",
                    "PrimaryOutcomeTimeFrame":"Post-intervention 3 months after completion of all implementation strategies"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Changes to determinants of implementation behavior as assessed by the DIBQ",
                    "SecondaryOutcomeDescription":"Quantitative assessment using a 25-item adaptation to the Determinants of Implementation Behavior Questionnaire (DIBQ). The DIBQ measures multiple domains from within the Theoretical Domains Framework (e.g., perceived behavioral control, optimism, attitude, outcome expectancy, intentions) that are posited as mechanisms of action that mediate behavior change among health care workers. Mean scores for individual items and mean scores for subscales will reflect the response category range, from 1 (Very difficult) to 7 (Very easy), with higher scores indicating ease related to that domain.",
                    "SecondaryOutcomeTimeFrame":"(1) Baseline, pre-intervention, (2) Post-intervention 1 week after completion of mHealth component, (3) Post-intervention 1 week after completion of the in-person workshop, (4) Post-intervention 3 months after completion of all implementation strategies"
                  },{
                    "SecondaryOutcomeMeasure":"Changes to knowledge about anal health and sexuality as assessed by the iASK",
                    "SecondaryOutcomeDescription":"Quantitative assessment using the 10-item Inventory of Anal Sex Knowledge (iASK). The iASK measures knowledge as a potential mediator of behavior change. All items are scored as True/False for a total percentage of correct responses, ranging from 0-10, with higher scores indicating greater knowledge.",
                    "SecondaryOutcomeTimeFrame":"(1) Baseline, pre-intervention, (2) Post-intervention 1 week after completion of mHealth component, (3) Post-intervention 1 week after completion of the in-person workshop, (4) Post-intervention 3 months after completion of all implementation strategies"
                  },{
                    "SecondaryOutcomeMeasure":"Changes to comfort discussing anal health and sexuality as assessed by 6 study-specific items",
                    "SecondaryOutcomeDescription":"Quantitative assessment using 6 items developed for the current study to measure changes to comfort discussing anal health and sexuality with clients (e.g., Asking male clients about their sexual orientation; Asking male clients about their anal sex practices; Initiating a conversation about anal health; Asking MSM clients about their specific questions or concerns related to anal health). Mean scores for individual items will reflect the response category range, from 0 (Not at all comfortable) to 6 (Very comfortable), with higher scores indicating greater comfort related to that activity.",
                    "SecondaryOutcomeTimeFrame":"(1) Baseline, pre-intervention, (2) Post-intervention 1 week after completion of mHealth component, (3) Post-intervention 1 week after completion of the in-person workshop, (4) Post-intervention 3 months after completion of all implementation strategies"
                  },{
                    "SecondaryOutcomeMeasure":"Changes to the quality of care as assessed by 6 study-specific items",
                    "SecondaryOutcomeDescription":"Quantitative assessment using 6 items developed for the current study to measure changes to frequency of discussing anal health and sexuality with clients (e.g., Asking male clients about their sexual orientation; Asking male clients about their anal sex practices; Initiating a conversation about anal health; Asking MSM clients about their specific questions or concerns related to anal health). Mean scores for individual items will reflect the response category range, from 0 (Not at all comfortable) to 6 (Very comfortable), with higher scores indicating greater reported frequency of each activity.",
                    "SecondaryOutcomeTimeFrame":"(1) Baseline, pre-intervention, (2) Post-intervention 3 months after completion of all implementation strategies"
                  },{
                    "SecondaryOutcomeMeasure":"Changes to the engagement MSM in HIV-related services as measured by electronic health record (EHR) in two HIV service delivery sites",
                    "SecondaryOutcomeDescription":"In two HIV service delivery sites, among all sites involved in the study, engagement of MSM will be assessed via EHR by measuring the number over the past 30 days of self-identified gay and bisexual men who have sought (a) HIV testing, (b) screening for PrEP eligibility, (c) received anogenital cytology for sexually transmitted infection, and (d) been retained in HIV care (as defined by returning for their most recent 3-month visit, if living with HIV). EHR will also be reviewed to assess documentation for self-identified gay and bisexual men over the past 30 days of (a) anal health conditions, (b) sexual history and (c) sexual behavior.",
                    "SecondaryOutcomeTimeFrame":"(1) Baseline, pre-intervention, (2) Post-intervention 3 months after completion of all implementation strategies"
                  },{
                    "SecondaryOutcomeMeasure":"Impact of implementation strategies on the quality of care and engagement of MSM clients as assessed by qualitative interviews",
                    "SecondaryOutcomeDescription":"Impact of the implementation strategies (i.e., mHealth education, in-person workshop, coaching calls, email listserv, and any additional implementation strategies developed over the course of the study) will be assessed through in-depth interviews following completion of quantitative assessments, as part of an explanatory sequential mixed-methods design.",
                    "SecondaryOutcomeTimeFrame":"Post-intervention 3 months after completion of all implementation strategies"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"MSM Participants\n\nInclusion Criteria:\n\nbe aged 18 or older\nreport being assigned male at birth and identifying currently as male\nreside in the United States\nread and communicate in English\nhave had anal intercourse with a man in the past year or intend to in the next year Exclusion Criteria: Not applicable\n\nHealthcare Worker Participants\n\nInclusion Criteria:\n\nbe aged 18 or older\nread and communicate in English\nbear a role responsibility for HIV-related screening and referral (e.g., as a peer/outreach worker, test counselor, case manager, social worker, medical assistant, nurse, physician assistant, physician) Exclusion Criteria: Not applicable",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "GenderBased":"Yes",
              "GenderDescription":"For the formative phase of in-depth interviews, we will require MSM (N = 30) to identify as male and to report being assigned male at birth. Formative in-depth interviews with healthcare workers as well as advisory board membership to develop the intervention and the pilot evaluation of the eventual intervention will not be limited by gender identity.",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Bryan Kutner, PhD, MPH",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"(646) 774-6935",
                    "CentralContactEMail":"bryan.kutner@nyspi.columbia.edu"
                  },{
                    "CentralContactName":"Theo Sandfort, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"(646) 774-6946",
                    "CentralContactEMail":"tgs2001@columbia.edu"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"New York State Psychiatric Institute",
                    "LocationCity":"New York",
                    "LocationState":"New York",
                    "LocationZip":"10032",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Masud Rahman, MS, MBA",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"646-774-6950",
                          "LocationContactEMail":"masud.rahman@nyspi.columbia.edu"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000000163",
                    "ConditionMeshTerm":"Acquired Immunodeficiency Syndrome"
                  },{
                    "ConditionMeshId":"D000015658",
                    "ConditionMeshTerm":"HIV Infections"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000007153",
                    "ConditionAncestorTerm":"Immunologic Deficiency Syndromes"
                  },{
                    "ConditionAncestorId":"D000007154",
                    "ConditionAncestorTerm":"Immune System Diseases"
                  },{
                    "ConditionAncestorId":"D000016180",
                    "ConditionAncestorTerm":"Lentivirus Infections"
                  },{
                    "ConditionAncestorId":"D000012192",
                    "ConditionAncestorTerm":"Retroviridae Infections"
                  },{
                    "ConditionAncestorId":"D000012327",
                    "ConditionAncestorTerm":"RNA Virus Infections"
                  },{
                    "ConditionAncestorId":"D000014777",
                    "ConditionAncestorTerm":"Virus Diseases"
                  },{
                    "ConditionAncestorId":"D000015229",
                    "ConditionAncestorTerm":"Sexually Transmitted Diseases, Viral"
                  },{
                    "ConditionAncestorId":"D000012749",
                    "ConditionAncestorTerm":"Sexually Transmitted Diseases"
                  },{
                    "ConditionAncestorId":"D000012897",
                    "ConditionAncestorTerm":"Slow Virus Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M16833",
                    "ConditionBrowseLeafName":"HIV Infections",
                    "ConditionBrowseLeafAsFound":"Human Immunodeficiency Virus",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M2103",
                    "ConditionBrowseLeafName":"Acquired Immunodeficiency Syndrome",
                    "ConditionBrowseLeafAsFound":"Human Immunodeficiency Virus",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M16105",
                    "ConditionBrowseLeafName":"Virus Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8782",
                    "ConditionBrowseLeafName":"Immunologic Deficiency Syndromes",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14938",
                    "ConditionBrowseLeafName":"Syndrome",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8783",
                    "ConditionBrowseLeafName":"Immune System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M17223",
                    "ConditionBrowseLeafName":"Lentivirus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13609",
                    "ConditionBrowseLeafName":"Retroviridae Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13732",
                    "ConditionBrowseLeafName":"RNA Virus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14141",
                    "ConditionBrowseLeafName":"Sexually Transmitted Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M16516",
                    "ConditionBrowseLeafName":"Sexually Transmitted Diseases, Viral",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M14283",
                    "ConditionBrowseLeafName":"Slow Virus Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC20",
                    "ConditionBrowseBranchName":"Immune System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXS",
                    "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":81,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779723",
              "OrgStudyIdInfo":{
                "OrgStudyId":"MMDC-2018-023"
              },
              "Organization":{
                "OrgFullName":"Multan Medical And Dental College",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"30-Days Post-Operative Complications in Bariatric Surgery",
              "OfficialTitle":"Comparison of Laparoscopic Sleeve Gastrectomy (LSG) With Laparoscopic Gastric Bypass (LRYGB) in Bariatric Surgery; 30-Days Post-Operative Complications in Bariatric Surgery",
              "Acronym":"Bariatric"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"June 13, 2018",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"February 12, 2019",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"October 12, 2019",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 7, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Manzar Ali",
                "ResponsiblePartyInvestigatorTitle":"Consultant General and laparoscopic Surgeon",
                "ResponsiblePartyInvestigatorAffiliation":"Multan Medical And Dental College"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Multan Medical And Dental College",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"comparison of 30-days post-operative outcomes of laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB)",
              "DetailedDescription":"Obesity is one of the most challenging chronic diseases in the western world as well as in Pakistan. Half of the people in this world consider themselves overweight or obese. Obesity is one of the most challenging chronic diseases in the western world as well as in Pakistan . Half of the people in this world consider themselves overweight or obese. Obesity is challenging to control by medical therapy and drug treatment. The most effective way to treat obesity is bariatric surgery. Laparoscopic Roux-en-Y gastric bypass (LRYGB) is a \"gold standard\" bariatric surgical procedure. Recently there is much attention gained by laparoscopic sleeve gastrectomy (LSG). Therefore, we decided to conduct this comparative study to compare the early post-op complications of LSG with LRYGB technique in patients undergoing bariatric surgery."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Bariatric Surgery"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Bariatric surgery",
                  "Laparoscopic Roux-en-Y gastric bypass",
                  "Laparoscopic sleeve gastrectomy"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"116",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"LRYGB Procedure",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"LRYGB technique was performed by placing 4 to 6 trocars, a 150 cm ante-colic Roux-limb gastric pouch (30 to 50 ml) was created with linear stapled or circular stapled gastro-jejunostomy, a 50-cm long biliopancreatic limb was chosen. A passive drainage was kept near to the gastro-jejunostomy.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Comparison of two Techniques of bariatric surgery"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"LSG Procedure",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"35 Fr bougie was used for the calibration of a gastric tube. 3 to 6 cm of longitudinal incision of the stomach was done at pylorus to the angle of His. Using of absorbable suture, the staple line was sewn.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Comparison of two Techniques of bariatric surgery"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"Comparison of two Techniques of bariatric surgery",
                    "InterventionDescription":"We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "LRYGB Procedure",
                        "LSG Procedure"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Frequency of Anastomotic Leakage in Each Study Arm",
                    "PrimaryOutcomeDescription":"Patients were examined on postoperative 30 days for the presence of Anastomotic leakage",
                    "PrimaryOutcomeTimeFrame":"within the first 30 days after surgery"
                  },{
                    "PrimaryOutcomeMeasure":"Frequency of Bleeding in Each Study Arm",
                    "PrimaryOutcomeDescription":"Patients were examined postoperative for the presence of bleeding",
                    "PrimaryOutcomeTimeFrame":"24 hours after surgery"
                  },{
                    "PrimaryOutcomeMeasure":"Number of Infections in Each Study Arm",
                    "PrimaryOutcomeDescription":"Patients were examined on postoperative 30 days for the presence of Wound infections",
                    "PrimaryOutcomeTimeFrame":"30 days"
                  },{
                    "PrimaryOutcomeMeasure":"Mortality in Each Study Arm",
                    "PrimaryOutcomeDescription":"Patients were followed for 30 days and number of mortalities was noted on each arm",
                    "PrimaryOutcomeTimeFrame":"30 days"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Hospital Stay",
                    "SecondaryOutcomeDescription":"Duration of hospitalization",
                    "SecondaryOutcomeTimeFrame":"30 days"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\npatients of age 18 to 65 years\nbody mass index (BMI) >35 kg/m2 (Morbidly obese)\nPatients with failed conservative treatment of weight control\n\nExclusion Criteria:\n\nSevere indicative gastroesophageal reflux disease (GERD)\nConversion of another bariatric procedure\nLarge hiatal hernia\nPatients with inflammatory bowel disease",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Multan Medical and Dental College",
                    "LocationCity":"Multan",
                    "LocationState":"Punjab",
                    "LocationZip":"57000",
                    "LocationCountry":"Pakistan"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"18775352",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Gallagher EJ, LeRoith D, Karnieli E. The metabolic syndrome--from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am. 2008 Sep;37(3):559-79, vii. doi: 10.1016/j.ecl.2008.05.002. Review."
                  },{
                    "ReferencePMID":"30253139",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019 Mar;92:6-10. doi: 10.1016/j.metabol.2018.09.005. Epub 2018 Sep 22. Review."
                  },{
                    "ReferenceType":"background",
                    "ReferenceCitation":"Siddiqui M, Hameed R, Nadeem M, Mohammad T, Simbak N, Latif A, et al. Obesity in Pakistan; current and future perceptions. J Curr Trends Biomed Eng Biosci. 2018;17:001-004"
                  },{
                    "ReferencePMID":"22990271",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, Strong MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV, Nuttall RT, Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC, Smith SC, Hunt SC. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012 Sep 19;308(11):1122-31."
                  },{
                    "ReferencePMID":"21772127",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Suter M, Donadini A, Romy S, Demartines N, Giusti V. Laparoscopic Roux-en-Y gastric bypass: significant long-term weight loss, improvement of obesity-related comorbidities and quality of life. Ann Surg. 2011 Aug;254(2):267-73. doi: 10.1097/SLA.0b013e3182263b66."
                  },{
                    "ReferencePMID":"24901132",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Li K, Gao F, Xue H, Jiang Q, Wang Y, Shen Q, Tian Y, Yang Y. Comparative study on laparoscopic sleeve gastrectomy and laparoscopic gastric bypass for treatment of morbid obesity patients. Hepatogastroenterology. 2014 Mar-Apr;61(130):319-22."
                  },{
                    "ReferencePMID":"23989054",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Peterli R, BorbÃ©ly Y, Kern B, Gass M, Peters T, Thurnheer M, Schultes B, Laederach K, Bueter M, Schiesser M. Early results of the Swiss Multicentre Bypass or Sleeve Study (SM-BOSS): a prospective randomized trial comparing laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass. Ann Surg. 2013 Nov;258(5):690-4; discussion 695. doi: 10.1097/SLA.0b013e3182a67426."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000011183",
                    "ConditionMeshTerm":"Postoperative Complications"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M12648",
                    "ConditionBrowseLeafName":"Postoperative Complications",
                    "ConditionBrowseLeafAsFound":"Post-operative Complications",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":82,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779710",
              "OrgStudyIdInfo":{
                "OrgStudyId":"222255"
              },
              "Organization":{
                "OrgFullName":"Manchester Metropolitan University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"How Does Dysphagia Assessment in Acute Stroke Affect Pneumonia?",
              "OfficialTitle":"How Does Variation in Assessment and Clinical Management of Dysphagia in Acute Stroke Affect Development of Stroke-associated Pneumonia (SAP)?"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"September 2, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"October 20, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"October 20, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 24, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Sabrina Eltringham",
                "ResponsiblePartyInvestigatorTitle":"Principal Investigator",
                "ResponsiblePartyInvestigatorAffiliation":"Manchester Metropolitan University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Manchester Metropolitan University",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"The Stroke Association, United Kingdom",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Stroke-associated pneumonia (SAP) is common in acute stroke. A significant risk factor is dysphagia. To identify dysphagia, patients are screened using a bedside tool and those suspected of dysphagia then have a specialist Speech and Language Therapy (SLT) assessment. Currently there is a wide range of screening protocols used. The aim of this research is to investigate the variation in dysphagia assessment and management to identify what factors affect the risk of SAP. The type of screen and other variations in management and practice (such as time from hospital admission to when the screen is done) will be investigated to identify any associations with higher risk of SAP. A mixed methods study will include a systematic review of the literature, interviews with patients, carers and staff and a review of medical records to investigate the patient journey during the first 72 hours from admission. Findings will be triangulated to inform a national survey of dysphagia screening and management in hospitals registered with the Sentinel Stroke National Audit Programme (SSNAP). Data from the survey will be cross-referenced with the SSNAP register and analysed to identify relationships. Results will inform development of an intervention to reduce SAP for subsequent feasibility testing.",
              "DetailedDescription":"Research Questions: 1. How do methods of dysphagia assessment and clinical management during the first 72 hours of admission affect the risk of stroke patients developing Stroke-Associated Pneumonia (SAP)? 2. During the first 72 hours of admission, what organisational factors (for example; oral hygiene routine, adherence of the speech and language therapy recommendations) affect the risk of stroke patients developing SAP? Aims and objectives: 1. To explore how variations in dysphagia assessment and management within the first 72 hours post stroke, impacts on developing SAP? 2. What and how do other organisational factors affect the development of SAP? Background to the project: Dysphagia (swallowing problems) occurs in 37-55% of acute stroke patients and is associated with difficulty swallowing foods, liquids and saliva. Inhalation of oral or gastric contents into the lungs (aspiration) can lead to pneumonia which increases the risk of mortality and is one of the main causes of death in the first few days and weeks after stroke. Aspiration pneumonia is also independently associated with worse rehabilitation outcomes, increased length of hospitalisation and associated healthcare costs. Aspiration pneumonia develops most frequently in the first few days of stroke, therefore timely detection and management of dysphagia is essential. In England and Wales, patients with acute stroke are recommended to have their swallow screened using a validated multi item screening tool within four hours of admission and a comprehensive speech and language therapy (SLT) assessment within 72 hours of admission. However, the Royal College of Physicians (RCP) National Clinical Guideline for Stroke does not specify the exact screening tool to be used (2016).\n\nThe Sentinel Stroke National Audit Programme (SSNAP) is the national register of stroke in England and Wales and collects data for stroke patients in the majority of acute hospitals. Using this national dataset, Bray et al. (2016) found an association between a delay in screening and specialist SLT assessment with an increased risk of stroke-associated pneumonia (SAP) and that reducing the risk of SAP might also reduce mortality after stroke. There are several possible mechanisms for why delays in dysphagia assessment might lead to an increased risk of SAP, including variation in who, when and how the screening is carried out. Anecdotal evidence from the clinical team has found that a number of patients who pass the screen, are subsequently referred to SLT because of ongoing concerns about risk of aspiration. This raises the question of whether the timing of the screen is too early for some patients whose neurological symptoms may still be evolving. Other possible reasons might be that the screen is not sufficiently sensitive to detect aspiration or the competencies of the staff undertaking the screen are inadequate. Further studies are required to test these uncertainties and confirm or refute a causal relationship not only between dysphagia assessment and management and development of SAP but other potential outcomes, including death, alternative nutrition and return to normal diet.\n\nMethods: Ethical approval will be sought from the Yorkshire and the Humber Sheffield Research Ethics Committee and the Research Ethics Committee at Sheffield Hallam University. Most hospital (aggregate) level SSNAP data are publicly accessible. A data request will be submitted for non-publicly available aggregate data, if necessary. Accessing anonymised patient level data from SSNAP involves applying for data access from Healthcare Quality Improvement Programme (HQIP) who commission SSNAP and are the data controller. Phase 1 (6 months) Systematic search and review of the literature: A systematic search and review of the literature will be undertaken on the nature and evidence for early assessment and management of dysphagia in acute stroke and the risk of developing stroke aspiration pneumonia, using the Centre for Reviews and Dissemination guidance on systematic reviews . The search strategies adopted RCP clinical guideline for Stroke will be utilised and developed, following a building-block approach which will identify search terms for the different concepts of the search question and culminating in a search of electronic databases. Manual search methods will also be carried out. The findings from the literature will be synthesised and used as one of the methods to inform the development of a national survey. A peer-reviewed, open-access paper will be submitted for publication based on the findings of the literature. Alongside this, a review of the evidence on questionnaire design to inform the development of the national survey will be carried out. During this phase, participant information sheets and consent forms and data collection tools for Phase 2 will be developed. Service users feedback on the study protocol and design, information accessibility of participant materials and research outcomes will be sought from stroke survivors and carers. Phase 2 (18 months) Mixed Methods Study: This phase will further inform the development of the national survey across the 199 hospitals registered with the SSNAP. The survey will be to find out about the dysphagia screening protocols used and details of the comprehensive SLT assessments so as to understand the variations in patient management during the 72 hours from admission. In addition, the questionnaire will investigate other organisational factors (e.g. training protocols) or care processes (e.g. policies on positioning, oral hygiene, early mobilisation) which may affect the development of SAP. To inform this development phase, data will be collected using two methods; a medical note review and interviews. Patient information will be collected from the medical notes of 30 consecutive patients admitted to the Hyper Acute Stroke Unit (HASU) in Sheffield Teaching Hospitals NHS Foundation Trust. Information will be collected on time/day of admission and dysphagia screen, outcome of screen, other investigations and assessments during 4 hours from admission, outcome of SLT assessment if indicated and whether SAP is recorded within the first 7 days post stroke. The data collected from this 72-hour timeline will be descriptively analysed to identify key events which occur on the patient pathway during the 72-hours. Staff and patient interviews will explore the views of different groups about what happens during these first 72 hours and how different factors may impact on patients developing SAP. Patients will be asked if they would like a carer to attend the interview. The role of the carer would be to support the patient during the interview recognising that some patients may appreciate a carer being present. All participants will be provided information about the study and a consent form and asked to indicate their consent to be involved. Possible areas for investigation include: Are the SLT dysphagia management plans put in place? Are patients put nil by mouth (NBM)? Who is responsible for providing oral hygiene for patients and how frequently is it carried out? Are patients positioned appropriately at mealtimes? Fifteen local and regional interviews will be undertaken with different staff groups e.g. Stroke Nurse Specialists, staff trained in dysphagia screening, SLT Stroke Team Leaders, Ward Sisters, Dysphagia Trained Practitioners/SLTs working in HASUs in Sheffield Teaching Hospitals and other regional NHS Trust HASUs. User perspectives will be gathered from five interviews with stroke patients and carers of patients who have received the dysphagia screen and/or had a comprehensive SLT swallow assessment. Patient participants will be those who have been admitted via the Neurological Assessment Unit where I work as part of their care team and routinely have access to their records. All the interviews will be recorded and transcribed. A framework approach will be used to analyse the interview transcripts and textual data from the interviews will be managed and coded using QSR NIVO software. The findings from the 72 hour time line and interviews will be triangulated to gain a more complete picture and to inform the content of the survey for the follow-on cross-sectional study of national practice. Phase 3 (12 months) National Survey: This phase will involve the development of the survey, in the form of a questionnaire. Service users will be involved in reviewing the format and accessibility of the language used. The electronic questionnaire will be piloted across a target group of SLTs from the Trent Dysphagia Clinical Excellence Network (CEN) who will access the pilot questionnaire and provide feedback via their virtual Basecamp network. The questionnaire will be adapted following their feedback before being distributed nationally to the SLT Clinical Lead for Stroke working in each Hyper/Acute Stroke Unit (H/ASU) in hospitals in England and Wales registered on the Sentinel Stroke National Audit Programme (SSNAP) register. The SLT Clinical Lead for Stroke will be identified from the researcher and research team existing professional networks, wider research networks, for example, the Council for Allied Health Professions Research (CAPHR), social media networks such as Twitter, and information that is publicly available. In instances where there is no pre-existing professional relationship or the information about the appropriate person is not publicly available the researcher would contact a third party, with the request that they circulate information about the study with the researcher's contact details, with a further request that the most appropriate person contact the researcher about the survey if they are interested in receiving more information. Phase 4 (12 months) Data Analysis: The survey data will be analysed and data extracted from the SSNAP register. Cross-referencing information from the questionnaire with centre-level SSNAP data will explore associations between date, time and type of screen, SLT assessment and the risk of developing SAP. The adjusted odds of developing SAP will be estimated by fitting multivariable logistic regression models. The data sets from the seminal research by Bray et al. (2016) will be used for consistency and comparison of data. The findings of this analysis will be published in an open-access, peer reviewed journal. Phase 5: (1 year) Write up and development of future research projects: The programme of work will be written up and the next stages developed."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Dysphagia",
                  "Pneumonia",
                  "Acute Stroke"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "assessment",
                  "acute stroke",
                  "dysphagia",
                  "aspiration pneumonia",
                  "screening"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Cross-Sectional"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"113",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Staff Survey",
                    "InterventionDescription":"A mixed mode survey design comprising of a self-administered electronic survey with a secondary option of a postal survey. The survey population was Speech and Language Therapy (SLT) Clinical Leads for Acute Stroke in Hyper/Acute Hospital Stroke Units in England and Wales. The sample frame was Routinely Admitting, and Non-Routinely Admitting Acute Stroke Hospital Teams registered on the Sentinel Stroke National Audit Programme (SSNAP) register. One hundred and sixty-six hospital teams were included after exclusions. Survey participants were asked to respond about assessment and management of dysphagia and other clinical processes during the first seven days of a person's admission to hospital following a stroke. Respondents were asked to respond about practice on behalf of the Stroke Unit rather than as an individual practitioner."
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Relationship between incidence of stroke-associated pneumonia and hospital teams using dysphagia screening protocols which use water only compared to water and other consistencies",
                    "PrimaryOutcomeDescription":"Stroke-associated pneumonia was defined as the administration of antibiotics for a new clinical diagnosis of pneumonia in the first 7 days of admission as recorded on the SSNAP register",
                    "PrimaryOutcomeTimeFrame":"SSNAP 2019 Patient Centred Post 72 hour cohort data will be used for stroke-associated pneumonia"
                  },{
                    "PrimaryOutcomeMeasure":"Relationship between incidence of stroke-associated pneumonia and hospital teams using written guidelines for the first specialist swallow assessment compared to hospital teams that do not use written guidelines for the first specialist assessment",
                    "PrimaryOutcomeDescription":"Stroke-associated pneumonia was defined as the administration of antibiotics for a new clinical diagnosis of pneumonia in the first 7 days of admission as recorded on the SSNAP register",
                    "PrimaryOutcomeTimeFrame":"SSNAP 2019 Patient Centred Post 72 hour cohort data will be used for stroke-associated pneumonia"
                  },{
                    "PrimaryOutcomeMeasure":"Relationship between incidence of stroke-associated pneumonia and hospital teams that insert nasogastric tubes overnight compared to hospital teams that do not insert nasogastric tubes overnight",
                    "PrimaryOutcomeDescription":"Stroke-associated pneumonia was defined as the administration of antibiotics for a new clinical diagnosis of pneumonia in the first 7 days of admission as recorded on the SSNAP register",
                    "PrimaryOutcomeTimeFrame":"SSNAP 2019 Patient Centred Post 72 hour cohort data will be used for stroke-associated pneumonia"
                  },{
                    "PrimaryOutcomeMeasure":"Relationship between incidence of stroke-associated pneumonia and hospital teams with a written oral care protocol compared to hospital teams that do not have a written oral care protocol",
                    "PrimaryOutcomeDescription":"Stroke-associated pneumonia was defined as the administration of antibiotics for a new clinical diagnosis of pneumonia in the first 7 days of admission as recorded on the SSNAP register",
                    "PrimaryOutcomeTimeFrame":"SSNAP 2019 Patient Centred Post 72 hour cohort data will be used for stroke-associated pneumonia"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nSpeech and Language Therapist working in a National Health Service (NHS) Hospital Stroke Unit in England and Wales\n\nExclusion Criteria:\n\nNon speech and language therapists\nSpeech and Language Therapists not working in a NHS Hospital Stroke Unit in England and Wales",
              "Gender":"All",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Speech and Language Therapy Clinical Leads in Hyper/Acute Stroke Units in hospitals in England and Wales",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Sabrina Eltringham",
                    "OverallOfficialAffiliation":"Manchester Metropolitan University",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Sheffield Teaching Hospitals NHS Foundation Trust",
                    "LocationCity":"Sheffield",
                    "LocationZip":"S10 2JF",
                    "LocationCountry":"United Kingdom"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"16269630",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke. 2005 Dec;36(12):2756-63. Epub 2005 Nov 3. Review."
                  },{
                    "ReferencePMID":"12855836",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Vernino S, Brown RD Jr, Sejvar JJ, Sicks JD, Petty GW, O'Fallon WM. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke. 2003 Aug;34(8):1828-32. Epub 2003 Jul 10."
                  },{
                    "ReferencePMID":"21868737",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Ingeman A, Andersen G, Hundborg HH, Svendsen ML, Johnsen SP. In-hospital medical complications, length of stay, and mortality among stroke unit patients. Stroke. 2011 Nov;42(11):3214-8. doi: 10.1161/STROKEAHA.110.610881. Epub 2011 Aug 25."
                  },{
                    "ReferencePMID":"17536051",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Katzan IL, Dawson NV, Thomas CL, Votruba ME, Cebul RD. The cost of pneumonia after acute stroke. Neurology. 2007 May 29;68(22):1938-43."
                  },{
                    "ReferencePMID":"21933425",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol. 2011 Sep 20;11:110. doi: 10.1186/1471-2377-11-110. Review."
                  },{
                    "ReferencePMID":"27298147",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Bray BD, Smith CJ, Cloud GC, Enderby P, James M, Paley L, Tyrrell PJ, Wolfe CD, Rudd AG; SSNAP Collaboration. The association between delays in screening for and assessing dysphagia after acute stroke, and the risk of stroke-associated pneumonia. J Neurol Neurosurg Psychiatry. 2017 Jan;88(1):25-30. doi: 10.1136/jnnp-2016-313356. Epub 2016 Jun 13."
                  },{
                    "ReferencePMID":"30199856",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Eltringham SA, Kilner K, Gee M, Sage K, Bray BD, Pownall S, Smith CJ. Impact of Dysphagia Assessment and Management on Risk of Stroke-Associated Pneumonia: A Systematic Review. Cerebrovasc Dis. 2018;46(3-4):99-107. doi: 10.1159/000492730. Epub 2018 Sep 10."
                  },{
                    "ReferencePMID":"31493069",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Eltringham SA, Kilner K, Gee M, Sage K, Bray BD, Smith CJ, Pownall S. Factors Associated with Risk of Stroke-Associated Pneumonia in Patients with Dysphagia: A Systematic Review. Dysphagia. 2020 Oct;35(5):735-744. doi: 10.1007/s00455-019-10061-6. Epub 2019 Sep 6. Review."
                  },{
                    "ReferencePMID":"31731452",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Eltringham SA, Smith CJ, Pownall S, Sage K, Bray B. Variation in Dysphagia Assessment and Management in Acute Stroke: An Interview Study. Geriatrics (Basel). 2019 Oct 25;4(4). pii: E60. doi: 10.3390/geriatrics4040060."
                  },{
                    "ReferencePMID":"31817883",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Eltringham SA, Pownall S, Bray B, Smith CJ, Piercy L, Sage K. Experiences of Dysphagia after Stroke: An Interview Study of Stroke Survivors and Their Informal Caregivers. Geriatrics (Basel). 2019 Dec 7;4(4). pii: E67. doi: 10.3390/geriatrics4040067."
                  }
                ]
              },
              "SeeAlsoLinkList":{
                "SeeAlsoLink":[
                  {
                    "SeeAlsoLinkLabel":"Sentinel Stroke National Audit Programme",
                    "SeeAlsoLinkURL":"https://www.strokeaudit.org/Home"
                  },{
                    "SeeAlsoLinkLabel":"Centre for Reviews and Dissemination",
                    "SeeAlsoLinkURL":"https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DocumentSection":{
            "LargeDocumentModule":{
              "LargeDocList":{
                "LargeDoc":[
                  {
                    "LargeDocTypeAbbrev":"SAP",
                    "LargeDocHasProtocol":"No",
                    "LargeDocHasSAP":"Yes",
                    "LargeDocHasICF":"No",
                    "LargeDocLabel":"Statistical Analysis Plan",
                    "LargeDocDate":"January 20, 2021",
                    "LargeDocUploadDate":"02/02/2021 11:23",
                    "LargeDocFilename":"SAP_000.pdf"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003680",
                    "ConditionMeshTerm":"Deglutition Disorders"
                  },{
                    "ConditionMeshId":"D000011014",
                    "ConditionMeshTerm":"Pneumonia"
                  },{
                    "ConditionMeshId":"D000020521",
                    "ConditionMeshTerm":"Stroke"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000002561",
                    "ConditionAncestorTerm":"Cerebrovascular Disorders"
                  },{
                    "ConditionAncestorId":"D000001927",
                    "ConditionAncestorTerm":"Brain Diseases"
                  },{
                    "ConditionAncestorId":"D000002493",
                    "ConditionAncestorTerm":"Central Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000014652",
                    "ConditionAncestorTerm":"Vascular Diseases"
                  },{
                    "ConditionAncestorId":"D000002318",
                    "ConditionAncestorTerm":"Cardiovascular Diseases"
                  },{
                    "ConditionAncestorId":"D000008171",
                    "ConditionAncestorTerm":"Lung Diseases"
                  },{
                    "ConditionAncestorId":"D000012140",
                    "ConditionAncestorTerm":"Respiratory Tract Diseases"
                  },{
                    "ConditionAncestorId":"D000012141",
                    "ConditionAncestorTerm":"Respiratory Tract Infections"
                  },{
                    "ConditionAncestorId":"D000004935",
                    "ConditionAncestorTerm":"Esophageal Diseases"
                  },{
                    "ConditionAncestorId":"D000005767",
                    "ConditionAncestorTerm":"Gastrointestinal Diseases"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  },{
                    "ConditionAncestorId":"D000010608",
                    "ConditionAncestorTerm":"Pharyngeal Diseases"
                  },{
                    "ConditionAncestorId":"D000010038",
                    "ConditionAncestorTerm":"Otorhinolaryngologic Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M20890",
                    "ConditionBrowseLeafName":"Stroke",
                    "ConditionBrowseLeafAsFound":"Acute Stroke",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M5465",
                    "ConditionBrowseLeafName":"Deglutition Disorders",
                    "ConditionBrowseLeafAsFound":"Dysphagia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M12487",
                    "ConditionBrowseLeafName":"Pneumonia",
                    "ConditionBrowseLeafAsFound":"Pneumonia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M12488",
                    "ConditionBrowseLeafName":"Pneumonia, Aspiration",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4393",
                    "ConditionBrowseLeafName":"Cerebrovascular Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3786",
                    "ConditionBrowseLeafName":"Brain Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4325",
                    "ConditionBrowseLeafName":"Central Nervous System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M15983",
                    "ConditionBrowseLeafName":"Vascular Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M9751",
                    "ConditionBrowseLeafName":"Lung Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13560",
                    "ConditionBrowseLeafName":"Respiratory Tract Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13561",
                    "ConditionBrowseLeafName":"Respiratory Tract Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6668",
                    "ConditionBrowseLeafName":"Esophageal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M12098",
                    "ConditionBrowseLeafName":"Pharyngeal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M11544",
                    "ConditionBrowseLeafName":"Otorhinolaryngologic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC14",
                    "ConditionBrowseBranchName":"Heart and Blood Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC09",
                    "ConditionBrowseBranchName":"Ear, Nose, and Throat Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC08",
                    "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC07",
                    "ConditionBrowseBranchName":"Mouth and Tooth Diseases"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":83,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779697",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2000027868"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"2R01DK099039-06",
                    "SecondaryIdType":"U.S. NIH Grant/Contract",
                    "SecondaryIdLink":"https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=2R01DK099039-06&Fy=all"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"Yale University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight",
              "OfficialTitle":"GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 1, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 30, 2025",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 30, 2025",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 10, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Yale University",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "CollaboratorClass":"NIH"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"Yes",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"Yes"
            },
            "DescriptionModule":{
              "BriefSummary":"To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.",
              "DetailedDescription":"A randomized, double-blind, placebo-controlled 12-week study with GLP-1 analogue (semaglutide) in men and women with obesity (BMI 30-49.9 kg/m2) in a validated laboratory model to identifying processes underlying greater food craving, intake and weight change, in order to test mechanisms by which a GLP-1 analogues may exerts significant weight effects in obesity."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Obesity"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Factorial Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"96",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"GLP-1a",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: GLP-1 analogue - semaglutide"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Placebo pen administered weekly over 12 weeks",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"GLP-1 analogue - semaglutide",
                    "InterventionDescription":"GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "GLP-1a"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "Semaglutide"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"Placebo - administered once weekly for a total of 12 weeks",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Placebo"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Change in Craving",
                    "PrimaryOutcomeDescription":"Craving will be measured using a validated questionnaire called Food Craving Scale (FCS). FCS is an 28-item questionnaire that measures how often participates experienced a craving for a food type. Participants can respond to each item from \"never\" to \"always/ almost every\". HIgher scores indicate greater craving.",
                    "PrimaryOutcomeTimeFrame":"week 0 and week 12"
                  },{
                    "PrimaryOutcomeMeasure":"Change in Hunger",
                    "PrimaryOutcomeDescription":"Hunger will be measured in a Visual Analog Scale (VAS) range from 0 to 9. Higher VAS indicates greater hunger.",
                    "PrimaryOutcomeTimeFrame":"week 0 and week 12"
                  },{
                    "PrimaryOutcomeMeasure":"Change in Food Intake",
                    "PrimaryOutcomeDescription":"Food intake will be measured in KCalories during a validated observed laboratory task",
                    "PrimaryOutcomeTimeFrame":"week 0 and week 12"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Change in weight",
                    "SecondaryOutcomeDescription":"Weight in kilograms will be assessed using a bioimpedance scale",
                    "SecondaryOutcomeTimeFrame":"weekly for 12 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Change in food intake - real-life",
                    "SecondaryOutcomeDescription":"Food intake will be measured in Kcalories using 3-day 24hr recall (ASA24)",
                    "SecondaryOutcomeTimeFrame":"week 0, 4, 8, 12"
                  },{
                    "SecondaryOutcomeMeasure":"Change in stress",
                    "SecondaryOutcomeDescription":"Stress, measured as total score on the 14-item Perceived Stress Scale, with higher scores indicating greater subjective stress.",
                    "SecondaryOutcomeTimeFrame":"week 0, 4, 8, 12"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nBMI ranging from 30-49.9 kg/m2\nNo significant medical problems, including diabetes\nNo history of HgbA1c <6.5%\nEnglish speaking and able to read English and complete study evaluations\nAble to provide informed written and verbal consent\n\nExclusion Criteria:\n\nAny significant current medical conditions, including neurological, renal, thyroid, cardiovascular, liver, endocrine or immune conditions, including diagnosis of T2DM or T1DM by American Diabetes Association (ADA) criteria\nMeet current or past DSM-IVR criteria for alcohol dependence or any substance use disorders, including nicotine, or psychiatric disorders, including eating disorders, or use of any psychiatric medications, including anxiolytics, antidepressants, naltrexone or antabuse, anti-smoking medications\nCurrent active participation in a weight loss program or weight loss of >10% of total body weight during the prior 6 months\nTaking any other anti-obesity medication\nHistory of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who are pregnant or lactating, or peri/postmenopausal",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"55 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Ania Jastreboff, MD, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"(203) 737-5015",
                    "CentralContactEMail":"ania.jastreboff@yale.edu"
                  },{
                    "CentralContactName":"Rajita Sinha, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"(203) 737-1272",
                    "CentralContactEMail":"rajita.sinha@yale.edu"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Ania Jastreboff, MD, PhD",
                    "OverallOfficialAffiliation":"Internal Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology);",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Rajita Sinha, PhD",
                    "OverallOfficialAffiliation":"Psychiatry; Director Yale Stress Center",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"The Yale Stress Center: Yale University",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"New Haven",
                    "LocationState":"Connecticut",
                    "LocationZip":"06519",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Seungju Hwang, BS",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"203-737-4011",
                          "LocationContactEMail":"seungju.hwang@yale.edu"
                        },{
                          "LocationContactName":"Ania Jastreboff, MD, PHD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"ania.jastreboff@yale.edu"
                        },{
                          "LocationContactName":"Ania Jastreboff, MD, PhD",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M11284",
                    "ConditionBrowseLeafName":"Obesity",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3696",
                    "ConditionBrowseLeafName":"Body Weight",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC18",
                    "ConditionBrowseBranchName":"Nutritional and Metabolic Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M25584",
                    "InterventionBrowseLeafName":"Glucagon-Like Peptide 1",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":84,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779684",
              "OrgStudyIdInfo":{
                "OrgStudyId":"ACPbp"
              },
              "Organization":{
                "OrgFullName":"University of Lausanne Hospitals",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Promoting Self-determination for Institutionalized Older People Without Decision-making Capacity: Advance Care Planning by Proxy",
              "OfficialTitle":"Promoting Self-determination for Institutionalized Older People Without Decision-making Capacity: Advance Care Planning by Proxy",
              "Acronym":"PROSPECT"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 1, 2022",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 1, 2022",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 23, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor-Investigator",
                "ResponsiblePartyInvestigatorFullName":"Ralf J. Jox",
                "ResponsiblePartyInvestigatorTitle":"Professor",
                "ResponsiblePartyInvestigatorAffiliation":"University of Lausanne Hospitals"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Ralf J. Jox",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This study aims to test the acceptability and feasibility of an advance care planning (ACP) intervention which has been developed to be used with the health care proxies of residential aged care facility (RACF) residents who no longer have decision making capacity for medical decisions. The intervention involves two discussions that are facilitated by a trained health professional. The first discussion aims to discuss the resident's life story, values, previous medical treatments and experiences with illness and death and whether or not they have previously documented their wishes for future care. The second discussion also involves the treating physician and aims to document anticipatory decisions for emergency situations. Follow-up discussions after 12 months or any change in situation will be conducted.",
              "DetailedDescription":"Patient-centered care involves treating patients in the way that is the most aligned with their values and their self-determination. This is the aim of Advance Care Planning (ACP), a communication-based complex intervention. ACP involves accompanied reflection about one's values, anticipation of potential health problems in future states of impaired decision-making capacity, consideration of a range of treatment and care options, anticipatory decision making and the documentation and communication of these decisions to family members and health care professionals. This process ensures that a person's self-determination is respected even when she is no longer able to make health care decisions. ACP programs are well established in the English-speaking world and are currently being developed across Asia and Europe.\n\nParticipation in ACP requires decision-making capacity. Yet, many people lose this capacity before having formally expressed their care preferences. In these cases, their health care proxies, families and health professionals are called upon to make decisions on their behalf, based on what they believe the person would have wanted (presumed will). This is problematic and distressing for both family members and health professionals. The fact that many people do not participate in ACP or complete advanced directives, along with an increasing prevalence of neuro-degenerative diseases entailing a loss of decision-making capacity, means that growing numbers of people are likely to require others to make medical decisions on their behalf.\n\nThe investigator's exploratory research, confirmed by the literature, highlights an urgent unmet need for comprehensive and systematic interventions to assist in promoting self-determination of older people who lack decision making capacity. ACP by proxy (ACP-bp) has been suggested as a model to help proxies of incapacitated patients plan ahead and prepare for future care decisions. However, this model has never been specifically developed nor tested. This is why the investigators have developed a specific model of ACP-bp and aim to test it in a pilot study among proxies of residential aged care facility (RACF) residents who lack decision making capacity, primarily due to advanced dementia.\n\nThe investigators aim to test the acceptability and feasibility of this intervention and the appropriateness of outcome measures through a pilot study in two RACFs in the Swiss canton of Vaud over a period of one year. A process evaluation will be conducted through the triangulation of mixed-method data: self-report scales, semi-structured interviews, document analyses, resident health care records and an economic cost analysis. This will form the basis for a subsequent cluster-randomized control trial to test the intervention's effectiveness. This novel approach of ACP-bp has potential to promote self-determination and patient-centered care that improves both the ethical appropriateness and economic sustainability of care. It may lead to patients being treated in accordance with their wishes, reduce unnecessary overtreatment and avoid distress for family members and health care professionals. This approach also responds to calls for models of ACP which can be used in people with dementia and people living in RACFs, vulnerable populations that have generally remained invisible in ACP research so far."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Advanced Dementia",
                  "Loss of Medical Decision Making Capacity"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Advance Care Planning by proxy",
                  "Surrogate decision making",
                  "Advanced Dementia",
                  "Decision making capacity"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignInterventionModelDescription":"Pilot study of acceptability and fesability",
                "DesignPrimaryPurpose":"Other",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"20",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"ACP by proxy pilot intervention group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"All participants are included in the intervention group",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Advance care planning by proxy for health care proxies of people without medical decision making capacity"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Advance care planning by proxy for health care proxies of people without medical decision making capacity",
                    "InterventionDescription":"Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "ACP by proxy pilot intervention group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Acceptability of the ACP by proxy intervention",
                    "PrimaryOutcomeDescription":"Acceptability of the intervention from the perspectives of health care proxies, RACF health professionals and physicians will be assessed through qualitative interviews asking about their experiences of the intervention. Interviews will be conducted 12 months after the start of the intervention",
                    "PrimaryOutcomeTimeFrame":"12 months"
                  },{
                    "PrimaryOutcomeMeasure":"Feasibility of the ACP by proxy intervention in RACFs",
                    "PrimaryOutcomeDescription":"Feasibility of the intervention from the perspectives of health care proxies, RACF health professionals and physicians will be assessed through qualitative interviews asking about their experiences of the intervention. Interviews will be conducted 12 months after the start of the intervention.",
                    "PrimaryOutcomeTimeFrame":"12 month"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Decisional conflict",
                    "SecondaryOutcomeDescription":"Health care proxy decisional conflict in making decisions on behalf of an RACF resident who no longer has medical decision making capacity (as measured by the Decisional Conflict Scale). Higher scores indicate more decisional conflict (minimum score: 0, maximum score: 64).",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  },{
                    "SecondaryOutcomeMeasure":"Self-efficacy in giving care concordent with resident wishes",
                    "SecondaryOutcomeDescription":"Health professional self-efficacy in providing care that is consistent with the wishes of a person who no longer has medical decision making capacity will be assessed through a single item numerical rating scale from 1-10 (higher scores indicate more self-efficacy)",
                    "SecondaryOutcomeTimeFrame":"12 months"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Health Care Proxy Inclusion Criteria:\n\nIs the legally authorized health care proxy for an RACF resident who: no longer has medical decision making capacity (according to medical judgement), is over 70 years of age and lives in an RACF in the canton of Vaud;\nHas sufficient language proficiency to complete a written questionnaire and participate in discussions.\n\nHealth Care Proxy Exclusion Criteria:\n\nHas insufficient language proficiency to complete a written questionnaire and participate in discussions.\nLacks decision making capacity",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"70 Years",
              "MaximumAge":"110 Years",
              "StdAgeList":{
                "StdAge":[
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Laura Jones, PhD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+4479 556 51 57",
                    "CentralContactEMail":"laura.jones@chuv.ch"
                  },{
                    "CentralContactName":"Corinne Rime",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+4421 314 71 05",
                    "CentralContactEMail":"corinne.rime@chuv.ch"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Ralf J Jox, MD,PhD",
                    "OverallOfficialAffiliation":"Lausanne University Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Lausanne University Hospital",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Lausanne",
                    "LocationState":"Vaud",
                    "LocationZip":"1011",
                    "LocationCountry":"Switzerland",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Laura Jones, PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+4479 556 51 57",
                          "LocationContactEMail":"laura.jones@chuv.ch"
                        },{
                          "LocationContactName":"Ralf J Jox, MD, PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+4479 556 62 58",
                          "LocationContactEMail":"ralf.jox@chuv.ch"
                        },{
                          "LocationContactName":"Ralf J Jox, MD, PhD",
                          "LocationContactRole":"Principal Investigator"
                        },{
                          "LocationContactName":"Laura Jones, PhD",
                          "LocationContactRole":"Sub-Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003704",
                    "ConditionMeshTerm":"Dementia"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000001927",
                    "ConditionAncestorTerm":"Brain Diseases"
                  },{
                    "ConditionAncestorId":"D000002493",
                    "ConditionAncestorTerm":"Central Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000009422",
                    "ConditionAncestorTerm":"Nervous System Diseases"
                  },{
                    "ConditionAncestorId":"D000019965",
                    "ConditionAncestorTerm":"Neurocognitive Disorders"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5487",
                    "ConditionBrowseLeafName":"Dementia",
                    "ConditionBrowseLeafAsFound":"Dementia",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3786",
                    "ConditionBrowseLeafName":"Brain Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4325",
                    "ConditionBrowseLeafName":"Central Nervous System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20420",
                    "ConditionBrowseLeafName":"Neurocognitive Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":85,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779671",
              "OrgStudyIdInfo":{
                "OrgStudyId":"202002283B0"
              },
              "Organization":{
                "OrgFullName":"Chang Gung Memorial Hospital",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Effects of the Fully Immersive VR Cognitive Training Based on Leisure Activities for the Elderly With MCI and SCD.",
              "OfficialTitle":"Effects of the Fully Immersive Virtual Reality Cognitive Training Based on Leisure Activities for the Elderly With Mild Cognitive Impairment and Subjective Cognitive Decline."
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"July 31, 2024",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"July 31, 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Chang Gung Memorial Hospital",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Mild cognitive impairment (MCI) and subjective cognitive decline (SCD) are risk groups for dementia, and thus appropriate interventions are required. Cognitive training is a common intervention applied to the elderly with cognitive decline.\n\nCognitive training integrated into leisure activities can increase the training motivation of the elderly, while improving cognitive performance and daily functions. Virtual reality (VR) can simulate daily living situations, and it can be an effective intervention with cognitive training. Although a few studies have found immersive VR cognitive training can improve the cognitive function of the elderly with cognitive decline, these studies have shown inconsistent results. In addition, it is yet not clear the long-term effect of fully immersive VR cognitive training and its impact on daily function. Furthermore, for immersive VR cognitive training, there is still a lack of training programs that integrate into the context of leisure activities. This type of VR cognitive training could help the effectiveness of cognitive training to be transferred into daily functions.",
              "DetailedDescription":"This study aims to (1) determine the feasibility and usability of immersive leisure-based VR cognitive training; (2) identify the intervention effects of immersive leisure-based VR cognitive training on cognitive function, daily function, and quality of life for elderly with MCI and SCD; (3) compare the intervention effects between elderly with MCI and SCD on outcome measures.\n\nWe will recruit 30 elderly with MCI, 30 elderly with SCD, and 15 specialists for the feasibility and usability study. They will receive one immersive leisure-based VR cognitive training for 30 minutes. VR cognitive training receives four gardening activities. The cognitive elements including attention, working memory, processing speed, and executive function incorporated training. We will use the Acceptance of the Virtual Reality (VR) Experience Questionnaire and System Usability Scales. For effectiveness study, we will recruit 60 elderly with MCI and 70 elderly with SCD. Participants will be randomly assigned to VR group and control group. All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions. The content of VR training is the same as before. The control group is performing traditional cognitive training program. The primary cognitive outcome measurements will include the Montreal Cognitive Assessment, Wechsler Memory Scale, Stroop test, and color trials test. Other outcomes will include measurements that evaluate the cognitive, daily functions, and quality of life of elderly with MCI and SCD. Participants will be assessed at baseline, after the intervention, and at 3-month follow-up. Repeated measures of analysis of variance (ANOVA) will be used to evaluate the changes in outcome measures at three different time points.\n\nWe anticipate the VR training can facilitate cognitive function, daily function, and quality of life. The significance of this study is identifying the effect of immersive VR cognitive training based on leisure activities, and it is appropriate to provide this training for elderly with MCI and SCD. It could delay and prevent the progression to dementia and lead the field of technological assistance to new opportunities for training."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "MCI",
                  "SCD",
                  "Virtual Reality"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"190",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"VR group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: VR cognitive training"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"control group",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Behavioral: Traditional cognitive training"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Behavioral",
                    "InterventionName":"VR cognitive training",
                    "InterventionDescription":"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.\n\nThey will receive one immersive leisure-based VR cognitive training for 30 minutes. VR cognitive training receives four gardening activities.\n\nThe cognitive elements including attention, working memory, processing speed, and executive function incorporated training.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "VR group"
                      ]
                    }
                  },{
                    "InterventionType":"Behavioral",
                    "InterventionName":"Traditional cognitive training",
                    "InterventionDescription":"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.\n\nThe control group is performing traditional cognitive training program.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Change scores of the Montreal Cognitive Assessment (MoCA)",
                    "PrimaryOutcomeDescription":"The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.",
                    "PrimaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  },{
                    "PrimaryOutcomeMeasure":"Change scores of the Wechsler Memory Scale - Third Edition (WMS-III)",
                    "PrimaryOutcomeDescription":"Several subtests of Wechsler Memory Scale - Third Edition (WMS-III) including Faces Recognition (total scale=48), Verbal Paired Associates (total scale = 32), Word Lists (total scale = 48), and Spatial Span (total scale=32) will be used to assess the immediate, delayed, and working memory tests. For each subtest, a higher number indicates better performance in memory function. The raw score of subtests will also be transferred to standardized Z scores and summed to represent an index of general memory function.",
                    "PrimaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  },{
                    "PrimaryOutcomeMeasure":"Change scores of Stroop Color-Word Test",
                    "PrimaryOutcomeDescription":"The Stroop Color-Word test assesses the abilities of selective attention, inhibition and executive function. The participants will be tested under congruent and incongruent conditions. In the congruent condition, the participant will name the color ink of a word which is consistent with the written color name; whereas in the incongruent condition the participant will name the color ink differs from the written color name. In both conditions, the number of colors correctly named within 45 seconds will be measured and the performance in the congruent condition will be compared with the incongruent condition.",
                    "PrimaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Change scores of the Wechsler Adult Intelligence Scale (WAIS)",
                    "SecondaryOutcomeDescription":"The dual-task tests will be assessed to determine the ability for an individual to perform 2 tasks simultaneously. The investigators will assess the dual-task performance during walking and performing box and block test. The results of the dual-task tests will provide information regarding to whether the 2 tasks compete for the same class of neural resources or one of the tasks can be carried out automatically",
                    "SecondaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Change scores of the Everyday Cognition scales (ECog)-12 items",
                    "SecondaryOutcomeDescription":"To detect cognitive and functional decline. The ECog shows promise as a useful tool for the measurement of general and domain-specific everyday functions in the elderly. There are six domains (Everyday Memory, Language, Visuospatial Abilities, Planning, Organization, and Divided Attention) in ECog. Lower scores represent a higher level of function in daily life.",
                    "SecondaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Change scores of the Lawton Instrumental Activities of Daily Living Scale (IADL)",
                    "SecondaryOutcomeDescription":"Assess activities of daily living. There are 8 domains of function measured with the Lawton IADL scale, including ability to use phone,shopping, food preparation, housekeeping, laundering, mode of transportation, responsibility for own medications,and ability to handle finances. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent). For each category, circle the item description that most closely resembles the client's highest functional level (either 0 or 1).",
                    "SecondaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Change scores of the WHOQOL-BREF Taiwan Version",
                    "SecondaryOutcomeDescription":"Exploratory and confirmatory factor analyses revealed a four-factor (physical, psychological, social, and environmental) model. The internal consistency (Cronbach's Î±) coefficients ranged from 0.70 to 0.77 for the four domains. The test-retest reliability coefficients with intervals of 2 to 4 weeks ranged from 0.41 to 0.79 at item/facet level and 0.76 to 0.80 at domain level (all p < 0.01). Content validity coefficients were in the range of 0.53 to 0.78 for item-domain correlations and 0.51 to 0.64 for inter-domain correlations (all p < 0.01). The four domains of the brief form can explain 88% of the variance of the total QOL score and 60% of the variance of the Facet G score (measuring overall quality of life and general health).",
                    "SecondaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Change scores of Geriatric Depression Scale (GDS)",
                    "SecondaryOutcomeDescription":"The Geriatric Depression Scale (GDS) - 15 items version is a self-administered questionnaire used to evaluate mood and depressive symptoms. The scores range is 0-15 and a score of 5 or greater taken as a possible indicator of depression.",
                    "SecondaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  },{
                    "SecondaryOutcomeMeasure":"Change scores of The Chinese Aging Well Profile (CAWP)",
                    "SecondaryOutcomeDescription":"The 31-item Chinese Aging Well Profile comprised seven subscales-'physical', 'psychological', 'independence', 'learning & growth', 'material', 'environmental', and 'social' well-being.",
                    "SecondaryOutcomeTimeFrame":"baseline, posttest (around 12 weeks after baseline)"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"MCI Inclusion Criteria:\n\nage range from 60 to 90 years\nself- or informant-reported memory or cognitive complaint.\nable to follow instruction\nMMSE score <26\ndose not have dementia.\n\nSCD Inclusion Criteria:\n\nage range from 60 to 90 years;\nMMSE>=26;\nECog-12 score >1;\ndoes not conform the standards of MCI and dementia .\n\nExclusion Criteria:\n\ndizziness or epilepsy history;\nneurological or other orthopedic diseases with neurological or other orthopedic diseases unstable physical condition of VR cognitive training;\nRecent psychiatric diagnosis, such as depression.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"60 Years",
              "MaximumAge":"90 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"I-Ching Chuang, Ph.D",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"#886-3-2118800",
                    "CentralContactPhoneExt":"3954",
                    "CentralContactEMail":"ichin@mail.cgu.edu.tw"
                  },{
                    "CentralContactName":"Ching-yi Wu, ScD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"#886-3-2118800",
                    "CentralContactPhoneExt":"5761",
                    "CentralContactEMail":"cywu@mail.cgu.edu.tw"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"I-Ching Chuan, Ph.D",
                    "OverallOfficialAffiliation":"Chang Gung Memorial Hospital",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Chang Gung University",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Taoyuan",
                    "LocationZip":"333",
                    "LocationCountry":"Taiwan",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"I-Ching Chuang, PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"#886-3-2118800",
                          "LocationContactPhoneExt":"3954",
                          "LocationContactEMail":"ichin@mail.cgu.edu.tw"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M28292",
                    "ConditionBrowseLeafName":"Cognitive Dysfunction",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":86,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779658",
              "OrgStudyIdInfo":{
                "OrgStudyId":"RECHMPL21_0087"
              },
              "Organization":{
                "OrgFullName":"University Hospital, Montpellier",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Laparoscopic Essure Device Removal",
              "OfficialTitle":"Essure Removal for Device-attributed Symptoms: Quality of Life Evaluation Before and After Surgical Removal",
              "Acronym":"ESSURE"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 1, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 29, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 30, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 18, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University Hospital, Montpellier",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"In recent years, several symptoms have been attributed to Essure, including pelvic pain and other general symptoms. Consequently, an increasing number of patients request Essure removal for alleged adverse reactions to the device.\n\nStudy Objective: To evaluate the quality of life of patients who underwent Essure_ device removal and morbidity of this surgery.\n\nDesign: Prospective observational cohort study. Setting: Academic hospitals of La Conception, Marseille, and Arnaud-de-Villeneuve, Montpellier, France.\n\nPatients: Women who underwent Essure_ device removal by salpingectomy, between February 2017 and August 2018.\n\nMethods : The following information have been collected during preoperative clinics: demographic data, medical history, clinical symptoms attributed to the Essure device, time between Essure sterilization and early symptoms, time between the beginning of symptoms and surgical removal. Follow-up visits have benne scheduled at one month and three months post-operation. The evolution of symptoms was collected during the follow-up visit at three months based on clinical reports and a dedicated questionnaire. Evaluation of Quality of life have been evaluated thanks to SF36 and HAD questionnaires. Alle these patients will be contacted by phone call to assess to evolution of symptoms and to complete SF 36 and HAD questionnaires.\n\nHypothesis : Recovery of symptoms due to ESSURE device and improvement of quality of life after surgery."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Contraception"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Essure device removal",
                  "Quality of life"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"90",
                "EnrollmentType":"Anticipated"
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Evaluation of quality of life after ESSURE removal",
                    "PrimaryOutcomeDescription":"Evaluation of quality of life after ESSURE removal by SF 36 questionnaire Preoperative questionnaires will be collected from medical record. Patients will be contacted by phone call to answer to this questionnaire for the long term follow-up",
                    "PrimaryOutcomeTimeFrame":"Preoperative"
                  },{
                    "PrimaryOutcomeMeasure":"Evaluation of quality of life after ESSURE removal",
                    "PrimaryOutcomeDescription":"Evaluation of quality of life after ESSURE removal by SF 36 questionnaire three-months post-operative questionnaires will be collected from medical record. Patients will be contacted by phone call to answer to this questionnaire for the long term follow-up",
                    "PrimaryOutcomeTimeFrame":"three-months post-operative"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Evaluation of morbidity of ESSURE removal",
                    "SecondaryOutcomeDescription":"description of per et postoperative complications (patient's medical record and by phone call)",
                    "SecondaryOutcomeTimeFrame":"1 day"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion criteria:\n\nage >18 years old\nsymptoms related to ESSURE device\nsalpingectomy for ESSURE removal\n\nExclusion criteria:\n\n- Exclusion criteria were failure to perform a complete removal of the Essure and second surgery to remove fragments left behind from a previous procedure.",
              "HealthyVolunteers":"No",
              "Gender":"Female",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"Women who underwent Essure_ device removal by salpingectomy, between February 2017 and August 2018.",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"GAUTHIER RATHAT",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"467336421",
                    "CentralContactPhoneExt":"33",
                    "CentralContactEMail":"g-rathat@chu-montpllier.fr"
                  },{
                    "CentralContactName":"Martha DURAES, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"631329158",
                    "CentralContactPhoneExt":"33",
                    "CentralContactEMail":"duraesmartha@gmail.com"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Martha DURAES, Md",
                    "OverallOfficialAffiliation":"University Hospital, Montpellier",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Uhmontpellier",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Montpellier",
                    "LocationZip":"34295",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"RATHAT GAUTHIER, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"467336421",
                          "LocationContactPhoneExt":"33",
                          "LocationContactEMail":"g-rathat@chu-montpellier.fr"
                        },{
                          "LocationContactName":"DURAES Martha",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"631329158",
                          "LocationContactPhoneExt":"33",
                          "LocationContactEMail":"duraesmartha@gmail.com"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided",
              "IPDSharingDescription":"NC"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"T6034",
                    "ConditionBrowseLeafName":"Quality of Life",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":87,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779645",
              "OrgStudyIdInfo":{
                "OrgStudyId":"UC-MEDJP-04"
              },
              "Organization":{
                "OrgFullName":"University of California, San Diego",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Effects of GRA in Patients With Type 1",
              "OfficialTitle":"The Effects of Glucagon Antagonism on Insulin Sensitivity, Cardiovascular Risk, and Ketogenesis in Type 1 Diabetes"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 30, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 31, 2024",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"March 31, 2025",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 22, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Jeremy Pettus, MD",
                "ResponsiblePartyInvestigatorTitle":"Clinical Professor",
                "ResponsiblePartyInvestigatorAffiliation":"University of California, San Diego"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of California, San Diego",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"REMD Biotherapeutics, Inc.",
                    "CollaboratorClass":"INDUSTRY"
                  }
                ]
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"Yes",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This study will examine the effects a Glucagon Receptor Antagonist (GRA), has on Insulin Sensitivity, Cardiovascular risks (CVD), and Ketone body formation in participants with Type 1 diabetes. The participants will complete blood tests, tests to measure energy expenditure, CVD risks, and insulin resistance. These tests will be performed prior to start of treatment and again after 12-weeks of treatment with the GRA (called REMD-477).",
              "DetailedDescription":"This single-center, double-blind, placebo-controlled, multi-dose study is designed to evaluate the effects of glucagon antagonism on insulin sensitivity, cardiovascular risk and ketogenesis in individuals with Type 1 Diabetes. To accomplish the specific aims proposed, a single clinical trial will be conducted in which a maximum of 30 subjects with T1D, who are otherwise healthy, will be treated with REMD-477 or matching placebo for up to 12 weeks at a dose of 70mg (administered subcutaneously each week) with assessments done pre- and post-therapy. Subjects will be randomized on a 1:1 basis to either the REMD-477 group or placebo group and all subjects will remain on their standard of care insulin therapy throughout the study. There will be 19 study visits as outlined below:\n\nScreening - Complete consenting process, complete medical history and physical exam, review of current medications, collect height/weight, vital signs, and fasting laboratory (blood and urine) tests.\nBaseline Visit 1 - Participants that meet screening criteria will complete cardiovascular tests including flow mediated dilation and EndoPat, complete vital signs, weight and laboratory tests for safety and CVD markers.\nBaseline Visit 2 - Participants will complete a 2-Step Hyperinsulinemic/Euglycemic clamp with tracer, Indirect Calorimetry, muscle and adipose tissue biopsies.\nBaseline Visit 3 - Insulin withdrawal challenge and injection #1 of REMD-477 or placebo. Participants will suspend insulin delivery and remove insulin pump. Blood sugars and ketones will be monitored for up to 8 hours.\nVisit 4 - Injection #2 of REMD-477 or placebo and blood collection for safety labs.\nVisit 5 - Injection #3 of REMD-477 or placebo.\nVisit 6 - Injection #4 of REMD-477 or placebo and blood collection for safety labs.\nVisit 7 - Injection #5 of REMD-477 or placebo.\nVisit 8 - Injection #6 of REMD-477 or placebo and blood collection for safety labs.\nVisit 9 - Injection #7 of REMD-477 or placebo.\nVisit 10 - Injection #8 of REMD-477 or placebo and blood collection for safety labs.\nVisit 11 - Injection #9 of REMD-477 or placebo.\nVisit 12 - Injection #10 of REMD-477 or placebo and blood collection for safety labs.\nVisit 13 - Injection #11 of REMD-477 or placebo.\nVisit 14 - Injection #12 of REMD-477 or placebo and blood collection for safety labs.\nVisit 15 - Repeat cardiovascular tests including flow mediated dilation and EndoPat, complete vital signs, weight and laboratory tests for safety and CVD markers.\nVisit 16 - Repeat 2-Step Hyperinsulinemic/Euglycemic clamp with tracer, Indirect Calorimetry, muscle and adipose tissue biopsies.\nVisit 17 - Repeat Insulin withdrawal challenge. Participants will suspend insulin delivery and remove insulin pump. Blood sugars and ketones will be monitored for up to 8 hours.\nVisit 18 - Safety follow-up visit that includes physical exam, vitals, blood and urine sample collection."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Type 1 Diabetes"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"Single-center, double-blind, placebo-controlled, multi-dose study.",
                "DesignPrimaryPurpose":"Basic Science",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignMaskingDescription":"Double-blind",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"30",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"GRA (REMD-477) Group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Once weekly, subcutaneous injection of 70mg REMD-477 (in 1 mL solution) for up to 12 weeks.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: REMD-477"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo Group",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Once weekly, subcutaneous injection of 1mL saline solution for up to 12 weeks.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"REMD-477",
                    "InterventionDescription":"12-Week, once weekly subcutaneous injection with 70mg REMD-477",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "GRA (REMD-477) Group"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"12-Week, once weekly subcutaneous injection with placebo",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Placebo Group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Metabolic Clearance Rate of Insulin",
                    "PrimaryOutcomeDescription":"The change from baseline in calculated metabolic clearance rate of insulin as measured by the 2-step Hyperinsulinemic-Euglycemic Clamp.",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Rate of Resting Energy Expenditure (REE)",
                    "PrimaryOutcomeDescription":"Change from baseline REE as measured by indirect calorimetry.",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Change in Beta-hydroxybutyrate (BHB) Level",
                    "PrimaryOutcomeDescription":"The change from baseline in peak BHB production as measured by the insulin withdrawal challenge.",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Change in Free Fatty Acid (FFA) Level",
                    "PrimaryOutcomeDescription":"The change from baseline in peak FFA production as measured by the insulin withdrawal challenge.",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Change in mRNA Expression",
                    "PrimaryOutcomeDescription":"The change from baseline in gene mRNA expression as measured by adipose and muscle tissue samples.",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Change in Peripheral Macrovascular Vasodilation",
                    "PrimaryOutcomeDescription":"The change from baseline in post-stimulus vessel diameter as measured by flow mediated dilation.",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Change in Peripheral Microvascular Vasodilation",
                    "PrimaryOutcomeDescription":"The change from baseline in reactive hyperemia index as measured by reactive hyperemia-peripheral arterial tonometry (RH-PAT).",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Change in Cardiovascular Disease (CVD) Risk Markers.",
                    "PrimaryOutcomeDescription":"The change in pg/mL from baseline in CVD risk markers (SAA, CRP, VCAM-1 and ICAM-1) as measure by blood samples.",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Change in Cardiovascular Disease (CVD) Risk Markers.",
                    "PrimaryOutcomeDescription":"The change in ng/mL from baseline in CVD risk markers (Thrombomodulin, ICAM-3, E-Selectin and P-Selectin) as measure by blood samples.",
                    "PrimaryOutcomeTimeFrame":"12-Weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nMen and women between the ages of 18 and 65 years old, inclusive, at the time of screening;\nFemales of non-child bearing potential must be â‰¥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product;\nMale subjects must be willing to use clinically acceptable method of contraception during the entire study and for an additional 6 months after the end of the treatment period;\nDiagnosed with Type 1 diabetes based on clinical history or as defined by the current American Diabetes Association (ADA) criteria for > 5 years;\nTreatment with a stable insulin regimen for at least 8 weeks before screening with continuous subcutaneous insulin infusion (CSII) via an insulin pump;\nCurrently using a Continuous Glucose Monitoring (CGM) system;\nHbA1c â‰¤ 8.5 % at screening;\nA minimum weight of 50kg;\neGFR â‰¥ 60 mL/min/1.73mÂ²\nAble to provide written informed consent approved by an Institutional Review Board (IRB).\n\nExclusion Criteria:\n\nHistory or evidence of clinically-significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion;\nHistory of pancreatitis, medullary thyroid carcinoma and/or liver disease;\nClinically significant diagnosis of anemia;\nBody Mass Index (BMI) < 18.5 kg/m2 and/or weight less than 50kg;\nWhole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion;\nCurrent or recent (within 1 month of screening) use of diabetes medications other than insulin;\nWomen who are pregnant or lactating/breastfeeding;\nUnable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits;\nAny other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Todd May",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"8582462169",
                    "CentralContactEMail":"tmay@ucsd.edu"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000003922",
                    "ConditionMeshTerm":"Diabetes Mellitus, Type 1"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000003920",
                    "ConditionAncestorTerm":"Diabetes Mellitus"
                  },{
                    "ConditionAncestorId":"D000044882",
                    "ConditionAncestorTerm":"Glucose Metabolism Disorders"
                  },{
                    "ConditionAncestorId":"D000008659",
                    "ConditionAncestorTerm":"Metabolic Diseases"
                  },{
                    "ConditionAncestorId":"D000004700",
                    "ConditionAncestorTerm":"Endocrine System Diseases"
                  },{
                    "ConditionAncestorId":"D000001327",
                    "ConditionAncestorTerm":"Autoimmune Diseases"
                  },{
                    "ConditionAncestorId":"D000007154",
                    "ConditionAncestorTerm":"Immune System Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M5698",
                    "ConditionBrowseLeafName":"Diabetes Mellitus",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5700",
                    "ConditionBrowseLeafName":"Diabetes Mellitus, Type 1",
                    "ConditionBrowseLeafAsFound":"Type 1 Diabetes",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8601",
                    "ConditionBrowseLeafName":"Hypersensitivity",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10222",
                    "ConditionBrowseLeafName":"Metabolic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M23990",
                    "ConditionBrowseLeafName":"Glucose Metabolism Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M6445",
                    "ConditionBrowseLeafName":"Endocrine System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3210",
                    "ConditionBrowseLeafName":"Autoimmune Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M8783",
                    "ConditionBrowseLeafName":"Immune System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC18",
                    "ConditionBrowseBranchName":"Nutritional and Metabolic Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC19",
                    "ConditionBrowseBranchName":"Gland and Hormone Related Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC20",
                    "ConditionBrowseBranchName":"Immune System Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"C000629677",
                    "InterventionMeshTerm":"REMD-477"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000007004",
                    "InterventionAncestorTerm":"Hypoglycemic Agents"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M275348",
                    "InterventionBrowseLeafName":"REMD-477",
                    "InterventionBrowseLeafAsFound":"BerodualÂ®",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M8948",
                    "InterventionBrowseLeafName":"Insulin",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M178017",
                    "InterventionBrowseLeafName":"Insulin, Globin Zinc",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M20444",
                    "InterventionBrowseLeafName":"Pharmaceutical Solutions",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M7626",
                    "InterventionBrowseLeafName":"Glucagon",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M25584",
                    "InterventionBrowseLeafName":"Glucagon-Like Peptide 1",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M8637",
                    "InterventionBrowseLeafName":"Hypoglycemic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Hypo",
                    "InterventionBrowseBranchName":"Hypoglycemic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"PhSol",
                    "InterventionBrowseBranchName":"Pharmaceutical Solutions"
                  },{
                    "InterventionBrowseBranchAbbrev":"Gast",
                    "InterventionBrowseBranchName":"Gastrointestinal Agents"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":88,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779632",
              "OrgStudyIdInfo":{
                "OrgStudyId":"D227"
              },
              "Organization":{
                "OrgFullName":"University of Copenhagen",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Fish Oil Affects Cognition and ADHD Symptoms in Adults With Autism Spectrum Disorder",
              "OfficialTitle":"Fish Oil Affects Cognition and ADHD Symptoms in Adults With Autism Spectrum Disorder: A Randomized Crossover Study"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"December 10, 2019",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"February 13, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"February 13, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 3, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Professor Lotte Lauritzen",
                "ResponsiblePartyInvestigatorTitle":"Professor Lotte Lauritzen",
                "ResponsiblePartyInvestigatorAffiliation":"University of Copenhagen"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of Copenhagen",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The prevalence of autism spectrum disorder (ASD) is rising and was estimated to have a prevalence of around 1.5% in developed countries in 2016. ASD is characterized by impairments in social interaction and repetitive behavior and is associated with executive dysfunction such as impaired working memory, inhibition, and flexibility. Furthermore, ASD is often associated with multiple comorbidities such as attention-deficit/hyperactivity disorder (ADHD), depression, and anxiety.\n\nSystematic reviews and meta-analyses indicate that fish oil (FO) supplementation improves attention, impulsivity, and hyperactivity in children with ADHD and beneficial effects in adults with depression and anxiety. Some randomized trials in children with ASD have shown improvements on selected executive functions, but results from meta-analysis are inconsistent and no trial has examined the effect in adults with ASD. Furthermore, most of the previous studies have mainly assessed effects by questionnaires and no objective tests, only provided low doses (<1.5 g/d of n-3 long-chain polyunsaturated fatty acids) and none of them have examined the potential influence of comorbid ADHD, depression, or anxiety.\n\nThe aim of the study was to examine the effect of FO on sustained attention and visuospatial short-term memory memory, as well as cognitive inhibition, executive function, and core symptoms of ASD, and of ADHD, and social function in adults with ASD. In light of the shared and additive cognitive impairments in individuals with both ASD and ADHD, the hypothesis was that individuals with comorbid ADHD will show the most pronounced effects. The study furthermore aimed to examine potential interaction with depression, anxiety, and gender.\n\nThis was investigated in a randomized double-blind head-to-tail crossover trial in 26 adults with ASD, who are provided with FO and safflower oil (SO) for 4 weeks each. The subjects were examined at baseline and after each period with tests of attention and working memory (primary endpoints) as well as a test of cognitive flexibility and clinical questionnaires.",
              "DetailedDescription":"The aim of the study was to examine the effect of fish oil (FO) on sustained attention and visuospatial short-term memory memory, as well as cognitive inhibition, executive function, and core symptoms of ASD, and of ADHD, and social function in adults with ASD. In light of the shared and additive cognitive impairments in individuals with both ASD and ADHD, the hypothesis was that individuals with comorbid ADHD will show the most pronounced effects. The study furthermore aimed to examine potential interaction with depression, anxiety, and gender.\n\nThis was investigated in a 2 Ã— 4 week randomized double-blind head-to-tail crossover study with FO and safflower oil (SO).\n\nParticipants were recruited by advertisements posted in autism-related institutions and autism forums on Facebook as well as via personal networking. The study aimed to recruit up to thirty participants and ended up with twenty six participants.\n\nThe intervention in the two periods consisted of four capsules two times per day of FO (corresponding to approximately 5,2 g/d long-chain polyunsaturated fatty acids) and SO (1.2 g/day of linoleic acid), respectively. The intervention sequences: FO â†’ SO or SO â†’ FO was determined by a randomization list generated by a person, who was not involved in the data collection and FO and SO capsules were packed in white containers of similar appearance in the same known excess amount of what was required for four weeks. The participants were allotted to one of the intervention sequences by ID numbers based on date and time of their first visit and were provided with the appropriate pre-ID labelled container in the beginning of each period.\n\nThe participants were examined at baseline and after each period. The assessment consisted of the following: attention (The d2 Test of Attention) and spatial working memory (Corsi Block-Tapping Test) as primary outcomes and as secondary outcomes, inhibition and flexibility (The Stroop Word-Color Test), ADHD symptoms (Conners Rating Scale), and executive and social functions assessed by the Behavioral Inventory of Executive Function and Social Responsiveness Scale, respectively. Compliance was verified by whole-blood fatty acid analysis."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Autism Spectrum Disorder",
                  "Attention Deficit Hyperactivity Disorder"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Crossover Assignment",
                "DesignInterventionModelDescription":"Randomized 2 x 4 weeks head-to-tail crossover trial.",
                "DesignPrimaryPurpose":"Basic Science",
                "DesignMaskingInfo":{
                  "DesignMasking":"Triple",
                  "DesignMaskingDescription":"A person, who was not involved in the data collection generated the randomization list (online tool) and packed both types of capsules in containers of similar appearance and labeled them with ID and period. The participants were allotted to ID numbers based on date and time of their first visit and supplied with the relevant capsule container in the beginning of each period.\n\nThe oil capsules were provided by two different companies and not the same size: 1 ml Eskimo-3 High 65% (Midsona MalmÓ§, Sweden) and 0.75 ml SO (Natur-Drogeriet A/S, HÃ¸rning, Denmark). Containers were only handled by colleagues and participants and the investigator tried to prevent un-blinding due to differences in rattling sound by use of noise-cancelling in-ear headphones.\n\nBlinding was checked by asking the participants and the investigator to guess which oil they had received at the end of the interventions. Formal un-blinding did not occur before the primary statistical analyses was completed.",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"26",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Crossover study: Fish Oil --> Safflower Oil",
                    "ArmGroupType":"Other",
                    "ArmGroupDescription":"4 weeks of fish oil supplementation followed by 4 weeks of safflower oil supplementation",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Experimental: Fish Oil",
                        "Dietary Supplement: Comparator: Safflower Oil"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Crossover study: Safflower Oil --> Fish Oil",
                    "ArmGroupType":"Other",
                    "ArmGroupDescription":"4 weeks of safflower oil supplementation followed by 4 weeks of fish oil supplementation",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Dietary Supplement: Experimental: Fish Oil",
                        "Dietary Supplement: Comparator: Safflower Oil"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Experimental: Fish Oil",
                    "InterventionDescription":"Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Crossover study: Fish Oil --> Safflower Oil",
                        "Crossover study: Safflower Oil --> Fish Oil"
                      ]
                    }
                  },{
                    "InterventionType":"Dietary Supplement",
                    "InterventionName":"Comparator: Safflower Oil",
                    "InterventionDescription":"Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing ~ 3000 mg of linoleic acid) for 4 weeks.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Crossover study: Fish Oil --> Safflower Oil",
                        "Crossover study: Safflower Oil --> Fish Oil"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Change in short-term spatial working memory",
                    "PrimaryOutcomeDescription":"Total Score (based on the total number of blocks in correct runs) in Corsi Block-Tapping Test (a higher is better)",
                    "PrimaryOutcomeTimeFrame":"Baseline, 4 and 8 weeks"
                  },{
                    "PrimaryOutcomeMeasure":"Change in attention",
                    "PrimaryOutcomeDescription":"Total errors percent in d2-Test of Attention (d2-ToA): a measure of sustained attention",
                    "PrimaryOutcomeTimeFrame":"Baseline, 4 and 8 weeks"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Cognitive flexibility and inhibition",
                    "SecondaryOutcomeDescription":"Reading time for color-word card (sec and relative to word and color card) in Stroop Color & Word Test (SCWT)",
                    "SecondaryOutcomeTimeFrame":"baseline, 4 and 8 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"ADHD symptoms",
                    "SecondaryOutcomeDescription":"The total symptoms score in Conners' Adult ADHD Rating Scale - Short: Self Report (CAARS - S:S) (range 0-54) including the subscores for attention (range 0-26) and hyperactivity/impulsivity (range 0-26) (higher scores are worse)",
                    "SecondaryOutcomeTimeFrame":"baseline, 4 and 8 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"Executive function",
                    "SecondaryOutcomeDescription":"The composite score in Behavioral Rating Inventory of Executive Function - Adult (BRIEF-A) (range 75-225) including the subscore for the metacognition index (range 45-135) and behavioral regulatory index (range 30-90) with focus on working memory, inhibition and flexibility from the two subscales, respectively (higher scores are worse)",
                    "SecondaryOutcomeTimeFrame":"baseline, 4 and 8 weeks"
                  },{
                    "SecondaryOutcomeMeasure":"ASD symptoms",
                    "SecondaryOutcomeDescription":"The total score in Social Responsiveness Scale, Second Edition - Adult, Self-Report (SRS-2-ASR) (range 0-195) including the sub-scores for social communication and interaction (range for all sub-scores combined 0-159) and the score for repetitive behaviours and restricted interests (range 0-36) (higher scores are worse)",
                    "SecondaryOutcomeTimeFrame":"baseline, 4 and 8 weeks"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nA clinical diagnosis of ASD (Asperger's syndrome, Autistic disorder, or a not otherwise specified pervasive developmental disorder).\n\nExclusion Criteria:\n\nSupplementation with n-3 long-chain polyunsaturated fatty acids 1 mo prior to the intervention or during the intervention.\nMajor changes to psychopharmacological treatment 1 mo prior to the intervention or during the intervention.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"45 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"University of Copenhagen - Department of Nutrition & Exercise",
                    "LocationCity":"Copenhagen",
                    "LocationState":"Frederiksberg",
                    "LocationZip":"1958",
                    "LocationCountry":"Denmark"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000004194",
                    "ConditionMeshTerm":"Disease"
                  },{
                    "ConditionMeshId":"D000001321",
                    "ConditionMeshTerm":"Autistic Disorder"
                  },{
                    "ConditionMeshId":"D000001289",
                    "ConditionMeshTerm":"Attention Deficit Disorder with Hyperactivity"
                  },{
                    "ConditionMeshId":"D000067877",
                    "ConditionMeshTerm":"Autism Spectrum Disorder"
                  },{
                    "ConditionMeshId":"D000002659",
                    "ConditionMeshTerm":"Child Development Disorders, Pervasive"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  },{
                    "ConditionAncestorId":"D000065886",
                    "ConditionAncestorTerm":"Neurodevelopmental Disorders"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  },{
                    "ConditionAncestorId":"D000019958",
                    "ConditionAncestorTerm":"Attention Deficit and Disruptive Behavior Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3204",
                    "ConditionBrowseLeafName":"Autistic Disorder",
                    "ConditionBrowseLeafAsFound":"Autism",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M3175",
                    "ConditionBrowseLeafName":"Attention Deficit Disorder with Hyperactivity",
                    "ConditionBrowseLeafAsFound":"Attention Deficit Hyperactivity Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M206",
                    "ConditionBrowseLeafName":"Autism Spectrum Disorder",
                    "ConditionBrowseLeafAsFound":"Autism Spectrum Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8582",
                    "ConditionBrowseLeafName":"Hyperkinesis",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4486",
                    "ConditionBrowseLeafName":"Child Development Disorders, Pervasive",
                    "ConditionBrowseLeafAsFound":"Autism Spectrum Disorder",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M4485",
                    "ConditionBrowseLeafName":"Developmental Disabilities",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M29231",
                    "ConditionBrowseLeafName":"Neurodevelopmental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M20414",
                    "ConditionBrowseLeafName":"Attention Deficit and Disruptive Behavior Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"T406",
                    "InterventionBrowseLeafName":"Linoleate",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T415",
                    "InterventionBrowseLeafName":"Omega 3 Fatty Acid",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Ot",
                    "InterventionBrowseBranchName":"Other Dietary Supplements"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":89,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779619",
              "OrgStudyIdInfo":{
                "OrgStudyId":"264525 EMER"
              },
              "Organization":{
                "OrgFullName":"Sussex Partnership NHS Foundation Trust",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Exploring a New Measure of Emotion Regulation",
              "OfficialTitle":"An Online Survey to Explore the Psychometric Properties of a New and Theory-driven Measure of Emotion Regulation (the Perth Emotion Regulation Competency Inventory) When Used in a Range of Clinical and Non-clinical Populations.",
              "Acronym":"EMER"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 31, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 31, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 23, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Sussex Partnership NHS Foundation Trust",
                "LeadSponsorClass":"OTHER"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"University of Sussex",
                    "CollaboratorClass":"OTHER"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Background: Emotion regulation has been established as an important concept in mental health research across a range of different diagnoses. There are numerous questionnaires used to measure emotion regulation but only one (the Perth Emotion Regulation Competency Inventory - PERCI) is based on the most recent and widely accepted model of emotion regulation (Gross' extended process model of emotion regulation). This recently developed measure has not yet been extensively used or psychometrically tested in clinical populations. However, it may be more theoretically and psychometrically sound than other measures widely used in the research literature to date.\n\nMethods/Design: An online survey including this new measure with other relevant questionnaires will sample non-clinical and two specific clinical populations in order to explore the reliability, validity and utility of this measure.\n\nDiscussion: This will inform the ways in which emotion regulation competency is measured in future research and clinical practice.",
              "DetailedDescription":"Despite the term 'emotion' being commonly used in day-to-day language, within the research literature on emotion regulation (both within the health field and more broadly) there is great variety in the terminology and scales of measurement used. So much so that Buck describes the field as \"conceptual and definitional chaos\" (Buck 1990, p.330). However Gross has recently renewed his extended process model of emotion regulation and this is now a widely established model although used more frequently in cognition research than in health research (see Gross 2015 for a full description of the model)\n\nIn 1998 Gross described emotion regulation as \"shaping which emotions one has, when one has them, and how one experiences or expresses those emotions\" (Gross 1998). One of the key points which this model suggests is that each of the 5 steps offer potential for emotion regulation and that there is no limit as to the number or type of activities which might serve this purpose.\n\nIt is this ability to regulate emotions (i.e. a person's capacity to successfully modify the trajectory of their emotions), which has been established as an important but complex concept in health research. A number of systematic reviews have explored what is known about emotion regulation across a variety of mental health diagnoses (e.g. Sloan et al 2017, Hu et al 2014). Fernandez et al 2014 argue that it is a key transdiagnostic concept using the Research Domain Criteria framework.\n\nAs poor emotion regulation has therefore been implicated in the onset and maintenance of a range of mental health conditions, it has subsequently been the target of a number of psychological interventions. Given that affective instability and reactivity, and the use of problematic regulation strategies, are some of the core criteria for EUPD, many of the treatment approaches for this clinical group address emotion regulation. It remains unclear what the mediating or moderating role of emotion regulation is in influencing treatment outcome. A comprehensive, theoretically and psychometrically sound instrument to measure emotion regulation is therefore vital for the development or adaptation of these types of interventions and the subsequent research examining mechanisms of action.\n\nThere are numerous self-report questionnaires which are used to quantify emotion regulation. However many of these have psychometric and/or theoretical weaknesses which could potentially impact on the quality of research and the conclusions drawn from this research. Preece and colleagues (2018) describe and evaluate the existing 13 self-report measures relevant to the concept of emotion regulation. In summary they argue that none of these scales :\n\nmeasure emotion regulation across both negative and positive emotions\nmeasure across all four components of emotion regulation\nclearly distinguish between emotion recognition/description (alexithymia) and emotion regulation.\n\nPreece and colleagues therefore developed the PERCI on the basis of Gross' model in order to overcome these deficits. Preece and colleagues (2018) published research outlining the process of scale development and reported good indices of reliability and validity for this measure in a non-clinical population. They recommend replication of reliability and validity research in clinical populations. Factor structure was examined through the use of a series of confirmatory factor analyses. They found the factor structure to be replicable and consistent with the theoretical basis of the Gross model. In the non-clinical population (N = 1175) the PERCI total score had an excellent internal reliability (Cronbach's alpha Î±) of 0.95. They also reported excellent internal reliability of the four subscales of the PERCI: Negative emotion regulation (Î± 0.93), Positive emotion regulation (Î± 0.92), General facilitating hedonic goals (Î± 0.94) and Positive containing emotions (Î± 0.93). Concurrent and criterion validity analyses were also reported and confirmed the hypotheses of the researchers in that higher reporting of emotion regulation difficulties on the PERCI was associated with measures of maladaptive regulation strategies, higher levels of alexithymia, more insecure attachments and higher levels of depression, anxiety and stress.\n\nThe current study will be a cross-sectional survey using online self-report questionnaires. The study seeks to test the psychometric properties of the scale in mental health populations, as poor emotion regulation is particularly pertinent yet the psychometric properties of the scale are unknown in this population. It is possible that the factor structure and other psychometric properties of the scale are different between clinical and non-clinical populations and this could have important implications for theory, research and practice.\n\nThe clinical group will be separated in to people with low and high 'EUPD' traits to allow comparison. The diagnosis of EUPD is controversial and frequently stigmatised. Some people using mental health services will meet criteria for EUPD but not have been told this directly by clinicians, others may have been told they have EUPD informally or after insufficient assessment. This complexity and heterogeneity has led to the decision not to rely on reported diagnosis but to measure current EUPD symptomatology and allocate people to two clinical groups on the basis of clinical cut-offs.\n\nThe population accessing the NHS talking therapies service, Improving Access to Psychological Therapy (IAPT), has been found to have high rates of people meeting diagnostic criteria for EUPD (Hepgel and colleagues 2016) and even higher levels of people with traits of personality disorder. As this is a large and relatively accessible group of people this is the population the researchers will target for recruitment for the clinical group.\n\nThe researchers will initially recruit a non-clinical group from NHS staff members as they may be more representative of the general population in terms of broad demographics than a student sample."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Emotional Instability",
                  "Borderline Personality"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Cross-Sectional"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"903",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Non-clinical Control",
                    "ArmGroupDescription":"people who score below clinical cut off on measures of anxiety and depression (scoring <10 on PHQ-9 and <8 on GAD-7) and emotionally unstable personality traits (BSL-23) and are not currently using mental health services",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Online self-report questionnaire completion"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Clinical Group A",
                    "ArmGroupDescription":"people who are accessing treatment through IAPT services and score above clinical cut off on measures of anxiety and/or depression (>9 on PHQ-9 and/or >7 on GAD-7) but below clinical cut off on a measure of emotionally unstable personality traits (BSL-23)",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Online self-report questionnaire completion"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Clinical Group B",
                    "ArmGroupDescription":"people who are accessing treatment through IAPT services and score above clinical cut off on (BSL-23) a measure of emotionally unstable personality traits (irrespective of their scores on the PHQ-9 and GAD-7)",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Online self-report questionnaire completion"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Online self-report questionnaire completion",
                    "InterventionDescription":"After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Clinical Group A",
                        "Clinical Group B",
                        "Non-clinical Control"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Perth Emotion Regulation Competency Inventory",
                    "PrimaryOutcomeDescription":"self report measure of ability to regulate positive and negative emotions",
                    "PrimaryOutcomeTimeFrame":"at recruitment"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Difficulties in Emotion Regulation Scale - 36",
                    "SecondaryOutcomeDescription":"self report measure of difficulties in regulating negative emotions",
                    "SecondaryOutcomeTimeFrame":"at recruitment"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"Five Facets Mindfulness Questionnaire - 15",
                    "OtherOutcomeDescription":"self report measure of trait mindfulness",
                    "OtherOutcomeTimeFrame":"at recruitment"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAll participants will be 18 or older. Non-clinical Group: people who score below clinical cut off on measures of anxiety and depression (scoring <10 on PHQ-9 and <8 on GAD-7) and emotionally unstable personality traits (BSL-23) and are not currently using mental health services.\n\nClinical Group A: people who are accessing treatment through IAPT services and score above clinical cut off on measures of anxiety and/or depression (>9 on PHQ-9 and/or >7 on GAD-7) but below clinical cut off on a measure of emotionally unstable personality traits (BSL-23) Clinical Group B: people who are accessing treatment through IAPT services and score above clinical cut off on (BSL-23) a measure of emotionally unstable personality traits (irrespective of their scores on the PHQ-9 and GAD-7).\n\nExclusion Criteria:\n\nNon-clinical Group: people who have been recruited as part of the non-clinical group but who score above clinical cut off on any of the symptom measures will be excluded rather than transferred to the clinical group as they are non-treatment seeking.",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              },
              "StudyPopulation":"NHS staff for non-clinical group Primary care mental health service users for clinical groups",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Sussex Partnership NHS Foundation Trust",
                    "LocationCity":"Brighton",
                    "LocationState":"Sussex",
                    "LocationCountry":"United Kingdom"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001883",
                    "ConditionMeshTerm":"Borderline Personality Disorder"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000010554",
                    "ConditionAncestorTerm":"Personality Disorders"
                  },{
                    "ConditionAncestorId":"D000001523",
                    "ConditionAncestorTerm":"Mental Disorders"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M3743",
                    "ConditionBrowseLeafName":"Borderline Personality Disorder",
                    "ConditionBrowseLeafAsFound":"Borderline Personality",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M12045",
                    "ConditionBrowseLeafName":"Personality Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M13056",
                    "ConditionBrowseLeafName":"Psychotic Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3396",
                    "ConditionBrowseLeafName":"Mental Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":90,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779606",
              "OrgStudyIdInfo":{
                "OrgStudyId":"CHL.3-01-2020"
              },
              "Organization":{
                "OrgFullName":"Sintetica SA",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"Efficacy, Safety and Local Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers",
              "OfficialTitle":"A Phase I/II, Randomized, Placebo-controlled, Double-masked, Efficacy, Safety and Local Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers"
            },
            "StatusModule":{
              "StatusVerifiedDate":"January 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"June 16, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"October 13, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"October 20, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"January 19, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Sintetica SA",
                "LeadSponsorClass":"INDUSTRY"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The study evaluate the efficacy, safety and local tolerability of Chloroprocaine 3% ophthalmic gel as compared to matching placebo in healthy subjects.",
              "DetailedDescription":"One hundred and five (105) healthy male and female subjects will be randomised in a 4:1 ratio to receive a single ocular instillation of Chloroprocaine 3% ophthalmic gel or matching placebo (vehicle) (84 subjects will receive chloroprocaine and 21 subjects will receive placebo). The assigned investigational product (3 drops) will be instilled in the right eye of each subject. Administrations will be performed at the clinical centre by the Investigator or his deputy on study day 1. For each administration, the 3 drops will be instilled at a 1 min Â± 15 sec interval."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Healthy Subjects"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 1",
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"105",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Chloroprocaine",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Chloroprocaine 3% ocular gel (30 mg/mL), 3 drops instilled at a 1 min Â± 15 sec interval.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Ocular gel"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"Vehicle for chloroprocaine 3% ocular gel, 3 drops instilled at a 1 min Â± 15 sec interval.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Ocular gel"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Ocular gel",
                    "InterventionDescription":"3 drops instilled in the right eye",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Chloroprocaine",
                        "Placebo"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "No other intervention names"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Proportion of subjects gaining full conjunctival anesthesia of the ocular surface",
                    "PrimaryOutcomeDescription":"Proportion of subjects gaining full conjunctival anesthesia of the ocular surface, evaluated by conjunctiva pinching (0.3-mm forceps), 5 minutes after administration of Chloroprocaine 3% ophthalmic gel, in comparison to placebo - only study eye (right eye)",
                    "PrimaryOutcomeTimeFrame":"Day 1"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Time to anesthesia, evaluated by conjunctiva pinching (0.3-mm forceps) - only study eye (right eye)",
                    "SecondaryOutcomeDescription":"Time to anesthesia, evaluated by conjunctiva pinching (0.3-mm forceps) - only study eye (right eye)",
                    "SecondaryOutcomeTimeFrame":"Day 1"
                  },{
                    "SecondaryOutcomeMeasure":"Duration of anesthesia, evaluated by conjunctiva pinching (0.3-mm forceps) - only study eye (right eye)",
                    "SecondaryOutcomeDescription":"Duration of anesthesia, evaluated by conjunctiva pinching (0.3-mm forceps) - only study eye (right eye)",
                    "SecondaryOutcomeTimeFrame":"Day 1"
                  },{
                    "SecondaryOutcomeMeasure":"Visual acuity (EDTRS chart) - both eyes",
                    "SecondaryOutcomeDescription":"Visual acuity will be assessed, for all subjects and both eyes using an EDTRS chart.",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  },{
                    "SecondaryOutcomeMeasure":"Ocular symptoms",
                    "SecondaryOutcomeDescription":"The ocular symptoms will be assessed: burning, stinging, itching, foreign body sensation.\n\nScores will be determined using a 100 mm VAS where 0 means \"no symptoms\" and 100 means \"worst possible discomfort\".",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  },{
                    "SecondaryOutcomeMeasure":"Ocular signs by slit lamp examination - both eyes",
                    "SecondaryOutcomeDescription":"Slit lamp biomicroscopy will be performed for the assessment of the following parameters:\n\nconjunctival redness, anterior chamber flare, conjunctival chemosis, eyelid swelling.\n\nPresence and severity will be graded according to a 4 point scale, where (0) none, (1) mild, (2) moderate, (3) severe.",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  },{
                    "SecondaryOutcomeMeasure":"Corneal fluorescein staining by slit lamp examination - both eyes",
                    "SecondaryOutcomeDescription":"Fluorescein will be used to detect corneal epithelial defects using slit lamp biomicroscopy. As grading scale for corneal damage, the NEI/Industry Workshop guidelines will be used. The cornea will be divided into five sectors (central, superior, inferior, nasal and temporal), each of which is scored on a scale of 0-3, where 0 means no staining and 3 means maximum staining, with a maximal score of 15.",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  },{
                    "SecondaryOutcomeMeasure":"Intraocular pressure (IOP) - both eyes",
                    "SecondaryOutcomeDescription":"Intraocular pressure will be measured with a slit-lamp mounted Goldmann applanation tonometer. Before each measurement one drop of oxybuprocaine hydrochloride combined with sodium fluorescein will be used for local anaesthesia of the cornea.",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  },{
                    "SecondaryOutcomeMeasure":"Fundus ophthalmoscopy (vitreous, macula, retina and optic nerve head) with the slit lamp - both eyes",
                    "SecondaryOutcomeDescription":"Indirect fundus ophthalmoscopy will be performed, for all subjects and both eyes, at the slit lamp using a +90 diopters Volk lens",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  },{
                    "SecondaryOutcomeMeasure":"Adverse events",
                    "SecondaryOutcomeDescription":"Treatment-emergent adverse events (TEAEs), assessed throughout the study",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  },{
                    "SecondaryOutcomeMeasure":"Vital signs (blood pressure)",
                    "SecondaryOutcomeDescription":"Subjects blood pressure will be measured by the Investigator or his/her deputy",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  },{
                    "SecondaryOutcomeMeasure":"Vital Signs (heart rate)",
                    "SecondaryOutcomeDescription":"Subjects heart rate will be measured by the Investigator or his/her deputy",
                    "SecondaryOutcomeTimeFrame":"Up to day 7"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nInformed consent: Signed written informed consent before inclusion in the study\nSex and age: Healthy men and women, 18 - 55 years inclusive\nBody Mass Index: 18.5-30 kg/m2 inclusive\nVital signs: Systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position\nFull comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study\n\nContraception and fertility: women of child-bearing potential must be using at least one of the following reliable methods of contraception:\n\nHormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit;\nA non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit\nA male sexual partner who agrees to use a male condom with spermicide\nA sterile sexual partner Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all women, urine pregnancy test result must be negative at screening.\n\nExclusion Criteria:\n\nPhysical findings: Clinically significant abnormal physical findings which could interfere with the objectives of the study\nVisual acuity: Best corrected visual acuity < 1/10\nConcomitant medications: Medications, including over the counter medications and herbal remedies, systemic opioids and morphine drugs, topical ocular products with anaesthetic action, systemic analgesic drugs, for 2 weeks before study screening\nOphthalmic diseases: Clinically significant ocular disease; eye movement disorder (i.e. nystagmus); dacryocystitis and all others pathologies of tears drainage system; corneal, epithelial, stromal or endothelial, residual or evolutionary disease (including corneal ulceration and superficial punctuate keratitis); history of inflammatory ocular disease (iritis, uveitis, herpetic keratitis), history of ocular traumatism, infection or inflammation within the last 3 months or history of any other ocular disease that may affect the outcome of the study or the subject's safety\nOphthalmic surgery: History of ophthalmic surgical complications (e.g. cystoid macular oedema) in the last 6 months\nDiseases: Significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, psychiatric or neurological diseases or surgeries that may interfere with the aim of the study\nAllergy: Ascertained or presumptive hypersensitivity to the active principle and/or ingredients of investigational products; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study\nInvestigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study\nDrug, alcohol, caffeine, tobacco: history of drug, alcohol [greater than 1 drink/day for women and greater than 2 drinks/day for men, defined according to the USDA Dietary Guidelines 2015-2020], caffeine (greater than 5 cups coffee/tea/day) or tobacco abuse (greater than or equal 10 cigarettes/day)\nAlcohol test: positive alcohol breath test at Day 1\nPregnancy (women only): positive or missing pregnancy test at screening, pregnant or lactating women",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"55 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Milko Radicioni",
                    "OverallOfficialAffiliation":"CROSS Research S.A., Phase I Clinical Unit, Arzo, Switzerland",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"CROSS Research S.A.",
                    "LocationCity":"Arzo",
                    "LocationCountry":"Switzerland"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M11397",
                    "InterventionBrowseLeafName":"Ophthalmic Solutions",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M240285",
                    "InterventionBrowseLeafName":"Chloroprocaine",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"PhSol",
                    "InterventionBrowseBranchName":"Pharmaceutical Solutions"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"CNSDep",
                    "InterventionBrowseBranchName":"Central Nervous System Depressants"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":91,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779593",
              "OrgStudyIdInfo":{
                "OrgStudyId":"35RC19_8985_Quali-SAT"
              },
              "Organization":{
                "OrgFullName":"Rennes University Hospital",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis",
              "OfficialTitle":"Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis",
              "Acronym":"Quali-SAT"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 2025",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"April 2025",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 2, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Rennes University Hospital",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Patients in maintenance treatment for HFE hemochromatosis since at least one year will be included in a two year study period and randomized in two groups experimental and control group. Because proton pump inhibitors are widely used as chronic medication, and because they can significantly modify iron absorption, patients will be stratified according to the use of proton pump inhibitors and gender. A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients. Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group (patients treated with bloodletting according to current guidelines \"ferritin alone\" versus patients treated with bloodletting according to \"transferrin saturation and serum ferritin\").Blood count and iron metabolism parameters will be performed at each bloodletting and follow-up visits. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit. Volume and schedule for bloodlettings will be determined according to guidelines specifically designed for this study to assure harmonization of treatment management, and centrally validated through the recording of the biological tests in the electronic Case Report Form which will provide the investigator with the volume and schedule of the next bloodletting. There will be two ways of treatment modification: either change of schedule or volume of bloodletting. Patients will undergo follow-up visit every six months with clinical examination, questionnaires at J0, M12 and M24 (SF-36; AIMS2-SF, WOMAC, EQ-5D-5L), and biological test. For health economics analysis, data will be obtained thanks to a dedicated extraction from SNDS database SNDS database will allow to gather hospital stays, visits, and other healthcare-related costs as well as vital status (date (month/year) of death) and cause of death. A de-identified copy of the clinical database, restricted to the relevant variables, will be sent for semideterministic matching purpose with SNDS extraction using four key variables: gender, same date (month/year) of birth, same date (day/month/year) of visit for bloodletting; pending, of course, regulatory authorization."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Haemochromatosis"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"240",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"experimental group",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Patients treated with bloodletting according to \"transferrin saturation and serum ferritin\".",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Clinical examination",
                        "Other: SF36 questionnaire",
                        "Other: AIMS2_SF questionnaire",
                        "Other: WOMAC questionnaire",
                        "Other: EQ-5D-5L questionnaire",
                        "Biological: Blood Sample Complete blood count",
                        "Biological: Blood Sample Iron panel",
                        "Biological: Blood Sample Fasting Glucose",
                        "Biological: Blood sample lipid panel",
                        "Biological: Blood sample liver panel",
                        "Biological: Blood sample C reactive protein",
                        "Biological: BioBank",
                        "Other: Medico-economical",
                        "Procedure: Bloodletting - experimental group"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"control group",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Patients treated with bloodletting according to current guidelines \"ferritin alone\"",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Clinical examination",
                        "Other: SF36 questionnaire",
                        "Other: AIMS2_SF questionnaire",
                        "Other: WOMAC questionnaire",
                        "Other: EQ-5D-5L questionnaire",
                        "Biological: Blood Sample Complete blood count",
                        "Biological: Blood Sample Iron panel",
                        "Biological: Blood Sample Fasting Glucose",
                        "Biological: Blood sample lipid panel",
                        "Biological: Blood sample liver panel",
                        "Biological: Blood sample C reactive protein",
                        "Procedure: Bloodletting - control group",
                        "Biological: BioBank",
                        "Other: Medico-economical"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Clinical examination",
                    "InterventionDescription":"Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"SF36 questionnaire",
                    "InterventionDescription":"At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.\n\nItems are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).\n\nScoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life).",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"AIMS2_SF questionnaire",
                    "InterventionDescription":"At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"WOMAC questionnaire",
                    "InterventionDescription":"At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"EQ-5D-5L questionnaire",
                    "InterventionDescription":"At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Biological",
                    "InterventionName":"Blood Sample Complete blood count",
                    "InterventionDescription":"Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Biological",
                    "InterventionName":"Blood Sample Iron panel",
                    "InterventionDescription":"Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Biological",
                    "InterventionName":"Blood Sample Fasting Glucose",
                    "InterventionDescription":"Blood Sample Fasting Glucose at D0 and M24/end follow-up visit",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Biological",
                    "InterventionName":"Blood sample lipid panel",
                    "InterventionDescription":"Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Biological",
                    "InterventionName":"Blood sample liver panel",
                    "InterventionDescription":"Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Biological",
                    "InterventionName":"Blood sample C reactive protein",
                    "InterventionDescription":"Blood sample C reactive protein at D0 and M24/end follow-up visit",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Procedure",
                    "InterventionName":"Bloodletting - control group",
                    "InterventionDescription":"Patients treated with bloodletting according to current guidelines (ferritin alone). Patient will undergo bloodletting with a goal of maintaining a serum ferritin equal or lower than 50 g/L according to current clinical practice guidelines (French and European).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group"
                      ]
                    }
                  },{
                    "InterventionType":"Biological",
                    "InterventionName":"BioBank",
                    "InterventionDescription":"Blood sample will be collected for BioBank at D0, M12 and M24.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"Medico-economical",
                    "InterventionDescription":"Medico-economic data will be collected at each follow up visit.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "control group",
                        "experimental group"
                      ]
                    }
                  },{
                    "InterventionType":"Procedure",
                    "InterventionName":"Bloodletting - experimental group",
                    "InterventionDescription":"Patients treated with bloodletting according to \"transferrin saturation and serum ferritin\". Patients will undergo bloodletting with a goal of maintaining a serum transferrin saturation equal or lower than 50 % and a serum ferritin lower than the upper limit of the normal range (300 g/L for men and 200 g/L for women).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "experimental group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"The primary evaluation criteria is the Physical Component Score of the SF-36 questionnaire at the end of the study period (two years)",
                    "PrimaryOutcomeDescription":"The primary evaluation criteria is the Physical Component Score of the SF-36 questionnaire at the end of the study period (two years). Physical Component score of the SF-36 has been chosen because SF-36 it is a widely validated and reproducible questionnaire, and this component is best susceptible to reflect both fatigue and joint involvement.",
                    "PrimaryOutcomeTimeFrame":"At Month 24"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"the AIMS2- SF (short form of the Arthritis Impact Measurement Scales 2) questionnaire",
                    "SecondaryOutcomeDescription":"Assessment of Arthropathy and joint pain related quality of life as assessed by the AIMS2- SF (short form of the Arthritis Impact Measurement Scales 2) questionnaire throughout the study, as performed at J0, M12 and M24 follow-up visit (every 12 months).",
                    "SecondaryOutcomeTimeFrame":"at Day 0, Month 12 and Month 24 follow-up visit"
                  },{
                    "SecondaryOutcomeMeasure":"the WOMAC (Western Ontario and McMaster Universities Arthritis Index) questionnaire",
                    "SecondaryOutcomeDescription":"Assessment of Arthropathy and joint pain related quality of life as assessed by the WOMAC (Western Ontario and McMaster Universities Arthritis Index) questionnaire throughout the study, as performed at J0, M12 and M24 follow-up visit (every 12 months).",
                    "SecondaryOutcomeTimeFrame":"at Day 0, Month 12 and Month 24 follow-up visit"
                  },{
                    "SecondaryOutcomeMeasure":"Evolution of the Mental Component Score of the SF-36 questionnaire",
                    "SecondaryOutcomeDescription":"Evolution of the Mental Component Score of the SF-36 questionnaire between inclusion and the end of the study period (two years).",
                    "SecondaryOutcomeTimeFrame":"At Month 24"
                  },{
                    "SecondaryOutcomeMeasure":"Evolution of the Physical Component Score of the SF-36",
                    "SecondaryOutcomeDescription":"Evolution of the Physical Component Score of the SF-36 throughout the study, as performed at J0, M12 and M24 follow-up visit (every 12 months).",
                    "SecondaryOutcomeTimeFrame":"at Day 0, Month 12 and Month 24 follow-up visit"
                  },{
                    "SecondaryOutcomeMeasure":"Evolution of the Mental Component Score of the SF-36",
                    "SecondaryOutcomeDescription":"Evolution of the Mental Component Score of the SF-36 throughout the study, as performed at J0, M12 and M24 follow-up visit (every 12 months).",
                    "SecondaryOutcomeTimeFrame":"at Day 0, Month 12 and Month 24 follow-up visit"
                  },{
                    "SecondaryOutcomeMeasure":"Evolution of of the EQ-5D-5L score",
                    "SecondaryOutcomeDescription":"Evolution of of the EQ-5D-5L score throughout the study, as performed at J0, M12 and M24 follow-up visit (every 12 months).",
                    "SecondaryOutcomeTimeFrame":"at Day 0, Month 12 and Month 24 follow-up visit"
                  },{
                    "SecondaryOutcomeMeasure":"Evolution of Serum ferritin and serum transferrin saturation",
                    "SecondaryOutcomeDescription":"Evolution of Serum ferritin and serum transferrin saturation determined at each follow-up visit (every 6 months).",
                    "SecondaryOutcomeTimeFrame":"Day 0, Month 6, Month 12, Month 18 and Month 24/follow-up visit"
                  },{
                    "SecondaryOutcomeMeasure":"Occurrence of anaemia",
                    "SecondaryOutcomeDescription":"Occurrence of anaemia defined as haemoglobin lower than 13g/L (men) and 12 g/L (women) at any follow-up visit.",
                    "SecondaryOutcomeTimeFrame":"Day 0, Month 6, Month 12, Month 18 and Month 24/follow-up visit"
                  },{
                    "SecondaryOutcomeMeasure":"Occurrence of malaise",
                    "SecondaryOutcomeDescription":"Occurrence of malaise after a bloodletting procedure",
                    "SecondaryOutcomeTimeFrame":"At Month 24"
                  },{
                    "SecondaryOutcomeMeasure":"Total number of phlebotomy performed",
                    "SecondaryOutcomeDescription":"Total number of phlebotomy performed by each patient during the study period.",
                    "SecondaryOutcomeTimeFrame":"At Month 24"
                  },{
                    "SecondaryOutcomeMeasure":"Incremental Cost-Effectiveness Ratio",
                    "SecondaryOutcomeDescription":"Incremental Cost-Effectiveness Ratio (ICER) defined as the cost for QALY gained in the \"transferrin saturation + ferritin\" strategy versus \"ferritin alone\" strategy.",
                    "SecondaryOutcomeTimeFrame":"At Month 24"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\n- Patients treated with iron chelators;\nPatients treated with erythroid growth factors (erythropoietin);\nPatient with excessive alcohol consumption (> 20g/day and > 30 g/day for women and men respectively);\nPatients with chronic haematological condition;\nPatients having uncontrolled chronic blood loss (of digestive or gynaecological origin);\nPatients with chronic kidney failure;\nPatients with a diagnosis of cancer or history of cancer in the last year;\nPregnancy or breast feeding.\nPatient who are included in another research protocol\nAdults legally protected (judicial protection, guardianship, or supervision), persons deprived of their freedom.\nwith C282Y homozygous HFE hemochromatosis;\nhaving finished the initial phase of HFE hemochromatosis treatment and in maintenance treatment for at least one year;\nhaving signed an informed consent form.\n\nExclusion Criteria:\n\nPatients treated with iron chelators;\nPatients treated with erythroid growth factors (erythropoietin);\nPatient with excessive alcohol consumption (> 20g/day and > 30 g/day for women and men respectively);\nPatients with chronic haematological condition;\nPatients having uncontrolled chronic blood loss (of digestive or gynaecological origin);\nPatients with chronic kidney failure;\nPatients with a diagnosis of cancer or history of cancer in the last year;\nPregnancy or breast feeding.\nPatient who are included in another research protocol\nAdults legally protected (judicial protection, guardianship, or supervision), persons deprived of their freedom.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Hopital Avicenne",
                    "LocationCity":"Bobigny",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Nathalie GANNE",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"01 48 95 55 55",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"nathalie.ganne@aphp.fr"
                        },{
                          "LocationContactName":"Nathalie GANNE",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CHU Dupuytren",
                    "LocationCity":"Limoges",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"VÃ©ronique LOUSTAUD-RATTI",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"05. 55. 05. 66. 84",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"veronique.loustaud-ratti@unilim.fr"
                        },{
                          "LocationContactName":"VÃ©ronique LOUSTAUD-RATTI",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"GHBS site du Scorff",
                    "LocationCity":"Lorient",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Florent EHRHARD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"02 97 06 94 98",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"f.ehrhard@ghbs.bzh"
                        },{
                          "LocationContactName":"Florent EHRHARD",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"GHRMSA - HÃ´pital Emile Muller",
                    "LocationCity":"Mulhouse",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Bernard DRENOU",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"03 89 64 77 55",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"drenoub@ghrmsa.fr"
                        },{
                          "LocationContactName":"Bernard DRENOU",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CHR OrlÃ©ans",
                    "LocationCity":"OrlÃ©ans",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Xavier CAUSSE",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"02 38 22 96 58",
                          "LocationContactEMail":"xavier.causse@chr-orleans.fr"
                        },{
                          "LocationContactName":"Xavier CAUSSE",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CHU Rennes",
                    "LocationCity":"Rennes",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Edouard Bardou-Jacquet",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"02.99.28.53.08",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"edouard.bardou-jacquet@chu-rennes.fr"
                        },{
                          "LocationContactName":"Edouard Bardou-Jacquet",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CH Yves le Foll",
                    "LocationCity":"Saint-Brieuc",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Antonia LE GRUYER",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"02 96 01 73 78",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"antonia.le-gruyer@ch-stbrieuc.fr"
                        },{
                          "LocationContactName":"Antonia LE GRUYER",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"CH de St Malo",
                    "LocationCity":"Saint-Malo",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Christine Beusnel",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"02 99 21 27 83",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"c.beusnel@ch-stmalo.fr"
                        },{
                          "LocationContactName":"Christine Beusnel",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"HÃ´pital Rangueil",
                    "LocationCity":"Toulouse",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Christophe BUREAU",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"05 61 32 36 86",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"bureau.c@chu-toulouse.fr"
                        },{
                          "LocationContactName":"BUREAU",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"Centre hospitalier Bretagne Atlantique",
                    "LocationCity":"Vannes",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"GaÃ«lle BILLET",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"02 97 01 99 01",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"gaelle.billet@ch-bretagne-atlantique.fr"
                        },{
                          "LocationContactName":"GaÃ«lle BILLET",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  },{
                    "LocationFacility":"HÃ´pital Paul Brousse",
                    "LocationCity":"Villejuif",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Rodolphe Sobesky",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"01 45 59 67 81",
                          "LocationContactPhoneExt":"+33",
                          "LocationContactEMail":"rodolphe.sobesky@aphp.fr"
                        },{
                          "LocationContactName":"Rodolphe Sobesky",
                          "LocationContactRole":"Contact"
                        },{
                          "LocationContactName":"Rodolphe Sobesky",
                          "LocationContactRole":"Principal Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000006432",
                    "ConditionMeshTerm":"Hemochromatosis"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000008664",
                    "ConditionAncestorTerm":"Metal Metabolism, Inborn Errors"
                  },{
                    "ConditionAncestorId":"D000008661",
                    "ConditionAncestorTerm":"Metabolism, Inborn Errors"
                  },{
                    "ConditionAncestorId":"D000030342",
                    "ConditionAncestorTerm":"Genetic Diseases, Inborn"
                  },{
                    "ConditionAncestorId":"D000019190",
                    "ConditionAncestorTerm":"Iron Overload"
                  },{
                    "ConditionAncestorId":"D000019189",
                    "ConditionAncestorTerm":"Iron Metabolism Disorders"
                  },{
                    "ConditionAncestorId":"D000008659",
                    "ConditionAncestorTerm":"Metabolic Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8101",
                    "ConditionBrowseLeafName":"Hemochromatosis",
                    "ConditionBrowseLeafAsFound":"Hemochromatosis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M10224",
                    "ConditionBrowseLeafName":"Metabolism, Inborn Errors",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10227",
                    "ConditionBrowseLeafName":"Metal Metabolism, Inborn Errors",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M22270",
                    "ConditionBrowseLeafName":"Genetic Diseases, Inborn",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19762",
                    "ConditionBrowseLeafName":"Iron Overload",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10222",
                    "ConditionBrowseLeafName":"Metabolic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19761",
                    "ConditionBrowseLeafName":"Iron Metabolism Disorders",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T6034",
                    "ConditionBrowseLeafName":"Quality of Life",
                    "ConditionBrowseLeafAsFound":"Quality of Life",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"T2699",
                    "ConditionBrowseLeafName":"Hemochromatosis Type 3",
                    "ConditionBrowseLeafAsFound":"Hemochromatosis",
                    "ConditionBrowseLeafRelevance":"high"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC16",
                    "ConditionBrowseBranchName":"Diseases and Abnormalities at or Before Birth"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC18",
                    "ConditionBrowseBranchName":"Nutritional and Metabolic Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXM",
                    "ConditionBrowseBranchName":"Behaviors and Mental Disorders"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M9116",
                    "InterventionBrowseLeafName":"Iron",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2358",
                    "InterventionBrowseLeafName":"Ethanol",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M9693",
                    "InterventionBrowseLeafName":"Liver Extracts",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M3530",
                    "InterventionBrowseLeafName":"Bilirubin",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M17242",
                    "InterventionBrowseLeafName":"N-Methylaspartate",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T0",
                    "InterventionBrowseLeafName":"Alanine",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T3",
                    "InterventionBrowseLeafName":"Aspartic Acid",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Micro",
                    "InterventionBrowseBranchName":"Micronutrients"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"Infe",
                    "InterventionBrowseBranchName":"Anti-Infective Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"CNSDep",
                    "InterventionBrowseBranchName":"Central Nervous System Depressants"
                  },{
                    "InterventionBrowseBranchAbbrev":"Hemat",
                    "InterventionBrowseBranchName":"Hematinics"
                  },{
                    "InterventionBrowseBranchAbbrev":"AA",
                    "InterventionBrowseBranchName":"Amino Acids"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":92,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779580",
              "OrgStudyIdInfo":{
                "OrgStudyId":"JSBF01"
              },
              "Organization":{
                "OrgFullName":"The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Can a Subcostal Nerve Block Add Benefit to a Lateral Femoral Cutaneous Nerve Block for Open Hip Surgery",
              "OfficialTitle":"Optimising Analgesia for Lateral Hip Arthroplasty Incision: Can a Subcostal Nerve Block Add Benefit to a Lateral Femoral Cutaneous Nerve Block?"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 1, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"August 1, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 21, 2021",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Hip Surgery is a very common form of surgery carried out across many hospitals within the UK in emergency and elective form. There is a variation between amongst surgeons with regard to the initial surgical incision required for the operation. It is fairly common practice to anaesthetise the Lateral Cutaneous Nerve of the thigh for analgesic reasons prior to the start of surgery, however due to the variation in surgical practice (and evolving surgical practices) this may not cover the entire surgical incision site. Another group of nerves termed the subcostal nerves has been described in the texts to perhaps cover the area of surgical incision along with blockade of the lateral cutaneous nerve of the thigh. On healthy volunteers the investigators plan to anaesthetise the lateral cutaneous nerve of the thigh, and the subcostal nerve on healthy participants to ascertain and map out the area of anaesthesia to see whether this could be a viable technique for analgesia for hip surgery in the future.",
              "DetailedDescription":"Hip replacement and hemiarthroplasty of the hip for neck of femur fracture are common orthopaedic procedures. The National Joint Registry in 2017 reported that 96.3% of hip replacements were performed using the anterolateral and posterior approach. NICE guidelines have suggested to utilise the anterolateral approach for hip fracture hemiarthroplasty due to decrease dislocation rates and thus, cost savings.\n\nDespite these two commonly use approaches, the traditional incisions have, in the investigators experience, been modified. This is to accommodate the increasing evidence and emphasis on the acetabular components. Besides that, in hemiarthroplasty, various incisions have been described for the 'anterolateral' approach, such as direct lateral, curved posteriorly. 'Mini' and 'micro' incisions of the posterior approach has also been described all with the aim as tissue-sparing procedures, improving outcomes and length of stay.\n\nIn this study, the investigators aim to describe the 'traditionally' described posterior and anterolateral incisions to the hip by Moore and Hardinge:\n\nPosterior - 5cm distally from the greater trochanter along the femoral diaphysis, curving the incision proximally 3-8cm towards the PSIS\nAnterolateral - 3cm distally from the greater trochanter along the femoral diaphysis, continuing proximally 3-8cm along the femoral diaphysis\n\nThe cutaneous innervation for this area is largely supplied by the lateral femoral cutaneous nerve of the thigh; however some anatomical texts also describe contribution to this area from the subcostal nerve, or the lateral branches of the iliohypogastric nerve.\n\nThe lateral femoral cutaneous nerve can be readily identified using ultrasound, and has recently been categorised into 3 distinct types; the 'Sartorius', Posterior' and the 'Fan' types. The Sartorius type, accounting for roughly one-third, describes a dominant anterior branch running along the border of the Sartorius muscle, with no or few posterior branches.\n\nThe posterior type, accounting for roughly one-third, describes a strong posterior branch, equal in thickness to, or thicker than, the anterior branch running laterally and crossing the medial border of the tensor fasciae latae muscle immediately distal to the ASIS.\n\nThe fan type, accounting for roughly one-third, describes multiple nerve branches of equal thickness spreading over the anterolateral region of the proximal aspect of the thigh, crossing over the tensor fasciae latae muscle and the lateral border of the sartorius.\n\nThe lateral femoral cutaneous nerve can readily be identified using ultrasound and is readily blocked.\n\nThe subcostal nerve describes the distal continuation of the twelfth intercostal nerve.\n\nIts lateral cutaneous branch perforates the obliquus internus and externus, descends over the iliac crest in front of the lateral cutaneous branch of the iliohypogastric, and is distributed to the skin of the front part of the gluteal region, extending as low as the greater trochanter.\n\nThe iliohypogastric nerve is usually a branch of the lumbar plexus originating from the L1 ventral ramus. Above the iliac crest, it enters the posterior part of the transversus abdominis. Between the transversus abdominis and internal oblique it divides into lateral and anterior cutaneous branches. The lateral cutaneous branch runs through the internal and external oblique above the iliac crest, a little behind the iliac branch of the T12 spinal nerve. It is distributed to the posterolateral gluteal skin. The iliohypogastric nerve usually gives communicating branches to the subcostal and ilioinguinal nerves. The iliac branch of the iliohypogastric nerve can be absent, replaced by the lateral cutaneous branch of the subcostal nerve. The iliohypogastric nerve is sometimes derived from the twelfth thoracic nerve and can also receive a root from the eleventh. Anloague and Huijbregts (2009) demonstrated the absence of the iliohypogastric nerve in 20.6% of the lumbar plexuses they investigated.\n\nAnaesthesia for this incision can therefore only partly be achieved by a lateral femoral cutaneous nerve block; however this is not always complete for the territory of the incision, particularly if the incision is longer and extending more proximally. Due to the variation and sharing between the subcostal and iliohypogastric nerves, and their similar course, we will consider sonographically identified descending nerves to the gluteal region as a single entity, referred to as the subcostal nerve.\n\nThe Investigators have identified the subcostal nerve using ultrasound on volunteers and found it to lie above the superficial fascia directly above gluteus medius at the cranial aspect of the buttock, originating from the lateral abdominal wall musculature, where it can be tracked proximally to visualise its descent through the muscle layers of the lateral abdominal wall.\n\nThe investigators hypothesise that a lateral femoral cutaneous nerve block alone will not reliably provide cutaneous anaesthesia to the territory of our commonly observed incisions for hip arthroplasty. Our secondary hypothesis is that a blockade of the subcostal nerve will extend the cutaneous anaesthesia to reliably cover that area.\n\nThis study is to be conducted in three parts. Firstly, surgeons within the investigators department will be canvassed to mark out their likely line of incision for a routine elective primary hip arthroplasty. Pictorial evidence and variation will be gathered for overlay. Secondly, on volunteers, the lateral femoral cutaneous nerve will be identified using ultrasound in its course distal to the inguinal ligament, and the relevant type will be ascertained. The nerve will then be blocked using a short-acting local anaesthetic, and the area of numbness demarcated. Pictorial evidence will be gathered.\n\nThirdly, the subcostal nerve will be identified, and blocked using a short-acting local anaesthetic. The resulting area of numbness will be further demarcated, and further pictorial evidence gathered.\n\nThe relevant demarcated areas and incisions will be then be compared for analysis."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Anesthesia, Local"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Regional Anaesthesia",
                  "Hip Surgery",
                  "Lateral Femoral Cutaneous Nerve",
                  "Subcostal Nerve",
                  "Analgesia",
                  "Hip Arthroplasty"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"10",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Intervention Group (Only Group)",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Only one group in this study. 10 participants to have intervention.\n\nLateral femoral cutaneous nerve block and evaluation:\n\nRoutine ECG, pulse oximetry and blood pressure monitoring will be available. Using a sterile technique, the lateral femoral nerve will be approached using an in-plane ultrasound-guided technique, using a Stimuplex Ultra 360 50mm needle (B Braun, UK). Following negative aspiration, a one off STAT injection of 5mls lidocaine 1% will be administered subcutaneously.\n\nAfter 10 minutes, any altered sensation will be assessed using ice to differentiate normal and altered sensation. This area will be marked on the skin using a black marker pen. Photographs will be taken and images of the procedure will be recorded.\n\nThe above will then be repeated for the subcostal nerve block.\n\nThe total area of anaesthesia will then be compared to the standard surgical incision for hip surgery to assess whether the subcostal nerve block will offer any further analgesia.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic",
                        "Procedure: Subcostal Nerve Block Using Local Anaesthetic"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic",
                    "InterventionDescription":"Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Intervention Group (Only Group)"
                      ]
                    }
                  },{
                    "InterventionType":"Procedure",
                    "InterventionName":"Subcostal Nerve Block Using Local Anaesthetic",
                    "InterventionDescription":"Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Intervention Group (Only Group)"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Cutaneous area anaesthetised by lateral cutaneous nerve of thigh and subcostal nerve block using local anaesthetic",
                    "PrimaryOutcomeDescription":"Demarcated area of sensory loss after lateral femoral cutaneous nerve block and subcostal nerve block - reported by the participant upon testing the area with cold ice by the investigators. The area will then be assessed by the investigators to assess whether the area of anaesthesia will cover the surgical incision site for hip arthroplasties.",
                    "PrimaryOutcomeTimeFrame":"Duration of Study (approximately 5 months)"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nParticipant is willing and able to give informed consent for participation in the study.\nMale or Female, aged 18 years or above.\n\nExclusion Criteria:\n\nThe participant may not enter the study if ANY of the following apply:\n\nPeripheral neuropathy of any aetiology\nDiabetes mellitus\nMeralgia paraesthetica\nPrevious Total Hip Arthroplasty\nSciatica\nSpinal Stenosis\nLocalised infection of the inguinal or gluteal regions\nAllergy to local anaesthetic or excipients\nInability to identify either the lateral femoral cutaneous nerve or the subcostal nerve using ultrasound",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"75 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"James Stimpson, FRCA",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"07791089440",
                    "CentralContactEMail":"jimstimpy64@gmail.com"
                  },{
                    "CentralContactName":"Daniel P White, FRCA",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"07791197596",
                    "CentralContactEMail":"dpw1g08@doctors.org.uk"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"James Stimpson, FRCA",
                    "OverallOfficialAffiliation":"Queen Elizabeth Hospital NHS Trust",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"27053584",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Rudin D, Manestar M, Ullrich O, Erhardt J, Grob K. The Anatomical Course of the Lateral Femoral Cutaneous Nerve with Special Attention to the Anterior Approach to the Hip Joint. J Bone Joint Surg Am. 2016 Apr 6;98(7):561-7. doi: 10.2106/JBJS.15.01022."
                  },{
                    "ReferencePMID":"20830791",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Ray B, D'Souza AS, Kumar B, Marx C, Ghosh B, Gupta NK, Marx A. Variations in the course and microanatomical study of the lateral femoral cutaneous nerve and its clinical importance. Clin Anat. 2010 Nov;23(8):978-84. doi: 10.1002/ca.21043."
                  },{
                    "ReferencePMID":"19587628",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Bodner G, Bernathova M, Galiano K, Putz D, Martinoli C, Felfernig M. Ultrasound of the lateral femoral cutaneous nerve: normal findings in a cadaver and in volunteers. Reg Anesth Pain Med. 2009 May-Jun;34(3):265-8. doi: 10.1097/AAP.0b013e31819a4fc6."
                  },{
                    "ReferencePMID":"20140146",
                    "ReferenceType":"background",
                    "ReferenceCitation":"Anloague PA, Huijbregts P. Anatomical variations of the lumbar plexus: a descriptive anatomy study with proposed clinical implications. J Man Manip Ther. 2009;17(4):e107-14."
                  }
                ]
              },
              "SeeAlsoLinkList":{
                "SeeAlsoLink":[
                  {
                    "SeeAlsoLinkLabel":"Truncal Blocks. Patrick Narchi, et al. Raj's Practical Management of Pain (Fourth Edition), 2008",
                    "SeeAlsoLinkURL":"https://www.elsevier.com/books/rajs-practical-management-of-pain/9780323041843"
                  },{
                    "SeeAlsoLinkLabel":"Variations of the Lumbar and Sacral Plexuses and Their Branches. Nihal Apaydin. Nerves and Injuries. 2015",
                    "SeeAlsoLinkURL":"https://www.sciencedirect.com/topics/neuroscience/sacral-plexus"
                  },{
                    "SeeAlsoLinkLabel":"Surgical Exposures for Nerves of the Lower Limb. Nihal Apaydin et al. Nerves and Injuries. 2015",
                    "SeeAlsoLinkURL":"https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/ilioinguinal-nerve"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No",
              "IPDSharingDescription":"There is no plan to make IPD available to other researchers"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M1112",
                    "ConditionBrowseLeafName":"Surgical Wound",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC26",
                    "ConditionBrowseBranchName":"Wounds and Injuries"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000000777",
                    "InterventionMeshTerm":"Anesthetics"
                  },{
                    "InterventionMeshId":"D000000779",
                    "InterventionMeshTerm":"Anesthetics, Local"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000002492",
                    "InterventionAncestorTerm":"Central Nervous System Depressants"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  },{
                    "InterventionAncestorId":"D000018689",
                    "InterventionAncestorTerm":"Sensory System Agents"
                  },{
                    "InterventionAncestorId":"D000018373",
                    "InterventionAncestorTerm":"Peripheral Nervous System Agents"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2688",
                    "InterventionBrowseLeafName":"Anesthetics",
                    "InterventionBrowseLeafAsFound":"Mindfulness",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M2690",
                    "InterventionBrowseLeafName":"Anesthetics, Local",
                    "InterventionBrowseLeafAsFound":"Tested",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M9597",
                    "InterventionBrowseLeafName":"Lidocaine",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"CNSDep",
                    "InterventionBrowseBranchName":"Central Nervous System Depressants"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"AnArAg",
                    "InterventionBrowseBranchName":"Anti-Arrhythmia Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"ChanBlk",
                    "InterventionBrowseBranchName":"Channel Blockers"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":93,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779567",
              "OrgStudyIdInfo":{
                "OrgStudyId":"180328004"
              },
              "Organization":{
                "OrgFullName":"Pontificia Universidad Catolica de Chile",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Usefulness of Acetaminophen Associated With Strong Opioids for Acute Pain in Cancer Patients",
              "OfficialTitle":"Randomized Double-blind Controlled Study to Assess the Efficacy of Intravenous Acetaminophen Associated With Strong Opioids in the Management of Acute Pain in Adult Cancer Patients"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"June 10, 2019",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 11, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 14, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"November 18, 2020",
              "StudyFirstSubmitQCDate":"March 2, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 2, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Pontificia Universidad Catolica de Chile",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Cancer pain is one of the most frequent and relevant symptoms in cancer patients and has a great impact on a patient's quality of life. International and local standards recommend as an initial strategy, the use of an analgesic scheme composed of strong opioids (morphine, methadone or fentanyl) associated with adjuvants such as paracetamol, based upon the assumption that the use of combined analgesics could have a better analgesic effect, could allow the use of lower dose of opioids and that also could prevent the occurrence of adverse effects of opioids. However, there is uncertainty about the impact of paracetamol as an adjuvant in patients who use strong opioids for pain management in cancer patients with moderate to severe pain.\n\nTo clarify this question, this study aims to evaluate the efficacy and safety of intravenous paracetamol associated with strong opioids in hospitalized cancer patients who have pain associated with cancer of moderate to severe intensity, (4 or more), older than 18 years.\n\nRandomized double-blinded controlled study comparing intravenous acetaminophen 1 gr 4 times a day versus placebo for 48 hours as an adjuvant to strong opioids. We will assess pain intensity as a primary outcome validated assessments that estimate Verbal Numerical Rating Scale (VNRS) analogous verbal pain from 0 to 10, and de visual Analog Scale (VAS). We estimated that a decrease of 1 point on the verbal numerical scale would be statistically significant. In addition, the investigators will calculate the amount of total opioid dose in 24 hours and then perform the intervention. As a secondary outcome, adverse effects such as drowsiness, constipation, nausea and vomiting would be evaluated",
              "DetailedDescription":"This is a randomized, controlled, double blind, parallel-group, single center clinical trial. This study received ethical approval by the Ethics Committee of the Pontificia Universidad CatÃ³lica de Chile (ID #180328004). The study protocol was designed using the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) statement.\n\nThe setting of this study is the General Internal Medicine Ward of a tertiary level university hospital (UC Christus Clinical Hospital) where patients will be recruited.\n\nThe hypothesis of this study is that in hospitalized oncology patients over 18 years of age, acute pain management with strong opioids plus intravenous paracetamol is not superior to the use of strong opioids alone.\n\nParticipants Patients 18 years old or older, diagnosed with cancer and admitted to UC Christus Clinical Hospital of any ethnicity or nationality with moderate to severe pain.All participate in the study will sign an informed consent form.\n\nTreatments Opioid administration - Before starting the study a standardized pain management protocol for cancer patients with moderate to severe pain will be implemented across the institution. In this protocol, a standard analgesic protocol (scheduled strong opioids plus rescue doses, such as morphine, methadone or fentanyl) will be started by the ward team upon admission in order to ensure that all cancer patients with moderate to severe pain will have an adequate analgesic scheme for pain control regardless study enrollment. Briefly, cancer patients with moderate to severe pain who are opioid naive will be started on scheduled morphine, methadone or fentanyl by continuous infusion plus rescue doses. Standard doses will be recommended but these doses could be changed by treating clinicians according to clinical judgement. For patients with prior use of opioids, ward or treating clinicians could start scheduled methadone or morphine or fentanyl continuous infusion increasing the prior opioid dose. Early consultation to palliative care clinicians will be recommended for this population.\n\nAcetaminophen - experimental group - Intravenous acetaminophen is usually delivered in a 100cc solution that is prepared in a transparent glass bottle. As the placebo cannot be prepared in the same type of bottle, the content of the acetaminophen preparation will be transferred to a standard 100cc plastic flask for IV infusions, which will be labeled with the name and ID number of the patient, with the drug to be administered labeled acetaminophen/placebo (including both names) and with the allocation number for the randomization. The preparation of the acetaminophen plastic flask will be indistinguishable from the placebo plastic flask. As the intervention will last 48 hours, 8 plastic flasks with the drug will be sent directly to the clinical nurse in charge of the administration of the drug in the general ward.\n\nPlacebo - control group - The placebo will be prepared using the same plastic flask as used in the acetaminophen group. In the placebo group it will be filled with 100cc of saline, and will have the same label as the acetaminophen group, therefore they will be indistinguishable from each other. In the case of the placebo group, 8 plastic flasks with the placebo will be sent directly to the clinical nurse in charge of the administration of the drug in the general ward.\n\nOther treatments - As the research group wants to assess the impact of this intervention in the real clinical setting, treating clinicians will be allowed to be added according to clinical judgement. Non-steroidal anti inflammatories (NSAIDS), steroids, anticonvulsants, or other adjuvants could be added.\n\nRandomization - After informed consent, eligible patients will be randomized into two arms: (A) acetaminophen or (B) placebo. The randomization procedure will be performed by the institution's pharmacist using a web-based randomization software platform specifically designed to support data collection for research studies (Research Electronic Data Capture, REDCapÂ®), platform that provides automated export procedures for data downloads. The randomization will be performed following a stratified block randomization, with blocks of 4 or 6 patients among which 50% of each block will receive placebo and 50% will receive acetaminophen. The study will be blind with randomization concealment. Once the pharmacist has identified the allocated arm of the enrolled patient, a total of 8 identical plastic flasks will be prepared in the pharmacy service, with a total amount of 100ml of volume each and each one labeled as previously described. For arm (A), IV acetaminophen will be prepared, for arm (B), IV saline will be prepared. The eight plastic flasks will be delivered to the general ward and the clinical nurses will be in charge of administering the infusions during the 48 hours study period. Precautions will be taken to ensure that treating physicians, clinical nurses, data collectors, data adjudicators, patients and researchers will be blind to patient allocation.\n\nFollow-up and data collection - Patients will be asked to complete a baseline assessment questionnaire and then two other questionnaires at 24 and 48 hours after enrollment. The questionnaires were selected seeking to assess the primary and secondary outcomes and variables that could impact patients' pain experience. We included a variety of questionnaires and instruments, to assess eligibility criteria, the primary and secondary outcomes and possible affect modifiers, including instruments to assess delirium (Memorial Delirium [MDAS]), pain (Verbal Numerical Rating Scale [VNRS] and Visual Analog Scale [VAS]), use of analgesia prior to admission, alcohol and drug consumption, risk of chemical coping, symptoms, psychological distress (Hospital Anxiety Depression Scale [HADS]), quality of life and symptoms associated with their current hospitalization .\n\nData collection and management Sample size - To estimate the sample size, we decided to use the strategy of identifying the minimum clinically important difference (MCID) in pain according to the ESAS scale, which evaluates pain on a scale from 0 to 10, similar to the VNRS, which we will use as our main outcome. The MCID is defined as \"the smallest change in a measurement that signifies an important difference in a patient's symptoms\". In a study conducted by Farrar, et al, the MCID for pain was defined as 2 points, which was evaluated in a short in-hospital follow-up period, a scenario that is similar to that of our study. In another study, conducted by Hui, et al , published in 2015, different methods for establishing MCID were evaluated. In that study, using the anchor-based method through the calculation of the ROC curve, it was recognized that an improvement in pain intensity by 1 point on the ESAS scale was identified by patients as a clinically significant improvement, i.e. patients detect 1 point on the ESAS scale as an improvement in pain control, scale similar to the VNRS. In this study the standard deviation for the pain score was 3 points, similarly to what was found in previous studies. Using other similar strategies, a difference between 1 and 2 points was identified as clinically significant. However, in this study the pain assessment was performed on an outpatient basis and with a 3-week difference between the first and the last assessment.\n\nIn an unpublished sample of 100 advanced cancer patients assessed in our PC unit, we found that the mean intensity of pain using the VNRS among patients with moderate to severe pain was 5,8 points with a standard deviation (SD) of 1.7 points.\n\nFrom the data obtained from prior publications, considering an alpha of 0.025, with a power of 0.8, we estimated that a sample size 112 patients would be required, with 56 patients in each group to detect a difference of 1 point in pain intensity between the groups, with a standard deviation (SD) of 1.7. These assumptions are supported by the following reasons:\n\nBecause a difference of 1 point is considered to be what is clinically defined as significant, so we should try to detect a difference greater than that.\n\nBecause we reported an SD of 1.7 in the initial pain scale in a sample of cancer patients in our unit.\n\nIn this way the investigators could be able to recommend, not to use intravenous paracetamol, which would generate an indirect recommendation not to use oral paracetamol in patients with moderate to severe acute pain associated with cancer. This not only has an economic impact, but also could affect the well-being of patients who are sometimes in a great pharmacological burden, in the context of low oral intake and frequent nausea and vomiting."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Acute Pain",
                  "Cancer Pain"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 4"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"Prospective, Single center parallel-group, randomized double-blinded controlled study",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignMaskingDescription":"matching placebo. prepared by pharmacist",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"112",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Acetaminophen",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Acetaminophen 1 gr in 100 ml saline 0,9% iv 4 times a day",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Acetaminophen"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"100 ml saline 0.9% iv 4 times a day",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Acetaminophen",
                    "InterventionDescription":"Acetaminophen 1 gr iv 4 times a day",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Acetaminophen"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"100 ml saline 0.9% iv 4 times a day",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Placebo"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Efficacy of acetaminophen by Verbal Numerical Rating Scale (VNRS)",
                    "PrimaryOutcomeDescription":"The primary outcome of this study will be the difference in pain intensity between baseline (T=0) and 48 hours (T=2) using the Verbal Numerical Rating Scale (VNRS) reported by the patient to assess the effects of the intervention in pain intensity. We will compare the difference in pain intensity between the groups. The VNRS is a tool in which the patient is asked to score the mean intensity of pain during the last 24 hours in a scale from 0 to 10 with 0 meaning no pain at all and 10 meaning the worst possible pain.",
                    "PrimaryOutcomeTimeFrame":"48 hours"
                  },{
                    "PrimaryOutcomeMeasure":"Efficacy of acetaminophen by Visual Analog scale (VAS), in a scale from 0 to 10 with 0 meaning no pain at all and 10 meaning the worst possible pain.",
                    "PrimaryOutcomeDescription":"The VAS uses a right triangle drawn on a paper, with a base of 10 cm wide and a height of 1cm on the right, in which its ends are delimited by a mark that expresses \"without pain\" on the left side and\" worst pain I have ever felt\" on the right side. The patient is asked to mark a vertical line crossing the horizontal line indicating the intensity of the pain. On the reverse, there is a superimposed line, with a graduation of 1 cm wide, which allows the data collector to identify the position in which the line marked by the patient is located. This indicates patientsÂ´ pain intensity score assigned by the patient on a scale from 0 to 10. We will also estimate the difference in pain intensity between baseline and 48 hours using the VAS and compare the magnitude of the difference between the arms.",
                    "PrimaryOutcomeTimeFrame":"48 hours"
                  },{
                    "PrimaryOutcomeMeasure":"Efficacy of acetaminophen by total morphine equivalent daily dose (MEDD)",
                    "PrimaryOutcomeDescription":"MEDD at 48 hours. The MEDD represents the total dose of opioids used within the last 24 hours converted into an equivalent dose of parenteral morphine, following standard equianalgesic conversion tables",
                    "PrimaryOutcomeTimeFrame":"48 Hours"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Incidence of Treatment-Emergent Adverse Events",
                    "SecondaryOutcomeDescription":"Incidence of treatment-emergent adverse Events: Drowsiness, constipation, nausea and vomit, allergy reactions.The patient is asked if he has presented any adverse effect to the treatment and this is classified as mild, moderate and severe",
                    "SecondaryOutcomeTimeFrame":"T1: 24 hours and T2: 48 Hours"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nCancer patients hospitalized at UC Christus Clinical Hospital of any ethnicity or nationality.\nWith acute pain> or = a 4 in Verbal Numerical Rating Scale (VNRS)\nThey can be patients who are virgins to opioids or previous users of weak or strong opioids.\nThey may have somatic, visceral or neuropathic pain\nThey may be users of NSAIDs or corticosteroids\n\nExclusion Criteria:\n\nPatients who refuse to enter the study\nPatients who donÂ´t speak Spanish a mother language\nPatients who present a qualitative or quantitative awareness commitment that prevents the assessment of pain.\nPatients with acute liver failure or chronic liver damage Child C.\nPatients allergic or hypersensitive to paracetamol.\nPatients with a prognosis of life less than 72 hours (evaluated according to clinical criteria)",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Ofelia Leiva, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+56997180826",
                    "CentralContactEMail":"ofelia.leiva@gmail.com"
                  },{
                    "CentralContactName":"Luz Maria Letelier, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"+56 9 9239 5893",
                    "CentralContactEMail":"lmletel@med.puc.cl"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Ofelia Leiva, MD",
                    "OverallOfficialAffiliation":"Universidad CatÃ³lica de Chile",
                    "OverallOfficialRole":"Study Director"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Universidad Catolica de Chile",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Santiago",
                    "LocationZip":"8330024",
                    "LocationCountry":"Chile",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Ofelia Leiva, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+56997180826",
                          "LocationContactEMail":"ofelia.leiva@gmail.com"
                        },{
                          "LocationContactName":"Luz maria letelier, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"+56 9 9239 5893",
                          "LocationContactEMail":"lmletel@med.puc.cl"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"17916403",
                    "ReferenceType":"result",
                    "ReferenceCitation":"van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain. 2007 Dec 5;132(3):312-320. doi: 10.1016/j.pain.2007.08.022. Epub 2007 Oct 3."
                  },{
                    "ReferencePMID":"17509812",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007 Jul;34(1):94-104. Epub 2007 May 23. Review."
                  },{
                    "ReferencePMID":"15813511",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Goudas LC, Bloch R, Gialeli-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain. Cancer Invest. 2005;23(2):182-90. Review."
                  },{
                    "ReferencePMID":"24799466",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Portenoy RK, Ahmed E. Principles of opioid use in cancer pain. J Clin Oncol. 2014 Jun 1;32(16):1662-70. doi: 10.1200/JCO.2013.52.5188. Epub 2014 May 5. Review."
                  },{
                    "ReferencePMID":"25761441",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Jimenez de la Jara J, Bastias G, Ferreccio C, Moscoso C, Sagues S, Cid C, Bronstein E, Herrera C, Nervi B, Corvalan A, Velasquez EV, Gonzalez P, Castellon E, Bustamante E, OÃ±ate S, McNerney E, Sullivan R, Owen GI. A snapshot of cancer in Chile: analytical frameworks for developing a cancer policy. Biol Res. 2015 Jan 26;48:10. doi: 10.1186/0717-6287-48-10. Review."
                  },{
                    "ReferencePMID":"24799495",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Hui D, Bruera E. A personalized approach to assessing and managing pain in patients with cancer. J Clin Oncol. 2014 Jun 1;32(16):1640-6. doi: 10.1200/JCO.2013.52.2508. Epub 2014 May 5. Review."
                  },{
                    "ReferencePMID":"11033377",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Johnston M, Pollard B, Hennessey P. Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res. 2000 Jun;48(6):579-84."
                  },{
                    "ReferencePMID":"10813730",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000 May 1;88(9):2164-71."
                  },{
                    "ReferencePMID":"22952129",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Delgado-Guay MO, Parsons HA, Hui D, De la Cruz MG, Thorney S, Bruera E. Spirituality, religiosity, and spiritual pain among caregivers of patients with advanced cancer. Am J Hosp Palliat Care. 2013 Aug;30(5):455-61. doi: 10.1177/1049909112458030. Epub 2012 Sep 4."
                  },{
                    "ReferencePMID":"23354635",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Latorres M, Huidobro A. [Prevalence of alcohol consumption among medical students at the Universidad CatÃ³lica del Maule, Chile]. Rev Med Chil. 2012 Sep;140(9):1140-4. doi: 10.4067/S0034-98872012000900006. Spanish."
                  },{
                    "ReferencePMID":"11013380",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000 Oct 1;89(7):1634-46."
                  },{
                    "ReferencePMID":"7500538",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA. 1995 Dec 20;274(23):1870-3. Review."
                  },{
                    "ReferencePMID":"11331334",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V; Expert Working Group of the European Association of Palliative Care Network. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001 May 1;19(9):2542-54. Review."
                  },{
                    "ReferencePMID":"9848918",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Barnes J, Abban M, Howarth P. Deaths from low dose paracetamol poisoning. Executive action is needed to change national guidelines. BMJ. 1998 Dec 12;317(7173):1654."
                  },{
                    "ReferencePMID":"18843665",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Toms L, McQuay HJ, Derry S, Moore RA. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004602. doi: 10.1002/14651858.CD004602.pub2. Review."
                  },{
                    "ReferencePMID":"16869819",
                    "ReferenceType":"result",
                    "ReferenceCitation":"McQuay HJ, Moore RA. Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. Br J Clin Pharmacol. 2007 Mar;63(3):271-8. Epub 2006 Jul 21. Review."
                  },{
                    "ReferencePMID":"25530283",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ. Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain. 2015 Oct;19(9):1213-23. doi: 10.1002/ejp.649. Epub 2014 Dec 22. Review."
                  },{
                    "ReferencePMID":"27839957",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Politi JR, Davis RL 2nd, Matrka AK. Randomized Prospective Trial Comparing the Use of Intravenous versus Oral Acetaminophen in Total Joint Arthroplasty. J Arthroplasty. 2017 Apr;32(4):1125-1127. doi: 10.1016/j.arth.2016.10.018. Epub 2016 Oct 21."
                  },{
                    "ReferencePMID":"28276273",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Hansen RN, Pham AT, BÃ¶ing EA, Lovelace B, Wan GJ, Miller TE. Comparative analysis of length of stay, hospitalization costs, opioid use, and discharge status among spine surgery patients with postoperative pain management including intravenous versus oral acetaminophen. Curr Med Res Opin. 2017 May;33(5):943-948. doi: 10.1080/03007995.2017.1297702. Epub 2017 Mar 9."
                  },{
                    "ReferencePMID":"22300860",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012 Feb;13(2):e58-68. doi: 10.1016/S1470-2045(12)70040-2. Review."
                  },{
                    "ReferencePMID":"24799483",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014 Jun 1;32(16):1677-90. doi: 10.1200/JCO.2013.52.8356. Epub 2014 May 5. Review."
                  },{
                    "ReferencePMID":"15310785",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol. 2004 Aug 15;22(16):3389-94."
                  },{
                    "ReferencePMID":"14694929",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Axelsson B, Borup S. Is there an additive analgesic effect of paracetamol at step 3? A double-blind randomized controlled study. Palliat Med. 2003 Dec;17(8):724-5."
                  },{
                    "ReferencePMID":"20083373",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Israel FJ, Parker G, Charles M, Reymond L. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage. 2010 Mar;39(3):548-54. doi: 10.1016/j.jpainsymman.2009.07.008. Epub 2010 Jan 18."
                  },{
                    "ReferencePMID":"19421788",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Cubero DI, del Giglio A. Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study. Support Care Cancer. 2010 Feb;18(2):235-42. doi: 10.1007/s00520-009-0649-8. Epub 2009 May 7."
                  },{
                    "ReferencePMID":"19343373",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Tasmacioglu B, Aydinli I, Keskinbora K, Pekel AF, Salihoglu T, Sonsuz A. Effect of intravenous administration of paracetamol on morphine consumption in cancer pain control. Support Care Cancer. 2009 Dec;17(12):1475-81. doi: 10.1007/s00520-009-0612-8. Epub 2009 Apr 3."
                  },{
                    "ReferencePMID":"22126843",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Nabal M, Librada S, Redondo MJ, Pigni A, Brunelli C, Caraceni A. The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliat Med. 2012 Jun;26(4):305-12. doi: 10.1177/0269216311428528. Epub 2011 Nov 29. Review."
                  },{
                    "ReferencePMID":"28323080",
                    "ReferenceType":"result",
                    "ReferenceCitation":"PÃ©rez-Cruz PE, Padilla PÃ©rez O, Bonati P, Thomsen Parisi O, Tupper Satt L, Gonzalez Otaiza M, Ceballos YÃ¡Ã±ez D, Maldonado Morgado A. Validation of the Spanish Version of the Quality of Dying and Death Questionnaire (QODD-ESP) in a Home-Based Cancer Palliative Care Program and Development of the QODD-ESP-12. J Pain Symptom Manage. 2017 Jun;53(6):1042-1049.e3. doi: 10.1016/j.jpainsymman.2017.02.005. Epub 2017 Mar 16."
                  },{
                    "ReferencePMID":"20332509",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c332. doi: 10.1136/bmj.c332."
                  },{
                    "ReferencePMID":"24760709",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Hui D, dos Santos R, Chisholm G, Bansal S, Silva TB, Kilgore K, Crovador CS, Yu X, Swartz MD, Perez-Cruz PE, Leite Rde A, Nascimento MS, Reddy S, Seriaco F, Yennu S, Paiva CE, Dev R, Hall S, Fajardo J, Bruera E. Clinical signs of impending death in cancer patients. Oncologist. 2014 Jun;19(6):681-7. doi: 10.1634/theoncologist.2013-0457. Epub 2014 Apr 23."
                  },{
                    "ReferencePMID":"26059846",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Hui D, Shamieh O, Paiva CE, Perez-Cruz PE, Kwon JH, Muckaden MA, Park M, Yennu S, Kang JH, Bruera E. Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study. Cancer. 2015 Sep 1;121(17):3027-35. doi: 10.1002/cncr.29437. Epub 2015 Jun 8."
                  },{
                    "ReferencePMID":"11068116",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000 Dec 1;88(3):287-294. doi: 10.1016/S0304-3959(00)00339-0."
                  },{
                    "ReferencePMID":"30776210",
                    "ReferenceType":"result",
                    "ReferenceCitation":"WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: World Health Organization; 2018."
                  },{
                    "ReferencePMID":"28700092",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Wiffen PJ, Derry S, Moore RA, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017 Jul 12;7:CD012637. doi: 10.1002/14651858.CD012637.pub2. Review."
                  }
                ]
              },
              "SeeAlsoLinkList":{
                "SeeAlsoLink":[
                  {
                    "SeeAlsoLinkLabel":"Health Ministry",
                    "SeeAlsoLinkURL":"https://www.minsal.cl/portal/url/item/72213ed52c2723d1e04001011f011398.pdf"
                  },{
                    "SeeAlsoLinkLabel":"National Pain Relief and Palliative Care Program Standard",
                    "SeeAlsoLinkURL":"https://www.uss.cl/biblioteca/wp-content/uploads/2016/10/Norma-Programa-Nacional-alivio-del-dolor-por-cÃ¡ncer-y-cuidados-paliativos-MINSAL.pdf"
                  },{
                    "SeeAlsoLinkLabel":"Cancer pain relief. With a Guide to opioid availability",
                    "SeeAlsoLinkURL":"https://apps.who.int/iris/bitstream/handle/10665/37896/9241544821.pdf;jsessionid=46F526101B59DBB6773822B1A44B3A5E?sequence=1"
                  },{
                    "SeeAlsoLinkLabel":"Palliative care guideline",
                    "SeeAlsoLinkURL":"http://www.who.int/cancer/palliative/painladder/en/"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"For numerical variables, baseline characteristic data were analyzed and represented with meanÂ±SD, or median with interquartile range (IQR), according to data type and distribution. Categorical variables are presented as frequency and percentage.\n\nFor bivariate analysis, Student T-test or ANOVA were used for enough sample size to assume Normal distribution of the averages by Central Limit Theorem, and Wilcoxon's rank sum test for non-normal distribution data.\n\nFinally, multivariate mixed models will be adjusted for interest scores: VAS, VNRS and MEEDs at 48 hours. As fixed effects in the model, we will consider de intervention (placebo or paracetamol) and other factors (as tabacco) and the patient as the random effect. A significance of 0.05 will be considered. The analyzes will be performed using the statistical package STATA 14.0.",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol"
                ]
              },
              "IPDSharingTimeFrame":"We are unable to make the data available in a public repository or uploaded as supplementary information because this is not permitted by our organisation's research governance policy and Ethics committee regulations. Anonymised data can be made available to researchers who meet the conditions of the ethics approval and research governance policy that applies to this study. Researchers may request anonymized data access by contacting Universidad CatÃ³lica's School of Medicine Research Office (DIDEMUC) at didemuc@med.puc.cl."
            }
          },
          "DocumentSection":{
            "LargeDocumentModule":{
              "LargeDocList":{
                "LargeDoc":[
                  {
                    "LargeDocTypeAbbrev":"ICF",
                    "LargeDocHasProtocol":"No",
                    "LargeDocHasSAP":"No",
                    "LargeDocHasICF":"Yes",
                    "LargeDocLabel":"Informed Consent Form",
                    "LargeDocDate":"January 28, 2021",
                    "LargeDocUploadDate":"02/04/2021 13:20",
                    "LargeDocFilename":"ICF_000.pdf"
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000059787",
                    "ConditionMeshTerm":"Acute Pain"
                  },{
                    "ConditionMeshId":"D000072716",
                    "ConditionMeshTerm":"Cancer Pain"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000010146",
                    "ConditionAncestorTerm":"Pain"
                  },{
                    "ConditionAncestorId":"D000009461",
                    "ConditionAncestorTerm":"Neurologic Manifestations"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M28112",
                    "ConditionBrowseLeafName":"Acute Pain",
                    "ConditionBrowseLeafAsFound":"Acute Pain",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M1091",
                    "ConditionBrowseLeafName":"Cancer Pain",
                    "ConditionBrowseLeafAsFound":"Cancer Pain",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M11649",
                    "ConditionBrowseLeafName":"Pain",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10987",
                    "ConditionBrowseLeafName":"Neurologic Manifestations",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000000082",
                    "InterventionMeshTerm":"Acetaminophen"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000018712",
                    "InterventionAncestorTerm":"Analgesics, Non-Narcotic"
                  },{
                    "InterventionAncestorId":"D000000700",
                    "InterventionAncestorTerm":"Analgesics"
                  },{
                    "InterventionAncestorId":"D000018689",
                    "InterventionAncestorTerm":"Sensory System Agents"
                  },{
                    "InterventionAncestorId":"D000018373",
                    "InterventionAncestorTerm":"Peripheral Nervous System Agents"
                  },{
                    "InterventionAncestorId":"D000045505",
                    "InterventionAncestorTerm":"Physiological Effects of Drugs"
                  },{
                    "InterventionAncestorId":"D000058633",
                    "InterventionAncestorTerm":"Antipyretics"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2029",
                    "InterventionBrowseLeafName":"Acetaminophen",
                    "InterventionBrowseLeafAsFound":"Physical activity",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M2614",
                    "InterventionBrowseLeafName":"Analgesics, Opioid",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M19370",
                    "InterventionBrowseLeafName":"Analgesics, Non-Narcotic",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2613",
                    "InterventionBrowseLeafName":"Analgesics",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M27763",
                    "InterventionBrowseLeafName":"Antipyretics",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Antipy",
                    "InterventionBrowseBranchName":"Antipyretics"
                  },{
                    "InterventionBrowseBranchAbbrev":"Analg",
                    "InterventionBrowseBranchName":"Analgesics"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"CNSDep",
                    "InterventionBrowseBranchName":"Central Nervous System Depressants"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":94,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779554",
              "OrgStudyIdInfo":{
                "OrgStudyId":"MCC-20-GI-115"
              },
              "Organization":{
                "OrgFullName":"University of Kentucky",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC",
              "OfficialTitle":"A Randomized Phase 2 Trial of Flat Dose vs. Weight-based Dose of Intra-peritoneal (IP) Chemotherapy for Patients Undergoing Cytoreductive Surgery and Heated Intra-peritoneal Chemotherapy (CRS/HIPEC) for Advanced Gastrointestinal Malignancy"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 28, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"February 2024",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"February 2024",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 27, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor-Investigator",
                "ResponsiblePartyInvestigatorFullName":"Prakash Pandalai",
                "ResponsiblePartyInvestigatorTitle":"Assistant Professor",
                "ResponsiblePartyInvestigatorAffiliation":"University of Kentucky"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Prakash Pandalai",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"Yes",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"Yes"
            },
            "DescriptionModule":{
              "BriefSummary":"Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (â‰¤ 12 months) with few treatment options. Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules, combined with direct administration of heated intra-peritoneal (IP) chemotherapy (HIPEC) to the affected peritoneal surfaces, has been shown to be an effective treatment option that extends overall survival among certain cases of peritoneal carcinomatosis. IP chemotherapy allows delivery of a high dose of cytostatic drug directly onto the peritoneal surfaces at risk for microscopic residual disease while systemic exposure remains limited. Additionally, hyperthermia is known to enhance the cytotoxicity of several agents (including Mitomycin C) and improves the depth of peritoneal penetration.\n\nThis trial will be a randomized phase 2 comparison of flat dose versus weight-based dose Mitomycin C. The hypothesis of this study is that HIPEC weight-based dosing may result in similarly effective peritoneal Mitomycin C concentrations with less systemic absorption and potential systemic toxicity, compared with the HIPEC flat dosing approach in patients undergoing CRS/HIPEC."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Peritoneal Carcinomatosis"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "cytoreductive surgery",
                  "colorectal cancer",
                  "pseudomyxoma peritonei",
                  "appendiceal mucinous neoplasm",
                  "mitomycin C",
                  "pharmacokinetics",
                  "CRS/HIPEC",
                  "HIPEC",
                  "Appendix cancer",
                  "LAMN"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"100",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Flat Dose Mitomycin C",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Participants in this group will receive flat doses of mitomycin C intra-operatively: 1) 30mg at minute 0 and 2) 10mg at minute 60. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Mitomycin C, flat dose 40 mg"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Weight-Based Mitomycin C",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Participants in this group will receive weight-based dosing of mitomycin C intra-operatively: 1) 9 mg/m2 at minute 0 and 2) 3.5 mg/m2 at minute 60 for total dose of 12.5 mg/m2. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Drug: Mitomycin C, weight-based dose 12.5 mg/m2"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Drug",
                    "InterventionName":"Mitomycin C, flat dose 40 mg",
                    "InterventionDescription":"Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Flat Dose Mitomycin C"
                      ]
                    }
                  },{
                    "InterventionType":"Drug",
                    "InterventionName":"Mitomycin C, weight-based dose 12.5 mg/m2",
                    "InterventionDescription":"Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Weight-Based Mitomycin C"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Area Under the Curve (AUC) - Pharmacokinetics",
                    "PrimaryOutcomeDescription":"Drug exposure will be measured by calculating the area under the curve (AUC) or integral of a plasma concentration-time curve. Samples will be collected at 0,15, 30, 60 and 90 minutes intra-operatively, and 2, 4, and 12 hours postoperatively.",
                    "PrimaryOutcomeTimeFrame":"Approximately 20 hours"
                  },{
                    "PrimaryOutcomeMeasure":"Drug Clearance (CL) - Pharmacokinetics",
                    "PrimaryOutcomeDescription":"Drug clearance will be calculated as the volume of plasma cleared per unit time. Samples will be collected at 0,15, 30, 60 and 90 minutes intra-operatively, and 2, 4, and 12 hours postoperatively.",
                    "PrimaryOutcomeTimeFrame":"Approximately 20 hours"
                  },{
                    "PrimaryOutcomeMeasure":"Drug Half-Life (T1/2) - Pharmacokinetics",
                    "PrimaryOutcomeDescription":"Drug half-life will be calculated as the time required for the plasma Mitomycin C concentration to be half of its maximum concentration. Samples will be collected at 0,15, 30, 60 and 90 minutes intra-operatively, and 2, 4, and 12 hours postoperatively.",
                    "PrimaryOutcomeTimeFrame":"Approximately 20 hours"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPatients diagnosed with one of the following: low-grade appendiceal mucinous neoplasm, appendiceal cancer with peritoneal carcinomatosis, colorectal cancer with peritoneal carcinomatosis\nECOG performance status < 3\nCandidate for grossly complete cytoreductive surgery\nLife expectancy greater than 3 months\nAdequate organ and marrow function\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nAny extra-abdominal metastases\nUntreated lung metastases\nLiver metastases not amenable to resection or ablation\nKnown brain metastases\nChemotherapy or radiotherapy within 4 weeks prior to entering the study\nPresence of residual significant adverse events attributed to prior cancer treatment\nCurrently receiving any other investigational therapeutic agents\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Mitomycin C.\nPregnant or breast-feeding women\nUncontrolled ongoing illness",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Prakash Pandalai, MD",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"859-323-8920",
                    "CentralContactEMail":"Prakash.Pandalai@uky.edu"
                  }
                ]
              },
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Prakash Pandalai, MD",
                    "OverallOfficialAffiliation":"University of Kentucky",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"University of Kentucky",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Lexington",
                    "LocationState":"Kentucky",
                    "LocationZip":"40536",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Prakash Pandalai, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactEMail":"Prakash.Pandalai@uky.edu"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000002277",
                    "ConditionMeshTerm":"Carcinoma"
                  },{
                    "ConditionMeshId":"D000010534",
                    "ConditionMeshTerm":"Peritoneal Neoplasms"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000009375",
                    "ConditionAncestorTerm":"Neoplasms, Glandular and Epithelial"
                  },{
                    "ConditionAncestorId":"D000009370",
                    "ConditionAncestorTerm":"Neoplasms by Histologic Type"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  },{
                    "ConditionAncestorId":"D000000008",
                    "ConditionAncestorTerm":"Abdominal Neoplasms"
                  },{
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  },{
                    "ConditionAncestorId":"D000004067",
                    "ConditionAncestorTerm":"Digestive System Neoplasms"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  },{
                    "ConditionAncestorId":"D000010532",
                    "ConditionAncestorTerm":"Peritoneal Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M16473",
                    "ConditionBrowseLeafName":"Colorectal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3696",
                    "ConditionBrowseLeafName":"Body Weight",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M12993",
                    "ConditionBrowseLeafName":"Pseudomyxoma Peritonei",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4116",
                    "ConditionBrowseLeafName":"Carcinoma",
                    "ConditionBrowseLeafAsFound":"Carcinomatosis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M12026",
                    "ConditionBrowseLeafName":"Peritoneal Neoplasms",
                    "ConditionBrowseLeafAsFound":"Peritoneal Carcinomatosis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M10903",
                    "ConditionBrowseLeafName":"Neoplasms, Glandular and Epithelial",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10898",
                    "ConditionBrowseLeafName":"Neoplasms by Histologic Type",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7",
                    "ConditionBrowseLeafName":"Abdominal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5839",
                    "ConditionBrowseLeafName":"Digestive System Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7469",
                    "ConditionBrowseLeafName":"Gastrointestinal Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M12024",
                    "ConditionBrowseLeafName":"Peritoneal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"T4790",
                    "ConditionBrowseLeafName":"Pseudomyxoma Peritonei",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"Rare",
                    "ConditionBrowseBranchName":"Rare Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000008937",
                    "InterventionMeshTerm":"Mitomycins"
                  },{
                    "InterventionMeshId":"D000016685",
                    "InterventionMeshTerm":"Mitomycin"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000000903",
                    "InterventionAncestorTerm":"Antibiotics, Antineoplastic"
                  },{
                    "InterventionAncestorId":"D000000970",
                    "InterventionAncestorTerm":"Antineoplastic Agents"
                  },{
                    "InterventionAncestorId":"D000000477",
                    "InterventionAncestorTerm":"Alkylating Agents"
                  },{
                    "InterventionAncestorId":"D000045504",
                    "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
                  },{
                    "InterventionAncestorId":"D000019384",
                    "InterventionAncestorTerm":"Nucleic Acid Synthesis Inhibitors"
                  },{
                    "InterventionAncestorId":"D000004791",
                    "InterventionAncestorTerm":"Enzyme Inhibitors"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M10486",
                    "InterventionBrowseLeafName":"Mitomycins",
                    "InterventionBrowseLeafAsFound":"Unresectable",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M17636",
                    "InterventionBrowseLeafName":"Mitomycin",
                    "InterventionBrowseLeafAsFound":"Unresectable",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M2803",
                    "InterventionBrowseLeafName":"Anti-Bacterial Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2805",
                    "InterventionBrowseLeafName":"Antibiotics, Antitubercular",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2401",
                    "InterventionBrowseLeafName":"Alkylating Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"ANeo",
                    "InterventionBrowseBranchName":"Antineoplastic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"Infe",
                    "InterventionBrowseBranchName":"Anti-Infective Agents"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":95,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779541",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2021-028"
              },
              "SecondaryIdInfoList":{
                "SecondaryIdInfo":[
                  {
                    "SecondaryId":"ar20-0031v1",
                    "SecondaryIdType":"Other Identifier",
                    "SecondaryIdDomain":"research GDPR register"
                  }
                ]
              },
              "Organization":{
                "OrgFullName":"University Hospital, Angers",
                "OrgClass":"OTHER_GOV"
              },
              "BriefTitle":"National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units",
              "OfficialTitle":"National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units",
              "Acronym":"VACOVID-SENIOR"
            },
            "StatusModule":{
              "StatusVerifiedDate":"March 2021",
              "OverallStatus":"Recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"February 8, 2021",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"April 8, 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"April 8, 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"March 1, 2021",
              "StudyFirstSubmitQCDate":"March 1, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"March 1, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University Hospital, Angers",
                "LeadSponsorClass":"OTHER_GOV"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The COVID-19 pandemic is a challenge for the French healthcare system, particularly among the elderly due to their particular vulnerability to the serious consequences of the disease, with an estimated mortality rate of around 30-35% among the frail elderly. The management of the health crisis could take a new turn in 2021 with the arrival in France of vaccines against the SARS-CoV-2 virus.\n\nThe objectives of this vaccination campaign are to reduce the morbi-mortality attributable to COVID-19 on the one hand, and to maintain essential activities related to the functioning of the country on the other hand and in particular the health system.\n\nHowever, the distrust of vaccination, traditionally strong in France, could have a negative impact on this strategy. While the President of the Republic announced on November 24, 2020 that vaccination against SARS-CoV-2 would not be made compulsory, almost one French person in two declared in several surveys that they did not want to be vaccinated; the main criterion for acceptance of vaccination being advanced age (the older they are, the more French people declare accepting to be vaccinated).\n\nIn view of the gradual vaccine supply schedule for the year 2021, the French National Authority for Health established at the end of 2020 a prioritization by vaccine availability phases. The critical initial supply phase,which is currently taking place, is the one during which residents of retirement home and long-term care units are prioritized because of their particular vulnerability (age and co-morbidities) and their increased exposure to SARS-CoV-2.\n\nFor these reasons, and in order to carry out the current vaccination campaign in the most optimal way possible, this national survey is launching to evaluate the acceptance rate of the SARS-CoV-2 vaccine among people living in retirement homes and long-term care units, to understand the mechanisms of acceptance or rejection, and to draw up an initial large-scale inventory of the symptoms observed following vaccination."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "SARS-CoV-2",
                  "Covid19"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Retrospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"1000",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"observation",
                    "InterventionDescription":"observation of the mechanisms of acceptance or rejection of the vaccine"
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Acceptance rate of the SARS-CoV-2 vaccine among people living in nursing homes and long-term care units",
                    "PrimaryOutcomeDescription":"Number of acceptances of the vaccine with analysis of the reason for refusal.",
                    "PrimaryOutcomeTimeFrame":"at baseline"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Symptoms related to vaccination against COVID-19",
                    "SecondaryOutcomeDescription":"description and identification of symptoms presented after vaccination of elderly patients",
                    "SecondaryOutcomeTimeFrame":"at baseline"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nPeople aged 75 years and older in retirement homes or long-term care units who have accepted the SARS CoV-2 vaccine\nPeople aged 75 years and older in retirement homes or long-term care units who have refused the SARS CoV-2 vaccine\nNational survey in france\n\nExclusion Criteria:\n\nOpposition of the elderly person and/or his or her relatives",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"75 Years",
              "StdAgeList":{
                "StdAge":[
                  "Older Adult"
                ]
              },
              "StudyPopulation":"all french seniors in retirement homes or long-term care units by SARS-CoV-2",
              "SamplingMethod":"Non-Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"CÃ©dric Annweiler, M.D., Ph.D.",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"0241354725",
                    "CentralContactPhoneExt":"+33",
                    "CentralContactEMail":"cedric.annweiler@chu-angers.fr"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Angers University Hospital",
                    "LocationStatus":"Recruiting",
                    "LocationCity":"Angers",
                    "LocationZip":"49933",
                    "LocationCountry":"France",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Cedric ANNWEILER, MD, PhD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"(+33)241354725",
                          "LocationContactEMail":"cedric.annweiler@chu-angers.fr"
                        }
                      ]
                    }
                  }
                ]
              }
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M15943",
                    "InterventionBrowseLeafName":"Vaccines",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":96,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779528",
              "OrgStudyIdInfo":{
                "OrgStudyId":"442/2021/67"
              },
              "Organization":{
                "OrgFullName":"University of Jordan",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Awake Nasal Fiber-optic Intubation of Severely Obese Patients in Lateral Position",
              "OfficialTitle":"Awake Nasal Fiber-optic Intubation of Severely Obese Patients in Lateral Position: a Prospective Randomized Controlled Trial"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"December 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 27, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"omar ahmad ababneh",
                "ResponsiblePartyInvestigatorTitle":"Principal investigator",
                "ResponsiblePartyInvestigatorAffiliation":"University of Jordan"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of Jordan",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Airway management in severely obese patients remains a challenging issue for anesthetists and may lead to life-threatening situations. Awake Fiber-Optic Bronchoscopy Intubation (FOBI) technique is considered as the gold standard when a difficult airway is anticipated to secure the airway and to facilitate the surgery. FOBI is usually done in supine position, while (in conscious patients) lateral position is the most recommended position to keep the upper airway patent. This prospective clinical trial study will test whether awake FOBI in Lateral position will provide a safe profile or a significant advantage over FOBI in supine position, in morbidly obese patients undergoing elective bariatric surgery.",
              "DetailedDescription":"Airway management in severely obese patients remains a challenging issue for anesthetists and may lead to life-threatening situations. Awake Fiber-Optic Bronchoscopy Intubation (FOBI) technique is considered as the gold standard when a difficult airway is anticipated to secure the airway and to facilitate the surgery. FOBI is usually done in supine position, while (in conscious patients) lateral position is the most recommended position to keep the upper airway patent.\n\nThis prospective clinical trial study will test whether awake FOBI in Lateral position will provide a safe profile or a significant advantage over FOBI in supine position, in morbidly obese patients undergoing elective bariatric surgery. The main outcome is success rate and duration of the procedure. Secondary outcomes are oxygenation maintenance, hemodynamic stability, airway complication, sedation score, and postoperative airway morbidity in 6 hours after surgery."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Anesthesia",
                  "Intubation;Difficult",
                  "Intubation; Difficult or Failed",
                  "Anesthesia Intubation Complication"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Anesthesia",
                  "Intubation",
                  "obesity",
                  "fiberoptic"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"60",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Group S",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Patients will undergo fiberoptic intubation in supine position.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Fiberoptic intubation in supine position."
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Group L",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Patients will undergo fiberoptic intubation in lateral position.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: Fiberoptic intubation in lateral position."
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"Fiberoptic intubation in supine position.",
                    "InterventionDescription":"Patients will be placed in supine position after the establishment of full vital signs monitoring and the insertion of an intravenous line.\n\nUnder sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Group S"
                      ]
                    }
                  },{
                    "InterventionType":"Procedure",
                    "InterventionName":"Fiberoptic intubation in lateral position.",
                    "InterventionDescription":"Patients will be placed in lateral position after the establishment of full vital signs monitoring and the insertion of an intravenous line.\n\nUnder sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina.",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Group L"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Duration of fiberoptic intubation.",
                    "PrimaryOutcomeDescription":"The investigators will compare between the supine and lateral positions in terms of the duration needed for the insertion of an endotracheal tube via fiberoptic intubation.",
                    "PrimaryOutcomeTimeFrame":"5 minutes"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Complications during airway manipulation.",
                    "SecondaryOutcomeDescription":"The investigators will document the occurrence of adverse events during fiberoptic intubation, and compare these complications between the two groups.",
                    "SecondaryOutcomeTimeFrame":"5 minutes"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAmerican Society of Anesthesiologists physical status classification two and three.\nPatients scheduled for elective bariatric surgeries under general anesthesia.\n\nExclusion Criteria:\n\nRefusal of fiberoptic intubation.\nAllergy to local anesthetics.\nCoagulopathy.\nRaised intracranial or intraocular pressure.",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"65 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Omar A Ababneh",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"00962 5353000",
                    "CentralContactPhoneExt":"2389",
                    "CentralContactEMail":"omar.ababneh@ju.edu.jo"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Jordan University Hospital",
                    "LocationCity":"Amman",
                    "LocationZip":"11942",
                    "LocationCountry":"Jordan"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M11284",
                    "ConditionBrowseLeafName":"Obesity",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC18",
                    "ConditionBrowseBranchName":"Nutritional and Metabolic Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M2688",
                    "InterventionBrowseLeafName":"Anesthetics",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M9597",
                    "InterventionBrowseLeafName":"Lidocaine",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M1696",
                    "InterventionBrowseLeafName":"Remifentanil",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M26173",
                    "InterventionBrowseLeafName":"Pseudoephedrine",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M6549",
                    "InterventionBrowseLeafName":"Ephedrine",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"CNSDep",
                    "InterventionBrowseBranchName":"Central Nervous System Depressants"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"AnArAg",
                    "InterventionBrowseBranchName":"Anti-Arrhythmia Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"ChanBlk",
                    "InterventionBrowseBranchName":"Channel Blockers"
                  },{
                    "InterventionBrowseBranchAbbrev":"Analg",
                    "InterventionBrowseBranchName":"Analgesics"
                  },{
                    "InterventionBrowseBranchAbbrev":"VaCoAg",
                    "InterventionBrowseBranchName":"Vasoconstrictor Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"Resp",
                    "InterventionBrowseBranchName":"Respiratory System Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"CNSSti",
                    "InterventionBrowseBranchName":"Central Nervous System Stimulants"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":97,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779515",
              "OrgStudyIdInfo":{
                "OrgStudyId":"2243"
              },
              "Organization":{
                "OrgFullName":"University of Jordan",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Effect of Low-pressure Pneumoperitoneum on Pain and Inflammation Post Laparoscopic Cholecystectomy",
              "OfficialTitle":"Effect of Low-pressure Pneumoperitoneum on Pain and Inflammation Post Laparoscopic Cholecystectomy: A Randomized, Double-blinded, Controlled, Clinical Trial."
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 20, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"January 22, 2021",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"January 22, 2021",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 27, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Hanan Ibrahim Mansour",
                "ResponsiblePartyInvestigatorTitle":"Dr. Hanan Mansour, post-graduate, general surgery resident",
                "ResponsiblePartyInvestigatorAffiliation":"University of Jordan"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of Jordan",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"The purpose of this study is to assess the effect of low-pressure pneumoperitoneum on post operative pain and inflammation in patients undergoing elective laparoscopic cholecystectomy by comparing it to standard practice.",
              "DetailedDescription":"After obtaining informed consent from eligible study participants. patients were randomized into one of two masked groups, labelled red and green. The red-label group was operated at standard-pressure pneumoperitoneum, while the green-label group was operated at low-pressure pneumoperitoneum. Baseline blood samples were obtained pre-operatively for ten inflammatory markers, patients' demographics and intra-operative details collected, then post-operative pain and change in inflammatory markers were followed."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Pneumoperitoneum",
                  "Pain",
                  "Inflammation"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "low-pressure pneumoperitoneum, lap chole"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignInterventionModelDescription":"participants were divided into two masked groups, labelled red and green; those operated at low-pressure pneumoperitoneum (green-label) and those operated at standard-pressure pneumoperitoneum (red-label).",
                "DesignPrimaryPurpose":"Supportive Care",
                "DesignMaskingInfo":{
                  "DesignMasking":"Quadruple",
                  "DesignMaskingDescription":"none of the participants knew at which pressure they will be operated on, nor the physicians who followed participants at floor or those analyzing blood samples, not the assigned physician to collect data, nor the personnel doing the analysis.\n\nonly the operating surgeon and circulating nurse were aware of the meaning of the participant assigned label at time of operation. The masking was revealed post completion of analysis.",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator",
                      "Outcomes Assessor"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"100",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Low-pressure",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Participants undergone laparoscopic cholecystectomy by creation of a low-pressure pneumoperitoneum, set at 8-10 mm Hg",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: low-pressure pneumoperitoneum"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Standard-pressure",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Participants undergone laparoscopic cholecystectomy by creation of a standard-pressure pneumoperitoneum, set at 12-14 mm Hg",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Procedure: standard-pressure pneumoperitoneum"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Procedure",
                    "InterventionName":"low-pressure pneumoperitoneum",
                    "InterventionDescription":"insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Low-pressure"
                      ]
                    }
                  },{
                    "InterventionType":"Procedure",
                    "InterventionName":"standard-pressure pneumoperitoneum",
                    "InterventionDescription":"insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Standard-pressure"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"change from baseline in pain on the 11-point short pain scale (SPS-11) at hour 12 post-op",
                    "PrimaryOutcomeDescription":"the SPS-11 is a validated, self-reported numeric instrument assessing pain intensity, ranging from 0 to 10; where 0 is no pain, and 10 is the worst pain felt ever.\n\nchange = (pain score at 12-hr post-op) - (baseline pain score assessed at 6-hr post-op)",
                    "PrimaryOutcomeTimeFrame":"baseline and 12 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in pain on the 11-point short pain scale (SPS-11) at hour 24 post-op",
                    "PrimaryOutcomeDescription":"the SPS-11 is a validated, self-reported numeric instrument assessing pain intensity, ranging from 0 to 10; where 0 is no pain, and 10 is the worst pain felt ever.\n\nchange = (pain score at 24-hr post-op) - (baseline pain score assessed at 6-hr post-op)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in pain on the 11-point short pain scale (SPS-11) at day 7 post-op",
                    "PrimaryOutcomeDescription":"the SPS-11 is a validated, self-reported numeric instrument assessing pain intensity, ranging from 0 to 10; where 0 is no pain, and 10 is the worst pain felt ever.\n\nchange = (pain score at post-op day 7) - (baseline pain score assessed at 6-hr post-op)",
                    "PrimaryOutcomeTimeFrame":"baseline and 7 days post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in WBC count at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in white blood cycles count as inflammatory marker post-op in 1000 cells per cubic millimeter of blood.\n\nchange = (post-op WBC count) - (baseline WBC count)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in Plt count at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in platelets count as inflammatory marker post-op in Ã— 10^9/L of blood change = (post-op Plt count) - (baseline Plt count)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in ESR value at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in erythrocyte sedimentation rate value as inflammatory marker post-op in millimeters per hour.\n\nchange = (post-op ESR) - (baseline ESR)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in CRP level at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in C reactive protein level as inflammatory marker post-op in mg/L change = (post-op CRP) - (baseline CRP)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in Alb level at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the drop in albumin level as inflammatory marker post-op in g/dL change = (baseline Alb) - (post-op baseline Alb)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in cortisol level at 4hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in cortisol level as inflammatory marker post-op in nmol/L change = (post-op cortisol ) - (baseline cortisol )",
                    "PrimaryOutcomeTimeFrame":"baseline and 4 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in IL-6 level at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in interleukin 6 level as inflammatory marker post-op in pg/mL change = (post-op IL-6) - (baseline IL-6)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in IL-17 level at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in interleukin 17 level as inflammatory marker post-op in pg/mL change = (post-op IL-17) - (baseline IL-17)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in IL-1 level at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in interleukin 1 level as inflammatory marker post-op in pg/mL change = (post-op IL-1) - (baseline IL-1)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  },{
                    "PrimaryOutcomeMeasure":"change from baseline in TNF level at 24hr post op",
                    "PrimaryOutcomeDescription":"calculate the rise in tumor necrosis factor alpha level as inflammatory marker post-op in pg/mL change = (post-op TNF) - (baseline TNF)",
                    "PrimaryOutcomeTimeFrame":"baseline and 24 hours post-op"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"Difference in surgery difficulty level among two groups",
                    "SecondaryOutcomeDescription":"assessing level of surgery difficulty between low and standard pressure pneumoperitoneum groups.\n\nDifficulty was self reported by operating surgeon as easy (score=1), moderate (score=2), or difficult (score=3).\n\nDifference assessed by calculating average between groups",
                    "SecondaryOutcomeTimeFrame":"total surgery duration"
                  },{
                    "SecondaryOutcomeMeasure":"Difference in surgery time among two groups",
                    "SecondaryOutcomeDescription":"assessing difference in insufflation time calculated in minutes between low and standard pressure pneumoperitoneum groups.\n\ninsufflation time was calculated from time of creation of pneumoperitoneum to deflation of the abdomen.\n\nDifference assessed by calculating average between groups",
                    "SecondaryOutcomeTimeFrame":"time spent while abdomen insufflated"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nElective admission for laparoscopic cholecystectomy\n\nExclusion Criteria:\n\nCurrent or previous diagnosis of acute cholecystitis confirmed by ultrasound\nprevious GI surgeries, except bariatric and anti-reflux surgeries\nCurrently on immunosuppressant agents\nPregnancy\nBreastfeeding\nCurrently diagnosed with drug addiction\nAmerican Society of Anesthesiologists (ASA) score 3 and more",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"12 Years",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Salam Daradkeh, Prof.",
                    "OverallOfficialAffiliation":"University of Jordan",
                    "OverallOfficialRole":"Study Chair"
                  },{
                    "OverallOfficialName":"Mohammad Rashdan, Prof.",
                    "OverallOfficialAffiliation":"University of Jordan",
                    "OverallOfficialRole":"Principal Investigator"
                  },{
                    "OverallOfficialName":"Raed Al-Taher, Prof.",
                    "OverallOfficialAffiliation":"University of Jordan",
                    "OverallOfficialRole":"Study Director"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Jordan University Hospital",
                    "LocationCity":"Amman",
                    "LocationState":"Jubaiha",
                    "LocationZip":"13046",
                    "LocationCountry":"Jordan"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Yes",
              "IPDSharingDescription":"we are willing to share all study data for interested researchers to conduct secondary studies of their own.",
              "IPDSharingInfoTypeList":{
                "IPDSharingInfoType":[
                  "Study Protocol",
                  "Statistical Analysis Plan (SAP)",
                  "Informed Consent Form (ICF)",
                  "Clinical Study Report (CSR)",
                  "Analytic Code"
                ]
              },
              "IPDSharingTimeFrame":"the data will be available from April,2021 up to the end of 2021 year",
              "IPDSharingAccessCriteria":"Data will be shared for medical investigators interested in the topic of pneumoperitoneum, to request please contact (hanan.ju@gmail.com)"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000011027",
                    "ConditionMeshTerm":"Pneumoperitoneum"
                  },{
                    "ConditionMeshId":"D000007249",
                    "ConditionMeshTerm":"Inflammation"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  },{
                    "ConditionAncestorId":"D000010532",
                    "ConditionAncestorTerm":"Peritoneal Diseases"
                  },{
                    "ConditionAncestorId":"D000004066",
                    "ConditionAncestorTerm":"Digestive System Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M12500",
                    "ConditionBrowseLeafName":"Pneumoperitoneum",
                    "ConditionBrowseLeafAsFound":"Pneumoperitoneum",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M8876",
                    "ConditionBrowseLeafName":"Inflammation",
                    "ConditionBrowseLeafAsFound":"Inflammation",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M11649",
                    "ConditionBrowseLeafName":"Pain",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M12024",
                    "ConditionBrowseLeafName":"Peritoneal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M5838",
                    "ConditionBrowseLeafName":"Digestive System Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M7466",
                    "ConditionBrowseLeafName":"Gastrointestinal Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC06",
                    "ConditionBrowseBranchName":"Digestive System Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":98,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779502",
              "OrgStudyIdInfo":{
                "OrgStudyId":"131619"
              },
              "Organization":{
                "OrgFullName":"University of Baghdad",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"The Efficacy of Oregano Essential Oil in Reducing Oral Halitosis",
              "OfficialTitle":"The Efficacy of Oregano Essential Oil in Reducing Oral Halitosis :A Randomized Controlled Trial"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"January 12, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"November 15, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"November 17, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"February 27, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"MOHAMED SAEED M. ALI",
                "ResponsiblePartyInvestigatorTitle":"mohamed saeed",
                "ResponsiblePartyInvestigatorAffiliation":"University of Baghdad"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of Baghdad",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"the efficacy of commercially available oregano essential oil mouthwash in the reduction of oral halitosis was compared to chlorhexidine and distilled water and the results showed significant reduction of organoleptic tongue and floss scores and BANA test scores compared to placebo",
              "DetailedDescription":"the results showed that oregawash showed a comparable effect to chx in reducing oral halitosis"
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Halitosis"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "oral halitosis",
                  "oregano essential oil",
                  "mouthwash"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Not Applicable"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Parallel Assignment",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Double",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Investigator"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"54",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"oregano",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"oregawash mouthwash was used twice times daily for 7 days",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: oregawash"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"distilled water was used twice times daily for 7 days",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: placebo"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"chlorhexidine",
                    "ArmGroupType":"Active Comparator",
                    "ArmGroupDescription":"Corsodyl with 0.2%CHX mouthwash was used twice times daily for 7 days",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: corsodyl"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"oregawash",
                    "InterventionDescription":"mouthwash containing oregano essential oil",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "oregano"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"corsodyl",
                    "InterventionDescription":"0.2% chlorhexidine mouthwash",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "chlorhexidine"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "chlorhexdine"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"placebo",
                    "InterventionDescription":"distilled water",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "placebo"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "distilled water"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"organoleptic tongue and floss scores",
                    "PrimaryOutcomeDescription":"organoleptic measuements",
                    "PrimaryOutcomeTimeFrame":"9 month"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"BANA test",
                    "SecondaryOutcomeDescription":"chair side BANA test",
                    "SecondaryOutcomeTimeFrame":"9 month"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nOrganoleptic score was >2 at baseline.\nParticipants between 18-23 years of age.\nThe subjects had no systemic disease and were not taking antibiotics or receiving other antimicrobial therapy.\nThe subjects did not receive the same time treatment for their halitosis.\n\nExclusion Criteria:\n\nSmokers, alcoholics and drug addicts.\nPatients with periodontitis or pocket depth >6 mm.\nPatients taking drugs which induced xerostomia.\nSubjects consuming spicy food: garlic or onions two days before examination.\nPatients with orthodontic appliances or removable dentures.\npregnancy",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "MaximumAge":"23 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"mohamed s albana, director",
                    "OverallOfficialAffiliation":"univeristy of baghdad",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Univeristy of Baghdad",
                    "LocationCity":"Baghdad",
                    "LocationState":"Rasafa",
                    "LocationZip":"00964",
                    "LocationCountry":"Iraq"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000006209",
                    "ConditionMeshTerm":"Halitosis"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000012817",
                    "ConditionAncestorTerm":"Signs and Symptoms, Digestive"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M7884",
                    "ConditionBrowseLeafName":"Halitosis",
                    "ConditionBrowseLeafAsFound":"Halitosis",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M14205",
                    "ConditionBrowseLeafName":"Signs and Symptoms, Digestive",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionMeshList":{
                "InterventionMesh":[
                  {
                    "InterventionMeshId":"D000002710",
                    "InterventionMeshTerm":"Chlorhexidine"
                  },{
                    "InterventionMeshId":"C000010882",
                    "InterventionMeshTerm":"Chlorhexidine gluconate"
                  }
                ]
              },
              "InterventionAncestorList":{
                "InterventionAncestor":[
                  {
                    "InterventionAncestorId":"D000000891",
                    "InterventionAncestorTerm":"Anti-Infective Agents, Local"
                  },{
                    "InterventionAncestorId":"D000000890",
                    "InterventionAncestorTerm":"Anti-Infective Agents"
                  },{
                    "InterventionAncestorId":"D000004202",
                    "InterventionAncestorTerm":"Disinfectants"
                  },{
                    "InterventionAncestorId":"D000003879",
                    "InterventionAncestorTerm":"Dermatologic Agents"
                  }
                ]
              },
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M4536",
                    "InterventionBrowseLeafName":"Chlorhexidine",
                    "InterventionBrowseLeafAsFound":"Peak pressure",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M217888",
                    "InterventionBrowseLeafName":"Chlorhexidine gluconate",
                    "InterventionBrowseLeafAsFound":"Peak pressure",
                    "InterventionBrowseLeafRelevance":"high"
                  },{
                    "InterventionBrowseLeafId":"M2795",
                    "InterventionBrowseLeafName":"Anti-Infective Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M2796",
                    "InterventionBrowseLeafName":"Anti-Infective Agents, Local",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M5966",
                    "InterventionBrowseLeafName":"Disinfectants",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M5657",
                    "InterventionBrowseLeafName":"Dermatologic Agents",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T245",
                    "InterventionBrowseLeafName":"Oregano",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Infe",
                    "InterventionBrowseBranchName":"Anti-Infective Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"Derm",
                    "InterventionBrowseBranchName":"Dermatologic Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"HB",
                    "InterventionBrowseBranchName":"Herbal and Botanical"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":99,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779489",
              "OrgStudyIdInfo":{
                "OrgStudyId":"STU-2021-0114"
              },
              "Organization":{
                "OrgFullName":"University of Texas Southwestern Medical Center",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Checkpoint Inhibitor and Radiation Therapy in Node-Positive Bladder Cancer",
              "OfficialTitle":"Checkpoint Inhibitor and Radiation Therapy in Node-Positive Bladder Cancer",
              "Acronym":"CIRTiN-BC"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"June 1, 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"June 1, 2025",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"June 1, 2025",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 26, 2021",
              "StudyFirstSubmitQCDate":"February 26, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 26, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Solomon Woldu",
                "ResponsiblePartyInvestigatorTitle":"Assistant Professor, Urology",
                "ResponsiblePartyInvestigatorAffiliation":"University of Texas Southwestern Medical Center"
              },
              "LeadSponsor":{
                "LeadSponsorName":"University of Texas Southwestern Medical Center",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"Yes",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy. Immune checkpoint inhibitor (ICI) therapy is FDA-approved in advanced bladder cancer for patients unable to receive or failing to respond to platinum-based chemotherapy. The present study seeks to determine if next-generation radiation therapy (personalized ultrafractionated stereotactic ablative radiotherapy, or PULSAR) is feasible and effective in patients receiving ICI for bulky cN+ bladder cancer.",
              "DetailedDescription":"Patients are eligible for the trial if they have bulky, clinically node-positive (cN+) bladder cancer and have either recently initiated (within â‰¤ 1 week) or are planned to initiate immune checkpoint inhibitor (ICI) therapy due to either 1) ineligibility for/refusal of platinum-based downstaging chemotherapy; or 2) failure to achieve a complete clinical response to platinum-based downstaging chemotherapy. Patients will initiate PULSAR treatment 1-2 weeks after initiating ICI. PULSAR will be administered in 3 fractions of 12 Gy each (36 Gy total) at 12-16 day intervals and patients will undergo radical cystectomy with bilateral extended pelvic lymph node dissection within 4-8 weeks after completion of PULSAR. ICI therapy will be administered according to the FDA-approved dosing route and schedule and will be continued during PULSAR treatments.\n\nPULSAR treatment will be initiated 1-2 weeks after the patient is initiated on an FDA-approved ICI agent. PULSAR will be administered in 3 fractions of 12 Gy each at 12-16 day intervals. Target areas will include the region of the bladder containing the primary tumor (confirmed, if necessary, on office flexible cystoscopy at UTSW) and to up to five targetable, pathologically enlarged bulky lymph nodes (as deemed feasible by the treating radiation oncologist). Non-enlarged pelvic lymph nodes will be spared to minimize adverse effects on the tumor immune response."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Bladder Cancer"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "bladder cancer",
                  "lymph node metastasis",
                  "immunotherapy",
                  "radiation therapy"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 2"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"N/A",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignInterventionModelDescription":"single-arm interventional study",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"None (Open Label)",
                  "DesignMaskingDescription":"open label"
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"27",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"PULSAR",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"Eligible patients will receive next-generation stereotactic radiotherapy (PULSAR) 30-36 Gy in 3 fractions to the bladder and targetable, pathologically enlarged lymph nodes",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Radiation: personalized ultrafractionated stereotactic ablative radiotherapy"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Radiation",
                    "InterventionName":"personalized ultrafractionated stereotactic ablative radiotherapy",
                    "InterventionDescription":"next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "PULSAR"
                      ]
                    },
                    "InterventionOtherNameList":{
                      "InterventionOtherName":[
                        "PULSAR"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"protocol completion",
                    "PrimaryOutcomeDescription":"proportion of patients completing PULSAR and undergoing radical cystectomy",
                    "PrimaryOutcomeTimeFrame":"16 wk"
                  }
                ]
              },
              "SecondaryOutcomeList":{
                "SecondaryOutcome":[
                  {
                    "SecondaryOutcomeMeasure":"progression-free survival",
                    "SecondaryOutcomeDescription":"proportion of patients without disease progression",
                    "SecondaryOutcomeTimeFrame":"2 years"
                  }
                ]
              },
              "OtherOutcomeList":{
                "OtherOutcome":[
                  {
                    "OtherOutcomeMeasure":"major complication rate",
                    "OtherOutcomeDescription":"patients experiencing Clavien-Dindo Grade III+ surgical complication",
                    "OtherOutcomeTimeFrame":"90 days"
                  },{
                    "OtherOutcomeMeasure":"pathologic complete response",
                    "OtherOutcomeDescription":"patients achieving pathologic ypT0 N0 status",
                    "OtherOutcomeTimeFrame":"at time of radical cystectomy"
                  },{
                    "OtherOutcomeMeasure":"pathologic non-muscle invasive downstaging",
                    "OtherOutcomeDescription":"patients achieving pathologic â‰¤ ypT1 N0 status",
                    "OtherOutcomeTimeFrame":"at time of radical cystectomy"
                  },{
                    "OtherOutcomeMeasure":"pathologic organ-confined downstaging",
                    "OtherOutcomeDescription":"patients achieving pathologic â‰¤ ypT2 N0 status",
                    "OtherOutcomeTimeFrame":"at time of radical cystectomy"
                  },{
                    "OtherOutcomeMeasure":"pathologic complete nodal response",
                    "OtherOutcomeDescription":"patients achieving pathologic ypN0 status",
                    "OtherOutcomeTimeFrame":"at time of radical cystectomy"
                  },{
                    "OtherOutcomeMeasure":"residual disease at surgery",
                    "OtherOutcomeDescription":"patients with microscopic (R1) or gross (R2) residual disease",
                    "OtherOutcomeTimeFrame":"at time of radical cystectomy"
                  },{
                    "OtherOutcomeMeasure":"ureteroenteric stricture rate",
                    "OtherOutcomeDescription":"proportion of patients requiring procedural intervention for ureteroenteric stricture",
                    "OtherOutcomeTimeFrame":"2 years"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria\n\nBladder cancer, confirmed pathologically on transurethral resection of bladder tumor (TURBT) or on bladder biopsy. Pure urothelial, variant urothelial, or any proportion of squamous cell carcinoma are permitted. Questions about eligibility may be resolved by consultation with UTSW pathology but formal pathologic review is not required.\nBulky, clinically node positive disease (cN+) defined as: 1) a single pelvic lymph node of â‰¥ 1.5 cm largest diameter on CT or MRI; or 2) multiple pelvic lymph nodes â‰¥ 1 cm largest diameter on CT or MRI. Pathologic confirmation is not required. Imaging to establish eligibility must have been obtained no more than 60 days prior to trial enrollment. The scans must be personally reviewed by the enrolling clinician. For imaging studies obtained outside of UT Southwestern, imaging review of node status and sign off by the enrolling investigator is required. Review and sign off by a UTSW radiologist is optional in ambiguous or questionable cases, but is not mandatory.\nAge â‰¥ 18 years.\nECOG performance status 0-1.\nAppropriate candidate for radical cystectomy, as determined by the treating urologist.\nAppropriate candidate for stereotactic ablative radiotherapy, as determined by the treating radiation oncologist.\nPatient is planned to initiate or is within 1-3 weeks of initiation of FDA-approved immune checkpoint inhibitor therapy based on ineligibility to receive platinum-based downstaging chemotherapy (DCT) (Cohort 1, as detailed below) or failure to achieve clinical complete response to platinum-based DCT (Cohort 2, as detailed below).\n\nCohort 1 (chemotherapy-ineligible) - either of:\n\npatient staged with bulky cN+ disease as defined above, medically ineligible to receive any platinum-based chemotherapy or, after appropriate and documented counseling, refusing to receive any-platinum-based chemotherapy; or\npatient staged with bulky cN+ disease as defined above, medically ineligible to receive cisplatin-based chemotherapy, with PD-L1 positive tumor (according to methodology described in the FDA approval label for the respective ICI agent)\n\nCohort 2 (chemotherapy non-responding) - any of:\n\npatient, initially staged with bulky cN+ disease as defined above, with radiologic progression after two cycles of platinum-based DCT (per RECIST 1.1 criteria: â‰¥20% increase in summed short-axis diameter of visible lesions with â‰¥ 5 mm absolute increase)\npatient, initially staged with bulky cN+ disease as defined above, failing to achieve radiologic complete response after three or four cycles of platinum-based DCT (failure of all enlarged lymph nodes to decrease to < 1 cm short-axis diameter)\npatient, initially staged with bulky cN+ disease as defined above, failing to achieve radiologic complete response after one or two cycles of platinum-based DCT which was discontinued due to patient intolerance\npatient, initially not staged with bulky cN+ disease as defined above, who progresses to cN+ disease as defined above after two or more of cycles of platinum-based DCT\nPermitted downstaging chemotherapy regimens are gemcitabine/cisplatin (gem/cis), gemcitabine/carboplatin (gem/carbo), and methotrexate/vinblastine/doxorubin/cisplatin (MVAC, in any dose variant).\nPermitted immune checkpoint inhibitor agents are those FDA-approved for platinum-ineligible (Cohort 1) or platinum-refractory (Cohort 2) bladder cancer: atezolizumab or pembrolizumab for Cohort 1; atezolizumab, avelumab, nivolumab, or pembrolizumab for Cohort 2. If additional immune checkpoint inhibitor (anti-PD1, anti-PD-L1, and/or anti-CTLA4) agents are approved for use in advanced urothelial carcinoma during the study, these agents will be permitted as well.\nWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\nAbility to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria\n\nMedical or anatomic contraindication to any of the study treatment modalities (radical cystectomy, stereotactic ablative radiotherapy, immune checkpoint inhibitor therapy).\nNon-urothelial histology (other than pure squamous cell, which is permitted) including pure adenocarcinoma, pure small cell carcinoma, sarcoma, lymphoma, non-genitourinary primary (e.g. colorectal).\nMetastatic (cM1) disease, defined as 1) lymph nodes â‰¥ 1 cm above the aortic bifurcation (cM1a), or metastases to bone, brain, or any visceral site (cM1b). Patients with a single enlarged retroperitoneal lymph node will be eligible with an adequately performed lymph node biopsy showing no metastatic disease or with a PET scan showing absence of FDG avidity.\nSecond primary malignancy, except: 1) non-metastatic (cM0) prostate cancer, 2) non-metastatic (cM0) endometrial cancer, 3) non-melanoma skin cancer, 4) cervical squamous cell carcinoma in situ, 4) any AJCC Stage I/II or organ-confined primary malignancy for which the patient has undergone curative treatment and has been without evidence of disease for three years.\nPrior pelvic radiation therapy.\nAutoimmune disease rendering the patient ineligible for ICI.\nTreatment with any immunosuppressive agent within 14 days of study entry, excluding topical or inhaled corticosteroids or adrenal-replacement steroids.\nEnd stage renal disease requiring dialysis.\nHIV infection, unless stable on HAART with CD4+ count > 400.\nSubjects may not be receiving any other investigational agents for the treatment of the cancer under study.\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab, avelumab, durvalumab, nivolumab, pembrolizumab, or other agents used in study.\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation / atrial flutter), or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.\nSubjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.",
              "HealthyVolunteers":"No",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Solomon L Woldu, MD",
                    "OverallOfficialAffiliation":"University of Texas Southwestern Medical Center",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"University of Texas Southwestern Medical Center",
                    "LocationCity":"Dallas",
                    "LocationState":"Texas",
                    "LocationZip":"75390",
                    "LocationCountry":"United States",
                    "LocationContactList":{
                      "LocationContact":[
                        {
                          "LocationContactName":"Solomon L Woldu, MD",
                          "LocationContactRole":"Contact",
                          "LocationContactPhone":"214-648-9558",
                          "LocationContactEMail":"solomon.woldu@utsouthwestern.edu"
                        },{
                          "LocationContactName":"Solomon L Woldu, MD",
                          "LocationContactRole":"Principal Investigator"
                        },{
                          "LocationContactName":"Vitaly Margulis, MD",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Raquibul Hannan, MD",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Aurelie Garant, MD",
                          "LocationContactRole":"Sub-Investigator"
                        },{
                          "LocationContactName":"Suzanne Cole, MD",
                          "LocationContactRole":"Sub-Investigator"
                        }
                      ]
                    }
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000001749",
                    "ConditionMeshTerm":"Urinary Bladder Neoplasms"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000014571",
                    "ConditionAncestorTerm":"Urologic Neoplasms"
                  },{
                    "ConditionAncestorId":"D000014565",
                    "ConditionAncestorTerm":"Urogenital Neoplasms"
                  },{
                    "ConditionAncestorId":"D000009371",
                    "ConditionAncestorTerm":"Neoplasms by Site"
                  },{
                    "ConditionAncestorId":"D000009369",
                    "ConditionAncestorTerm":"Neoplasms"
                  },{
                    "ConditionAncestorId":"D000001745",
                    "ConditionAncestorTerm":"Urinary Bladder Diseases"
                  },{
                    "ConditionAncestorId":"D000014570",
                    "ConditionAncestorTerm":"Urologic Diseases"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M10890",
                    "ConditionBrowseLeafName":"Neoplasm Metastasis",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3612",
                    "ConditionBrowseLeafName":"Urinary Bladder Neoplasms",
                    "ConditionBrowseLeafAsFound":"Bladder Cancer",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M15903",
                    "ConditionBrowseLeafName":"Urologic Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M15898",
                    "ConditionBrowseLeafName":"Urogenital Neoplasms",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M3608",
                    "ConditionBrowseLeafName":"Urinary Bladder Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M15902",
                    "ConditionBrowseLeafName":"Urologic Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC04",
                    "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BXS",
                    "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                  }
                ]
              }
            }
          }
        }
      },{
        "Rank":100,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04779476",
              "OrgStudyIdInfo":{
                "OrgStudyId":"FRP/2021/319"
              },
              "Organization":{
                "OrgFullName":"Riyadh Elm University",
                "OrgClass":"OTHER"
              },
              "BriefTitle":"Effectiveness of Alveogyl and Cutanplast Dressing on Postoperative Pain Following Tooth Extraction: A Clinical Trial",
              "OfficialTitle":"Effectiveness of Alveogyl and Cutanplast Dressing on Postoperative Pain Following Tooth Extraction: A Clinical Trial"
            },
            "StatusModule":{
              "StatusVerifiedDate":"February 2021",
              "OverallStatus":"Not yet recruiting",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"March 2021",
                "StartDateType":"Anticipated"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"September 2021",
                "PrimaryCompletionDateType":"Anticipated"
              },
              "CompletionDateStruct":{
                "CompletionDate":"December 2021",
                "CompletionDateType":"Anticipated"
              },
              "StudyFirstSubmitDate":"February 27, 2021",
              "StudyFirstSubmitQCDate":"February 27, 2021",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"March 3, 2021",
                "StudyFirstPostDateType":"Estimate"
              },
              "LastUpdateSubmitDate":"February 27, 2021",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"March 3, 2021",
                "LastUpdatePostDateType":"Estimate"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Principal Investigator",
                "ResponsiblePartyInvestigatorFullName":"Ahmad Assari",
                "ResponsiblePartyInvestigatorTitle":"Dr. Ahmad Assari",
                "ResponsiblePartyInvestigatorAffiliation":"Riyadh Elm University"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Riyadh Elm University",
                "LeadSponsorClass":"OTHER"
              }
            },
            "OversightModule":{
              "OversightHasDMC":"No",
              "IsFDARegulatedDrug":"No",
              "IsFDARegulatedDevice":"No"
            },
            "DescriptionModule":{
              "BriefSummary":"This study aims to assess the post-dental extraction pain following the application of two different dressing materials.\n\nAlvogylÂ® and Absorbable gelatin sponges",
              "DetailedDescription":"Effective postoperative pain relief improves the quality of recovery and the resumption of normal activities. Many options are available for postoperative pain relief following tooth extraction including systemic analgesic, intra-alveolar socket dressing medicaments and follow the postoperative instructions; the medications choice determined by drug availability, chance of side effect of some drugs and financial considerations. The use of intra-alveolar dressing materials is widely suggested in the literature such as AlvogylÂ® that used as palliative treatment which includes eugenol (analgesic, anti- inflammatory), iodoform (antimicrobial), and butamen (anesthetic) (Bloomer CR.,2000; Summers L et al.,1976; Kaur G et al.,2010). Absorbable gelatin sponges contain haemostatic material and may be used for local application in surgical procedures where traditional haemostasis is difficult (Gerald AG.2007). In addition to its haemostatic effect, an absorbable gelatin sponge can be used as a drug reservoir to provide sustained release of drugs (Kafali H et al.,2008; Feroci F et al.,2009).\n\nThe aim of this study is to measure the pain intensity after using socket dressing materials following tooth extraction."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Facial Pain",
                  "Pain, Postoperative",
                  "Pain, Orofacial"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "Alveogyl",
                  "Eugenol",
                  "Dental extraction",
                  "Post extraction pain"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Observational",
              "PatientRegistry":"No",
              "DesignInfo":{
                "DesignObservationalModelList":{
                  "DesignObservationalModel":[
                    "Cohort"
                  ]
                },
                "DesignTimePerspectiveList":{
                  "DesignTimePerspective":[
                    "Prospective"
                  ]
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"50",
                "EnrollmentType":"Anticipated"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"Control Group",
                    "ArmGroupDescription":"No dressing material will be used post dental extraction"
                  },{
                    "ArmGroupLabel":"Alveogyl Group",
                    "ArmGroupDescription":"Alveogyl will be placed in the dental socket after extraction",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Socket Dressing"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Cutanplast Group",
                    "ArmGroupDescription":"Absorbable gelatin sponges contain will be placed in the dental socket after extraction",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Socket Dressing"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Other",
                    "InterventionName":"Socket Dressing",
                    "InterventionDescription":"Following dental extraction immediately, the socket will be dressed with one of the materials tested",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "Alveogyl Group",
                        "Cutanplast Group"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"3 hrs post extraction pain",
                    "PrimaryOutcomeDescription":"Visual analogue scale score for pain",
                    "PrimaryOutcomeTimeFrame":"three hours after the extraction"
                  },{
                    "PrimaryOutcomeMeasure":"6 hrs post extraction pain",
                    "PrimaryOutcomeDescription":"Visual analogue scale score for pain",
                    "PrimaryOutcomeTimeFrame":"six hours after the extraction"
                  },{
                    "PrimaryOutcomeMeasure":"12 hrs post extraction pain",
                    "PrimaryOutcomeDescription":"Visual analogue scale score for pain",
                    "PrimaryOutcomeTimeFrame":"twelve hours after the extraction"
                  },{
                    "PrimaryOutcomeMeasure":"24 hrs post extraction pain",
                    "PrimaryOutcomeDescription":"Visual analogue scale score for pain",
                    "PrimaryOutcomeTimeFrame":"twenty-four hours after the extraction"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nSingle tooth extraction\nUpper and lower teeth\n\nExclusion Criteria:\n\nSurgical extraction\nMedically compromised patients\nPresence of active infection\nPresence of pathology",
              "Gender":"All",
              "MinimumAge":"13 Years",
              "MaximumAge":"22 Years",
              "StdAgeList":{
                "StdAge":[
                  "Child",
                  "Adult"
                ]
              },
              "StudyPopulation":"Patients referred from the orthodontic department for extraction of p",
              "SamplingMethod":"Probability Sample"
            },
            "ContactsLocationsModule":{
              "CentralContactList":{
                "CentralContact":[
                  {
                    "CentralContactName":"Ahmad Assari",
                    "CentralContactRole":"Contact",
                    "CentralContactPhone":"966569360748",
                    "CentralContactEMail":"Ahmad.Assari@riyadh.edu.sa"
                  }
                ]
              }
            },
            "ReferencesModule":{
              "ReferenceList":{
                "Reference":[
                  {
                    "ReferencePMID":"10982947",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Bloomer CR. Alveolar osteitis prevention by immediate placement of medicated packing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Sep;90(3):282-4."
                  },{
                    "ReferencePMID":"1070322",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Summers L, Matz LR. Extraction wound sockets. Histological changes and paste packs--a trial. Br Dent J. 1976 Dec 21;141(12):377-9."
                  },{
                    "ReferencePMID":"20043298",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Kaur G, Athar M, Alam MS. Eugenol precludes cutaneous chemical carcinogenesis in mouse by preventing oxidative stress and inflammation and by inducing apoptosis. Mol Carcinog. 2010 Mar;49(3):290-301. doi: 10.1002/mc.20601."
                  },{
                    "ReferencePMID":"18971135",
                    "ReferenceType":"result",
                    "ReferenceCitation":"Kafali H, Iltemur Duvan C, GÃ¶zdemir E, Simavli S, OztÃ¼rk Turhan N. Placement of bupivacaine-soaked Spongostan in episiotomy bed is effective treatment modality for episiotomy-associated pain. J Minim Invasive Gynecol. 2008 Nov-Dec;15(6):719-22. doi: 10.1016/j.jmig.2008.08.006."
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"Undecided",
              "IPDSharingDescription":"The anticipated number may not be reached"
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"March 03, 2021"
            },
            "ConditionBrowseModule":{
              "ConditionMeshList":{
                "ConditionMesh":[
                  {
                    "ConditionMeshId":"D000010149",
                    "ConditionMeshTerm":"Pain, Postoperative"
                  },{
                    "ConditionMeshId":"D000005157",
                    "ConditionMeshTerm":"Facial Pain"
                  }
                ]
              },
              "ConditionAncestorList":{
                "ConditionAncestor":[
                  {
                    "ConditionAncestorId":"D000011183",
                    "ConditionAncestorTerm":"Postoperative Complications"
                  },{
                    "ConditionAncestorId":"D000010335",
                    "ConditionAncestorTerm":"Pathologic Processes"
                  },{
                    "ConditionAncestorId":"D000010146",
                    "ConditionAncestorTerm":"Pain"
                  },{
                    "ConditionAncestorId":"D000009461",
                    "ConditionAncestorTerm":"Neurologic Manifestations"
                  }
                ]
              },
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M11652",
                    "ConditionBrowseLeafName":"Pain, Postoperative",
                    "ConditionBrowseLeafAsFound":"Pain, Postoperative",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M6883",
                    "ConditionBrowseLeafName":"Facial Pain",
                    "ConditionBrowseLeafAsFound":"Facial Pain",
                    "ConditionBrowseLeafRelevance":"high"
                  },{
                    "ConditionBrowseLeafId":"M19673",
                    "ConditionBrowseLeafName":"Facies",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M11649",
                    "ConditionBrowseLeafName":"Pain",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M12648",
                    "ConditionBrowseLeafName":"Postoperative Complications",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M10987",
                    "ConditionBrowseLeafName":"Neurologic Manifestations",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC23",
                    "ConditionBrowseBranchName":"Symptoms and General Pathology"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC10",
                    "ConditionBrowseBranchName":"Nervous System Diseases"
                  }
                ]
              }
            },
            "InterventionBrowseModule":{
              "InterventionBrowseLeafList":{
                "InterventionBrowseLeaf":[
                  {
                    "InterventionBrowseLeafId":"M7479",
                    "InterventionBrowseLeafName":"Gelatin Sponge, Absorbable",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"M6780",
                    "InterventionBrowseLeafName":"Eugenol",
                    "InterventionBrowseLeafRelevance":"low"
                  },{
                    "InterventionBrowseLeafId":"T391",
                    "InterventionBrowseLeafName":"Eugenol",
                    "InterventionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "InterventionBrowseBranchList":{
                "InterventionBrowseBranch":[
                  {
                    "InterventionBrowseBranchAbbrev":"Coag",
                    "InterventionBrowseBranchName":"Coagulants"
                  },{
                    "InterventionBrowseBranchAbbrev":"All",
                    "InterventionBrowseBranchName":"All Drugs and Chemicals"
                  },{
                    "InterventionBrowseBranchAbbrev":"Infe",
                    "InterventionBrowseBranchName":"Anti-Infective Agents"
                  },{
                    "InterventionBrowseBranchAbbrev":"Ot",
                    "InterventionBrowseBranchName":"Other Dietary Supplements"
                  }
                ]
              }
            }
          }
        }
      }
    ]
  }
}